<SEC-DOCUMENT>0001628280-21-022421.txt : 20211109
<SEC-HEADER>0001628280-21-022421.hdr.sgml : 20211109
<ACCEPTANCE-DATETIME>20211109092313
ACCESSION NUMBER:		0001628280-21-022421
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		72
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211109
DATE AS OF CHANGE:		20211109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ocugen, Inc.
		CENTRAL INDEX KEY:			0001372299
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36751
		FILM NUMBER:		211390138

	BUSINESS ADDRESS:	
		STREET 1:		263 GREAT VALLEY PARKWAY
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355
		BUSINESS PHONE:		484-328-4701

	MAIL ADDRESS:	
		STREET 1:		263 GREAT VALLEY PARKWAY
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HISTOGENICS CORP
		DATE OF NAME CHANGE:	20060810
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ocgn-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:37cdbff3-15f4-4881-8cd5-68abc4a291de,g:c6584426-cf6c-4c9a-b04f-fdc200c901b8,d:9ff348f1ca104ec598a35c61fa9fc977--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ocgn="http://www.deitaxonomy.com/20210930" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ocgn-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180L2ZyYWc6MzQ0ZDE3M2MxZjdlNDlhMjk2MzkzMzVmNDQyYmIzYzcvdGFibGU6ZjdkNjE1ZDg1N2Q1NGIwZTgwNTgyMWFkOGU1NDIxZmQvdGFibGVyYW5nZTpmN2Q2MTVkODU3ZDU0YjBlODA1ODIxYWQ4ZTU0MjFmZF8xLTEtMS0xLTA_694bf128-574c-4f86-a02d-5f091498cc23">0001372299</ix:nonNumeric><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180L2ZyYWc6MzQ0ZDE3M2MxZjdlNDlhMjk2MzkzMzVmNDQyYmIzYzcvdGFibGU6ZjdkNjE1ZDg1N2Q1NGIwZTgwNTgyMWFkOGU1NDIxZmQvdGFibGVyYW5nZTpmN2Q2MTVkODU3ZDU0YjBlODA1ODIxYWQ4ZTU0MjFmZF8yLTEtMS0xLTA_7fe8f8a7-25f4-49dd-a163-5f1468a7d07e">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180L2ZyYWc6MzQ0ZDE3M2MxZjdlNDlhMjk2MzkzMzVmNDQyYmIzYzcvdGFibGU6ZjdkNjE1ZDg1N2Q1NGIwZTgwNTgyMWFkOGU1NDIxZmQvdGFibGVyYW5nZTpmN2Q2MTVkODU3ZDU0YjBlODA1ODIxYWQ4ZTU0MjFmZF8zLTEtMS0xLTA_aa80a44b-7e27-402d-a854-f04176062354">2021</ix:nonNumeric><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180L2ZyYWc6MzQ0ZDE3M2MxZjdlNDlhMjk2MzkzMzVmNDQyYmIzYzcvdGFibGU6ZjdkNjE1ZDg1N2Q1NGIwZTgwNTgyMWFkOGU1NDIxZmQvdGFibGVyYW5nZTpmN2Q2MTVkODU3ZDU0YjBlODA1ODIxYWQ4ZTU0MjFmZF80LTEtMS0xLTA_3f54f82c-8c5f-47c6-a145-03ec9a090122">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180L2ZyYWc6MzQ0ZDE3M2MxZjdlNDlhMjk2MzkzMzVmNDQyYmIzYzcvdGFibGU6ZjdkNjE1ZDg1N2Q1NGIwZTgwNTgyMWFkOGU1NDIxZmQvdGFibGVyYW5nZTpmN2Q2MTVkODU3ZDU0YjBlODA1ODIxYWQ4ZTU0MjFmZF81LTEtMS0xLTA_ade2daed-56a7-4bb5-ab87-a1f83110f95d">false</ix:nonNumeric><ix:nonNumeric contextRef="id5d5a29609664c35b78098fb9dd71398_D20210101-20210930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfNDM5ODA0NjU4MjIzNg_2f5f7cef-a3ff-41b9-b3bd-1ded51f7bc02">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i20ba81fe7dcd4e0d8c7f7e1bd42e7108_D20210101-20210930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfNDM5ODA0NjU4MjMwOQ_2aaf4aaa-5250-4fad-95da-0d6844c093cb">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="ic0845e0a879f4a8f9b00281ea8a23506_D20210101-20210930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTI5NTc_1b0f22b6-1741-4551-9fe9-ad65976104fa">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ocgn-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i52d9db304374467785253218ec6f15f0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i37c782c18fab4541b52948ee02ff0fe1_I20211102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i68178daf3b96459db15e2b75995f88d1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0aa9d9e8ef714df892f133c7484c0b4a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28b02ce452d34ea6b3c2e1dff6d45d00_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i552c85d6331e4cad97ea9f15ee20104a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i429a8518eebf4e0cb714c17e78e150bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd58335a3dab4d87a7550d4a5dd940cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ad0bf3a315f43d3b971e83e4328a6c4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03ee12167fe649b08a8573352b78366f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf7ffe1af99e468485a7fa0473a357c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63c582794c9241548ff9038b8f5f5a27_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebacd414b4044a8fbc5c8c5207a7b86f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib511b5a36eaf40048ec9ee98f00551c1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9d460c203374d7880f0ec3fae34b578_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i221ecffa66144040873151eb590dd8b3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:ATMTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2ffbcae57d0459f8b8815522daa3dc3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:ATMTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b6cae5ed98647219290e0100ca91343_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:ATMTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2588abf7c6e477fbe29c509564b8f4b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i442e9159fb0046dcaf7dd1b46149c00e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06dadc3f8b824b8c91fc0f114505344d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if996ab97fcf74a548c34b4f5941439b4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34d4430baa0f44abb229c0dd32cdcbae_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86140f763e9c47098d573fe17ae24f7d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cdbf08cfea2418e9a09ae632d0e329d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c3ef4ab08b246bea75a9049a1509d61_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9466d66e75764cf9aefaf1eb61c6a86a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28b699982fb94ef9b501dc59505bd27b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bfcaa4bfe9b4fd88d8461664e684474_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb8526a2a5a242e7812303c1e35ea461_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib42ad3d8f0264d0d8f1893b83054daf9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if26f766056584bd6b3d8be57c4c75510_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd48f822ec024053ba61f26d03cd9402_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24d28352102d488e81a31df53860a386_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5af0d4e54fa04902b86c568fffb94928_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib49cc7013dca487eac750b80929881ce_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf8f98fd3caa4d46bcf11d8083135a3c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0071733638ed4178b0c2f37e29b4c541_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id63858f31e204ae6b02d0f95495b173a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf7c1094d10a4d97959c21e8669b2a25_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44f7ffb2eea24ee9a6de6a5ce40eef9e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i098bebd384304520a79fe2559dfb9c27_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie51ec8f7c79f40878c0fde67d905e922_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf94f103b7b048a097f0defcf2650f43_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0775f4cfa17343e6913d2da04f38f67a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0f6174d8ece4a44b930465233df749d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f39d7650e794a7b81d454b1bb5ac6cd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ff2e3800b044563861e8dbb3d568544_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2df3c91a1e2141808ceb139a8c692d4f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e80709cb7a44684bc5d9a7c7d3d7fdc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ceacdb4b4eb427992b8f810605259bb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if74b21443ee54787a0b6b5788b176165_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bcc6879e812488a8c638047e2739ebd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb3652c42f6d42209a1beabd6597843e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4a4fa5cea03410b9c6bd3abe049132a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaeb9a66837754ddcabb2a790c8f98a21_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i092375e2b99d47569a5f2b88a00b645c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4be4818227b84eeb8a47645a43378ca9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae0a865b8bbb423886ea964fbed8d991_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72fb329722534fb0a4ca4b9bf0f15d18_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1690154692b5483f8a0c27ebf8b7ea8c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia331e4fce5e04537ac0252d8c85aa3db_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i181e5dd0f5cf473ebe3032f6bdf59b2f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8558526a156344b6bc64e01cde3185fd_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i743620ea9f5e4eb5b6754c10390f4947_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a53051ca1af479a8e8848d3241934d7_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieee5f8f38b444a81a3531727a4653ee8_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i619b2ecf063d405c93c789d3a0e98721_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85efaefef16a413d938e44c4b5777c0e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib56ddb546f364c00b070ff8a2cab7021_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5b044d2e6b9422992ea59179bc567f3_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9973a4a90424a12a7dc55d2dce30953_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7939caa4e524cc88ac3e5aff4177860_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if337d9153dc545129019175c2d4f63ac_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i431ea463f15d497aac6934b546008514_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6e7f2c707054cd683451662d8ed7372_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:SubscriptionAgreementsAndWarrantExercisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i711b829d5ee345eebc50acfa4b930a61_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:SubscriptionAgreementsAndWarrantExercisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e011586eab7413c970320b1703ebf08_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:SubscriptionAgreementsAndWarrantExercisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9e589df88b2465ba4294cb791b7dc17_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:ATMTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iede14896071c4ee49fa119a80f14fbab_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:ATMTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia439f49486224935ad3477d5b4185130_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:ATMTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb4586bd1771477fae5877934605f9b3_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74784bdd498745d5ae511cab1b360837_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc519bce743c46c398e1d5dead4107f7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafa83b4739574d758beec4c0757ed122_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d3554a78cc8449d9aad5b8c1c4503fd_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f107ec3ae1e4116afeb1163e6492976_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb989f73c9d1445fa69a483600870562_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6eb68a3826b24dfe8726311fa8f753a4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia772fd167d25491e80c5e09f8d26ca55_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d2b34877c824fb39ecf988264920e54_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:ATMTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49fc5d8a06784ed3b66029a5fdb2c35b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:ATMTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4fa370f40af4910a583132f5726f913_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:ATMTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8964c98e4b14da7a9f597f5fed0edb0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i878a0f96a8194299acd620d27ea9d9bf_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cba47cf2f404ee9a035c63dae2423f3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib05383973c11499c94ee4d3e3f64f0b8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id86823ae63164e52b4c42f119b89ed4d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e710c24c8df431ba6ae05089ef01062_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if224aca6e98d4c9f87473c21091780ac_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7033dd63053e40b9b5c54b579a67eebc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>ocgn:segment</xbrli:measure></xbrli:unit><xbrli:unit id="dose"><xbrli:measure>ocgn:dose</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i3eb7b92dc9494a35b5033ab8674abe63_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="geneticmutation"><xbrli:measure>ocgn:geneticMutation</xbrli:measure></xbrli:unit><xbrli:unit id="product"><xbrli:measure>ocgn:product</xbrli:measure></xbrli:unit><xbrli:unit id="orphan_drug_designation"><xbrli:measure>ocgn:orphan_drug_designation</xbrli:measure></xbrli:unit><xbrli:context id="id5d5a29609664c35b78098fb9dd71398_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2a762caa8434142a4d6522864319751_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20ba81fe7dcd4e0d8c7f7e1bd42e7108_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ocgn:MachineryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i835d59b4a71c4ca48581fa3806494a4a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ocgn:MachineryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0845e0a879f4a8f9b00281ea8a23506_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib31b92c5c40747a3bd257cecf9f1c22b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1978e8a33197491fab4e85b515ca427c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:COVAXINPreferredStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ce37d1044984e42b76ce49925a5ea86_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i930c6519bb45486a8510eab5f83f11b2_D20190927-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocgn:CollaborationAgreementWithCansinoBiologicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-27</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83096eac0fe34c3aae4e263271cd518e_I20210413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5db9a3b809794a18ba41b819b7fb0e60_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11ce6b5f7e39456fa1c454b1333db3bf_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia025bf7e0a1345c280160a2e194f23fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3aea31e66e540dc9949d6f9c0490ecb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i812612c51e3f4f04bd8fb9b027a8a7ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d4ea904d71e4543b361e76a666f0756_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefda904c07ce43da981ece8db16559f3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fa83702d12344a2b6ed8e9210300c3c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i451fd097deb743d79f6ad34002e75526_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="renewaloption"><xbrli:measure>ocgn:renewalOption</xbrli:measure></xbrli:unit><xbrli:unit id="employee"><xbrli:measure>ocgn:employee</xbrli:measure></xbrli:unit><xbrli:context id="ic0c6fee7c66143fa90b7e09a8bd0054b_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6931d48727f42d1b569e46c6b6c8cf1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdfb9af1602f4e02a9cc734469158ec9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib105875697514235a32c3d55a59c407f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i892c2505d70d4215b4f0550ad9b0627e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02962ee3f8774d3c8d322068b02a66c8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8440034266a4aa291b14ebaf3980ba1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44daf8bae7c343758ee6b618e75c35f6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01a12a6485e345b6ab72567171ec0eb0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i058f0a613fdb4fac8d51eb184f27c5b6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92ea040ac4094cb2a62e60e72ca77b3c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i745fb75cca5b4c23886a4754e42262f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85638365ecb449f89cd737e151a543eb_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b1b73d8695b4c07b67f45b9ef51765e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0894763e64ad446393df6c07eb805c5f_I20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4082401304e4bc3881503b617da5ec7_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b01d2f4d0c54ea186a70f5469b418fa_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48e097bc118a40018d9f9179ffd7ca57_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1f83da91a62482bafefc243a5610119_D20210301-20210301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:COVAXINPreferredStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia223aa6547ab48e8a989ed4c643adeaa_I20210301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:COVAXINPreferredStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i246cca5ff04f4a438cabbffe4ac0798c_I20210429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefbd2c9026804907ae58afb0f262bb0d_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide0135d45c4941c9938e0383f70a9804_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:COVAXINPreferredStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4ef9e6106c44af9adc546620f7b1580_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90ca97f6066a4d9a810636493e1c9aac_D20210423-20210423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-23</xbrli:startDate><xbrli:endDate>2021-04-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77df7a80e56a4e8facf772024c0e4945_I20210423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5862a96aeadd4f89b932761cb5f2e124_D20210427-20210427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-27</xbrli:startDate><xbrli:endDate>2021-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15f4aa0e8bfb449a842dfc32748a2a55_D20210207-20210207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-07</xbrli:startDate><xbrli:endDate>2021-02-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a5e15fc5e9f4ab8b85dee2ee164fe5c_I20210207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8cedc3486594d78b30a563076ebf2ad_D20210210-20210210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-10</xbrli:startDate><xbrli:endDate>2021-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="at-the-marketoffering"><xbrli:measure>ocgn:at-the-marketOffering</xbrli:measure></xbrli:unit><xbrli:context id="i8b074737fd3840e3a89e6bc467ec5352_D20200501-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab0d59da4af045118182091dce3984c8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00ccc0ff720749b1b14d75b3c93faa0d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa7b11c7997941d7a2ebe1202ae40792_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8019c49fc2b41d8809f0fc4847ce9b0_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:SubscriptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5068c87588174140afe885f4e47d066a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:SubscriptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e02ac8495184af4af04566df93db8f7_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:SubscriptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8bd5469fd534b5fa1a3c3286b4599c4_I20210715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:CanadaConsultingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="seriesofwarrant"><xbrli:measure>ocgn:seriesOfWarrant</xbrli:measure></xbrli:unit><xbrli:context id="i1e39c130cffe499eaae2b4c55fef5b42_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24e2b7c0b5b1441cad39027ec7574d10_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if01d7fad0a3f48a8bd13b30a1b84b704_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99f2d4d98be64d7ea57dfff1f984ef8b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie002070f257c4c608068b1b07255b1d5_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:WarrantsExchangedForCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06658032e2704ab282cc346ef006ef8f_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:WarrantExchangePromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8612a2a4329d46479292b57b3cd408f0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:WarrantExchangePromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86fc446c1c3b4958be93eb3d966f598a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:WarrantExchangePromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6e306f60ac94b79a20c2e697c2d41e0_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SPAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a0df3b2c63543fd93b3be04483ec5a2_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0677fbde7da642e0bd593d8fa763f607_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04d1f309d9f74029a1b219a85f77a940_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:OpCoWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i275b6ac4e97c4be5aa1a51af8502831b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:OpCoWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae6a400180f04a07b8febf2d6e0fa554_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:OpCoWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0a8b70d6fb84c5a9789d450871ed83a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8acfe33635854458877463fc16a751b4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7caedf65c1494e419cbafa5a7b2af8d9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i830ec46fb29342e8a14435d6c8374e8f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34df5c33daa84097bbeb2f7aa78e9881_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d5d5de7375c464ebdd9941535b546d4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27f8c3a424b04ee8a9158f75127eec6e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfe523d076894ad581734cd76ae76f7e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6efde1790e4d4c3f820f75713f6e84b9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ocgn:ShareBasedPaymentArrangementPerformanceBasedOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe51744fe7ab46b2a3e9f306f2e205ef_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ocgn:ShareBasedPaymentArrangementPerformanceBasedOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab3b4c48ef4b48df90d794b934740c1f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ocgn:ShareBasedPaymentArrangementPerformanceBasedOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa3c7dd5eddd468da3b9df0f9934469a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ocgn:ShareBasedPaymentArrangementPerformanceBasedOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3571bc8a75ac48659cc316e5763f4ed2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05d88bc2fdb94bfb85adba0bb8b27884_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocgn:A2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcf0789a7cf8450dac2a8c051cc629b3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocgn:A2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8deb7fe79a024352817ef6e8af8f0441_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fe71549bdba4e09bf1e6455238c6445_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ocgn:ShareBasedPaymentArrangementPerformanceBasedOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78eaa94bd702419a8ec49cbc777b5ba7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ocgn:ShareBasedPaymentArrangementPerformanceBasedOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97535b68d960495f906585585e65538d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91c5fecaa1c64c49ad9e64d6f08ce782_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieee22d5c75984530a1d4feb9b3bd71e6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a2d954d52484db09e819f3e3cd26b4b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eef00380be74ee2b45ff66ba9497e4c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21ed7d9935d24634bdbfe1f4c69a732b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3904f01ad36d4b3796750e5c00692693_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d1c263247244eaaa85b9923b449d851_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89a977d9b97c40d9bc231523d757c614_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8bcebbd1f9f4a1fa9c7f2ecc3c2a2b4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb2b6076d55a4c4fbc505ce09032f9ec_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeb64bda41ad44658c1917090d93aee7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42cfc7b660d247bca3e1269304b94198_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb9ae3b6217944d08b6ef5b9486ae59c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia60015f8c05f4fb2a0ff02e090d1939c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e6344f1ce2a45b3b3086bff6d187fd7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04f8d6a8b17d410195fd2437e938b245_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1226d893b7c34174b451b927f02c2ad5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4aa5009a02d54151a673eb8679eca4f3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dfb43b76ce743459ec23fb4489a7d43_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife7f80154864442eb1f4fff86b29fb57_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia634f5e3056b43e9a810bc77f3d0f942_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i656ac6e78d97406398ff128f89376446_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c6b3eaa0af149b0b68069f2bcf0750e_I20211015"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="extension"><xbrli:measure>ocgn:extension</xbrli:measure></xbrli:unit><xbrli:context id="i1801f4052b89458296349d07431dc823_D20211015-20211015"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-15</xbrli:startDate><xbrli:endDate>2021-10-15</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">___________________________________________________________</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF8yMzA3_7de3de62-0dcd-48e2-9ec9-554e499bad90">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">___________________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGFibGU6NmQzZDQwY2U0Y2Q4NDVkZjk1YWU4M2Y3NWUwMmYwYzMvdGFibGVyYW5nZTo2ZDNkNDBjZTRjZDg0NWRmOTVhZTgzZjc1ZTAyZjBjM18wLTAtMS0xLTA_1d9040dd-a928-4ac1-bad4-d6008fbdeb97">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF8yMjk3_46848a11-ede7-4508-a099-2f4b87eb94b1">September 30, 2021</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGFibGU6OGExMDA4YmEzMjNhNGZmYmI1NGZkN2VkY2NjNjY5ZWUvdGFibGVyYW5nZTo4YTEwMDhiYTMyM2E0ZmZiYjU0ZmQ3ZWRjY2M2NjllZV8wLTAtMS0xLTA_07c9c5e5-727e-41a1-b203-914931152154">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF8yMzAx_da0d2faf-624d-4a07-bcbe-2a091612ff72">001-36751</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">___________________________________________________________</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF8yMzA4_275731aa-1d4c-4da9-9dd2-f36731827034">OCUGEN, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">___________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGFibGU6YmVmODNiNjZkMDZhNDk5Njg5ZjRkY2NhOTcyOTBmNjMvdGFibGVyYW5nZTpiZWY4M2I2NmQwNmE0OTk2ODlmNGRjY2E5NzI5MGY2M18wLTAtMS0xLTA_dff505b0-09c7-48e6-9fb2-3552c140db6e">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGFibGU6YmVmODNiNjZkMDZhNDk5Njg5ZjRkY2NhOTcyOTBmNjMvdGFibGVyYW5nZTpiZWY4M2I2NmQwNmE0OTk2ODlmNGRjY2E5NzI5MGY2M18wLTEtMS0xLTA_d9d1c38a-de45-4edc-b4dd-16efd7a1577c">04-3522315</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF8yMzAz_b96a211c-1621-4686-9c54-8914f1bfefd8">263 Great Valley Parkway</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF8yMjk4_4ede2fb8-6e48-4ccd-a8a4-23fa2bc3d123">Malvern</ix:nonNumeric>, <ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF8yMzA1_0c2e2a30-c83e-45ee-8e01-3ec2ac60178b">Pennsylvania</ix:nonNumeric> <ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF81NDA_cf4d151f-ba3c-427c-8bcf-34adbac8249b">19355</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF82MDU_fb57cdf0-0d0d-4a3c-b0ab-3a6e162d9d51">484</ix:nonNumeric>) <ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF8yMjk5_a4c0f8ac-8dee-473b-9a2f-822be2bdcbbd">328-4701</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">___________________________________________________________</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Trading<br/>symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGFibGU6Yzg4ODEyZTM4NjMwNDA4ZGE4OGNlYmE0MTkzYjc2MWYvdGFibGVyYW5nZTpjODg4MTJlMzg2MzA0MDhkYTg4Y2ViYTQxOTNiNzYxZl8xLTAtMS0xLTA_a648140a-2260-47b9-a7f7-98ce60829863">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGFibGU6Yzg4ODEyZTM4NjMwNDA4ZGE4OGNlYmE0MTkzYjc2MWYvdGFibGVyYW5nZTpjODg4MTJlMzg2MzA0MDhkYTg4Y2ViYTQxOTNiNzYxZl8xLTItMS0xLTA_75424880-5ef5-467d-b607-cbb09c602350">OCGN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGFibGU6Yzg4ODEyZTM4NjMwNDA4ZGE4OGNlYmE0MTkzYjc2MWYvdGFibGVyYW5nZTpjODg4MTJlMzg2MzA0MDhkYTg4Y2ViYTQxOTNiNzYxZl8xLTQtMS0xLTAvdGV4dHJlZ2lvbjowM2IzNjVlM2RjMDM0NmFjYmFkZGJlMWZiZTFiYTY2M180_82a8a7c1-9a43-4d6c-a960-d37612265365">The Nasdaq Stock Market LLC</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(The Nasdaq Capital Market)</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF8yMzA2_84d3fd11-8167-48c1-9d33-d510fece367a">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF8yMzAy_0a9548d0-404f-4980-9920-bea95ebdfb20">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGFibGU6ZDI0YWQzMDlkZjJkNDk3OWI2ZjU2NDNjZWQ1ZjVlY2UvdGFibGVyYW5nZTpkMjRhZDMwOWRmMmQ0OTc5YjZmNTY0M2NlZDVmNWVjZV8xLTAtMS0xLTA_851e23e9-c772-47dc-a832-87e158f26968">Non-accelerated Filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGFibGU6ZDI0YWQzMDlkZjJkNDk3OWI2ZjU2NDNjZWQ1ZjVlY2UvdGFibGVyYW5nZTpkMjRhZDMwOWRmMmQ0OTc5YjZmNTY0M2NlZDVmNWVjZV8xLTMtMS0xLTA_57f40c66-875d-40c4-a136-2705a85dcf58">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGFibGU6ZDI0YWQzMDlkZjJkNDk3OWI2ZjU2NDNjZWQ1ZjVlY2UvdGFibGVyYW5nZTpkMjRhZDMwOWRmMmQ0OTc5YjZmNTY0M2NlZDVmNWVjZV8yLTMtMS0xLTA_9f80b374-e87f-4534-984a-241c6abba3be">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B)&#160;of the Securities Act.&#160;&#160;&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;<ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF8yMzAw_b5940f64-1509-49a1-9e99-b2bb5ecfef47">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of November&#160;2, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i37c782c18fab4541b52948ee02ff0fe1_I20211102" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF8yMjE0_a74cd628-eccf-4a3c-a4c7-f02888522d51">199,185,877</ix:nonFraction> outstanding shares of the registrant&#8217;s common stock, $0.01 par value per share.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OCUGEN, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT ON FORM 10-Q</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.686%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_13">PART&#160;I&#8212;FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_16">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_16">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_19">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_19">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_19"> 30, 2021 and December 31, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_22">Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_22">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_22"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_22">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_22"> 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_25">Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit) for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_25">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_25"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_25">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_25"> 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_28">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_28">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_28"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_28">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_28"> 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_31">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_73">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_73">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_73">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_100">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_100">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_100">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_103">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_103">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_103">35</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_106">PART&#160;II&#8212;OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_106">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_109">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_109">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_109">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_112">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_112">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_112">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_115">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_115">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_115">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_118">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_118">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_118">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_121">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_121">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_121">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_124">Item&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_124">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_124">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_127">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_127">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_127">38</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_130">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_130">39</a></span></div></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless the context otherwise requires, references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us&#8221; in this report refer to Ocugen, Inc. and its subsidiaries, and references to &#8220;OpCo&#8221; refer to Ocugen OpCo, Inc., the Company&#8217;s wholly owned subsidiary.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form&#160;10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts contained in this Quarterly Report on Form 10-Q regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, and objectives of management are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," &#8220;will,&#8221; &#8220;would,&#8221; or the negative of such terms and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are based on assumptions and expectations that may not be realized and are inherently subject to risks, uncertainties, and other factors, many of which cannot be predicted with accuracy and some of which might not even be anticipated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Quarterly Report on Form 10-Q and contained in our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (&#8220;SEC&#8221;) on March 19, 2021 (the "2020 Annual Report") include, among other things, statements about:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements, and timing and availability of and the need for additional financing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain sufficient additional capital to continue to advance our product candidates and our preclinical programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our activities with respect to BBV152, known as COVAXIN outside the United States, our vaccine candidate for the prevention of COVID-19 caused by SARS-CoV-2 in humans, in collaboration with Bharat Biotech International Limited (&#8220;Bharat Biotech&#8221;), including our plans and expectations regarding clinical development, manufacturing, pricing, regulatory review and compliance, reliance on third parties, and commercialization, if authorized or approved in the United States and Canada;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our submission of a request to the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) for Emergency Use Authorization for COVAXIN for pediatric use in children ages two to 18 years in the United States, which was based on the results of a Phase 2/3 immuno-bridging pediatric clinical trial conducted by Bharat Biotech in India;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans regarding the submission of a Biologics License Application ("BLA") to the FDA for COVAXIN for ages 18 years and older, including the need for a Phase 3 immuno-bridging study to support a BLA submission as well as a safety-bridging study if required by the FDA;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully obtain adequate supply of COVAXIN from Bharat Biotech and to complete a technology transfer to Jubilant HollisterStier or another third-party manufacturer and engage such manufacturer on commercially acceptable terms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipated market demand for COVAXIN in the United States or Canada, including for both the pediatric and adult population;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which health epidemics and other outbreaks of communicable diseases, including the COVID-19 pandemic, could disrupt our business and operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the uncertainties associated with the clinical development and regulatory authorization or approval of our product candidates, including potential delays in the commencement, enrollment, and completion of clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market and the risk that products will not achieve broad market acceptance;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with regulatory schemes applicable to our business and other regulatory developments in the United States, Canada, and other foreign countries; including the extent to which developments with respect to the COVID-19 pandemic will affect the regulatory pathway available for vaccines in the United States, Canada, or other jurisdictions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the performance of third-parties upon which we depend, including third-party contract development and manufacturing organizations, and third-party suppliers, manufacturers, group purchasing organizations, distributors, and logistics providers;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing and reimbursement of our product candidates, if authorized or approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain patent protection, or obtain licenses to intellectual property and defend our intellectual property rights against third-parties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain our relationships, profitability, and contracts with our key collaborators and commercial partners; including with Bharat Biotech, and our ability to establish additional collaborations and/or partnerships;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recruit or retain key scientific, technical, commercial, and management personnel or to retain our executive officers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with stringent U.S., Canada, and other foreign government regulation in the manufacture of pharmaceutical products, including Good Manufacturing Practice compliance and other relevant regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic on our development programs, global supply chain, and collaborators and manufacturers, including Bharat Biotech; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other matters discussed under the heading &#8220;Risk Factors&#8221; contained in this Quarterly Report on Form 10-Q, the 2020 Annual Report, and in any other documents we file with the SEC.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report on Form 10-Q and in the 2020 Annual Report, particularly under the sections titled &#8220;Risk Factors,&#8221; that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, collaborations, or investments we may make.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. Except as required by law, we do not assume any obligation to update any forward-looking statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. We qualify all of our forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Solely for convenience, tradenames and trademarks referred to in this Quarterly Report on Form 10-Q appear without the &#174; or TM symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these tradenames or trademarks, as applicable. All tradenames, trademarks, and service marks included or incorporated by reference in this Quarterly Report on Form 10-Q are the property of their respective owners.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div><span><br/></span></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_16"></div><div><span><br/></span></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_19"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OCUGEN,&#160;INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMy0xLTEtMS0w_2ebd21bc-ac1a-4db3-9298-4225e6bd7511">107,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMy0zLTEtMS0w_ff063e09-19d6-43e8-ae6d-0efd895900c1">24,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advance for COVAXIN supply</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdvancesOnInventoryPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfNC0xLTEtMS0w_8a0121d0-9f98-45ba-b23f-320880b240fa">4,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AdvancesOnInventoryPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfNC0zLTEtMS0w_377713b0-de40-4281-b153-37d6c3975b85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfNS0xLTEtMS0w_7df98345-7ec5-4fb6-a6d0-4cdabe7aa19d">1,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfNS0zLTEtMS0w_f5135b1f-e3fe-4d6d-a7d4-cf30607f4e06">1,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfNi0xLTEtMS0w_9f92ec67-e30e-466f-9380-4871f51894f8">113,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfNi0zLTEtMS0w_e3141d7c-1019-4799-bf32-02844dbbbba8">25,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfNy0xLTEtMS0w_4e07083f-4120-4ba6-823d-aaecac486c55">1,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfNy0zLTEtMS0w_a99a2dc0-47b6-42a1-b4e4-4a4350105ac4">633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfOC0xLTEtMS0w_32a07304-9d9d-48bd-b39c-86d7ed20aa96">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfOC0zLTEtMS0w_5944d5f2-f304-4735-8d1d-553a45910b4e">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfOS0xLTEtMS0w_5575c07a-8710-4398-b8a9-4b4817500856">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfOS0zLTEtMS0w_741bedcb-bd52-46bd-b838-42ad30a84a0f">714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTAtMS0xLTEtMA_b995882b-c87c-420b-8f52-d52c8288205d">116,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTAtMy0xLTEtMA_98465a6b-b795-437a-a5b0-9da87a8eb31f">27,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTMtMS0xLTEtMA_f5d5178c-a79d-45b4-a466-ee3ff44abd71">2,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTMtMy0xLTEtMA_06f417bb-7725-42d1-b620-a3a4999ce299">395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTQtMS0xLTEtMA_2d8cb57a-7133-4b20-95cd-c0197f6b5f57">3,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTQtMy0xLTEtMA_60c9202b-a5a8-46da-bac7-2c611d5f019d">2,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ShortTermBorrowings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTUtMS0xLTEtMA_7d44c9c5-e160-4b09-995f-ae426ea3603a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" name="us-gaap:ShortTermBorrowings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTUtMy0xLTEtMA_781b63dc-770e-4495-9c47-4cfe47f6e98f">234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTYtMS0xLTEtMA_cb0b027d-3d57-4f7b-9bc1-c651a86e91e8">172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTYtMy0xLTEtMA_20639ad5-b72a-4f42-be32-752224f4dc0a">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTctMS0xLTEtMA_5de89138-841a-4719-9f24-83f1227c9801">6,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTctMy0xLTEtMA_75f47771-730b-4517-8c20-fb59713bdfa4">3,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligation, less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTktMS0xLTEtMA_bf4b6883-df37-41fa-8432-29be2860a3b9">1,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTktMy0xLTEtMA_c9efa736-d473-46e3-a8c7-e7c64aed0d9e">389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjAtMS0xLTEtMA_2ac289b1-42a3-43f5-9a13-2c37f9ca3cb3">1,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjAtMy0xLTEtMA_9ef0dc74-e217-496f-9203-1036309468b3">1,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjEtMS0xLTEtMA_64a833e0-6cfc-4f86-91da-cfc34be784c8">2,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjEtMy0xLTEtMA_3f68c22c-4f0a-4142-90ed-d95f4d32650b">2,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjItMS0xLTEtMA_e8086655-23b5-4dff-ba0f-4b70127b28c8">9,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjItMy0xLTEtMA_65a59c69-0d73-405a-acb3-f5157b3c444d">5,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 13)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjMtMS0xLTEtMA_699c3387-8c3a-4b9e-b9c9-21a62c48c83d"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjMtMy0xLTEtMA_068838a4-6a65-4f00-9ffd-98331e7f6000"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock; $<ix:nonFraction unitRef="usdPerShare" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjBhZWFiZTQxNGM1ZDQ5MjI5OTIzMWJlNGJjMzBhOWVjXzMz_3317d162-dfab-4605-9799-e41f1feb81cb"><ix:nonFraction unitRef="usdPerShare" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjBhZWFiZTQxNGM1ZDQ5MjI5OTIzMWJlNGJjMzBhOWVjXzMz_47edea46-262a-4936-9c23-8dd3522a17cd">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjBhZWFiZTQxNGM1ZDQ5MjI5OTIzMWJlNGJjMzBhOWVjXzQ3_7113986b-be47-4317-b3bf-f09272336683"><ix:nonFraction unitRef="shares" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjBhZWFiZTQxNGM1ZDQ5MjI5OTIzMWJlNGJjMzBhOWVjXzQ3_7d1c0132-0bba-481c-8653-1a2237255e89">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized at September&#160;30, 2021 and December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A; <ix:nonFraction unitRef="shares" contextRef="i68178daf3b96459db15e2b75995f88d1_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmVlY2EzNjM4OWE2NDQ5NDA5Mjg4NDUxMDczMWQ3NTYwXzE0_7051ef6a-b154-4312-b235-6050faae0698"><ix:nonFraction unitRef="shares" contextRef="i0aa9d9e8ef714df892f133c7484c0b4a_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmVlY2EzNjM4OWE2NDQ5NDA5Mjg4NDUxMDczMWQ3NTYwXzE0_934568cf-a9ed-4e75-bdbe-03d283342326"><ix:nonFraction unitRef="shares" contextRef="i68178daf3b96459db15e2b75995f88d1_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmVlY2EzNjM4OWE2NDQ5NDA5Mjg4NDUxMDczMWQ3NTYwXzE0_96a24ce6-63d3-471b-9de9-88684aa058af"><ix:nonFraction unitRef="shares" contextRef="i0aa9d9e8ef714df892f133c7484c0b4a_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmVlY2EzNjM4OWE2NDQ5NDA5Mjg4NDUxMDczMWQ3NTYwXzE0_b934d7c2-b3d7-48bf-b90a-5fd2b567ca5c">seven</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding at September&#160;30, 2021 and December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68178daf3b96459db15e2b75995f88d1_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjYtMS0xLTEtMA_6b59a55a-2eec-4dc6-b744-32fc8d45ed98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aa9d9e8ef714df892f133c7484c0b4a_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjYtMy0xLTEtMA_b007b200-7ee4-4826-b403-fbd2cfe80e23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B; <ix:nonFraction unitRef="shares" contextRef="i28b02ce452d34ea6b3c2e1dff6d45d00_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjE4YmY2YmM0NWZjODRlZWNiYzQwMzI0ZTFlOTAwMDZiXzE0_a5fa6a19-54c1-4131-96c9-10d52596da38"><ix:nonFraction unitRef="shares" contextRef="i28b02ce452d34ea6b3c2e1dff6d45d00_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjE4YmY2YmM0NWZjODRlZWNiYzQwMzI0ZTFlOTAwMDZiXzE0_e37aa7c1-442d-45f9-94de-49d6045f2977">54,745</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i552c85d6331e4cad97ea9f15ee20104a_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjE4YmY2YmM0NWZjODRlZWNiYzQwMzI0ZTFlOTAwMDZiXzIx_9b39ab2b-5a5e-4631-a73c-f3741bdf34af"><ix:nonFraction unitRef="shares" contextRef="i552c85d6331e4cad97ea9f15ee20104a_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjE4YmY2YmM0NWZjODRlZWNiYzQwMzI0ZTFlOTAwMDZiXzIx_ac2343b7-9c63-4cf8-8447-44126ccd82b0">zero</ix:nonFraction></ix:nonFraction> issued and outstanding at September&#160;30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b02ce452d34ea6b3c2e1dff6d45d00_I20210930" decimals="-3" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjctMS0xLTEtMA_7e420874-578f-475f-87f9-948a4557330d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i552c85d6331e4cad97ea9f15ee20104a_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjctMy0xLTEtMA_a8e06a90-ce47-489e-9173-9b3e2bebb480">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock; $<ix:nonFraction unitRef="usdPerShare" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmJiNzk4MjE5MTNmODRmM2E4MTQ5YzkyZDM3YmFmMzA2XzE4_432da948-dc48-45d5-87f4-276c28085d20"><ix:nonFraction unitRef="usdPerShare" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmJiNzk4MjE5MTNmODRmM2E4MTQ5YzkyZDM3YmFmMzA2XzE4_7eeb2967-cb91-4d19-938d-5b87bb08079c">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmJiNzk4MjE5MTNmODRmM2E4MTQ5YzkyZDM3YmFmMzA2XzMy_916204e1-ca35-4cf2-8a82-db05ef3ab0d1">295,000,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmJiNzk4MjE5MTNmODRmM2E4MTQ5YzkyZDM3YmFmMzA2XzM5_c9289fee-4be8-4ada-bbe6-84063d1816f5">200,000,000</ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmJiNzk4MjE5MTNmODRmM2E4MTQ5YzkyZDM3YmFmMzA2XzYx_9cb81701-3217-414c-abe8-f194afc63e6c">199,049,329</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmJiNzk4MjE5MTNmODRmM2E4MTQ5YzkyZDM3YmFmMzA2XzY4_bd101612-4b59-460a-aa33-f6dea7988732">184,133,384</ix:nonFraction> shares issued, and <ix:nonFraction unitRef="shares" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmJiNzk4MjE5MTNmODRmM2E4MTQ5YzkyZDM3YmFmMzA2Xzkw_9455943d-7d49-4ea9-a405-ff9792c41e0f">198,927,829</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmJiNzk4MjE5MTNmODRmM2E4MTQ5YzkyZDM3YmFmMzA2Xzk3_eb0b17c0-92d8-4d70-b3e1-f67772bf1247">184,011,884</ix:nonFraction> shares outstanding at September&#160;30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjgtMS0xLTEtMA_12ec823c-752a-4090-ad54-9ecc2ff1e2cf">1,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjgtMy0xLTEtMA_70decc32-d75b-45cb-b5f5-4ddc60ee6062">1,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost, <ix:nonFraction unitRef="shares" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjM4ZjNkZWI2ZTAyODRiYjg4YWU4ZDBmODRlNTEyMzQ0XzI5_3e05ba2c-4600-4817-bd54-bea4b375781a"><ix:nonFraction unitRef="shares" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjM4ZjNkZWI2ZTAyODRiYjg4YWU4ZDBmODRlNTEyMzQ0XzI5_7070be8a-d484-4726-b427-624608489957">121,500</ix:nonFraction></ix:nonFraction> shares at September&#160;30, 2021 and December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjktMS0xLTEtMA_148c66d2-b0c0-4bea-ace1-05ecf49da022">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjktMy0xLTEtMA_9aae3ebc-3cb5-46be-b687-527ff8a43222">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMzAtMS0xLTEtMA_f67af93c-866a-4c2c-b143-63fb6bcfdf61">222,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMzAtMy0xLTEtMA_0a19b253-2c04-4106-8364-283e0168b8da">93,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMzEtMS0xLTEtMA_19c89db9-bed6-4f9f-a3b0-779ae365f832">117,086</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMzEtMy0xLTEtMA_946ac030-174b-4ad4-b908-275e3da8564e">73,302</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMzItMS0xLTEtMA_9766d76b-eaba-45ec-8477-5e8eaa45cf72">107,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMzItMy0xLTEtMA_7f1fb959-2a9f-4fb5-8a03-f5c1197edb71">21,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMzMtMS0xLTEtMA_0e43fb88-1648-4b48-9152-70bd4e216e4d">116,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMzMtMy0xLTEtMA_feacd00b-336b-471f-b829-0165d09c4a69">27,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OCUGEN,&#160;INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMy0xLTEtMS0w_a670ad2d-984f-450a-9fe9-4be07bc29570">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMy0zLTEtMS0w_f235b3c1-71e6-4439-b53d-b79014cc0ef7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMy01LTEtMS0w_3753d65f-5f15-42ab-b2da-502b62f60511">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMy03LTEtMS0w_d04e4456-76fe-45f9-bf7f-473af6c78331">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfNC0xLTEtMS0w_5dffd211-143d-4aad-9281-a03855b7b0c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfNC0zLTEtMS0w_62a8a6b3-ada2-48c2-947d-067cdeb07047">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfNC01LTEtMS0w_84ce4000-83f1-4867-b327-c0aa3a5c6c70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfNC03LTEtMS0w_2fdb61f1-3ae2-4a42-9ba1-fb6e55edc55e">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfNi0xLTEtMS0w_92fc4f32-0e90-4dcb-b17e-bc5acdcf5a9b">6,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfNi0zLTEtMS0w_2ee03027-53b7-4c73-bc96-e76a18fa2348">1,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfNi01LTEtMS0w_104227f6-a1ed-4f24-a65c-f556935c2022">28,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfNi03LTEtMS0w_605d02a8-6362-43fd-956b-2b65e731c5d7">4,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfNy0xLTEtMS0w_e35c8703-9839-402f-a77e-30a2558caa42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfNy0zLTEtMS0w_d59449b8-f420-4cd5-b2f5-9ebae177179b">7,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfNy01LTEtMS0w_5e4e8f10-5218-4df0-9148-b7d7cdd45ec5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfNy03LTEtMS0w_1892b848-898d-437f-afec-8acbcbd2c3b9">7,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfOC0xLTEtMS0w_197b93a5-389c-4ca1-a7bc-c90844c9cbf8">4,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfOC0zLTEtMS0w_707cc179-2cc5-4904-96f4-9a08f11ea234">1,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfOC01LTEtMS0w_5204b8d1-ccaa-4d6a-b1fc-1d0094572a73">15,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfOC03LTEtMS0w_682ef4a2-5b01-44b6-93b9-6739c4d09125">5,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfOS0xLTEtMS0w_d344f02e-9f67-4640-84e0-c086872b2d51">10,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfOS0zLTEtMS0w_33080b53-b22c-4ff5-b9ac-aaa193758f2a">10,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfOS01LTEtMS0w_94eee86a-98ea-4070-a8b7-798efe768fbb">43,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfOS03LTEtMS0w_0f890925-0a97-4e51-b93d-eada2e6d8432">17,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTAtMS0xLTEtMA_5a380af2-eb9a-42cc-85bb-364e55863291">10,789</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTAtMy0xLTEtMA_2637a775-b69f-446d-9086-aaa445c8c8c4">10,182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTAtNS0xLTEtMA_2e55d663-21ad-498c-99a8-d83e8880089c">43,456</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTAtNy0xLTEtMA_b6cafd25-400d-4d83-81fd-6211538edf46">17,477</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTItMS0xLTEtMA_0344d669-9f00-4deb-ad4f-2e9a2e4f932f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTItMy0xLTEtMA_2aa6d649-e315-4b03-bd69-a78f53675974">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTItNS0xLTEtMA_116e2583-eaa1-4ac3-9c88-ca5c8b481881">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTItNy0xLTEtMA_177bb3ea-0556-45ab-ba89-4f4c1bf58a0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTMtMS0xLTEtMA_d61389ad-aabd-4070-9203-0177f8e34d64">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTMtMy0xLTEtMA_e3de8c49-a0be-4132-952c-56a2f169a745">292</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTMtNS0xLTEtMA_e635a147-082c-4aee-9504-5e80121a551e">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTMtNy0xLTEtMA_1575f292-b6c2-4688-82b8-e68a2c120d65">555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTQtMS0xLTEtMA_3619d9d9-19c5-453c-9b4c-8306f97d3fd2">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTQtMy0xLTEtMA_7b102d24-46c1-4710-8473-a0161d8667b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTQtNS0xLTEtMA_a85bea18-6c96-470e-9c61-b91d98b650c1">336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTQtNy0xLTEtMA_bd772dc4-7ded-484e-be9c-929ca21ce640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTUtMS0xLTEtMA_9ed9b219-9dcf-42ad-b25f-4a43b23b9371">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTUtMy0xLTEtMA_0ef08ae4-d9bc-48fc-93e1-934a5f96dbbc">292</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTUtNS0xLTEtMA_abc87bc7-bf54-4065-a403-bdcabf952dc9">380</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTUtNy0xLTEtMA_41b2bb3b-b6bd-4d38-b086-5790dc0708a1">555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTYtMS0xLTEtMzM0ODg_f8bcc554-4d41-49db-9611-ada56ae5383d">10,807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTYtMy0xLTEtMzM0ODg_c208f031-cabd-48a1-896b-40f3be0c4fa4">10,474</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTYtNS0xLTEtMzM0ODg_cecfaf09-a592-4a83-a8d0-0febd8a52848">43,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTYtNy0xLTEtMzM0ODg_c3ab767b-caea-4ccb-bcf4-f76e5ca89f28">18,032</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTctMS0xLTEtMzM0ODg_de6f0946-2ef6-43a8-952b-fbd6ccbe85fb">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTctMy0xLTEtMzM0ODg_5368821d-1919-430c-a1c8-83a02bb7bd35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTctNS0xLTEtMzM0ODg_a34381f1-8b68-4583-b4f6-2d1176b70bf9">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTctNy0xLTEtMzM0ODg_8b943d65-e55a-4323-8554-9e7da0a770f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTYtMS0xLTEtMA_24be3b5b-61b8-4250-a2ff-7dff8d1f7a1a"><ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTYtMS0xLTEtMA_a012501e-ce1a-40b8-8dd1-58612b9cf108">10,755</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTYtMy0xLTEtMA_3e914785-5501-4003-8981-c459a27f9d89"><ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTYtMy0xLTEtMA_9fc574e5-24f2-4be0-bca6-14a4306b10b7">10,474</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTYtNS0xLTEtMA_0fe9698d-ba0b-4473-a401-4be0e472799a"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTYtNS0xLTEtMA_4bd0b560-828b-4731-bd53-a8d1ddfb4e77">43,784</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTYtNy0xLTEtMA_4dd4d7ca-2ad4-4b71-8bc1-d0a721cbb8a4"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTYtNy0xLTEtMA_4e3f82db-8eaf-4366-ae98-c5afbe1ca712">18,032</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend related to Warrant Exchange</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTctMS0xLTEtMA_7189559a-64ad-4d27-9ce8-cd8cd12d97b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTctMy0xLTEtMA_d0b1d3eb-ace9-4b61-8f92-9b3303deeea5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTctNS0xLTEtMA_ea5b62de-a295-410a-a020-3cdbe51be17c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTctNy0xLTEtMA_de5826f1-1e56-4b1a-82ce-04307a0626ee">12,546</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTgtMS0xLTEtMA_31e2ec02-1016-4caf-bceb-5cd7afc3cadf">10,755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTgtMy0xLTEtMA_6f511037-d285-479a-bcdc-d5bcba1b1caf">10,474</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTgtNS0xLTEtMA_24449db0-a29d-4f09-9caf-e75561becf2e">43,784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTgtNy0xLTEtMA_5b56f2a0-f74a-427e-a441-8fd8eeff68b4">30,578</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in calculating net loss per common share &#8212; basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjAtMS0xLTEtMA_7a2916d5-a798-400a-8fd3-022e21583430"><ix:nonFraction unitRef="shares" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjAtMS0xLTEtMA_c0906105-c7a1-4b2a-8584-eac9f18ab700">198,790,980</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjAtMy0xLTEtMA_36595e09-cf81-4896-90e0-7390a04d14b8"><ix:nonFraction unitRef="shares" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjAtMy0xLTEtMA_f0cb2bf6-6106-4072-aea9-87d0c6326ede">141,591,218</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjAtNS0xLTEtMA_2d67b44a-910d-4001-bfff-484990363d85"><ix:nonFraction unitRef="shares" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjAtNS0xLTEtMA_3f0457d9-1060-4564-9392-c99887f868e3">193,599,525</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjAtNy0xLTEtMA_43aba45d-d6f3-4da1-a211-cd7f1ee12746"><ix:nonFraction unitRef="shares" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjAtNy0xLTEtMA_ee8672d0-c974-4ec3-b28f-2e1354a95ffd">92,764,157</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of common stock &#8212; basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjEtMS0xLTEtMA_d674b57b-0fae-4604-8a33-9b0b32d435eb"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjEtMS0xLTEtMA_f1b88b98-8b84-4499-90b2-0a0f55a833a6">0.05</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjEtMy0xLTEtMA_25ad9b8c-bb29-4e40-bca0-16573d2c3074"><ix:nonFraction unitRef="usdPerShare" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjEtMy0xLTEtMA_607a3582-010c-4e2d-962e-b9a64311c4e8">0.07</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjEtNS0xLTEtMA_7978457e-59ba-4cde-b640-ee6d640be29f"><ix:nonFraction unitRef="usdPerShare" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjEtNS0xLTEtMA_f25d64a5-4e74-4e02-a4a6-d2e0636ef6b0">0.23</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjEtNy0xLTEtMA_5b7dda49-8556-42d1-a173-48294b75a7f9"><ix:nonFraction unitRef="usdPerShare" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjEtNy0xLTEtMA_7fe76218-97fe-45c6-a47e-b2d3beba8082">0.33</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OCUGEN,&#160;INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.813%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i429a8518eebf4e0cb714c17e78e150bb_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMi0xLTEtMS0w_2824cfb3-54dc-4726-a392-b9561e90b910">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i429a8518eebf4e0cb714c17e78e150bb_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMi0zLTEtMS0w_4f1884de-d72d-42db-9d1a-e5c25aa834e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd58335a3dab4d87a7550d4a5dd940cd_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMi01LTEtMS0w_abadb636-5530-4518-8716-728ee03585e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd58335a3dab4d87a7550d4a5dd940cd_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMi03LTEtMS0w_343a5249-2a48-471e-890b-6f8b94aadf4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ad0bf3a315f43d3b971e83e4328a6c4_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMi05LTEtMS0w_2cf61b92-67a7-441b-a2cb-d7962bed510d">184,133,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ad0bf3a315f43d3b971e83e4328a6c4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMi0xMS0xLTEtMA_9c75a388-8c9b-4a2d-8028-c559e05f0dc8">1,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03ee12167fe649b08a8573352b78366f_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMi0xMy0xLTEtMA_a412807a-3662-4af8-b8e1-8379593d52bc">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7ffe1af99e468485a7fa0473a357c5_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMi0xNS0xLTEtMA_284172ed-3696-4668-8eef-72de2190b849">93,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63c582794c9241548ff9038b8f5f5a27_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMi0xOS0xLTEtMA_59e04768-90d7-44ac-82ce-a358307a4de2">73,302</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMi0yMS0xLTEtMA_3e216311-b4cc-428a-8f83-7388a741eb98">21,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebacd414b4044a8fbc5c8c5207a7b86f_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMy0xNS0xLTEtMA_fe31c671-23eb-449a-81a4-39ba7c650954">833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib511b5a36eaf40048ec9ee98f00551c1_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMy0yMS0xLTEtMA_84cdae39-67ab-44b9-9e5b-3f7de6976ea2">833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9d460c203374d7880f0ec3fae34b578_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNC05LTEtMS0w_5279b91e-96d9-4559-93bc-e25f44612d5c">157,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d460c203374d7880f0ec3fae34b578_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNC0xMS0xLTEtMA_a49bc805-2c1e-4124-985d-0298be5166c6">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebacd414b4044a8fbc5c8c5207a7b86f_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNC0xNS0xLTEtMA_4a58c3f1-a925-497b-9ce2-4b4f2b67d93d">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib511b5a36eaf40048ec9ee98f00551c1_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNC0yMS0xLTEtMA_77431e53-cde2-488d-b1c9-fd5520cd5074">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">At-the-market common stock issuance, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i221ecffa66144040873151eb590dd8b3_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNS05LTEtMS0w_0439a765-5bac-458b-ae42-3fad05b927a1">987,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221ecffa66144040873151eb590dd8b3_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNS0xMS0xLTEtMA_33667c6e-1d5d-49b5-9382-5dbae18f99f5">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ffbcae57d0459f8b8815522daa3dc3_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNS0xNS0xLTEtMA_c20adb2f-e14d-4644-bddf-fddfc68f834b">4,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b6cae5ed98647219290e0100ca91343_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNS0yMS0xLTEtMA_5d33d6b9-966c-411c-a38e-1b95bef7ea34">4,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Registered direct offering common stock issuance, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2588abf7c6e477fbe29c509564b8f4b_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNi05LTEtMS0w_7940925c-2062-4667-bbf6-73f4a6f64032">3,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2588abf7c6e477fbe29c509564b8f4b_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNi0xMS0xLTEtMA_1064758c-0ebe-4d35-9a99-ce99391f314c">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i442e9159fb0046dcaf7dd1b46149c00e_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNi0xNS0xLTEtMA_23a0c798-b38b-4551-9324-1c41a27bbd83">21,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dadc3f8b824b8c91fc0f114505344d_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNi0yMS0xLTEtMA_2b259250-0382-4beb-be2d-b47c66251af2">21,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock issuance, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if996ab97fcf74a548c34b4f5941439b4_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNy01LTEtMS0w_ed51b10e-2372-4be6-9cd0-87442476827f">54,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if996ab97fcf74a548c34b4f5941439b4_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNy03LTEtMS0w_a077a839-7055-49fc-8232-f7945667c8cb">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d4430baa0f44abb229c0dd32cdcbae_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNy0xNS0xLTEtMA_988a899e-d599-4a62-a4b2-5b2dba8c56a5">4,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86140f763e9c47098d573fe17ae24f7d_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNy0yMS0xLTEtMA_9692684b-ddb7-460f-9636-959caa659e15">4,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cdbf08cfea2418e9a09ae632d0e329d_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfOC0xOS0xLTEtMA_1e1d31f5-eedf-47e9-beb9-9f3236ae635a">7,077</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib511b5a36eaf40048ec9ee98f00551c1_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfOC0yMS0xLTEtMA_68c76649-bb78-4787-aa43-85b9e0b3976a">7,077</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c3ef4ab08b246bea75a9049a1509d61_I20210331" decimals="INF" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfOS0xLTEtMS0w_790b2ad8-3a40-440d-9558-88af6d83cac6">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3ef4ab08b246bea75a9049a1509d61_I20210331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfOS0zLTEtMS0w_ef377a59-aa49-441e-912f-6d1eb7744339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9466d66e75764cf9aefaf1eb61c6a86a_I20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfOS01LTEtMS0w_4af09779-a62d-42db-b3e5-fca8d6b20393">54,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9466d66e75764cf9aefaf1eb61c6a86a_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfOS03LTEtMS0w_8f1da8a7-ca75-45f2-8c1e-627b68459f3d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28b699982fb94ef9b501dc59505bd27b_I20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfOS05LTEtMS0w_7be59f15-15d8-4c60-a26d-4d08d2955944">188,277,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b699982fb94ef9b501dc59505bd27b_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfOS0xMS0xLTEtMA_64a4e5c9-5fbc-44c6-b8db-27cec93bcead">1,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bfcaa4bfe9b4fd88d8461664e684474_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfOS0xMy0xLTEtMA_59a2f9c7-789f-4f5e-b64f-d5d6e883be37">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb8526a2a5a242e7812303c1e35ea461_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfOS0xNS0xLTEtMA_f898f9bb-4553-4837-aa4d-3a6d7df8ca3e">125,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib42ad3d8f0264d0d8f1893b83054daf9_I20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfOS0xOS0xLTEtMA_03d4713f-b3d4-4445-b072-410f41a2ceae">80,379</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if26f766056584bd6b3d8be57c4c75510_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfOS0yMS0xLTEtMA_ee402eb4-1620-4aab-9981-7c978a931a7e">46,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd48f822ec024053ba61f26d03cd9402_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTAtMTUtMS0xLTA_96dadc18-3c7d-4c80-bd04-af6e70ef0a0a">2,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d28352102d488e81a31df53860a386_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTAtMjEtMS0xLTA_220b036b-d953-446f-a208-8688c8248e91">2,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for option and warrant exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5af0d4e54fa04902b86c568fffb94928_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="ocgn:StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTEtOS0xLTEtMA_1154c050-cf22-4db5-907e-eb990e4a72f5">538,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5af0d4e54fa04902b86c568fffb94928_D20210401-20210630" decimals="-3" name="ocgn:StockIssuedDuringPeriodValueOptionsAndWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTEtMTEtMS0xLTA_3ceffe5b-115b-42b3-8b42-307fdfad1129">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd48f822ec024053ba61f26d03cd9402_D20210401-20210630" decimals="-3" name="ocgn:StockIssuedDuringPeriodValueOptionsAndWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTEtMTUtMS0xLTA_d3c2f81e-ff50-4db5-bd13-bd676b91be73">366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d28352102d488e81a31df53860a386_D20210401-20210630" decimals="-3" name="ocgn:StockIssuedDuringPeriodValueOptionsAndWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTEtMjEtMS0xLTA_fb117d47-0061-48b9-866e-5bf8c8c88b00">371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Registered direct offering common stock issuance, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib49cc7013dca487eac750b80929881ce_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTItOS0xLTEtMA_82c6258e-6f6f-4f5e-9322-66724f358a22">10,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib49cc7013dca487eac750b80929881ce_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTItMTEtMS0xLTA_4bc22bb2-4452-44cf-94c6-ae879a1a97f6">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf8f98fd3caa4d46bcf11d8083135a3c_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTItMTUtMS0xLTA_ee34f8d1-e5ff-4807-865b-2f128a375ede">93,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0071733638ed4178b0c2f37e29b4c541_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTItMjEtMS0xLTA_c88e9f1d-d83b-4226-80d9-296dfcd55d8b">93,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id63858f31e204ae6b02d0f95495b173a_D20210401-20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTMtMTktMS0xLTA_bb46f4b3-7121-4305-93fe-314811f09119">25,952</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24d28352102d488e81a31df53860a386_D20210401-20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTMtMjEtMS0xLTA_a3c3af93-a97b-4f4e-8408-9e8f43f91dd0">25,952</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf7c1094d10a4d97959c21e8669b2a25_I20210630" decimals="INF" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTQtMS0xLTEtMA_79924985-8ac8-4583-a02d-acc2a9c06b1a">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf7c1094d10a4d97959c21e8669b2a25_I20210630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTQtMy0xLTEtMA_f01fcc2f-1fe5-4e39-95ad-d323273b6805">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44f7ffb2eea24ee9a6de6a5ce40eef9e_I20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTQtNS0xLTEtMA_e43b154e-8c01-4bf2-a137-075548dac0fa">54,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44f7ffb2eea24ee9a6de6a5ce40eef9e_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTQtNy0xLTEtMA_beb8c10b-3740-4dae-bf70-12c280a39331">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i098bebd384304520a79fe2559dfb9c27_I20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTQtOS0xLTEtMA_4e0d1214-ecdd-4803-826f-9e14ee5d5038">198,816,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i098bebd384304520a79fe2559dfb9c27_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTQtMTEtMS0xLTA_a2e99fae-9b42-4c12-8707-d72e4c2cf71d">1,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie51ec8f7c79f40878c0fde67d905e922_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTQtMTMtMS0xLTA_98c6c87e-c58c-4f4c-b9d9-0b8bbc3e1509">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf94f103b7b048a097f0defcf2650f43_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTQtMTUtMS0xLTA_d58c36ad-1e97-4414-8a44-c72b36e4238b">220,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0775f4cfa17343e6913d2da04f38f67a_I20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTQtMTktMS0xLTA_20b6ef02-362a-4ece-9f70-fdddb5dd0bd6">106,331</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0f6174d8ece4a44b930465233df749d_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTQtMjEtMS0xLTA_d992f06a-207a-4cb7-afad-a85976db9ea8">116,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f39d7650e794a7b81d454b1bb5ac6cd_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTUtMTUtMS0xLTMw_21980ac8-1ec4-4f92-9efe-5adcce9f5bcb">1,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTUtMjEtMS0xLTQ2_7351f53d-7d62-494a-8b5a-27a96810c596">1,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ff2e3800b044563861e8dbb3d568544_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTYtOS0xLTEtMjkxNDE_cb9046e2-2304-494c-a9f5-e9a0270fb2a5">232,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ff2e3800b044563861e8dbb3d568544_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTYtMTEtMS0xLTI5MTQx_7804f815-3711-44a4-bbe3-57df5e873910">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f39d7650e794a7b81d454b1bb5ac6cd_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTYtMTUtMS0xLTI5MTQx_25624325-0268-4be5-8028-062727516e3b">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTYtMjEtMS0xLTI5MTQx_0ea0b0c3-daa6-43f0-965e-b8aa4baec1fe">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df3c91a1e2141808ceb139a8c692d4f_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTYtMTktMS0xLTMw_49cc143b-26fb-490e-bba2-5cfe66a5e370">10,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTYtMjEtMS0xLTQ2_b21d0013-25ff-4e74-bc65-6240e121da19">10,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e80709cb7a44684bc5d9a7c7d3d7fdc_I20210930" decimals="INF" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTctMS0xLTEtMzA_fafb3c55-f44a-43a0-a25b-490203d203fa">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e80709cb7a44684bc5d9a7c7d3d7fdc_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTctMy0xLTEtMzA_36ca400e-dc64-44bc-8953-4b5662c7f0c4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ceacdb4b4eb427992b8f810605259bb_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTctNS0xLTEtMzA_cc0009a0-d443-46e9-813d-2cb6996bba34">54,745</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ceacdb4b4eb427992b8f810605259bb_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTctNy0xLTEtMzA_16fdde93-e131-4abc-a320-01489f9ea7f6">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if74b21443ee54787a0b6b5788b176165_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTctOS0xLTEtMzA_1e4b16e1-8803-46a9-bc3d-2d7c4d0a0ac3">199,049,329</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if74b21443ee54787a0b6b5788b176165_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTctMTEtMS0xLTMw_3c27cf60-e51a-4877-b377-181ff0ff952e">1,990</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bcc6879e812488a8c638047e2739ebd_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTctMTMtMS0xLTMw_7bdd09f9-9ec5-4c43-9412-cf818d50ef38">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb3652c42f6d42209a1beabd6597843e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTctMTUtMS0xLTMw_4f383017-c746-4c88-abc2-09c142db0e8c">222,253</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4a4fa5cea03410b9c6bd3abe049132a_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTctMTktMS0xLTMw_ce99159b-de06-4e1c-aa1a-ccc9c6210858">117,086</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTctMjEtMS0xLTQ2_af8293db-91d8-4662-bb73-d600d678a60c">107,110</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OCUGEN,&#160;INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT) (CONTINUED)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.813%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaeb9a66837754ddcabb2a790c8f98a21_I20191231" decimals="INF" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMi0xLTEtMS0w_6b09668c-15b8-44b7-83e1-6b58e2429856">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb9a66837754ddcabb2a790c8f98a21_I20191231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMi0zLTEtMS0w_7f7eae7d-d51d-4b73-9b8e-9a77944ca837">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i092375e2b99d47569a5f2b88a00b645c_I20191231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMi01LTEtMS0w_e9c54dcf-ea0e-4351-b70a-3dd7b53fb513">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092375e2b99d47569a5f2b88a00b645c_I20191231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMi03LTEtMS0w_9dbb622e-d07b-4d47-a4f0-36126332e1d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4be4818227b84eeb8a47645a43378ca9_I20191231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMi05LTEtMS0w_9e033a39-0154-4caa-a2f9-59077af24c2a">52,746,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4818227b84eeb8a47645a43378ca9_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMi0xMS0xLTEtMA_b5183880-77ae-442b-913e-8fec2dfd5d62">528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae0a865b8bbb423886ea964fbed8d991_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMi0xMy0xLTEtMA_3e11e0f8-8724-4e4e-8786-e859398d0445">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72fb329722534fb0a4ca4b9bf0f15d18_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMi0xNS0xLTEtMA_fca1c4a4-7112-49f7-becb-a4103c2b1590">62,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1690154692b5483f8a0c27ebf8b7ea8c_I20191231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMi0xOS0xLTEtMA_b612582f-fbea-4485-a0d3-322dc023311b">51,480</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia331e4fce5e04537ac0252d8c85aa3db_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMi0yMS0xLTEtMA_0925837b-9ff5-4a61-a203-02eeadcc1c52">11,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i181e5dd0f5cf473ebe3032f6bdf59b2f_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMy0xNS0xLTEtMA_d0e27e16-5c96-448b-a6dc-b9f1b35cf7d4">222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8558526a156344b6bc64e01cde3185fd_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMy0yMS0xLTEtMA_c0a28367-b6aa-45ed-b775-7447a7926f54">222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i743620ea9f5e4eb5b6754c10390f4947_D20200101-20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNC0xOS0xLTEtMA_43153485-7eaf-481b-9514-3b1d57d4bc7b">3,944</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8558526a156344b6bc64e01cde3185fd_D20200101-20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNC0yMS0xLTEtMA_bd1100cf-9fdd-4052-9228-e5e4e8e4280d">3,944</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9a53051ca1af479a8e8848d3241934d7_I20200331" decimals="INF" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNS0xLTEtMS0w_aeabbb5b-10e7-4588-af0a-5662f75baa5b">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a53051ca1af479a8e8848d3241934d7_I20200331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNS0zLTEtMS0w_c6599cec-9987-47b3-b931-6911b7d86cf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieee5f8f38b444a81a3531727a4653ee8_I20200331" decimals="INF" format="ixt:fixed-zero" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNS01LTEtMS0w_86dd31fd-39b7-4259-8b3c-bb02e8664776">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieee5f8f38b444a81a3531727a4653ee8_I20200331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNS03LTEtMS0w_3f7819aa-826a-4cfa-bde7-24ac1aa978dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i619b2ecf063d405c93c789d3a0e98721_I20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNS05LTEtMS0w_d5f2ffad-4d96-4981-9947-89f27d4b7570">52,746,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i619b2ecf063d405c93c789d3a0e98721_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNS0xMS0xLTEtMA_3a0ebebd-a825-4ea4-931d-01130bade240">528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85efaefef16a413d938e44c4b5777c0e_I20200331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNS0xMy0xLTEtMA_67798541-1f22-4564-a6b2-fe376baccbf5">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56ddb546f364c00b070ff8a2cab7021_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNS0xNS0xLTEtMA_507702e5-baad-447c-a309-5b2c3ce0ee46">62,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5b044d2e6b9422992ea59179bc567f3_I20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNS0xOS0xLTEtMA_da344434-fcd1-402f-858e-d83454fce6cf">55,424</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9973a4a90424a12a7dc55d2dce30953_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNS0yMS0xLTEtMA_ee66397c-033c-4c88-b6df-bfc87feb6cb8">7,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7939caa4e524cc88ac3e5aff4177860_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNi0xNS0xLTEtMA_bf69eb50-da3b-4ae5-9fe3-d823f3d4290f">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if337d9153dc545129019175c2d4f63ac_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNi0yMS0xLTEtMA_fd8ef64c-462c-4246-96e7-bcec14370494">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrant Exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i431ea463f15d497aac6934b546008514_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="ocgn:StockIssuedDuringPeriodSharesWarrantExchange" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNy05LTEtMS0w_4d732e42-069f-49ea-9cf6-f5579c30b5f3">21,920,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i431ea463f15d497aac6934b546008514_D20200401-20200630" decimals="-3" name="ocgn:StockIssuedDuringPeriodValueWarrantExchange" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNy0xMS0xLTEtMA_dae6e75a-b8e7-4491-ade3-df5b97afd965">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7939caa4e524cc88ac3e5aff4177860_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="ocgn:StockIssuedDuringPeriodValueWarrantExchange" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNy0xNS0xLTEtMA_01ad4a7e-a62d-4a0b-8437-931c99605fa3">5,197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if337d9153dc545129019175c2d4f63ac_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="ocgn:StockIssuedDuringPeriodValueWarrantExchange" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNy0yMS0xLTEtMA_75b2eb2d-4ffe-43b8-88be-d8d272b1a224">4,978</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for subscription agreements and warrant exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6e7f2c707054cd683451662d8ed7372_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfOC05LTEtMS0w_654b1fec-7317-4b62-a083-6d590567d19b">1,328,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e7f2c707054cd683451662d8ed7372_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfOC0xMS0xLTEtMA_cb240e77-c064-420a-bb81-4a2b3860a17c">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i711b829d5ee345eebc50acfa4b930a61_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfOC0xNS0xLTEtMA_24030a00-1c4e-49a5-b12b-6fe86eac9d55">319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e011586eab7413c970320b1703ebf08_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfOC0yMS0xLTEtMA_c67c15de-ac7d-48af-9a2d-64ece53431ef">332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">At-the-market common stock issuance, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9e589df88b2465ba4294cb791b7dc17_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfOS05LTEtMS0w_138164e2-81f6-43ec-81e4-0d62ba50b4d9">59,132,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9e589df88b2465ba4294cb791b7dc17_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfOS0xMS0xLTEtMA_2be52a65-10fb-4e3f-86d3-79aa4ececb33">591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iede14896071c4ee49fa119a80f14fbab_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfOS0xNS0xLTEtMA_5b82b9e7-b78a-4d17-bf20-cfca0d2215ce">14,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia439f49486224935ad3477d5b4185130_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfOS0yMS0xLTEtMA_cce127fb-13e8-4d1d-8b77-5f79d2dd3f8e">15,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb4586bd1771477fae5877934605f9b3_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTAtMTktMS0xLTA_eb5d6a47-964a-4fb6-b241-a1b00926b456">3,614</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if337d9153dc545129019175c2d4f63ac_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTAtMjEtMS0xLTA_0f3231b5-d66c-4508-9048-e2c30e10bce5">3,614</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74784bdd498745d5ae511cab1b360837_I20200630" decimals="INF" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTEtMS0xLTEtMA_da1eb964-0c70-42eb-86aa-ed3c28516964">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74784bdd498745d5ae511cab1b360837_I20200630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTEtMy0xLTEtMA_230e9b8c-6fed-4a6d-887d-7ae4d8ce0d8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc519bce743c46c398e1d5dead4107f7_I20200630" decimals="INF" format="ixt:fixed-zero" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTEtNS0xLTEtMA_474b0d80-f00f-4978-8d3b-af45cd1ce24b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc519bce743c46c398e1d5dead4107f7_I20200630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTEtNy0xLTEtMA_c1b11fc6-5974-4812-b7b3-ff04114163b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iafa83b4739574d758beec4c0757ed122_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTEtOS0xLTEtMA_042e4291-39bd-4f84-a470-8a14c40afb90">135,128,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafa83b4739574d758beec4c0757ed122_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTEtMTEtMS0xLTA_5403ada5-3d4c-4d85-9508-0f3518bc999f">1,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d3554a78cc8449d9aad5b8c1c4503fd_I20200630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTEtMTMtMS0xLTA_8a0de34f-17b4-4307-b832-9206c2f4b4d7">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f107ec3ae1e4116afeb1163e6492976_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTEtMTUtMS0xLTA_28f4b13b-caf2-4a25-bfd1-dc8e086d06cc">72,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb989f73c9d1445fa69a483600870562_I20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTEtMTktMS0xLTA_37239c4c-d2c9-496a-9b4d-d6b3d9c9529a">59,038</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eb68a3826b24dfe8726311fa8f753a4_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTEtMjEtMS0xLTA_43756001-b46c-40af-b699-c7124b0ce5e0">14,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia772fd167d25491e80c5e09f8d26ca55_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTItMTUtMS0xLTUy_59b6095b-b87d-41e1-b473-be6dd66f0b0e">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTItMjEtMS0xLTUy_c89cdd79-9a20-4f29-8c46-481c9eb6f2da">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">At-the-market common stock issuance, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d2b34877c824fb39ecf988264920e54_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTMtOS0xLTEtMzA1_727e2135-1884-4689-a4df-cac337dfda8f">27,019,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d2b34877c824fb39ecf988264920e54_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTMtMTEtMS0xLTMwNQ_6b5902fd-dea0-4822-bfaf-43cd593e4d87">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49fc5d8a06784ed3b66029a5fdb2c35b_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTMtMTUtMS0xLTMwNQ_f3b76d4e-148e-4196-b202-26519218a0e5">9,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4fa370f40af4910a583132f5726f913_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTMtMjEtMS0xLTMwNQ_39f7992e-9606-4189-85f2-e02939f2e5fb">10,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8964c98e4b14da7a9f597f5fed0edb0_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTMtMTktMS0xLTUy_3f200b72-1cdc-4587-ad7b-55f702744b8a">10,474</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTMtMjEtMS0xLTUy_f235fd71-f37d-48ca-acc0-0792b34bcf5f">10,474</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i878a0f96a8194299acd620d27ea9d9bf_I20200930" decimals="INF" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTQtMS0xLTEtNTc_a996d782-1420-4c49-ba1c-5819a22be26f">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i878a0f96a8194299acd620d27ea9d9bf_I20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTQtMy0xLTEtNTc_75cf4deb-93d1-4b6b-b7b3-9fe20ec3eec2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6cba47cf2f404ee9a035c63dae2423f3_I20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTQtNS0xLTEtNTc_6fd1c1ff-6d58-4009-9bc3-ac7d5362fc1d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cba47cf2f404ee9a035c63dae2423f3_I20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTQtNy0xLTEtNTc_092a3bb5-b63f-466c-8927-2ab79f6e02e8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib05383973c11499c94ee4d3e3f64f0b8_I20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTQtOS0xLTEtNTc_7b82f39a-14bf-4132-8c1a-18db272e8184">162,147,973</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05383973c11499c94ee4d3e3f64f0b8_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTQtMTEtMS0xLTU3_2dbf6162-1c28-4b1f-8076-6d09eb39f2f3">1,621</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id86823ae63164e52b4c42f119b89ed4d_I20200930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTQtMTMtMS0xLTU3_d47135fc-38b6-4c11-86e7-ebb7ce8f846c">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e710c24c8df431ba6ae05089ef01062_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTQtMTUtMS0xLTU3_dd552bad-2984-40a4-a21d-83e6813ebb61">82,360</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if224aca6e98d4c9f87473c21091780ac_I20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTQtMTktMS0xLTU3_5545bcc1-55c1-4571-86b7-c2adf305f73d">69,512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dd63053e40b9b5c54b579a67eebc_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTQtMjEtMS0xLTU3_47f1de40-7d1a-4c3c-8195-e660c5f19fb6">14,421</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OCUGEN,&#160;INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMy0xLTEtMS0w_7512aaca-5d85-4645-a5e4-550dca4b5a07">43,784</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMy0zLTEtMS0w_9bf01cab-16da-4e81-aa40-03c1dacaacbc">18,032</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfNS0xLTEtMS0w_a53106a0-4445-4c76-a1f6-86872a173c9d">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfNS0zLTEtMS0w_163adf78-9650-4c5d-8042-31f0c0555dc3">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" name="ocgn:NonCashInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfNi0xLTEtMS0w_cdd4f012-1b33-42f6-97ee-d3258cb2b08c">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" name="ocgn:NonCashInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfNi0zLTEtMS0w_cf7b8146-0905-4b14-ad63-d6347bc4eb47">555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" name="ocgn:NoncashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfNy0xLTEtMS0w_ed3e4a0e-1faf-4959-b0c2-08f353cef607">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" name="ocgn:NoncashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfNy0zLTEtMS0w_3df17e9d-287d-43c9-96c0-c85aed104705">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfOC0xLTEtMS0w_d662f777-f07e-4df0-93d1-006b15c332d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfOC0zLTEtMS0w_7f03da04-7b77-4784-89fa-4c2015abdcb5">7,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfOS0xLTEtMS0w_2ada2827-4748-4bb8-86d7-66d49a06f094">4,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfOS0zLTEtMS0w_2c1f3943-6f0f-4cda-afda-24b9717f1229">497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncomeTaxCreditsAndAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTAtMS0xLTEtMzM3NTc_0d706d5a-cf00-4098-8b47-c84b71f93ef3">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxCreditsAndAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTAtMy0xLTEtMzM3NjQ_84aa61d4-de94-4004-b9c0-38743b550550">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on forgiveness of PPP Note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTAtMS0xLTEtMA_f0d54dbf-91fe-499a-9267-21ce4594ff80">426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTAtMy0xLTEtMA_34414bdd-f3d6-41a7-9b13-a1b7df61e3da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment on note receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" name="us-gaap:ProvisionForLoanLossesExpensed" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTEtMS0xLTEtMA_48fa6c97-dc61-419c-867e-f1647c7ab015">761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProvisionForLoanLossesExpensed" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTEtMy0xLTEtMA_da0332bd-ff75-4b32-bd4e-7f2cdd159a64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTItMS0xLTEtMA_9db6abdc-5292-4820-9659-6dd31beaefec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTItMy0xLTEtMA_0f04337f-dcd8-4ae5-a00a-f368fb2d0d35">166</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTQtMS0xLTEtMA_16189653-a127-44af-bf05-e2daed804d8f">845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTQtMy0xLTEtMA_c4da0086-1701-44c7-a673-833ab8b5e740">796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTUtMS0xLTEtMA_c9096443-aad6-45de-bbee-efbeec19751c">2,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTUtMy0xLTEtMA_ef8a3c7d-40a1-4022-8bb5-ac9415535dda">1,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTYtMS0xLTEtMA_50ced664-dbfd-479f-9e0c-878cd9bd6916">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTYtMy0xLTEtMA_d1a2d0e2-7e4a-4d54-b604-8d148a6904ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" sign="-" name="ocgn:IncreaseDecreaseInLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTctMS0xLTEtMA_b9deeea2-55f4-4e5a-8a95-792a1d305ca5">191</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" sign="-" name="ocgn:IncreaseDecreaseInLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTctMy0xLTEtMA_a1e8a198-f429-4c21-9c98-79ed1aba4975">144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTgtMS0xLTEtMA_a66663ba-20ef-47d2-b0d3-dd80bdd16eb7">35,137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTgtMy0xLTEtMA_c2227e33-6ee9-488a-a4ee-7125a5af4638">10,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjAtMS0xLTEtMA_76962014-d50d-439a-9415-655769805709">747</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjAtMy0xLTEtMA_1d470252-2ab2-40e1-83f5-2acb9b96fbf1">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjEtMS0xLTEtMjQ1MTE_a6378680-348f-4c00-bfad-cb0311060a5c">127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjEtMy0xLTEtMjQ1MTE_db80b9dd-776d-4a91-bfe2-5fb5317a4e4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of note receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" name="ocgn:IssuanceOfFinancingReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjEtMS0xLTEtMA_0780062b-c788-4265-83be-5357c9074b21">750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="ocgn:IssuanceOfFinancingReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjEtMy0xLTEtMA_60ad9005-47de-43cd-9b35-18850fee5414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjItMS0xLTEtMA_9e5d5156-a345-4461-b151-e2f22fbdf5e5">1,624</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjItMy0xLTEtMA_2459bbb1-3f77-48f3-b7c8-0141e9726e4a">56</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjQtMS0xLTEtMA_71ae7612-4371-4aa4-8707-452d06a5f306">128,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjQtMy0xLTEtMA_a5cdfbe5-b04d-4561-b71a-c26b6f62f17f">26,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of equity issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjUtMS0xLTEtMA_f9cafa29-9f16-426a-b1dc-4064e0935c96">8,525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjUtMy0xLTEtMA_e85555a7-1fcd-47b0-b586-125285c16de3">1,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjYtMS0xLTEtMA_e67713b7-c8a5-4109-8a45-27a6278931cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjYtMy0xLTEtMA_a191cf37-432f-4893-96d6-7f20136f7cd4">921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjctMS0xLTEtMA_dffae2da-2e5d-45a8-b1bf-bcdaa829e605">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjctMy0xLTEtMA_2d77ef6a-c090-45c9-b621-19482430fff5">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RepaymentsOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjgtMS0xLTEtMA_e4195afb-b069-4fe7-8b92-1484c95df8b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjgtMy0xLTEtMA_bf6d9ddf-0f0a-4312-a196-259ef742152c">4,362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease principal payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjktMS0xLTEtMA_8d1bde1b-6ff1-4d49-a27e-40523e61144e">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjktMy0xLTEtMA_80ef52af-04fa-4ccc-9ab8-165a37dab35d">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMzAtMS0xLTEtMA_2dd0f4bb-07e3-4a1d-b4e9-a1b6e0272f8e">120,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMzAtMy0xLTEtMA_fcfc4c0b-4b75-4447-87d2-92bbc1f6965a">22,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net increase in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMzEtMS0xLTEtMA_f7bcb4ac-30bc-4c0e-afc8-a25c93f10832">83,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMzEtMy0xLTEtMA_7f7559b7-021e-4f04-83f7-825e0564dc16">11,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMzItMS0xLTEtMA_c3cf625c-069b-4bae-ad7b-63155377afb5">24,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia331e4fce5e04537ac0252d8c85aa3db_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMzItMy0xLTEtMA_173c3370-ce6e-4c08-9c52-7fdcbbe64892">7,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMzMtMS0xLTEtMA_92462991-4818-4c0a-879f-f772a83fdc2d">107,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dd63053e40b9b5c54b579a67eebc_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMzMtMy0xLTEtMA_22276e7a-59c2-470d-b3b9-fb32fa638df9">19,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OCUGEN,&#160;INC.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash investing and financing transactions:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of warrants</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfNC0xLTEtMS0yNjY1Mw_38dcb490-fa39-401d-b404-3c41f47287e6">603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfNC0zLTEtMS0yNjY1Mw_ce2a0cd2-b09b-4eab-b328-56907a2d84d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock issuance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfMy0xLTEtMS0yMzE1_5ea198db-f4d7-4f98-a814-b2e02f4102b3">4,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfMy0zLTEtMS0yMzMz_262c6864-fd9f-4d02-82aa-eb9dee5b4fbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forgiveness of PPP Note</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" name="ocgn:GainLossOnForgivenessOfPaycheckProtectionProgramNote" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfNS0xLTEtMS0yMzE1_79842eef-ab85-4550-b908-70e32da5a2c3">426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="ocgn:GainLossOnForgivenessOfPaycheckProtectionProgramNote" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfNS0zLTEtMS0yMzMz_bb9198b3-3524-4859-a8be-258b4c4bfc58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfNy0xLTEtMS0yNjY5Ng_942f12a1-47ec-43f4-a267-1ce8cb24f41f">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfNy0zLTEtMS0yNjY5Ng_cec4a2d5-481e-47e6-95db-2c5bed1b069a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset related to operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" name="ocgn:NoncashOrPartNoncashOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfOC0xLTEtMS0yNjY5Ng_be01db9c-e7ad-4a07-a0af-ec44f695a24f">926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="ocgn:NoncashOrPartNoncashOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfOC0zLTEtMS0yNjY5Ng_4fd20d98-85b7-48c0-8c8a-d203c5e0854c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Warrant Exchange Promissory Notes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NotesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfNi0xLTEtMS0yMzE1_7934850b-4c8d-4a37-983a-2b1ee7a74964">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfNi0zLTEtMS0yMzMz_03cd5e0e-68f4-46e6-ae33-e8f4641195d2">5,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligation settled with common stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfNy0xLTEtMS0yMzE1_11c8d39a-ffc0-40a6-a63e-8a14c8450043">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" name="us-gaap:StockIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfNy0zLTEtMS0yMzMz_bd9c6ef5-22a8-4e62-9e28-8794ef6f2f31">331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity issuance costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="ocgn:NoncashOrPartNoncashAmountOfDeferredTransactionCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfOC0xLTEtMS0yMzE1_7a5bef6e-d804-4d17-b481-cbf82727e722">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" name="ocgn:NoncashOrPartNoncashAmountOfDeferredTransactionCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfOC0zLTEtMS0yMzMz_46dd6649-c8e3-4a41-88da-d05a91274e03">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OCUGEN, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_34"></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfMTA3NTU_a8e0db34-a94c-4294-82fa-d0cd80ab0301" continuedAt="ic924214f96214defa70b8f72095205ea" escape="true">Nature of Business</ix:nonNumeric></span></div><ix:continuation id="ic924214f96214defa70b8f72095205ea" continuedAt="ifb2c516f3c0844849fdd71f77f56d31e"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ocugen, Inc., together with its wholly owned subsidiaries (&#8220;Ocugen&#8221; or the &#8220;Company&#8221;), is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The Company is headquartered in Malvern, Pennsylvania, and manages its business as <ix:nonFraction unitRef="segment" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfMzQx_5f9e61ff-233b-4867-96cc-e55d758fa66b">one</ix:nonFraction> operating segment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Vaccine</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company entered into a Co-Development, Supply and Commercialization Agreement with Bharat Biotech International Limited ("Bharat Biotech"), pursuant to which the Company obtained an exclusive right and license under certain of Bharat Biotech's intellectual property rights, with the right to grant sublicenses to develop, manufacture, and commercialize BBV152, known as COVAXIN outside the United States, for the prevention of COVID-19 caused by SARS-CoV-2 in humans in the United States, its territories, and possessions. In June 2021, the Company entered into an amendment to the Co-Development, Supply and Commercialization Agreement (as so amended, the "Covaxin Agreement") pursuant to which the parties agreed to expand the Company's rights to develop, manufacture, and commercialize COVAXIN to include Canada in addition to the United States, its territories, and possessions (the &#8220;Ocugen Covaxin Territory&#8221;).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus, an antigen, and an adjuvant. COVAXIN requires a <ix:nonFraction unitRef="dose" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="ocgn:NumberOfVaccinationDoseRegimen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfMTQ0NA_a18ef404-99c9-4d8e-9b06-243f6ed05ff1">two</ix:nonFraction>-dose vaccination regimen given <ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" format="ixt-sec:durday" name="ocgn:VaccinationDoseRegimenDurationApart" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfMTQ3OA_0ec79baa-82a5-4bff-a04b-28b18e3f7f66">28</ix:nonNumeric> days apart and is stored in standard vaccine storage conditions (2-8&#176;C). COVAXIN has been authorized for emergency use in India for ages 18 years and older. In November 2021, COVAXIN was awarded an Emergency Use Listing ("EUL") by the World Health Organization ("WHO").</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company announced that COVAXIN demonstrated an overall vaccine efficacy against COVID-19 disease of <ix:nonFraction unitRef="number" contextRef="i3eb7b92dc9494a35b5033ab8674abe63_D20210701-20210731" decimals="3" name="ocgn:OverallVaccineEfficacyPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfMTc4Nw_5bcf729e-61ac-45dd-8eae-b53b2e31c13d">77.8</ix:nonFraction>%, with efficacy against severe COVID-19 disease of <ix:nonFraction unitRef="number" contextRef="i3eb7b92dc9494a35b5033ab8674abe63_D20210701-20210731" decimals="3" name="ocgn:EfficacySevereCasesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfMTg0MA_94269ba3-7fd3-4dbe-ae02-3d80461a8e21">93.4</ix:nonFraction>%, and efficacy against asymptomatic COVID-19 disease of <ix:nonFraction unitRef="number" contextRef="i3eb7b92dc9494a35b5033ab8674abe63_D20210701-20210731" decimals="3" name="ocgn:EfficacyAsymptomaticInfectionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfMTg5OA_9ea89c7c-681a-44e5-9d96-7ecc3dd713d0">63.6</ix:nonFraction>% in the Phase 3 clinical trial conducted by Bharat Biotech in India. Adverse events in the COVAXIN and control arms of the Phase 3 clinical trial were observed in <ix:nonFraction unitRef="number" contextRef="i3eb7b92dc9494a35b5033ab8674abe63_D20210701-20210731" decimals="3" name="ocgn:AdverseEventsSideEffectsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfMjA2NA_c5cf4507-05d4-491b-93b9-326f21f21464">12.4</ix:nonFraction>% of subjects, with less than <ix:nonFraction unitRef="number" contextRef="i3eb7b92dc9494a35b5033ab8674abe63_D20210701-20210731" decimals="3" name="ocgn:AdverseEventsSeriousAdverseSideEffectsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfMjA5NQ_e82e68ad-4dd9-4e98-a0b4-8072d7a6b7e8">0.5</ix:nonFraction>% of subjects experiencing serious adverse side effects. The majority of the symptomatic cases identified in aggregate in the COVAXIN and control arms in the Phase 3 clinical trial were COVID-19 variants, the majority of which were identified to be the Delta variant, B.1.617.2. Subjects vaccinated with COVAXIN in the Phase 3 clinical trial showed protection against the Delta variant, B.1.617.2, showing a vaccine efficacy of <ix:nonFraction unitRef="number" contextRef="i3eb7b92dc9494a35b5033ab8674abe63_D20210701-20210731" decimals="3" name="ocgn:EfficacyAgainstDeltaVariantB16172Percent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfMjUzNA_6dfc99cd-6fa2-4775-a3ab-e91444fe6d1b">65.2</ix:nonFraction>%. Additionally, in in-vitro studies conducted by the Indian Council of Medical Research ("ICMR") &#8212; National Institute of Virology, COVAXIN demonstrated potential effectiveness against the Zeta variant, B.1.1.28.2, the Alpha variant, B.1.1.7, and the Beta variant, B.1.351.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the U.S. Food and Drug Administration (the "FDA") provided feedback to the Company regarding the data and information contained in a "Master File" that was previously submitted to the FDA and recommended that the Company pursue a Biologics License Application ("BLA") submission instead of an Emergency Use Authorization ("EUA") application for COVAXIN for ages 18 years and older in the United States. As part of the feedback provided by the FDA regarding the "Master File," the FDA also requested additional information and data. The Company has continued discussions with the FDA regarding the appropriate regulatory pathway for COVAXIN for ages 18 years and older in the United States as well as the data requirements for COVAXIN under a BLA submission. In October 2021, the Company filed an Investigational New Drug ("IND") application with the FDA to initiate a Phase 3 immuno-bridging study evaluating COVAXIN for ages 18 years and older. The Company will also initiate a safety-bridging study under the IND, if required by the FDA, to support a BLA submission. The Company anticipates filing a BLA submission with the FDA by the end of 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company submitted a request to the FDA for EUA for COVAXIN for pediatric use in children ages two to 18 years in the United States. The EUA submission was based on the results of a Phase 2/3 immuno-bridging pediatric clinical trial conducted by Bharat Biotech in India.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also pursuing approval for COVAXIN in Canada. In July 2021, the Company announced it had completed its rolling submission to Health Canada for COVAXIN. The rolling submission process, which permits companies to submit safety and efficacy data and information as they become available, was recommended and accepted under the Minister of Health&#8217;s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the "Interim Order") and transitioned to a New Drug Submission ("NDS") for COVID-19. The submission was conducted through the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><ix:continuation id="ifb2c516f3c0844849fdd71f77f56d31e" continuedAt="i8f9530d02cbc4a7e815799d48440f4a5"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company's Canadian affiliate, Vaccigen, Ltd. ("Vaccigen"). The Interim Order expired on September 16, 2021. The expiration of the Interim Order has not impacted the Company's NDS.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is evaluating its commercialization strategy for COVAXIN in the United States and Canada, if authorized or approved in either jurisdiction. In June 2021, the Company selected Jubilant HollisterStier as its manufacturing partner for COVAXIN to prepare for the potential commercial manufacturing for the Ocugen Covaxin Territory. The Company expects to enter into a master services agreement with Jubilant HollisterStier for the manufacture of COVAXIN and the technology transfer process to Jubilant HollisterStier has been initiated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into a Development and Commercial Supply Agreement (the &#8220;Supply Agreement&#8221;) with Bharat Biotech, pursuant to which </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bharat Biotech will supply the Company with clinical trial materials and commercial supplies of COVAXIN finished drug product prior to the completion of the Company&#8217;s technology transfer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jubilant HollisterStier</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Following the completion of the Company&#8217;s technology transfer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jubilant HollisterStier</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bharat Biotech will supply COVAXIN drug product components and continue to supply finished drug product as necessary for commercial manufacture and supply of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVAXIN </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent to a regulatory authorization or approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Modifier Gene Therapy Platform</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is developing a breakthrough modifier gene therapy platform to generate therapies designed to fulfill unmet medical needs in the area of retinal diseases, including inherited retinal diseases ("IRDs") and dry age-related macular degeneration ("AMD"). The Company's modifier gene therapy platform is based on nuclear hormone receptors (&#8220;NHRs&#8221;), which have the potential to restore homeostasis, the basic biological processes in the retina. Unlike single-gene replacement therapies, which only target <ix:nonFraction unitRef="geneticmutation" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="ocgn:SingleGeneReplacementTherapiesNumberOfGeneticMutationsTarget" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfNTg0NQ_194849eb-7b73-410f-90d6-c0555a27b6a2">one</ix:nonFraction> genetic mutation, the Company believes that its gene therapy platform, through its use of NHRs, represents a novel approach in that it may address multiple retinal diseases with <ix:nonFraction unitRef="product" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="ocgn:ModifierGeneTherapyPlatformNumberOfProducts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfNjAyNg_79be4072-cf5c-471c-b4dd-5fcbf8a42704">one</ix:nonFraction> product.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that OCU400, its first product candidate being developed with its modifier gene therapy platform, has the potential to be broadly effective in restoring retinal integrity and function across a range of genetically diverse IRDs, including retinitis pigmentosa ("RP") and leber congenital amaurosis ("LCA"). OCU400 has received <ix:nonFraction unitRef="orphan_drug_designation" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="ocgn:NumberOfOrphanDrugDesignations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfNjM4NQ_13f8e567-bea1-459e-981d-1b8756df9ebd">four</ix:nonFraction> Orphan Drug Designations ("ODDs") from the FDA for the treatment of certain disease genotypes: nuclear receptor subfamily 2 group E member 3 ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NR2E3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"), centrosomal protein 290 ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CEP290</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"), rhodopsin ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RHO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"), and phosphodiesterase 6B ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PDE6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#223;") mutation-associated inherited retinal degenerations. In November 2021, the Company filed an IND application with the FDA for OCU400 for the treatment of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NR2E3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RHO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disease genotypes. The Company is planning to initiate a Phase 1/2 clinical trial for OCU400 for the treatment of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NR2E3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RHO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disease genotypes in the United States near the end of 2021. OCU400 additionally has received Orphan Medicinal Product Designation ("OMPD") from the European Commission ("EC"), based on the recommendation of the European Medicines Agency ("EMA"), for RP and LCA, which the Company believes further supports the potential broad spectrum application of OCU400 to treat many IRDs. The Company is currently evaluating options to commence OCU400 clinical trials in Europe in 2022. The Company's second gene therapy candidate, OCU410, is being developed to utilize the nuclear receptor genes RAR-related orphan receptor A ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RORA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">") for the treatment of dry AMD. The Company is currently executing IND-enabling preclinical studies to support a Phase 1/2 clinical trial. The Company has engaged CanSino Biologics, Inc. ("CanSinoBIO") to manufacture clinical supplies and be responsible for the chemistry, manufacturing, and controls ("CMC") development for OCU400 and OCU410. See Note 3 for additional information about the Company's collaboration with CanSinoBIO.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novel Biologic Therapy for Retinal Diseases</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's biologic product candidate, OCU200, is a novel fusion protein being developed to treat diabetic macular edema ("DME"), diabetic retinopathy ("DR"), and wet AMD. The Company is currently executing IND-enabling preclinical studies to support a Phase 1 clinical trial. The Company has completed the technology transfer of manufacturing processes to the Company's contract development and manufacturing organization ("CDMO") that will manufacture OCU200 clinical supplies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred recurring net losses since inception and has funded its operations to date through the sale of common stock, warrants to purchase common stock, the issuance of convertible notes, debt, and grant proceeds. The Company incurred net losses of approximately $<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfODYzNA_4d1b1d0a-23f1-4f28-9651-f87ebebb08ce">43.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfODY0MQ_ff71793b-d1e8-4da5-abea-a64396781e5c">18.0</ix:nonFraction>&#160;million for the nine months ended September 30, 2021 and 2020, respectively. As of September&#160;30, 2021, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfODcyOQ_226a10ab-a52b-4850-97a0-4c2499b503fe">117.1</ix:nonFraction>&#160;million and cash, cash equivalents, and restricted cash totaling $<ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfODc4OQ_c36dc4a8-3775-43da-b6d0-550c6f99f41d">107.5</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><ix:continuation id="i8f9530d02cbc4a7e815799d48440f4a5"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a limited operating history and its prospects are subject to risks, expenses, and uncertainties frequently encountered by companies in its industry. The Company intends to continue its research, development, and commercialization efforts for its product candidates, which will require significant additional funding. If the Company is unable to obtain additional financing in the future or its research, development, and commercialization efforts require higher than anticipated capital, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital through public and private placements of equity and/or debt, payments from potential strategic research and development arrangements, sales of assets, government grants, licensing and/or collaboration arrangements with pharmaceutical companies or other institutions, or other funding from the government or other third parties. Such financing may not be available at all, or on terms that are favorable to the Company. While management of the Company believes that it has a plan to fund ongoing operations, its plan may not be successfully implemented. Failure to generate sufficient cash flows from operations, raise additional capital, or appropriately manage certain discretionary spending could have a material adverse effect on the Company&#8217;s ability to achieve its intended business objectives.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these factors, together with the anticipated increase in spending that will be necessary to continue to research, develop, and commercialize the Company&#8217;s product candidates, there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. The condensed consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties.</span></div></ix:continuation><div id="i9ff348f1ca104ec598a35c61fa9fc977_37"></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MzE_da79b299-974b-4b9d-b3f3-e626c4ccd959" continuedAt="i137cdb3b74654175aa9531e630f9d220" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i137cdb3b74654175aa9531e630f9d220" continuedAt="i289306275b9a4913a9eda4aec9d36612"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MjA_a69c4a75-6d79-413f-9925-10099ca8cc1b" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements included herein have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) and under the rules&#160;and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. The accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, that are necessary to present fairly the Company&#8217;s financial position, results of operations, and cash flows. The condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosures of the Company normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted under the SEC&#8217;s rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto for the year ended December&#160;31, 2020, included in the Company's Annual Report on Form 10-K filed with the SEC on March 19, 2021 (the "2020 Annual Report").</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2Mjk_b6d6fcde-01ee-4b59-95ed-8e3417ea9b2e" escape="true">The condensed consolidated financial statements include the accounts of Ocugen and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform with current period presentation.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MzI_2917eae5-9301-4b27-a263-f7db0e635a46" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the condensed consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions primarily include those used in the accounting for research and development accruals, the fair value measurement of equity instruments, and the collectibility of the note receivable.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MTU_8a6b8e7a-c453-42b2-b540-45428eb22965" continuedAt="i8b1dbadc5fa24c84ab310f7d8ab87121" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether collaboration agreements are subject to Financial Accounting Standards Board ("FASB") Accounting Standards Codification (&#8220;ASC&#8221;) Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;), based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of ASC 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner represent consideration from a customer, the Company accounts for those payments within the scope of FASB ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. However, if the Company concludes that its collaboration partner is not a customer, the Company will record royalty payments received as collaboration revenue in the period in which the underlying sale occurs and record expenses and expense reimbursements as either research and </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><ix:continuation id="i289306275b9a4913a9eda4aec9d36612" continuedAt="if91b2d67d3a24fcc91ada349b849e870"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8b1dbadc5fa24c84ab310f7d8ab87121">development expense or general and administrative expense, or a reduction thereof, based on the underlying nature of the expense or expense reimbursement. During the nine months ended September 30, 2020, the Company recorded collaboration revenue from an agreement accounted for as a collaborative arrangement within the scope of ASC 808. <ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMzgxOQ_fa091602-941a-433f-9a1e-34a416757b57">No</ix:nonFraction> collaboration revenue was recorded during the nine months ended September 30, 2021.</ix:continuation></span></div><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MTY_cd909a24-f52f-4894-9340-93e73d1e1e86" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exit and Disposal Activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records liabilities for one-time termination benefits in accordance with FASB ASC Topic 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit and Disposal Cost Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 420"). In accordance with ASC 420, an arrangement for one-time termination benefits exists at the date the plan of the termination meets the following criteria: (i) management commits to a plan of termination, (ii) the plan identifies the impacted employees and expected completion date, (iii) the plan identifies the terms of the benefits arrangement, (iv) it is unlikely significant changes to the plan will be made or the plan will be withdrawn, and (v) the plan has been communicated to employees. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits, are recognized ratably over the future service period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records liabilities for employee termination benefits covered by ongoing benefit arrangements in accordance with FASB ASC Topic 712, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nonretirement Postemployment Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 712"). In accordance with ASC 712, costs for termination benefits under ongoing benefits arrangements are recognized when management has committed to a plan of termination and the costs are probable and estimable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance-related charges, once incurred, are recognized as either research and development expense or general and administrative expense within the condensed consolidated statements of operations and comprehensive loss depending on the job function of the former employee.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MzA_a5978c98-a5ce-4671-ba0d-1727793bbcce" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the provisions of FASB ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8212; quoted prices in active markets for identical assets or liabilities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8212; quoted prices for similar assets and liabilities in active markets or inputs that are observable</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8212; inputs that are unobservable (for example cash flow modeling inputs based on assumptions)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of certain financial instruments, including cash and cash equivalents, accounts payable, and accrued expenses approximates their fair values due to the short-term nature of these instruments. As of September&#160;30, 2021, the Company believes the fair value using Level 2 inputs of the borrowings under the EB-5 Loan Agreement (as defined in Note 8) approximate their carrying value. See Note 8 for additional information.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MTc_979dc4af-c378-4a9c-af54-c1142dafa0b7" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash equivalents may include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposit, commercial paper, and U.S. government and U.S. government agency obligations. The Company&#8217;s restricted cash balance consists of cash held to collateralize a corporate credit card account.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><ix:continuation id="if91b2d67d3a24fcc91ada349b849e870" continuedAt="i30eec3629cc94d789bf1873d8622b589"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="ocgn:ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MjM_3f61d5d5-60d8-403a-9a3d-055a28fa75b7" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash in the condensed consolidated balance sheets to the total amount shown in the condensed consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RhYmxlOmE0M2U4NGRlZTEzYTRmMTNhYmM5NTlkZmY0NTZhMjNkL3RhYmxlcmFuZ2U6YTQzZTg0ZGVlMTNhNGYxM2FiYzk1OWRmZjQ1NmEyM2RfMi0xLTEtMS0w_0c165c14-af22-4890-a140-deceee729097">107,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dd63053e40b9b5c54b579a67eebc_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RhYmxlOmE0M2U4NGRlZTEzYTRmMTNhYmM5NTlkZmY0NTZhMjNkL3RhYmxlcmFuZ2U6YTQzZTg0ZGVlMTNhNGYxM2FiYzk1OWRmZjQ1NmEyM2RfMi0zLTEtMS0w_bf1c5683-4758-4e94-bc1e-a8f6c5bbd6fe">19,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RhYmxlOmE0M2U4NGRlZTEzYTRmMTNhYmM5NTlkZmY0NTZhMjNkL3RhYmxlcmFuZ2U6YTQzZTg0ZGVlMTNhNGYxM2FiYzk1OWRmZjQ1NmEyM2RfMy0xLTEtMS0w_040b9cb5-7782-43ba-9070-68c59e01b1f9">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dd63053e40b9b5c54b579a67eebc_I20200930" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RhYmxlOmE0M2U4NGRlZTEzYTRmMTNhYmM5NTlkZmY0NTZhMjNkL3RhYmxlcmFuZ2U6YTQzZTg0ZGVlMTNhNGYxM2FiYzk1OWRmZjQ1NmEyM2RfMy0zLTEtMS0w_94b8de90-bf9d-4410-b045-ec31b487e655">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RhYmxlOmE0M2U4NGRlZTEzYTRmMTNhYmM5NTlkZmY0NTZhMjNkL3RhYmxlcmFuZ2U6YTQzZTg0ZGVlMTNhNGYxM2FiYzk1OWRmZjQ1NmEyM2RfNC0xLTEtMS0w_f19deda4-b82c-4655-99b5-353db656e212">107,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dd63053e40b9b5c54b579a67eebc_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RhYmxlOmE0M2U4NGRlZTEzYTRmMTNhYmM5NTlkZmY0NTZhMjNkL3RhYmxlcmFuZ2U6YTQzZTg0ZGVlMTNhNGYxM2FiYzk1OWRmZjQ1NmEyM2RfNC0zLTEtMS0w_b0a8ee2d-f842-4fd2-a8ca-01bc5016c36d">19,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MjE_a02c0b00-d075-4814-8ff1-c813d44cc0c1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is recorded at historical cost. Significant additions or improvements are capitalized, and expenditures for repairs and maintenance are charged to expense as incurred. Gains and losses on disposal of assets are included in the condensed consolidated statements of operations and comprehensive loss. Depreciation is calculated using the straight-line method and is recognized over the expected useful life of the underlying asset. The Company's property and equipment currently includes furniture and fixtures, machinery and equipment, leasehold improvements, and construction in progress. The Company's furniture and fixtures have an expected useful life of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfNDM5ODA0NjU4MjIzNg_2f5f7cef-a3ff-41b9-b3bd-1ded51f7bc02">three</span> to <ix:nonNumeric contextRef="ie2a762caa8434142a4d6522864319751_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMzg0ODI5MDc0OTI0OA_e06a2f6d-478a-479a-9186-50ea74cd4bd4">seven years</ix:nonNumeric>. The Company's machinery and equipment have an expected useful life of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfNDM5ODA0NjU4MjMwOQ_2aaf4aaa-5250-4fad-95da-0d6844c093cb">five</span> to <ix:nonNumeric contextRef="i835d59b4a71c4ca48581fa3806494a4a_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMzg0ODI5MDc0OTI2OQ_62c212d7-4c40-4cec-9b4f-da1185192bfd">seven years</ix:nonNumeric>. Leasehold improvements are amortized over the shorter of their expected useful lives or the remaining lease term. If a leasehold improvement transfers ownership to the Company at the end of the lease term, the leasehold improvement is amortized over its expected useful life. Construction in progress is not depreciated until such time that the asset is completed and placed into service. Once placed into service, the asset is depreciated over its expected useful life.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MjU_0b3b396f-cbac-4b3c-bd77-4b138b46f256" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company&#8217;s current and historical lease agreements include lease and non-lease components, which the Company has elected not to account for separately for all classes of underlying assets. Lease expense for variable lease components is recognized when the obligation is probable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases are included in other assets and operating lease obligations in the Company&#8217;s condensed consolidated balance sheets. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. Operating lease payments are recognized as lease expense on a straight-line basis over the lease term and recognized as research and development expense or general and administrative expense based on the underlying nature of the expense. The Company currently leases real estate classified as operating leases. FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 842") requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. The implicit interest rate was not readily determinable in the Company&#8217;s current and historical operating leases, therefore the incremental borrowing rate was used based on the information available at the commencement date in determining the present value of lease payments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease term for the Company&#8217;s leases includes the non-cancellable period of the lease plus any additional periods covered by either an option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease payments included in the measurement of the lease liability are comprised of fixed payments, variable payments that depend on index or rate, and amounts probable to be payable under the exercise of an option to purchase the underlying asset if reasonably certain.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable payments not dependent on an index or rate associated with the Company&#8217;s leases are recognized when the event, activity, or circumstance is probable. Variable payments include the Company's proportionate share of certain utilities and other operating expenses and are presented as operating expenses in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss in the same line item as expense arising from fixed payments.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><ix:continuation id="i30eec3629cc94d789bf1873d8622b589" continuedAt="i91fd25b01ce640529de514412c832080"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MzQ_9bf83d60-dfc4-483f-a347-f2a9afaf49aa" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation &#8212; Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 718&#8221;). The Company has issued stock-based compensation awards including stock options and restricted stock units ("RSUs"), and also accounts for certain issuances of preferred stock and warrants in accordance with ASC 718. ASC 718 requires all stock-based payments, including grants of stock options and RSUs, to be recognized in the condensed consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options granted. For RSUs, the fair value of the RSUs is determined by the market price of a share of the Company's common stock at the grant date. The Company recognizes forfeitures as they occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to stock-based compensation awards granted with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Stock-based compensation awards generally vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTI5NTc_1b0f22b6-1741-4551-9fe9-ad65976104fa">one</span> to <ix:nonNumeric contextRef="ib31b92c5c40747a3bd257cecf9f1c22b_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MTg_91fddb1f-ce67-4859-b425-cc35b4635970">three year</ix:nonNumeric> requisite service period and have a contractual term of <ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTMwMjc_cd4feb19-cc09-4fd4-b9bc-a577a9ed65a5">10</ix:nonNumeric> years. To the extent a stock-based compensation award is subject to performance-based vesting conditions, the amount of compensation expense recorded reflects an assessment of the probability of achieving the performance conditions. Compensation expense for stock-based compensation awards with performance-based vesting conditions is only recognized when the performance-based vesting condition is deemed probable to occur. Shares issued upon stock option exercise and RSU vesting are newly issued common shares.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of stock options requires the input of subjective assumptions, including the expected life of the stock option, stock price volatility, the risk-free interest rate, and expected dividends. The assumptions used in the Company&#8217;s Black-Scholes option-pricing model represent management&#8217;s best estimates and involve a number of variables, uncertainties, assumptions, and the application of management&#8217;s judgment, as they are inherently subjective. If any assumptions change, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="ocgn:AssetHeldForSalePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMzg0ODI5MDczMzYzNA_767a9464-7655-4a5c-a901-0b383c7a5610" escape="true"><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Held for Sale</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company had an intangible asset held for sale that was carried at its original fair value less cost to sell of $<ix:nonFraction unitRef="usd" contextRef="ia331e4fce5e04537ac0252d8c85aa3db_I20191231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTA5OTUxMTY1NTA5NA_815398e4-8b41-4d3b-b073-6ffc63e0105f">7.0</ix:nonFraction>&#160;million. The Company concluded during the three and nine months ended September&#160;30, 2020, that a sale of the intangible asset was no longer probable to be completed within one year from the date the intangible asset was initially recorded as held for sale. As such, the carrying value of the intangible asset was reduced to <ix:nonFraction unitRef="usd" contextRef="i7033dd63053e40b9b5c54b579a67eebc_I20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTA5OTUxMTY1NTU3NQ_6384a34f-ab44-4b33-a1c1-0b0011291a64">zero</ix:nonFraction> with the corresponding charge of $<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTA5OTUxMTY1NTYzMA_7ab41a7e-9d1d-47e5-873d-dcc3217c7bff"><ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTA5OTUxMTY1NTYzMA_bf6279e0-09d2-4139-bcf8-7d504e917413">7.0</ix:nonFraction></ix:nonFraction>&#160;million recognized as in-process research and development expense in the condensed consolidated statements of operations and comprehensive loss during the three and nine months ended September&#160;30, 2020 as the in-process research and development did not have an alternative future use.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MjY_47c32c31-4015-410a-8434-96f920e0addd" continuedAt="i66e4d64cffd04064b50ee4ce16ded766" escape="true"><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued Accounting Standards Update ("ASU") No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocations, and calculating income taxes in interim periods. This standard also adds guidance to reduce complexity in certain areas, including recognizing franchise tax, recognizing deferred taxes for the tax basis of goodwill, allocating taxes to the members of a consolidated group, and recognizing the effect of enacted changes in tax laws or rates during an interim period. This standard was effective for the Company on January 1, 2021. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share (Topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8212; Stock Compensation (Topic 718), and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard will have an effective and transition date of January 1, 2022. This standard clarifies and reduces diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options, including warrants, that remain equity-classified after modification or exchange. The standard requires an entity to treat a modification or an exchange of a freestanding equity-classified written call option that remains equity-classified after the modification or exchange as an exchange of the original instrument for a new instrument. The standard additionally provides guidance on measuring and recognizing the effect of a modification or an exchange. The Company does not currently expect the adoption of this standard to have a material impact on the Company's condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><ix:continuation id="i91fd25b01ce640529de514412c832080"><ix:continuation id="i66e4d64cffd04064b50ee4ce16ded766"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt &#8212; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8212; Contracts in Entity's Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard will have an effective and transition date of January 1, 2024. Early adoption is currently permitted. This standard simplifies an issuer's accounting for convertible instruments by eliminating two of the three models that require separate accounting for embedded conversion features as well as simplifies the settlement assessment that entities are required to perform to determine whether a contract qualifies for equity classification. This standard also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of potential share settlement (if the effect is more dilutive) for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. The standard requires new disclosures about events that occur during the reporting period and cause conversion contingencies to be met and about the fair value of a public business entity's convertible debt at the instrument level, among other things. The Company does not currently expect the adoption of this standard to have a material impact on the Company's condensed consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8212; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The FASB subsequently issued amendments to ASU No. 2016-13, which have the same effective date and transition date of January 1, 2023. ASU No. 2016-13, as amended, requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company does not currently expect the adoption of this standard to have a material impact on the Company's condensed consolidated financial statements.</span></div></ix:continuation></ix:continuation><div id="i9ff348f1ca104ec598a35c61fa9fc977_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180MC9mcmFnOmQ3NTI3ZjBkNTk3YzRjNzdiNWMyZTRhY2ZlNzFlOGFiL3RleHRyZWdpb246ZDc1MjdmMGQ1OTdjNGM3N2I1YzJlNGFjZmU3MWU4YWJfNDMwMA_0c7d43d5-3e62-4f64-ae21-9c7583db264f" continuedAt="i43b56d3fe8824ec69ada89daccf300f2" escape="true">License and Development Agreements</ix:nonNumeric></span></div><ix:continuation id="i43b56d3fe8824ec69ada89daccf300f2" continuedAt="ib400cc09dc0947bcb2cfe1f2de97ffc8"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Co-Development, Supply and Commercialization Agreement with Bharat Biotech</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into the Covaxin Agreement with Bharat Biotech to co-develop COVAXIN, a whole-virion inactivated COVID-19 vaccine being developed to prevent COVID-19 infection, for the U.S. and Canadian markets. The Covaxin Agreement was originally entered into in February 2021 with respect to the U.S. market and was subsequently amended in June 2021 to add rights to the Canadian market. Pursuant to the Covaxin Agreement, the Company obtained an exclusive right and license under certain of Bharat Biotech&#8217;s intellectual property rights, with the right to grant sublicenses, to develop, manufacture, and commercialize COVAXIN in the Ocugen Covaxin Territory. In consideration of the license and other rights granted by Bharat Biotech to the Company, the parties agreed to share any profits generated from the commercialization of COVAXIN in the Ocugen Covaxin Territory, with the Company retaining <ix:nonFraction unitRef="number" contextRef="i1978e8a33197491fab4e85b515ca427c_I20210630" decimals="INF" name="ocgn:CollaborativeArrangementProfitsGeneratedSharedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180MC9mcmFnOmQ3NTI3ZjBkNTk3YzRjNzdiNWMyZTRhY2ZlNzFlOGFiL3RleHRyZWdpb246ZDc1MjdmMGQ1OTdjNGM3N2I1YzJlNGFjZmU3MWU4YWJfOTUw_0e1ebbc9-e048-480f-8d45-748eceeafa1c">45</ix:nonFraction>% of such profits, and Bharat Biotech receiving the balance of such profits. In consideration of the expansion of the Ocugen Covaxin Territory to include Canada, the Company paid Bharat Biotech a non-refundable, upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i0ce37d1044984e42b76ce49925a5ea86_D20210601-20210630" decimals="-5" format="ixt:num-dot-decimal" name="ocgn:CollaborationAgreementUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180MC9mcmFnOmQ3NTI3ZjBkNTk3YzRjNzdiNWMyZTRhY2ZlNzFlOGFiL3RleHRyZWdpb246ZDc1MjdmMGQ1OTdjNGM3N2I1YzJlNGFjZmU3MWU4YWJfMTE4Mw_b9035c59-cd1b-4373-b85d-abb6787d14f9">15.0</ix:nonFraction>&#160;million in June 2021, which was recognized as research and development expense in the condensed consolidated statements of operations and comprehensive loss during the nine months ended September 30, 2021. The Company additionally agreed to pay Bharat Biotech $<ix:nonFraction unitRef="usd" contextRef="i0ce37d1044984e42b76ce49925a5ea86_D20210601-20210630" decimals="-5" format="ixt:num-dot-decimal" name="ocgn:CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180MC9mcmFnOmQ3NTI3ZjBkNTk3YzRjNzdiNWMyZTRhY2ZlNzFlOGFiL3RleHRyZWdpb246ZDc1MjdmMGQ1OTdjNGM3N2I1YzJlNGFjZmU3MWU4YWJfMTQyMA_afbbc667-8186-496f-8574-78f089c5e44d">10.0</ix:nonFraction>&#160;million within 30 days after the first commercial sale of COVAXIN in Canada. The Covaxin Agreement is a collaboration arrangement within the scope of ASC 808.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Covaxin Agreement, the Company and Bharat Biotech will collaborate to develop COVAXIN for their respective territories. Except with respect to manufacturing rights under certain circumstances subsequently described, the Company has the exclusive right and is solely responsible for researching, developing, manufacturing, and commercializing COVAXIN for the Ocugen Covaxin Territory. Bharat Biotech is responsible for researching, developing, manufacturing, and commercializing COVAXIN outside of the Ocugen Covaxin Territory. Bharat Biotech has agreed to provide to the Company all preclinical and clinical data, and to transfer to the Company certain proprietary technology owned or controlled by Bharat Biotech, that is necessary for the successful commercial manufacture and supply of COVAXIN to support commercial sale in the Ocugen Covaxin Territory. In September 2021, the Company entered into the Supply Agreement with Bharat Biotech, pursuant to which </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bharat Biotech will supply the Company with clinical trial materials and commercial supplies of COVAXIN finished drug product prior to the completion of the Company&#8217;s technology transfer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jubilant HollisterStier</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Following the completion of the Company&#8217;s technology transfer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jubilant HollisterStier</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bharat Biotech will supply COVAXIN drug product components and continue to supply finished drug product as necessary for commercial manufacture and supply of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVAXIN </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent to a regulatory authorization or approval. The technology transfer process to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jubilant HollisterStier has been initiated. In March 2021, the Company issued shares of Series B Convertible Preferred Stock (as defined in Note 9) as an advance payment for the supply of COVAXIN to be provided by Bharat Biotech under the Supply Agreement. See Note 9 for additional information about the Series B Convertible Preferred Stock issuance to Bharat Biotech. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><ix:continuation id="ib400cc09dc0947bcb2cfe1f2de97ffc8"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Covaxin Agreement continues in effect for the commercial life of COVAXIN, subject to the earlier termination of the Covaxin Agreement in accordance with its terms. The Covaxin Agreement also contains customary representations and warranties made by both parties and customary provisions relating to indemnification, limitation of liability, confidentiality, information and data sharing, and other matters. The Supply Agreement expires upon expiration of the Covaxin Agreement and may be earlier terminated by either party in the event of an uncured material breach or bankruptcy of the other party.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Co-Development and Commercialization Agreement with CanSinoBIO</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company entered into a co-development and commercialization agreement with CanSinoBIO with respect to the development and commercialization of OCU400. The co-development and commercialization agreement was subsequently amended in September 2021 (as so amended, the "CanSinoBIO Agreement"), whereby OCU410 was added to the Company's existing collaboration with CanSinoBIO. Pursuant to the CanSinoBIO Agreement, the Company and CanSinoBIO will collaborate on the development of OCU400 and OCU410 and CanSinoBIO will be responsible for the CMC development and manufacture of clinical supplies of such products and be responsible for the costs associated with such activities. CanSinoBIO will have an exclusive option to obtain a non-exclusive license from the Company to manufacture OCU400 and OCU410 for commercial sale by the Company. CanSinoBIO has an exclusive license to develop, manufacture, and commercialize OCU400 and OCU410 in and for China, Hong Kong, Macau, and Taiwan (the &#8220;CanSinoBIO Territory&#8221;), and the Company maintains exclusive development, manufacturing, and commercialization rights with respect to OCU400 and OCU410 outside the CanSinoBIO Territory (the &#8220;Company Territory&#8221;).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CanSinoBIO will pay to the Company an annual royalty between mid- and high-single digits based on Net Sales (as defined in the CanSinoBIO Agreement) of OCU400 and OCU410 in the CanSinoBIO Territory. The Company will pay to CanSinoBIO an annual royalty between low- and mid-single digits based on Net Sales (as defined in the CanSinoBIO Agreement) of OCU400 and OCU410 in the Company Territory.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated in accordance with its terms, the CanSinoBIO Agreement will continue in force on a country-by-country and product-by-product basis until the later of (a) the expiration of the last valid claim of patent rights of the Company covering such products and (b) the <ix:nonNumeric contextRef="i930c6519bb45486a8510eab5f83f11b2_D20190927-20190927" format="ixt-sec:duryear" name="ocgn:CollaborationAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180MC9mcmFnOmQ3NTI3ZjBkNTk3YzRjNzdiNWMyZTRhY2ZlNzFlOGFiL3RleHRyZWdpb246ZDc1MjdmMGQ1OTdjNGM3N2I1YzJlNGFjZmU3MWU4YWJfMzg0ODI5MDc1OTE0Mw_6c5c8377-a226-42c5-9d0c-eb3e424bbbca">10</ix:nonNumeric>th anniversary of the first commercial sale of such products in such country.</span></div></ix:continuation><div id="i9ff348f1ca104ec598a35c61fa9fc977_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180My9mcmFnOmNlZTg5ZTQ5NGVlMjRhYjFhYmI4NWQ2YzE0NDE2ZjlmL3RleHRyZWdpb246Y2VlODllNDk0ZWUyNGFiMWFiYjg1ZDZjMTQ0MTZmOWZfMTQ1OQ_97731b9b-d068-4ce4-848a-f8c156a980b5" continuedAt="i334d97066d4d46889a3e11fe1f4fa6e6" escape="true">Notes Receivable</ix:nonNumeric></span></div><ix:continuation id="i334d97066d4d46889a3e11fe1f4fa6e6"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 13, 2021, the Company received a promissory note in the principal amount of $<ix:nonFraction unitRef="usd" contextRef="i83096eac0fe34c3aae4e263271cd518e_I20210413" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesReceivableGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180My9mcmFnOmNlZTg5ZTQ5NGVlMjRhYjFhYmI4NWQ2YzE0NDE2ZjlmL3RleHRyZWdpb246Y2VlODllNDk0ZWUyNGFiMWFiYjg1ZDZjMTQ0MTZmOWZfMTEx_cceea330-0428-4cb7-a269-ff74f359a977">0.8</ix:nonFraction>&#160;million from a company in connection with a potential collaboration. The promissory note bore interest at a rate per annum of <ix:nonFraction unitRef="number" contextRef="i83096eac0fe34c3aae4e263271cd518e_I20210413" decimals="INF" name="ocgn:FinancingReceivableInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180My9mcmFnOmNlZTg5ZTQ5NGVlMjRhYjFhYmI4NWQ2YzE0NDE2ZjlmL3RleHRyZWdpb246Y2VlODllNDk0ZWUyNGFiMWFiYjg1ZDZjMTQ0MTZmOWZfMjMy_4fd6f01a-f58f-4f10-8f81-38d75b74f717">5</ix:nonFraction>% and the outstanding principal balance of the promissory note plus any accrued and unpaid interest thereon was payable in full on April 13, 2022 (the "Maturity Date"). Effective July 2021, the Company accepted an amended and restated promissory note (as so amended and restated, the "Promissory Note") pursuant to which the parties agreed to extend the Maturity Date of the Promissory Note to June 30, 2022 and increase the interest rate per annum to <ix:nonFraction unitRef="number" contextRef="i5db9a3b809794a18ba41b819b7fb0e60_I20210731" decimals="INF" name="ocgn:FinancingReceivableInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180My9mcmFnOmNlZTg5ZTQ5NGVlMjRhYjFhYmI4NWQ2YzE0NDE2ZjlmL3RleHRyZWdpb246Y2VlODllNDk0ZWUyNGFiMWFiYjg1ZDZjMTQ0MTZmOWZfNjg1_4c5313bc-4b33-4bc0-9205-94967b69cf2e">9</ix:nonFraction>% with quarterly interest payments. The Promissory Note may be prepaid in whole or in part at any time, together with accrued and unpaid interest. The Promissory Note contains customary covenants and events of default, including, among others, failure to make payment, breach of agreement, and bankruptcy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the probability of collecting the full principal and accrued interest balance under the terms of the Promissory Note and determined that collection was not probable. During the nine months ended September 30, 2021, the Company wrote off the full principal and accrued interest balance of the Promissory Note and recorded the write-off as a loss within other income (expense) within the condensed consolidated statements of operations and comprehensive loss.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RleHRyZWdpb246ODM2ZDI3ZDUzOGM4NGZlNzhjNGIyN2U2ZjkyZTg3N2RfMTk1_ef86e71f-a7c9-4096-9eed-4ab45bde6d66" continuedAt="i27c7009a60d34846bb35b2ec09a65a0a" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="i27c7009a60d34846bb35b2ec09a65a0a"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RleHRyZWdpb246ODM2ZDI3ZDUzOGM4NGZlNzhjNGIyN2U2ZjkyZTg3N2RfMTk2_eeeb1134-33db-4fcf-a0f3-2fc58394ec1f" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the major components of property and equipment as reflected on the condensed consolidated balance sheets (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ce6b5f7e39456fa1c454b1333db3bf_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfMS0xLTEtMS0w_c9da25a0-3b58-4029-a2b7-68b3aa0b2092">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia025bf7e0a1345c280160a2e194f23fe_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfMS0zLTEtMS0w_12e12035-5bf9-47cd-9b52-f1781d8c3c8b">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3aea31e66e540dc9949d6f9c0490ecb_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfMi0xLTEtMS0w_9c340be2-2ed4-4631-a3c7-65f05bcd2c7b">856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i812612c51e3f4f04bd8fb9b027a8a7ef_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfMi0zLTEtMS0w_c5f8bc61-2ba5-403e-a18e-7a2accb7177a">452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d4ea904d71e4543b361e76a666f0756_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfMy0xLTEtMS0w_f3a8674f-5164-4f52-875e-11037495b2b5">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefda904c07ce43da981ece8db16559f3_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfMy0zLTEtMS0w_4aa58c35-d118-47b3-b71d-34fc3ad95acf">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fa83702d12344a2b6ed8e9210300c3c_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfNC0xLTEtMS0yNTg0Mw_f6be2e83-8e7b-48ca-97b5-d532e012748a">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i451fd097deb743d79f6ad34002e75526_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfNC0zLTEtMS0yNTg0Mw_6763879d-ac76-47f2-97ef-4cf0c409dde3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfNC0xLTEtMS0w_686900c6-1fd7-4940-827c-6d69dba69d10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfNC0zLTEtMS0w_a6b1c290-55b1-4618-9464-cba00ce761d9">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfNS0xLTEtMS0w_e5a5aa76-6369-4239-a61f-83563e464b0f">1,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfNS0zLTEtMS0w_a8885775-5c61-4163-87d5-90a7bbd739a9">859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfNi0xLTEtMS0w_3ab30f0c-db35-4941-8656-8680761e5783">334</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfNi0zLTEtMS0w_caae973d-aacf-4bff-ab23-6db3fee9393b">226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfNy0xLTEtMS0w_8ec7574b-d3a3-45dc-9a04-8bb50450b3e4">1,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfNy0zLTEtMS0w_d4f781e8-821a-43dc-875b-4a8b14fe58a3">633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized depreciation expense of $<ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RleHRyZWdpb246ODM2ZDI3ZDUzOGM4NGZlNzhjNGIyN2U2ZjkyZTg3N2RfMTY0OTI2NzQ0NDAwOQ_c13b53c8-3a9c-45d3-86bc-787b023d6fe3">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RleHRyZWdpb246ODM2ZDI3ZDUzOGM4NGZlNzhjNGIyN2U2ZjkyZTg3N2RfMTY0OTI2NzQ0NDAxMw_d6770e76-7315-48d5-8a21-d931ff1e2cd6">0.2</ix:nonFraction> million during the three and nine months ended September&#160;30, 2021, respectively. The Company recognized depreciation expense of $<ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-2" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RleHRyZWdpb246ODM2ZDI3ZDUzOGM4NGZlNzhjNGIyN2U2ZjkyZTg3N2RfMjE5OTAyMzI1NzEzNw_7c4bff8e-3777-4cdc-a038-6dd903ea9868">19.8</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RleHRyZWdpb246ODM2ZDI3ZDUzOGM4NGZlNzhjNGIyN2U2ZjkyZTg3N2RfMjE5OTAyMzI1NzE1MQ_3f352bfe-21f3-4ded-9f12-6728dac6c48f">0.1</ix:nonFraction>&#160;million during the three and nine months ended September&#160;30, 2020, respectively.</span></div></ix:continuation><div id="i9ff348f1ca104ec598a35c61fa9fc977_49"></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RleHRyZWdpb246NDYwODhlNjUyZDg4NDBiNzk0MzFhNWQwNzYyZDQyMzRfMTYyOA_4584e6d6-c11a-42d8-89e1-955603028771" continuedAt="i4dabf417cf5844239e6f1a417656bddf" escape="true">Operating Leases</ix:nonNumeric></span></div><ix:continuation id="i4dabf417cf5844239e6f1a417656bddf" continuedAt="i7685c29fe6394add8965ae672f9ba88a"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has commitments under an operating lease for certain facilities used in its operations including for the use of laboratory, office, and storage space located in Malvern, Pennsylvania (the &#8220;Lease Agreement&#8221;). The Lease Agreement was determined to have two lease components per ASC 842, a laboratory space lease component (the "Initial Premises") and an office, storage, and future expanded laboratory space lease component (the "Expansion Premises"), with varying commencement dates. The Initial Premises commencement date occurred in December 2020 and the Expansion Premises commencement date occurred in January 2021. The Lease Agreement has an initial term of <ix:nonNumeric contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RleHRyZWdpb246NDYwODhlNjUyZDg4NDBiNzk0MzFhNWQwNzYyZDQyMzRfNzM2_40702a61-84a3-466e-86a6-2f6de9f3e361">seven years</ix:nonNumeric> and the Company has the option to extend the Lease Agreement for <ix:nonFraction unitRef="renewaloption" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="ocgn:LesseeOperatingLeaseNumberOfRenewalTerms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RleHRyZWdpb246NDYwODhlNjUyZDg4NDBiNzk0MzFhNWQwNzYyZDQyMzRfODA0_2ed54252-5573-4287-915a-00e0da322c57">one</ix:nonFraction> additional <ix:nonNumeric contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RleHRyZWdpb246NDYwODhlNjUyZDg4NDBiNzk0MzFhNWQwNzYyZDQyMzRfMTYyNA_eecf3fef-245f-4ddb-8833-6eab59892305">five-year</ix:nonNumeric> term. The option for extension has been excluded from the lease term (and lease liability) for the Lease Agreement as it is not reasonably certain that the Company will exercise such option. The Company terminated a former lease agreement for its previous office space with the same landlord without penalty upon the commencement of the Expansion Premises in January 2021.</span></div><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RleHRyZWdpb246NDYwODhlNjUyZDg4NDBiNzk0MzFhNWQwNzYyZDQyMzRfMTYzMA_85fd2873-8e59-422f-badd-82cf45e84a8e" continuedAt="i4fc104ea1f4e45be9e1182a6cc0f9717" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjIzNzYzNmU3ODYwODRlNWE5YzhiN2VlNWNhNzc0MTA0L3RhYmxlcmFuZ2U6MjM3NjM2ZTc4NjA4NGU1YTljOGI3ZWU1Y2E3NzQxMDRfMi0xLTEtMS0w_24395344-2696-4c81-ae8b-916816c82a64">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjIzNzYzNmU3ODYwODRlNWE5YzhiN2VlNWNhNzc0MTA0L3RhYmxlcmFuZ2U6MjM3NjM2ZTc4NjA4NGU1YTljOGI3ZWU1Y2E3NzQxMDRfMi0zLTEtMS0w_2f4c2d0d-81f0-4328-9d6a-a83e2cd3d616">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjIzNzYzNmU3ODYwODRlNWE5YzhiN2VlNWNhNzc0MTA0L3RhYmxlcmFuZ2U6MjM3NjM2ZTc4NjA4NGU1YTljOGI3ZWU1Y2E3NzQxMDRfMi01LTEtMS0w_d267d025-5fda-489c-ac5f-50349c12c7ed">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjIzNzYzNmU3ODYwODRlNWE5YzhiN2VlNWNhNzc0MTA0L3RhYmxlcmFuZ2U6MjM3NjM2ZTc4NjA4NGU1YTljOGI3ZWU1Y2E3NzQxMDRfMi03LTEtMS0w_84a1241e-bc89-4ac4-b1c9-e8f3b6ad8f46">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjIzNzYzNmU3ODYwODRlNWE5YzhiN2VlNWNhNzc0MTA0L3RhYmxlcmFuZ2U6MjM3NjM2ZTc4NjA4NGU1YTljOGI3ZWU1Y2E3NzQxMDRfMy0xLTEtMS0w_12db3ec9-d9ea-40fe-b699-dc05eadd5bb0">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjIzNzYzNmU3ODYwODRlNWE5YzhiN2VlNWNhNzc0MTA0L3RhYmxlcmFuZ2U6MjM3NjM2ZTc4NjA4NGU1YTljOGI3ZWU1Y2E3NzQxMDRfMy0zLTEtMS0w_bc2b4a0b-b02e-48b9-b28d-ccdb8f9fdf74">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjIzNzYzNmU3ODYwODRlNWE5YzhiN2VlNWNhNzc0MTA0L3RhYmxlcmFuZ2U6MjM3NjM2ZTc4NjA4NGU1YTljOGI3ZWU1Y2E3NzQxMDRfMy01LTEtMS0w_c1487ffd-1d22-4c9a-9548-53d4c9c9a99d">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjIzNzYzNmU3ODYwODRlNWE5YzhiN2VlNWNhNzc0MTA0L3RhYmxlcmFuZ2U6MjM3NjM2ZTc4NjA4NGU1YTljOGI3ZWU1Y2E3NzQxMDRfMy03LTEtMS0w_53cd61f9-5a6d-4171-8e48-ca1e7e0e8d06">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjIzNzYzNmU3ODYwODRlNWE5YzhiN2VlNWNhNzc0MTA0L3RhYmxlcmFuZ2U6MjM3NjM2ZTc4NjA4NGU1YTljOGI3ZWU1Y2E3NzQxMDRfNC0xLTEtMS0w_1c82fb70-930c-432b-b514-3ac59e4d5a2a">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjIzNzYzNmU3ODYwODRlNWE5YzhiN2VlNWNhNzc0MTA0L3RhYmxlcmFuZ2U6MjM3NjM2ZTc4NjA4NGU1YTljOGI3ZWU1Y2E3NzQxMDRfNC0zLTEtMS0w_e8f4b05f-0fbb-4a03-a8b3-5388571b0cd8">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjIzNzYzNmU3ODYwODRlNWE5YzhiN2VlNWNhNzc0MTA0L3RhYmxlcmFuZ2U6MjM3NjM2ZTc4NjA4NGU1YTljOGI3ZWU1Y2E3NzQxMDRfNC01LTEtMS0w_f7055964-2016-4e18-abf9-32450e499451">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjIzNzYzNmU3ODYwODRlNWE5YzhiN2VlNWNhNzc0MTA0L3RhYmxlcmFuZ2U6MjM3NjM2ZTc4NjA4NGU1YTljOGI3ZWU1Y2E3NzQxMDRfNC03LTEtMS0w_57c67914-00b7-4b74-8bd7-5595af7016e0">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="ocgn:SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RleHRyZWdpb246NDYwODhlNjUyZDg4NDBiNzk0MzFhNWQwNzYyZDQyMzRfMTYyMg_2d852568-9689-484c-8866-9852ed1b4edb" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjI1YjUxM2Y4OTU0YjQ3YjM5YWM2ZjhiN2FlYTEyMjAxL3RhYmxlcmFuZ2U6MjViNTEzZjg5NTRiNDdiMzlhYzZmOGI3YWVhMTIyMDFfMS0xLTEtMS0w_917875fa-fe63-4683-a94d-e310c43e1a15">1,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjI1YjUxM2Y4OTU0YjQ3YjM5YWM2ZjhiN2FlYTEyMjAxL3RhYmxlcmFuZ2U6MjViNTEzZjg5NTRiNDdiMzlhYzZmOGI3YWVhMTIyMDFfMS0zLTEtMS0w_c5707f6c-3b4e-44d1-b9d3-13fd62c41f88">434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current lease obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjI1YjUxM2Y4OTU0YjQ3YjM5YWM2ZjhiN2FlYTEyMjAxL3RhYmxlcmFuZ2U6MjViNTEzZjg5NTRiNDdiMzlhYzZmOGI3YWVhMTIyMDFfMy0xLTEtMS0w_a87c1e44-7e5c-4949-a3b5-1acf2d99d18e">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjI1YjUxM2Y4OTU0YjQ3YjM5YWM2ZjhiN2FlYTEyMjAxL3RhYmxlcmFuZ2U6MjViNTEzZjg5NTRiNDdiMzlhYzZmOGI3YWVhMTIyMDFfMy0zLTEtMS0w_53e5e061-2ddf-42ab-aa3f-03b571dfc376">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjI1YjUxM2Y4OTU0YjQ3YjM5YWM2ZjhiN2FlYTEyMjAxL3RhYmxlcmFuZ2U6MjViNTEzZjg5NTRiNDdiMzlhYzZmOGI3YWVhMTIyMDFfNC0xLTEtMS0w_1fea1e0e-2110-44c2-979e-287a08000525">1,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjI1YjUxM2Y4OTU0YjQ3YjM5YWM2ZjhiN2FlYTEyMjAxL3RhYmxlcmFuZ2U6MjViNTEzZjg5NTRiNDdiMzlhYzZmOGI3YWVhMTIyMDFfNC0zLTEtMS0w_4238623a-9eee-4250-863d-6d6af946a010">389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjI1YjUxM2Y4OTU0YjQ3YjM5YWM2ZjhiN2FlYTEyMjAxL3RhYmxlcmFuZ2U6MjViNTEzZjg5NTRiNDdiMzlhYzZmOGI3YWVhMTIyMDFfNS0xLTEtMS0w_5bc3b16c-8b05-4da4-bd4c-22bed19513b6">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjI1YjUxM2Y4OTU0YjQ3YjM5YWM2ZjhiN2FlYTEyMjAxL3RhYmxlcmFuZ2U6MjViNTEzZjg5NTRiNDdiMzlhYzZmOGI3YWVhMTIyMDFfNS0zLTEtMS0w_add4522e-5983-4efe-8e3c-260f89be12d6">433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><ix:continuation id="i7685c29fe6394add8965ae672f9ba88a"><ix:continuation id="i4fc104ea1f4e45be9e1182a6cc0f9717"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental information related to leases was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term &#8212; operating leases (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjA1M2U0ZWZjZTQ1OTQ5NDQ5ZmM0MWIzMjY0ZGUyNGFlL3RhYmxlcmFuZ2U6MDUzZTRlZmNlNDU5NDk0NDlmYzQxYjMyNjRkZTI0YWVfMi0xLTEtMS0w_930e412d-ebb9-4dbb-9275-38cdc2632085">6.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7033dd63053e40b9b5c54b579a67eebc_I20200930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjA1M2U0ZWZjZTQ1OTQ5NDQ5ZmM0MWIzMjY0ZGUyNGFlL3RhYmxlcmFuZ2U6MDUzZTRlZmNlNDU5NDk0NDlmYzQxYjMyNjRkZTI0YWVfMi0zLTEtMS0w_d49397d2-b7d5-447a-823d-92355b22b5c2">1.4</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate &#8212; operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjA1M2U0ZWZjZTQ1OTQ5NDQ5ZmM0MWIzMjY0ZGUyNGFlL3RhYmxlcmFuZ2U6MDUzZTRlZmNlNDU5NDk0NDlmYzQxYjMyNjRkZTI0YWVfMy0xLTEtMS0w_9481b31d-2363-4486-a0ee-e430d8ce6b8a">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7033dd63053e40b9b5c54b579a67eebc_I20200930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjA1M2U0ZWZjZTQ1OTQ5NDQ5ZmM0MWIzMjY0ZGUyNGFlL3RhYmxlcmFuZ2U6MDUzZTRlZmNlNDU5NDk0NDlmYzQxYjMyNjRkZTI0YWVfMy0zLTEtMS0w_327d4755-54fd-46f5-b49e-58745b95816d">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RleHRyZWdpb246NDYwODhlNjUyZDg4NDBiNzk0MzFhNWQwNzYyZDQyMzRfMTYzMw_7b8e2740-18ef-40ac-889b-552220d4e8db" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum operating lease base rent payments are approximately as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOmE0MjFhYTFlMTEwZDQwMTA5OWYwYzlkMDZlYzZlMmYzL3RhYmxlcmFuZ2U6YTQyMWFhMWUxMTBkNDAxMDk5ZjBjOWQwNmVjNmUyZjNfMS0xLTEtMS0w_0a46f606-6a2b-4905-9d02-e3c52f0695b6">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOmE0MjFhYTFlMTEwZDQwMTA5OWYwYzlkMDZlYzZlMmYzL3RhYmxlcmFuZ2U6YTQyMWFhMWUxMTBkNDAxMDk5ZjBjOWQwNmVjNmUyZjNfMi0xLTEtMS0w_858e7bc9-848c-4c60-a9d3-c029fa5075a4">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOmE0MjFhYTFlMTEwZDQwMTA5OWYwYzlkMDZlYzZlMmYzL3RhYmxlcmFuZ2U6YTQyMWFhMWUxMTBkNDAxMDk5ZjBjOWQwNmVjNmUyZjNfMy0xLTEtMS0w_852572ed-ff91-4451-bbc4-e9414984dd91">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOmE0MjFhYTFlMTEwZDQwMTA5OWYwYzlkMDZlYzZlMmYzL3RhYmxlcmFuZ2U6YTQyMWFhMWUxMTBkNDAxMDk5ZjBjOWQwNmVjNmUyZjNfNC0xLTEtMS0w_caa7dbd3-501e-4c4e-b8f9-e1fcd036570e">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOmE0MjFhYTFlMTEwZDQwMTA5OWYwYzlkMDZlYzZlMmYzL3RhYmxlcmFuZ2U6YTQyMWFhMWUxMTBkNDAxMDk5ZjBjOWQwNmVjNmUyZjNfNS0xLTEtMS0w_d3a72f8a-beb8-42e1-a4ba-b37aaee131a3">277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" name="ocgn:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOmE0MjFhYTFlMTEwZDQwMTA5OWYwYzlkMDZlYzZlMmYzL3RhYmxlcmFuZ2U6YTQyMWFhMWUxMTBkNDAxMDk5ZjBjOWQwNmVjNmUyZjNfNi0xLTEtMS0w_d39f6b46-ae98-49b4-9a9b-cc6a795c39d9">578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOmE0MjFhYTFlMTEwZDQwMTA5OWYwYzlkMDZlYzZlMmYzL3RhYmxlcmFuZ2U6YTQyMWFhMWUxMTBkNDAxMDk5ZjBjOWQwNmVjNmUyZjNfNy0xLTEtMS0w_6ac340f2-acbf-438b-954f-98591a7ffafc">1,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOmE0MjFhYTFlMTEwZDQwMTA5OWYwYzlkMDZlYzZlMmYzL3RhYmxlcmFuZ2U6YTQyMWFhMWUxMTBkNDAxMDk5ZjBjOWQwNmVjNmUyZjNfOC0xLTEtMS0w_112e5133-62ba-4978-8a1f-3586bb7167b5">226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of minimum lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOmE0MjFhYTFlMTEwZDQwMTA5OWYwYzlkMDZlYzZlMmYzL3RhYmxlcmFuZ2U6YTQyMWFhMWUxMTBkNDAxMDk5ZjBjOWQwNmVjNmUyZjNfOS0xLTEtMS0w_aec7675c-16cd-4f41-ae64-1a105259bb20">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to September&#160;30, 2021, the Company entered into a lease agreement for additional office space located in Malvern, Pennsylvania. See Note 14 for additional information.</span></div></ix:continuation><div id="i9ff348f1ca104ec598a35c61fa9fc977_52"></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfMTE5OQ_c875e796-7075-43fd-9f0e-52f61a50f980" continuedAt="i0ba39fd67ecd4a5fb5ea218bb2ee6aab" escape="true">Accrued Expenses and Other Current Liabilities</ix:nonNumeric></span></div><ix:continuation id="i0ba39fd67ecd4a5fb5ea218bb2ee6aab"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfMTIwNA_58c8b5dc-16a2-495a-b165-603b4c4103f0" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research&#160;and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="ocgn:ResearchAndDevelopmentExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfMS0xLTEtMS0w_1ac08317-c431-400a-b18b-bfe7e2e4d039">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" name="ocgn:ResearchAndDevelopmentExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfMS0zLTEtMS0w_d1e2928f-ac87-44ff-9a5d-33b7668f7b8a">512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" name="ocgn:AccruedLiabilitiesClinical" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfMi0xLTEtMS0w_ddc30696-5024-4a1d-8f14-7bf909448b77">585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" name="ocgn:AccruedLiabilitiesClinical" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfMi0zLTEtMS0w_b6d2d94e-75ca-4a6a-9e65-f8f9dd87d88d">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" name="ocgn:AccruedLiabilitiesProfessionalFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfMy0xLTEtMS0w_38ea2b04-f619-41e4-bbde-8cddbe0e2790">610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" name="ocgn:AccruedLiabilitiesProfessionalFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfMy0zLTEtMS0w_5f7bc660-4408-40d8-bc01-8f99345cd5a0">405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee-related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfNC0xLTEtMS0w_90a5889c-2fef-4d24-8e1a-06c3964621a4">1,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfNC0zLTEtMS0w_93918847-17c4-4d43-81fc-b71c10753782">963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance-related (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" name="ocgn:AccruedSeveranceRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfNS0xLTEtMS0w_321cf29b-ce91-4e11-8576-d7bc9dc7cf40">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" name="ocgn:AccruedSeveranceRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfNS0zLTEtMS0w_f5061c8b-5af6-4339-a7cf-af630998c3f2">712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfNi0xLTEtMS0w_d51cf85b-9707-4b47-bde4-0476b7673be1">422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfNi0zLTEtMS0w_de524347-1724-4449-8fb3-01206e8a18aa">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfNy0xLTEtMS0w_9f8537bf-2d35-44ac-a236-44c6235a3bab">3,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfNy0zLTEtMS0w_cc021caa-485f-4567-9f06-96b87b322701">2,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) In June 2020, the Company communicated notice to <ix:nonFraction unitRef="employee" contextRef="ic0c6fee7c66143fa90b7e09a8bd0054b_D20200601-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfMjEz_a555f8b1-01db-4b41-a13b-f25fd7915c76">five</ix:nonFraction> employees of the termination of their employment as a result of the discontinuation of a product candidate. This reduction represented one-third of the Company&#8217;s workforce at the time of communication. All terminations were &#8220;without cause&#8221; and each employee received termination benefits upon departure. The termination dates varied for each employee and ranged from June 30, 2020 to December 31, 2020.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized <ix:nonFraction unitRef="usd" contextRef="if6931d48727f42d1b569e46c6b6c8cf1_D20210701-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:RestructuringCharges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfNjE2_4284e81e-e17f-45b9-8419-8707ec0f2d98">no</ix:nonFraction> severance-related charges and a de minimis amount of severance-related charges during the three and nine months ended September&#160;30, 2021, respectively. The Company recognized severance-related charges of $<ix:nonFraction unitRef="usd" contextRef="icdfb9af1602f4e02a9cc734469158ec9_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfMjE5OTAyMzI2Mjk3OQ_9657b61f-6d35-452b-b9b2-001dfe1a0a5f">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib105875697514235a32c3d55a59c407f_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfMTY0OTI2NzQ0Mjg5NA_1db3a6ea-8338-45d8-8e6e-e6be91af9306">1.1</ix:nonFraction> million during the three and nine months ended September&#160;30, 2020, respectively. For the three months ended September 30, 2020, the Company recognized a de minimis amount of severance-related charges within general and administrative expense and $<ix:nonFraction unitRef="usd" contextRef="i892c2505d70d4215b4f0550ad9b0627e_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfMjE5OTAyMzI2MjE4Mw_23db16d0-8639-4918-a37f-e610d2b95534">0.4</ix:nonFraction> million of severance-related charges within research and development expense. For the nine months ended September 30, 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i02962ee3f8774d3c8d322068b02a66c8_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfMjE5OTAyMzI2MjIxNQ_b83be5ac-ec3b-4568-acb8-2a9f8cf9e810">0.2</ix:nonFraction> million of severance-related charges within general and administrative expense and $<ix:nonFraction unitRef="usd" contextRef="ie8440034266a4aa291b14ebaf3980ba1_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfMjE5OTAyMzI2MjIzNA_bed42898-c2c9-427b-90e6-915677ffe799">0.9</ix:nonFraction> million of severance-related charges within research and development expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made severance payments of $<ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfOTcx_87345347-1482-4c8f-95c5-fa578959dd18">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfOTc4_d09b8e49-e539-4a26-ba0c-38ef23daeb14">0.6</ix:nonFraction>&#160;million during the three and nine months ended September&#160;30, 2021, respectively. The Company made severance payments of $<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfMTY0OTI2NzQ0Mjk5OA_12364b95-d9cc-4438-afd5-597091522219"><ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfMTY0OTI2NzQ0Mjk5OA_de32f680-b723-4af0-8a21-22b9acf3618e">0.2</ix:nonFraction></ix:nonFraction> million during the three and nine months ended September&#160;30, 2020. The Company expects to pay the remaining severance benefits of $<ix:nonFraction unitRef="usd" contextRef="i44daf8bae7c343758ee6b618e75c35f6_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfMTE2NQ_01bf22ad-1a02-433f-b629-707a8c5918ac">0.1</ix:nonFraction>&#160;million throughout the remainder of 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RleHRyZWdpb246N2FkNDczODUxZmU3NDk2N2E4ZGZiYzM2ODNiMTczMGJfMjk4Mg_15faa3ff-4575-4ba8-aaf7-a8cf22a38dc1" continuedAt="i580aa2ff8e0d4156835b5f1bf0548d22" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="i580aa2ff8e0d4156835b5f1bf0548d22"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RleHRyZWdpb246N2FkNDczODUxZmU3NDk2N2E4ZGZiYzM2ODNiMTczMGJfMjk3NQ_c53d0bc0-daec-4167-9c6d-839c35c0f7a6" continuedAt="i7d8e6a7cda7b4deca44c020deb2c54ad" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the carrying values for the components of debt as reflected on the condensed consolidated balance sheets (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PPP Note</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01a12a6485e345b6ab72567171ec0eb0_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjVhZjIyY2I0MTc5MDQ0MTdhNjgwNmRmMzZmODNlYTgyL3RhYmxlcmFuZ2U6NWFmMjJjYjQxNzkwNDQxN2E2ODA2ZGYzNmY4M2VhODJfMS0xLTEtMS0w_ce7b15bc-76b9-4068-a1e9-e577d6d10512">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i058f0a613fdb4fac8d51eb184f27c5b6_I20201231" decimals="-3" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjVhZjIyY2I0MTc5MDQ0MTdhNjgwNmRmMzZmODNlYTgyL3RhYmxlcmFuZ2U6NWFmMjJjYjQxNzkwNDQxN2E2ODA2ZGYzNmY4M2VhODJfMS0zLTEtMS0w_4979565a-49ab-4c9a-9525-bdd5044506ae">421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EB-5 Loan Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ea040ac4094cb2a62e60e72ca77b3c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjVhZjIyY2I0MTc5MDQ0MTdhNjgwNmRmMzZmODNlYTgyL3RhYmxlcmFuZ2U6NWFmMjJjYjQxNzkwNDQxN2E2ODA2ZGYzNmY4M2VhODJfMi0xLTEtMS0w_1d365688-58a7-451c-a253-c5438662a186">1,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i745fb75cca5b4c23886a4754e42262f8_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjVhZjIyY2I0MTc5MDQ0MTdhNjgwNmRmMzZmODNlYTgyL3RhYmxlcmFuZ2U6NWFmMjJjYjQxNzkwNDQxN2E2ODA2ZGYzNmY4M2VhODJfMi0zLTEtMS0w_e88a52d8-d9f9-465e-a5c8-98939b2760a3">1,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjVhZjIyY2I0MTc5MDQ0MTdhNjgwNmRmMzZmODNlYTgyL3RhYmxlcmFuZ2U6NWFmMjJjYjQxNzkwNDQxN2E2ODA2ZGYzNmY4M2VhODJfMy0xLTEtMS0w_2a37604a-88cf-49b0-b755-70cdfe35370c">1,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjVhZjIyY2I0MTc5MDQ0MTdhNjgwNmRmMzZmODNlYTgyL3RhYmxlcmFuZ2U6NWFmMjJjYjQxNzkwNDQxN2E2ODA2ZGYzNmY4M2VhODJfMy0zLTEtMS0w_783343f1-ea21-4786-888c-84c4035703e1">2,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PPP Note</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company was granted a loan from Silicon Valley Bank ("SVB"), in the amount of $<ix:nonFraction unitRef="usd" contextRef="i85638365ecb449f89cd737e151a543eb_I20200430" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RleHRyZWdpb246N2FkNDczODUxZmU3NDk2N2E4ZGZiYzM2ODNiMTczMGJfMjc3_d623168f-7eb5-4079-a002-7c6a00cbc061">0.4</ix:nonFraction>&#160;million, pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) of the Coronavirus Aid, Relief and Economic Security Act of 2020 (the &#8220;CARES Act&#8221;). Under the PPP, the loan was eligible for forgiveness to the extent the funds received were used for qualifying expenses as described by the CARES Act. The loan was in the form of a promissory note dated April 30, 2020 in favor of SVB (the "PPP Note"). The PPP Note had a maturity date of April 30, 2022 and bore interest at a rate of <ix:nonFraction unitRef="number" contextRef="i85638365ecb449f89cd737e151a543eb_I20200430" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RleHRyZWdpb246N2FkNDczODUxZmU3NDk2N2E4ZGZiYzM2ODNiMTczMGJfNzMx_4308e78b-64a4-4cbb-b923-2d854f9a5e7f">1.0</ix:nonFraction>% per annum. The Company did not provide any collateral or guarantees for the loan, nor did the Company pay any facility charge to obtain the loan. The PPP Note provided for customary events of default, including, among others, failure to make payment, bankruptcy, breaches of representations, and material adverse events. In May 2021, the Company received notice from the Small Business Administration that the PPP Note was forgiven in its entirety, including both principal and accrued interest. The Company recognized a $<ix:nonFraction unitRef="usd" contextRef="i5b1b73d8695b4c07b67f45b9ef51765e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RleHRyZWdpb246N2FkNDczODUxZmU3NDk2N2E4ZGZiYzM2ODNiMTczMGJfMTI2Nw_a130f55b-17ae-436d-a9af-4d21c4f6aaca">0.4</ix:nonFraction>&#160;million gain on loan extinguishment within other income (expense) for the forgiveness of the PPP Note within the condensed consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EB-5 Loan Agreement</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September&#160;2016, pursuant to the U.S. government&#8217;s Immigrant Investor Program, commonly known as the EB-5 program (the &#8220;EB-5 Program&#8221;), the Company entered into an arrangement (the &#8220;EB-5 Loan Agreement&#8221;) to borrow up to $<ix:nonFraction unitRef="usd" contextRef="i0894763e64ad446393df6c07eb805c5f_I20160930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RleHRyZWdpb246N2FkNDczODUxZmU3NDk2N2E4ZGZiYzM2ODNiMTczMGJfMTcxNg_9233c948-071e-46f9-a3ed-702b619c1818">10.0</ix:nonFraction>&#160;million from EB5 Life Sciences,&#160;L.P. (&#8220;EB-5 Life Sciences&#8221;) in $<ix:nonFraction unitRef="usd" contextRef="if4082401304e4bc3881503b617da5ec7_D20160901-20160930" decimals="INF" format="ixt:num-dot-decimal" name="ocgn:LineOfCreditBorrowingEachDraw" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RleHRyZWdpb246N2FkNDczODUxZmU3NDk2N2E4ZGZiYzM2ODNiMTczMGJfMTc3NA_df7bec3f-ac2c-4693-813e-31af61684a1a">0.5</ix:nonFraction>&#160;million increments. Borrowings may be limited by the amount of funds raised by EB-5 Life Sciences and are subject to certain job creation requirements by the Company. Borrowings are at a fixed interest rate of <ix:nonFraction unitRef="number" contextRef="i0894763e64ad446393df6c07eb805c5f_I20160930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RleHRyZWdpb246N2FkNDczODUxZmU3NDk2N2E4ZGZiYzM2ODNiMTczMGJfMTk4Mg_553759cc-4a17-43c8-aa63-a7e993e4eaec">4.0</ix:nonFraction>% per annum and are to be utilized in the clinical development, manufacturing, and commercialization of the Company&#8217;s product candidates and for the general working capital needs of the Company. Outstanding borrowings pursuant to the EB-5 Loan Agreement, including accrued interest, become due upon the seventh anniversary of the final disbursement. Amounts repaid cannot be re-borrowed. The EB-5 Loan Agreement borrowings are secured by substantially all assets of the Company, except for any patents, patent applications, pending patents, patent licenses, patent sublicenses, trademarks, and other intellectual property rights.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms and conditions of the EB-5 Loan Agreement, the Company borrowed $<ix:nonFraction unitRef="usd" contextRef="i2b01d2f4d0c54ea186a70f5469b418fa_I20161231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RleHRyZWdpb246N2FkNDczODUxZmU3NDk2N2E4ZGZiYzM2ODNiMTczMGJfMjY5Mw_2f9d7766-4f3f-4b2b-a03b-27dcc9d106ac">1.0</ix:nonFraction> million in 2016 and an additional $<ix:nonFraction unitRef="usd" contextRef="i48e097bc118a40018d9f9179ffd7ca57_I20200331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RleHRyZWdpb246N2FkNDczODUxZmU3NDk2N2E4ZGZiYzM2ODNiMTczMGJfMjcyMg_5349fb3d-cddd-47ee-ba14-562c7f92baac">0.5</ix:nonFraction> million in March 2020. Issuance costs were recognized as a reduction to the loan balance and are amortized to interest expense over the term of the loan.</span></div><ix:continuation id="i7d8e6a7cda7b4deca44c020deb2c54ad"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of the EB-5 Loan Agreement borrowings as of September&#160;30, 2021 and December&#160;31, 2020 are summarized below (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal outstanding</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ea040ac4094cb2a62e60e72ca77b3c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjc2MzMzYjY3MGI2YTRlY2ZiYzZiMmYxZWQ2NjEyOWY0L3RhYmxlcmFuZ2U6NzYzMzNiNjcwYjZhNGVjZmJjNmIyZjFlZDY2MTI5ZjRfMS0xLTEtMS0w_cee502da-6c68-44aa-a64c-1c6c6052ed3f">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i745fb75cca5b4c23886a4754e42262f8_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjc2MzMzYjY3MGI2YTRlY2ZiYzZiMmYxZWQ2NjEyOWY0L3RhYmxlcmFuZ2U6NzYzMzNiNjcwYjZhNGVjZmJjNmIyZjFlZDY2MTI5ZjRfMS0zLTEtMS0w_32911d1f-e2bb-40ee-b9b8-61826cc0e567">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ea040ac4094cb2a62e60e72ca77b3c_I20210930" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjc2MzMzYjY3MGI2YTRlY2ZiYzZiMmYxZWQ2NjEyOWY0L3RhYmxlcmFuZ2U6NzYzMzNiNjcwYjZhNGVjZmJjNmIyZjFlZDY2MTI5ZjRfMi0xLTEtMS0w_e9cab1db-e4b1-4e25-9f29-659649427525">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i745fb75cca5b4c23886a4754e42262f8_I20201231" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjc2MzMzYjY3MGI2YTRlY2ZiYzZiMmYxZWQ2NjEyOWY0L3RhYmxlcmFuZ2U6NzYzMzNiNjcwYjZhNGVjZmJjNmIyZjFlZDY2MTI5ZjRfMi0zLTEtMS0w_1c904be2-83fa-49c7-8b0d-7bffdd92e3ab">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92ea040ac4094cb2a62e60e72ca77b3c_I20210930" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjc2MzMzYjY3MGI2YTRlY2ZiYzZiMmYxZWQ2NjEyOWY0L3RhYmxlcmFuZ2U6NzYzMzNiNjcwYjZhNGVjZmJjNmIyZjFlZDY2MTI5ZjRfMy0xLTEtMS0w_06463af5-4585-49b2-a84a-6a15e2292892">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i745fb75cca5b4c23886a4754e42262f8_I20201231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjc2MzMzYjY3MGI2YTRlY2ZiYzZiMmYxZWQ2NjEyOWY0L3RhYmxlcmFuZ2U6NzYzMzNiNjcwYjZhNGVjZmJjNmIyZjFlZDY2MTI5ZjRfMy0zLTEtMS0w_1d45b0e8-ddfb-49b2-a9cc-dc8dc094cc9d">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ea040ac4094cb2a62e60e72ca77b3c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjc2MzMzYjY3MGI2YTRlY2ZiYzZiMmYxZWQ2NjEyOWY0L3RhYmxlcmFuZ2U6NzYzMzNiNjcwYjZhNGVjZmJjNmIyZjFlZDY2MTI5ZjRfNC0xLTEtMS0w_8a717057-539e-497a-8cec-730a669d59cf">1,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i745fb75cca5b4c23886a4754e42262f8_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjc2MzMzYjY3MGI2YTRlY2ZiYzZiMmYxZWQ2NjEyOWY0L3RhYmxlcmFuZ2U6NzYzMzNiNjcwYjZhNGVjZmJjNmIyZjFlZDY2MTI5ZjRfNC0zLTEtMS0w_d8506e2f-e685-4f9f-8cd9-001caa08c294">1,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNjE5Mw_0cdd37a4-f895-4b38-b554-82befeb26cc9" continuedAt="idc1f3824888f46bab034b84c34006f7a" escape="true">Equity</ix:nonNumeric></span></div><ix:continuation id="idc1f3824888f46bab034b84c34006f7a" continuedAt="if76f6fe92a6c4e2d89128300fa001849"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVAXIN Preferred Stock Purchase Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2021, the Company entered into a preferred stock purchase agreement, pursuant to which the Company agreed to issue and sell <ix:nonFraction unitRef="shares" contextRef="ie1f83da91a62482bafefc243a5610119_D20210301-20210301" decimals="-5" format="ixt:num-dot-decimal" name="ocgn:SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMTk1_94ab77d0-0e6a-4ebf-b094-684ea0bf0a6e">0.1</ix:nonFraction>&#160;million shares of the Company&#8217;s Series B Convertible Preferred Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ia223aa6547ab48e8a989ed4c643adeaa_I20210301" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMjcw_fa946827-0697-40ab-90ea-9a70e4ee8b8a">0.01</ix:nonFraction> per share (the &#8220;Series B Convertible Preferred Stock&#8221;), at a price per share equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="ia223aa6547ab48e8a989ed4c643adeaa_I20210301" decimals="2" name="ocgn:SaleOfStockAgreementToSellPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMzU5_638875c6-7070-4837-8090-f749b5969c36">109.60</ix:nonFraction>, to Bharat Biotech. On March 18, 2021, the Company issued the Series B Convertible Preferred Stock as an advance payment for the supply of COVAXIN to be provided by Bharat Biotech pursuant to the Supply Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Series B Convertible Preferred Stock is convertible, at the option of Bharat Biotech, into <ix:nonFraction unitRef="shares" contextRef="ia223aa6547ab48e8a989ed4c643adeaa_I20210301" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNzc5_1d670f34-9d55-48da-a42e-4cc0534e1eaf">10</ix:nonFraction> shares of the Company&#8217;s common stock (the "Conversion Ratio") only after (i) the Company received stockholder approval to increase the number of authorized shares of common stock under its Sixth Amended and Restated Certificate of Incorporation and (ii) the Company&#8217;s receipt of shipments by Bharat Biotech of the first <ix:nonFraction unitRef="dose" contextRef="ia223aa6547ab48e8a989ed4c643adeaa_I20210301" decimals="-5" format="ixt:num-dot-decimal" name="ocgn:SupplyAgreementNumberOfDoses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMTEwNg_10e47db9-7a39-402d-bf3e-cfc474afed07">10.0</ix:nonFraction>&#160;million doses of COVAXIN manufactured by Bharat Biotech pursuant to the Supply Agreement, and further on the terms and subject to the conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (the "Certificate of Designation"). In April 2021, the Company's stockholders approved an increase in the number of the Company's authorized shares of common stock from <ix:nonFraction unitRef="shares" contextRef="i246cca5ff04f4a438cabbffe4ac0798c_I20210429" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMTUzOA_62c7f5d9-d315-4ab8-b1b0-a7d9555550dc">200.0</ix:nonFraction>&#160;million to <ix:nonFraction unitRef="shares" contextRef="iefbd2c9026804907ae58afb0f262bb0d_I20210430" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMTU0NA_405a3213-38d2-4ed9-8b5a-4ecd1bec8943">295.0</ix:nonFraction>&#160;million. As of September&#160;30, 2021, the conversion condition relating to the delivery of the first <ix:nonFraction unitRef="dose" contextRef="ide0135d45c4941c9938e0383f70a9804_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="ocgn:SupplyAgreementNumberOfDoses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMzg0ODI5MDcxODk4Mg_2ea28c8c-95ab-4b06-8499-8a5fc6213679">10.0</ix:nonFraction>&#160;million doses of COVAXIN had not been met. The conversion rate of the Series B Convertible Preferred Stock is subject to adjustment in the event of a stock dividend, stock split, reclassification, or similar event with respect to the Company&#8217;s common stock. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bharat Biotech is entitled to receive dividends on the Series B Convertible Preferred Stock equal (on an as-converted to common stock basis) to and in the same form as dividends actually paid on shares of common stock, when and if such dividends are paid. Except as provided by law and certain protective provisions set forth in the Certificate of Designation, the Series B Convertible Preferred Stock has no voting rights. Upon a liquidation or dissolution of the Company, holders of Series B Convertible Preferred Stock would be entitled to receive the same amount that a holder of common stock would receive if the Series B Convertible Preferred Stock were fully converted to common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for the issuance of the Series B Convertible Preferred Stock in accordance with ASC 718 and recorded the fair value of $<ix:nonFraction unitRef="usd" contextRef="i28b02ce452d34ea6b3c2e1dff6d45d00_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValueOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMjcwOQ_c2acdc91-d83b-4570-8322-acb7a86641b8">5.0</ix:nonFraction>&#160;million within equity during the nine months ended September 30, 2021, with a corresponding short-term asset for the advanced payment for the doses of COVAXIN. The Company utilized the traded common stock price, adjusted by the Conversion Ratio, to value the Series B Convertible Preferred Stock and the Finnerty model to estimate a <ix:nonFraction unitRef="number" contextRef="ie4ef9e6106c44af9adc546620f7b1580_I20210930" decimals="INF" name="ocgn:PreferredStockMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMzAwMw_d253c799-b84a-483b-8b7a-1ce3fdcdb8c0">15</ix:nonFraction>% discount rate for the lack of marketability of the instrument. The valuation incorporates Level 3 inputs in the fair value hierarchy, including the estimated time until the instrument's liquidity and the estimated volatility of the Company's common stock as of the grant date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Registered Direct Offerings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2021, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company agreed to issue and sell in a registered direct offering (the "April 2021 Registered Direct Offering") an aggregate of <ix:nonFraction unitRef="shares" contextRef="i90ca97f6066a4d9a810636493e1c9aac_D20210423-20210423" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMzU2OQ_9d6f58fc-78e6-4ba9-9cb7-04204e9a427c">10.0</ix:nonFraction>&#160;million shares of the Company's common stock at an offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i77df7a80e56a4e8facf772024c0e4945_I20210423" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMzYzMw_4f1c7361-5562-4ba5-9422-a4fb7c80e1bc">10.00</ix:nonFraction> per share. The closing of the April 2021 Registered Direct Offering occurred on April 27, 2021 and the Company received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i5862a96aeadd4f89b932761cb5f2e124_D20210427-20210427" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMzc3Mg_df20ba1b-c0ed-4765-8d45-23211476fab6">93.4</ix:nonFraction>&#160;million after deducting equity issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i5862a96aeadd4f89b932761cb5f2e124_D20210427-20210427" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMzgxNg_b114a7fe-794e-4bb2-9e2f-3d186dcd4f9c">6.6</ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2021, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company agreed to issue and sell in a registered direct offering (the "February 2021 Registered Direct Offering") an aggregate of <ix:nonFraction unitRef="shares" contextRef="i15f4aa0e8bfb449a842dfc32748a2a55_D20210207-20210207" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNDA4Nw_b23d675c-5638-42b7-a5fa-c10cfcf01d13">3.0</ix:nonFraction>&#160;million shares of the Company's common stock at an offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8a5e15fc5e9f4ab8b85dee2ee164fe5c_I20210207" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNDE1MQ_58741986-cbb2-4d70-b7ea-7ac68cbfd59a">7.65</ix:nonFraction> per share. The closing of the February 2021 Registered Direct Offering occurred on February 10, 2021 and the Company received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ia8cedc3486594d78b30a563076ebf2ad_D20210210-20210210" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNDI5Ng_a9514965-67e1-4869-84d5-8cffde61ee1b">21.2</ix:nonFraction>&#160;million after deducting equity issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ia8cedc3486594d78b30a563076ebf2ad_D20210210-20210210" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNDM0MA_7afd78ba-ca41-4c72-82e0-05f7d3183f33">1.7</ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Offerings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company commenced <ix:nonFraction unitRef="at-the-marketoffering" contextRef="i8b074737fd3840e3a89e6bc467ec5352_D20200501-20200831" decimals="INF" format="ixt-sec:numwordsen" name="ocgn:NumberOfAtTheMarketOfferings" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNDM5MA_6dd9829b-c61d-4de0-abf3-3d8f91b39274">three</ix:nonFraction> separate at-the-market offerings (each an "ATM", and collectively, the "ATMs") in May 2020, June 2020, and August 2020. The offerings were made pursuant to the Company's effective "shelf" registration statement on Form S-3 filed with the SEC on March 27, 2020, the base prospectus contained therein dated May 5, 2020, and the prospectus supplements related to the offerings dated May 8, 2020, June 12, 2020, and August 17, 2020. During the nine months ended September 30, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="iab0d59da4af045118182091dce3984c8_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNDg4NA_2c7447c0-b943-40d6-a150-d42772d25518">1.0</ix:nonFraction>&#160;million shares of the Company's common stock under the August 2020 ATM and received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="iab0d59da4af045118182091dce3984c8_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNDk3OQ_b9c3e743-1800-4eb0-9f7b-446825b1c24b">4.8</ix:nonFraction>&#160;million after deducting equity issuance costs of $<ix:nonFraction unitRef="usd" contextRef="iab0d59da4af045118182091dce3984c8_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNTAyMw_712591a5-7520-4787-8f59-afb006def3d5">0.1</ix:nonFraction>&#160;million. During the three and nine months </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><ix:continuation id="if76f6fe92a6c4e2d89128300fa001849"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended September&#160;30, 2020, the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="i00ccc0ff720749b1b14d75b3c93faa0d_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMTY0OTI2NzQ0ODY3NQ_8b19801a-0489-44ca-b03a-d5016bf1c1f7">27.0</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="iaa7b11c7997941d7a2ebe1202ae40792_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMTY0OTI2NzQ0ODY4OQ_4a349284-22e4-4d1d-a128-11fe0c663057">86.2</ix:nonFraction>&#160;million shares of the Company's common stock under the ATMs, respectively. During the three months ended September 30, 2020, the Company received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i00ccc0ff720749b1b14d75b3c93faa0d_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMTY0OTI2NzQ0ODc4Nw_58c02766-6d7e-4d09-9bcc-90ef1069549b">10.1</ix:nonFraction>&#160;million after deducting equity issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i00ccc0ff720749b1b14d75b3c93faa0d_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMTY0OTI2NzQ0ODgwMg_3238fa2d-dca1-4a27-8633-9187eb303ec6">0.4</ix:nonFraction>&#160;million. During the nine months ended September 30, 2020, the Company received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="iaa7b11c7997941d7a2ebe1202ae40792_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMTY0OTI2NzQ0ODg1Nw_4c2494bb-d6f2-423c-a334-9a9dd2517477">25.6</ix:nonFraction>&#160;million after deducting equity issuance costs of $<ix:nonFraction unitRef="usd" contextRef="iaa7b11c7997941d7a2ebe1202ae40792_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMTY0OTI2NzQ0ODg3Mg_ac469bde-36e3-47ed-ab5d-3dfba87074b3">1.1</ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subscription Agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into a subscription agreement with an accredited investor for the issuance of <ix:nonFraction unitRef="shares" contextRef="ia8019c49fc2b41d8809f0fc4847ce9b0_D20200601-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNTM3MQ_788565d6-d5a9-4955-b8a4-b599154e3d1b">1.3</ix:nonFraction>&#160;million shares of the Company's common stock in a private placement. The shares of common stock were issued as part of a transaction in settlement of an outstanding obligation of the Company to the accredited investor, in which (i) the Company agreed to make certain cash payments, (ii) the Company issued the <ix:nonFraction unitRef="shares" contextRef="ia8019c49fc2b41d8809f0fc4847ce9b0_D20200601-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNTY3Ng_8198e8a9-eb88-43b9-adde-d1a05a0f746b">1.3</ix:nonFraction>&#160;million shares of the Company's common stock in exchange for the accredited investor's agreement to cancel $<ix:nonFraction unitRef="usd" contextRef="i5068c87588174140afe885f4e47d066a_I20200630" decimals="-5" format="ixt:num-dot-decimal" name="ocgn:SaleOfStockOutstandingObligationCancelledInExchangeForStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNTc2NA_c3e403f3-b757-4b03-8217-46f5d0a1b83c">0.3</ix:nonFraction>&#160;million of the outstanding obligation, and (iii) the accredited investor agreed to cancel an additional portion of the amount owed by the Company representing a discount of $<ix:nonFraction unitRef="usd" contextRef="i5068c87588174140afe885f4e47d066a_I20200630" decimals="-5" format="ixt:num-dot-decimal" name="ocgn:SaleOfStockAdditionalDebtCancelledInExchangeForStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNTkzMg_d5f9e1fb-e0fb-48b0-9263-9d2a55a38a85">0.2</ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company entered into a subscription agreement with an accredited investor for the issuance of <ix:nonFraction unitRef="shares" contextRef="i8e02ac8495184af4af04566df93db8f7_D20200401-20200430" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNjA0OQ_e81cda54-130e-4c5f-825f-5bf90a82cedc">1,000</ix:nonFraction> shares of the Company's common stock in a private placement for an aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="i8e02ac8495184af4af04566df93db8f7_D20200401-20200430" decimals="0" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNjE0Nw_0fb6bcf8-5cd3-49a9-952d-504b8f1105b9">395</ix:nonFraction> (the "April 2020 Subscription Agreement").</span></div></ix:continuation><div id="i9ff348f1ca104ec598a35c61fa9fc977_61"></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="ocgn:WarrantsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMzU3OQ_6fbe9e89-dd4a-4531-b443-33cacc60c9c3" continuedAt="ic931c4a9c36644d4b4e5a7b6c4f5c1c2" escape="true">Warrants</ix:nonNumeric></span></div><ix:continuation id="ic931c4a9c36644d4b4e5a7b6c4f5c1c2" continuedAt="i13460e51eb8249f3bd668955c9b165c7"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Canada Warrants</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2021, the Company entered into a consulting agreement with an individual to provide services to the Company with regard to the Company's Canadian operations (the "Canada Consulting Agreement"). Compensation under the Canada Consulting Agreement includes, among other forms of compensation, the issuance of warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="ic8bd5469fd534b5fa1a3c3286b4599c4_I20210715" decimals="-5" format="ixt:num-dot-decimal" name="ocgn:ClassOfWarrantOrRightExercisable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfNDM5ODA0NjU0MzUxNg_ac6fe7b9-a7ca-4128-bec1-b571f5231578">0.2</ix:nonFraction>&#160;million shares of the Company's common stock (the "Canada Warrants") and cash payments of up to $<ix:nonFraction unitRef="usd" contextRef="ic8bd5469fd534b5fa1a3c3286b4599c4_I20210715" decimals="-5" format="ixt:num-dot-decimal" name="ocgn:ClassOfWarrantOrRightExpectedMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfNDM5ODA0NjU0MzYxMw_23f6f237-3ea1-4265-be82-b7d3e0c8ae5d">3.0</ix:nonFraction>&#160;million upon the achievement of certain milestones related to COVAXIN. The Canada Consulting Agreement terminates on July 15, 2023, unless earlier terminated in accordance with its terms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Canada Warrants were issued on July 15, 2021 in a private placement transaction. The warrantholder has the right to exercise the Canada Warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="ic8bd5469fd534b5fa1a3c3286b4599c4_I20210715" decimals="-5" format="ixt:num-dot-decimal" name="ocgn:ClassOfWarrantOrRightExercisable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfNDM5ODA0NjU0Mzk3Ng_7dcff5d3-adb9-4e33-b8e4-bf88dd27af2f">0.2</ix:nonFraction> million shares of the Company's common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic8bd5469fd534b5fa1a3c3286b4599c4_I20210715" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfNDM5ODA0NjU0NDA0MQ_848ccbee-5234-44fb-b6e6-70f2693ac490">6.36</ix:nonFraction> per share upon the achievement of certain milestones related to COVAXIN. The Canada Warrants terminate on July 15, 2031, unless earlier terminated in accordance with their terms. As of September&#160;30, 2021, all of the Canada Warrants were outstanding and unvested. The Canada Warrants are accounted for in accordance with ASC 718.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SPA Warrants</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company issued <ix:nonFraction unitRef="seriesofwarrant" contextRef="i1e39c130cffe499eaae2b4c55fef5b42_D20191001-20191031" decimals="INF" format="ixt-sec:numwordsen" name="ocgn:NumberOfSeriesOfWarrantsIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfNjc_a21f9bd2-f76c-49b0-989e-e62045ef26cf">three</ix:nonFraction> series of warrants to purchase shares of the Company&#8217;s common stock (the &#8220;Series A Warrants,&#8221; the &#8220;Series B Warrants&#8221;, and the &#8220;Series C Warrants&#8221; and collectively, the &#8220;SPA Warrants&#8221;) under a securities purchase agreement with certain accredited investors. In April 2020, the Company entered into the April 2020 Subscription Agreement, as discussed within Note 9, which represented a dilutive issuance as defined by the Series A Warrants and resulted in adjustments to the number of issuable Series A Warrants and the exercise price of the Series A Warrants. Immediately prior to the Company entering into the April 2020 Subscription Agreement, <ix:nonFraction unitRef="shares" contextRef="i24e2b7c0b5b1441cad39027ec7574d10_I20200331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfNzYz_12103ee1-6549-49b1-833a-8eea9d8de295">8.8</ix:nonFraction>&#160;million Series A Warrants, <ix:nonFraction unitRef="shares" contextRef="if01d7fad0a3f48a8bd13b30a1b84b704_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfNzg1_f8b658d7-993d-42a9-a63e-2642d27228dd">1,000</ix:nonFraction> Series B Warrants, and <ix:nonFraction unitRef="shares" contextRef="i99f2d4d98be64d7ea57dfff1f984ef8b_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfODEx_a5cdec48-2cb7-4a35-a10c-d0675bf4aeae">1,000</ix:nonFraction> Series C Warrants were outstanding. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contemporaneously with the April 2020 Subscription Agreement, the Company and OpCo entered into Amendment and Exchange Agreements (each an "Exchange Agreement" and collectively, the "Exchange Agreements") with the accredited investors. Pursuant to the Exchange Agreements, the Company, OpCo, and the accredited investors agreed, among other things, after giving effect to the dilutive issuance, to amend the Series A Warrants to provide for an adjustment to the number of common stock issuable upon the exercise of the Series A Warrants. Concurrently with such amendments, the accredited investors exchanged the Series A Warrants for (i) an aggregate of <ix:nonFraction unitRef="shares" contextRef="ie002070f257c4c608068b1b07255b1d5_D20200401-20200430" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMTUwNQ_f17950fb-741e-4355-a34c-f876107ef270">21.9</ix:nonFraction>&#160;million shares of the Company's common stock and (ii) promissory notes of $<ix:nonFraction unitRef="usd" contextRef="i06658032e2704ab282cc346ef006ef8f_I20200430" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMTU2Mg_7277543c-78f4-4ada-891f-5196a2a1926d">5.6</ix:nonFraction>&#160;million (the "Warrant Exchange Promissory Notes" and collectively with the common stock issued, the "Warrant Exchange"). During the three and nine months ended September&#160;30, 2020, the Company made payments to the Warrant Exchange Promissory Notes holders of $<ix:nonFraction unitRef="usd" contextRef="i8612a2a4329d46479292b57b3cd408f0_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMTY0OTI2NzQ0NTI5Nw_314c3627-b87c-4c93-bbae-3060cf875eda">3.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i86fc446c1c3b4958be93eb3d966f598a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMTY0OTI2NzQ0NTMxMQ_fae4c506-121f-40ba-950e-209c4cbfc959">4.4</ix:nonFraction>&#160;million, respectively. As of December&#160;31, 2020, the Warrant Exchange Promissory Notes had been repaid in full. Immediately following the consummation of the Warrant Exchange and the concurrent exercise of the remaining Series B Warrants and Series C Warrants, there were <ix:nonFraction unitRef="shares" contextRef="ib6e306f60ac94b79a20c2e697c2d41e0_I20200430" decimals="0" format="ixt:fixed-zero" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMjAyMw_a9580c13-d3d6-4c06-a344-55dd01b2a04d">no</ix:nonFraction> SPA Warrants outstanding.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><ix:continuation id="i13460e51eb8249f3bd668955c9b165c7"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for the Warrant Exchange by recognizing the fair value of the consideration transferred in excess of the carrying value of the Series A Warrants as a reduction of additional paid-in capital. The fair value of the Series A Warrants immediately prior to the Warrant Exchange was $<ix:nonFraction unitRef="usd" contextRef="i2a0df3b2c63543fd93b3be04483ec5a2_I20200430" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMjM1MQ_c216df03-49b6-4c3d-9bd0-f8b483e3424d">1.1</ix:nonFraction>&#160;million, which was estimated using a Black-Scholes valuation model utilizing Level 3 inputs. The fair value of the consideration transferred to settle the Series A Warrants was approximately $<ix:nonFraction unitRef="usd" contextRef="i0677fbde7da642e0bd593d8fa763f607_D20200401-20200430" decimals="-5" format="ixt:num-dot-decimal" name="ocgn:ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMjUzNw_68faf1b6-6b0b-40e7-aac5-e44c98d98fef">13.6</ix:nonFraction>&#160;million, comprised of $<ix:nonFraction unitRef="usd" contextRef="i0677fbde7da642e0bd593d8fa763f607_D20200401-20200430" decimals="-5" format="ixt:num-dot-decimal" name="ocgn:ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMjU1NA_e498c2b1-79ca-49bb-abe3-518ebb95005a">8.6</ix:nonFraction>&#160;million in shares of the Company's common stock and the fair value of the Warrant Exchange Promissory Notes of $<ix:nonFraction unitRef="usd" contextRef="i0677fbde7da642e0bd593d8fa763f607_D20200401-20200430" decimals="-5" format="ixt:num-dot-decimal" name="ocgn:ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMjY0Ng_521329ae-7ddf-4a3c-9b65-0e417c187f89">5.0</ix:nonFraction>&#160;million. The fair value of consideration transferred to settle the Series A Warrants was in excess of the fair value of the Series A Warrants immediately prior to the Warrant Exchange by approximately $<ix:nonFraction unitRef="usd" contextRef="i0677fbde7da642e0bd593d8fa763f607_D20200401-20200430" decimals="-5" format="ixt:num-dot-decimal" name="ocgn:ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMjg0Mg_a705dc5d-e65b-4ccf-80a8-85c78691aaa0">12.5</ix:nonFraction>&#160;million. The excess consideration was accounted for as a deemed dividend to the Series A Warrant holders and was reflected as an additional net loss to common stockholders in the calculation of basic and diluted net loss per common share for the nine months ended September 30, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">OpCo Warrants</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2016, OpCo issued warrants to purchase the Company's common stock (the "OpCo Warrants") to investors of the Company pursuant to a stockholders' agreement and to <ix:nonFraction unitRef="employee" contextRef="i04d1f309d9f74029a1b219a85f77a940_I20161231" decimals="INF" format="ixt-sec:numwordsen" name="ocgn:NumberOfFormerEmployeesWithWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMzI4Nw_30a1015d-12b3-4e3c-a244-2bd7eb6f411c">two</ix:nonFraction> employees of the Company pursuant to their respective employment agreements. As of September&#160;30, 2021 and December&#160;31, 2020, <ix:nonFraction unitRef="shares" contextRef="i275b6ac4e97c4be5aa1a51af8502831b_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="ocgn:ClassOfWarrantOrRightExercisable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMjE5OTAyMzI2MDY5Mw_49825420-e335-47d5-9c61-b2a401e308e1">0.8</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="iae6a400180f04a07b8febf2d6e0fa554_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="ocgn:ClassOfWarrantOrRightExercisable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMjE5OTAyMzI2MDY5Nw_1fb6a745-7397-4354-99f5-68611becbae3">0.9</ix:nonFraction> million OpCo Warrants were outstanding, respectively. As of September&#160;30, 2021 the outstanding OpCo Warrants had a weighted-average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i275b6ac4e97c4be5aa1a51af8502831b_I20210930" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMjE5OTAyMzI2MTQ5Mg_53d72b79-2afa-412c-9198-8190f58e3e5b">4.97</ix:nonFraction>. The outstanding OpCo Warrants expire between 2026 and 2027.</span></div></ix:continuation><div id="i9ff348f1ca104ec598a35c61fa9fc977_64"></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMjE3NA_a4162556-c72f-4e9d-90e1-f47f21c41963" continuedAt="id9930745d5464598a33c823d0b0a40df" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="id9930745d5464598a33c823d0b0a40df" continuedAt="i7861c76cdf794c2f87915339903f7f9a"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMjE3MQ_8786fef0-eced-4f4f-b926-cc3e7e77ebb4" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for stock options and RSUs is reflected in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0a8b70d6fb84c5a9789d450871ed83a_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmUxYTA1YTU4YWExYzQ1YmRiOWZmZTRlNmViYjA2NTA5L3RhYmxlcmFuZ2U6ZTFhMDVhNThhYTFjNDViZGI5ZmZlNGU2ZWJiMDY1MDlfMi0xLTEtMS0w_c0e619c2-0276-4356-bb36-6971df6d1517">840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8acfe33635854458877463fc16a751b4_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmUxYTA1YTU4YWExYzQ1YmRiOWZmZTRlNmViYjA2NTA5L3RhYmxlcmFuZ2U6ZTFhMDVhNThhYTFjNDViZGI5ZmZlNGU2ZWJiMDY1MDlfMi0zLTEtMS0w_8a163584-550c-43e3-a65f-74638f59a8dd">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7caedf65c1494e419cbafa5a7b2af8d9_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmUxYTA1YTU4YWExYzQ1YmRiOWZmZTRlNmViYjA2NTA5L3RhYmxlcmFuZ2U6ZTFhMDVhNThhYTFjNDViZGI5ZmZlNGU2ZWJiMDY1MDlfMi01LTEtMS0w_62a9a875-3e11-4f3c-a94f-5df2c27b2676">2,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830ec46fb29342e8a14435d6c8374e8f_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmUxYTA1YTU4YWExYzQ1YmRiOWZmZTRlNmViYjA2NTA5L3RhYmxlcmFuZ2U6ZTFhMDVhNThhYTFjNDViZGI5ZmZlNGU2ZWJiMDY1MDlfMi03LTEtMS0w_7536fd42-e8a1-47da-9bd8-fb536d61af0e">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34df5c33daa84097bbeb2f7aa78e9881_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmUxYTA1YTU4YWExYzQ1YmRiOWZmZTRlNmViYjA2NTA5L3RhYmxlcmFuZ2U6ZTFhMDVhNThhYTFjNDViZGI5ZmZlNGU2ZWJiMDY1MDlfMy0xLTEtMS0w_3720d38a-55f0-469a-b6e3-b54757278569">507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d5d5de7375c464ebdd9941535b546d4_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmUxYTA1YTU4YWExYzQ1YmRiOWZmZTRlNmViYjA2NTA5L3RhYmxlcmFuZ2U6ZTFhMDVhNThhYTFjNDViZGI5ZmZlNGU2ZWJiMDY1MDlfMy0zLTEtMS0w_ef1530e8-ecc4-4045-af67-5376c90ca7cb">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27f8c3a424b04ee8a9158f75127eec6e_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmUxYTA1YTU4YWExYzQ1YmRiOWZmZTRlNmViYjA2NTA5L3RhYmxlcmFuZ2U6ZTFhMDVhNThhYTFjNDViZGI5ZmZlNGU2ZWJiMDY1MDlfMy01LTEtMS0w_26c33a1a-2acd-4512-a628-b83c1eaee9b6">1,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfe523d076894ad581734cd76ae76f7e_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmUxYTA1YTU4YWExYzQ1YmRiOWZmZTRlNmViYjA2NTA5L3RhYmxlcmFuZ2U6ZTFhMDVhNThhYTFjNDViZGI5ZmZlNGU2ZWJiMDY1MDlfMy03LTEtMS0w_9b496e4a-74f9-4aab-9cc5-afe5e4dbbb43">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmUxYTA1YTU4YWExYzQ1YmRiOWZmZTRlNmViYjA2NTA5L3RhYmxlcmFuZ2U6ZTFhMDVhNThhYTFjNDViZGI5ZmZlNGU2ZWJiMDY1MDlfNC0xLTEtMS0w_9fe4b025-1713-42d0-b87d-d3501b027df1">1,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmUxYTA1YTU4YWExYzQ1YmRiOWZmZTRlNmViYjA2NTA5L3RhYmxlcmFuZ2U6ZTFhMDVhNThhYTFjNDViZGI5ZmZlNGU2ZWJiMDY1MDlfNC0zLTEtMS0w_3e1d7cb7-ade4-460b-976c-fa728c29de75">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmUxYTA1YTU4YWExYzQ1YmRiOWZmZTRlNmViYjA2NTA5L3RhYmxlcmFuZ2U6ZTFhMDVhNThhYTFjNDViZGI5ZmZlNGU2ZWJiMDY1MDlfNC01LTEtMS0w_71ce3fd1-65f4-4fa6-9264-680c1b06d0dd">4,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmUxYTA1YTU4YWExYzQ1YmRiOWZmZTRlNmViYjA2NTA5L3RhYmxlcmFuZ2U6ZTFhMDVhNThhYTFjNDViZGI5ZmZlNGU2ZWJiMDY1MDlfNC03LTEtMS0w_87223300-3e76-4e03-a577-9dac050e46e6">497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense during the three and nine months ended September&#160;30, 2021 included $<ix:nonFraction unitRef="usd" contextRef="i6efde1790e4d4c3f820f75713f6e84b9_D20210701-20210930" decimals="-2" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMjg2_22748423-4b7b-4aa7-9096-a5d654b51e1b">41.3</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="ibe51744fe7ab46b2a3e9f306f2e205ef_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMTY0OTI2NzQ0OTQ3Nw_344dd615-ea97-4b44-81eb-cb5ed8a8c1f2">1.1</ix:nonFraction> million of expense related to stock options with performance-based vesting conditions, respectively. <ix:nonFraction unitRef="usd" contextRef="iab3b4c48ef4b48df90d794b934740c1f_D20200701-20200930" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMzY4_b05027b5-91ed-43a1-9900-a049933e0f97"><ix:nonFraction unitRef="usd" contextRef="iaa3c7dd5eddd468da3b9df0f9934469a_D20200101-20200930" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMzY4_b4b37c43-e687-42e9-b098-7991d86e557f">No</ix:nonFraction></ix:nonFraction> stock-based compensation expense during the three and nine months ended September&#160;30, 2020 was related to stock options with performance-based vesting conditions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfNTMy_f9c85acc-3e01-4669-acbc-0f8b1d6f043f">13.9</ix:nonFraction>&#160;million of unrecognized stock-based compensation expense related to stock options and RSUs outstanding. This expense is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i3571bc8a75ac48659cc316e5763f4ed2_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfNzAx_6ca5b447-ef84-41fd-805d-21e642a29923">2.2</ix:nonNumeric> years as of September&#160;30, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Plans</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains <ix:nonFraction unitRef="segment" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="ocgn:NumberOfEquityCompensationPlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfNzQ5_0015d221-9abb-43f8-a50b-a11a28863133">two</ix:nonFraction> equity compensation plans, the 2014 Ocugen OpCo, Inc. Stock Option Plan (the &#8220;2014 Plan&#8221;) and the Ocugen, Inc. 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;, collectively with the 2014 Plan, the "Plans"). As of September&#160;30, 2021, the 2014 Plan and 2019 Plan authorize for the granting of up to <ix:nonFraction unitRef="shares" contextRef="i05d88bc2fdb94bfb85adba0bb8b27884_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMTAzMA_f3c9d261-e371-4a91-8ee3-44dd36bcc350">0.8</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="idcf0789a7cf8450dac2a8c051cc629b3_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMTAzNw_37796ef5-c4ed-4d26-b018-1ad1d57ae0cd">11.5</ix:nonFraction>&#160;million equity awards in respect to the Company's common stock, respectively. In addition to stock options and RSUs granted under the Plans, the Company has granted certain stock options and RSUs as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4), which were granted outside of the Plans.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><ix:continuation id="i7861c76cdf794c2f87915339903f7f9a"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options to Purchase Common Stock</span></div><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMjE3Mg_454ae3de-8763-4ae9-a4a0-be12f3e9f778" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfMS0xLTEtMS0w_63973849-8859-4ad2-94b2-3fb0803f1550">4,224,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfMS0zLTEtMS0w_23abd1f3-636e-4136-aaa6-d6f8f3c3726a">0.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8deb7fe79a024352817ef6e8af8f0441_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfMS01LTEtMS0w_c8aaf517-8a85-4e15-adac-02b71c93bf72">8.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfMS03LTEtMS0w_3f01a169-4e3d-4cd4-91d3-9483c5ed3ab0">5,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfMi0xLTEtMS0w_03b09915-4ca2-4f80-9f9f-2d152b1ca7b1">7,469,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfMi0zLTEtMS0w_0907a94e-29a3-4e14-a8bb-98838c116004">3.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfMy0xLTEtMS0w_9336f842-ec0b-4e7a-a420-8bbf754c5f99">901,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfMy0zLTEtMS0w_3b2ee551-2534-4a83-b2be-ccacb5e03ca2">0.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfMy03LTEtMS0w_b8c71a7e-b398-4dc9-baa4-18dabfebb846">8,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfNC0xLTEtMS0w_2c0c8b78-9d21-4ac0-bb67-b7dab4d1f51f">274,220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfNC0zLTEtMS0w_7a90d29b-c335-473c-b7ff-afa61eac760a">2.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="ocgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfNC03LTEtMS0w_04a7bb02-44f8-4c11-a396-94e10cd724fa">1,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfNS0xLTEtMS0w_4ec77515-5997-43b4-b964-ecfdb8d9a499">10,518,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfNS0zLTEtMS0w_8a3e0566-a043-4aea-a558-5f9fe0eac92e">2.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfNS01LTEtMS0w_21d2db93-4745-4d87-a965-0583da1ef1a5">9.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfNS03LTEtMS0w_5dc6f4a8-7d0f-4d89-9db4-8153aaf3fc0e">49,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfNi0xLTEtMS0w_f5ab33b1-430d-41b3-9672-238b85c25677">991,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfNi0zLTEtMS0w_94a8ad39-e745-4ac3-bcd9-67906cb6075b">1.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfNi01LTEtMS0w_4841858f-9cad-483f-8c43-a22e64fc6119">7.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfNi03LTEtMS0w_c4e24adb-1cc8-427a-8b6d-864979022a49">5,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options not yet exercisable as of September&#160;30, 2021 includes <ix:nonFraction unitRef="shares" contextRef="i5fe71549bdba4e09bf1e6455238c6445_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="ocgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMTY0OTI2NzQ0OTk1Mw_ccf6a1b1-c738-40b5-8d7a-bad43a23841e">1.5</ix:nonFraction>&#160;million stock options with performance-based vesting conditions. There were <ix:nonFraction unitRef="shares" contextRef="i78eaa94bd702419a8ec49cbc777b5ba7_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMTY0OTI2NzQ0OTc5Mg_e5a46cfe-b781-4853-a2d1-402bb6925611">no</ix:nonFraction> stock options with performance-based vesting conditions as of December&#160;31, 2020. The weighted-average grant date fair values of stock options granted during the three and nine months ended September&#160;30, 2021 were $<ix:nonFraction unitRef="usdPerShare" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMTc1NQ_0f52e449-2e35-4f83-9a3e-9893baebbe62">5.97</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMTc2Mg_b51ae21c-3bb3-4bf0-ad38-ab74c99d2823">2.77</ix:nonFraction>, respectively. The weighted-average grant date fair value of stock options granted during both the three and nine months ended September&#160;30, 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMTg4NA_1facc052-b4f1-41cf-890d-e747f67df243"><ix:nonFraction unitRef="usdPerShare" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMTg4NA_8a7af7b5-facc-414e-b69d-f446cd1ea0e8">0.34</ix:nonFraction></ix:nonFraction> per share. The total fair values of stock options vested during the three and nine months ended September&#160;30, 2021 were $<ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMTk4OA_f33625da-e1f4-4bcf-aacd-99c9ebef16df">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMTk5NQ_febb8593-46b5-4a15-9e1d-dfb24d0a949c">0.7</ix:nonFraction>&#160;million, respectively. The total fair values of stock options vested during the three and nine months ended September&#160;30, 2020 were $<ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMjA5Mg_f96447dd-0dac-41cc-8d60-6a94b9845313">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMjA5OQ_8bd9d238-95fe-46ac-815b-59701a03750d">0.3</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSUs</span></div><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMjE3Mw_f8b408ac-3339-464d-bd3c-d428d88647e2" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the RSU activity:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97535b68d960495f906585585e65538d_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmFjMmJkMDgzMWFiNjQ3YzViY2FiYzFkNzY4NjY1YjYwL3RhYmxlcmFuZ2U6YWMyYmQwODMxYWI2NDdjNWJjYWJjMWQ3Njg2NjViNjBfMS0xLTEtMS0w_b3e20854-41bb-47ed-b729-d2c1449e001b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i97535b68d960495f906585585e65538d_I20201231" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmFjMmJkMDgzMWFiNjQ3YzViY2FiYzFkNzY4NjY1YjYwL3RhYmxlcmFuZ2U6YWMyYmQwODMxYWI2NDdjNWJjYWJjMWQ3Njg2NjViNjBfMS0zLTEtMS0w_56fd9ca9-87b7-4b3d-bfa9-d21467335a09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97535b68d960495f906585585e65538d_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmFjMmJkMDgzMWFiNjQ3YzViY2FiYzFkNzY4NjY1YjYwL3RhYmxlcmFuZ2U6YWMyYmQwODMxYWI2NDdjNWJjYWJjMWQ3Njg2NjViNjBfMS01LTEtMS0w_942993f8-a5ef-4e28-a0a4-b171e7a22883">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91c5fecaa1c64c49ad9e64d6f08ce782_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmFjMmJkMDgzMWFiNjQ3YzViY2FiYzFkNzY4NjY1YjYwL3RhYmxlcmFuZ2U6YWMyYmQwODMxYWI2NDdjNWJjYWJjMWQ3Njg2NjViNjBfMi0xLTEtMS0w_6def0ff7-9d8e-46e1-98f8-e75b2dc1bc8b">179,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i91c5fecaa1c64c49ad9e64d6f08ce782_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmFjMmJkMDgzMWFiNjQ3YzViY2FiYzFkNzY4NjY1YjYwL3RhYmxlcmFuZ2U6YWMyYmQwODMxYWI2NDdjNWJjYWJjMWQ3Njg2NjViNjBfMi0zLTEtMS0w_d2352132-779e-4789-8144-7808db00ef20">6.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91c5fecaa1c64c49ad9e64d6f08ce782_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="ocgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmFjMmJkMDgzMWFiNjQ3YzViY2FiYzFkNzY4NjY1YjYwL3RhYmxlcmFuZ2U6YWMyYmQwODMxYWI2NDdjNWJjYWJjMWQ3Njg2NjViNjBfMi01LTEtMS0w_53adfac6-c248-4264-a194-6f7d164af89e">1,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i91c5fecaa1c64c49ad9e64d6f08ce782_D20210101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmFjMmJkMDgzMWFiNjQ3YzViY2FiYzFkNzY4NjY1YjYwL3RhYmxlcmFuZ2U6YWMyYmQwODMxYWI2NDdjNWJjYWJjMWQ3Njg2NjViNjBfMy0xLTEtMS0w_7f24e97e-26cc-4fa0-8bba-8c4df0e7ae7c">900</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i91c5fecaa1c64c49ad9e64d6f08ce782_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmFjMmJkMDgzMWFiNjQ3YzViY2FiYzFkNzY4NjY1YjYwL3RhYmxlcmFuZ2U6YWMyYmQwODMxYWI2NDdjNWJjYWJjMWQ3Njg2NjViNjBfMy0zLTEtMS0w_03391200-5593-437e-891b-aceff3a98f68">8.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91c5fecaa1c64c49ad9e64d6f08ce782_D20210101-20210930" decimals="-3" name="ocgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmFjMmJkMDgzMWFiNjQ3YzViY2FiYzFkNzY4NjY1YjYwL3RhYmxlcmFuZ2U6YWMyYmQwODMxYWI2NDdjNWJjYWJjMWQ3Njg2NjViNjBfMy01LTEtMS0w_07a635ef-3c2e-4cc6-bea3-6ee31025d236">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieee22d5c75984530a1d4feb9b3bd71e6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmFjMmJkMDgzMWFiNjQ3YzViY2FiYzFkNzY4NjY1YjYwL3RhYmxlcmFuZ2U6YWMyYmQwODMxYWI2NDdjNWJjYWJjMWQ3Njg2NjViNjBfNC0xLTEtMS0w_9f300bde-fe69-43b9-baf8-e43c43553113">179,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieee22d5c75984530a1d4feb9b3bd71e6_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmFjMmJkMDgzMWFiNjQ3YzViY2FiYzFkNzY4NjY1YjYwL3RhYmxlcmFuZ2U6YWMyYmQwODMxYWI2NDdjNWJjYWJjMWQ3Njg2NjViNjBfNC0zLTEtMS0w_ab0e29bc-ae44-4522-addc-36e11f7cec5c">6.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieee22d5c75984530a1d4feb9b3bd71e6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmFjMmJkMDgzMWFiNjQ3YzViY2FiYzFkNzY4NjY1YjYwL3RhYmxlcmFuZ2U6YWMyYmQwODMxYWI2NDdjNWJjYWJjMWQ3Njg2NjViNjBfNC01LTEtMS0w_78293f10-b8a3-46ad-a57c-00641d54c07a">1,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i9ff348f1ca104ec598a35c61fa9fc977_67"></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RleHRyZWdpb246OWVlNjEyOGE1OTRmNDRjZDhlMjI3MDk2M2U1MjE3ZTlfNDAz_25014c38-f45b-4a7f-be9f-a1de25b22dfa" continuedAt="i6b43f8c3ee414227907dd6569f5f89ac" escape="true">Net Loss Per Share of Common Stock</ix:nonNumeric></span></div><ix:continuation id="i6b43f8c3ee414227907dd6569f5f89ac" continuedAt="i7c3dccc8bc3c4b8d96003e7e774d2955"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RleHRyZWdpb246OWVlNjEyOGE1OTRmNDRjZDhlMjI3MDk2M2U1MjE3ZTlfNDA0_25424df8-8961-4759-aaa2-db5c4441f553" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share for the three and nine months ended September&#160;30, 2021 and 2020 (in thousands, except share and per share amounts):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss &#8212; basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfMi0xLTEtMS0w_750dfbb2-dfe1-49fa-bfb2-8434f2856693">10,755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfMi0zLTEtMS0w_8d40be6f-f19a-49b7-8700-98bd2dab7904">10,474</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfMi01LTEtMS0w_1b52db52-cb9f-4ab6-a660-39acca5cdee5">43,784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfMi03LTEtMS0w_bf1fe4cd-3b92-489e-a4c0-debde0693e5e">18,032</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend related to Warrant Exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfMy0xLTEtMS0w_e45aa646-d9c5-4de3-bae2-2333a008da39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfMy0zLTEtMS0w_f0be2921-13a4-4198-b50d-4e8193cf18f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfMy01LTEtMS0w_59ab5fa0-0142-4c79-8be1-18c40db49945">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfMy03LTEtMS0w_fbdfd729-fbab-4720-975f-8387df7f112f">12,546</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNC0xLTEtMS0w_500605f3-65b2-421b-a348-1b71c6ebff24"><ix:nonFraction unitRef="usd" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNC0xLTEtMS0w_b918c329-d165-4bb1-92cf-f909415cfc4f">10,755</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNC0zLTEtMS0w_3227bfaf-183c-41f0-b0fe-930969676b8c"><ix:nonFraction unitRef="usd" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNC0zLTEtMS0w_9675abcb-bce7-46cd-ba2b-d1bf3001bf57">10,474</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNC01LTEtMS0w_36cc12c6-696c-4143-8dc5-5e8ff6167490"><ix:nonFraction unitRef="usd" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNC01LTEtMS0w_74aea869-2ef4-4139-8339-75ad024e2d62">43,784</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNC03LTEtMS0w_589db492-afe3-44e5-b65d-1da464e5c336"><ix:nonFraction unitRef="usd" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNC03LTEtMS0w_5d5e406f-bbac-48be-8536-09c3c330c170">30,578</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in calculating net loss per common share &#8212; basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNS0xLTEtMS0w_94723c6b-5dc0-4e12-8c1a-103d0fc166e9"><ix:nonFraction unitRef="shares" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNS0xLTEtMS0w_979c7182-f8b0-4e98-94ef-4edd3761803f">198,790,980</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNS0zLTEtMS0w_73fa6ab4-600f-4eed-99e4-74acb81353c0"><ix:nonFraction unitRef="shares" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNS0zLTEtMS0w_b837220e-4303-427e-8b70-e7c1d094a46b">141,591,218</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNS01LTEtMS0w_48dee16f-10e7-4957-a751-ec7a9bdf6eb3"><ix:nonFraction unitRef="shares" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNS01LTEtMS0w_5d939db3-f73e-4f25-ab13-0a21127c94c7">193,599,525</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNS03LTEtMS0w_0423dcc1-8943-40fb-b4df-30b004313f5f"><ix:nonFraction unitRef="shares" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNS03LTEtMS0w_cb9ffc46-cb70-4ad4-b768-7d3c2c99b8c8">92,764,157</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share &#8212; basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNi0xLTEtMS0w_61701a2b-38a1-4fe9-8640-23fc1d18d05e"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNi0xLTEtMS0w_b988e84d-7ab9-4dbc-9c28-3fa5744c6439">0.05</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNi0zLTEtMS0w_157021aa-6201-4780-91f8-2c0f64ffc8a6"><ix:nonFraction unitRef="usdPerShare" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNi0zLTEtMS0w_8fc9e1d4-b981-40b1-87b0-975f6289a0fe">0.07</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNi01LTEtMS0w_0bfd0435-fd9b-4968-99c4-aca5c7b3b7fe"><ix:nonFraction unitRef="usdPerShare" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNi01LTEtMS0w_fe83490f-df9b-4cf6-ac37-7830b480b85f">0.23</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNi03LTEtMS0w_6b4910bd-4daf-43b3-9aa0-89469d64366a"><ix:nonFraction unitRef="usdPerShare" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNi03LTEtMS0w_e1ea5883-5895-42cb-8a6b-4cdd19688d9e">0.33</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><ix:continuation id="i7c3dccc8bc3c4b8d96003e7e774d2955"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RleHRyZWdpb246OWVlNjEyOGE1OTRmNDRjZDhlMjI3MDk2M2U1MjE3ZTlfNDA2_4424af15-d7d0-4ed5-ace1-ce11d7cc3408" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding, as their inclusion would have been antidilutive:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a2d954d52484db09e819f3e3cd26b4b_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfMi0xLTEtMS0w_e3997be7-fc26-4edd-84ad-8fb0440a048a">10,518,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6eef00380be74ee2b45ff66ba9497e4c_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfMi0zLTEtMS0w_58a9589d-b6b4-41f4-888e-570b397f6785">4,268,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21ed7d9935d24634bdbfe1f4c69a732b_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfMi01LTEtMS0w_d470744d-073e-4583-9d8c-c19a84ee39eb">10,518,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3904f01ad36d4b3796750e5c00692693_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfMi03LTEtMS0w_38598dd1-53e5-4fd3-8da3-c616ac27d9a5">4,268,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d1c263247244eaaa85b9923b449d851_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfMy0xLTEtMS0w_1c07ca18-1050-4be3-8c21-116a28fbcb96">179,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89a977d9b97c40d9bc231523d757c614_D20200701-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfMy0zLTEtMS0w_d27070dc-942d-499b-82d9-bdda9e5845f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8bcebbd1f9f4a1fa9c7f2ecc3c2a2b4_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfMy01LTEtMS0w_7f2af3f7-9c69-40a5-bf1b-f0be01d1d44c">179,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifb2b6076d55a4c4fbc505ce09032f9ec_D20200101-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfMy03LTEtMS0w_1ad04b87-30c3-405e-bbd2-b7510ff97216">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaeb64bda41ad44658c1917090d93aee7_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNC0xLTEtMS0w_35da35b0-67f8-42f8-8216-5ee22c9b2650">946,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42cfc7b660d247bca3e1269304b94198_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNC0zLTEtMS0w_617dafac-8321-458a-afca-cb1450bc19f7">870,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibb9ae3b6217944d08b6ef5b9486ae59c_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNC01LTEtMS0w_ee689824-e0a4-496d-b167-5ac5681c2499">946,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia60015f8c05f4fb2a0ff02e090d1939c_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNC03LTEtMS0w_100821a9-0f46-471c-aeb5-5edb6883d2a9">870,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock (as converted to common stock)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e6344f1ce2a45b3b3086bff6d187fd7_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNS0xLTEtMS0w_6d83e4c5-03a4-4424-9d06-b6e89c2cf47f">3,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04f8d6a8b17d410195fd2437e938b245_D20200701-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNS0zLTEtMS0w_9f97db0f-78aa-4e4c-90f7-00d02eb33f11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1226d893b7c34174b451b927f02c2ad5_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNS01LTEtMS0w_36fb0787-6ba2-49af-ad6a-5bc1a6bdffe7">3,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4aa5009a02d54151a673eb8679eca4f3_D20200101-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNS03LTEtMS0w_109731c8-7c28-4311-97f2-b457b6b7206c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock (as converted to common stock)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5dfb43b76ce743459ec23fb4489a7d43_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNi0xLTEtMS0w_b5e36d63-b1d0-4cbd-be4a-f3bb63a0078b">547,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife7f80154864442eb1f4fff86b29fb57_D20200701-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNi0zLTEtMS0w_7de745e1-1bad-4c78-bc41-3906c1b7ee10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia634f5e3056b43e9a810bc77f3d0f942_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNi01LTEtMS0w_205e5a70-4041-423c-a6f1-0a91eea40deb">547,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i656ac6e78d97406398ff128f89376446_D20200101-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNi03LTEtMS0w_ebb159fb-c89e-4285-8a1b-6369db621b1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNy0xLTEtMS0w_0aa456b9-c61b-4946-b2e5-93105b26f1b7">12,194,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNy0zLTEtMS0w_e9bb8383-213d-47d6-9f1b-7e8ee79a4cb7">5,138,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNy01LTEtMS0w_8c8a5d44-bb27-4a62-9626-1bc9a34db9a1">12,194,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNy03LTEtMS0w_6a125ca4-4c18-48ea-9a3f-de92d97ad111">5,138,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i9ff348f1ca104ec598a35c61fa9fc977_70"></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N183MC9mcmFnOmI0NDQyYWNjMGZhMDRjZmY4NDlhNmIzNjgzNzM3NTFlL3RleHRyZWdpb246YjQ0NDJhY2MwZmEwNGNmZjg0OWE2YjM2ODM3Mzc1MWVfMjgwMQ_ac665305-f250-454e-b731-0eebabbdbdc5" continuedAt="id39833254831416d9f5c24a8a25f8ec4" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="id39833254831416d9f5c24a8a25f8ec4" continuedAt="i4ab0983749b144d68aeee1fe0c856bd9"><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has commitments under certain license agreements, lease agreements, debt agreements, separation agreements, and consulting agreements. Commitments under certain license agreements primarily include annual payments, payments upon the achievement of certain milestones, and royalty payments based on net sales of licensed products. Commitments under the Company's licensing agreements are more fully described within Note 3 and within the Company's 2020 Annual Report. Commitments under lease agreements are future minimum lease payments for operating leases. See Note 6 and Note 14 for additional information about commitments under lease agreements. Commitments under debt agreements are the future payment of principal and accrued interest under the EB-5 Loan Agreement. See Note 8 for additional information about commitments under debt agreements. Commitments under separation agreements are severance payments to be paid throughout the remainder of 2021 as a result of the reduction in force in connection with the Company's discontinuation of a product candidate. See Note 7 for additional information about commitments under separation agreements. Commitments under consulting agreements include payments upon the achievement of certain milestones related to COVAXIN. See Note 10 for additional information about commitments under consulting agreements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 17, 2021, a securities class action lawsuit was filed against the Company and certain of its officers and directors in the U.S. District Court for the Eastern District of Pennsylvania (Case No. 2:21-cv-02725) that purported to state a claim for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, based on statements made by the Company concerning the announcement of the Company's decision to pursue the submission of a BLA for COVAXIN for ages 18 years and older rather than pursuing EUA for the vaccine candidate. On July 16, 2021, a second securities class action was filed against the Company and certain of its officers and directors in the U.S. District Court for the Eastern District of Pennsylvania (Case No. 2:21-cv-03182) that also purported to state a claim for alleged violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder, based on the same statements as the first complaint. The complaints seek unspecified damages, interest, attorneys&#8217; fees, and other costs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, a stockholder derivative lawsuit was filed derivatively on behalf of the Company against certain of its officers and directors and the nominal defendant Ocugen in the U.S. District Court for the Eastern District of Pennsylvania (Case No. 2:21-cv-03876) that purported to state a claim for breach of fiduciary duty and contribution for violations of Sections 10(b) and 21(d) of the Exchange Act, based on facts and circumstances relating to the securities class action lawsuits and seeking contribution and indemnification in connection with claims asserted in the securities class action lawsuits. On September 22, 2021, a second stockholder derivative lawsuit was filed derivatively on behalf of the Company against certain of its officers and directors and the nominal defendant Ocugen in the U.S. District Court for the Eastern District of Pennsylvania (Case No. 2:21-cv-04169) that purported to state a claim for breach of fiduciary duties, unjust enrichment, abuse of control, waste of corporate assets, and contribution for violations of Sections 10(b) and 21(d) of the Exchange Act, based on the same allegations as the first complaint. The parties to both stockholder derivative lawsuits have stipulated to the consolidation of the two stockholder derivative lawsuits and also have submitted to the court in each action a proposed order requesting a stay of the litigation pending a decision on any motion to dismiss filed in the securities class action lawsuits, which remains pending before each court, and this status could change.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4ab0983749b144d68aeee1fe0c856bd9">The Company believes that the lawsuits are without merit and intends to vigorously defend against them. At this time, no assessment can be made as to their likely outcome or whether the outcome will be material to the Company. No information is available to indicate that it is probable that a loss has been incurred and can be reasonably estimated as of the date of the condensed consolidated financial statements and, as such, no accrual for the loss has been recorded within the condensed consolidated financial statements.</ix:continuation></span></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_1138"></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xMTM4L2ZyYWc6N2FkMTA3ZWI3NTlmNGEyY2EwNTJjMzBlN2NjYWQ3ZmEvdGV4dHJlZ2lvbjo3YWQxMDdlYjc1OWY0YTJjYTA1MmMzMGU3Y2NhZDdmYV8zODQ4MjkwNjk4Mjkw_ce39f265-4498-4e9b-bc72-040f77be6623" continuedAt="i0a139063045346e794fae63c5b97bc87" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0a139063045346e794fae63c5b97bc87">On October 15, 2021, the Company entered into a lease agreement for additional office space located in Malvern, Pennsylvania. The lease has an expected commencement date in 2022 and has an initial term of <ix:nonNumeric contextRef="i9c6b3eaa0af149b0b68069f2bcf0750e_I20211015" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xMTM4L2ZyYWc6N2FkMTA3ZWI3NTlmNGEyY2EwNTJjMzBlN2NjYWQ3ZmEvdGV4dHJlZ2lvbjo3YWQxMDdlYjc1OWY0YTJjYTA1MmMzMGU3Y2NhZDdmYV8yMTk5MDIzMjU2NTY0_554703eb-8aa7-40c9-a11d-40f55a1d5777">seven years</ix:nonNumeric>. The aggregate estimated base rent payments due over the initial <ix:nonNumeric contextRef="i9c6b3eaa0af149b0b68069f2bcf0750e_I20211015" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xMTM4L2ZyYWc6N2FkMTA3ZWI3NTlmNGEyY2EwNTJjMzBlN2NjYWQ3ZmEvdGV4dHJlZ2lvbjo3YWQxMDdlYjc1OWY0YTJjYTA1MmMzMGU3Y2NhZDdmYV8zODQ4MjkwNzAyMjY0_6b46a6f4-2098-4eb9-b789-a40dac2cc5dc">seven year</ix:nonNumeric> term are $<ix:nonFraction unitRef="usd" contextRef="i9c6b3eaa0af149b0b68069f2bcf0750e_I20211015" decimals="-3" format="ixt:num-dot-decimal" name="ocgn:BaseRentPaymentsExpectedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xMTM4L2ZyYWc6N2FkMTA3ZWI3NTlmNGEyY2EwNTJjMzBlN2NjYWQ3ZmEvdGV4dHJlZ2lvbjo3YWQxMDdlYjc1OWY0YTJjYTA1MmMzMGU3Y2NhZDdmYV8yMTk5MDIzMjU2MjE3_abae822d-76fd-4d43-ad69-6373dfeae9df">3.8</ix:nonFraction>&#160;million. Additionally, the Company will be responsible for the operating expenses and utilities associated with the leased premises. The Company has the option to extend the lease agreement for <ix:nonFraction unitRef="extension" contextRef="i1801f4052b89458296349d07431dc823_D20211015-20211015" decimals="INF" format="ixt-sec:numwordsen" name="ocgn:NumberOfAdditionalLeaseAgreementExtensions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xMTM4L2ZyYWc6N2FkMTA3ZWI3NTlmNGEyY2EwNTJjMzBlN2NjYWQ3ZmEvdGV4dHJlZ2lvbjo3YWQxMDdlYjc1OWY0YTJjYTA1MmMzMGU3Y2NhZDdmYV8zODQ4MjkwNzAyMjM2_5fdda312-33fc-4c2a-8cf8-e6a255e55834">two</ix:nonFraction> additional <ix:nonNumeric contextRef="i1801f4052b89458296349d07431dc823_D20211015-20211015" format="ixt-sec:durwordsen" name="ocgn:LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement" id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xMTM4L2ZyYWc6N2FkMTA3ZWI3NTlmNGEyY2EwNTJjMzBlN2NjYWQ3ZmEvdGV4dHJlZ2lvbjo3YWQxMDdlYjc1OWY0YTJjYTA1MmMzMGU3Y2NhZDdmYV8zODQ4MjkwNzAyMjc5_5e8d563b-19da-4ebf-a5f0-2395653555cf">five year</ix:nonNumeric> terms, provided the Company is not under an event of default pursuant to the terms of the lease agreement</ix:continuation>.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the financial statements and the notes thereto included elsewhere in this Quarterly Report on Form&#160;10-Q and with our audited financial statements for the year ended December&#160;31, 2020, included in our 2020 Annual Report. Some of the information contained in this discussion and analysis, including information with respect to our plans and strategy for our business and related financing, include forward-looking statements that involve risks, uncertainties, and assumptions. These statements are based on our beliefs and expectations about future outcomes and are subject to risks and uncertainties that could cause our actual results to differ materially from anticipated results. Except as required by law, we undertake no obligation to publicly update these forward-looking statements, whether as a result of new information, future events, or otherwise. You should read the &#8220;Risk Factors&#8221; section included in our 2020 Annual Report and the "Risk Factors" and &#8220;Disclosure Regarding Forward-Looking Statements&#8221; sections of this Quarterly Report on Form&#160;10-Q for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our technology pipeline includes:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">COVID-19 Vaccine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate being developed to prevent COVID-19 infection in humans. We are co-developing COVAXIN with Bharat Biotech for the U.S. and Canadian markets.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Modifier Gene Therapy Platform </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Based on NHRs, we believe our gene therapy platform has the potential to address many retinal diseases, including RP, LCA, and dry AMD.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Novel Biologic Therapy for Retinal Diseases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; We are developing OCU200, a novel biologic product candidate, to treat DME, DR, and wet AMD.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Vaccine</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we entered into the Covaxin Agreement with Bharat Biotech, pursuant to which we obtained an exclusive right and license under certain of Bharat Biotech's intellectual property rights, with the right to grant sublicenses to develop, manufacture, and commercialize COVAXIN for the prevention of COVID-19 in humans in the United States, its territories, and possessions. The Covaxin Agreement was subsequently amended in June 2021 by which we and Bharat Biotech agreed to expand our rights to develop, manufacture, and commercialize COVAXIN to include Canada in addition to the United States, its territories, and possessions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus, an antigen, and an adjuvant. COVAXIN requires a two-dose vaccination regimen given 28 days apart and is stored in standard vaccine storage conditions (2-8&#176;C). COVAXIN has been authorized for emergency use in India for ages 18 years and older and the Subject Expert Committee has recommended the Drugs Controller General of India authorize COVAXIN for emergency use in India for children ages two years and older. In November 2021, COVAXIN was awarded an EUL by the WHO. Over 98.0&#160;million doses of COVAXIN globally have been administered to date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we announced that COVAXIN demonstrated an overall vaccine efficacy against COVID-19 disease of 77.8%, with efficacy against severe COVID-19 disease of 93.4%, and efficacy against asymptomatic COVID-19 disease of 63.6% in the Phase 3 clinical trial conducted by Bharat Biotech in India. The aforementioned efficacy results represent point estimates of vaccine efficacy with a 95% confidence interval of 65.2% to 86.4% against COVID-19 disease, 57.1% to 99.8% against severe COVID-19 disease, and 29.0% to 82.4% against asymptomatic COVID-19 disease. The Phase 3 clinical trial enrolled 25,798 participants over the age of 18 in India, including 10.7% of participants over the age of 60 and 27.5% of participants with at least one pre-existing condition. Adverse events in the COVAXIN and control arms of the Phase 3 clinical trial were observed in 12.4% of subjects, with less than 0.5% of subjects experiencing serious adverse side effects. The majority of the symptomatic cases identified in aggregate in the COVAXIN and control arms in the Phase 3 clinical trial were COVID-19 variants, the majority of which were identified to be the Delta variant, B.1.617.2. Subjects vaccinated with COVAXIN in the Phase 3 clinical trial showed protection against the Delta variant, B.1.617.2, showing a vaccine efficacy of 65.2%, which represents a point estimate of vaccine efficacy with a 95% confidence interval of 33.1% to 83.0%. Additionally, in in-vitro studies conducted by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the ICMR &#8212; National Institute of Virology, COVAXIN demonstrated potential effectiveness against the Zeta variant, B.1.1.28.2, the Alpha variant, B.1.1.7, and the Beta variant, B.1.351.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the FDA provided feedback to us regarding the data and information contained in the "Master File" that was previously submitted to the FDA and recommended that we pursue a BLA submission instead of an EUA application for COVAXIN for ages 18 years and older in the United States. As part of the feedback provided by the FDA regarding the "Master File," the FDA also requested additional information and data. We have continued discussions with the FDA regarding the appropriate regulatory pathway for COVAXIN for ages 18 years and older in the United States as well as the data requirements for COVAXIN under a BLA submission. In October 2021, we filed an IND application with the FDA to initiate a Phase 3 immuno-bridging study evaluating COVAXIN for ages 18 years and older. We will also initiate a safety-bridging study under the IND, if required by the FDA, to support a BLA submission. We anticipate filing a BLA submission with the FDA by the end of 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we submitted a request to the FDA for EUA for COVAXIN for pediatric use in children ages two to 18 years in the United States. The EUA submission was based on the results of a Phase 2/3 immuno-bridging pediatric clinical trial conducted by Bharat Biotech in India.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are pursuing approval for COVAXIN in Canada. In July 2021, we announced that we had completed our rolling submission to Health Canada for COVAXIN. The rolling submission process, which permits companies to submit safety and efficacy data and information as they become available, was recommended and accepted under the Interim Order and transitioned to an NDS for COVID-19. The submission was conducted through our Canadian affiliate, Vaccigen. The Interim Order expired on September 16, 2021. The expiration of the Interim Order has not impacted our NDS.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are evaluating our commercialization strategy for COVAXIN in the United States and Canada, if authorized or approved in either jurisdiction. In June 2021, we selected Jubilant HollisterStier as our manufacturing partner for COVAXIN to prepare for the potential commercial manufacturing for the Ocugen Covaxin Territory. We expect to enter into a master services agreement with Jubilant HollisterStier for the manufacture of COVAXIN and the technology transfer process to Jubilant HollisterStier has been initiated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we entered into the Supply Agreement with Bharat Biotech, pursuant to which </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bharat Biotech will supply us with clinical trial materials and commercial supplies of COVAXIN finished drug product prior to the completion of our technology transfer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jubilant HollisterStier</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Following the completion of our technology transfer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jubilant HollisterStier</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bharat Biotech will supply COVAXIN drug product components and continue to supply finished drug product as necessary for commercial manufacture and supply of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVAXIN </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent to a regulatory authorization or approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Modifier Gene Therapy Platform</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing a breakthrough modifier gene therapy platform to generate therapies designed to fulfill unmet medical needs in the area of retinal diseases, including IRDs and dry AMD. Our modifier gene therapy platform is based on NHRs, which have the potential to restore homeostasis, the basic biological processes in the retina. Unlike single-gene replacement therapies, which only target one genetic mutation, we believe that our gene therapy platform, through its use of NHRs, represents a novel approach in that it may address multiple retinal diseases with one product. IRDs such as RP, a group of rare genetic disorders that involve a breakdown and loss of cells in the retina and can lead to visual impairment and blindness, affect over 2.0 million people worldwide. Over 150 gene mutations have been associated with RP and this number represents only 60% of the RP population. The remaining 40% of RP patients cannot be genetically diagnosed, making it difficult to develop individual treatments. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that OCU400, our first product candidate being developed with our modifier gene therapy platform, has the potential to be broadly effective in restoring retinal integrity and function across a range of genetically diverse IRDs, including RP and LCA. For example, we believe OCU400 has the potential to eliminate the need for developing more than 150 individual products and provide one treatment option for all RP patients. OCU400 has received four ODDs from the FDA for the treatment of certain disease genotypes: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NR2E3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CEP290</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RHO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PDE6&#223;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mutation-associated inherited retinal degenerations. In November 2021, we filed an IND application with the FDA for OCU400 for the treatment of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NR2E3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RHO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disease genotypes. We are planning to initiate a Phase 1/2 clinical trial for OCU400 for the treatment of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NR2E3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RHO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disease genotypes in the United States near the end of 2021. OCU400 additionally has received OMPD from the EC, based on the recommendation of the EMA, for RP and LCA, which we believe further supports the potential broad spectrum application of OCU400 to treat many IRDs. We are currently evaluating options to commence OCU400 clinical trials in Europe in 2022. Our second gene therapy candidate, OCU410, is being developed to utilize the nuclear receptor genes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RORA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of dry AMD. We are currently executing IND-enabling preclinical studies to support a Phase 1/2 clinical trial. In 2019, we entered </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">into the CanSinoBIO Agreement with respect to the development and commercialization of OCU400, which was subsequently amended in September 2021, pursuant to which OCU410 was added to our existing collaboration with CanSinoBIO. CanSinoBIO will be responsible for the CMC development and manufacture of clinical supplies for OCU400 and OCU410 and will be responsible for the costs associated with such activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novel Biologic Therapy for Retinal Diseases</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our biologic product candidate, OCU200, is a novel fusion protein being developed to treat DME, DR, and wet AMD. We are currently executing IND-enabling preclinical studies to support a Phase 1 clinical trial. We have completed the technology transfer of manufacturing processes to our CDMO that will manufacture OCU200 clinical supplies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Candidate for the Treatment of Ocular Graft-Versus-Host Disease</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were developing OCU300, a small molecule therapeutic for the treatment of symptoms associated with ocular graft-versus-host disease. The Phase 3 clinical trial for OCU300 was discontinued in 2020 based on the results of a pre-planned interim sample size analysis conducted by an independent Data Monitoring Committee, which indicated the trial was unlikely to meet its co-primary endpoints upon completion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19 on our Business</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic is continually evolving and we are closely monitoring the situation. Impacts from the COVID-19 pandemic remain highly uncertain and subject to change and, as such, we cannot predict the specific duration or impact that the COVID-19 pandemic may have on our operations including our preclinical activities, future clinical trials, and potential commercialization. The extent to which the COVID-19 pandemic may impact our operations is dependent on future developments, including but not limited to: (i) the duration of the spread of the SARS-CoV-2 virus, including the spread of variants, (ii) the future actions taken by governmental authorities and regulators with respect to the COVID-19 pandemic, and (iii) the impact on our partners, collaborators, and suppliers. We will continue to monitor the situation closely as these effects could have a material impact on our operations.</span></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_79"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale and have not generated significant revenue to date. We have never been profitable and have incurred net losses in each year since inception. We incurred net losses of approximately $43.8&#160;million and $18.0 million for the nine months ended September 30, 2021 and 2020, respectively. As of September&#160;30, 2021, we had an accumulated deficit of $117.1&#160;million and a cash, cash equivalents, and restricted cash balance of $107.5&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. These costs consist of internal and external expenses, as well as depreciation on assets used within our research and development activities. Internal expenses include the cost of salaries, benefits, severance, and other related costs, including stock-based compensation, for personnel serving in our research and development functions, as well as allocated rent and utilities expenses. External expenses include development, clinical trials, patent costs, and regulatory compliance costs incurred with research organizations, contract manufacturers, and other third-party vendors. License fees paid to acquire access to proprietary technology are expensed to research and development unless it is determined that the technology is expected to have an alternative future use. All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred to research and development expense due to the uncertainty about the recovery of the expenditure. We record costs for certain development activities, such as preclinical studies and clinical trials, based on our evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid or accrued research and development expense, as applicable. Our recording of costs for certain development activities requires us to use estimates. We believe our estimates and assumptions are reasonable under the current conditions; however, actual results may differ from these estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses account for a significant portion of our operating expenses. We plan to incur research and development expenses for the foreseeable future as we expect to continue the development of our product candidates. We anticipate that our research and development expenses will be higher in 2021 and subsequent periods as compared to prior periods as we evaluate the regulatory and commercialization path for COVAXIN in the United States and Canada as well as conduct preclinical and clinical activities with respect to our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses are not currently tracked on a program-by-program basis for indirect and overhead costs. We use our personnel and infrastructure resources across multiple research and development programs directed toward identifying, developing, and commercializing product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, due to the inherently unpredictable nature of preclinical and clinical developments as well as regulatory approval (or authorization) and commercialization, we are unable to estimate with any certainty the costs we will incur and the timelines we will require in our continued development and commercialization efforts. As a result of these uncertainties, successful development and completion of clinical trials as well as regulatory approval (or authorization) and commercialization are uncertain and may not result in approved (or authorized) and commercialized products. Completion dates and completion costs can vary significantly for each product candidate and are difficult to predict. We will continue to make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to our ability to enter into collaborations with respect to each product candidate, the scientific and clinical success of each product candidate as well as ongoing assessments as to the commercial potential of each product candidate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and administrative expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense consists primarily of personnel expenses, including salaries, benefits, severance, insurance, and stock-based compensation expense, for employees in executive, accounting, commercialization, human resources, and other administrative functions. General and administrative expense also includes corporate facility costs, including allocated rent and utilities, insurance premiums, legal fees related to corporate matters, and fees for auditing, accounting, and other consulting services.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will be higher in 2021 as compared to prior periods as a result of higher corporate infrastructure costs including, but not limited to, accounting, legal, human resources, consulting, investor relations, and public company insurance fees. Additionally, we anticipate an increase in general and administrative expenses as we prepare to support the potential commercialization of COVAXIN, if authorized or approved.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Severance-related expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we communicated notice to five employees of the termination of their employment as a result of the discontinuation of a product candidate. This reduction represented one-third of our workforce at the time of communication. All terminations were &#8220;without cause&#8221; and each employee received termination benefits upon departure. The termination dates varied for each employee and ranged from June&#160;30, 2020 to December&#160;31, 2020. As a result of the workforce reduction, we expect to pay severance benefits of $0.1&#160;million throughout the remainder of 2021. We made severance payments of $0.1 million and $0.6 million during the three and nine months ended September&#160;30, 2021, respectively. We made severance payments of $0.2 million during the three and nine months ended September&#160;30, 2020.</span></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_82"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires us to make judgments, estimates, and assumptions in the preparation of our condensed consolidated financial statements. Actual results could differ from those estimates. There were no material changes to our critical accounting policies and estimates as reported in our 2020 Annual Report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended September&#160;30, 2021 and 2020</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the three months ended September 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,789&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,789)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,182)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(607)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,807)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,474)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,755)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,474)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense increased by $4.8&#160;million for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. The increase was primarily due to increases of $1.6&#160;million in COVAXIN development and regulatory activities, $1.4&#160;million in OCU400 preclinical and clinical activities, $1.1&#160;million in employee-related expenses, and $0.5&#160;million in stock-based compensation expense.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-process research and development</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development expense decreased by $7.0 million for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. The decrease was due to the write-off of an intangible asset held for sale during the three months ended September 30, 2020 as a sale of the intangible asset was deemed not probable to be completed within one year from the date the intangible asset was initially recorded as held for sale.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense increased by $2.8&#160;million for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. The increase was primarily due to increases of $0.8&#160;million in employee-related expenses, $0.7&#160;million in stock-based compensation expense, and $0.7&#160;million in professional fees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense decreased by $0.3&#160;million for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. Interest expense during the three months ended September 30, 2021 primarily includes debt coupon interest and amortization of debt issuance costs. Interest expense during the three months ended September 30, 2020 primarily related to the accretion of the debt discount on the Warrant Exchange Promissory Notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Nine Months Ended September&#160;30, 2021 and 2020</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the nine months ended September 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,456&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,520&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,936&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,456)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,477)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,979)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(380)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(555)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,836)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,032)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,804)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,784)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,032)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,752)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense increased by $23.2 million for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. The increase was primarily due to the $15.0&#160;million upfront payment to Bharat Biotech in connection with the amendment to the Covaxin Agreement to add rights to the Canadian market in June 2021 as well as increases of $2.9&#160;million in OCU400 preclinical and clinical activities, $2.5&#160;million in COVAXIN development and regulatory activities, $1.4&#160;million in employee-related expenses, $1.1&#160;million in stock-based compensation expense, and $1.0&#160;million in OCU200 preclinical activities. The increases were partially offset by a $1.1&#160;million decrease for the discontinuation of OCU300 clinical trial activities in 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-process research and development</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development expense decreased by $7.0 million for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. The decrease was due to the write-off of an intangible asset held for sale during the nine months ended September 30, 2020 as a sale of the intangible asset was deemed not probable to be completed within one year from the date the intangible asset was initially recorded as held for sale.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense increased by $9.7 million for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. The increase was primarily due to increases of $3.1&#160;million in expenses for stockholder meetings and proxy solicitation, $2.7&#160;million in stock-based compensation expense, $1.5&#160;million in professional fees, and $1.3&#160;million in employee-related expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense decreased by $0.5 million for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. Interest expense during the nine months ended September 30, 2021 primarily includes debt coupon interest </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and amortization of debt issuance costs. Interest expense during the nine months ended September 30, 2020 primarily related to the accretion of the debt discount on the Warrant Exchange Promissory Notes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income (expense)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) increased by $0.3 million for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. The increase was primarily due to $0.8&#160;million related to a loss on the write-off of the Promissory Note deemed uncollectible, partially offset by a gain on loan extinguishment of $0.4&#160;million for PPP Note forgiveness obtained in May 2021.</span></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, we had $107.5&#160;million in cash, cash equivalents, and restricted cash. We have not generated significant revenue to date and have primarily funded our operations to date through the sale of common stock, warrants to purchase common stock, the issuance of convertible notes, debt, and grant proceeds. Since our inception and through September&#160;30, 2021, we have raised an aggregate of $218.9&#160;million to fund our operations, of which $206.3&#160;million was from gross proceeds from the sale of our common stock and warrants, $10.3&#160;million was from the issuance of convertible notes, $2.1&#160;million was from debt, and $0.2&#160;million was from grant proceeds.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we issued and sold 10.0&#160;million shares of our common stock at an offering price of $10.00 per share in the April 2021 Registered Direct Offering pursuant to a securities purchase agreement with certain institutional investors. We received net proceeds of $93.4&#160;million. In February 2021, we issued and sold 3.0&#160;million shares of our common stock at an offering price of $7.65 per share in the February 2021 Registered Direct Offering pursuant to a securities purchase agreement with certain institutional investors. We received net proceeds of $21.2&#160;million. For additional information about the April 2021 Registered Direct Offering and the February 2021 Registered Direct Offering, see Note 9 in the notes to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during the nine months ended September 30, 2021, we sold 1.0&#160;million shares of our common stock under the August 2020 ATM and received net proceeds of $4.8&#160;million. The offering was made pursuant to our effective "shelf" registration statement on Form S-3 filed with the SEC on March 27, 2020, the base prospectus contained therein dated May 5, 2020, and the prospectus supplement related to the offering dated August 17, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have devoted substantial resources to research and development and have incurred significant net losses and may continue to incur net losses in the future. We incurred net losses of approximately $43.8&#160;million and $18.0&#160;million for the nine months ended September 30, 2021 and 2020, respectively. As of September&#160;30, 2021, we had an accumulated deficit of $117.1&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for the nine months ended September 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,137)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,426)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,624)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents, and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,310&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,662&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities was $35.1 million for the nine months ended September 30, 2021 compared to $10.4&#160;million for the nine months ended September 30, 2020. The increase in cash used in operating activities was primarily driven by the $15.0&#160;million upfront payment to Bharat Biotech in connection with the amendment to the Covaxin Agreement to add rights to the Canadian market in June 2021, an increase in our research and development expenses for our product candidates, an increase in employee-related expenses as we expand our headcount to support our development, commercialization, and business efforts, and an increase in expenses for stockholder meetings and proxy solicitation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities was $1.6 million for the nine months ended September 30, 2021 compared to $0.1 million for the nine months ended September 30, 2020. The increase in cash used in investing activities was primarily driven by the receipt of the Promissory Note of $0.8&#160;million in April 2021, an increase of $0.7&#160;million in purchases of property and equipment, and the acquisition of an intangible asset of $0.1&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities was $120.1 million for the nine months ended September 30, 2021 compared to $22.1&#160;million for the nine months ended September 30, 2020. During the nine months ended September 30, 2021, cash provided by financing activities primarily consisted of gross proceeds of $100.0&#160;million and $22.9&#160;million received from the April 2021 Registered Direct Offering and the February 2021 Registered Direct Offering, respectively, and gross proceeds of $5.0&#160;million received under the August 2020 ATM, partially offset by payments of equity issuance costs of $8.5&#160;million. During the nine months ended September 30, 2020, cash provided by financing activities primarily consisted of gross proceeds of $26.7&#160;million received under the ATMs and $0.9&#160;million in proceeds from the issuance of debt, partially offset by payments of equity issuance costs of $1.1&#160;million and repayments of debt of $4.4&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indebtedness</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, pursuant to the EB-5 program, we entered into the EB-5 Loan Agreement to borrow up to $10.0&#160;million from EB-5 Life Sciences in $0.5&#160;million increments. Borrowings are at a fixed interest rate of 4.0% per annum and are to be utilized in the clinical development, manufacturing, and commercialization of our product candidates and for our general working capital needs. Outstanding borrowings pursuant to the EB-5 Program become due upon the seventh anniversary of the final disbursement. Amounts repaid cannot be re-borrowed. As of September&#160;30, 2021, there was $1.5&#160;million of principal outstanding under the EB-5 Loan Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding requirements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses in connection with our ongoing activities, particularly as we continue research and development, including preclinical and clinical development of our product candidates, contract to manufacture our product candidates, prepare for potential commercialization of our product candidates, add operational, financial, and information systems to execute our business plan, maintain, expand, and protect our patent portfolio, expand headcount to support our development, commercialization, and business efforts, and operate as a public company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our commitments and contingencies, see Note 13 in the notes to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. Factors impacting our future funding requirements include, without limitation, the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">the initiation, progress, timing, costs, and results of clinical trials for our product candidates, including the need for a Phase 3 immuno-bridging study to support a BLA submission for COVAXIN for ages 18 years and older as well as a safety-bridging study if required by the FDA;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">the outcome, timing, and cost of the regulatory authorization or approval process for our product candidates; including with respect to COVAXIN in the United States and Canada;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">the costs of manufacturing and commercialization, including with respect to COVAXIN, if authorized or approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs related to doing business internationally with respect to our proposed development and commercialization of COVAXIN in Canada;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">the cost of filing, prosecuting, defending, and enforcing our patent claims and other intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">the costs of expanding infrastructure to support our development, commercialization, and business efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expenses needed to attract and retain skilled personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we in-license or acquire other products, product candidates, or technologies; and</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, we had $107.5&#160;million in cash, cash equivalents, and restricted cash. This amount will not meet our capital requirements over the next 12 months. Our management is currently evaluating different strategies to obtain the required funding for future operations. These strategies may include, but are not limited to: public and private placements of equity and/or debt, payments from potential strategic research and development arrangements, sales of assets, government grants, licensing and/or collaboration arrangements with pharmaceutical companies or other institutions, or other funding from the government or other third parties. There can be no assurance that these funding efforts will be successful. If we cannot obtain the necessary funding, we will need to delay, scale back, or eliminate some or all of our research and development programs&#894; consider other various strategic alternatives, including a merger or sale&#894; or cease operations. If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition, and results of operations could be materially adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these factors, together with the anticipated increase in spending that will be necessary to continue to develop and commercialize our product candidates, there is substantial doubt about our ability to continue as a going concern within one year after the date that the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q are issued. See Note 1 to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for additional information.</span></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any off-balance sheet arrangements during the periods presented, and we do not currently have any off-balance sheet arrangements as defined in the rules&#160;and regulations of the SEC.</span></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of recently adopted accounting pronouncements, see Note 2 in the notes to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.</span></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Company Information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_100"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_103"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act), as of&#160;September&#160;30, 2021. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that (a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules&#160;and forms, and (b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;under the Exchange Act) that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II&#160;&#8212;&#160;OTHER INFORMATION</span></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_109"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of legal proceedings, see Note 13 in the notes to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.</span></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_112"></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as set forth below and in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2021 and June 30, 2021, there have been no material changes in our risk factors as previously disclosed in our 2020 Annual Report. The risks described in our 2020 Annual Report, our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2021 and June 30, 2021, and this Quarterly Report on Form 10-Q are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, or future results.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have submitted an EUA application for COVAXIN for pediatric use. The FDA may not grant us the EUA for pediatric use, and, even if they do, absent supplemental Biologics License Application approval for that indication, such EUA would be revoked when the COVID-19 emergency terminates, and, prior to that time, we would face significant competition from other pharmaceutical and biotechnology companies, and may not be able to compete effectively.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we submitted a request to the FDA for EUA for COVAXIN for pediatric use in children ages two to 18 years in the United States. The EUA submission was based on the results of a Phase 2/3 immuno-bridging pediatric clinical trial conducted by Bharat Biotech in India.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has the authority to grant an EUA to allow unapproved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions when there are no adequate, approved, and available alternatives. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, EUAs for unapproved products require that manufacturers distribute factsheets for healthcare providers, addressing significant known and potential benefits and risks, and the extent to which benefits and risks are unknown, and the fact that the FDA has authorized emergency use; and, distribution of factsheets for recipients of the product, addressing significant known and potential benefits and risks, and the extent to which benefits and risks are unknown, the option to accept or refuse the product, the consequences of refusing, available alternatives, and the fact that FDA has authorized emergency use.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EUAs for unapproved products also include requirements for adverse event monitoring and reporting, and other recordkeeping and reporting requirements. In addition, the FDA may include various requirements in an EUA as a matter of discretion as deemed necessary to protect the public health, including restrictions on which entities may distribute the product, and how to perform distribution (including requiring that distribution be limited to government entities), restrictions on who may administer the product, requirements for collection and analysis of safety and effectiveness data, waivers of Current Good Manufacturing Practice, and restrictions applicable to prescription drugs or restricted devices (including advertising and promotion restrictions).</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Quarterly Report on Form 10-Q, we have not received any correspondence from the FDA regarding the EUA, other than an acknowledgement of the submission. Therefore, the timing of a potential grant of EUA for pediatric use, if at all, is currently unknown. In addition, there can be no guarantee that the data and results from the preclinical and clinical studies of COVAXIN, which have been conducted by Bharat Biotech in India, will be accepted by the FDA or otherwise sufficient to support our EUA submission.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are granted an EUA by the FDA for COVAXIN for pediatric use, we would be able to commercialize it for that use without FDA approval. However, the FDA may revoke the EUA where it is determined that the COVID-19 public health emergency no longer exists or warrants such authorization, and we cannot predict how long, if ever, an EUA would remain in place. Such revocation could adversely impact our business in a variety of ways including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we, Bharat Biotech, and our manufacturing partners have invested in the supply chain to provide COVAXIN for pediatric use under an EUA in the United States. In addition, the FDA may revoke or terminate the EUA sooner if, for example, we fail to comply with the conditions of authorization or other terms of the EUA or if COVAXIN is determined to be less effective or safe than it was initially believed to be. We cannot predict how long, if ever, an EUA for the pediatric use of COVAXIN would remain in place.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">many biotechnology and pharmaceutical companies are developing treatments for COVID-19 or vaccines against SARS-CoV-2, the virus that causes COVID-19. Many of these companies, which include large pharmaceutical companies, have greater resources for development and established commercialization capabilities than us. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, some of these companies </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have already received regulatory approval or a grant of EUA for their respective products, some of which include authorization for the administration of COVID-19 vaccines in certain pediatric patient populations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Given the products currently approved or authorized for use as well as those in development by others, even if our EUA is approved for pediatric use, we will face significant competition. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If existing vaccines in the market or if competitors develop and commercialize additional COVID-19 vaccines before we can complete regulatory review and obtain an EUA for pediatric use or regulatory approval for COVAXIN, or if they develop and commercialize one or more COVID-19 vaccines that are safer, more effective, have fewer or less severe side effects, have broader market acceptance, are more convenient, or are less expensive than COVAXIN, our business, financial condition, and results of operations would be materially adversely affected.</span></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_115"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2021, we entered into the Canada Consulting Agreement with an individual to provide services to us with regard to our Canadian operations. In connection therewith, we issued to such individual the Canada Warrants to purchase up to 0.2 million shares of our common stock at an exercise price of $6.36 per share upon the achievement of certain milestones related to COVAXIN. The Canada Warrants terminate on July&#160;15, 2031, unless earlier terminated in accordance with their terms.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Canada Warrants were issued on July 15, 2021 in a private placement transaction pursuant to Rule 4(a)(2) of the Securities Act. We did not receive any proceeds from the issuance of the Canada Warrants. See Note 10 in the notes to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for additional information.</span></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_118"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;Defaults Upon Senior Securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_121"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Mine Safety Disclosures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_124"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;Other Information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits.</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ocgn-20210930x10qxex101.htm">Development and Commercial Supply Agreement, dated September 29, 2021, by and between the Registrant and Bharat Biotech International Limited</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2*#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ocgn-20210930x10qxex102.htm">First Amendment to </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ocgn-20210930x10qxex102.htm">the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ocgn-20210930x10qxex102.htm">Co-Development and Commercialization Agreement, dated September 30, 2021, by and between the Registrant and CanSino Biologics, Inc.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ocgn-20210930x10qxex311.htm">Certification of the Chief Executive Officer, as required by Section&#160;302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ocgn-20210930x10qxex312.htm">Certification of the Chief Financial Officer, as required by Section&#160;302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ocgn-20210930x10qxex321.htm">Certifications of the Chief Executive Officer and Chief Financial Officer as required by 18 U.S.C. 1350</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from this Quarterly Report on Form 10-Q, formatted in Inline XBRL</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i9ff348f1ca104ec598a35c61fa9fc977_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9ff348f1ca104ec598a35c61fa9fc977_7"> Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ocugen, Inc.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: November 9, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Shankar Musunuri</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shankar Musunuri, Ph.D., MBA<br/>Chief Executive Officer&#160;and Chairman<br/>(Principal Executive Officer)</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: November 9, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Sanjay Subramanian</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanjay Subramanian<br/>Chief Financial Officer<br/>(Principal Financial Officer and Principal Accounting Officer)</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ocgn-20210930x10qxex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i0f0093be76fa4905b1e461f1392cd12d_1"></div><div style="min-height:99pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain portions of this document have been omitted pursuant to Item 601(b)(10)&#160;of Regulation S-K and, where applicable, have been marked with &#8220;&#91;***&#93;&#8221; to indicate where omissions have been made. The marked information has been omitted because it is (i)&#160;not material and (ii)&#160;the type that the registrant treats as private or confidential. The registrant hereby undertakes to provide further information regarding such marked information to the Securities and Exchange Commission upon request.</font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DEVELOPMENT AND COMMERCIAL SUPPLY AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DEVELOPMENT AND COMMERCIAL SUPPLY AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is made and entered into as of the </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) by and between Bharat Biotech International Limited, whose registered office address is at Genome Valley, Shameerpet, Hyderabad &#8211; 500 078 Telangana India (together with its Affiliates, subsidiaries, successors and permitted assigns, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BBIL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and Ocugen, Inc., with an address at 263 Great Valley Parkway, Malvern, PA 19355, USA (together with its Affiliates, subsidiaries, successors and permitted assigns, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ocugen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ocugen and BBIL are parties to that certain Co-Development, Supply and Commercialization Agreement, dated as of January 31, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Co-Development Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), pursuant to which BBIL granted Ocugen the exclusive right to Develop, Manufacture and Commercialize the Product for use in the Field in and for the Ocugen Territory&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, pursuant to Section 7.1(a) of the Co-Development Agreement, BBIL has agreed to Manufacture and supply all of the Clinical Trial Materials required for Ocugen&#8217;s non-clinical and clinical Development of the Product in the Field in and for the Ocugen Territory (including the performance of the Ocugen Development Activities), subject to and in accordance with the terms of this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pursuant to Section 7.2(a) of the Co-Development Agreement, BBIL has also agreed to Manufacture and supply all of Ocugen&#8217;s requirements of commercial quantities of the Product for Ocugen&#8217;s use and Commercialization of the Product in the Field in and for the Ocugen Territory, subject to and in accordance with the terms of this Agreement until such time as the Initial Technology Transfer has been completed&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ocugen desires that BBIL Manufacture and supply Ocugen&#8217;s requirements of COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance and Drug Product Components necessary for Ocugen&#8217;s Commercialization of the Product in the Field in and for the Ocugen Territory, and BBIL desires to Manufacture and supply such COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance and Drug Product Components, subject to and in accordance with the terms of this Agreement during the Term&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capitalized terms that are not defined in this Agreement shall have the meanings ascribed to such terms in the Co-Development Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in consideration of the foregoing and the mutual covenants and promises set forth herein, the Parties hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For the purposes of this Agreement, unless this Agreement expressly provides otherwise or unless the context otherwise requires, the following initially capitalized terms in this Agreement, whether used in the singular or plural, will have the respective meanings set forth below&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aluminum Hydroxide&#47;TLR Complex</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">&#8220;Adjuvant&#8221; means the BBIL proprietary adjuvant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">aluminum hydroxide + IMDG </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">used for manufacture of the Product.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BBIL Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 11.2.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cell Banks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate of Analysis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a document signed by an authorized representative of BBIL, describing the testing methods applied to the Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components, as applicable, and the results of testing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate of Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a document signed by an authorized representative of BBIL, certifying that a particular batch of the Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components, as applicable, was manufactured in accordance with cGMP, Applicable Laws, and the Specifications therefor.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">cGMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means then current Good Manufacturing Practices as described in 21 CFR Parts 210 and 211, and such other FDA, EMA and International Conference on Harmonisation (ICH) guidance, directives, rules, orders and documents pertaining to manufacturing and quality control practice, all as updated, amended and&#47;or revised from time to time.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Drug Substance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Reagents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Drug Product Components</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the intermediate raw materials and formulation and other components necessary to Manufacture and supply the Product (prior to the performance of fill and finish activities), including without limitation, Aluminum Hydroxide&#47;TLR Complex, IMDG, Cell Banks, Virus Seed, Reference Standards and any other Critical Reagents necessary to Manufacture and supply the Product (prior to the performance of fill and finish activities).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Facility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the BBIL facility located at Hyderabad, India.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMDG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Initial Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the technology transfer described in Section 7.3(a) of the Co-Development Agreement as it relates to the Product (in finished form after the performance of all fill and finish activities).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inspection Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 4.5(a).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Latent Defect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a failure of the Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components, as applicable, to comply with cGMP or the Specifications therefor that could not reasonably have been identified through Ocugen&#8217;s review of the applicable Records or the initial testing and inspection of the Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 11.1.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ocugen Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 11.1.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Ocugen and BBIL together.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means either Ocugen or BBIL, as the context requires.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the separate agreement which applies to the Services to be performed under cGMP requirements, signed by each of the Parties and setting forth the mutual responsibilities of the Parties with respect to quality assurance and cGMP guidelines </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable to the Services performed by BBIL hereunder. Such responsibilities of BBIL and Ocugen are as defined in the Quality Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recalls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 4.8.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 3.1.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reference Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Secondary Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the technology transfer described in Section 7.3(b) of the Co-Development Agreement, as it relates to COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance and Drug Product Components. For clarity, in addition to the technical assistance and cooperation described in Section 7.3(c) of the Co-Development Agreement, any such Secondary Technology Transfer shall include the provision by BBIL to Ocugen or its designee of any quality assistance for process and methods of manufacture that Ocugen may reasonably require in order to effectuate such Secondary Technology Transfer and support the successful commercial Manufacture of the Product by Ocugen for commercial sale by Ocugen of the Product in the Field in and for the Ocugen Territory.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 2.2.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Specifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the specifications, quality standards, formulas, requirements, quality assurance standards, processes, and all modifications or improvements of such specifications, quality standards, formulas, requirements, quality assurance standards and processes for the Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components, as applicable, that are set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit A </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">attached hereto or that are otherwise mutually agreed to by the Parties in writing.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 8.1.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any Person other than the Parties and their respective Affiliates.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Virus Seed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt;text-decoration:underline">The Services.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Supply and Purchase of Adjuvants, Clinical Trial Materials, Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance and Drug Product Components.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Subject to the terms and conditions set forth herein, prior to the completion of the Initial Technology Transfer, BBIL shall exclusively Manufacture and supply to Ocugen, and Ocugen shall purchase from BBIL, such form and quantity of Adjuvants, Clinical Trial Materials as Ocugen reasonably requires to conduct the Ocugen Development Activities and carry out Clinical Trials necessary to seek and obtain Regulatory Approval of the Product in the Field in and for the Ocugen Territory&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Subject to the terms and conditions set forth herein, prior to completion of the Initial Technology Transfer, BBIL shall Manufacture and supply to Ocugen, and Ocugen shall purchase from BBIL, all of Ocugen&#8217;s requirements of commercial quantities of the Product for Ocugen&#8217;s use and Commercialization of the Product in the Field in and for the Ocugen Territory, subject to any reasonable limitations on BBIL&#8217;s capacity, after Ocugen&#8217;s receipt of EUA, BLA or Regulatory Approval for the Product in the Ocugen Territory&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Subject to the terms and conditions set forth herein, after completion of the Initial Technology Transfer and even following the completion of the Secondary Technology Transfer, BBIL shall Manufacture and supply to Ocugen, and Ocugen shall purchase from BBIL such quantities of the COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance and Drug Product Components and exclusively purchase such quantities of Adjuvant from BBIL as are reasonably necessary or useful to support the successful commercial Manufacture of the Product for commercial sale of the Product in the Field in and for the Ocugen Territory after Ocugen&#8217;s receipt of EUA, BLA or other Regulatory Approval for the Product in the Ocugen Territory.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Release and Stability Testing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to the terms and conditions set forth herein, BBIL shall perform release and stability testing of the Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance and Drug Product Components, as applicable, for use in the Field in the Ocugen Territory in accordance with FDA requirements, Applicable Laws, and the terms of the Quality Agreement (such activities under Section 2.1 and this Section 2.2, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Notwithstanding the foregoing, Ocugen shall take commercially reasonable steps to promptly qualify an alternative supplier of the Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance and Drug Product Components after the Effective Date to cover limited events of supply failure where, for some reason, BBIL is unable to Manufacture and supply the Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components for&#47;to Ocugen pursuant to the terms and conditions of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Communications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Party will appoint a representative who will have primary responsibility for day-to-day interactions with the other Party&#8217;s representative concerning the Services. Either Party may appoint a substitute or successor representative by providing written notice thereof to the other Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Subcontracting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon the prior written agreement of Ocugen, BBIL may subcontract the performance of certain of its obligations under this Agreement to its Affiliates or to qualified Third Parties, provided that such Affiliates or Third Parties execute an agreement containing provisions that that (a) are consistent with the cooperation, records and reports, ownership, confidentiality and intellectual property provisions set forth in this Agreement, and (b) assign any and all intellectual property rights discovered or invented by the Third Party contractor thereunder to BBIL or Ocugen, as applicable. BBIL will remain liable for the actions or inactions of any Third Party with whom it contracts for any obligations under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Quality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Within &#91;***&#93; days after the Effective Date and prior to BBIL conducting any Services that are subject to cGMP requirements, the Parties will enter into the Quality Agreement to establish the Parties&#8217; respective quality assurance responsibilities relating to the Services. Following execution of the Quality Agreement, in the event of a conflict between the terms of the Quality Agreement and this Agreement, the terms of the Quality Agreement will govern or control with respect to all quality control and quality assurance matters, and this Agreement will govern or control with respect to all other matters.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt;text-decoration:underline">Records&#59; Personnel and Inspection.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. BBIL will keep complete and accurate records of all Manufacturing and testing by BBIL in the course of its performance of the Services and with respect to the Specifications in sufficient detail to permit Ocugen to confirm that the Services are or have been performed in compliance with this Agreement and Applicable Laws, and to verify the amounts that Ocugen has paid BBIL for the performance of such Services (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). While in the possession or control of BBIL, the Records will be made available for inspection, examination and copying by or on behalf of Ocugen and at Ocugen&#8217;s expense&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that BBIL may exclude or redact from such Records any confidential or proprietary information of Third Parties. Upon the expiration or termination of this Agreement, BBIL will transfer to Ocugen, at Ocugen&#8217;s expense, the Records&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that BBIL may (a) retain one copy of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such Records solely for the purposes of internal record-keeping, and monitoring its obligations under this Agreement and as required by Applicable Laws and (b) exclude or redact from such Records any confidential or proprietary information of Third Parties.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Inspections, Visits, and Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Inspections and Visits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Ocugen or its duly designated representative will have the right, upon at least &#91;***&#93; prior written notice without cause, to have &#91;***&#93; Ocugen employees or representatives, during normal business hours, at Ocugen&#8217;s cost, to (i) observe the Manufacturing of the Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components, as applicable, at the Facility&#59; (ii) review the Records&#59; and (iii) otherwise inspect the relevant portions of the Facility during the performance of the Services.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Ocugen or its duly designated representative that is reasonably acceptable to BBIL will have the right, at Ocugen&#8217;s cost, upon &#91;***&#93; prior written notice, and no more than &#91;***&#93; every Calendar Year unless for cause, in which case, as frequently as necessary to audit the Facility and Records to ascertain compliance by BBIL with the terms of this Agreement, the Quality Agreement, Applicable Laws, and the Specifications.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Ocugen employees and representatives who inspect, visit, or audit BBIL&#8217;s Facility and Records will do so during normal business hours and at all times comply with BBIL&#8217;s rules, regulations and SOPs relating to inspections and visits to the Facility, and Ocugen retains full responsibility and liability for the presence and actions of its employees on BBIL&#8217;s premises. Any representative conducting any inspection, visit or audit hereunder shall be subject to confidentiality obligations no less restrictive than those set forth in this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Each Party shall bear its own costs associated with all such inspections, visits and audits under this Section 3.2, unless provided otherwise in this Section 3.2.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt;text-decoration:underline">Minimum 2021 Supply Commitment&#59; Forecasts&#59; Purchase Orders&#59; Shipping&#59; Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Minimum 2021 Supply Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding the consummation of the Initial Technology Transfer, for and during Calendar Year 2021, BBIL shall Manufacture and supply to Ocugen, its Affiliates or Sublicensees, not less than (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, at least) &#91;***&#93; doses of finished commercial Product (sufficient for a minimum of &#91;***&#93; patients) for Ocugen&#8217;s, its Affiliates&#8217; and Sublicensees&#8217; use in the Field in and for the Ocugen Territory. Notwithstanding the foregoing, in the event that Ocugen&#8217;s receipt of an EUA and&#47;or BLA for the Product in the Field in and for the Ocugen Territory is delayed beyond &#91;***&#93;, the Parties shall discuss in good faith and use best efforts to revise the quantities of finished commercial Product to be Manufactured and supplied by BBIL for and during Calendar Year 2021, such that BBIL shall remain obligated to Manufacture &#91;***&#93; doses of finished commercial Product for and during the remainder of Calendar Year 2021, provided, however, in no event shall BBIL&#8217;s monthly supply commitment during such period exceed &#91;***&#93; doses per &#91;***&#93;, with supply of such finished commercial Product to commence during July 2021 and continue through December 2021.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Forecasts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Commencing upon the Effective Date and on a &#91;***&#93; basis thereafter until the termination or expiration of this Agreement, Ocugen will provide to BBIL a rolling &#91;***&#93; forecast of its, its Affiliates&#8217; or Sublicensees&#8217; pre-clinical, clinical and commercial requirements for the Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance and Drug Product Components (separately identifying its, its Affiliates&#8217; or Sublicensees&#8217; pre-clinical, clinical and commercial requirements of Aluminum Hydroxide&#47;TLR Complex, IMDG, Cell Banks, Virus Seed, Reference Standards and any other Critical </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reagents), as applicable (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forecast</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The first &#91;***&#93; of each Forecast will be considered the firm order period and will be binding on the Parties (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Binding Forecast</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and the following &#91;***&#93; will be a non-binding, good faith estimate. Forecasts will be updated by Ocugen to BBIL in writing on a &#91;***&#93; basis, with each subsequent &#91;***&#93; forecast adding an additional &#91;***&#93; to the firm period (e.g., a rolling &#91;***&#93; firm period). Notwithstanding the foregoing, during Calendar Year 2021 the Parties will collaborate, discuss in good faith and mutually agree upon each Forecast.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Purchase Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Together with each Forecast, Ocugen will submit firm, non-cancellable purchase orders for Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance and&#47;or Drug Product Components, as applicable, under the applicable Binding Forecast. All purchase orders for Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance and&#47;or Drug Product Components shall state the quantities of Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance and&#47;or Drug Product Components (separately specifying the Aluminum Hydroxide&#47;TLR Complex, IMDG, Cell Banks, Virus Seed, Reference Standards and any other Critical Reagents) to be purchased pursuant to such purchase orders, the requested delivery dates, and shipping instructions. Purchase orders for Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance and&#47;or Drug Product Components (separately specifying the IMDG, Aluminum Hydroxide&#47;TLR Complex, Virus Seed, Cell Banks, and any other Critical Reagents) shall state the ordered quantity, including with respect to the Product, in increments of full batches. For clarity, each purchase order placed by Ocugen will be deemed as accepted by BBIL to the extent that it is consistent with the Binding Forecast. BBIL may, in writing, object within &#91;***&#93; after submission by Ocugen, to any purchase order that is inconsistent with the Binding Forecast by more than a &#91;***&#93; variance. BBIL will have &#91;***&#93; after its receipt of a purchase order to accept such purchase order, which will become firm upon its acceptance by BBIL. If the quantity of Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components (separately specifying the Aluminum Hydroxide&#47;TLR Complex, IMDG, Cell Banks, Virus Seed, Reference Standards and any other Critical Reagents), as applicable, ordered in a purchase order exceeds &#91;***&#93; of the applicable Binding Forecast related to such Clinical Trial Materials, Adjuvant, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components (separately specifying the Aluminum Hydroxide&#47;TLR Complex, IMDG, Cell Banks, Virus Seed, Reference Standards and any other Critical Reagents), as applicable, BBIL will use commercially reasonable efforts to accommodate the excess quantity thereof so ordered by Ocugen. Notwithstanding the foregoing, during Calendar Year 2021, the Parties shall abide by the mutually agreed terms with respect to forecast and accommodation for the excess quantity.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Shipping&#59; Storage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Shipments of the Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance and Drug Product Components shall be made EXW (as defined in Incoterms 2020) from the Facility. Title to same and risk of loss or damage shall pass to Ocugen accordingly after the Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components, as applicable, is loaded onto the carrier&#8217;s vehicle for shipment at the EXW point. All shipping instructions of Ocugen will be accompanied by the name and address of the recipient and the shipping date and any costs and insurance associated with shipping will be borne by Ocugen. BBIL must provide all required documentation, including without limitation a Certificate of Analysis and Certificate of Compliance, and the Records including analytical testing data, if any, for each lot of Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components, certifying conformity with the Specifications, Applicable Laws, and cGMP. In addition, BBIL must provide all product&#47;process documentation and analytical raw data of each lot, as well as supplementing documentation as requested (e.g., for regulatory filings). Should Ocugen require special handling, packaging or services, then the cost of such special handling, packaging or services will be borne entirely by Ocugen at BBIL&#8217;s prevailing rates. On Ocugen&#8217;s written request, and at Ocugen&#8217;s cost and expense, BBIL will store Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components, as applicable, for up to an additional &#91;***&#93; following an initial period of &#91;***&#93; which shall also be at Ocugen&#8217;s cost following the release of such Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components by Ocugen. Such additional storage will be subject to storage fees to be mutually agreed upon by the Parties.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Inspection and Rejection</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Inspection</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. BBIL will ship the Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components, as applicable, in accordance with Section 4.4 upon successful completion of the release testing required to be performed thereon by BBIL. Ocugen will have &#91;***&#93; after receipt (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inspection Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to inspect and test the Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components, as applicable, in accordance with Applicable Laws, the terms of this Agreement, the Quality Agreement, and the Specifications. Prior to the expiration of the Inspection Period for a shipment of Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components, as applicable, Ocugen will provide prompt written notice to BBIL if any such Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components does not comply with Applicable Laws, the terms of the Agreement (including the Quality Agreement), and&#47;or the Specifications. Such notice will specify the nature of the Adjuvant, Clinical Trial Materials&#8217;, Product&#8217;s, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance&#8217;s or Drug Product Components&#8217; non-compliance. Subject to Section 4.5(b), failure by Ocugen to provide such notice within the applicable Inspection Period will be deemed an acceptance of such Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components by Ocugen.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Latent Defect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Ocugen may, no later than &#91;***&#93; after Ocugen&#8217;s acceptance of a batch of Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components under Section 4.5(a), reject such Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components if it discovers that such Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components has a Latent Defect. Ocugen must notify BBIL of such Latent Defect in writing within &#91;***&#93; after its first discovery of such Latent Defect. Such notice will state in a reasonably sufficient detail the reason for the Latent Defect, if known.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Referee Laboratory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In case of any disagreement between the Parties as to whether any Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components conforms to the applicable Specifications, the Parties shall attempt, in good faith, to resolve such dispute. If Ocugen and BBIL cannot resolve such dispute, a representative sample of such Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components, as applicable, will be submitted to an independent testing laboratory mutually agreed upon by the Parties (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Referee Lab</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) for tests and final determination of whether such Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components, as applicable, conforms to such Specifications. The Referee Lab must meet the requirements of cGMP, be of recognized standing in the industry, and consent to the appointment of such laboratory, which will not be unreasonably withheld, conditioned or delayed by either Party. The Referee Lab will use the test methods contained in the applicable Specifications. The determination of conformance by the Referee Lab with respect to all or part of such Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components, as applicable, will be final and binding on the Parties. The fees and expenses of the Referee Lab incurred in making such determination will be paid by the Party against whom the determination is made.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If BBIL agrees or the Referee Lab determines that Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components, as applicable, do not conform to the applicable Specifications as a result of BBIL&#8217;s (i) failure to follow Applicable Laws, (ii) breach of this Agreement or the Quality Agreement, or (iii) negligence or willful misconduct, then Ocugen will have the right to reject such non-conforming Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components. Ocugen will promptly return any such rejected Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components to BBIL, or at BBIL&#8217;s direction dispose of such Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components at BBIL&#8217;s expense. BBIL will replace such non-conforming Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components with Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components that conforms to the applicable Specifications as soon as reasonably practicable after receipt of notice of rejection thereof. BBIL will bear all reasonable costs directly related to the replacement of the non-conforming Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components. If the Parties, through their Quality Assurance groups, agree in writing, the replacement of the non-conforming Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components can be satisfied through reprocessing or reworking the non-conforming Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Recalls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The handling of field alerts, recalls and market withdrawals (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recalls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of the Product, to the extent the Product is then being Commercialized in the Field in and for the Ocugen Territory, will be within the sole discretion of Ocugen, and Ocugen will notify BBIL promptly of any such Recall of Product. Notification to any Regulatory Authority and the conduct of such Recall will be the sole responsibility of Ocugen. BBIL will (a)&#160;cooperate fully with Ocugen in the event of any such Recall and (b) provide such assistance in connection with the Recall as Ocugen may reasonably request. Ocugen will bear all expenses of any such Recall and BBIL&#8217;s assistance unless and to the extent such Recall directly results from BBIL&#8217;s (i) negligence or willful misconduct, (ii) failure to comply with its obligations under this Agreement in respect of the Product that is subject to Recall, or (iii) breach of any representation, warranty or covenant contained herein with respect to the Product that is subject to Recall, whereupon in each case BBIL will (A) bear the actual, documented and reasonable expenses of the Parties in carrying out the Recall and (B) replace the Product subject to such Recall with conforming Product as soon as reasonably practicable at BBIL&#8217;s expense.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt;text-decoration:underline">Price and Payments.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Ocugen will pay BBIL the purchase price for the Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance and Drug Product Components (separately specifying the purchase price for the Aluminum Hydroxide&#47;TLR Complex, IMDG, Cell Banks, Virus Seed, Reference Standards and any other Critical Reagents) as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit B </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">attached hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), which </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit B </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shall be updated by the Parties at the appropriate time to reflect the actual Purchase Price paid by Ocugen to BBIL for the Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components (separately specifying the Purchase Price actually paid for the Aluminum Hydroxide&#47;TLR Complex, IMDG, Cell Banks, Virus Seed, Reference Standards and any other Critical Reagents), as applicable. Notwithstanding the foregoing, the maximum Purchase Price payable by Ocugen for Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or any Drug Product Component Manufactured and supplied hereunder shall be at such price as is mutually agreed in writing by the Parties.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. BBIL will invoice Ocugen upon release of each batch of Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components, as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable, by BBIL&#8217;s Quality Department. Payment of undisputed amounts of invoices will be due thirty (30) days after the date each invoice is received by Ocugen. Ocugen shall pay all undisputed fees, expenses and other charges as and when due. The Parties shall use good faith efforts to resolve any disputed amounts within &#91;***&#93; and if the dispute is not resolved within such &#91;***&#93;, the Parties reserve all rights respecting the disputed amount. Interest on unpaid balances shall accrue at the rate of &#91;***&#93; from the date payment is due, provided that interest on amounts that Ocugen had timely disputed shall not begin to run until &#91;***&#93; after the date the payment is due, and provided further that such interest shall not be payable on any invoice or portion of an invoice which is determined to not be due to BBIL, but where determined to be due to BBIL, the interest period shall run from the date when originally due.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Invoices.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> All payments hereunder will be made in United States Dollars. Ocugen will make all payments pursuant to this Agreement by wire transfer to a bank account designated in writing by BBIL.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any use, sales, excise or value added tax, duty, custom, inspection or testing fee, or any other tax, fee or charge of any nature whatsoever imposed by any governmental authority on or measured by the transaction between BBIL and Ocugen (other than BBIL&#8217;s income tax), will be paid by Ocugen in addition to the prices quoted or invoiced by BBIL. In the event BBIL is required to pay any such tax, fee, or charge, Ocugen will reimburse BBIL for such payment, or in lieu of such payment, Ocugen will provide BBIL at the time the order is submitted an exemption certificate or other document acceptable to the authority imposing the tax, fee or charge.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">By Both Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. BBIL and Ocugen each represents and warrants to the other that&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">It is, and will remain, a corporation duly organized, validly existing and in good standing under the laws of its jurisdiction of organization.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The execution and delivery of this Agreement has been authorized by all requisite corporate action. This Agreement is and will remain a valid and binding obligation of the executing Party, enforceable in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">It is under no contractual or other obligation or restriction that is inconsistent with its execution or performance of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">It will comply with cGMP and all Applicable Laws while performing its obligations hereunder.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">By BBIL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. BBIL represents and warrants to Ocugen that&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The Services will be performed (i) in a professional and workmanlike manner using only properly qualified and trained personnel, and (ii) in accordance with Applicable Laws and cGMP, and, upon delivery, the Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance and Drug Product Components, as applicable, will meet the Specifications therefor.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Title to any Adjuvant, Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components provided to Ocugen under this Agreement shall pass as provided in this Agreement, free and clear of any security interest, lien or other encumbrance.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">BBIL will promptly notify Ocugen in writing should it become aware of any claim asserting that the use of BBIL Technology in the performance of the Services infringes the intellectual property rights of any Third Party.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Neither BBIL nor any of its employees providing the Services has been debarred, or convicted, or is subject to a pending debarment or conviction, pursuant to section 306 of the United States Food, Drug, and Cosmetic Act, 21&#160;U.S.C. &#167;&#160;335a, the Generic Drug Enforcement Act of 1992, 21 U.S.C. Sec. 335a, or any foreign equivalent hereto related to the transactions contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">BBIL has all appropriate training, registrations, licenses and other governmental authorizations required to carry out its obligations under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">By Ocugen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; Ocugen represents and warrants to BBIL that&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">It shall maintain the COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance, Drug Product Components and Product in a facility that is properly equipped to store the COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance, Drug Product Components and Product and have in place appropriate product security measures in accordance with Applicable Law.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">In the event Ocugen uses the COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Drug Substance supplied by BBIL hereunder in a Product and packages such Product for use in Ocugen Development Activities, it shall do so, and shall distribute such Product, in accordance with all Applicable Laws.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Neither Ocugen nor any of its employees performing Ocugen&#8217;s obligations under this Agreement has been debarred, or convicted, or is subject to a pending debarment or conviction, pursuant to section 306 of the United States Food, Drug, and Cosmetic Act, 21&#160;U.S.C. &#167;&#160;335a, the Generic Drug Enforcement Act of 1992, 21 U.S.C. Sec. 335a, or any foreign equivalent thereto.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Ocugen or its personnel with responsibilities related to this Agreement, as applicable, have all appropriate training, registrations, licenses and&#47;or other governmental authorizations required to carry out its&#47;their obligations under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">DISCLAIMER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt;text-decoration:underline">Government Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As more fully described in the Co-Development Agreement, Ocugen will be responsible for obtaining, at its expense, all regulatory and governmental approvals and permits necessary for Ocugen to use and Commercialize the Product in the Field, in and for the Ocugen Territory that is provided to Ocugen by BBIL under this Agreement, including without limitation, all submissions filed with the FDA or other Regulatory Authorities.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt;text-decoration:underline">Expiration, Initial Technology Transfer and Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Expiration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Agreement will become effective as of the Effective Date. Unless earlier terminated in accordance with this Section 8, this Agreement will be and remain effective until the expiration or termination of the Co-Development Agreement (such period, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Effects of Initial Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon completion of the Initial Technology Transfer&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Ocugen shall be responsible, at its sole cost and expense, for the Manufacture and supply of the finished Product in its commercial packaging presentation, for use and Commercialization by Ocugen in the Field in and for the Ocugen Territory, except that BBIL shall continue to Manufacture and supply Adjuvant, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance and Drug Product Components after the completion of the Secondary Technology Transfer to Ocugen for the remainder of the Term to the extent forecasted and ordered by Ocugen pursuant to the terms of the Agreement and consistent with Section 7.2(b) of the Co-Development Agreement, provided however that notwithstanding anything to the contrary contained in this Agreement, BBIL shall not be required to and shall not transfer any technology related to the Adjuvant to Ocugen and Ocugen shall only be entitled to supplies of Adjuvant from BBIL on a long term basis&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">notwithstanding Ocugen&#8217;s exclusive right to Manufacture the Product in and for the Ocugen Territory, BBIL shall continue to be a back-up supplier of the Product for Ocugen, its Affiliates or Sublicensees, as applicable, in and for the Ocugen Territory, provided that the purchase price payable by Ocugen for any such back-up supply shall be negotiated between the Parties within a reasonable period of time prior to BBIL manufacturing such supply for Ocugen&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">BBIL shall continue to have a non-exclusive right to Manufacture the Product in the BBIL Territory for the use and Commercialization of such Product by Ocugen, its Affiliates or Sublicensees in the Field in and for the Ocugen Territory, solely as may be requested by Ocugen, its Affiliates or Sublicensees pursuant to and in accordance with the terms of this Agreement, provided that, after the completion of the Initial Technology Transfer, Ocugen shall have and retain, except as otherwise set forth in this Agreement, the sole and exclusive right to Manufacture the Product in the Field in and for the Ocugen Territory, subject only to the limitations described in this Section 8.2(c)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">the technology for the COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance and Drug Product Components shall have been fully transferred to Ocugen, provided not withstanding such transfer, Ocugen shall have the right to request that BBIL supply, on an as-needed basis, the Aluminum Hydroxide&#47;TLR Complex to Ocugen for the Manufacture and supply by Ocugen of the Product in the Field in and for the Ocugen Territory. For clarity, all costs related to the Initial Technology Transfer shall be for the account of and shall be paid by Ocugen.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Termination for Breach or Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Either Party will have the right to terminate this Agreement in accordance with Sections 12.2(a)(i) or 12.2(a)(iii), but subject to Section 12.2(b), of the Co-Development Agreement as if such provisions were contained in and applied to the Parties under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Obligations on Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Of BBIL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon termination of this Agreement pursuant to this Section 8, BBIL will suspend work as early as possible and&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">perform only those Services and other activities mutually agreed upon by Ocugen and BBIL as being necessary or advisable&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">use commercially reasonable efforts to cancel any Third Party obligations&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.03pt">promptly deliver to Ocugen all materials ordered by BBIL for Ocugen after receipt of undisputed amounts applicable to such materials by Ocugen&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">promptly return all Confidential Information of Ocugen that it has received pursuant to this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Of Ocugen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon termination of this Agreement pursuant to this Section 8, Ocugen will&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">promptly pay BBIL any undisputed monies due and owing BBIL, up to the time of termination, for Services actually performed, all authorized expenses actually incurred and, except for any termination by Ocugen under Section 8.1 or Section 8.3, any uncancellable commitments made by BBIL in connection with the Services&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">promptly return all Confidential Information of BBIL that it has received pursuant to this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Surviving Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Expiration or termination of this Agreement for any reason will not affect and rights or obligation of either Party that accrued prior to such expiration or termination. Further, the rights and obligations of the Parties under the following provisions of this Agreement will survive in accordance with their terms&#58; Sections 1, 4.7, 4.8, 5.2, 5.4, 6, 7, 8.2, 8.3, 8.4, 8.5, 11.3 through 11.11 and 12.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt;text-decoration:underline">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of any Force Majeure hereunder, the Parties shall approach and resolve the matter in accordance with Section 14.1 of the Co-Development Agreement, and the provisions of such Section 14.1 of the Co-Development Agreement shall apply in interpreting this Agreement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as if the same was incorporated herein.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to confidentiality and publicity, the terms of Article XI of the Co-Development Agreement shall apply </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to this Agreement, as if the same was incorporated herein.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt;text-decoration:underline">Indemnification&#59; Limited Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt;text-decoration:underline">Indemnification by BBIL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. BBIL will indemnify, defend and hold harmless Ocugen, its Affiliates and Sublicensees, and its and their respective directors, officers, employees, and agents, and their respective successors, heirs and assigns (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ocugen Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) against any and all damages, liabilities, losses and expenses, including reasonable attorneys&#8217; fees and expenses of litigation (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) incurred by or imposed upon the Ocugen Indemnitees, or any of them, including as a direct result of Claims of Third Parties, including personal injury and product liability claims (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ocugen Indemnity Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), to the extent arising out of&#58; (a) any breach of this Agreement by BBIL or any of its Affiliates or agents, including its representations, warranties and covenants&#59; or (b) the gross negligence or willful misconduct of or fraud by any BBIL Indemnitee or agent of BBIL, excluding any BBIL Indemnity Claim or Losses for which Ocugen has an obligation to indemnify BBIL Indemnitees pursuant to Section 11.2, as to which Claims or Losses each Party shall indemnify the other to the extent of their respective liability for such Losses.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt;text-decoration:underline">Indemnification by Ocugen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Ocugen will indemnify, defend and hold harmless BBIL and its Affiliates, and its and their respective directors, officers, employees, and agents, and their respective successors, heirs and assigns (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BBIL Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) against all Losses incurred by or imposed upon the BBIL Indemnitees, or any of them, including as a direct result of Claims of Third Parties, including personal injury and product liability claims (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BBIL Indemnity Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), to the extent arising out of&#58; (a) the Development, Manufacture or Commercialization of the Product by Ocugen or any of its agents in the Field in and for the Ocugen Territory&#59; (b) any breach of this Agreement by Ocugen or any of its Affiliates or Sublicensees, and its and their respective agents, including its representations, warranties and covenants&#59; or (c) the gross negligence or willful misconduct of or fraud by any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ocugen Indemnitee or agent of Ocugen, excluding any Ocugen Indemnity Claim or Losses for which BBIL has an obligation to indemnify Ocugen Indemnitees pursuant to Section 11.1, as to which Claims or Losses each Party shall indemnify the other to the extent of their respective liability for such Losses.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt;text-decoration:underline">Conditions to Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A Person seeking indemnification under this Section 11 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) in respect of a BBIL Indemnity Claim or an Ocugen Indemnity Claim, as applicable (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnity Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) shall give prompt written notice of such Indemnity Claim to the Party from whom indemnification is sought (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#59; provided, that the Indemnifying Party is not contesting its obligation under this Section 11, and shall permit the Indemnifying Party to control the investigation, defense and settlement of such Indemnity Claim&#59; and further provided, that the Indemnifying Party shall (a) act reasonably and in good faith with respect to all matters relating to the settlement or disposition of such Indemnity Claim as the settlement or disposition relates to such Indemnified Party and (b) not settle or otherwise resolve such Indemnity Claim without the prior written consent of such Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed). Each Indemnified Party shall cooperate with the Indemnifying Party in its investigation, defense and settlement of any such Indemnity Claim in all reasonable respects and shall have the right to be present in person or through counsel at all legal proceedings with respect to such Indemnity Claim. If the Indemnifying Party does not assume and conduct the defense of the Indemnity Claim as provided above, (i) the Indemnified Party may defend against, consent to the entry of any judgment, or enter into any settlement with respect to such Indemnity Claim in any manner the Indemnified Party may deem appropriate (and the Indemnified Party need not consult with, or obtain any consent from, the Indemnifying Party in connection therewith), and (ii) the Indemnifying Party shall remain responsible to indemnify the Indemnified Party as provided in this Section 11. The Indemnifying Party shall have no liability for any settlement of Indemnity Claims entered into by the Indemnified Party without the prior written consent of the Indemnifying Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt;text-decoration:underline">Limited Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES OR ITS SUBLICENSEES FOR ANY SPECIAL, PUNITIVE, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING LOST PROFITS OR LOST REVENUES, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 11.4 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY UNDER SECTIONS 11.1 OR 11.2, FOR DAMAGES AVAILABLE FOR A PARTY&#8217;S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OR A BREACH OF CONFIDENTIALITY OBLIGATION UNDER SECTION 10.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Party shall procure and maintain insurance in accordance with Section 13.5 of the Co-Development Agreement, and the provisions of such Section 13.5 of the Co-Development Agreement shall apply in interpreting this Agreement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as if the same were incorporated herein.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt;text-decoration:underline">Maximum Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Except to the extent of a Party&#8217;s gross negligence or willful misconduct in the performance of this Agreement, or to the extent any BBIL Indemnity Claim or Losses in respect of a BBIL Indemnity Claim relates to or arises from or is in any way connected to the Ocugen Territory (the liability of Ocugen thereto being uncapped), the maximum aggregate liability of either Party in respect of any Claim, including an Indemnity Claim, under this Agreement, notwithstanding anything to the contrary contained in this Agreement shall not exceed an amount equal to &#91;***&#93; preceding the date on which the action or omission alleged to have caused such Claim or Indemnity Claim occurred.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt;text-decoration:underline">Otherwise Compensated</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If the Indemnifying Party makes any payment by way of Losses in respect of a Claim under this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Damages Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and the Indemnified Party </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequently receives any monetary payment (exclusive of payments from the Indemnifying Party), which payment compensates the Indemnified Party for the same Loss as the Damages Payment, the Indemnified Party shall, once it has received such monetary payment, forthwith repay (net of any taxes actually paid or withheld with respect thereto) to the Indemnifying Party an amount equal to the amount (if any) by which the amount of the Damages Payment, aggregated with the amount of such monetary payment, exceeds the total amount of the Losses suffered by the Indemnified Party in respect of such Claim.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt;text-decoration:underline">No Double Recovery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. No Indemnified Party shall be entitled to recover damages or obtain payment, reimbursement, restitution or indemnity more than once for the same loss, damage, deficiency or breach whether under this Agreement or the Co-Development Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt;text-decoration:underline">Mitigation Not Affected</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Both Parties shall procure that commercially reasonable steps are taken and commercially reasonable assistance is given to avoid or mitigate any Losses which, in the absence of mitigation, might give rise to a liability in respect of any Claim.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.5pt;text-decoration:underline">Time Limitation for Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. BBIL shall not be liable for any Claim unless a notice of the Claim is given by Ocugen to BBIL specifying the matters set out in Section 11.11 and in the case of any Claims of Third Parties, including personal injury and product liability claims, within twelve (12) months from the expiry date of the shelf life of the applicable Clinical Trial Materials, Product, COVAXIN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Substance or Drug Product Components supplied by BBIL under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.5pt;text-decoration:underline">Notification of Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notice of any Claim shall be given by Ocugen to BBIL within the time limits specified in Section 11.10 and shall not be valid unless it specifies full information (to the extent available) in relation to the legal and factual basis of the Claim and the evidence on which Ocugen is making such Claim relies (including, where the Claim is the result of or in connection with a Third Party Claim, evidence of the Third Party Claim) and setting out Ocugen&#8217;s good faith estimate of the amount of Losses which are, or are to be, the subject of the Claim (including any Losses which are contingent on the occurrence of any future event).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Neither Party may assign or transfer this Agreement or any rights or obligations hereunder, either in whole or in part, without the prior written consent of the other Party. Notwithstanding the foregoing, either Party may assign this Agreement without the other Party&#8217;s consent to one or more of its Affiliates, to any person or entity into which the assigning Party has merged, or to any person or entity which has otherwise succeeded to all or substantially all of the assigning Party&#8217;s business and assets to which this Agreement pertains, whether such succession results from sale of assets, stock, merger, consolidation, reorganization or otherwise. The assigning Party shall provide the other Party with prompt written notice of any such assignment. Any permitted assignee shall assume all obligations of its assignor under this Agreement, and no permitted assignment shall relieve the assignor of liability for its obligations hereunder. Any attempted or purported assignment in violation of this section shall be null and void. This Agreement, and each Party&#8217;s rights and obligations hereunder will bind and inure to the benefit of its respective successors, heirs, executors, administrators, and permitted assigns.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each provision in this Agreement is independent and severable from the others, and no provision will be rendered unenforceable because any other provision is found by a proper authority to be invalid or unenforceable in whole or in part. If any provision of this Agreement is found by such an authority to be invalid or unenforceable in whole or in part, such provision will be changed and interpreted so as to best accomplish the objectives of such unenforceable or invalid provision and the intent of the Parties, within the limits of Applicable Laws.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All notices which either Party is required or may desire to give hereunder shall be provided in accordance with Section 14.4 of the Co-Development Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt;text-decoration:underline">Choice of Law and Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The validity, construction and performance of this Agreement shall be governed by and construed in accordance with the laws of the United Kingdom, without regard to the application of principles of conflicts of law.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt;text-decoration:underline">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In respect of any dispute concerning this Agreement, the Parties shall resolve the matter in accordance with Section 14.6 of the Co-Development Agreement, and the provisions of such Section 14.6 of the Co-Development Agreement shall apply in interpreting this Agreement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as if the same was incorporated herein.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt;text-decoration:underline">Entire Agreement&#59; Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Agreement constitutes the final, complete and exclusive statement of the terms between Ocugen and BBIL with respect to the subject matter hereof and supersedes and terminates any and all prior agreements and understandings (other than the Co-Development Agreement), whether written or oral, between the Parties with respect to the subject matter hereof.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt;text-decoration:underline">Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If there is any conflict, discrepancy, or inconsistency between the terms of this Agreement and any purchase order hereunder or other form used by the Parties, the terms of this Agreement will control. If there is conflict, discrepancy, or inconsistency between the terms of this Agreement and the Co-Development Agreement, the terms of the Co-Development Agreement will control.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt;text-decoration:underline">Headings&#59; Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Section headings are intended for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. Both Parties have participated equally in the formation of this Agreement and the language of this Agreement will not be presumptively construed against either Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt;text-decoration:underline">No Partnership or Employment Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All Services will be rendered by BBIL as an independent contractor for federal, state and local income tax purposes and for all other purposes. BBIL will not in any way represent itself to be a partner or joint venturer of or with Ocugen. This Agreement does not create an employer-employee relationship between Ocugen on the one hand and BBIL or any employee, subcontractors, Affiliate of BBIL, or any BBIL personnel on the other. BBIL is acting under this Agreement as an independent contractor with full power and authority to determine the means, manner and method of performance of BBIL&#8217;s duties. Each Party will be responsible for and will withhold and&#47;or pay any and all applicable federal, state or local taxes, payroll taxes, workers&#8217; compensation contributions, unemployment insurance contributions, or other payroll deductions from the compensation of such Party&#8217;s employees and other personnel. Each Party understands and agrees that it is solely responsible for such matters and that it will indemnify the other Party and hold the other Party harmless from all claims and demands in connection with such matters.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.5pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. No term or condition of this Agreement shall be deemed to have been waived, nor shall there be any estoppel against the enforcement of any provision of this Agreement, except by a written instrument signed by the Party against whom enforcement of such waiver or estoppel is sought. No such written waiver shall be deemed a continuing waiver unless specifically stated therein, and each such waiver shall operate only as to the specific term or condition waived and shall not constitute a waiver of such term or condition for the future or as to any act other than that specifically waived.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.5pt;text-decoration:underline">Amendments or Modifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Agreement cannot be amended or modified except in a writing executed by both Parties.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.5pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any covenant or provision of this Agreement which by its express terms is required to be observed, kept or performed after expiration or termination hereof, or which by its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nature and effect is intended to survive expiration or termination of this Agreement shall so survive.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.5pt;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Parties hereby covenant and agree without the necessity of any further consideration, to execute, acknowledge and deliver any and all such other documents and take any such other action as may be reasonably necessary or appropriate to carry out the intent and purposes of this Agreement.</font></div><div style="margin-bottom:36pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.5pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Agreement and any amendments hereof may be executed in counterparts and by original, facsimile, PDF or other electronic signatures.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Parties have caused this Agreement to be executed by their duly authorized representatives, effective as of the Effective Date.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.840%"><tr><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OCUGEN, INC.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BHARAT BIOTECH INTERNATIONAL LIMITED</font></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Sanjay Subramanian</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; V. Krishna Mohan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanjay Subramanian</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. V. Krishna Mohan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CFO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whole-time Director</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9&#47;29&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9&#47;29&#47;2021</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div><div id="i0f0093be76fa4905b1e461f1392cd12d_126"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIFICATIONS</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i0f0093be76fa4905b1e461f1392cd12d_96"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font><br></font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT B</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURCHASE PRICE</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ocgn-20210930x10qxex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic54c9358d6be470fbb9dfe9734477f0d_1"></div><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain portions of this document have been omitted pursuant to Item 601(b)(10)&#160;of Regulation S-K and, where applicable, have been marked with &#8220;&#91;***&#93;&#8221; to indicate where omissions have been made. The marked information has been omitted because it is (i)&#160;not material and (ii)&#160;the type that the registrant treats as private or confidential. The registrant hereby undertakes to provide further information regarding such marked information to the Securities and Exchange Commission upon request.</font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Amendment to the CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT</font></div><div style="margin-bottom:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Amendment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) by and between Ocugen, Inc. previously having a place of business at 5 Great Valley Parkway, Suite 160, Malvern, PA 19355, now with an address at 263 Great Valley Parkway, Malvern, PA 19355, USA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ocugen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and CanSino Biologics, Inc., whose registered office address is at 185 South Ave, TEDA West District, Tianjin, 300457, China (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CanSino</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is made and effective as of the last date of signature below (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ocugen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CanSino</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hereinafter also individually referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;, and collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Parties have entered into a CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT effective as of September 27, 2019 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original Collaboration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), under which Ocugen and CanSino has established co-development and commercialization relationship on the gene therapy product of OCU400&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Parties agree that the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is still in full force and effect&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Ocugen is willing to establish additional co-development and commercialization relationship with CanSino on the other gene therapy product known as OCU410 for use in the Field of OCU410 under the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, CanSino, representing itself and its Affiliates, wishes to obtain the exclusive right regarding Ocugen Technology and Ocugen Patent Rights of OCU410 to collaborate and cooperate with Ocugen to co-development and commercialization under the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, pursuant to Section 11.2, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> desire to amend the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as provided for herein.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in consideration of the premises and mutual covenants, agreements and provisions herein contained, and intending to be legally bound, the Parties have entered into the present Amendment as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.85pt">Definitions</font></div><div style="margin-bottom:12pt;padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.35pt">Unless otherwise established herein, the terms that are in bold letters or capitalized and defined and&#47;or used in the Original Collaboration Agreement shall have the same meanings set out in this Amendment.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="margin-bottom:6pt"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.35pt">In the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Section 1 &#8220;Definitions&#8221; is amended to include the following new terms&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.840%"><tr><td style="width:1.0%"></td><td style="width:4.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">CanSino Development Activities of OCU410&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">shall mean All Development activities to be conducted by or on behalf of CanSino with respect to the Development Program of OCU410 as specified in the Development Plan pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Amendment.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Clinical Data of OCU410&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">shall mean any and all data (together with all clinical trial reports and the result of analyses thereof) derived or generated from any Clinical Trial involving OCU410 Product conducted by or on behalf of a Party or from the testing of subjects or the analysis of samples used in any such Clinical Trial.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Development Plan of OCU410&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ocugen Development Activities and the CanSino Development Activities regarding to OCU410 to be carried out by the Parties as set forth in the Appendix A under this Amendment.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Field of OCU410&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">shall mean the treatment of the following diseases in humans&#58; Dry Age-Related Macular Degeneration.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">OCU410&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">shall mean the novel gene therapy known as OCU410 consisting of an adeno-associated virus serotype 5-based vector containing the human RORA gene in an expression cassette comprised of&#58; a) AAV2 inverted terminal repeat (AAV2 ITR)&#59; b) the cytomegalovirus (CMV) enhancer&#59; c) the chicken beta actin (CBA) promoter&#59; d) chimeric intron&#59; e) the cloned cDNA coding for human RORA (Retinoic Acid Receptor-Related Orphan Receptor Alpha) protein&#59; f) the SV40 polyadenylation (PolyA) region&#59; and g) inverted AAV2 ITR.</font></div></td></tr></table></div><div style="margin-bottom:12pt;padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.35pt">In the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Section 1 &#8220;Definitions&#8221; is amended to include the following new terms&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.840%"><tr><td style="width:1.0%"></td><td style="width:4.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Confidential Information&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">shall mean all (a) documents and information provided by or on behalf of one Party to the other Party in connection with or in furtherance of this Agreement, including at any meeting of the JSC, (b) the terms of this Agreement, and (c) all Ocugen Technology, Ocugen Patent Rights, Joint Program Technology, and Ocugen Technology and Ocugen Patent Rights, including but not limited to information related to OCU400 and OCU410 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, Joint Program Patent Rights and Joint Program Materials and that are disclosed or provided by or on behalf of a Party to the other Party, or to any of its employees, consultants or Affiliates during the Term.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="margin-bottom:6pt"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.840%"><tr><td style="width:1.0%"></td><td style="width:4.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The term </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> shall not include </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> that (a) are within the public domain or enters into the public domain, through no act or omission of the receiving party&#59; or (b) comes within the possession of the receiving party by disclosure from a third party having a legal right to disclose the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, but only to the extent allowed by such a third party&#59; or (c) was already in the receiving party's possession prior to receipt from the disclosing party&#59; or (d) is independently developed by the receiving party without reference to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> of the disclosing party.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> further agree that no portion of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> shall be construed as coming within exceptions (a) through (d) of this definition, solely on the basis that more generalized information embracing such portion of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> falls within any of the exceptions or on the basis that elements of such portion of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> are independently within any of the exceptions.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Ocugen Patent Rights&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">shall mean the Patent Rights that contain one or more claims to the Ocugen Technology, which as of the Effective Date are set forth in Schedule 1 of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Original Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Appendix B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> including, but not limited to, any claims contained in any patents and&#47;or patent applications related to OCU400 and&#47;or OCU410</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Ocugen Technology&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any Technology that (a) is necessary for the conduct of the Development Program for OCU400 and OCU410, and (b) (i) is Controlled by Ocugen or its Affiliates as of the Effective Date of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Original Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> or Effective Date of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> or (ii) is Controlled by Ocugen or its Affiliates during the Term and conceived or first reduced to practice by Ocugen or its Affiliates or employees or subcontractors of, consultants to, or collaborators with Ocugen or its Affiliates outside of the conduct of the Development Program, or that otherwise relates to a Product (including its composition of matter, formulation, method of delivery or use, and&#47;or its Manufacture). For clarity, Ocugen Technology shall exclude any Joint Program Technology.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Product(s)&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">shall mean in any country of the Territory, any biopharmaceutical preparation, substance, formulation or product comprised, in whole or in part, of OCU400 and&#47;or OCU410 including any modification or derivative thereof.</font></div></td></tr></table></div><div style="margin-bottom:12pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.85pt">Amendment to Section 2.1 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grant of Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original Collaboration Agreement</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.35pt">The Parties hereby agree to expand the granted rights scope to OCU410 based on the OCU400 according to section 2 of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including&#58;</font></div><div style="padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.36pt">an exclusive, non-sub-licensable, royalty-bearing license to use, research, Develop, Manufacture and Commercialize Products in the Field of OCU410 in and for the CanSino Territory&#59;</font></div><div style="padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.79pt">an exclusive, royalty-bearing license, including the right to grant sublicenses solely as provided in Section 2.3 of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under Ocugen&#8217;s rights in the Joint Program </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="margin-bottom:6pt"><font><br></font></div><div><font><br></font></div></div><div style="padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technology and Joint Program Patent Rights, to use, research, Develop, Manufacture and Commercialize Products in the Field of OCU410 in and for the CanSino Territory&#59;</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.36pt">an exclusive Option on OCU410 as set forth in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.35pt">All clauses under section 2 of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall applied to the expanded scope as above mentioned.</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.85pt">Section 3 &#8220;Co-Development of Products&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall be amended by adding the following addendum&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with the remaining terms and requirements of the Original Collaboration Agreement, the Parties agree to use their Commercially Reasonable Efforts to conduct the their respective Development Activities as set forth in the Appendix A Development Plan of OCU410 and the cost of such Development shall be borne by CanSino or Ocugen based on their responsibilities in the Appendix A according to clause 3.3 under the Original Collaboration Agreement.</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.85pt">Section 4 &#8220;Commercialization&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall be amended by adding the following addendum&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with the remaining terms and requirements of the Original Collaboration Agreement, besides the Commercialization of Products of OCU400, each Party shall be solely responsible for Commercialization of Products of OCU410 in the Field of OCU410 in its Territory.</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.85pt">Section 5 &#8220;Payment&#47;Consideration&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall be amended by adding the following addendum&#58;</font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the licenses granted under section 2 of this Amendment and the rights of each Party to Commercialize Products of OCU410 in its Territory, each Party agrees to pay the other Party royalties with the same procedures and requirements as section 5 under the Original Collaboration Agreement but the percentage of the royalties should be adjusted as following&#58;</font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) On a Product-by-Product and country-by-country basis, Ocugen will pay CanSino a royalty equal to &#91;***&#93; of the cumulative Net Sales of such Products of OCU410 in such country in the Ocugen Territory in a given calendar year (or partial calendar year), commencing with the First Commercial Sale of such Product of OCU410 in such country and ending upon the last day of the Term in such country pursuant to Section 7 below&#59; and</font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) On a Product-by-Product and country-by-country basis, CanSino will pay Ocugen a royalty equal to &#91;***&#93; of the cumulative Net Sales of such Product in such country in the CanSino Territory in a given calendar year (or partial calendar year), commencing with the First Commercial Sale of such Product of OCU410 in such country and ending upon the last day of the Term in such country pursuant to Section 7 below.</font></div><div style="margin-bottom:12pt;padding-left:24pt;text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments of OCU400 remains applicable according to the Original Collaboration Agreement.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.5pt">Section 6 &#8220;Intellectual Property&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall be amended by adding the following addendum&#58;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.35pt">As between the Parties, Ocugen shall have sole and exclusive Control of all right, title and interest on a worldwide basis in and to any and all Ocugen Technology and Ocugen Patent Rights including, but not limited to, those related to OCU410, subject to the licenses provided to CanSino pursuant to this Agreement. The Parties shall jointly Control all right, title and interest on a worldwide basis in and to any and all Joint Program Technology, Joint Program Patent Rights and Joint Program Materials including OCU410.</font></div><div style="margin-bottom:12pt;padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.35pt">The management, including filing, prosecution and maintenance, enforcement and defense, and infringement settlement regarding Products of OCU410 shall be the same as the section 6 of the Original Collaboration Agreement.</font></div><div style="margin-bottom:12pt;padding-left:21.25pt;text-align:justify;text-indent:-22.51pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.01pt">Section 9 &#8220;Term and Termination&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall be amended as follows&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="margin-bottom:6pt"><font><br></font></div><div><font><br></font></div></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.35pt">Paragraph 9.1 of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall be replaced by the following rewritten paragraph 9.1&#58;</font></div><div style="padding-left:21.25pt;text-align:justify;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1. This Agreement, and the licenses granted hereunder, shall come into effect on the Effective Date and, unless terminated earlier in accordance with this Section 9, shall continue in force on a country-by-country and Product-by-Product basis until the later of&#58;</font></div><div style="padding-left:21.25pt;text-align:justify;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) the expiration of the last Valid Claim included within the Ocugen Patent Rights regarding to OCU400 and OCU410 claiming or Covering such Product that, but for this Agreement, would be infringed by such Product, as applicable, in such country&#59; and</font></div><div style="padding-left:21.25pt;text-align:justify;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) the tenth (10th) anniversary of the First Commercial Sale of such Product of OCU410 in such country (the &#8220;Term&#8221;), and on such date this Agreement and the licenses granted hereunder shall terminate automatically by expiry with respect to such Product in such country.</font></div><div style="padding-left:21.25pt;text-align:justify;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To avoid any doubts, according to Section 5 of the Original Collaboration Agreement, the royalties of Product OCU400 shall be paid commencing with the First Commercial Sale of such Product in such country and ending upon the last day of the tenth (10th) anniversary of the First Commercial Sale of such Product of OCU400 in such country unless the Agreement terminated earlier based on (a) of this clause.</font></div><div style="margin-bottom:12pt;padding-left:21.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, this Agreement shall terminate contemporaneously upon any termination of the SERI Agreement, provided, that if at the time of such termination CanSino is not in breach or default of this Agreement, CanSino shall have the right to request conversion of this Agreement to an agreement&#47;license directly between SERI and CanSino, and SERI shall not unreasonably withhold its acceptance of such conversion if CanSino agrees to be bound by all of the provisions of the SERI Agreement.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:56.7pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Paragraph 9.4 (d) of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall be replaced by the following rewritten paragraph 9.4(d)&#58;</font></div><div style="margin-bottom:12pt;padding-left:21.25pt;text-align:justify;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;(d)Effective upon such termination and request by Ocugen for such license, CanSino hereby grants to Ocugen a perpetual, irrevocable, exclusive (even as to CanSino, except with respect to Manufacturing if a supply agreement between the Parties is then in effect in accordance with Section 9.4(e)) license, with the right to grant sublicenses, under CanSino&#8217;s rights in the Joint Program Technology and Joint Program Patent Rights, used in the Development, Manufacture or Commercialization of Products on the date of termination, solely to continue to Develop, Manufacture (subject to Section 9.4(e)) and&#47;or Commercialize Products in the Field in the CanSino Territory. The foregoing license shall be royalty-bearing as follows&#58; (i) Ocugen shall pay CanSino a royalty of &#91;***&#93; of the Net Sales of Products by Ocugen or its sublicensees (to the extent such Products are thereafter Commercialized by Ocugen or its sublicensees) until such time as the amounts paid under this Section 9.4(d) equals the sum of the actual documented and audited out-of-pocket expenses paid by CanSino to conduct CanSino Development Activities and other Develop Products in the Field in and for the CanSino Territory as part of the Development Program (the &#8220;CanSino Development Costs&#8221;)&#59; and (ii) Sections 5.2, 5.3, 5.4 and 5.5 shall apply mutatis mutandis to Ocugen&#8217;s payment of such royalties. Thereafter, the license granted under this Section 9.4(d) shall be a fully paid-up, non-royalty bearing, perpetual, non-exclusive license in and for the CanSino Territory.&#8221;</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.35pt">Paragraph 9.5 (a) of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall be replaced by the following rewritten paragraph 9.5(a)&#58;</font></div><div style="margin-bottom:12pt;padding-left:21.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;(a) The licenses granted to CanSino under Section 2.1(a) and Section 2.1(b) shall continue to be valid in accordance with this Agreement, and to the extent permitted by the SERI Agreement and Applicable Laws. The foregoing license shall be royalty-bearing as follows&#58; (i) CanSino shall pay Ocugen a royalty of &#91;***&#93; of the Net Sales of Products by CanSino or its sublicensees (to the extent such Products are thereafter Commercialized by CanSino or its sublicensees) for the balance of the Term&#59; and (ii) Sections 5.2, 5.3, 5.4 and 5.5 shall apply mutatis mutandis to CanSino&#8217;s payment of such royalties.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:21.25pt;text-align:justify;text-indent:-22.51pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.01pt">Section 11.5 &#8220;Notices&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original Collaboration Agreement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shall be amended by updating the address and emails for both Parties as follows&#58;</font></div><div style="text-indent:21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The address and emails of CanSino shall be entirely replaced by the following&#58;</font></div><div style="padding-left:21.25pt;text-align:justify;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Dongxu Qiu</font></div><div style="padding-left:21.25pt;text-align:justify;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; Executive Director</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="margin-bottom:6pt"><font><br></font></div><div><font><br></font></div></div><div style="padding-left:21.25pt;text-align:justify;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Address&#58; 185 South Avenue, West District of TEDA, Tianjin, China</font></div><div style="padding-left:21.25pt;text-align:justify;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tel&#58; &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:21.25pt;text-align:justify;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Email&#58; &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:21.25pt;text-align:justify;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">with a copy to&#58;</font></div><div style="padding-left:21.25pt;text-align:justify;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Yuan Zhou</font></div><div style="padding-left:21.25pt;text-align:justify;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; Legal Manager</font></div><div style="padding-left:21.25pt;text-align:justify;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Address&#58; 185 South Avenue, West District of TEDA, Tianjin, China</font></div><div style="padding-left:21.25pt;text-align:justify;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tel&#58; &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:21.25pt;text-align:justify;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Email&#58; &#91;***&#93;</font></div><div style="text-indent:21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The address and emails of Ocugen shall be entirely replaced by the following&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shankar Musunuri</font></div><div style="padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chairman, CEO and Co-Founder</font></div><div style="padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ocugen, Inc.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">263 Great Valley Parkway</font></div><div style="padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Malvern, PA 19355, USA</font></div><div style="padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tel&#58; (610) 590-2140</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Email&#58; shankar.musunuri&#64;ocugen.com</font></div><div style="padding-left:45pt;text-align:justify;text-indent:0.21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with a copy to&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ocugen, Inc.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">263 Great Valley Parkway</font></div><div style="padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Malvern, PA 19355</font></div><div style="margin-bottom:24pt;padding-left:36pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attn&#58; Legal Department</font></div><div style="padding-left:21.25pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.75pt">Miscellaneous</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.35pt">All Ocugen&#8217;s Warranties under the Original Collaboration Agreement shall be applicable to OCU410 according this Amendment. Within &#91;***&#93; after the Effectiveness of this Amendment the Parties should conclude into a quality agreement on the Product of OCU410.</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.35pt">This Amendment shall take effectiveness upon the Effective Date.</font></div><div style="padding-left:56.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.35pt">In the event of any discrepancies between this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will prevail. Matters not expressly covered in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall be referred to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-right:-12.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">remainder of this page intentionally left blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Parties have caused their duly authorized representatives to execute this Amendment as of the Effective Date.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:0.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.176%"><tr><td style="width:1.0%"></td><td style="width:45.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:117%">Ocugen, Inc.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:117%">CanSino Biologics Inc.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Shankar Musunuri</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Tao Zhu</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Signature</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Signature</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Dr. Shankar Musunuri</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Tao Zhu</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Print name</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Print name</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chairman and CEO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Scientific Officer</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Title</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Title</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9&#47;30&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9&#47;30&#47;2021</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div></div></div><div id="ic54c9358d6be470fbb9dfe9734477f0d_152"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Appendix A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div id="ic54c9358d6be470fbb9dfe9734477f0d_238"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Appendix B</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ocgn-20210930x10qxex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if57ce57370b64258b35ebedaed5eef9e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Shankar Musunuri, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form&#160;10-Q of Ocugen,&#160;Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s)&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:21pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:21pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;9, 2021</font></div></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Shankar Musunuri, Ph.D., MBA</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shankar Musunuri, Ph.D., MBA</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Chairman</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ocgn-20210930x10qxex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7fddbe4d797940aaae0b5e101300b0d4_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Sanjay Subramanian, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form&#160;10-Q of Ocugen,&#160;Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s)&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:21pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:21pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;9, 2021</font></div></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sanjay Subramanian</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanjay Subramanian</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ocgn-20210930x10qxex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i0ca3dcf0baab49b098e3ebcc2d5ba0d9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Subsections (a)&#160;and (b)&#160;of Section&#160;1350, Chapter 63 of Title 18, United States Code)</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Ocugen,&#160;Inc. (the Company), does hereby certify, to the best of such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-bottom:18pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Quarterly Report on Form&#160;10-Q for the quarter ended September&#160;30, 2021 (the Form&#160;10-Q) of the Company fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934, and the information contained in the Form&#160;10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:18pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;9, 2021</font></div></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Shankar Musunuri, Ph.D., MBA</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shankar Musunuri, Ph.D., MBA</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Chairman</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;9, 2021</font></div></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sanjay Subramanian</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanjay Subramanian</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officer)</font></td></tr></table></div><div style="margin-top:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. This certification &#8220;accompanies&#8221; the Form&#160;10-Q to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form&#160;10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ocgn-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:37cdbff3-15f4-4881-8cd5-68abc4a291de,g:c6584426-cf6c-4c9a-b04f-fdc200c901b8-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ocgn="http://www.deitaxonomy.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.deitaxonomy.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ocgn-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ocgn-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ocgn-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ocgn-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.deitaxonomy.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS_1" roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS_1">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusiness" roleURI="http://www.deitaxonomy.com/role/NatureofBusiness">
        <link:definition>2101101 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessAdditionalInformationDetails" roleURI="http://www.deitaxonomy.com/role/NatureofBusinessAdditionalInformationDetails">
        <link:definition>2402401 - Disclosure - Nature of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandDevelopmentAgreements" roleURI="http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreements">
        <link:definition>2108103 - Disclosure - License and Development Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandDevelopmentAgreementsDetails" roleURI="http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreementsDetails">
        <link:definition>2409404 - Disclosure - License and Development Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesReceivable" roleURI="http://www.deitaxonomy.com/role/NotesReceivable">
        <link:definition>2110104 - Disclosure - Notes Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesReceivableDetails" roleURI="http://www.deitaxonomy.com/role/NotesReceivableDetails">
        <link:definition>2411405 - Disclosure - Notes Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.deitaxonomy.com/role/PropertyandEquipment">
        <link:definition>2112105 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.deitaxonomy.com/role/PropertyandEquipmentTables">
        <link:definition>2313302 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentScheduleofPropertyandEquipmentDetails" roleURI="http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails">
        <link:definition>2414406 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNarrativeDetails" roleURI="http://www.deitaxonomy.com/role/PropertyandEquipmentNarrativeDetails">
        <link:definition>2415407 - Disclosure - Property and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeases" roleURI="http://www.deitaxonomy.com/role/OperatingLeases">
        <link:definition>2116106 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesTables" roleURI="http://www.deitaxonomy.com/role/OperatingLeasesTables">
        <link:definition>2317303 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesOperatingLeasesDetails" roleURI="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesDetails">
        <link:definition>2418408 - Disclosure - Operating Leases - Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesOperatingLeasesComponentsOfLeaseExpenseDetails" roleURI="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesComponentsOfLeaseExpenseDetails">
        <link:definition>2419409 - Disclosure - Operating Leases - Operating Leases, Components Of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesOperatingLeasesSupplementalBalanceSheetInformationDetails" roleURI="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesSupplementalBalanceSheetInformationDetails">
        <link:definition>2420410 - Disclosure - Operating Leases - Operating Leases, Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesOperatingLeasesSupplementalInformationRelatedToLeasesDetails" roleURI="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesSupplementalInformationRelatedToLeasesDetails">
        <link:definition>2421411 - Disclosure - Operating Leases - Operating Leases, Supplemental Information Related To Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails" roleURI="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>2422412 - Disclosure - Operating Leases - Operating Leases, Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails_1">
        <link:definition>2422412 - Disclosure - Operating Leases - Operating Leases, Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>2123107 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>2324304 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>2425413 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.deitaxonomy.com/role/Debt">
        <link:definition>2126108 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.deitaxonomy.com/role/DebtTables">
        <link:definition>2327305 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSummaryoftheCarryingValuesfortheComponentsofDebtDetails" roleURI="http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesfortheComponentsofDebtDetails">
        <link:definition>2428414 - Disclosure - Debt - Summary of the Carrying Values for the Components of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtPPPNoteDetails" roleURI="http://www.deitaxonomy.com/role/DebtPPPNoteDetails">
        <link:definition>2429415 - Disclosure - Debt - PPP Note (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtEB5LoanAgreementBorrowingsDetails" roleURI="http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails">
        <link:definition>2430416 - Disclosure - Debt - EB 5 Loan Agreement Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSummaryoftheCarryingValuesoftheLoanAgreementBorrowingsDetails" roleURI="http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesoftheLoanAgreementBorrowingsDetails">
        <link:definition>2431417 - Disclosure - Debt - Summary of the Carrying Values of the Loan Agreement Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.deitaxonomy.com/role/Equity">
        <link:definition>2132109 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetails" roleURI="http://www.deitaxonomy.com/role/EquityDetails">
        <link:definition>2433418 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Warrants" roleURI="http://www.deitaxonomy.com/role/Warrants">
        <link:definition>2134110 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsDetails" roleURI="http://www.deitaxonomy.com/role/WarrantsDetails">
        <link:definition>2435419 - Disclosure - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation" roleURI="http://www.deitaxonomy.com/role/StockbasedCompensation">
        <link:definition>2136111 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationTables" roleURI="http://www.deitaxonomy.com/role/StockbasedCompensationTables">
        <link:definition>2337306 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails" roleURI="http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails">
        <link:definition>2438420 - Disclosure - Stock-based Compensation - Schedule of Compensation Expense for Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationNarrativeDetails" roleURI="http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails">
        <link:definition>2439421 - Disclosure - Stock-based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails" roleURI="http://www.deitaxonomy.com/role/StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails">
        <link:definition>2440422 - Disclosure - Stock-based Compensation - Schedule Options to Purchase Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofRSUActivityDetails" roleURI="http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofRSUActivityDetails">
        <link:definition>2441423 - Disclosure - Stock-based Compensation - Schedule of RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareofCommonStock" roleURI="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStock">
        <link:definition>2142112 - Disclosure - Net Loss Per Share of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareofCommonStockTables" roleURI="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockTables">
        <link:definition>2343307 - Disclosure - Net Loss Per Share of Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareofCommonStockComputationofbasicanddilutedearningspershareDetails" roleURI="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockComputationofbasicanddilutedearningspershareDetails">
        <link:definition>2444424 - Disclosure - Net Loss Per Share of Common Stock - Computation of basic and diluted earnings per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareofCommonStockPotentiallydilutivesecuritieshavebeenexcludedfromthecomputationofdilutedweightedaveragesharesoutstandingDetails" roleURI="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockPotentiallydilutivesecuritieshavebeenexcludedfromthecomputationofdilutedweightedaveragesharesoutstandingDetails">
        <link:definition>2445425 - Disclosure - Net Loss Per Share of Common Stock - Potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.deitaxonomy.com/role/CommitmentsandContingencies">
        <link:definition>2146113 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.deitaxonomy.com/role/SubsequentEvents">
        <link:definition>2147114 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.deitaxonomy.com/role/SubsequentEventsDetails">
        <link:definition>2448426 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ocgn_NoncashLeaseExpense" abstract="false" name="NoncashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_SubscriptionAgreementsAndWarrantExercisesMember" abstract="true" name="SubscriptionAgreementsAndWarrantExercisesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ocgn_WarrantsTextBlock" abstract="false" name="WarrantsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ocgn_IssuanceOfFinancingReceivable" abstract="false" name="IssuanceOfFinancingReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_AccruedLiabilitiesClinical" abstract="false" name="AccruedLiabilitiesClinical" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_NumberOfEquityCompensationPlans" abstract="false" name="NumberOfEquityCompensationPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ocgn_LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement" abstract="false" name="LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ocgn_CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada" abstract="false" name="CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction" abstract="false" name="SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ocgn_LineOfCreditBorrowingEachDraw" abstract="false" name="LineOfCreditBorrowingEachDraw" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_EfficacyAsymptomaticInfectionPercent" abstract="false" name="EfficacyAsymptomaticInfectionPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ocgn_SubscriptionAgreementsMember" abstract="true" name="SubscriptionAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ocgn_EfficacyAgainstDeltaVariantB16172Percent" abstract="false" name="EfficacyAgainstDeltaVariantB16172Percent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ocgn_FinancingReceivableInterestRateStatedPercentage" abstract="false" name="FinancingReceivableInterestRateStatedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ocgn_GainLossOnForgivenessOfPaycheckProtectionProgramNote" abstract="false" name="GainLossOnForgivenessOfPaycheckProtectionProgramNote" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_IncreaseDecreaseInLeaseObligations" abstract="false" name="IncreaseDecreaseInLeaseObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock" abstract="false" name="ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ocgn_LesseeOperatingLeaseNumberOfRenewalTerms" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ocgn_AdverseEventsSeriousAdverseSideEffectsPercent" abstract="false" name="AdverseEventsSeriousAdverseSideEffectsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ocgn_SeriesAWarrantsMember" abstract="true" name="SeriesAWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ocgn_ClassOfWarrantOrRightExpectedMilestonePayment" abstract="false" name="ClassOfWarrantOrRightExpectedMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_NumberOfAdditionalLeaseAgreementExtensions" abstract="false" name="NumberOfAdditionalLeaseAgreementExtensions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ocgn_EB5ProgramBorrowingsMember" abstract="true" name="EB5ProgramBorrowingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ocgn_EfficacySevereCasesPercent" abstract="false" name="EfficacySevereCasesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ocgn_CanadaConsultingWarrantsMember" abstract="true" name="CanadaConsultingWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ocgn_AdverseEventsSideEffectsPercent" abstract="false" name="AdverseEventsSideEffectsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ocgn_BaseRentPaymentsExpectedCost" abstract="false" name="BaseRentPaymentsExpectedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_NumberOfOrphanDrugDesignations" abstract="false" name="NumberOfOrphanDrugDesignations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ocgn_NumberOfFormerEmployeesWithWarrants" abstract="false" name="NumberOfFormerEmployeesWithWarrants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ocgn_NumberOfSeriesOfWarrantsIssued" abstract="false" name="NumberOfSeriesOfWarrantsIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants" abstract="false" name="ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_SaleOfStockAgreementToSellPricePerShare" abstract="false" name="SaleOfStockAgreementToSellPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ocgn_NumberOfAtTheMarketOfferings" abstract="false" name="NumberOfAtTheMarketOfferings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ocgn_SeriesCWarrantsMember" abstract="true" name="SeriesCWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ocgn_RegisteredDirectOfferingMember" abstract="true" name="RegisteredDirectOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ocgn_SaleOfStockOutstandingObligationCancelledInExchangeForStock" abstract="false" name="SaleOfStockOutstandingObligationCancelledInExchangeForStock" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_SeriesBWarrantsMember" abstract="true" name="SeriesBWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ocgn_StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ocgn_ControlledEquityOfferingSalesAgreementMember" abstract="true" name="ControlledEquityOfferingSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ocgn_ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue" abstract="false" name="ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost" abstract="false" name="NoncashOrPartNoncashAmountOfDeferredTransactionCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_ShareBasedPaymentArrangementPerformanceBasedOptionMember" abstract="true" name="ShareBasedPaymentArrangementPerformanceBasedOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ocgn_VaccinationDoseRegimenDurationApart" abstract="false" name="VaccinationDoseRegimenDurationApart" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ocgn_OpCoWarrantsMember" abstract="true" name="OpCoWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ocgn_NonCashInterestExpense" abstract="false" name="NonCashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_PaycheckProtectionProgramLoanMember" abstract="true" name="PaycheckProtectionProgramLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ocgn_NumberOfVaccinationDoseRegimen" abstract="false" name="NumberOfVaccinationDoseRegimen" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ocgn_CollaborationAgreementTerm" abstract="false" name="CollaborationAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ocgn_AccruedLiabilitiesProfessionalFees" abstract="false" name="AccruedLiabilitiesProfessionalFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_A2019PlanMember" abstract="true" name="A2019PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote" abstract="false" name="ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_StockIssuedDuringPeriodValueOptionsAndWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueOptionsAndWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_SPAWarrantsMember" abstract="true" name="SPAWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset" abstract="false" name="NoncashOrPartNoncashOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_MachineryMember" abstract="true" name="MachineryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_AccruedSeveranceRelatedLiabilitiesCurrent" abstract="false" name="AccruedSeveranceRelatedLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_SingleGeneReplacementTherapiesNumberOfGeneticMutationsTarget" abstract="false" name="SingleGeneReplacementTherapiesNumberOfGeneticMutationsTarget" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ocgn_SaleOfStockAdditionalDebtCancelledInExchangeForStock" abstract="false" name="SaleOfStockAdditionalDebtCancelledInExchangeForStock" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_ATMTransactionsMember" abstract="true" name="ATMTransactionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ocgn_ResearchAndDevelopmentExpensesCurrent" abstract="false" name="ResearchAndDevelopmentExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock" abstract="false" name="SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ocgn_CollaborativeArrangementProfitsGeneratedSharedPercentage" abstract="false" name="CollaborativeArrangementProfitsGeneratedSharedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ocgn_AssetHeldForSalePolicyTextBlock" abstract="false" name="AssetHeldForSalePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ocgn_StockIssuedDuringPeriodValueWarrantExchange" abstract="false" name="StockIssuedDuringPeriodValueWarrantExchange" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_ModifierGeneTherapyPlatformNumberOfProducts" abstract="false" name="ModifierGeneTherapyPlatformNumberOfProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ocgn_A2014PlanMember" abstract="true" name="A2014PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ocgn_ClassOfWarrantOrRightExercisable" abstract="false" name="ClassOfWarrantOrRightExercisable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ocgn_OverallVaccineEfficacyPercent" abstract="false" name="OverallVaccineEfficacyPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ocgn_StockIssuedDuringPeriodSharesWarrantExchange" abstract="false" name="StockIssuedDuringPeriodSharesWarrantExchange" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ocgn_COVAXINPreferredStockPurchaseAgreementMember" abstract="true" name="COVAXINPreferredStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ocgn_CollaborationAgreementWithCansinoBiologicsMember" abstract="true" name="CollaborationAgreementWithCansinoBiologicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock" abstract="false" name="ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_WarrantExchangePromissoryNotesMember" abstract="true" name="WarrantExchangePromissoryNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ocgn_CollaborationAgreementUpfrontPayment" abstract="false" name="CollaborationAgreementUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_SupplyAgreementNumberOfDoses" abstract="false" name="SupplyAgreementNumberOfDoses" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ocgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ocgn_WarrantsExchangedForCommonStockMember" abstract="true" name="WarrantsExchangedForCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ocgn_PreferredStockMeasurementInput" abstract="false" name="PreferredStockMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ocgn-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:37cdbff3-15f4-4881-8cd5-68abc4a291de,g:c6584426-cf6c-4c9a-b04f-fdc200c901b8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ocgn-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_2cf1f698-a030-43f0-a462-931a97e45b30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c97f7b73-26fc-4c29-adcd-96a9a3da3058" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_2cf1f698-a030-43f0-a462-931a97e45b30" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c97f7b73-26fc-4c29-adcd-96a9a3da3058" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fe4be26a-e171-4bb6-8beb-d604d18cb5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_2cf1f698-a030-43f0-a462-931a97e45b30" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_fe4be26a-e171-4bb6-8beb-d604d18cb5ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_56646ab4-2a3f-4b8f-920e-e233e78f025a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a177cfa4-7fc3-4227-933b-ecec48b78f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_56646ab4-2a3f-4b8f-920e-e233e78f025a" xlink:to="loc_us-gaap_LiabilitiesCurrent_a177cfa4-7fc3-4227-933b-ecec48b78f7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_2995b368-658c-470d-aaee-6af87fb8ed12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_56646ab4-2a3f-4b8f-920e-e233e78f025a" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_2995b368-658c-470d-aaee-6af87fb8ed12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d29e3673-c3ca-4b1c-a481-c58228095c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f4c694ac-1eca-41dd-965e-4bd2ce7dc84d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d29e3673-c3ca-4b1c-a481-c58228095c4d" xlink:to="loc_us-gaap_Liabilities_f4c694ac-1eca-41dd-965e-4bd2ce7dc84d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bca8608c-b8ab-4571-9e48-a5ee9983c02c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d29e3673-c3ca-4b1c-a481-c58228095c4d" xlink:to="loc_us-gaap_StockholdersEquity_bca8608c-b8ab-4571-9e48-a5ee9983c02c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_76c9bf5b-b9ba-48f1-a4a5-3b7f0f63e467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d29e3673-c3ca-4b1c-a481-c58228095c4d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_76c9bf5b-b9ba-48f1-a4a5-3b7f0f63e467" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a73c5faf-1749-4888-9852-16aeb3f2d3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_76b082e2-d87b-4318-be68-ccb93ca88376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a73c5faf-1749-4888-9852-16aeb3f2d3d6" xlink:to="loc_us-gaap_AccountsPayableCurrent_76b082e2-d87b-4318-be68-ccb93ca88376" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_01265077-aa9b-4714-8747-9378bc0cf26f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a73c5faf-1749-4888-9852-16aeb3f2d3d6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_01265077-aa9b-4714-8747-9378bc0cf26f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_647fb831-8690-4c9c-9abf-cff2f00104e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a73c5faf-1749-4888-9852-16aeb3f2d3d6" xlink:to="loc_us-gaap_ShortTermBorrowings_647fb831-8690-4c9c-9abf-cff2f00104e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_3fb8b91f-ac74-4372-95d3-a01fd9d32fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a73c5faf-1749-4888-9852-16aeb3f2d3d6" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_3fb8b91f-ac74-4372-95d3-a01fd9d32fe0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bf8dfee8-807d-40b5-86a8-03eb8f63f1df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1c37e3fa-fda3-4f01-b6c9-d07825fbcc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bf8dfee8-807d-40b5-86a8-03eb8f63f1df" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1c37e3fa-fda3-4f01-b6c9-d07825fbcc7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_c10d1960-73a0-43f6-ae2a-e1a5e6233adc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bf8dfee8-807d-40b5-86a8-03eb8f63f1df" xlink:to="loc_us-gaap_TreasuryStockValue_c10d1960-73a0-43f6-ae2a-e1a5e6233adc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_48e825ec-df44-46da-8401-3708412e0459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bf8dfee8-807d-40b5-86a8-03eb8f63f1df" xlink:to="loc_us-gaap_PreferredStockValue_48e825ec-df44-46da-8401-3708412e0459" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b03e98cb-d414-4a7c-9297-b5589797a155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bf8dfee8-807d-40b5-86a8-03eb8f63f1df" xlink:to="loc_us-gaap_CommonStockValue_b03e98cb-d414-4a7c-9297-b5589797a155" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a419201b-12a3-494e-8695-54b103d33256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bf8dfee8-807d-40b5-86a8-03eb8f63f1df" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a419201b-12a3-494e-8695-54b103d33256" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_23faf014-7367-4b1a-ae6c-b99472b3277f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e78d3b89-6b86-42af-8288-a009c6e783e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_23faf014-7367-4b1a-ae6c-b99472b3277f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e78d3b89-6b86-42af-8288-a009c6e783e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ca54bca0-0b98-45ad-98be-a03565cb5ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_23faf014-7367-4b1a-ae6c-b99472b3277f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ca54bca0-0b98-45ad-98be-a03565cb5ba0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvancesOnInventoryPurchases_70b3d7cc-643c-432b-8b30-a1373bb31bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvancesOnInventoryPurchases"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_23faf014-7367-4b1a-ae6c-b99472b3277f" xlink:to="loc_us-gaap_AdvancesOnInventoryPurchases_70b3d7cc-643c-432b-8b30-a1373bb31bd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5cd1878f-ebca-47e5-8da9-739e9ec8b646" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1600ffe9-41d5-4d2e-b275-8ad0e4cdee43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5cd1878f-ebca-47e5-8da9-739e9ec8b646" xlink:to="loc_us-gaap_AssetsCurrent_1600ffe9-41d5-4d2e-b275-8ad0e4cdee43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_3b23af2c-14ec-49f8-896a-7faf1a50ba6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5cd1878f-ebca-47e5-8da9-739e9ec8b646" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_3b23af2c-14ec-49f8-896a-7faf1a50ba6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_9229284a-539a-43d9-a776-2697835d9ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5cd1878f-ebca-47e5-8da9-739e9ec8b646" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_9229284a-539a-43d9-a776-2697835d9ed0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_daca044b-e12d-4afa-a8b2-6429aa603aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5cd1878f-ebca-47e5-8da9-739e9ec8b646" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_daca044b-e12d-4afa-a8b2-6429aa603aa2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="ocgn-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_37394b5d-b169-4827-982f-caf065c8a56c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6da44d8d-0a6c-4643-8484-8405d5a88090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_37394b5d-b169-4827-982f-caf065c8a56c" xlink:to="loc_us-gaap_OperatingIncomeLoss_6da44d8d-0a6c-4643-8484-8405d5a88090" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_568bd042-eabd-4b2d-958d-737417e98b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_37394b5d-b169-4827-982f-caf065c8a56c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_568bd042-eabd-4b2d-958d-737417e98b87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9b0e9bf1-b2bf-40d9-bfc6-70321057ab24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d0c5cafe-d918-4fbd-bde0-9f2eeafa8068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9b0e9bf1-b2bf-40d9-bfc6-70321057ab24" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d0c5cafe-d918-4fbd-bde0-9f2eeafa8068" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0fdda9e2-b270-4773-a9ab-1079e220d980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9b0e9bf1-b2bf-40d9-bfc6-70321057ab24" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0fdda9e2-b270-4773-a9ab-1079e220d980" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_62ec47bd-1d39-42bc-8995-c3d59787c9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_000dfd9c-a48e-42ce-9507-6af10936fd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_62ec47bd-1d39-42bc-8995-c3d59787c9fe" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_000dfd9c-a48e-42ce-9507-6af10936fd9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6bc0d955-a312-49a6-bd7c-d183748bd3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_62ec47bd-1d39-42bc-8995-c3d59787c9fe" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6bc0d955-a312-49a6-bd7c-d183748bd3a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b06b5a9c-619e-424c-be66-6dc18fd139b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5088480c-635e-42af-994f-35ba69bb9014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b06b5a9c-619e-424c-be66-6dc18fd139b0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5088480c-635e-42af-994f-35ba69bb9014" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_43b78108-eda2-4fb3-84a5-ceff416dd031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b06b5a9c-619e-424c-be66-6dc18fd139b0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_43b78108-eda2-4fb3-84a5-ceff416dd031" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1704c2d5-9f4c-4a64-ae81-10747ae2576d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_9735e7f8-0281-48a0-b697-a9e3ecd6e459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1704c2d5-9f4c-4a64-ae81-10747ae2576d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_9735e7f8-0281-48a0-b697-a9e3ecd6e459" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_17fa55b4-b1cd-4420-a85c-35efe1d8e2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1704c2d5-9f4c-4a64-ae81-10747ae2576d" xlink:to="loc_us-gaap_InterestExpense_17fa55b4-b1cd-4420-a85c-35efe1d8e2f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c115bf9c-110f-4532-9a1a-aa7b40b45bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1704c2d5-9f4c-4a64-ae81-10747ae2576d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c115bf9c-110f-4532-9a1a-aa7b40b45bdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a3997aa2-221e-4acb-8954-f78b47f5a048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7441ec42-7628-4e94-84f6-8930d7612dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a3997aa2-221e-4acb-8954-f78b47f5a048" xlink:to="loc_us-gaap_Revenues_7441ec42-7628-4e94-84f6-8930d7612dcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_adaaff51-21d7-43de-a4a3-887b80dd625e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a3997aa2-221e-4acb-8954-f78b47f5a048" xlink:to="loc_us-gaap_OperatingExpenses_adaaff51-21d7-43de-a4a3-887b80dd625e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_14bfd84d-c273-438f-9624-346e1181b083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_f729a0c5-149f-47bc-9e49-4e834c644990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_14bfd84d-c273-438f-9624-346e1181b083" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_f729a0c5-149f-47bc-9e49-4e834c644990" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_be163fc1-040f-45fb-ba16-2477cfc7471d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0e1e6952-3f72-46ae-a3f5-94cc98571c42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_be163fc1-040f-45fb-ba16-2477cfc7471d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0e1e6952-3f72-46ae-a3f5-94cc98571c42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_e5032357-792d-41d4-82d1-48af914b1cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_be163fc1-040f-45fb-ba16-2477cfc7471d" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_e5032357-792d-41d4-82d1-48af914b1cb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_283c20f1-3fb9-4052-aab3-8eefffada313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_be163fc1-040f-45fb-ba16-2477cfc7471d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_283c20f1-3fb9-4052-aab3-8eefffada313" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS_1" xlink:type="simple" xlink:href="ocgn-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS_1"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b64e6117-4247-422a-bbcc-f6744116685b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_72a125cf-f386-41c7-bfb2-83fb78ef8937" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b64e6117-4247-422a-bbcc-f6744116685b" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_72a125cf-f386-41c7-bfb2-83fb78ef8937" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dc1df135-34ce-46e1-b154-30a8fc006183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b64e6117-4247-422a-bbcc-f6744116685b" xlink:to="loc_us-gaap_NetIncomeLoss_dc1df135-34ce-46e1-b154-30a8fc006183" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ocgn-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fd89a023-4b28-4108-ac06-5179d1eea1df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_9e2d5a52-017d-48ca-a5c7-e3ecdfaa6467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fd89a023-4b28-4108-ac06-5179d1eea1df" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_9e2d5a52-017d-48ca-a5c7-e3ecdfaa6467" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_014abf6c-423f-4682-be06-f471a4b4f8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fd89a023-4b28-4108-ac06-5179d1eea1df" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_014abf6c-423f-4682-be06-f471a4b4f8c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_cbe60f99-a0af-446d-96a9-052920207395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fd89a023-4b28-4108-ac06-5179d1eea1df" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_cbe60f99-a0af-446d-96a9-052920207395" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ee25db91-f47d-49dc-b6e1-419d3895cf29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fd89a023-4b28-4108-ac06-5179d1eea1df" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ee25db91-f47d-49dc-b6e1-419d3895cf29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_093cbb5a-5a5a-4a07-81f9-0a992e0d0fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fd89a023-4b28-4108-ac06-5179d1eea1df" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_093cbb5a-5a5a-4a07-81f9-0a992e0d0fdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_d9693457-a8df-485d-ad53-967d29100ade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fd89a023-4b28-4108-ac06-5179d1eea1df" xlink:to="loc_us-gaap_RepaymentsOfDebt_d9693457-a8df-485d-ad53-967d29100ade" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e5855c98-76c4-46a9-83ec-f286d272fee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3f7cfe07-0186-4cfb-8263-f397b63758f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e5855c98-76c4-46a9-83ec-f286d272fee7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3f7cfe07-0186-4cfb-8263-f397b63758f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dedcabef-0b73-40f3-85b2-17430e47889d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e5855c98-76c4-46a9-83ec-f286d272fee7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dedcabef-0b73-40f3-85b2-17430e47889d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ec287d00-4c8a-4013-873e-d07180a45f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e5855c98-76c4-46a9-83ec-f286d272fee7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ec287d00-4c8a-4013-873e-d07180a45f7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_865220d7-5bb1-4723-b8b5-5a466685c312" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_IssuanceOfFinancingReceivable_9a5dc5b8-3da9-4dd3-bc14-df0bbf883827" xlink:href="ocgn-20210930.xsd#ocgn_IssuanceOfFinancingReceivable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_865220d7-5bb1-4723-b8b5-5a466685c312" xlink:to="loc_ocgn_IssuanceOfFinancingReceivable_9a5dc5b8-3da9-4dd3-bc14-df0bbf883827" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_4b93f9da-d534-4890-9312-6b2e2633e230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_865220d7-5bb1-4723-b8b5-5a466685c312" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_4b93f9da-d534-4890-9312-6b2e2633e230" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e9e94189-2811-47af-9871-c41327b9de9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_865220d7-5bb1-4723-b8b5-5a466685c312" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e9e94189-2811-47af-9871-c41327b9de9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a601ad7d-fef3-44a8-9b09-35fd53c17b58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2e470d89-2c9a-43ae-a634-78bf2048d14b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a601ad7d-fef3-44a8-9b09-35fd53c17b58" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2e470d89-2c9a-43ae-a634-78bf2048d14b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c8575667-2510-4cf6-a296-c47f05f7f068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a601ad7d-fef3-44a8-9b09-35fd53c17b58" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c8575667-2510-4cf6-a296-c47f05f7f068" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NoncashLeaseExpense_5c764cea-87e4-43ad-86ab-db1ebdf2c8d8" xlink:href="ocgn-20210930.xsd#ocgn_NoncashLeaseExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a601ad7d-fef3-44a8-9b09-35fd53c17b58" xlink:to="loc_ocgn_NoncashLeaseExpense_5c764cea-87e4-43ad-86ab-db1ebdf2c8d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NonCashInterestExpense_70e863e7-724c-4873-8384-60a497c89fee" xlink:href="ocgn-20210930.xsd#ocgn_NonCashInterestExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a601ad7d-fef3-44a8-9b09-35fd53c17b58" xlink:to="loc_ocgn_NonCashInterestExpense_70e863e7-724c-4873-8384-60a497c89fee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_dfc6015b-7607-403c-b689-2b328ac1e6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a601ad7d-fef3-44a8-9b09-35fd53c17b58" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_dfc6015b-7607-403c-b689-2b328ac1e6fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1c7944f6-a0c4-4118-ab8d-2b6b98ce8893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a601ad7d-fef3-44a8-9b09-35fd53c17b58" xlink:to="loc_us-gaap_NetIncomeLoss_1c7944f6-a0c4-4118-ab8d-2b6b98ce8893" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_2b30001d-90ac-48a3-97bb-78587d11f55c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a601ad7d-fef3-44a8-9b09-35fd53c17b58" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_2b30001d-90ac-48a3-97bb-78587d11f55c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLoanLossesExpensed_1056b61d-1df9-40f6-b06c-0ade0843d2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForLoanLossesExpensed"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a601ad7d-fef3-44a8-9b09-35fd53c17b58" xlink:to="loc_us-gaap_ProvisionForLoanLossesExpensed_1056b61d-1df9-40f6-b06c-0ade0843d2a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_IncreaseDecreaseInLeaseObligations_1762d56f-dde1-4ef6-a2d9-64ea3f5956ad" xlink:href="ocgn-20210930.xsd#ocgn_IncreaseDecreaseInLeaseObligations"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a601ad7d-fef3-44a8-9b09-35fd53c17b58" xlink:to="loc_ocgn_IncreaseDecreaseInLeaseObligations_1762d56f-dde1-4ef6-a2d9-64ea3f5956ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b5e8979a-6de1-42e8-9eba-7fb477d15178" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a601ad7d-fef3-44a8-9b09-35fd53c17b58" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b5e8979a-6de1-42e8-9eba-7fb477d15178" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_8f471ebf-3095-42c3-ba78-ddf46fdbbcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a601ad7d-fef3-44a8-9b09-35fd53c17b58" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_8f471ebf-3095-42c3-ba78-ddf46fdbbcb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_939cea92-c243-47a0-8322-bb142b09de87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a601ad7d-fef3-44a8-9b09-35fd53c17b58" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_939cea92-c243-47a0-8322-bb142b09de87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_772a39dd-b413-454b-8470-58879b5bd507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a601ad7d-fef3-44a8-9b09-35fd53c17b58" xlink:to="loc_us-gaap_Depreciation_772a39dd-b413-454b-8470-58879b5bd507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments_348dda2e-be7f-4e8a-a59e-25200fb94f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a601ad7d-fef3-44a8-9b09-35fd53c17b58" xlink:to="loc_us-gaap_IncomeTaxCreditsAndAdjustments_348dda2e-be7f-4e8a-a59e-25200fb94f6a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d5727de3-e1ae-47f8-9c16-b6d7083e0a27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1bb64f4b-6483-43b3-b1fb-8b28ad6656e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d5727de3-e1ae-47f8-9c16-b6d7083e0a27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1bb64f4b-6483-43b3-b1fb-8b28ad6656e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_469de00a-bf7c-47d9-8c5a-3d22dcf9aa87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d5727de3-e1ae-47f8-9c16-b6d7083e0a27" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_469de00a-bf7c-47d9-8c5a-3d22dcf9aa87" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_ce52e449-a0af-44fd-8019-ba15c3bb775b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_ffb28f9a-ae4f-42a6-a4bf-24fe9e61d71c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_ce52e449-a0af-44fd-8019-ba15c3bb775b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_ffb28f9a-ae4f-42a6-a4bf-24fe9e61d71c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8cabfb44-80cb-4a96-98fd-5066b38a34aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_ce52e449-a0af-44fd-8019-ba15c3bb775b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8cabfb44-80cb-4a96-98fd-5066b38a34aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_596baf76-b549-4338-a54c-088bf6d3b512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7e343a42-6aab-4465-9dd1-54644436fa6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_596baf76-b549-4338-a54c-088bf6d3b512" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7e343a42-6aab-4465-9dd1-54644436fa6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_2749ab86-5a0a-4616-b9d4-49c2091baacb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_596baf76-b549-4338-a54c-088bf6d3b512" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_2749ab86-5a0a-4616-b9d4-49c2091baacb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesComponentsOfLeaseExpenseDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#OperatingLeasesOperatingLeasesComponentsOfLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesComponentsOfLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_850d9452-5f79-467b-a944-b76d0d002e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c122a5a0-ed10-4f1b-b0c5-7efe4d9b73d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_850d9452-5f79-467b-a944-b76d0d002e99" xlink:to="loc_us-gaap_OperatingLeaseCost_c122a5a0-ed10-4f1b-b0c5-7efe4d9b73d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_6d335c0c-181f-4c54-9b88-b0838846ea20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_850d9452-5f79-467b-a944-b76d0d002e99" xlink:to="loc_us-gaap_VariableLeaseCost_6d335c0c-181f-4c54-9b88-b0838846ea20" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#OperatingLeasesOperatingLeasesSupplementalBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8406a7f9-c49a-4168-8844-21e6cb4dc780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b12a3f15-926e-4aec-bd0e-bf8b32b90f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_8406a7f9-c49a-4168-8844-21e6cb4dc780" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b12a3f15-926e-4aec-bd0e-bf8b32b90f8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cf81cc71-90c8-4d17-9338-b41b69a05839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_8406a7f9-c49a-4168-8844-21e6cb4dc780" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cf81cc71-90c8-4d17-9338-b41b69a05839" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f1441e2c-4cdd-484b-8f39-b09c44d7b388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b6598df2-0a25-4af4-a218-8477a7e21f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f1441e2c-4cdd-484b-8f39-b09c44d7b388" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b6598df2-0a25-4af4-a218-8477a7e21f7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_561cc2a5-8ebd-47bd-a159-c2d7cbdc2887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f1441e2c-4cdd-484b-8f39-b09c44d7b388" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_561cc2a5-8ebd-47bd-a159-c2d7cbdc2887" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e97ec085-7d3d-4358-b7cb-eb00be083107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f1441e2c-4cdd-484b-8f39-b09c44d7b388" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e97ec085-7d3d-4358-b7cb-eb00be083107" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ffb08056-9bb4-4c41-8d4c-8e3232b0c2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f1441e2c-4cdd-484b-8f39-b09c44d7b388" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ffb08056-9bb4-4c41-8d4c-8e3232b0c2d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_4ab33348-1df7-4197-935c-249142613a6d" xlink:href="ocgn-20210930.xsd#ocgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f1441e2c-4cdd-484b-8f39-b09c44d7b388" xlink:to="loc_ocgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_4ab33348-1df7-4197-935c-249142613a6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ba887b21-5c3f-4e46-995d-969b676d767f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f1441e2c-4cdd-484b-8f39-b09c44d7b388" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ba887b21-5c3f-4e46-995d-969b676d767f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="ocgn-20210930.xsd#OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_23a20321-0a5d-4817-8d27-f645f883da1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a0b038a2-a46c-495f-9dab-f92975b941f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_23a20321-0a5d-4817-8d27-f645f883da1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a0b038a2-a46c-495f-9dab-f92975b941f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b599accf-fecc-41cb-8ed5-578d3f8860bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_23a20321-0a5d-4817-8d27-f645f883da1d" xlink:to="loc_us-gaap_OperatingLeaseLiability_b599accf-fecc-41cb-8ed5-578d3f8860bb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_125f960d-6149-4545-8b69-d29322e2b570" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ResearchAndDevelopmentExpensesCurrent_16a8d894-3614-42f4-a219-0e94c808f367" xlink:href="ocgn-20210930.xsd#ocgn_ResearchAndDevelopmentExpensesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_125f960d-6149-4545-8b69-d29322e2b570" xlink:to="loc_ocgn_ResearchAndDevelopmentExpensesCurrent_16a8d894-3614-42f4-a219-0e94c808f367" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AccruedLiabilitiesProfessionalFees_e47962e1-cce6-47bf-bc6e-92c2b1fec0db" xlink:href="ocgn-20210930.xsd#ocgn_AccruedLiabilitiesProfessionalFees"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_125f960d-6149-4545-8b69-d29322e2b570" xlink:to="loc_ocgn_AccruedLiabilitiesProfessionalFees_e47962e1-cce6-47bf-bc6e-92c2b1fec0db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AccruedLiabilitiesClinical_9cae96b1-8b73-4d1e-bdca-55b8e215e9a4" xlink:href="ocgn-20210930.xsd#ocgn_AccruedLiabilitiesClinical"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_125f960d-6149-4545-8b69-d29322e2b570" xlink:to="loc_ocgn_AccruedLiabilitiesClinical_9cae96b1-8b73-4d1e-bdca-55b8e215e9a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e39a001f-9042-47b4-812f-0f0873b9d2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_125f960d-6149-4545-8b69-d29322e2b570" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e39a001f-9042-47b4-812f-0f0873b9d2b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_57642d28-8162-4dd3-aa3c-991cadf586b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_125f960d-6149-4545-8b69-d29322e2b570" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_57642d28-8162-4dd3-aa3c-991cadf586b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AccruedSeveranceRelatedLiabilitiesCurrent_39a64b9f-352e-49e5-b8c7-b6deaf769c76" xlink:href="ocgn-20210930.xsd#ocgn_AccruedSeveranceRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_125f960d-6149-4545-8b69-d29322e2b570" xlink:to="loc_ocgn_AccruedSeveranceRelatedLiabilitiesCurrent_39a64b9f-352e-49e5-b8c7-b6deaf769c76" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#DebtEB5LoanAgreementBorrowingsDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2c30336e-9d2b-4355-8788-e5efd5378555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_4ea27a3f-2f3e-491b-bbb3-00cbaed6612e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2c30336e-9d2b-4355-8788-e5efd5378555" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_4ea27a3f-2f3e-491b-bbb3-00cbaed6612e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_35376abd-621d-4151-93f7-5f72a2a6e020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2c30336e-9d2b-4355-8788-e5efd5378555" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_35376abd-621d-4151-93f7-5f72a2a6e020" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c67295e1-5a83-42a5-8bf6-74a54ada345c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2c30336e-9d2b-4355-8788-e5efd5378555" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c67295e1-5a83-42a5-8bf6-74a54ada345c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockComputationofbasicanddilutedearningspershareDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#NetLossPerShareofCommonStockComputationofbasicanddilutedearningspershareDetails"/>
  <link:calculationLink xlink:role="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockComputationofbasicanddilutedearningspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_964eeae9-a8d0-474c-a88a-9bbd7df8ef1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_e120899e-b282-40fe-84e7-3a9995fa7347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_964eeae9-a8d0-474c-a88a-9bbd7df8ef1a" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_e120899e-b282-40fe-84e7-3a9995fa7347" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2d7c8e71-82a0-4e98-bcc2-822bf75eb412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_964eeae9-a8d0-474c-a88a-9bbd7df8ef1a" xlink:to="loc_us-gaap_NetIncomeLoss_2d7c8e71-82a0-4e98-bcc2-822bf75eb412" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>ocgn-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:37cdbff3-15f4-4881-8cd5-68abc4a291de,g:c6584426-cf6c-4c9a-b04f-fdc200c901b8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ocgn-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="if1077f63b09d48198131bb047efd97c3_CONDENSEDCONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f8079163-7221-4028-b22f-e58f7d198f51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_cb45d1b9-c09a-4c63-8832-6b913d46eec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f8079163-7221-4028-b22f-e58f7d198f51" xlink:to="loc_us-gaap_AssetsAbstract_cb45d1b9-c09a-4c63-8832-6b913d46eec6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_748389f5-f7b5-4415-bf52-a3875230284c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_cb45d1b9-c09a-4c63-8832-6b913d46eec6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_748389f5-f7b5-4415-bf52-a3875230284c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_be234b21-daed-4a9f-9c88-516d71a81455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_748389f5-f7b5-4415-bf52-a3875230284c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_be234b21-daed-4a9f-9c88-516d71a81455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvancesOnInventoryPurchases_35e5fa85-270d-4057-b8d0-a10c99366ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvancesOnInventoryPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_748389f5-f7b5-4415-bf52-a3875230284c" xlink:to="loc_us-gaap_AdvancesOnInventoryPurchases_35e5fa85-270d-4057-b8d0-a10c99366ee5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_528cda44-d3b1-4381-a080-c565378c7a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_748389f5-f7b5-4415-bf52-a3875230284c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_528cda44-d3b1-4381-a080-c565378c7a9b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_77c7fffb-6678-40e7-a4d2-8b2bd2286227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_748389f5-f7b5-4415-bf52-a3875230284c" xlink:to="loc_us-gaap_AssetsCurrent_77c7fffb-6678-40e7-a4d2-8b2bd2286227" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0e5fc3a7-0126-4cf4-b60b-c60119af1d86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_cb45d1b9-c09a-4c63-8832-6b913d46eec6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0e5fc3a7-0126-4cf4-b60b-c60119af1d86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_030a0d92-8c05-407a-800a-ab2460f60d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_cb45d1b9-c09a-4c63-8832-6b913d46eec6" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_030a0d92-8c05-407a-800a-ab2460f60d5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5dc93398-bf6b-45af-8c5a-59e78d4fba00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_cb45d1b9-c09a-4c63-8832-6b913d46eec6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5dc93398-bf6b-45af-8c5a-59e78d4fba00" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1d238d97-4317-4629-b94a-213d6f1c0d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_cb45d1b9-c09a-4c63-8832-6b913d46eec6" xlink:to="loc_us-gaap_Assets_1d238d97-4317-4629-b94a-213d6f1c0d4c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4c2a59c0-b433-4a97-8446-336b7abfef4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f8079163-7221-4028-b22f-e58f7d198f51" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4c2a59c0-b433-4a97-8446-336b7abfef4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_7253c63f-2605-433e-a53c-11595572f855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4c2a59c0-b433-4a97-8446-336b7abfef4c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_7253c63f-2605-433e-a53c-11595572f855" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_03646c58-def8-464a-b285-754fa5decc03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7253c63f-2605-433e-a53c-11595572f855" xlink:to="loc_us-gaap_AccountsPayableCurrent_03646c58-def8-464a-b285-754fa5decc03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_4381d913-1e48-4152-b32c-da94f9be4ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7253c63f-2605-433e-a53c-11595572f855" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_4381d913-1e48-4152-b32c-da94f9be4ab8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_0450bda9-47a7-48eb-ba45-795318c46b89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7253c63f-2605-433e-a53c-11595572f855" xlink:to="loc_us-gaap_ShortTermBorrowings_0450bda9-47a7-48eb-ba45-795318c46b89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1fe13b8c-5a32-43d8-981f-c631e9a9a3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7253c63f-2605-433e-a53c-11595572f855" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1fe13b8c-5a32-43d8-981f-c631e9a9a3b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bdd5e036-f3c1-4b2d-8480-e4cfe26ddb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7253c63f-2605-433e-a53c-11595572f855" xlink:to="loc_us-gaap_LiabilitiesCurrent_bdd5e036-f3c1-4b2d-8480-e4cfe26ddb4d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_615ddb05-9e66-4c16-8637-d3a61ab53da3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4c2a59c0-b433-4a97-8446-336b7abfef4c" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_615ddb05-9e66-4c16-8637-d3a61ab53da3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2f41d60f-97ac-46a4-9378-086110852c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_615ddb05-9e66-4c16-8637-d3a61ab53da3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2f41d60f-97ac-46a4-9378-086110852c86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_b56b4c2b-fcdc-48b0-a4ba-171cce86605e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_615ddb05-9e66-4c16-8637-d3a61ab53da3" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_b56b4c2b-fcdc-48b0-a4ba-171cce86605e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_51e565a8-3eb9-4f78-8669-7dd805ab5af1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_615ddb05-9e66-4c16-8637-d3a61ab53da3" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_51e565a8-3eb9-4f78-8669-7dd805ab5af1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_912351ee-d67a-4bb1-8025-aefb3218399c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4c2a59c0-b433-4a97-8446-336b7abfef4c" xlink:to="loc_us-gaap_Liabilities_912351ee-d67a-4bb1-8025-aefb3218399c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_effda86b-8972-4fe5-9285-bf78646185c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4c2a59c0-b433-4a97-8446-336b7abfef4c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_effda86b-8972-4fe5-9285-bf78646185c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_762d5fd8-7fb7-49a4-a6c5-a7c8c04a99a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4c2a59c0-b433-4a97-8446-336b7abfef4c" xlink:to="loc_us-gaap_StockholdersEquityAbstract_762d5fd8-7fb7-49a4-a6c5-a7c8c04a99a3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5072d66f-cfe9-49c5-806e-3bbe3f68adc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_762d5fd8-7fb7-49a4-a6c5-a7c8c04a99a3" xlink:to="loc_us-gaap_PreferredStockValue_5072d66f-cfe9-49c5-806e-3bbe3f68adc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_de5c1683-e17c-4596-accc-aca5d5fc358e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_762d5fd8-7fb7-49a4-a6c5-a7c8c04a99a3" xlink:to="loc_us-gaap_CommonStockValue_de5c1683-e17c-4596-accc-aca5d5fc358e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_857e3675-85cb-412a-af0e-3a267c2099b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_762d5fd8-7fb7-49a4-a6c5-a7c8c04a99a3" xlink:to="loc_us-gaap_TreasuryStockValue_857e3675-85cb-412a-af0e-3a267c2099b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4b204bc3-ad02-4fdc-a33d-6de6fbe5f6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_762d5fd8-7fb7-49a4-a6c5-a7c8c04a99a3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_4b204bc3-ad02-4fdc-a33d-6de6fbe5f6c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d0b6a3d1-6491-4873-8e29-dd772346350a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_762d5fd8-7fb7-49a4-a6c5-a7c8c04a99a3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d0b6a3d1-6491-4873-8e29-dd772346350a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d5d288af-aeea-40c5-b72a-7bc88759ec74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_762d5fd8-7fb7-49a4-a6c5-a7c8c04a99a3" xlink:to="loc_us-gaap_StockholdersEquity_d5d288af-aeea-40c5-b72a-7bc88759ec74" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_75fc6fb3-67ad-4fd6-85c5-f67fe38a1e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4c2a59c0-b433-4a97-8446-336b7abfef4c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_75fc6fb3-67ad-4fd6-85c5-f67fe38a1e9e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f16a0502-4938-4082-be71-f3bc12c83c58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f8079163-7221-4028-b22f-e58f7d198f51" xlink:to="loc_us-gaap_StatementTable_f16a0502-4938-4082-be71-f3bc12c83c58" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_50aa78fc-08f2-4774-ad64-ee6acf12c3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f16a0502-4938-4082-be71-f3bc12c83c58" xlink:to="loc_us-gaap_StatementClassOfStockAxis_50aa78fc-08f2-4774-ad64-ee6acf12c3a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_50aa78fc-08f2-4774-ad64-ee6acf12c3a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_50aa78fc-08f2-4774-ad64-ee6acf12c3a3" xlink:to="loc_us-gaap_ClassOfStockDomain_50aa78fc-08f2-4774-ad64-ee6acf12c3a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4f3f3116-47a4-4fc0-9e23-275f52bf0de8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_50aa78fc-08f2-4774-ad64-ee6acf12c3a3" xlink:to="loc_us-gaap_ClassOfStockDomain_4f3f3116-47a4-4fc0-9e23-275f52bf0de8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_9b111810-2fb2-411d-9c9f-d951e029a173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4f3f3116-47a4-4fc0-9e23-275f52bf0de8" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_9b111810-2fb2-411d-9c9f-d951e029a173" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_b635fc54-37fd-49f9-b241-a6bdc185231f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4f3f3116-47a4-4fc0-9e23-275f52bf0de8" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_b635fc54-37fd-49f9-b241-a6bdc185231f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="ocgn-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="i845c3340d49b4463b7cd430688548d2b_CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f857fc52-b282-4771-b33c-45dc457fb14b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0eea08da-5bae-47a4-aafc-32c034ee68a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f857fc52-b282-4771-b33c-45dc457fb14b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0eea08da-5bae-47a4-aafc-32c034ee68a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_149b94bd-579c-4975-90fc-cdd4d7a3d990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f857fc52-b282-4771-b33c-45dc457fb14b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_149b94bd-579c-4975-90fc-cdd4d7a3d990" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b1f49dfc-b57c-431b-b18c-669846bf0af3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f857fc52-b282-4771-b33c-45dc457fb14b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b1f49dfc-b57c-431b-b18c-669846bf0af3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3abc9ed1-33f5-4af3-96b2-60864dcf8f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f857fc52-b282-4771-b33c-45dc457fb14b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3abc9ed1-33f5-4af3-96b2-60864dcf8f44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_01713fa2-5edd-4c99-a8a3-d07075f97d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f857fc52-b282-4771-b33c-45dc457fb14b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_01713fa2-5edd-4c99-a8a3-d07075f97d5e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_5c45ca52-52c5-4a92-9f52-d7effb94dd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f857fc52-b282-4771-b33c-45dc457fb14b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_5c45ca52-52c5-4a92-9f52-d7effb94dd7c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1ef1f5e4-e095-4dcf-89a4-fe354ca1ae33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f857fc52-b282-4771-b33c-45dc457fb14b" xlink:to="loc_us-gaap_CommonStockSharesIssued_1ef1f5e4-e095-4dcf-89a4-fe354ca1ae33" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_228394fe-6d61-4c9b-9acd-3bd1f311889d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f857fc52-b282-4771-b33c-45dc457fb14b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_228394fe-6d61-4c9b-9acd-3bd1f311889d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_e1f93c26-18fb-4468-bb75-82fe18f766b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f857fc52-b282-4771-b33c-45dc457fb14b" xlink:to="loc_us-gaap_TreasuryStockCommonShares_e1f93c26-18fb-4468-bb75-82fe18f766b3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_670f0d2e-49d9-4f69-a6ac-6ad8e5a7955f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f857fc52-b282-4771-b33c-45dc457fb14b" xlink:to="loc_us-gaap_StatementTable_670f0d2e-49d9-4f69-a6ac-6ad8e5a7955f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6af43b44-efee-4280-8c03-0a617b04e4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_670f0d2e-49d9-4f69-a6ac-6ad8e5a7955f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6af43b44-efee-4280-8c03-0a617b04e4d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6af43b44-efee-4280-8c03-0a617b04e4d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6af43b44-efee-4280-8c03-0a617b04e4d3" xlink:to="loc_us-gaap_ClassOfStockDomain_6af43b44-efee-4280-8c03-0a617b04e4d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_22a84a02-b713-4063-a6fa-08d478c8f49a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6af43b44-efee-4280-8c03-0a617b04e4d3" xlink:to="loc_us-gaap_ClassOfStockDomain_22a84a02-b713-4063-a6fa-08d478c8f49a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_731bb958-de98-456b-87ac-0b954a4b6e11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_22a84a02-b713-4063-a6fa-08d478c8f49a" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_731bb958-de98-456b-87ac-0b954a4b6e11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_472d3ea1-524e-43da-9c8c-0c25b903a4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_22a84a02-b713-4063-a6fa-08d478c8f49a" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_472d3ea1-524e-43da-9c8c-0c25b903a4ea" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="ocgn-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended" id="ia1a7d16227f54b759ee490bb08307940_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0fbb5ae9-056c-4d83-82da-625308cffcb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0fbb5ae9-056c-4d83-82da-625308cffcb1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_d1c680d1-d279-4234-a4db-7d071d1fdaec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_us-gaap_SharesOutstanding_d1c680d1-d279-4234-a4db-7d071d1fdaec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_52d3ef1d-9fca-4445-9c6c-4966cc01e016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_us-gaap_StockholdersEquity_52d3ef1d-9fca-4445-9c6c-4966cc01e016" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6444356c-8ce1-4a44-aff0-1a25bce63036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6444356c-8ce1-4a44-aff0-1a25bce63036" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a0544414-1211-4ef8-aecb-24c747bf8984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a0544414-1211-4ef8-aecb-24c747bf8984" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c7ca9f90-a846-455d-8788-062459360588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c7ca9f90-a846-455d-8788-062459360588" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e42ffa81-3b99-4bcf-a638-99dc664b84c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e42ffa81-3b99-4bcf-a638-99dc664b84c2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e677ef2b-4cda-4fe8-a9fd-0d490beee8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e677ef2b-4cda-4fe8-a9fd-0d490beee8bd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised_2a59eedb-1118-4896-b02b-3a790128c7c4" xlink:href="ocgn-20210930.xsd#ocgn_StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_ocgn_StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised_2a59eedb-1118-4896-b02b-3a790128c7c4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodValueOptionsAndWarrantsExercised_b8cb02d4-cca7-4e10-8eb9-a65201db3125" xlink:href="ocgn-20210930.xsd#ocgn_StockIssuedDuringPeriodValueOptionsAndWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_ocgn_StockIssuedDuringPeriodValueOptionsAndWarrantsExercised_b8cb02d4-cca7-4e10-8eb9-a65201db3125" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodSharesWarrantExchange_15d66189-13e4-4f7f-8d11-e266a6045bce" xlink:href="ocgn-20210930.xsd#ocgn_StockIssuedDuringPeriodSharesWarrantExchange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_ocgn_StockIssuedDuringPeriodSharesWarrantExchange_15d66189-13e4-4f7f-8d11-e266a6045bce" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodValueWarrantExchange_0ef4c15a-cea9-45c8-ac1f-a868c5308abb" xlink:href="ocgn-20210930.xsd#ocgn_StockIssuedDuringPeriodValueWarrantExchange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_ocgn_StockIssuedDuringPeriodValueWarrantExchange_0ef4c15a-cea9-45c8-ac1f-a868c5308abb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_00a75ded-a094-40f2-a98f-eb46b3ca6d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_us-gaap_NetIncomeLoss_00a75ded-a094-40f2-a98f-eb46b3ca6d3a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_014ec6b4-1b6d-4ae6-a610-ee0dcd1f34d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ca2a6363-83ef-45f2-90d3-78122c72b841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6cdcaec5-3966-4b22-8933-31cbf521b168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0fbb5ae9-056c-4d83-82da-625308cffcb1" xlink:to="loc_us-gaap_StatementTable_6cdcaec5-3966-4b22-8933-31cbf521b168" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b1a616c6-8346-4c0c-99c1-37e46b8f7e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6cdcaec5-3966-4b22-8933-31cbf521b168" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b1a616c6-8346-4c0c-99c1-37e46b8f7e99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b1a616c6-8346-4c0c-99c1-37e46b8f7e99_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b1a616c6-8346-4c0c-99c1-37e46b8f7e99" xlink:to="loc_us-gaap_EquityComponentDomain_b1a616c6-8346-4c0c-99c1-37e46b8f7e99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_53e3eb60-c545-4b2d-b3c0-574cd01472ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b1a616c6-8346-4c0c-99c1-37e46b8f7e99" xlink:to="loc_us-gaap_EquityComponentDomain_53e3eb60-c545-4b2d-b3c0-574cd01472ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_7c8e07ac-8d2b-4de6-99c1-a43d88a3c6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_53e3eb60-c545-4b2d-b3c0-574cd01472ed" xlink:to="loc_us-gaap_PreferredStockMember_7c8e07ac-8d2b-4de6-99c1-a43d88a3c6ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_95d311da-62df-41a3-bbca-5d5fad3c9a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_53e3eb60-c545-4b2d-b3c0-574cd01472ed" xlink:to="loc_us-gaap_CommonStockMember_95d311da-62df-41a3-bbca-5d5fad3c9a2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_d43b92dc-2ad6-4efd-a28f-e9543c068e29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_53e3eb60-c545-4b2d-b3c0-574cd01472ed" xlink:to="loc_us-gaap_TreasuryStockMember_d43b92dc-2ad6-4efd-a28f-e9543c068e29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fb4305ec-be7e-48e7-82a7-8c0d7870afdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_53e3eb60-c545-4b2d-b3c0-574cd01472ed" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fb4305ec-be7e-48e7-82a7-8c0d7870afdc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cbac6ba5-9bf4-42da-b9b7-d4a7fe73f4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_53e3eb60-c545-4b2d-b3c0-574cd01472ed" xlink:to="loc_us-gaap_RetainedEarningsMember_cbac6ba5-9bf4-42da-b9b7-d4a7fe73f4ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a27d323a-6239-450f-af3f-4106caede490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6cdcaec5-3966-4b22-8933-31cbf521b168" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a27d323a-6239-450f-af3f-4106caede490" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a27d323a-6239-450f-af3f-4106caede490_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a27d323a-6239-450f-af3f-4106caede490" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a27d323a-6239-450f-af3f-4106caede490_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70071fe8-d216-4478-8d13-f4395131ff2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a27d323a-6239-450f-af3f-4106caede490" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70071fe8-d216-4478-8d13-f4395131ff2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ATMTransactionsMember_e12bdc1e-b9eb-4bf5-91a8-e7ddd908908a" xlink:href="ocgn-20210930.xsd#ocgn_ATMTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70071fe8-d216-4478-8d13-f4395131ff2b" xlink:to="loc_ocgn_ATMTransactionsMember_e12bdc1e-b9eb-4bf5-91a8-e7ddd908908a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_RegisteredDirectOfferingMember_d2a38be8-8e8b-44a1-b39c-c11201a2c98c" xlink:href="ocgn-20210930.xsd#ocgn_RegisteredDirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70071fe8-d216-4478-8d13-f4395131ff2b" xlink:to="loc_ocgn_RegisteredDirectOfferingMember_d2a38be8-8e8b-44a1-b39c-c11201a2c98c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SubscriptionAgreementsAndWarrantExercisesMember_d677af6c-085c-41bf-848e-ce947bd6e8f5" xlink:href="ocgn-20210930.xsd#ocgn_SubscriptionAgreementsAndWarrantExercisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70071fe8-d216-4478-8d13-f4395131ff2b" xlink:to="loc_ocgn_SubscriptionAgreementsAndWarrantExercisesMember_d677af6c-085c-41bf-848e-ce947bd6e8f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f4979bd5-23e1-425e-b164-44b1194356a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6cdcaec5-3966-4b22-8933-31cbf521b168" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f4979bd5-23e1-425e-b164-44b1194356a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f4979bd5-23e1-425e-b164-44b1194356a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f4979bd5-23e1-425e-b164-44b1194356a1" xlink:to="loc_us-gaap_ClassOfStockDomain_f4979bd5-23e1-425e-b164-44b1194356a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1ebb3c3a-aec4-4258-9729-88ee501a65d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f4979bd5-23e1-425e-b164-44b1194356a1" xlink:to="loc_us-gaap_ClassOfStockDomain_1ebb3c3a-aec4-4258-9729-88ee501a65d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_81e8e4f3-47d0-4f86-adb8-5f954856efaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1ebb3c3a-aec4-4258-9729-88ee501a65d2" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_81e8e4f3-47d0-4f86-adb8-5f954856efaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_c3ba4804-11d5-4cac-b7b4-e9508486a547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1ebb3c3a-aec4-4258-9729-88ee501a65d2" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_c3ba4804-11d5-4cac-b7b4-e9508486a547" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="ic4f5e9820c2f413da26e23b3b7c4ad7c_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_63f208e7-a696-4df7-9d58-a56c19e75e95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_f407e2f8-9b9c-431e-82d8-2e0e05843fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_63f208e7-a696-4df7-9d58-a56c19e75e95" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_f407e2f8-9b9c-431e-82d8-2e0e05843fdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_eff9a60c-2171-487c-be39-9c899eec7d35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_63f208e7-a696-4df7-9d58-a56c19e75e95" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_eff9a60c-2171-487c-be39-9c899eec7d35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_07d15a1c-1aa3-45e0-a227-ed89264be54d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_63f208e7-a696-4df7-9d58-a56c19e75e95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_07d15a1c-1aa3-45e0-a227-ed89264be54d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_84f0843b-776a-4d82-871e-5e6c8d3a1cee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_63f208e7-a696-4df7-9d58-a56c19e75e95" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_84f0843b-776a-4d82-871e-5e6c8d3a1cee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_a30c6ce5-ce0e-4743-bb5f-c1b7abee6882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_63f208e7-a696-4df7-9d58-a56c19e75e95" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_a30c6ce5-ce0e-4743-bb5f-c1b7abee6882" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_709af16f-60e8-446a-ac1e-792dd984abea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_63f208e7-a696-4df7-9d58-a56c19e75e95" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_709af16f-60e8-446a-ac1e-792dd984abea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_4edafe54-c3d8-45dc-a669-c4dd1253be5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_63f208e7-a696-4df7-9d58-a56c19e75e95" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_4edafe54-c3d8-45dc-a669-c4dd1253be5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4be1aa8a-f352-4121-889b-b2b1163746dc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_4edafe54-c3d8-45dc-a669-c4dd1253be5e" xlink:to="loc_srt_RangeAxis_4be1aa8a-f352-4121-889b-b2b1163746dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4be1aa8a-f352-4121-889b-b2b1163746dc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4be1aa8a-f352-4121-889b-b2b1163746dc" xlink:to="loc_srt_RangeMember_4be1aa8a-f352-4121-889b-b2b1163746dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_980eaecb-30d1-4bc9-b1b8-cc7e735d8e58" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4be1aa8a-f352-4121-889b-b2b1163746dc" xlink:to="loc_srt_RangeMember_980eaecb-30d1-4bc9-b1b8-cc7e735d8e58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ed350e8e-58a6-4f1b-b371-4f8530980ea9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_980eaecb-30d1-4bc9-b1b8-cc7e735d8e58" xlink:to="loc_srt_MinimumMember_ed350e8e-58a6-4f1b-b371-4f8530980ea9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a1b58b69-4e48-477f-9e66-aa501065ae64" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_980eaecb-30d1-4bc9-b1b8-cc7e735d8e58" xlink:to="loc_srt_MaximumMember_a1b58b69-4e48-477f-9e66-aa501065ae64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_540a62f5-38c3-4034-b2ce-354f651057d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_4edafe54-c3d8-45dc-a669-c4dd1253be5e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_540a62f5-38c3-4034-b2ce-354f651057d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_540a62f5-38c3-4034-b2ce-354f651057d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_540a62f5-38c3-4034-b2ce-354f651057d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_540a62f5-38c3-4034-b2ce-354f651057d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_864b8443-594f-4c7e-8397-0813b92156d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_540a62f5-38c3-4034-b2ce-354f651057d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_864b8443-594f-4c7e-8397-0813b92156d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c9075b65-90c4-4411-bcf3-2d7c55fdcd78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_864b8443-594f-4c7e-8397-0813b92156d3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c9075b65-90c4-4411-bcf3-2d7c55fdcd78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_MachineryMember_2ba83815-a85a-455b-a9b6-8fcd26dcd549" xlink:href="ocgn-20210930.xsd#ocgn_MachineryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_864b8443-594f-4c7e-8397-0813b92156d3" xlink:to="loc_ocgn_MachineryMember_2ba83815-a85a-455b-a9b6-8fcd26dcd549" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreementsDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#LicenseandDevelopmentAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreementsDetails" xlink:type="extended" id="ib56ee6dcfda5412eb0412fe5ad209a55_LicenseandDevelopmentAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c29ed4ba-8426-48ae-9a16-59a6678293cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborativeArrangementProfitsGeneratedSharedPercentage_324b629e-ae1b-4437-b55d-3f3896bacd8e" xlink:href="ocgn-20210930.xsd#ocgn_CollaborativeArrangementProfitsGeneratedSharedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c29ed4ba-8426-48ae-9a16-59a6678293cd" xlink:to="loc_ocgn_CollaborativeArrangementProfitsGeneratedSharedPercentage_324b629e-ae1b-4437-b55d-3f3896bacd8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementUpfrontPayment_fbacbc8c-c072-4b0e-a010-9786ca52e1ce" xlink:href="ocgn-20210930.xsd#ocgn_CollaborationAgreementUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c29ed4ba-8426-48ae-9a16-59a6678293cd" xlink:to="loc_ocgn_CollaborationAgreementUpfrontPayment_fbacbc8c-c072-4b0e-a010-9786ca52e1ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada_1e95f17b-b626-43ed-a3d6-05096d2d9037" xlink:href="ocgn-20210930.xsd#ocgn_CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c29ed4ba-8426-48ae-9a16-59a6678293cd" xlink:to="loc_ocgn_CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada_1e95f17b-b626-43ed-a3d6-05096d2d9037" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementTerm_d01b4b3a-690a-4f7a-af13-6df80cdb2204" xlink:href="ocgn-20210930.xsd#ocgn_CollaborationAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c29ed4ba-8426-48ae-9a16-59a6678293cd" xlink:to="loc_ocgn_CollaborationAgreementTerm_d01b4b3a-690a-4f7a-af13-6df80cdb2204" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b426eaee-c1c1-4fb0-b138-46b03f8c8ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c29ed4ba-8426-48ae-9a16-59a6678293cd" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b426eaee-c1c1-4fb0-b138-46b03f8c8ab2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ad15b116-c6be-4d1d-a85f-a993e29d96e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b426eaee-c1c1-4fb0-b138-46b03f8c8ab2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ad15b116-c6be-4d1d-a85f-a993e29d96e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ad15b116-c6be-4d1d-a85f-a993e29d96e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ad15b116-c6be-4d1d-a85f-a993e29d96e2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ad15b116-c6be-4d1d-a85f-a993e29d96e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ccdbce87-61ef-4991-8c48-11939ce9447c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ad15b116-c6be-4d1d-a85f-a993e29d96e2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ccdbce87-61ef-4991-8c48-11939ce9447c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_COVAXINPreferredStockPurchaseAgreementMember_51bd36ee-385a-4027-a2a4-8a29f3cc65c2" xlink:href="ocgn-20210930.xsd#ocgn_COVAXINPreferredStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ccdbce87-61ef-4991-8c48-11939ce9447c" xlink:to="loc_ocgn_COVAXINPreferredStockPurchaseAgreementMember_51bd36ee-385a-4027-a2a4-8a29f3cc65c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_14ae6b86-dc92-463e-8201-2a8ef99fb344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b426eaee-c1c1-4fb0-b138-46b03f8c8ab2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_14ae6b86-dc92-463e-8201-2a8ef99fb344" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14ae6b86-dc92-463e-8201-2a8ef99fb344_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_14ae6b86-dc92-463e-8201-2a8ef99fb344" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14ae6b86-dc92-463e-8201-2a8ef99fb344_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c3338336-254b-49e6-8b7c-f8cdd70ed412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_14ae6b86-dc92-463e-8201-2a8ef99fb344" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c3338336-254b-49e6-8b7c-f8cdd70ed412" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_4dadb571-a3e9-49c0-954f-9ac8858139a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c3338336-254b-49e6-8b7c-f8cdd70ed412" xlink:to="loc_us-gaap_CollaborativeArrangementMember_4dadb571-a3e9-49c0-954f-9ac8858139a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementWithCansinoBiologicsMember_1b831e8d-605b-4938-92b4-46db4281a112" xlink:href="ocgn-20210930.xsd#ocgn_CollaborationAgreementWithCansinoBiologicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c3338336-254b-49e6-8b7c-f8cdd70ed412" xlink:to="loc_ocgn_CollaborationAgreementWithCansinoBiologicsMember_1b831e8d-605b-4938-92b4-46db4281a112" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended" id="i1faa7df91e394d749a1d4ce5481c3977_PropertyandEquipmentScheduleofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0ede63af-13df-46c0-a202-4f20574d6251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ee7b4a29-0e27-40f1-9565-405f6ac8350a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0ede63af-13df-46c0-a202-4f20574d6251" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ee7b4a29-0e27-40f1-9565-405f6ac8350a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_0762d58b-6695-4d59-ac63-ce0abeb4a71e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0ede63af-13df-46c0-a202-4f20574d6251" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_0762d58b-6695-4d59-ac63-ce0abeb4a71e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_33cd801d-7f64-4664-87c4-d5b5e06e06c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0ede63af-13df-46c0-a202-4f20574d6251" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_33cd801d-7f64-4664-87c4-d5b5e06e06c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_66a9c337-eaf7-4776-815f-d86a8379c349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0ede63af-13df-46c0-a202-4f20574d6251" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_66a9c337-eaf7-4776-815f-d86a8379c349" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_c32800ed-a3e0-4b07-ab98-c0a50ad28ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0ede63af-13df-46c0-a202-4f20574d6251" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_c32800ed-a3e0-4b07-ab98-c0a50ad28ec0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_56718feb-1739-4eba-845d-9ef4d1aa412b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0ede63af-13df-46c0-a202-4f20574d6251" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_56718feb-1739-4eba-845d-9ef4d1aa412b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8c30bfd2-90df-4288-b0af-a3faad96cfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_56718feb-1739-4eba-845d-9ef4d1aa412b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8c30bfd2-90df-4288-b0af-a3faad96cfa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8c30bfd2-90df-4288-b0af-a3faad96cfa5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8c30bfd2-90df-4288-b0af-a3faad96cfa5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8c30bfd2-90df-4288-b0af-a3faad96cfa5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d22663ee-daa6-4a99-a256-102b102110b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8c30bfd2-90df-4288-b0af-a3faad96cfa5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d22663ee-daa6-4a99-a256-102b102110b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_380447a1-8a69-41aa-8f0a-1e813c0dddaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d22663ee-daa6-4a99-a256-102b102110b0" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_380447a1-8a69-41aa-8f0a-1e813c0dddaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_452c6faa-8af3-47b5-b47c-9b87735a3177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d22663ee-daa6-4a99-a256-102b102110b0" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_452c6faa-8af3-47b5-b47c-9b87735a3177" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_a262da0f-8792-46a2-86df-061e483c7cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d22663ee-daa6-4a99-a256-102b102110b0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_a262da0f-8792-46a2-86df-061e483c7cd6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_03e1f725-378f-4a8c-ad72-f29e646f37a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d22663ee-daa6-4a99-a256-102b102110b0" xlink:to="loc_us-gaap_ConstructionInProgressMember_03e1f725-378f-4a8c-ad72-f29e646f37a8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended" id="iab8040c7fa074df18a89fdfe1044cfe5_AccruedExpensesandOtherCurrentLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ResearchAndDevelopmentExpensesCurrent_8064c81a-848e-4dbc-9827-3b6cb804cb1f" xlink:href="ocgn-20210930.xsd#ocgn_ResearchAndDevelopmentExpensesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:to="loc_ocgn_ResearchAndDevelopmentExpensesCurrent_8064c81a-848e-4dbc-9827-3b6cb804cb1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AccruedLiabilitiesClinical_216c4b7a-1b2c-4f1e-862d-03623521064f" xlink:href="ocgn-20210930.xsd#ocgn_AccruedLiabilitiesClinical"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:to="loc_ocgn_AccruedLiabilitiesClinical_216c4b7a-1b2c-4f1e-862d-03623521064f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AccruedLiabilitiesProfessionalFees_7aaa2b19-6084-4e41-8fac-20404eb45383" xlink:href="ocgn-20210930.xsd#ocgn_AccruedLiabilitiesProfessionalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:to="loc_ocgn_AccruedLiabilitiesProfessionalFees_7aaa2b19-6084-4e41-8fac-20404eb45383" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_edb249f4-9f25-43c3-8d5d-defd0f1ccaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_edb249f4-9f25-43c3-8d5d-defd0f1ccaa3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AccruedSeveranceRelatedLiabilitiesCurrent_faf89835-9cde-496d-845e-d5871757eea9" xlink:href="ocgn-20210930.xsd#ocgn_AccruedSeveranceRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:to="loc_ocgn_AccruedSeveranceRelatedLiabilitiesCurrent_faf89835-9cde-496d-845e-d5871757eea9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0aec7fd7-9852-4657-80a0-bc5962b0125f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0aec7fd7-9852-4657-80a0-bc5962b0125f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_e6f6d384-c82a-4673-81fc-9b5b1fbd0e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_e6f6d384-c82a-4673-81fc-9b5b1fbd0e8e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_ce4888e0-3552-438b-b10d-b5e55e183512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_ce4888e0-3552-438b-b10d-b5e55e183512" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_9696446e-e3ed-4be1-a284-53a380f2ba18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:to="loc_us-gaap_RestructuringCharges_9696446e-e3ed-4be1-a284-53a380f2ba18" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_af2e54a3-6879-4ca1-8ea2-f98c0349becd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:to="loc_us-gaap_SeveranceCosts1_af2e54a3-6879-4ca1-8ea2-f98c0349becd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_d8570c0b-276e-4acd-b1c3-b1543a3d8e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_d8570c0b-276e-4acd-b1c3-b1543a3d8e7d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c34786cd-3e04-40ad-ab4c-195b49937da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c34786cd-3e04-40ad-ab4c-195b49937da9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_39c72a34-df4d-41a1-9be7-ac164ebbfd73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c34786cd-3e04-40ad-ab4c-195b49937da9" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_39c72a34-df4d-41a1-9be7-ac164ebbfd73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_39c72a34-df4d-41a1-9be7-ac164ebbfd73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_39c72a34-df4d-41a1-9be7-ac164ebbfd73" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_39c72a34-df4d-41a1-9be7-ac164ebbfd73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_3af53085-0bba-4b7c-9d09-5dd4b8c9b194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_39c72a34-df4d-41a1-9be7-ac164ebbfd73" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_3af53085-0bba-4b7c-9d09-5dd4b8c9b194" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_ec4f2de0-b153-4daf-9ead-b4e9b30f0821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3af53085-0bba-4b7c-9d09-5dd4b8c9b194" xlink:to="loc_us-gaap_EmployeeSeveranceMember_ec4f2de0-b153-4daf-9ead-b4e9b30f0821" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a8b94260-cc24-420e-acde-764e872a2fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c34786cd-3e04-40ad-ab4c-195b49937da9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a8b94260-cc24-420e-acde-764e872a2fa0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a8b94260-cc24-420e-acde-764e872a2fa0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a8b94260-cc24-420e-acde-764e872a2fa0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a8b94260-cc24-420e-acde-764e872a2fa0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_47ad22b9-664c-45de-813a-d6b0d7f93545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a8b94260-cc24-420e-acde-764e872a2fa0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_47ad22b9-664c-45de-813a-d6b0d7f93545" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c5c7db1c-7fac-43ca-8025-ecdce4401009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_47ad22b9-664c-45de-813a-d6b0d7f93545" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c5c7db1c-7fac-43ca-8025-ecdce4401009" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f3e9b1a0-7578-4c6c-84c0-09145ad7686b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_47ad22b9-664c-45de-813a-d6b0d7f93545" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f3e9b1a0-7578-4c6c-84c0-09145ad7686b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesfortheComponentsofDebtDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#DebtSummaryoftheCarryingValuesfortheComponentsofDebtDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesfortheComponentsofDebtDetails" xlink:type="extended" id="if61d95dd21fb48c2bfd3abfa29b14811_DebtSummaryoftheCarryingValuesfortheComponentsofDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2bfc1905-313c-4520-9e17-d26bff77a920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_858df622-5246-4518-a75a-f5f4d0f8562c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bfc1905-313c-4520-9e17-d26bff77a920" xlink:to="loc_us-gaap_LongTermDebt_858df622-5246-4518-a75a-f5f4d0f8562c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f4b1fbcb-6d8f-42cb-8517-668cd879ec4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bfc1905-313c-4520-9e17-d26bff77a920" xlink:to="loc_us-gaap_DebtInstrumentTable_f4b1fbcb-6d8f-42cb-8517-668cd879ec4c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3d098e83-a230-415a-9c97-e1dafde6a315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f4b1fbcb-6d8f-42cb-8517-668cd879ec4c" xlink:to="loc_us-gaap_DebtInstrumentAxis_3d098e83-a230-415a-9c97-e1dafde6a315" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3d098e83-a230-415a-9c97-e1dafde6a315_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3d098e83-a230-415a-9c97-e1dafde6a315" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3d098e83-a230-415a-9c97-e1dafde6a315_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e6d7a5be-73db-4d1b-8847-cfcb44e17025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3d098e83-a230-415a-9c97-e1dafde6a315" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e6d7a5be-73db-4d1b-8847-cfcb44e17025" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_PaycheckProtectionProgramLoanMember_34ce95c9-47cc-49b4-a11c-9c70597da332" xlink:href="ocgn-20210930.xsd#ocgn_PaycheckProtectionProgramLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e6d7a5be-73db-4d1b-8847-cfcb44e17025" xlink:to="loc_ocgn_PaycheckProtectionProgramLoanMember_34ce95c9-47cc-49b4-a11c-9c70597da332" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EB5ProgramBorrowingsMember_c17d0725-9db7-48eb-9d4b-56ba7d14e012" xlink:href="ocgn-20210930.xsd#ocgn_EB5ProgramBorrowingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e6d7a5be-73db-4d1b-8847-cfcb44e17025" xlink:to="loc_ocgn_EB5ProgramBorrowingsMember_c17d0725-9db7-48eb-9d4b-56ba7d14e012" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ed69fc60-89f3-4c2a-bb0b-7e7599f38a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f4b1fbcb-6d8f-42cb-8517-668cd879ec4c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ed69fc60-89f3-4c2a-bb0b-7e7599f38a9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ed69fc60-89f3-4c2a-bb0b-7e7599f38a9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ed69fc60-89f3-4c2a-bb0b-7e7599f38a9e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ed69fc60-89f3-4c2a-bb0b-7e7599f38a9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_98becf46-70be-4adf-bf56-2073b5d87566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ed69fc60-89f3-4c2a-bb0b-7e7599f38a9e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_98becf46-70be-4adf-bf56-2073b5d87566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_8b2cd57b-c3c9-4a36-b8ac-4e5cb5c6b114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_98becf46-70be-4adf-bf56-2073b5d87566" xlink:to="loc_us-gaap_NotesPayableToBanksMember_8b2cd57b-c3c9-4a36-b8ac-4e5cb5c6b114" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_78a75b6c-b07a-4541-89e4-ebed484fde2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_98becf46-70be-4adf-bf56-2073b5d87566" xlink:to="loc_us-gaap_LoansPayableMember_78a75b6c-b07a-4541-89e4-ebed484fde2c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtPPPNoteDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#DebtPPPNoteDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/DebtPPPNoteDetails" xlink:type="extended" id="ifd3ae7054251473985b5976d8a834443_DebtPPPNoteDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_00308f51-5266-46f0-ba64-af3f4905cce8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_de76d5ce-7659-46e7-b6d3-689b775489c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00308f51-5266-46f0-ba64-af3f4905cce8" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_de76d5ce-7659-46e7-b6d3-689b775489c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_933ab3f9-9db7-4292-95c2-8379e46903a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00308f51-5266-46f0-ba64-af3f4905cce8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_933ab3f9-9db7-4292-95c2-8379e46903a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ae97c263-0188-4810-9b46-95a70a012e81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00308f51-5266-46f0-ba64-af3f4905cce8" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ae97c263-0188-4810-9b46-95a70a012e81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1f396d43-fc79-4a73-a4d4-112f9d2e403c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00308f51-5266-46f0-ba64-af3f4905cce8" xlink:to="loc_us-gaap_DebtInstrumentTable_1f396d43-fc79-4a73-a4d4-112f9d2e403c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d4a48016-d0fd-4a2c-b06f-ce913745b1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1f396d43-fc79-4a73-a4d4-112f9d2e403c" xlink:to="loc_us-gaap_DebtInstrumentAxis_d4a48016-d0fd-4a2c-b06f-ce913745b1fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d4a48016-d0fd-4a2c-b06f-ce913745b1fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d4a48016-d0fd-4a2c-b06f-ce913745b1fa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d4a48016-d0fd-4a2c-b06f-ce913745b1fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ec39e1d8-72b4-4c06-9b4e-d2359bdc4ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d4a48016-d0fd-4a2c-b06f-ce913745b1fa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ec39e1d8-72b4-4c06-9b4e-d2359bdc4ff5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_PaycheckProtectionProgramLoanMember_e84dfd20-4499-45e0-bb9e-21533270956e" xlink:href="ocgn-20210930.xsd#ocgn_PaycheckProtectionProgramLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ec39e1d8-72b4-4c06-9b4e-d2359bdc4ff5" xlink:to="loc_ocgn_PaycheckProtectionProgramLoanMember_e84dfd20-4499-45e0-bb9e-21533270956e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4753ef52-95bf-473b-85e2-70579fee9d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1f396d43-fc79-4a73-a4d4-112f9d2e403c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4753ef52-95bf-473b-85e2-70579fee9d89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4753ef52-95bf-473b-85e2-70579fee9d89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4753ef52-95bf-473b-85e2-70579fee9d89" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4753ef52-95bf-473b-85e2-70579fee9d89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dc6b0486-ce13-4c41-a588-ca50732c0516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4753ef52-95bf-473b-85e2-70579fee9d89" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dc6b0486-ce13-4c41-a588-ca50732c0516" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_8971f4df-481a-4872-afb4-41cef3359133" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dc6b0486-ce13-4c41-a588-ca50732c0516" xlink:to="loc_us-gaap_LoansPayableMember_8971f4df-481a-4872-afb4-41cef3359133" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#DebtEB5LoanAgreementBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails" xlink:type="extended" id="ifaf7a2d4578c4113b980efab999eba6d_DebtEB5LoanAgreementBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_36d63f37-9e62-438c-953e-875c9d40168c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2d1c9428-9817-45db-83da-4440dc579904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36d63f37-9e62-438c-953e-875c9d40168c" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2d1c9428-9817-45db-83da-4440dc579904" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LineOfCreditBorrowingEachDraw_d23f4821-e19c-484e-b5fe-dc0b3b40fe24" xlink:href="ocgn-20210930.xsd#ocgn_LineOfCreditBorrowingEachDraw"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36d63f37-9e62-438c-953e-875c9d40168c" xlink:to="loc_ocgn_LineOfCreditBorrowingEachDraw_d23f4821-e19c-484e-b5fe-dc0b3b40fe24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bcb8c0f6-e0fe-48cb-9e7c-e6beb671856d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36d63f37-9e62-438c-953e-875c9d40168c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bcb8c0f6-e0fe-48cb-9e7c-e6beb671856d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_1eddc74a-4e3b-4329-9b73-00e8c264eb20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36d63f37-9e62-438c-953e-875c9d40168c" xlink:to="loc_us-gaap_LineOfCredit_1eddc74a-4e3b-4329-9b73-00e8c264eb20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_08e9b238-053c-44ee-ae7f-acf41d507326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36d63f37-9e62-438c-953e-875c9d40168c" xlink:to="loc_us-gaap_DebtInstrumentTable_08e9b238-053c-44ee-ae7f-acf41d507326" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8dbb4e6e-f692-417c-ae38-7081afd0a1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_08e9b238-053c-44ee-ae7f-acf41d507326" xlink:to="loc_us-gaap_DebtInstrumentAxis_8dbb4e6e-f692-417c-ae38-7081afd0a1d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8dbb4e6e-f692-417c-ae38-7081afd0a1d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8dbb4e6e-f692-417c-ae38-7081afd0a1d3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8dbb4e6e-f692-417c-ae38-7081afd0a1d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_caa80f4b-3bff-4278-905b-f9daf82901b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8dbb4e6e-f692-417c-ae38-7081afd0a1d3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_caa80f4b-3bff-4278-905b-f9daf82901b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EB5ProgramBorrowingsMember_2d9222b3-c64d-43f5-91ab-ad5298c22ba8" xlink:href="ocgn-20210930.xsd#ocgn_EB5ProgramBorrowingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caa80f4b-3bff-4278-905b-f9daf82901b4" xlink:to="loc_ocgn_EB5ProgramBorrowingsMember_2d9222b3-c64d-43f5-91ab-ad5298c22ba8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6000bffa-eba9-4ce9-962c-382c15deefc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_08e9b238-053c-44ee-ae7f-acf41d507326" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6000bffa-eba9-4ce9-962c-382c15deefc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6000bffa-eba9-4ce9-962c-382c15deefc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6000bffa-eba9-4ce9-962c-382c15deefc5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6000bffa-eba9-4ce9-962c-382c15deefc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1772bab1-1c03-4930-9ae4-2f6885fcf9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6000bffa-eba9-4ce9-962c-382c15deefc5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1772bab1-1c03-4930-9ae4-2f6885fcf9b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_1fc24f82-06a5-4795-9d40-ffdc8e8e8851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1772bab1-1c03-4930-9ae4-2f6885fcf9b2" xlink:to="loc_us-gaap_LoansPayableMember_1fc24f82-06a5-4795-9d40-ffdc8e8e8851" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesoftheLoanAgreementBorrowingsDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#DebtSummaryoftheCarryingValuesoftheLoanAgreementBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesoftheLoanAgreementBorrowingsDetails" xlink:type="extended" id="idd8d5e5adcaa436a9d729545b69c1b08_DebtSummaryoftheCarryingValuesoftheLoanAgreementBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8e542761-a3fe-49f4-8a84-78cad1bb3231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ecd05e47-0a91-49b0-8abb-ff65d0eaee77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8e542761-a3fe-49f4-8a84-78cad1bb3231" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ecd05e47-0a91-49b0-8abb-ff65d0eaee77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_174b2bde-6782-4372-9f6e-5cf956c221e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8e542761-a3fe-49f4-8a84-78cad1bb3231" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_174b2bde-6782-4372-9f6e-5cf956c221e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_d1e1d7d9-4112-47d3-a549-31fcdd524033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8e542761-a3fe-49f4-8a84-78cad1bb3231" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_d1e1d7d9-4112-47d3-a549-31fcdd524033" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a6b5c201-9b40-4a96-9e11-755aea385bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8e542761-a3fe-49f4-8a84-78cad1bb3231" xlink:to="loc_us-gaap_LongTermDebt_a6b5c201-9b40-4a96-9e11-755aea385bb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e7966310-4d5e-4929-ae9b-e6202376652a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8e542761-a3fe-49f4-8a84-78cad1bb3231" xlink:to="loc_us-gaap_DebtInstrumentTable_e7966310-4d5e-4929-ae9b-e6202376652a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_39d06da8-7dd0-4706-9d76-2e1985c7cf21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e7966310-4d5e-4929-ae9b-e6202376652a" xlink:to="loc_us-gaap_DebtInstrumentAxis_39d06da8-7dd0-4706-9d76-2e1985c7cf21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_39d06da8-7dd0-4706-9d76-2e1985c7cf21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_39d06da8-7dd0-4706-9d76-2e1985c7cf21" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_39d06da8-7dd0-4706-9d76-2e1985c7cf21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f1cca789-3f53-427a-93a1-60e8a5f5cc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_39d06da8-7dd0-4706-9d76-2e1985c7cf21" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f1cca789-3f53-427a-93a1-60e8a5f5cc7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EB5ProgramBorrowingsMember_41d763d8-3284-49f5-95aa-5ab1399737d2" xlink:href="ocgn-20210930.xsd#ocgn_EB5ProgramBorrowingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f1cca789-3f53-427a-93a1-60e8a5f5cc7a" xlink:to="loc_ocgn_EB5ProgramBorrowingsMember_41d763d8-3284-49f5-95aa-5ab1399737d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_dd260377-ccbe-4ef0-b85c-c9ac23740d36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e7966310-4d5e-4929-ae9b-e6202376652a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_dd260377-ccbe-4ef0-b85c-c9ac23740d36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dd260377-ccbe-4ef0-b85c-c9ac23740d36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_dd260377-ccbe-4ef0-b85c-c9ac23740d36" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dd260377-ccbe-4ef0-b85c-c9ac23740d36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_01baa96f-3a8f-456f-9dca-46084bcf5d64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_dd260377-ccbe-4ef0-b85c-c9ac23740d36" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_01baa96f-3a8f-456f-9dca-46084bcf5d64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_0020f79d-6471-4bf1-b18e-9b9466277558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_01baa96f-3a8f-456f-9dca-46084bcf5d64" xlink:to="loc_us-gaap_LoansPayableMember_0020f79d-6471-4bf1-b18e-9b9466277558" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/EquityDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#EquityDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/EquityDetails" xlink:type="extended" id="i6ee33aa1fc4f4d20b28178b506064b97_EquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction_3151260c-9df3-463c-a13c-8d0a79c5a838" xlink:href="ocgn-20210930.xsd#ocgn_SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_ocgn_SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction_3151260c-9df3-463c-a13c-8d0a79c5a838" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7f077f98-5ab9-4968-898b-a4ac9a818309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7f077f98-5ab9-4968-898b-a4ac9a818309" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SaleOfStockAgreementToSellPricePerShare_5e369044-8afb-42be-b8e4-8c831ca62411" xlink:href="ocgn-20210930.xsd#ocgn_SaleOfStockAgreementToSellPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_ocgn_SaleOfStockAgreementToSellPricePerShare_5e369044-8afb-42be-b8e4-8c831ca62411" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_fcacf7d7-e351-4db9-8e09-c3aef4297ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_fcacf7d7-e351-4db9-8e09-c3aef4297ba5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SupplyAgreementNumberOfDoses_484ea425-1772-4d37-95a2-3ee848f566b6" xlink:href="ocgn-20210930.xsd#ocgn_SupplyAgreementNumberOfDoses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_ocgn_SupplyAgreementNumberOfDoses_484ea425-1772-4d37-95a2-3ee848f566b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_25720de1-168f-43f6-ba50-24544e8d0723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_25720de1-168f-43f6-ba50-24544e8d0723" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_2f6c41e6-2f9f-4223-8f19-bbe3f70a8bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_2f6c41e6-2f9f-4223-8f19-bbe3f70a8bf2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_PreferredStockMeasurementInput_cdc3c2e2-ed52-415c-b8f0-7355745b0c2c" xlink:href="ocgn-20210930.xsd#ocgn_PreferredStockMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_ocgn_PreferredStockMeasurementInput_cdc3c2e2-ed52-415c-b8f0-7355745b0c2c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d1d05dcc-8aed-41cf-ae68-1888f77d5da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d1d05dcc-8aed-41cf-ae68-1888f77d5da9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_cca127e8-5f25-4287-886f-6ba8eb178279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_cca127e8-5f25-4287-886f-6ba8eb178279" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5cde5232-6e54-4a03-92d1-090c7b1e3c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5cde5232-6e54-4a03-92d1-090c7b1e3c7f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_0b70be60-ee05-4bd5-9933-5c7eb35eb265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_0b70be60-ee05-4bd5-9933-5c7eb35eb265" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfAtTheMarketOfferings_d9bb620f-b08f-4bb5-bc2b-385737c0ead7" xlink:href="ocgn-20210930.xsd#ocgn_NumberOfAtTheMarketOfferings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_ocgn_NumberOfAtTheMarketOfferings_d9bb620f-b08f-4bb5-bc2b-385737c0ead7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SaleOfStockOutstandingObligationCancelledInExchangeForStock_1775cb4b-c8c6-4d82-baff-e328b338417c" xlink:href="ocgn-20210930.xsd#ocgn_SaleOfStockOutstandingObligationCancelledInExchangeForStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_ocgn_SaleOfStockOutstandingObligationCancelledInExchangeForStock_1775cb4b-c8c6-4d82-baff-e328b338417c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SaleOfStockAdditionalDebtCancelledInExchangeForStock_8e8c876d-5942-49b8-a250-8004f6fdf4bc" xlink:href="ocgn-20210930.xsd#ocgn_SaleOfStockAdditionalDebtCancelledInExchangeForStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_ocgn_SaleOfStockAdditionalDebtCancelledInExchangeForStock_8e8c876d-5942-49b8-a250-8004f6fdf4bc" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a4246d31-2c73-4c73-870e-8d6da41a4ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a4246d31-2c73-4c73-870e-8d6da41a4ec0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_246904e6-3907-494d-8065-d9b876683236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a4246d31-2c73-4c73-870e-8d6da41a4ec0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_246904e6-3907-494d-8065-d9b876683236" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_246904e6-3907-494d-8065-d9b876683236_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_246904e6-3907-494d-8065-d9b876683236" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_246904e6-3907-494d-8065-d9b876683236_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0438852-bfdd-49a1-a610-276f17112178" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_246904e6-3907-494d-8065-d9b876683236" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0438852-bfdd-49a1-a610-276f17112178" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_COVAXINPreferredStockPurchaseAgreementMember_b7eb979d-5e5f-485c-9c94-9d363f6b99b9" xlink:href="ocgn-20210930.xsd#ocgn_COVAXINPreferredStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0438852-bfdd-49a1-a610-276f17112178" xlink:to="loc_ocgn_COVAXINPreferredStockPurchaseAgreementMember_b7eb979d-5e5f-485c-9c94-9d363f6b99b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_RegisteredDirectOfferingMember_98ad90e5-21a4-4a99-abdf-7dc86cdd480d" xlink:href="ocgn-20210930.xsd#ocgn_RegisteredDirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0438852-bfdd-49a1-a610-276f17112178" xlink:to="loc_ocgn_RegisteredDirectOfferingMember_98ad90e5-21a4-4a99-abdf-7dc86cdd480d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ControlledEquityOfferingSalesAgreementMember_a30ec7a1-48dd-43e1-85ca-2dbc67a46fca" xlink:href="ocgn-20210930.xsd#ocgn_ControlledEquityOfferingSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0438852-bfdd-49a1-a610-276f17112178" xlink:to="loc_ocgn_ControlledEquityOfferingSalesAgreementMember_a30ec7a1-48dd-43e1-85ca-2dbc67a46fca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SubscriptionAgreementsMember_da5591fb-3272-4556-975a-2a5d7e627088" xlink:href="ocgn-20210930.xsd#ocgn_SubscriptionAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0438852-bfdd-49a1-a610-276f17112178" xlink:to="loc_ocgn_SubscriptionAgreementsMember_da5591fb-3272-4556-975a-2a5d7e627088" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8dfc0592-2e4f-44f0-bdaa-1ad3623b49a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a4246d31-2c73-4c73-870e-8d6da41a4ec0" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8dfc0592-2e4f-44f0-bdaa-1ad3623b49a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8dfc0592-2e4f-44f0-bdaa-1ad3623b49a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8dfc0592-2e4f-44f0-bdaa-1ad3623b49a2" xlink:to="loc_us-gaap_ClassOfStockDomain_8dfc0592-2e4f-44f0-bdaa-1ad3623b49a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fd906450-6fb1-43f3-accd-1e873bec09f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8dfc0592-2e4f-44f0-bdaa-1ad3623b49a2" xlink:to="loc_us-gaap_ClassOfStockDomain_fd906450-6fb1-43f3-accd-1e873bec09f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5e662022-b1f3-435f-82c4-4e2d76f00deb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_fd906450-6fb1-43f3-accd-1e873bec09f5" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5e662022-b1f3-435f-82c4-4e2d76f00deb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dcbc4753-dc9b-455c-8a57-2f6dfa8b300a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a4246d31-2c73-4c73-870e-8d6da41a4ec0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dcbc4753-dc9b-455c-8a57-2f6dfa8b300a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dcbc4753-dc9b-455c-8a57-2f6dfa8b300a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dcbc4753-dc9b-455c-8a57-2f6dfa8b300a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dcbc4753-dc9b-455c-8a57-2f6dfa8b300a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a98c6b9b-4b10-46ad-80e8-8a7dd849cb74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dcbc4753-dc9b-455c-8a57-2f6dfa8b300a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a98c6b9b-4b10-46ad-80e8-8a7dd849cb74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6aae88b3-fa34-4c8d-a9e3-7726dc2a8022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a98c6b9b-4b10-46ad-80e8-8a7dd849cb74" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6aae88b3-fa34-4c8d-a9e3-7726dc2a8022" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e1b2799b-b6f1-435d-a900-37e7790ccd48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a4246d31-2c73-4c73-870e-8d6da41a4ec0" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e1b2799b-b6f1-435d-a900-37e7790ccd48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e1b2799b-b6f1-435d-a900-37e7790ccd48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e1b2799b-b6f1-435d-a900-37e7790ccd48" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e1b2799b-b6f1-435d-a900-37e7790ccd48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_dbf820e0-db7c-4f8b-b8df-7a03098e26b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e1b2799b-b6f1-435d-a900-37e7790ccd48" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_dbf820e0-db7c-4f8b-b8df-7a03098e26b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_8ad9c0b5-b2f8-46d2-b814-771c1a6d047b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_dbf820e0-db7c-4f8b-b8df-7a03098e26b8" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_8ad9c0b5-b2f8-46d2-b814-771c1a6d047b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/WarrantsDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#WarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/WarrantsDetails" xlink:type="extended" id="iea3a223abfd343e5915d5aa363a7efab_WarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightExercisable_66395ac3-5eed-4e93-9eab-ca5bf62413ca" xlink:href="ocgn-20210930.xsd#ocgn_ClassOfWarrantOrRightExercisable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_ocgn_ClassOfWarrantOrRightExercisable_66395ac3-5eed-4e93-9eab-ca5bf62413ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightExpectedMilestonePayment_e22637d6-62d3-40af-8208-a77aaae1d418" xlink:href="ocgn-20210930.xsd#ocgn_ClassOfWarrantOrRightExpectedMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_ocgn_ClassOfWarrantOrRightExpectedMilestonePayment_e22637d6-62d3-40af-8208-a77aaae1d418" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ab53cce6-5d0c-4ee2-a6ef-b5f6e6d2d7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ab53cce6-5d0c-4ee2-a6ef-b5f6e6d2d7c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_12d655b6-9744-4cf4-a81e-64cd245d2263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_12d655b6-9744-4cf4-a81e-64cd245d2263" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfSeriesOfWarrantsIssued_0c560a68-3583-4eff-8795-f3a8a85653ae" xlink:href="ocgn-20210930.xsd#ocgn_NumberOfSeriesOfWarrantsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_ocgn_NumberOfSeriesOfWarrantsIssued_0c560a68-3583-4eff-8795-f3a8a85653ae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_55239496-d5ab-4bd2-87f8-afeca6f13b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_55239496-d5ab-4bd2-87f8-afeca6f13b62" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8c6e1289-fa3a-4312-b44b-eb0df1ebf5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8c6e1289-fa3a-4312-b44b-eb0df1ebf5bc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5330a6d7-7f12-40a1-a2b2-21fae342892f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5330a6d7-7f12-40a1-a2b2-21fae342892f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_a74ff2b4-017b-4985-8a84-1be30c31d1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_us-gaap_RepaymentsOfDebt_a74ff2b4-017b-4985-8a84-1be30c31d1a7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants_ef270760-65bc-415f-a990-27ea5f1a78aa" xlink:href="ocgn-20210930.xsd#ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants_ef270760-65bc-415f-a990-27ea5f1a78aa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock_00c795e7-36d8-4a7c-b16b-f9475673454d" xlink:href="ocgn-20210930.xsd#ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock_00c795e7-36d8-4a7c-b16b-f9475673454d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote_37cb21fd-b324-4a4d-acd2-338d1d63c6ae" xlink:href="ocgn-20210930.xsd#ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote_37cb21fd-b324-4a4d-acd2-338d1d63c6ae" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue_c62aea8d-3229-4e14-99bd-9e1dbc0af357" xlink:href="ocgn-20210930.xsd#ocgn_ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_ocgn_ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue_c62aea8d-3229-4e14-99bd-9e1dbc0af357" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfFormerEmployeesWithWarrants_fbd4d4cc-bb60-40b1-bfff-be710faa5af9" xlink:href="ocgn-20210930.xsd#ocgn_NumberOfFormerEmployeesWithWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_ocgn_NumberOfFormerEmployeesWithWarrants_fbd4d4cc-bb60-40b1-bfff-be710faa5af9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_2b31aa8a-05f3-4410-bc5b-39e97a4aa015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_2b31aa8a-05f3-4410-bc5b-39e97a4aa015" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_885de4a5-0bdf-40fe-bad3-f4f96aa5b9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2b31aa8a-05f3-4410-bc5b-39e97a4aa015" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_885de4a5-0bdf-40fe-bad3-f4f96aa5b9e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_885de4a5-0bdf-40fe-bad3-f4f96aa5b9e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_885de4a5-0bdf-40fe-bad3-f4f96aa5b9e0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_885de4a5-0bdf-40fe-bad3-f4f96aa5b9e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ce32ecf9-a5e6-4b9b-8660-a694805efdaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_885de4a5-0bdf-40fe-bad3-f4f96aa5b9e0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ce32ecf9-a5e6-4b9b-8660-a694805efdaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CanadaConsultingWarrantsMember_b85948b9-5945-4899-bc5a-d7df9a55cbd6" xlink:href="ocgn-20210930.xsd#ocgn_CanadaConsultingWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ce32ecf9-a5e6-4b9b-8660-a694805efdaa" xlink:to="loc_ocgn_CanadaConsultingWarrantsMember_b85948b9-5945-4899-bc5a-d7df9a55cbd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesAWarrantsMember_2557c176-97b9-448b-a632-16d86750f2be" xlink:href="ocgn-20210930.xsd#ocgn_SeriesAWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ce32ecf9-a5e6-4b9b-8660-a694805efdaa" xlink:to="loc_ocgn_SeriesAWarrantsMember_2557c176-97b9-448b-a632-16d86750f2be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesBWarrantsMember_3a9278e8-53b8-4a00-8d6d-b3042a05ff29" xlink:href="ocgn-20210930.xsd#ocgn_SeriesBWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ce32ecf9-a5e6-4b9b-8660-a694805efdaa" xlink:to="loc_ocgn_SeriesBWarrantsMember_3a9278e8-53b8-4a00-8d6d-b3042a05ff29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesCWarrantsMember_05f6daeb-a701-4710-9538-77b24ed5af2d" xlink:href="ocgn-20210930.xsd#ocgn_SeriesCWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ce32ecf9-a5e6-4b9b-8660-a694805efdaa" xlink:to="loc_ocgn_SeriesCWarrantsMember_05f6daeb-a701-4710-9538-77b24ed5af2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SPAWarrantsMember_58facf01-9d9a-493a-b3a6-815e19150626" xlink:href="ocgn-20210930.xsd#ocgn_SPAWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ce32ecf9-a5e6-4b9b-8660-a694805efdaa" xlink:to="loc_ocgn_SPAWarrantsMember_58facf01-9d9a-493a-b3a6-815e19150626" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_OpCoWarrantsMember_8615fdea-8f56-4ac1-84ba-9edc069fa2f2" xlink:href="ocgn-20210930.xsd#ocgn_OpCoWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ce32ecf9-a5e6-4b9b-8660-a694805efdaa" xlink:to="loc_ocgn_OpCoWarrantsMember_8615fdea-8f56-4ac1-84ba-9edc069fa2f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_fe62b6f6-3dba-46ea-bc47-c02d6a120a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2b31aa8a-05f3-4410-bc5b-39e97a4aa015" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_fe62b6f6-3dba-46ea-bc47-c02d6a120a4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe62b6f6-3dba-46ea-bc47-c02d6a120a4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fe62b6f6-3dba-46ea-bc47-c02d6a120a4e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe62b6f6-3dba-46ea-bc47-c02d6a120a4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_747ee14e-9f9f-49dd-8372-fc8a7599d6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fe62b6f6-3dba-46ea-bc47-c02d6a120a4e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_747ee14e-9f9f-49dd-8372-fc8a7599d6d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_WarrantsExchangedForCommonStockMember_f632c832-c618-4376-adf9-8caa99fd17aa" xlink:href="ocgn-20210930.xsd#ocgn_WarrantsExchangedForCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_747ee14e-9f9f-49dd-8372-fc8a7599d6d3" xlink:to="loc_ocgn_WarrantsExchangedForCommonStockMember_f632c832-c618-4376-adf9-8caa99fd17aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b64f8ce5-9abb-4f59-8e3e-12687be1cdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2b31aa8a-05f3-4410-bc5b-39e97a4aa015" xlink:to="loc_us-gaap_DebtInstrumentAxis_b64f8ce5-9abb-4f59-8e3e-12687be1cdd4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b64f8ce5-9abb-4f59-8e3e-12687be1cdd4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b64f8ce5-9abb-4f59-8e3e-12687be1cdd4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b64f8ce5-9abb-4f59-8e3e-12687be1cdd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bf02c857-36bf-4bbe-b6ac-6705a2ba544c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b64f8ce5-9abb-4f59-8e3e-12687be1cdd4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bf02c857-36bf-4bbe-b6ac-6705a2ba544c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_WarrantExchangePromissoryNotesMember_51326767-1b9e-48af-a2a8-3062b8b3ab31" xlink:href="ocgn-20210930.xsd#ocgn_WarrantExchangePromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bf02c857-36bf-4bbe-b6ac-6705a2ba544c" xlink:to="loc_ocgn_WarrantExchangePromissoryNotesMember_51326767-1b9e-48af-a2a8-3062b8b3ab31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6b31ea10-06fc-4727-8443-b5ac41f018f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2b31aa8a-05f3-4410-bc5b-39e97a4aa015" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6b31ea10-06fc-4727-8443-b5ac41f018f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6b31ea10-06fc-4727-8443-b5ac41f018f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6b31ea10-06fc-4727-8443-b5ac41f018f9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6b31ea10-06fc-4727-8443-b5ac41f018f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a6a0e057-c56b-4f31-8fad-1ad400e44d82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6b31ea10-06fc-4727-8443-b5ac41f018f9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a6a0e057-c56b-4f31-8fad-1ad400e44d82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_2b74ece8-63e4-4ab3-80d0-18e95c3444bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a6a0e057-c56b-4f31-8fad-1ad400e44d82" xlink:to="loc_us-gaap_NotesPayableToBanksMember_2b74ece8-63e4-4ab3-80d0-18e95c3444bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_addf8eaa-38d9-4b53-820d-23cc216aedc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2b31aa8a-05f3-4410-bc5b-39e97a4aa015" xlink:to="loc_us-gaap_FinancialInstrumentAxis_addf8eaa-38d9-4b53-820d-23cc216aedc8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_addf8eaa-38d9-4b53-820d-23cc216aedc8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_addf8eaa-38d9-4b53-820d-23cc216aedc8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_addf8eaa-38d9-4b53-820d-23cc216aedc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b2f9007-ab5d-4d3d-8d7c-9f32348ad1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_addf8eaa-38d9-4b53-820d-23cc216aedc8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b2f9007-ab5d-4d3d-8d7c-9f32348ad1ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_1eb899b5-bf79-4bf7-a6de-9295012abdce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b2f9007-ab5d-4d3d-8d7c-9f32348ad1ca" xlink:to="loc_us-gaap_WarrantMember_1eb899b5-bf79-4bf7-a6de-9295012abdce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4fcbbbb2-3845-4b91-8a54-9de213c6eb39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2b31aa8a-05f3-4410-bc5b-39e97a4aa015" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4fcbbbb2-3845-4b91-8a54-9de213c6eb39" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4fcbbbb2-3845-4b91-8a54-9de213c6eb39_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4fcbbbb2-3845-4b91-8a54-9de213c6eb39" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4fcbbbb2-3845-4b91-8a54-9de213c6eb39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6db44efb-f88b-428b-90d6-fa55fc430ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4fcbbbb2-3845-4b91-8a54-9de213c6eb39" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6db44efb-f88b-428b-90d6-fa55fc430ab0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_64d5d907-03bc-47d8-9d38-3799516e44d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6db44efb-f88b-428b-90d6-fa55fc430ab0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_64d5d907-03bc-47d8-9d38-3799516e44d6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#StockbasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails" xlink:type="extended" id="i3e1d104d71f74a59a35e5b1a0b3e8713_StockbasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cd949088-c067-4554-921d-55121c1de01c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d4567e03-e75b-42da-a6b1-33125cbe1559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cd949088-c067-4554-921d-55121c1de01c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d4567e03-e75b-42da-a6b1-33125cbe1559" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6627351-5477-416a-b206-9bd8349770c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cd949088-c067-4554-921d-55121c1de01c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6627351-5477-416a-b206-9bd8349770c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7d5f1c53-5935-44ce-aeb1-4c653306ab73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6627351-5477-416a-b206-9bd8349770c4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7d5f1c53-5935-44ce-aeb1-4c653306ab73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7d5f1c53-5935-44ce-aeb1-4c653306ab73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7d5f1c53-5935-44ce-aeb1-4c653306ab73" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7d5f1c53-5935-44ce-aeb1-4c653306ab73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9293a94c-2138-4767-a434-012c8dd36520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7d5f1c53-5935-44ce-aeb1-4c653306ab73" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9293a94c-2138-4767-a434-012c8dd36520" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_99eb5e01-78ac-41db-9e6e-7ac41ff62dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9293a94c-2138-4767-a434-012c8dd36520" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_99eb5e01-78ac-41db-9e6e-7ac41ff62dcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4838170e-9d18-4282-a704-f90e2165dd16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9293a94c-2138-4767-a434-012c8dd36520" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4838170e-9d18-4282-a704-f90e2165dd16" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#StockbasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails" xlink:type="extended" id="i5e39b424074a420191798d1c47731809_StockbasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9c89d94-5c2e-4b63-a1ee-7e02eec18fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_99cbada0-a2fd-4545-bdc3-d5aa4851b433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9c89d94-5c2e-4b63-a1ee-7e02eec18fb8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_99cbada0-a2fd-4545-bdc3-d5aa4851b433" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c4d4677c-f40c-45a9-afbe-a5c3df479500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9c89d94-5c2e-4b63-a1ee-7e02eec18fb8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c4d4677c-f40c-45a9-afbe-a5c3df479500" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_58f0c23f-bafa-4471-8f11-c2e85d47b361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9c89d94-5c2e-4b63-a1ee-7e02eec18fb8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_58f0c23f-bafa-4471-8f11-c2e85d47b361" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfEquityCompensationPlans_5adac12d-59f1-4ad1-a2ad-9c15eceaf0c5" xlink:href="ocgn-20210930.xsd#ocgn_NumberOfEquityCompensationPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9c89d94-5c2e-4b63-a1ee-7e02eec18fb8" xlink:to="loc_ocgn_NumberOfEquityCompensationPlans_5adac12d-59f1-4ad1-a2ad-9c15eceaf0c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_90aafc84-7d4f-46c0-a91a-beb80bb898be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9c89d94-5c2e-4b63-a1ee-7e02eec18fb8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_90aafc84-7d4f-46c0-a91a-beb80bb898be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber_38697ded-aa7c-439e-9780-a70e9ff11e1e" xlink:href="ocgn-20210930.xsd#ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9c89d94-5c2e-4b63-a1ee-7e02eec18fb8" xlink:to="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber_38697ded-aa7c-439e-9780-a70e9ff11e1e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_37f0455a-2b1a-4a47-adc4-a4ba6d0e4542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9c89d94-5c2e-4b63-a1ee-7e02eec18fb8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_37f0455a-2b1a-4a47-adc4-a4ba6d0e4542" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7c058d65-373e-4b82-8b91-e470b6c2e8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9c89d94-5c2e-4b63-a1ee-7e02eec18fb8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7c058d65-373e-4b82-8b91-e470b6c2e8b4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_e962e81c-b224-43c2-a946-fb255b3f5161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9c89d94-5c2e-4b63-a1ee-7e02eec18fb8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_e962e81c-b224-43c2-a946-fb255b3f5161" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ff7348c-1920-436e-864f-51f165cf73bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9c89d94-5c2e-4b63-a1ee-7e02eec18fb8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ff7348c-1920-436e-864f-51f165cf73bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_67667918-f674-4617-bcd2-0e5f40178296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ff7348c-1920-436e-864f-51f165cf73bd" xlink:to="loc_us-gaap_AwardTypeAxis_67667918-f674-4617-bcd2-0e5f40178296" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67667918-f674-4617-bcd2-0e5f40178296_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_67667918-f674-4617-bcd2-0e5f40178296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67667918-f674-4617-bcd2-0e5f40178296_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f88ca255-cf4f-4145-8e70-38521865ca27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_67667918-f674-4617-bcd2-0e5f40178296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f88ca255-cf4f-4145-8e70-38521865ca27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_08948111-297a-409c-a288-2ed9b49ede64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f88ca255-cf4f-4145-8e70-38521865ca27" xlink:to="loc_us-gaap_StockOptionMember_08948111-297a-409c-a288-2ed9b49ede64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_A2019PlanMember_2e4358d6-5262-4536-bed6-a6dc0c25e75c" xlink:href="ocgn-20210930.xsd#ocgn_A2019PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f88ca255-cf4f-4145-8e70-38521865ca27" xlink:to="loc_ocgn_A2019PlanMember_2e4358d6-5262-4536-bed6-a6dc0c25e75c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ShareBasedPaymentArrangementPerformanceBasedOptionMember_aae0deb8-4907-4831-8a6f-e91b1ebf9313" xlink:href="ocgn-20210930.xsd#ocgn_ShareBasedPaymentArrangementPerformanceBasedOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f88ca255-cf4f-4145-8e70-38521865ca27" xlink:to="loc_ocgn_ShareBasedPaymentArrangementPerformanceBasedOptionMember_aae0deb8-4907-4831-8a6f-e91b1ebf9313" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b0a1b482-df99-4f3e-8791-33b7f40702d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ff7348c-1920-436e-864f-51f165cf73bd" xlink:to="loc_us-gaap_PlanNameAxis_b0a1b482-df99-4f3e-8791-33b7f40702d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b0a1b482-df99-4f3e-8791-33b7f40702d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_b0a1b482-df99-4f3e-8791-33b7f40702d3" xlink:to="loc_us-gaap_PlanNameDomain_b0a1b482-df99-4f3e-8791-33b7f40702d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7152052e-5703-4896-b02f-6bc53e8cc298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_b0a1b482-df99-4f3e-8791-33b7f40702d3" xlink:to="loc_us-gaap_PlanNameDomain_7152052e-5703-4896-b02f-6bc53e8cc298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_A2014PlanMember_93428240-d62e-47cf-bd61-17e89f847fa4" xlink:href="ocgn-20210930.xsd#ocgn_A2014PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7152052e-5703-4896-b02f-6bc53e8cc298" xlink:to="loc_ocgn_A2014PlanMember_93428240-d62e-47cf-bd61-17e89f847fa4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_A2019PlanMember_9011eb2b-2a4d-4fd1-9ef1-9553738d94da" xlink:href="ocgn-20210930.xsd#ocgn_A2019PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7152052e-5703-4896-b02f-6bc53e8cc298" xlink:to="loc_ocgn_A2019PlanMember_9011eb2b-2a4d-4fd1-9ef1-9553738d94da" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofRSUActivityDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#StockbasedCompensationScheduleofRSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofRSUActivityDetails" xlink:type="extended" id="i6850f64d48724609bf256c9be423b9fd_StockbasedCompensationScheduleofRSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9949eecb-f09f-490b-a166-874dde361014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81fcb3e9-aaa0-4d23-8f64-d5fdc5710c57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9949eecb-f09f-490b-a166-874dde361014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81fcb3e9-aaa0-4d23-8f64-d5fdc5710c57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_441ee019-7d4e-47ce-8ade-6a3882d8e95c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81fcb3e9-aaa0-4d23-8f64-d5fdc5710c57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_441ee019-7d4e-47ce-8ade-6a3882d8e95c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2cceda5c-2b72-4898-92f9-c0f11b30bb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81fcb3e9-aaa0-4d23-8f64-d5fdc5710c57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2cceda5c-2b72-4898-92f9-c0f11b30bb5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7f7a48ce-6ad6-4e6b-946d-f0edbb2f25c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81fcb3e9-aaa0-4d23-8f64-d5fdc5710c57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7f7a48ce-6ad6-4e6b-946d-f0edbb2f25c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d0d734f1-fb7f-4f59-9a81-e7f4b854bf4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b6b2d5c-09e6-4df1-9213-f0983e3e7f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9949eecb-f09f-490b-a166-874dde361014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b6b2d5c-09e6-4df1-9213-f0983e3e7f89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c4104a5b-7e65-44b7-ba84-7baffbb72284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b6b2d5c-09e6-4df1-9213-f0983e3e7f89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c4104a5b-7e65-44b7-ba84-7baffbb72284" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f22deab9-54cf-4a80-911d-0cadfbe23839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b6b2d5c-09e6-4df1-9213-f0983e3e7f89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f22deab9-54cf-4a80-911d-0cadfbe23839" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fe3381c1-b973-4ed2-ba44-ed34f111a966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b6b2d5c-09e6-4df1-9213-f0983e3e7f89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fe3381c1-b973-4ed2-ba44-ed34f111a966" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_741d53d3-7183-4c09-8ec7-bd6826227aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_491cb183-70d8-47cb-9c6a-d7c6e8fc4534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9949eecb-f09f-490b-a166-874dde361014" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_491cb183-70d8-47cb-9c6a-d7c6e8fc4534" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_e8a0bfd8-f167-45ae-b306-c76adb2dddae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_491cb183-70d8-47cb-9c6a-d7c6e8fc4534" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_e8a0bfd8-f167-45ae-b306-c76adb2dddae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_a8309801-1902-4858-974b-2edce8a344fa" xlink:href="ocgn-20210930.xsd#ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_491cb183-70d8-47cb-9c6a-d7c6e8fc4534" xlink:to="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_a8309801-1902-4858-974b-2edce8a344fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod_12a92519-34d7-438b-bed5-6a41fbd9f417" xlink:href="ocgn-20210930.xsd#ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_491cb183-70d8-47cb-9c6a-d7c6e8fc4534" xlink:to="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod_12a92519-34d7-438b-bed5-6a41fbd9f417" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_c05c6054-fb5d-49a3-ae1a-05f712b6242c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6af7f36-ea26-456d-a761-662403e3fb02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9949eecb-f09f-490b-a166-874dde361014" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6af7f36-ea26-456d-a761-662403e3fb02" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4b34d7fe-28d5-4cc2-99ec-b68f3a294eac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6af7f36-ea26-456d-a761-662403e3fb02" xlink:to="loc_us-gaap_AwardTypeAxis_4b34d7fe-28d5-4cc2-99ec-b68f3a294eac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4b34d7fe-28d5-4cc2-99ec-b68f3a294eac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4b34d7fe-28d5-4cc2-99ec-b68f3a294eac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4b34d7fe-28d5-4cc2-99ec-b68f3a294eac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc12cde5-cb02-4995-b9b0-69dd9a5bba3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4b34d7fe-28d5-4cc2-99ec-b68f3a294eac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc12cde5-cb02-4995-b9b0-69dd9a5bba3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_247b4786-b3b3-4cbd-ae2a-8d1155b82634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc12cde5-cb02-4995-b9b0-69dd9a5bba3d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_247b4786-b3b3-4cbd-ae2a-8d1155b82634" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockPotentiallydilutivesecuritieshavebeenexcludedfromthecomputationofdilutedweightedaveragesharesoutstandingDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#NetLossPerShareofCommonStockPotentiallydilutivesecuritieshavebeenexcludedfromthecomputationofdilutedweightedaveragesharesoutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockPotentiallydilutivesecuritieshavebeenexcludedfromthecomputationofdilutedweightedaveragesharesoutstandingDetails" xlink:type="extended" id="id1f014d2a744401a9269409def4a40ce_NetLossPerShareofCommonStockPotentiallydilutivesecuritieshavebeenexcludedfromthecomputationofdilutedweightedaveragesharesoutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_827172aa-3291-4056-a20b-ff4eb58e7336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5fb3130b-dff8-4c00-8997-14fc5138bdec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_827172aa-3291-4056-a20b-ff4eb58e7336" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5fb3130b-dff8-4c00-8997-14fc5138bdec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c6d0274c-5dc9-4487-bc36-525972cadf3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_827172aa-3291-4056-a20b-ff4eb58e7336" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c6d0274c-5dc9-4487-bc36-525972cadf3a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1944a31a-2bc8-454e-9b6d-2755cf1c0471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c6d0274c-5dc9-4487-bc36-525972cadf3a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1944a31a-2bc8-454e-9b6d-2755cf1c0471" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1944a31a-2bc8-454e-9b6d-2755cf1c0471_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1944a31a-2bc8-454e-9b6d-2755cf1c0471" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1944a31a-2bc8-454e-9b6d-2755cf1c0471_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0bf93ae-d25a-4dae-a17f-ad8db1509970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1944a31a-2bc8-454e-9b6d-2755cf1c0471" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0bf93ae-d25a-4dae-a17f-ad8db1509970" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_5dce7596-d98d-4f18-9d25-97e121a2bb11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0bf93ae-d25a-4dae-a17f-ad8db1509970" xlink:to="loc_us-gaap_StockOptionMember_5dce7596-d98d-4f18-9d25-97e121a2bb11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7d631802-acfe-4ffe-a7f3-6b0d0a6c795d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0bf93ae-d25a-4dae-a17f-ad8db1509970" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7d631802-acfe-4ffe-a7f3-6b0d0a6c795d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b96c4dd8-c7a8-41f2-ad3b-a8819e7b1955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0bf93ae-d25a-4dae-a17f-ad8db1509970" xlink:to="loc_us-gaap_WarrantMember_b96c4dd8-c7a8-41f2-ad3b-a8819e7b1955" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_0c4fb03f-c574-4fc3-b686-1730c4ad97ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0bf93ae-d25a-4dae-a17f-ad8db1509970" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_0c4fb03f-c574-4fc3-b686-1730c4ad97ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_8b96cdff-044d-493a-9a5a-17d42e322ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0bf93ae-d25a-4dae-a17f-ad8db1509970" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_8b96cdff-044d-493a-9a5a-17d42e322ff7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.deitaxonomy.com/role/SubsequentEventsDetails" xlink:type="extended" id="i6c55ef1c404f411da60eff6ef92330d3_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_3b5dd883-6eb7-43e9-85b6-2bbb32f292d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ebed01fa-9e39-431d-b9e6-f311979e34b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3b5dd883-6eb7-43e9-85b6-2bbb32f292d1" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ebed01fa-9e39-431d-b9e6-f311979e34b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_BaseRentPaymentsExpectedCost_dd6510f1-b0bc-4d43-b0f0-111d8d5e5ee2" xlink:href="ocgn-20210930.xsd#ocgn_BaseRentPaymentsExpectedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3b5dd883-6eb7-43e9-85b6-2bbb32f292d1" xlink:to="loc_ocgn_BaseRentPaymentsExpectedCost_dd6510f1-b0bc-4d43-b0f0-111d8d5e5ee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfAdditionalLeaseAgreementExtensions_8bced8ec-de3a-4d55-907b-21aa5eec54a5" xlink:href="ocgn-20210930.xsd#ocgn_NumberOfAdditionalLeaseAgreementExtensions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3b5dd883-6eb7-43e9-85b6-2bbb32f292d1" xlink:to="loc_ocgn_NumberOfAdditionalLeaseAgreementExtensions_8bced8ec-de3a-4d55-907b-21aa5eec54a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement_f76490ab-d072-4edd-ae59-abc6e6c3a424" xlink:href="ocgn-20210930.xsd#ocgn_LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3b5dd883-6eb7-43e9-85b6-2bbb32f292d1" xlink:to="loc_ocgn_LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement_f76490ab-d072-4edd-ae59-abc6e6c3a424" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_a3140a9e-40ca-42bc-88ad-7c53db9bd6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_3b5dd883-6eb7-43e9-85b6-2bbb32f292d1" xlink:to="loc_us-gaap_SubsequentEventTable_a3140a9e-40ca-42bc-88ad-7c53db9bd6ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_cde4c73a-735a-48b1-9eea-942f3dbcd514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_a3140a9e-40ca-42bc-88ad-7c53db9bd6ba" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_cde4c73a-735a-48b1-9eea-942f3dbcd514" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cde4c73a-735a-48b1-9eea-942f3dbcd514_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cde4c73a-735a-48b1-9eea-942f3dbcd514" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cde4c73a-735a-48b1-9eea-942f3dbcd514_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e649ce3d-ace6-466c-8583-403def17f99b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cde4c73a-735a-48b1-9eea-942f3dbcd514" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e649ce3d-ace6-466c-8583-403def17f99b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_baf19a58-0fb1-41d7-a2e3-2f406f3adf52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e649ce3d-ace6-466c-8583-403def17f99b" xlink:to="loc_us-gaap_SubsequentEventMember_baf19a58-0fb1-41d7-a2e3-2f406f3adf52" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>ocgn-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:37cdbff3-15f4-4881-8cd5-68abc4a291de,g:c6584426-cf6c-4c9a-b04f-fdc200c901b8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_0d50b57a-b708-4d0d-b564-318ebae1320c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_AssetHeldForSalePolicyTextBlock_438ff6c6-e811-4de7-b345-2aa9694230b0_terseLabel_en-US" xlink:label="lab_ocgn_AssetHeldForSalePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Held for Sale</link:label>
    <link:label id="lab_ocgn_AssetHeldForSalePolicyTextBlock_label_en-US" xlink:label="lab_ocgn_AssetHeldForSalePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Held For Sale [Policy Text Block]</link:label>
    <link:label id="lab_ocgn_AssetHeldForSalePolicyTextBlock_documentation_en-US" xlink:label="lab_ocgn_AssetHeldForSalePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AssetHeldForSalePolicyTextBlock" xlink:href="ocgn-20210930.xsd#ocgn_AssetHeldForSalePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_AssetHeldForSalePolicyTextBlock" xlink:to="lab_ocgn_AssetHeldForSalePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8a719ee1-152e-4dde-8ff3-7df136ea4fda_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_1faca922-8577-4f2c-88ef-6eeecbf523c0_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_8d24f6d3-acf3-429f-9e77-217954699b6a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_1fc6da12-1041-4ded-a895-71192a50081c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_970634c0-9b04-4b64-b28f-e59c6c1af929_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_857ecd8a-0da7-4a0b-89d9-60c13744ddbf_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss - basic and diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_371d15cc-01ec-4736-ae54-2c6aef5978c2_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_41429b90-99c0-428f-95ed-73ecec1928ae_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_dd319b60-0535-456c-98d6-6e43c0882df3_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit and Disposal Activities</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_330cf1ed-97ee-4d06-a83d-dcbc613651f0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_dcecebbc-212b-40fb-8a03-3d6276f94ce0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_99787c5e-2e48-4b1f-a6d6-00de15cee0a1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_dffb76d4-9929-46fd-9b12-47dc63b3c1ca_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_41c8ff6b-03c0-4ea1-9f23-858a5188f734_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bef37c02-e338-4b44-88a1-a9e82088e702_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_2440170f-f469-484b-a8e4-9a1826a0d6a2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_6a68fe11-cf86-4c14-b82a-355c99b08ffd_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_f3bef231-bbf2-4a4d-a61f-6eaf021a0985_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9714958c-ab2a-4fcb-b141-8e79fbcaf7bf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease terms&#8212;operating leases (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_08888303-bc83-43a5-88d0-57b7d71c1adf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber_cf9066d7-ad68-418e-981e-f282a50741de_terseLabel_en-US" xlink:label="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options not yet exercisable (in shares)</link:label>
    <link:label id="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber_label_en-US" xlink:label="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Not Yet Exercisable, Number</link:label>
    <link:label id="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber_documentation_en-US" xlink:label="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Not Yet Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber" xlink:href="ocgn-20210930.xsd#ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber" xlink:to="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d3a7efcd-c13b-4aac-8e9c-428066a1bbfb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c837b929-6a7f-45da-9157-579e4f06b1ef_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e39c72ce-b94d-4929-b4f9-94340746b4e1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c565cec0-9c98-49a0-a086-722cdddbeb77_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0bca5966-ddd4-4624-af1a-13277bd6b3d4_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_WarrantsExchangedForCommonStockMember_be13232a-d886-45b5-a62f-cf6e5c4235c1_terseLabel_en-US" xlink:label="lab_ocgn_WarrantsExchangedForCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exchanged For Common Stock</link:label>
    <link:label id="lab_ocgn_WarrantsExchangedForCommonStockMember_label_en-US" xlink:label="lab_ocgn_WarrantsExchangedForCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exchanged For Common Stock [Member]</link:label>
    <link:label id="lab_ocgn_WarrantsExchangedForCommonStockMember_documentation_en-US" xlink:label="lab_ocgn_WarrantsExchangedForCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exchanged For Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_WarrantsExchangedForCommonStockMember" xlink:href="ocgn-20210930.xsd#ocgn_WarrantsExchangedForCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_WarrantsExchangedForCommonStockMember" xlink:to="lab_ocgn_WarrantsExchangedForCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_ad8aa09c-592c-4985-a74d-6b21aa487f60_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_8e45bafd-f076-43c9-8836-05d94e85340d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7abedb0f-9900-4432-b17e-fe0ef1c900e5_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_ddc2b2cb-0a48-41d1-96a8-949cbb1b18a6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding" xlink:to="lab_us-gaap_PreferredStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_aaf2d62e-2a02-49f8-b121-3e72492a8312_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0931e583-81d4-40ee-9169-19d108728fe9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive securities outstanding excluded from the computation of diluted weighted average shares outstanding</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d5db4b90-8a6a-4058-afa4-6e4ac34af8f4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate&#8212;operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_NumberOfVaccinationDoseRegimen_46b6b676-fdf7-49ee-9087-16568cfbfc68_terseLabel_en-US" xlink:label="lab_ocgn_NumberOfVaccinationDoseRegimen" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of vaccination dose regimen</link:label>
    <link:label id="lab_ocgn_NumberOfVaccinationDoseRegimen_label_en-US" xlink:label="lab_ocgn_NumberOfVaccinationDoseRegimen" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Vaccination Dose Regimen</link:label>
    <link:label id="lab_ocgn_NumberOfVaccinationDoseRegimen_documentation_en-US" xlink:label="lab_ocgn_NumberOfVaccinationDoseRegimen" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Vaccination Dose Regimen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfVaccinationDoseRegimen" xlink:href="ocgn-20210930.xsd#ocgn_NumberOfVaccinationDoseRegimen"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_NumberOfVaccinationDoseRegimen" xlink:to="lab_ocgn_NumberOfVaccinationDoseRegimen" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_cea759fb-e06c-4033-afa7-49e05a30268f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (in thousands)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4ccdb848-dfd7-483b-9974-764fdeb1a432_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_586b1d47-0a16-443e-8ca1-1fedb016bea9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_f3378c97-a3d9-48a8-bcbf-1eb4bfdbc1f1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForLoanLossesExpensed_da9e18a3-274d-4b0a-8846-9cb9b5be3ff6_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForLoanLossesExpensed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment on note receivable</link:label>
    <link:label id="lab_us-gaap_ProvisionForLoanLossesExpensed_label_en-US" xlink:label="lab_us-gaap_ProvisionForLoanLossesExpensed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Credit Loss, Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLoanLossesExpensed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForLoanLossesExpensed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForLoanLossesExpensed" xlink:to="lab_us-gaap_ProvisionForLoanLossesExpensed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_fe151ff7-d552-4db5-8207-97c1d8818d64_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f9264526-3164-42ce-a84f-38ec97b2b87f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_5a5fd8fb-8c63-4fbf-b036-4420490ac7d2_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_LesseeOperatingLeaseNumberOfRenewalTerms_8daabf59-87ce-456e-aa61-7cc5022e6190_terseLabel_en-US" xlink:label="lab_ocgn_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, number of renewal terms</link:label>
    <link:label id="lab_ocgn_LesseeOperatingLeaseNumberOfRenewalTerms_label_en-US" xlink:label="lab_ocgn_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number of Renewal Terms</link:label>
    <link:label id="lab_ocgn_LesseeOperatingLeaseNumberOfRenewalTerms_documentation_en-US" xlink:label="lab_ocgn_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number of Renewal Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:href="ocgn-20210930.xsd#ocgn_LesseeOperatingLeaseNumberOfRenewalTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:to="lab_ocgn_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_b07f95d1-c904-4b19-9dd4-4cbc658c96f6_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_b254fd25-e5aa-4d8c-8100-6b25a253ef11_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c1b74310-366b-49b9-8dd5-4abb4140a770_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_47b308f0-2293-4d9c-a0f9-1ccbfad882dd_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod_4b52d805-3562-4a31-ad33-389c069d1711_terseLabel_en-US" xlink:label="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, forfeited</link:label>
    <link:label id="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod_label_en-US" xlink:label="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Forfeitures In Period</link:label>
    <link:label id="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod_documentation_en-US" xlink:label="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Forfeitures In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod" xlink:href="ocgn-20210930.xsd#ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod" xlink:to="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_6f43de5c-c63b-4690-ae7e-54fe4ebf1116_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5d8bcd93-2894-44f1-bef6-639da52c6982_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_dd1d3b0e-4415-4e1d-b01c-614d2dfbd96c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_78559c47-9931-4b9b-8d07-7baac91e0e21_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c95f5a0f-3453-44d2-9e1b-b59b9b1858e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7ebb632d-65ad-4d83-8739-0c40b6000952_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_32b6f32c-d49c-4705-a617-a8e786ae2444_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_7d1ccb6c-0739-416c-a9f2-1d582dee2b58_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_53a34bb7-dd5b-4c8c-a298-eb878a632ffa_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0bc510e1-99d9-48e8-ae93-9e8d59e0e0ab_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11a4a255-04e2-46af-a882-24ff1fc2f6ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_aa1da084-8000-420e-9140-5100b51e743d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares, options outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20d35cb6-8d81-416d-b18c-5d52a493de54_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares, options outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_408310e9-5ddd-4be4-9f9e-6b958862bad3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f0336190-4e80-46e0-8329-a1628e84aa3b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_05a9585b-66e0-4bcb-a95b-ef6ee9fb7d52_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9bbdc783-3707-42c9-b5cd-e23ace8ecb18_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_e22a7ca9-df6d-44bc-8ad8-7a638afce5e9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c2f5f700-cb61-477b-8de7-f9b674161eb6_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue_a9a87e62-3c57-4469-8f5a-77858311ba5b_terseLabel_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of consideration transferred to settle warrants in excess of fair value of warrants</link:label>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue_label_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Consideration Transferred In Excess Of Fair Value</link:label>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue_documentation_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Consideration Transferred In Excess Of Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue" xlink:href="ocgn-20210930.xsd#ocgn_ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue" xlink:to="lab_ocgn_ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1db6cebb-4d98-4c53-8d83-91ce968d4678_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_AccruedLiabilitiesClinical_f635e7a9-4e9b-40d4-b857-4b70ce9a33df_terseLabel_en-US" xlink:label="lab_ocgn_AccruedLiabilitiesClinical" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical</link:label>
    <link:label id="lab_ocgn_AccruedLiabilitiesClinical_label_en-US" xlink:label="lab_ocgn_AccruedLiabilitiesClinical" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Clinical</link:label>
    <link:label id="lab_ocgn_AccruedLiabilitiesClinical_documentation_en-US" xlink:label="lab_ocgn_AccruedLiabilitiesClinical" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Clinical</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AccruedLiabilitiesClinical" xlink:href="ocgn-20210930.xsd#ocgn_AccruedLiabilitiesClinical"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_AccruedLiabilitiesClinical" xlink:to="lab_ocgn_AccruedLiabilitiesClinical" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightExpectedMilestonePayment_e532517f-caa3-4c53-9880-8bb51344ee6d_terseLabel_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightExpectedMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected milestone payment</link:label>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightExpectedMilestonePayment_label_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightExpectedMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Expected Milestone Payment</link:label>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightExpectedMilestonePayment_documentation_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightExpectedMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Expected Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightExpectedMilestonePayment" xlink:href="ocgn-20210930.xsd#ocgn_ClassOfWarrantOrRightExpectedMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ClassOfWarrantOrRightExpectedMilestonePayment" xlink:to="lab_ocgn_ClassOfWarrantOrRightExpectedMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_f9852650-a162-4bed-85ad-ccfbcd2cec7e_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_SeriesAWarrantsMember_0698659a-0f6a-4036-b7a7-6d790c9e2719_terseLabel_en-US" xlink:label="lab_ocgn_SeriesAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Warrants</link:label>
    <link:label id="lab_ocgn_SeriesAWarrantsMember_label_en-US" xlink:label="lab_ocgn_SeriesAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Warrants [Member]</link:label>
    <link:label id="lab_ocgn_SeriesAWarrantsMember_documentation_en-US" xlink:label="lab_ocgn_SeriesAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This member stands for Series A Warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesAWarrantsMember" xlink:href="ocgn-20210930.xsd#ocgn_SeriesAWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_SeriesAWarrantsMember" xlink:to="lab_ocgn_SeriesAWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_093b9426-888b-41d9-83f9-7d20d6cb7516_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ef1726b7-893a-487a-8f8e-3a644390ed16_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock_5527afe7-c359-4e60-a950-57f9721d06e4_terseLabel_en-US" xlink:label="lab_ocgn_SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information Related to Leases</link:label>
    <link:label id="lab_ocgn_SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock_label_en-US" xlink:label="lab_ocgn_SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information, Leases Disclosure [Table Text Block]</link:label>
    <link:label id="lab_ocgn_SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock_documentation_en-US" xlink:label="lab_ocgn_SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information, Leases Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock" xlink:href="ocgn-20210930.xsd#ocgn_SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock" xlink:to="lab_ocgn_SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_701551da-097b-4eb7-8bce-d1fbe905bc71_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease principal payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_217c4e00-afe1-4f91-a65d-27c8edcae37c_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_10f3c9b5-c644-438b-a539-1ae2134fc920_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_eb698305-f703-4213-a54a-a21b561f6655_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of common stock - basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_17c2ad22-7770-4bf7-b9c4-03ac0a3afa2e_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic and diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4c188519-dfc5-406c-a79a-e219502732ce_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_VaccinationDoseRegimenDurationApart_8008434b-4e28-4a41-bdca-8a3ff7973b7b_terseLabel_en-US" xlink:label="lab_ocgn_VaccinationDoseRegimenDurationApart" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaccination dose regimen, duration apart</link:label>
    <link:label id="lab_ocgn_VaccinationDoseRegimenDurationApart_label_en-US" xlink:label="lab_ocgn_VaccinationDoseRegimenDurationApart" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaccination Dose Regimen, Duration Apart</link:label>
    <link:label id="lab_ocgn_VaccinationDoseRegimenDurationApart_documentation_en-US" xlink:label="lab_ocgn_VaccinationDoseRegimenDurationApart" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaccination Dose Regimen, Duration Apart</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_VaccinationDoseRegimenDurationApart" xlink:href="ocgn-20210930.xsd#ocgn_VaccinationDoseRegimenDurationApart"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_VaccinationDoseRegimenDurationApart" xlink:to="lab_ocgn_VaccinationDoseRegimenDurationApart" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a3101c3b-cbf1-4899-bec6-87ba774db243_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_31d8889e-5796-4b86-bbb0-69ffb433da30_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1b27a5f5-ace8-43d5-bbd0-5caa0d09fcd7_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_SaleOfStockAgreementToSellPricePerShare_a882062f-632b-458a-802c-0ac79103350d_terseLabel_en-US" xlink:label="lab_ocgn_SaleOfStockAgreementToSellPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement to sell, price per share (in USD per share)</link:label>
    <link:label id="lab_ocgn_SaleOfStockAgreementToSellPricePerShare_label_en-US" xlink:label="lab_ocgn_SaleOfStockAgreementToSellPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Agreement to Sell, Price Per Share</link:label>
    <link:label id="lab_ocgn_SaleOfStockAgreementToSellPricePerShare_documentation_en-US" xlink:label="lab_ocgn_SaleOfStockAgreementToSellPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Agreement to Sell, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SaleOfStockAgreementToSellPricePerShare" xlink:href="ocgn-20210930.xsd#ocgn_SaleOfStockAgreementToSellPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_SaleOfStockAgreementToSellPricePerShare" xlink:to="lab_ocgn_SaleOfStockAgreementToSellPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_69e0717d-96ec-4269-9d43-c1f3a6d9212c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_06b2d118-5cd1-4415-ab3d-01adeeb93627_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_NumberOfSeriesOfWarrantsIssued_b6027e27-0956-4852-9d81-a4e1c604044f_terseLabel_en-US" xlink:label="lab_ocgn_NumberOfSeriesOfWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of series of warrants issued</link:label>
    <link:label id="lab_ocgn_NumberOfSeriesOfWarrantsIssued_label_en-US" xlink:label="lab_ocgn_NumberOfSeriesOfWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Series of Warrants Issued</link:label>
    <link:label id="lab_ocgn_NumberOfSeriesOfWarrantsIssued_documentation_en-US" xlink:label="lab_ocgn_NumberOfSeriesOfWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Series of Warrants Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfSeriesOfWarrantsIssued" xlink:href="ocgn-20210930.xsd#ocgn_NumberOfSeriesOfWarrantsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_NumberOfSeriesOfWarrantsIssued" xlink:to="lab_ocgn_NumberOfSeriesOfWarrantsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_7ce3e8bf-26c1-4a72-bac8-f54837d9ef55_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_17d41bbd-c33c-456a-93a2-2f0e23069bf5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_6893068e-256e-4604-8623-8dc13afa592a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_c94dba0e-123a-429c-b9ba-e9b5056f6e8e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees given notice of termination</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_8ba6f487-f119-4be7-98b6-c7df1d66df38_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1bd345ad-6c03-4525-9f66-138a355c25ba_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, vested in period, fair value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_82938a66-35fb-437d-9fd0-bf0c9063f129_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_51adb3e4-dbe5-46ce-b38f-38a581518ce6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total carrying value of debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_d71fccc2-0755-46cc-9f2d-fd390b2ac950_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_63226826-e165-4f5e-92d4-1ee47945f434_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_NonCashInterestExpense_2fccf43b-349a-40bb-92a3-d83643ae4513_terseLabel_en-US" xlink:label="lab_ocgn_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_ocgn_NonCashInterestExpense_label_en-US" xlink:label="lab_ocgn_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Expense</link:label>
    <link:label id="lab_ocgn_NonCashInterestExpense_documentation_en-US" xlink:label="lab_ocgn_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of non-cash interest expense during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NonCashInterestExpense" xlink:href="ocgn-20210930.xsd#ocgn_NonCashInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_NonCashInterestExpense" xlink:to="lab_ocgn_NonCashInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_cbca309b-3e84-47a0-95ef-b7cbaf3caa05_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote_4072c992-2eb1-401e-a4ed-c33a2b56033d_terseLabel_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred, warrant exchange promissory notes</link:label>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote_label_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Fair Value Of Consideration Transferred To Settle Warrants, Promissory Note</link:label>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote_documentation_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Fair Value Of Consideration Transferred To Settle Warrants, Promissory Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote" xlink:href="ocgn-20210930.xsd#ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote" xlink:to="lab_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_SingleGeneReplacementTherapiesNumberOfGeneticMutationsTarget_612057e6-51df-43aa-8625-3e88440e4cdf_terseLabel_en-US" xlink:label="lab_ocgn_SingleGeneReplacementTherapiesNumberOfGeneticMutationsTarget" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Single gene replacement therapies, number of genetic mutations target</link:label>
    <link:label id="lab_ocgn_SingleGeneReplacementTherapiesNumberOfGeneticMutationsTarget_label_en-US" xlink:label="lab_ocgn_SingleGeneReplacementTherapiesNumberOfGeneticMutationsTarget" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Single Gene Replacement Therapies, Number Of Genetic Mutations Target</link:label>
    <link:label id="lab_ocgn_SingleGeneReplacementTherapiesNumberOfGeneticMutationsTarget_documentation_en-US" xlink:label="lab_ocgn_SingleGeneReplacementTherapiesNumberOfGeneticMutationsTarget" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Single Gene Replacement Therapies, Number Of Genetic Mutations Target</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SingleGeneReplacementTherapiesNumberOfGeneticMutationsTarget" xlink:href="ocgn-20210930.xsd#ocgn_SingleGeneReplacementTherapiesNumberOfGeneticMutationsTarget"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_SingleGeneReplacementTherapiesNumberOfGeneticMutationsTarget" xlink:to="lab_ocgn_SingleGeneReplacementTherapiesNumberOfGeneticMutationsTarget" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_BaseRentPaymentsExpectedCost_d3e9c983-1612-4aa4-a378-45a9c2c54e40_terseLabel_en-US" xlink:label="lab_ocgn_BaseRentPaymentsExpectedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated base rent payments</link:label>
    <link:label id="lab_ocgn_BaseRentPaymentsExpectedCost_label_en-US" xlink:label="lab_ocgn_BaseRentPaymentsExpectedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rent Payments, Expected Cost</link:label>
    <link:label id="lab_ocgn_BaseRentPaymentsExpectedCost_documentation_en-US" xlink:label="lab_ocgn_BaseRentPaymentsExpectedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rent Payments, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_BaseRentPaymentsExpectedCost" xlink:href="ocgn-20210930.xsd#ocgn_BaseRentPaymentsExpectedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_BaseRentPaymentsExpectedCost" xlink:to="lab_ocgn_BaseRentPaymentsExpectedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0f2d4b8d-cc86-4901-bd8c-2effff96d41a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_c0a5b1af-dd60-48a9-af40-5cb1cb9bdfbe_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a46e9d2f-078b-4e78-b06f-c513de619a52_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_abd9de6b-cba6-45ec-9e40-19f61256565c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_NumberOfEquityCompensationPlans_5bbb49ed-62c4-410a-bb3b-e6ee6315afbe_terseLabel_en-US" xlink:label="lab_ocgn_NumberOfEquityCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of equity compensation plans</link:label>
    <link:label id="lab_ocgn_NumberOfEquityCompensationPlans_label_en-US" xlink:label="lab_ocgn_NumberOfEquityCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Equity Compensation Plans</link:label>
    <link:label id="lab_ocgn_NumberOfEquityCompensationPlans_documentation_en-US" xlink:label="lab_ocgn_NumberOfEquityCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Equity Compensation Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfEquityCompensationPlans" xlink:href="ocgn-20210930.xsd#ocgn_NumberOfEquityCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_NumberOfEquityCompensationPlans" xlink:to="lab_ocgn_NumberOfEquityCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_ee49d65e-3def-4db0-8301-559f85ccfea7_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing transactions:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost_44bc6809-837c-4d73-b73d-c3ff28a15d6a_terseLabel_en-US" xlink:label="lab_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity issuance costs</link:label>
    <link:label id="lab_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost_label_en-US" xlink:label="lab_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Or Part Noncash Amount of Deferred Transaction Cost</link:label>
    <link:label id="lab_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost_documentation_en-US" xlink:label="lab_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of noncash or part noncash amount of deferred transaction cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost" xlink:href="ocgn-20210930.xsd#ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost" xlink:to="lab_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bcf8ae34-0467-41b7-8931-d7e109cfa0d2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_0c07e59e-4d48-4cf4-9f27-a2aecfae9827_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share of Common Stock</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_2d6f99d0-e17f-4eeb-af21-ca19ef6c5017_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0ffba130-96d3-4b98-86d2-e1dd0211d63b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for option exercises</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement_d3ebaf88-7d3f-4a51-805c-952e2dc33c03_terseLabel_en-US" xlink:label="lab_ocgn_LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, term of contract for additional lease agreement</link:label>
    <link:label id="lab_ocgn_LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement_label_en-US" xlink:label="lab_ocgn_LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term Of Contract For Additional Lease Agreement</link:label>
    <link:label id="lab_ocgn_LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement_documentation_en-US" xlink:label="lab_ocgn_LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term Of Contract For Additional Lease Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement" xlink:href="ocgn-20210930.xsd#ocgn_LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement" xlink:to="lab_ocgn_LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_e9821a66-11bc-43ce-93ed-3f6567f0c107_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_GainLossOnForgivenessOfPaycheckProtectionProgramNote_b98713f4-9050-41b7-87b5-7fd5996f7fdb_terseLabel_en-US" xlink:label="lab_ocgn_GainLossOnForgivenessOfPaycheckProtectionProgramNote" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness of PPP Note</link:label>
    <link:label id="lab_ocgn_GainLossOnForgivenessOfPaycheckProtectionProgramNote_label_en-US" xlink:label="lab_ocgn_GainLossOnForgivenessOfPaycheckProtectionProgramNote" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Forgiveness Of Paycheck Protection Program Note</link:label>
    <link:label id="lab_ocgn_GainLossOnForgivenessOfPaycheckProtectionProgramNote_documentation_en-US" xlink:label="lab_ocgn_GainLossOnForgivenessOfPaycheckProtectionProgramNote" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Forgiveness Of Paycheck Protection Program Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_GainLossOnForgivenessOfPaycheckProtectionProgramNote" xlink:href="ocgn-20210930.xsd#ocgn_GainLossOnForgivenessOfPaycheckProtectionProgramNote"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_GainLossOnForgivenessOfPaycheckProtectionProgramNote" xlink:to="lab_ocgn_GainLossOnForgivenessOfPaycheckProtectionProgramNote" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_22943298-addc-4e41-9bbb-ddd59c6e80b6_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company borrowed</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7eba6a98-e866-4661-a8c2-0afad369cc1e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_436f8fb2-be52-4bc5-afa2-c17f9e436979_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_6d5d6db9-1ac1-4354-a8ca-4430a8d1d18c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, cancelled (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_9b49e9a0-2183-4c6a-9639-c2dc0a06696d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_97fd9937-ee0b-4d42-bc10-d0cf9f7b5dc4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_f41344cc-b7ba-4a01-8657-c3a6719ff3c2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_aa76e653-59d9-4fda-a9d2-1e068c99dbb6_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ATMTransactionsMember_80cd8971-261f-4b51-9827-0f255e26a138_terseLabel_en-US" xlink:label="lab_ocgn_ATMTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market Issuance</link:label>
    <link:label id="lab_ocgn_ATMTransactionsMember_label_en-US" xlink:label="lab_ocgn_ATMTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Transactions [Member]</link:label>
    <link:label id="lab_ocgn_ATMTransactionsMember_documentation_en-US" xlink:label="lab_ocgn_ATMTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ATMTransactionsMember" xlink:href="ocgn-20210930.xsd#ocgn_ATMTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ATMTransactionsMember" xlink:to="lab_ocgn_ATMTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_886969ba-22ad-4940-9302-0ee934dcb997_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_NumberOfAdditionalLeaseAgreementExtensions_f774fe35-9d1c-439b-aada-a9103cda06cd_terseLabel_en-US" xlink:label="lab_ocgn_NumberOfAdditionalLeaseAgreementExtensions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional lease agreement extensions</link:label>
    <link:label id="lab_ocgn_NumberOfAdditionalLeaseAgreementExtensions_label_en-US" xlink:label="lab_ocgn_NumberOfAdditionalLeaseAgreementExtensions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Additional Lease Agreement Extensions</link:label>
    <link:label id="lab_ocgn_NumberOfAdditionalLeaseAgreementExtensions_documentation_en-US" xlink:label="lab_ocgn_NumberOfAdditionalLeaseAgreementExtensions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Additional Lease Agreement Extensions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfAdditionalLeaseAgreementExtensions" xlink:href="ocgn-20210930.xsd#ocgn_NumberOfAdditionalLeaseAgreementExtensions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_NumberOfAdditionalLeaseAgreementExtensions" xlink:to="lab_ocgn_NumberOfAdditionalLeaseAgreementExtensions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_3a80a1f0-9fcd-4c26-904c-d6096161c482_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_7a02d749-ebe3-4008-a3f4-bcf2be228b80_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_AccruedLiabilitiesProfessionalFees_315373aa-b8c3-4819-85e3-2fd08b6d585c_terseLabel_en-US" xlink:label="lab_ocgn_AccruedLiabilitiesProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_ocgn_AccruedLiabilitiesProfessionalFees_label_en-US" xlink:label="lab_ocgn_AccruedLiabilitiesProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Professional Fees</link:label>
    <link:label id="lab_ocgn_AccruedLiabilitiesProfessionalFees_documentation_en-US" xlink:label="lab_ocgn_AccruedLiabilitiesProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AccruedLiabilitiesProfessionalFees" xlink:href="ocgn-20210930.xsd#ocgn_AccruedLiabilitiesProfessionalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_AccruedLiabilitiesProfessionalFees" xlink:to="lab_ocgn_AccruedLiabilitiesProfessionalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_582e6a64-904f-457b-84c7-0a727692d9a9_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_40b312f7-055a-496c-afd5-46ab413087ec_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_41622367-1e7d-41c3-a5fa-4a603e0d7176_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_a208548b-db46-4bee-ae01-6461d2cb8795_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_551703ea-05f5-4154-aee5-3bd98552497a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, options exercisable (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_48cf39c9-6e35-436b-8eb6-8445d3143b2a_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_0ed600ff-af4f-4eb9-90d3-c8f43924a29a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_16d66f7b-ff1b-4dfd-b67e-7265c707ce3c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_99960f5d-99cb-414b-bcfc-ba5ffe86b39e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock_9e4ee617-20e4-4909-a6b7-fc69a98cc7a9_terseLabel_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable</link:label>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock_label_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans, Notes, Trade and Other Receivables, Excluding Allowance for Credit Losses [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock" xlink:to="lab_us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_b1972ae9-4016-4c2a-9e45-6d984767c969_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_732ba6c4-cf9a-453b-a60d-a809378edc9e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_EfficacyAgainstDeltaVariantB16172Percent_f034dce0-6492-4d78-977a-9dac87aee61a_terseLabel_en-US" xlink:label="lab_ocgn_EfficacyAgainstDeltaVariantB16172Percent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Efficacy against delta variant, B.1.617.2 (percentage)</link:label>
    <link:label id="lab_ocgn_EfficacyAgainstDeltaVariantB16172Percent_label_en-US" xlink:label="lab_ocgn_EfficacyAgainstDeltaVariantB16172Percent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Efficacy Against Delta Variant, B.1.617.2, Percent</link:label>
    <link:label id="lab_ocgn_EfficacyAgainstDeltaVariantB16172Percent_documentation_en-US" xlink:label="lab_ocgn_EfficacyAgainstDeltaVariantB16172Percent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Efficacy Against Delta Variant, B.1.617.2, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EfficacyAgainstDeltaVariantB16172Percent" xlink:href="ocgn-20210930.xsd#ocgn_EfficacyAgainstDeltaVariantB16172Percent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_EfficacyAgainstDeltaVariantB16172Percent" xlink:to="lab_ocgn_EfficacyAgainstDeltaVariantB16172Percent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_52003a87-4620-4945-89af-1ed51498e9fe_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of equity issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4bed51a0-5b18-4302-8397-1e944d420816_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_0d010f9e-a562-4841-a70d-d8f88a3d55fd_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_ba6161f5-f360-4432-832c-397bb83cf053_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of minimum lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised_0874dfae-b3e8-4839-be98-66d0c0c7eeb6_terseLabel_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for option and warrant exercises (in shares)</link:label>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised_label_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Options And Warrants Exercised</link:label>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised_documentation_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Options And Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised" xlink:href="ocgn-20210930.xsd#ocgn_StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised" xlink:to="lab_ocgn_StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_1672adb9-8182-4800-9134-7074e0a6e5ad_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock; $0.01 par value; 295,000,000 and 200,000,000 shares authorized, 199,049,329 and 184,133,384 shares issued, and 198,927,829 and 184,011,884 shares outstanding at September&#160;30, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments_1e804122-5ee4-432a-b3f6-214d2f97b072_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend related to Warrant Exchange</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Dividends and Other Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_daf0fb8f-404f-4dc2-8a25-9ac622563554_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_10debc1b-ce55-4029-841d-83fd586a0eb6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense related to options outstanding, weighted average period for expense to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ccc264ed-55b8-4693-8bc7-b733c945f7c2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5cc04a94-c98e-40b5-b41b-e9e0005b6b26_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a6c23acf-0db7-4c77-88c0-de20acb6f3de_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_90fa1321-d533-457f-9737-498fee0fd921_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 13)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_15c7446f-467d-416d-b317-8bd67b8a29aa_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_a173c019-0fd9-4d91-80a8-15879ee7f2db_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_49fb7647-1a0a-40f8-a84b-2effa639c00a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada_96e088f3-6897-40a4-811c-05ba4e03c3b4_terseLabel_en-US" xlink:label="lab_ocgn_CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional payment</link:label>
    <link:label id="lab_ocgn_CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada_label_en-US" xlink:label="lab_ocgn_CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Additional Payment Within 30 Days Of First Commercial Sale In Canada</link:label>
    <link:label id="lab_ocgn_CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada_documentation_en-US" xlink:label="lab_ocgn_CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Additional Payment Within 30 Days Of First Commercial Sale In Canada</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada" xlink:href="ocgn-20210930.xsd#ocgn_CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada" xlink:to="lab_ocgn_CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_784bf810-b9b4-43e7-829b-006477a5ecdb_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_e2652f70-4a94-4528-be7a-7e957c74250a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6daf270b-24e8-471c-ad75-4cf7ce5c10eb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset_cad1c60e-09ea-45f4-9257-5b7422408e4e_terseLabel_en-US" xlink:label="lab_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset related to operating leases</link:label>
    <link:label id="lab_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash, Operating Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-to-use asset recognized upon adoption of ASU 2018-11.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset" xlink:href="ocgn-20210930.xsd#ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset" xlink:to="lab_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_cfc95676-1d72-4801-be1c-53e4e61ec23a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_AccruedSeveranceRelatedLiabilitiesCurrent_8cac603f-fa30-4bef-b308-5519aa25b07f_terseLabel_en-US" xlink:label="lab_ocgn_AccruedSeveranceRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance-related</link:label>
    <link:label id="lab_ocgn_AccruedSeveranceRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_ocgn_AccruedSeveranceRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Severance-Related Liabilities, Current</link:label>
    <link:label id="lab_ocgn_AccruedSeveranceRelatedLiabilitiesCurrent_documentation_en-US" xlink:label="lab_ocgn_AccruedSeveranceRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Severance-Related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AccruedSeveranceRelatedLiabilitiesCurrent" xlink:href="ocgn-20210930.xsd#ocgn_AccruedSeveranceRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_AccruedSeveranceRelatedLiabilitiesCurrent" xlink:to="lab_ocgn_AccruedSeveranceRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_d4a6b96c-99f2-497d-8c63-af3b63e5923b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_0d16a457-2bfc-473e-9498-8822209ad48f_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_652573e2-128e-4c92-a990-c2c62aa7cd59_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_ed77eb12-1e6c-467c-8b11-6776cc0ae6e5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e60ba79e-218d-41c4-bc1c-6d041eb55eec_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_39514df5-3bec-4339-aeac-9345a30a7215_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c4118f4b-1d3d-459e-b73a-2dfcebcd60aa_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_77fe1836-f44c-4a3d-85e9-491c903ecf3f_terseLabel_en-US" xlink:label="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, granted</link:label>
    <link:label id="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_label_en-US" xlink:label="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Granted</link:label>
    <link:label id="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_documentation_en-US" xlink:label="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:href="ocgn-20210930.xsd#ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:to="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_SaleOfStockOutstandingObligationCancelledInExchangeForStock_31f6ea65-c1a1-49c0-a730-b54e78f3498a_terseLabel_en-US" xlink:label="lab_ocgn_SaleOfStockOutstandingObligationCancelledInExchangeForStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accredited investors agreement to cancel outstanding obligation</link:label>
    <link:label id="lab_ocgn_SaleOfStockOutstandingObligationCancelledInExchangeForStock_label_en-US" xlink:label="lab_ocgn_SaleOfStockOutstandingObligationCancelledInExchangeForStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Outstanding Obligation Cancelled In Exchange For Stock</link:label>
    <link:label id="lab_ocgn_SaleOfStockOutstandingObligationCancelledInExchangeForStock_documentation_en-US" xlink:label="lab_ocgn_SaleOfStockOutstandingObligationCancelledInExchangeForStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Outstanding Obligation Cancelled In Exchange For Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SaleOfStockOutstandingObligationCancelledInExchangeForStock" xlink:href="ocgn-20210930.xsd#ocgn_SaleOfStockOutstandingObligationCancelledInExchangeForStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_SaleOfStockOutstandingObligationCancelledInExchangeForStock" xlink:to="lab_ocgn_SaleOfStockOutstandingObligationCancelledInExchangeForStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_A2014PlanMember_2f4580a7-8f05-4f67-b96b-3ebe3dea3f63_terseLabel_en-US" xlink:label="lab_ocgn_A2014PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Plan</link:label>
    <link:label id="lab_ocgn_A2014PlanMember_label_en-US" xlink:label="lab_ocgn_A2014PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Plan [Member]</link:label>
    <link:label id="lab_ocgn_A2014PlanMember_documentation_en-US" xlink:label="lab_ocgn_A2014PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_A2014PlanMember" xlink:href="ocgn-20210930.xsd#ocgn_A2014PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_A2014PlanMember" xlink:to="lab_ocgn_A2014PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9d3397d3-e150-46bf-995a-70194df59c33_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_48503d62-a6dd-4892-900d-e723eaf7e863_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_FinancingReceivableInterestRateStatedPercentage_c39ccdc2-c59f-4dcc-8425-93b3200ccad6_terseLabel_en-US" xlink:label="lab_ocgn_FinancingReceivableInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory note, interest rate</link:label>
    <link:label id="lab_ocgn_FinancingReceivableInterestRateStatedPercentage_label_en-US" xlink:label="lab_ocgn_FinancingReceivableInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_ocgn_FinancingReceivableInterestRateStatedPercentage_documentation_en-US" xlink:label="lab_ocgn_FinancingReceivableInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_FinancingReceivableInterestRateStatedPercentage" xlink:href="ocgn-20210930.xsd#ocgn_FinancingReceivableInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_FinancingReceivableInterestRateStatedPercentage" xlink:to="lab_ocgn_FinancingReceivableInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_4c2b2bd1-6ca8-48b0-a92c-4f5a276b6519_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commissions, fees and expenses</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_bfee5049-9caa-4d8e-aa6d-ef734650e472_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_50feabc4-5a26-46dd-bb5e-6010eaff50ec_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_d969b5c7-3f34-41c0-9c62-87572bb4bfa8_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_3fc1d658-170f-4cb7-bb5f-80554bdedb40_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_c63c987d-7b8c-4263-b4b9-2a90c1a47189_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d29d21e9-a685-48c7-b295-11372cd741e8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52647044-52a8-4f0d-b1c3-139ef3663215_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_559607cd-4d11-4eba-89de-621b07e816c3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease obligation</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_deed69df-ff68-486d-9d7e-74564585e4c2_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current lease obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_f0b3a283-8f1e-4a84-9203-971e9d496c6a_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Development Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_132463df-ab9f-4b80-9ce5-63f8ae512411_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25f23c2e-4fae-4e7e-94ec-095086719d4f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_99964ec4-1b08-483e-aa82-4aacf1be59fb_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f8039cfc-b064-4e95-93cb-0fa23237c59c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_332591a2-71cb-4f98-8623-c62001a7146a_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_4e3688e3-646b-4601-ba4a-cfae8d5a2c06_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_1775dd43-9ff0-4b88-9024-779b8fb0703f_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_NoncashLeaseExpense_351d207b-b2d5-4857-9556-5f906d2b418e_terseLabel_en-US" xlink:label="lab_ocgn_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_ocgn_NoncashLeaseExpense_label_en-US" xlink:label="lab_ocgn_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:label id="lab_ocgn_NoncashLeaseExpense_documentation_en-US" xlink:label="lab_ocgn_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NoncashLeaseExpense" xlink:href="ocgn-20210930.xsd#ocgn_NoncashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_NoncashLeaseExpense" xlink:to="lab_ocgn_NoncashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_4b1dbd32-e37f-46d8-9c9d-beaf1136dbf8_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_WarrantExchangePromissoryNotesMember_2c98bcaf-cbb2-4dc4-972f-22989ff7bee1_terseLabel_en-US" xlink:label="lab_ocgn_WarrantExchangePromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exchange Promissory Notes</link:label>
    <link:label id="lab_ocgn_WarrantExchangePromissoryNotesMember_label_en-US" xlink:label="lab_ocgn_WarrantExchangePromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exchange Promissory Notes [Member]</link:label>
    <link:label id="lab_ocgn_WarrantExchangePromissoryNotesMember_documentation_en-US" xlink:label="lab_ocgn_WarrantExchangePromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exchange Promissory Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_WarrantExchangePromissoryNotesMember" xlink:href="ocgn-20210930.xsd#ocgn_WarrantExchangePromissoryNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_WarrantExchangePromissoryNotesMember" xlink:to="lab_ocgn_WarrantExchangePromissoryNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_479ff6e8-9848-4f15-ad35-31083fee13b5_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_a1d08d86-8b78-478d-8965-d549a6eba7f5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plus: accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction_7c8072d1-e5c7-4152-a20f-971a2a755d65_terseLabel_en-US" xlink:label="lab_ocgn_SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement to sell, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_ocgn_SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_ocgn_SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Agreement to Sell, Number of Shares Issued in Transaction</link:label>
    <link:label id="lab_ocgn_SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction_documentation_en-US" xlink:label="lab_ocgn_SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Agreement to Sell, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction" xlink:href="ocgn-20210930.xsd#ocgn_SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction" xlink:to="lab_ocgn_SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93b1dd54-6636-4110-8a79-56f581308734_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_1595cafb-ace7-4ffe-9111-9e4c9f03a3c6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_e40d74a5-59b1-43b5-9103-baf24a03a719_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_78c72ff0-84a5-4585-aa2c-faf741c155ee_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligation settled with common stock</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b9fee81a-9f36-495a-ad59-f0e2225e4907_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_e46863d8-9034-45cf-832a-9b56456dacbd_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_748e1973-e5fa-4022-8bda-45d4ae45cc1c_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_3f872c40-4c82-4234-843f-bd363256151b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_ca810fa5-541c-426d-be16-26912b3223c7_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_03bf4c9d-83c4-4bef-8413-29f5932819f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5f32844f-54ef-404b-8d47-359ddb075820_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b253e2d1-c77f-4ddf-8f7f-664e0cf6c162_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ec5baa06-ff19-49fd-9fed-c8c5e8fd622f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c0183325-1243-459f-9980-c389d13ebc23_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_4fd1ffaa-a619-4040-bf63-179767c12a70_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesIssued1_cf652746-7e93-4bb8-8af4-8276b90b7000_terseLabel_en-US" xlink:label="lab_us-gaap_NotesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Warrant Exchange Promissory Notes</link:label>
    <link:label id="lab_us-gaap_NotesIssued1_label_en-US" xlink:label="lab_us-gaap_NotesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesIssued1" xlink:to="lab_us-gaap_NotesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_3b64e7e8-af5a-4b79-9aa8-f779cc48fde9_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d7273f76-3c9c-4e18-80d4-1d0be2835d16_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_83df753a-fceb-4918-94e0-57719e2b1f8d_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_WarrantsTextBlock_f6a5ce7f-4606-40b4-bcdc-a3d78cfbd943_terseLabel_en-US" xlink:label="lab_ocgn_WarrantsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_ocgn_WarrantsTextBlock_label_en-US" xlink:label="lab_ocgn_WarrantsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants [Text Block]</link:label>
    <link:label id="lab_ocgn_WarrantsTextBlock_documentation_en-US" xlink:label="lab_ocgn_WarrantsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_WarrantsTextBlock" xlink:href="ocgn-20210930.xsd#ocgn_WarrantsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_WarrantsTextBlock" xlink:to="lab_ocgn_WarrantsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_64b63155-c74e-4a5f-aa4e-c869d6bd8169_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_b8a8a16a-5571-49f4-8591-84b5adf102f6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_afe9df15-a188-4f34-8947-47df4311dd4f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_97b4fbb6-4e2a-4700-aed2-6ea44356e4d4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_SPAWarrantsMember_fb5e3343-f065-4420-bcce-df9c9ffdf8ef_terseLabel_en-US" xlink:label="lab_ocgn_SPAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPA Warrants</link:label>
    <link:label id="lab_ocgn_SPAWarrantsMember_label_en-US" xlink:label="lab_ocgn_SPAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPA Warrants [Member]</link:label>
    <link:label id="lab_ocgn_SPAWarrantsMember_documentation_en-US" xlink:label="lab_ocgn_SPAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPA Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SPAWarrantsMember" xlink:href="ocgn-20210930.xsd#ocgn_SPAWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_SPAWarrantsMember" xlink:to="lab_ocgn_SPAWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_5fd301d2-a41d-413e-ad2a-2f757407f104_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on forgiveness of PPP Note</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_767baf41-59c8-4009-b2fe-d1a6fb5f9f13_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ResearchAndDevelopmentExpensesCurrent_e274ae0f-e48a-4877-b5ff-3b7b35db1d6d_terseLabel_en-US" xlink:label="lab_ocgn_ResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research&#160;and development</link:label>
    <link:label id="lab_ocgn_ResearchAndDevelopmentExpensesCurrent_label_en-US" xlink:label="lab_ocgn_ResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expenses Current</link:label>
    <link:label id="lab_ocgn_ResearchAndDevelopmentExpensesCurrent_documentation_en-US" xlink:label="lab_ocgn_ResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ResearchAndDevelopmentExpensesCurrent" xlink:href="ocgn-20210930.xsd#ocgn_ResearchAndDevelopmentExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ResearchAndDevelopmentExpensesCurrent" xlink:to="lab_ocgn_ResearchAndDevelopmentExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_OverallVaccineEfficacyPercent_03d43bb5-dc43-4b30-a642-d4caa6879ce3_terseLabel_en-US" xlink:label="lab_ocgn_OverallVaccineEfficacyPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overall vaccine efficacy (percentage)</link:label>
    <link:label id="lab_ocgn_OverallVaccineEfficacyPercent_label_en-US" xlink:label="lab_ocgn_OverallVaccineEfficacyPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overall vaccine efficacy, Percent</link:label>
    <link:label id="lab_ocgn_OverallVaccineEfficacyPercent_documentation_en-US" xlink:label="lab_ocgn_OverallVaccineEfficacyPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overall vaccine efficacy, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_OverallVaccineEfficacyPercent" xlink:href="ocgn-20210930.xsd#ocgn_OverallVaccineEfficacyPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_OverallVaccineEfficacyPercent" xlink:to="lab_ocgn_OverallVaccineEfficacyPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_5ecd0c95-325f-4413-aa4d-9323d8bf4f6c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_a6257ee9-84ee-4a74-9b90-b434b4dd60ab_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_IssuanceOfFinancingReceivable_65cc05ca-dbab-499d-8508-129f3319738c_negatedTerseLabel_en-US" xlink:label="lab_ocgn_IssuanceOfFinancingReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of note receivable</link:label>
    <link:label id="lab_ocgn_IssuanceOfFinancingReceivable_label_en-US" xlink:label="lab_ocgn_IssuanceOfFinancingReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Financing Receivable</link:label>
    <link:label id="lab_ocgn_IssuanceOfFinancingReceivable_documentation_en-US" xlink:label="lab_ocgn_IssuanceOfFinancingReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Financing Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_IssuanceOfFinancingReceivable" xlink:href="ocgn-20210930.xsd#ocgn_IssuanceOfFinancingReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_IssuanceOfFinancingReceivable" xlink:to="lab_ocgn_IssuanceOfFinancingReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_adb807d4-0eff-4064-84fa-65454d692061_terseLabel_en-US" xlink:label="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, forfeited</link:label>
    <link:label id="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_label_en-US" xlink:label="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited in Period, Intrinsic Value</link:label>
    <link:label id="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_documentation_en-US" xlink:label="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" xlink:href="ocgn-20210930.xsd#ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" xlink:to="lab_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_327ae368-4a31-49c7-9edc-a7e012f065a3_terseLabel_en-US" xlink:label="lab_ocgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ocgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_ocgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:label id="lab_ocgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ocgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="ocgn-20210930.xsd#ocgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_ocgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_eae46e07-a5b3-4851-87e2-468aa8638daf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease obligation, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2c69df38-5513-4a34-a774-15945c5f5a5a_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current lease obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_bd48c3e9-b51a-497c-a8d3-6306210be6aa_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_a67181b7-ccc5-4341-83e6-941e619f494f_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_CanadaConsultingWarrantsMember_10afb8a6-38a4-48ca-b1f4-c965987c8508_terseLabel_en-US" xlink:label="lab_ocgn_CanadaConsultingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Consulting Warrants</link:label>
    <link:label id="lab_ocgn_CanadaConsultingWarrantsMember_label_en-US" xlink:label="lab_ocgn_CanadaConsultingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Consulting Warrants [Member]</link:label>
    <link:label id="lab_ocgn_CanadaConsultingWarrantsMember_documentation_en-US" xlink:label="lab_ocgn_CanadaConsultingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Consulting Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CanadaConsultingWarrantsMember" xlink:href="ocgn-20210930.xsd#ocgn_CanadaConsultingWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_CanadaConsultingWarrantsMember" xlink:to="lab_ocgn_CanadaConsultingWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_5b39fc70-f741-43c1-bbf3-1f28f33cadaa_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_63262360-4e29-4851-ac77-a924eaf22cc8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_d724d081-3df4-40e6-8d46-6bfda6034ab5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_4930949b-d245-4ad7-a73e-3f6a05ae0191_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, term of contract (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_45b2ea6e-f875-41ba-9042-9f0c1d6c210f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_803b9e64-5ddb-4501-8eb9-aea92e9e7e42_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_bd7961a3-74d0-4a21-b27d-a0b733d173e2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2e3a0e20-601b-43a7-b2d8-7ddcdf25747a_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_3952b976-db5e-45a3-aeec-3f17c2b26068_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_SupplyAgreementNumberOfDoses_cec3bd08-a12c-4ef0-bb58-c372864c5af3_terseLabel_en-US" xlink:label="lab_ocgn_SupplyAgreementNumberOfDoses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply agreement, number of doses</link:label>
    <link:label id="lab_ocgn_SupplyAgreementNumberOfDoses_label_en-US" xlink:label="lab_ocgn_SupplyAgreementNumberOfDoses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Agreement, Number of Doses</link:label>
    <link:label id="lab_ocgn_SupplyAgreementNumberOfDoses_documentation_en-US" xlink:label="lab_ocgn_SupplyAgreementNumberOfDoses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Agreement, Number of Doses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SupplyAgreementNumberOfDoses" xlink:href="ocgn-20210930.xsd#ocgn_SupplyAgreementNumberOfDoses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_SupplyAgreementNumberOfDoses" xlink:to="lab_ocgn_SupplyAgreementNumberOfDoses" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ModifierGeneTherapyPlatformNumberOfProducts_c2eb8528-04e8-4e9f-a07e-96f1417c68b6_terseLabel_en-US" xlink:label="lab_ocgn_ModifierGeneTherapyPlatformNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Modifier gene therapy platform, number of products</link:label>
    <link:label id="lab_ocgn_ModifierGeneTherapyPlatformNumberOfProducts_label_en-US" xlink:label="lab_ocgn_ModifierGeneTherapyPlatformNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Modifier Gene Therapy Platform, Number of Products</link:label>
    <link:label id="lab_ocgn_ModifierGeneTherapyPlatformNumberOfProducts_documentation_en-US" xlink:label="lab_ocgn_ModifierGeneTherapyPlatformNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Modifier Gene Therapy Platform, Number of Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ModifierGeneTherapyPlatformNumberOfProducts" xlink:href="ocgn-20210930.xsd#ocgn_ModifierGeneTherapyPlatformNumberOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ModifierGeneTherapyPlatformNumberOfProducts" xlink:to="lab_ocgn_ModifierGeneTherapyPlatformNumberOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_22a3946e-9a9c-49e2-97bd-54c62e2ee7aa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_MachineryMember_d39152f1-b6b6-4a97-9c2b-1250106d03a4_terseLabel_en-US" xlink:label="lab_ocgn_MachineryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery</link:label>
    <link:label id="lab_ocgn_MachineryMember_label_en-US" xlink:label="lab_ocgn_MachineryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery [Member]</link:label>
    <link:label id="lab_ocgn_MachineryMember_documentation_en-US" xlink:label="lab_ocgn_MachineryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_MachineryMember" xlink:href="ocgn-20210930.xsd#ocgn_MachineryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_MachineryMember" xlink:to="lab_ocgn_MachineryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c350387e-2404-4d89-9efd-a8a4d16ffb65_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c75f2d98-5fb8-488e-b6b0-9510f7e04e84_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2f5152f4-b50a-4ce0-ba9f-9dd5a196caba_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_2567a507-ed5c-453c-b0ec-a3c9531b9933_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_32b0fbcf-2e23-4114-840c-f320beb4903f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_bd7c04b3-5dbd-4cff-b6e0-811dbd0762ac_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_765e9313-8c20-4dde-a651-8a2073e14d65_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodSharesWarrantExchange_15e5126e-6a22-4df4-acb4-ed3f91747694_terseLabel_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodSharesWarrantExchange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exchange (in shares)</link:label>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodSharesWarrantExchange_label_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodSharesWarrantExchange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrant Exchange</link:label>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodSharesWarrantExchange_documentation_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodSharesWarrantExchange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrant Exchange</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodSharesWarrantExchange" xlink:href="ocgn-20210930.xsd#ocgn_StockIssuedDuringPeriodSharesWarrantExchange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_StockIssuedDuringPeriodSharesWarrantExchange" xlink:to="lab_ocgn_StockIssuedDuringPeriodSharesWarrantExchange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_19b80e8b-2cdc-4054-a409-d8b7ff223d63_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_a2282722-bcd4-4ff4-8e21-76d84086f98c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_6913583c-403a-46e0-af19-1c442f99e932_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9ff9d45c-e3c1-4e4b-96c1-578e753ad742_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_e8be246d-af03-4354-8599-929db6265aaa_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_COVAXINPreferredStockPurchaseAgreementMember_2fffa50e-aea6-4fcb-bc10-dc60e408bdb6_terseLabel_en-US" xlink:label="lab_ocgn_COVAXINPreferredStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVAXIN Preferred Stock Purchase Agreement</link:label>
    <link:label id="lab_ocgn_COVAXINPreferredStockPurchaseAgreementMember_label_en-US" xlink:label="lab_ocgn_COVAXINPreferredStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVAXIN Preferred Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_ocgn_COVAXINPreferredStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_ocgn_COVAXINPreferredStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVAXIN Preferred Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_COVAXINPreferredStockPurchaseAgreementMember" xlink:href="ocgn-20210930.xsd#ocgn_COVAXINPreferredStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_COVAXINPreferredStockPurchaseAgreementMember" xlink:to="lab_ocgn_COVAXINPreferredStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2b7ff076-bffd-4558-ba6d-cb3a5093282c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8f4911e3-a75a-458a-99a4-ddaea20f6652_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, grants in period, weighted average grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_03f6f036-acf1-4001-b14b-3fa1913228e7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants_e3333062-0547-4695-b7ed-392c22986024_terseLabel_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of consideration transferred to settle warrants</link:label>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants_label_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Fair Value Of Consideration Transferred To Settle Warrants</link:label>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants_documentation_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Fair Value Of Consideration Transferred To Settle Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants" xlink:href="ocgn-20210930.xsd#ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants" xlink:to="lab_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_813516f7-103f-49a8-aa5f-25138ed9d463_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_a5815e69-1d2c-4633-a169-7abdb9924c56_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable to Banks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableToBanksMember" xlink:to="lab_us-gaap_NotesPayableToBanksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_2552e7ae-f2fa-4ab2-b0ca-b9ba9ec5cd92_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_OpCoWarrantsMember_fa9d44ae-e735-472d-9b16-5b6228a39310_terseLabel_en-US" xlink:label="lab_ocgn_OpCoWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OpCo Warrants</link:label>
    <link:label id="lab_ocgn_OpCoWarrantsMember_label_en-US" xlink:label="lab_ocgn_OpCoWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OpCo Warrants [Member]</link:label>
    <link:label id="lab_ocgn_OpCoWarrantsMember_documentation_en-US" xlink:label="lab_ocgn_OpCoWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OpCo Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_OpCoWarrantsMember" xlink:href="ocgn-20210930.xsd#ocgn_OpCoWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_OpCoWarrantsMember" xlink:to="lab_ocgn_OpCoWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_75e2b4c0-7f2f-4f2c-8997-dd0d8946a223_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_25a68fff-08e6-4eab-8ed7-4b0caa9e54cb_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_EfficacySevereCasesPercent_fd4218cb-9e33-4633-af6b-bf0eb5dc9b2b_terseLabel_en-US" xlink:label="lab_ocgn_EfficacySevereCasesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Efficacy, severe cases (percentage)</link:label>
    <link:label id="lab_ocgn_EfficacySevereCasesPercent_label_en-US" xlink:label="lab_ocgn_EfficacySevereCasesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Efficacy, Severe Cases, Percent</link:label>
    <link:label id="lab_ocgn_EfficacySevereCasesPercent_documentation_en-US" xlink:label="lab_ocgn_EfficacySevereCasesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Efficacy, Severe Cases, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EfficacySevereCasesPercent" xlink:href="ocgn-20210930.xsd#ocgn_EfficacySevereCasesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_EfficacySevereCasesPercent" xlink:to="lab_ocgn_EfficacySevereCasesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_6ac1eefb-53b5-4aab-a0ca-b4b229ef0477_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_CollaborationAgreementUpfrontPayment_0f0a0e32-75cf-4734-a15a-67eec039d498_terseLabel_en-US" xlink:label="lab_ocgn_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_ocgn_CollaborationAgreementUpfrontPayment_label_en-US" xlink:label="lab_ocgn_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Upfront Payment</link:label>
    <link:label id="lab_ocgn_CollaborationAgreementUpfrontPayment_documentation_en-US" xlink:label="lab_ocgn_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementUpfrontPayment" xlink:href="ocgn-20210930.xsd#ocgn_CollaborationAgreementUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_CollaborationAgreementUpfrontPayment" xlink:to="lab_ocgn_CollaborationAgreementUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ae79fc06-b0b6-426b-844a-70e343843f50_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_RegisteredDirectOfferingMember_5c31d48d-2df7-4e01-b756-8c0aae93e19a_terseLabel_en-US" xlink:label="lab_ocgn_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering</link:label>
    <link:label id="lab_ocgn_RegisteredDirectOfferingMember_label_en-US" xlink:label="lab_ocgn_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
    <link:label id="lab_ocgn_RegisteredDirectOfferingMember_documentation_en-US" xlink:label="lab_ocgn_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_RegisteredDirectOfferingMember" xlink:href="ocgn-20210930.xsd#ocgn_RegisteredDirectOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_RegisteredDirectOfferingMember" xlink:to="lab_ocgn_RegisteredDirectOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_f0e7e0a0-260b-469f-aa38-11cecd562ae7_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_619e0f30-f65e-4822-887e-0d7106857a35_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Warrants</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock_ebef7bdb-a1f7-420a-90df-b5d1f3b9cb2b_terseLabel_en-US" xlink:label="lab_ocgn_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_ocgn_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock_label_en-US" xlink:label="lab_ocgn_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents, Restricted Cash [Table Text Block]</link:label>
    <link:label id="lab_ocgn_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock_documentation_en-US" xlink:label="lab_ocgn_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the components of cash and cash equivalents, restricted cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock" xlink:href="ocgn-20210930.xsd#ocgn_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock" xlink:to="lab_ocgn_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_09ed350a-3f9a-4967-b69f-f4c0b67859b4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_74413485-c0a6-4a09-a6c8-a22af8260113_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_f8b72961-47a0-4a3c-afdf-3855271f155b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e30032cb-5cd7-4070-bdc7-a1aa7aaa9ef4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2f11d45f-cdbc-4c58-b817-6adb5b2bb59f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3f9f0810-04d1-475d-a128-71cf0acd52f3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_bb67b28f-e6a3-4d23-8117-d156f16de4b5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_f8edc824-bfdf-4cc0-be56-813c31ad925a_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_NumberOfFormerEmployeesWithWarrants_a9d33817-9752-44cb-9b12-a23ea277b9c7_terseLabel_en-US" xlink:label="lab_ocgn_NumberOfFormerEmployeesWithWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of former employees with warrants</link:label>
    <link:label id="lab_ocgn_NumberOfFormerEmployeesWithWarrants_label_en-US" xlink:label="lab_ocgn_NumberOfFormerEmployeesWithWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Former Employees With Warrants</link:label>
    <link:label id="lab_ocgn_NumberOfFormerEmployeesWithWarrants_documentation_en-US" xlink:label="lab_ocgn_NumberOfFormerEmployeesWithWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Former Employees With Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfFormerEmployeesWithWarrants" xlink:href="ocgn-20210930.xsd#ocgn_NumberOfFormerEmployeesWithWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_NumberOfFormerEmployeesWithWarrants" xlink:to="lab_ocgn_NumberOfFormerEmployeesWithWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_421c6a3f-6786-4ea2-8a19-cddb7d99e0bd_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_11636812-b1aa-4c89-8840-8eb63770dd32_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_11b2c98b-c7db-4a45-bf31-0a3aea470362_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5c99531f-3086-464f-a2e3-63f49e4fcb37_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a32f35dc-f10b-4fa0-b7cf-acbe8d604f92_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b5fbd0d8-e76c-46c1-9404-4b3fbf4843fb_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_38f66ac2-6396-48d8-96e7-60d84c5a913d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense for Options Granted Reflected in the Consolidate Statement of Operations and Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_PreferredStockMeasurementInput_4cd8805c-e5b8-49f6-8e27-d7b5712af4bc_terseLabel_en-US" xlink:label="lab_ocgn_PreferredStockMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, measurement input</link:label>
    <link:label id="lab_ocgn_PreferredStockMeasurementInput_label_en-US" xlink:label="lab_ocgn_PreferredStockMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Measurement Input</link:label>
    <link:label id="lab_ocgn_PreferredStockMeasurementInput_documentation_en-US" xlink:label="lab_ocgn_PreferredStockMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_PreferredStockMeasurementInput" xlink:href="ocgn-20210930.xsd#ocgn_PreferredStockMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_PreferredStockMeasurementInput" xlink:to="lab_ocgn_PreferredStockMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvancesOnInventoryPurchases_97c742f6-e159-472d-a6f5-f1495e9c8e28_terseLabel_en-US" xlink:label="lab_us-gaap_AdvancesOnInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance for COVAXIN supply</link:label>
    <link:label id="lab_us-gaap_AdvancesOnInventoryPurchases_label_en-US" xlink:label="lab_us-gaap_AdvancesOnInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances on Inventory Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvancesOnInventoryPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvancesOnInventoryPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvancesOnInventoryPurchases" xlink:to="lab_us-gaap_AdvancesOnInventoryPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_d5855787-40a7-42d6-bb48-42fa0698a579_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_9e4c8a7a-7c42-4ae0-a49b-1314ec641cdd_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_be4048cc-5590-4bf9-85b3-ed5d90142bf0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_15202441-67df-4514-beb5-a49809c52123_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_NumberOfOrphanDrugDesignations_85f79d59-c412-41b2-af96-83867e928f72_terseLabel_en-US" xlink:label="lab_ocgn_NumberOfOrphanDrugDesignations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ODDs received (orphan drug designation)</link:label>
    <link:label id="lab_ocgn_NumberOfOrphanDrugDesignations_label_en-US" xlink:label="lab_ocgn_NumberOfOrphanDrugDesignations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Orphan Drug Designations</link:label>
    <link:label id="lab_ocgn_NumberOfOrphanDrugDesignations_documentation_en-US" xlink:label="lab_ocgn_NumberOfOrphanDrugDesignations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Orphan Drug Designations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfOrphanDrugDesignations" xlink:href="ocgn-20210930.xsd#ocgn_NumberOfOrphanDrugDesignations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_NumberOfOrphanDrugDesignations" xlink:to="lab_ocgn_NumberOfOrphanDrugDesignations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_d44a37ca-326f-4c72-8564-6bd9e746203d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_8e9bb458-2012-4d32-9b82-5cad145e88cc_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected severance benefits to be paid</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_AdverseEventsSideEffectsPercent_3c7b42ad-b7e8-4f39-bb03-36f9f25d7fa0_terseLabel_en-US" xlink:label="lab_ocgn_AdverseEventsSideEffectsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adverse events, side effects (percentage)</link:label>
    <link:label id="lab_ocgn_AdverseEventsSideEffectsPercent_label_en-US" xlink:label="lab_ocgn_AdverseEventsSideEffectsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adverse Events, Side Effects, Percent</link:label>
    <link:label id="lab_ocgn_AdverseEventsSideEffectsPercent_documentation_en-US" xlink:label="lab_ocgn_AdverseEventsSideEffectsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adverse Events, Side Effects, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AdverseEventsSideEffectsPercent" xlink:href="ocgn-20210930.xsd#ocgn_AdverseEventsSideEffectsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_AdverseEventsSideEffectsPercent" xlink:to="lab_ocgn_AdverseEventsSideEffectsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_0745f8ff-db98-4d16-a353-fb9c808b7827_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_PaycheckProtectionProgramLoanMember_1bd01ae4-8f30-4aec-acad-3fe279f3d0b7_terseLabel_en-US" xlink:label="lab_ocgn_PaycheckProtectionProgramLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPP Note</link:label>
    <link:label id="lab_ocgn_PaycheckProtectionProgramLoanMember_04da6070-bb0a-47a8-992f-db5da2a09860_verboseLabel_en-US" xlink:label="lab_ocgn_PaycheckProtectionProgramLoanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPP Note</link:label>
    <link:label id="lab_ocgn_PaycheckProtectionProgramLoanMember_label_en-US" xlink:label="lab_ocgn_PaycheckProtectionProgramLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program Loan [Member]</link:label>
    <link:label id="lab_ocgn_PaycheckProtectionProgramLoanMember_documentation_en-US" xlink:label="lab_ocgn_PaycheckProtectionProgramLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_PaycheckProtectionProgramLoanMember" xlink:href="ocgn-20210930.xsd#ocgn_PaycheckProtectionProgramLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_PaycheckProtectionProgramLoanMember" xlink:to="lab_ocgn_PaycheckProtectionProgramLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_bd2967c3-18c8-4341-a4bc-f779b3669b29_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ControlledEquityOfferingSalesAgreementMember_a1f104fc-c18c-4140-829a-90254155caea_terseLabel_en-US" xlink:label="lab_ocgn_ControlledEquityOfferingSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATMs</link:label>
    <link:label id="lab_ocgn_ControlledEquityOfferingSalesAgreementMember_label_en-US" xlink:label="lab_ocgn_ControlledEquityOfferingSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Controlled Equity Offering Sales Agreement [Member]</link:label>
    <link:label id="lab_ocgn_ControlledEquityOfferingSalesAgreementMember_documentation_en-US" xlink:label="lab_ocgn_ControlledEquityOfferingSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Controlled Equity Offering Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ControlledEquityOfferingSalesAgreementMember" xlink:href="ocgn-20210930.xsd#ocgn_ControlledEquityOfferingSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ControlledEquityOfferingSalesAgreementMember" xlink:to="lab_ocgn_ControlledEquityOfferingSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodValueWarrantExchange_f13af29a-e314-49ef-b6d6-d113a3e598a8_terseLabel_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodValueWarrantExchange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exchange</link:label>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodValueWarrantExchange_label_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodValueWarrantExchange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrant Exchange</link:label>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodValueWarrantExchange_documentation_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodValueWarrantExchange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrant Exchange</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodValueWarrantExchange" xlink:href="ocgn-20210930.xsd#ocgn_StockIssuedDuringPeriodValueWarrantExchange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_StockIssuedDuringPeriodValueWarrantExchange" xlink:to="lab_ocgn_StockIssuedDuringPeriodValueWarrantExchange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_ddb6d7eb-8047-4721-8043-0a3923f64f43_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease renewal term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_NumberOfAtTheMarketOfferings_65f257c7-2ea0-4844-bf42-2215c409ddcf_terseLabel_en-US" xlink:label="lab_ocgn_NumberOfAtTheMarketOfferings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of at-the-market offerings</link:label>
    <link:label id="lab_ocgn_NumberOfAtTheMarketOfferings_label_en-US" xlink:label="lab_ocgn_NumberOfAtTheMarketOfferings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of At-The-Market Offerings</link:label>
    <link:label id="lab_ocgn_NumberOfAtTheMarketOfferings_documentation_en-US" xlink:label="lab_ocgn_NumberOfAtTheMarketOfferings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of At-The-Market Offerings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfAtTheMarketOfferings" xlink:href="ocgn-20210930.xsd#ocgn_NumberOfAtTheMarketOfferings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_NumberOfAtTheMarketOfferings" xlink:to="lab_ocgn_NumberOfAtTheMarketOfferings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_5fb93d1e-47cd-4911-889b-c5b1f1fd63fe_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46183da0-3d8d-45bc-8199-58479843556a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_c005922c-3fb7-4043-939c-38707edb8fea_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4f598bfe-93ed-40f5-9d46-a45f5c76fe40_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_68925966-fb54-4c47-8ee9-8349a2c26e8c_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt, net</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_16fb0038-75b0-49b6-b7a5-2b3d86aee494_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_3a2536b8-3496-4301-9d03-c2f237cab8a5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_c34ac103-5128-48d1-ac38-b9de8452cb8b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_5bed7186-04e8-4088-b60f-9332f03ac6f5_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Lease Expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_91f142b4-5317-4565-b130-a046f8b17559_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_3a23ed27-6369-417d-bf17-42202a4ae5cf_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_500464d1-215b-4a87-bf6b-07a37caec02f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_8d1e0574-0eb3-4572-abea-a983597d016a_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_10084cfa-9ac4-43a6-9226-5cc28f502d86_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of common stock - diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a5aaad9f-4ac8-4226-9627-48591ae7f8c0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in calculating net loss per common share - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_f3caa09d-47f9-4e7c-9073-7b44b2e51369_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_76d27ee1-9ebf-4295-acfc-bb4089798603_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_aeed8365-16f7-40fb-8fe8-72f5fe6bc236_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_378f5ba6-be5f-4081-b70d-fe4eeb61233c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss and comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_14cad727-876d-4439-aced-927ece196465_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance-related charges</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_80e322db-66d2-4895-bd16-d22b1b38002a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_2765762f-3be1-4b8f-a046-03c023e17225_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost, 121,500 shares at September&#160;30, 2021 and December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_5f6a0419-1b27-425c-bf77-d72c2dbe436e_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5f996200-1cc0-4119-93eb-e80fe4f8dab0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_2b089249-99bc-4271-930f-ffd4475f53f3_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e70cd333-e674-4802-aee6-52db0902b6ba_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_SeriesBWarrantsMember_aaf25581-d4c2-42a1-a1af-5f900c5ee0be_terseLabel_en-US" xlink:label="lab_ocgn_SeriesBWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Warrants</link:label>
    <link:label id="lab_ocgn_SeriesBWarrantsMember_label_en-US" xlink:label="lab_ocgn_SeriesBWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Warrants [Member]</link:label>
    <link:label id="lab_ocgn_SeriesBWarrantsMember_documentation_en-US" xlink:label="lab_ocgn_SeriesBWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This member stands for Series B Warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesBWarrantsMember" xlink:href="ocgn-20210930.xsd#ocgn_SeriesBWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_SeriesBWarrantsMember" xlink:to="lab_ocgn_SeriesBWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2a64bb66-2501-46c2-8d26-a13048759e7f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_SaleOfStockAdditionalDebtCancelledInExchangeForStock_8a156d97-4fc3-4db4-b086-1beec91ac994_terseLabel_en-US" xlink:label="lab_ocgn_SaleOfStockAdditionalDebtCancelledInExchangeForStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accredited investors agreement to cancel additional portion owed representing a discount</link:label>
    <link:label id="lab_ocgn_SaleOfStockAdditionalDebtCancelledInExchangeForStock_label_en-US" xlink:label="lab_ocgn_SaleOfStockAdditionalDebtCancelledInExchangeForStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Additional Debt Cancelled In Exchange For Stock</link:label>
    <link:label id="lab_ocgn_SaleOfStockAdditionalDebtCancelledInExchangeForStock_documentation_en-US" xlink:label="lab_ocgn_SaleOfStockAdditionalDebtCancelledInExchangeForStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Additional Debt Cancelled In Exchange For Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SaleOfStockAdditionalDebtCancelledInExchangeForStock" xlink:href="ocgn-20210930.xsd#ocgn_SaleOfStockAdditionalDebtCancelledInExchangeForStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_SaleOfStockAdditionalDebtCancelledInExchangeForStock" xlink:to="lab_ocgn_SaleOfStockAdditionalDebtCancelledInExchangeForStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ed37ff49-780e-45d6-8b82-86f8d4ad62c8_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_LineOfCreditBorrowingEachDraw_a3fec257-3019-4b42-8013-5ea8cd9b643a_terseLabel_en-US" xlink:label="lab_ocgn_LineOfCreditBorrowingEachDraw" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing increments</link:label>
    <link:label id="lab_ocgn_LineOfCreditBorrowingEachDraw_label_en-US" xlink:label="lab_ocgn_LineOfCreditBorrowingEachDraw" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Borrowing Each Draw</link:label>
    <link:label id="lab_ocgn_LineOfCreditBorrowingEachDraw_documentation_en-US" xlink:label="lab_ocgn_LineOfCreditBorrowingEachDraw" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of borrowing that can be borrowed each draw from a line of credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LineOfCreditBorrowingEachDraw" xlink:href="ocgn-20210930.xsd#ocgn_LineOfCreditBorrowingEachDraw"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_LineOfCreditBorrowingEachDraw" xlink:to="lab_ocgn_LineOfCreditBorrowingEachDraw" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_53fe7f65-b88f-4e11-81fc-9874e9cc039d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodValueOptionsAndWarrantsExercised_60ddf4bc-6465-49ff-9056-a11bccb4c6db_terseLabel_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodValueOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for option and warrant exercises</link:label>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodValueOptionsAndWarrantsExercised_label_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodValueOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Options And Warrants Exercised</link:label>
    <link:label id="lab_ocgn_StockIssuedDuringPeriodValueOptionsAndWarrantsExercised_documentation_en-US" xlink:label="lab_ocgn_StockIssuedDuringPeriodValueOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Options And Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodValueOptionsAndWarrantsExercised" xlink:href="ocgn-20210930.xsd#ocgn_StockIssuedDuringPeriodValueOptionsAndWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_StockIssuedDuringPeriodValueOptionsAndWarrantsExercised" xlink:to="lab_ocgn_StockIssuedDuringPeriodValueOptionsAndWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxCreditsAndAdjustments_7386d8c8-af13-45bb-ba69-92d8504c6ca2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxCreditsAndAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Credits and Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:to="lab_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock_91e8473c-a16d-4ea3-a2e6-edfe6fe4dbb3_terseLabel_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred, common stock</link:label>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock_label_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Fair Value Of Consideration Transferred To Settle Warrants, Common Stock</link:label>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock_documentation_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Fair Value Of Consideration Transferred To Settle Warrants, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock" xlink:href="ocgn-20210930.xsd#ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock" xlink:to="lab_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_ec3dd216-c6f4-44d2-a832-02b7410b0c3e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_428aeff6-5c76-4084-8d21-e2c1461f9c45_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_03dbd478-cdf3-406f-9bbe-aa44c9c89fea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_4c27a6ff-c8c2-44b4-b200-e582db690d43_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_8d94592c-b6fe-46cf-acff-267dfd851cfa_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Components of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_112d446e-e217-404c-8a1a-17cb42e71315_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2a443f7d-59bb-459a-b08c-771b787551c6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_b6b6664e-e0c9-4b0e-84b8-03a6e04042b1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightExercisable_f4c7d323-031e-4229-bd1c-b495943a88d4_terseLabel_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, exercisable (in shares)</link:label>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightExercisable_label_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercisable</link:label>
    <link:label id="lab_ocgn_ClassOfWarrantOrRightExercisable_documentation_en-US" xlink:label="lab_ocgn_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightExercisable" xlink:href="ocgn-20210930.xsd#ocgn_ClassOfWarrantOrRightExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ClassOfWarrantOrRightExercisable" xlink:to="lab_ocgn_ClassOfWarrantOrRightExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_A2019PlanMember_8b0ec5f2-efac-492e-a3d7-b413d80395e7_terseLabel_en-US" xlink:label="lab_ocgn_A2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Plan</link:label>
    <link:label id="lab_ocgn_A2019PlanMember_label_en-US" xlink:label="lab_ocgn_A2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Plan [Member]</link:label>
    <link:label id="lab_ocgn_A2019PlanMember_documentation_en-US" xlink:label="lab_ocgn_A2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_A2019PlanMember" xlink:href="ocgn-20210930.xsd#ocgn_A2019PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_A2019PlanMember" xlink:to="lab_ocgn_A2019PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_d8b8cc88-70b4-4c23-8913-f7db4a244e42_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_0f0b7ca7-513f-467a-9f85-938e82bdda36_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_ec38b1fa-ea93-47f6-872e-96e08689cd31_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_770d5a6a-cc98-48c2-8431-bccf4f6b69fe_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_8715ebcc-7326-4059-a170-f435f97319b3_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covaxin Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_97f2a74c-8644-4790-aea7-b249558a1c05_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_d0bfa7a6-00b2-4d8a-a17c-dc8cc44665c0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_df950f16-a1c6-4e84-b3b4-dc92c7f5433d_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_78d34f58-2d4e-4276-8457-a2e9ba656722_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_719ba624-c500-4dd4-a5ce-c916b167d937_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_69d5eb2b-68d9-4f46-8a5e-4ed73db8abf6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock issuance</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b353eb26-15f6-4c2d-8715-79c0f9e7cb95_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial exercise price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_8223cc4e-b747-4f74-93cf-9f14a6f0bff2_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_338c70cd-cf6a-4ce9-8a61-6815d4a85639_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, weighted average exercise price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f480359a-3ef4-45df-9830-78107a5ae1b0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, weighted average exercise price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_74992564-015d-4b18-8286-af84e2b1cdf2_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_f8e0a285-b5df-4f8a-91c8-5530b6bef0fb_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_CollaborationAgreementTerm_d7da66f3-dbe5-4196-a5da-43e3495f936c_terseLabel_en-US" xlink:label="lab_ocgn_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Term</link:label>
    <link:label id="lab_ocgn_CollaborationAgreementTerm_label_en-US" xlink:label="lab_ocgn_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Term</link:label>
    <link:label id="lab_ocgn_CollaborationAgreementTerm_documentation_en-US" xlink:label="lab_ocgn_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementTerm" xlink:href="ocgn-20210930.xsd#ocgn_CollaborationAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_CollaborationAgreementTerm" xlink:to="lab_ocgn_CollaborationAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_8327c66f-9185-47ac-b82a-815e012b5d61_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_10fec807-3b27-4092-8c18-1409286aca01_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_9f1b2447-fe2b-4510-8ff7-71dd6d343e91_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life, options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_SubscriptionAgreementsAndWarrantExercisesMember_a11c7b98-62b5-4a82-b54d-b1e6efe29d08_terseLabel_en-US" xlink:label="lab_ocgn_SubscriptionAgreementsAndWarrantExercisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subscription Agreements and Warrant Exercises</link:label>
    <link:label id="lab_ocgn_SubscriptionAgreementsAndWarrantExercisesMember_label_en-US" xlink:label="lab_ocgn_SubscriptionAgreementsAndWarrantExercisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subscription Agreements And Warrant Exercises [Member]</link:label>
    <link:label id="lab_ocgn_SubscriptionAgreementsAndWarrantExercisesMember_documentation_en-US" xlink:label="lab_ocgn_SubscriptionAgreementsAndWarrantExercisesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subscription Agreements And Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SubscriptionAgreementsAndWarrantExercisesMember" xlink:href="ocgn-20210930.xsd#ocgn_SubscriptionAgreementsAndWarrantExercisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_SubscriptionAgreementsAndWarrantExercisesMember" xlink:to="lab_ocgn_SubscriptionAgreementsAndWarrantExercisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_66f443e0-b7a3-4126-aa66-274d4e6733e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant-Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_84ddd7c0-bd37-407c-b896-428829b981c1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_dcc50cdf-7c20-410e-8c85-4b10773b9c72_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares issued upon conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_a9415183-dba8-4ae5-b590-48888eb3a815_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_SeriesCWarrantsMember_ee2c66db-12eb-4e2d-ad4e-124aa4bd9f06_terseLabel_en-US" xlink:label="lab_ocgn_SeriesCWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Warrants</link:label>
    <link:label id="lab_ocgn_SeriesCWarrantsMember_label_en-US" xlink:label="lab_ocgn_SeriesCWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Warrants [Member]</link:label>
    <link:label id="lab_ocgn_SeriesCWarrantsMember_documentation_en-US" xlink:label="lab_ocgn_SeriesCWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This member stands for Series C Warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesCWarrantsMember" xlink:href="ocgn-20210930.xsd#ocgn_SeriesCWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_SeriesCWarrantsMember" xlink:to="lab_ocgn_SeriesCWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_IncreaseDecreaseInLeaseObligations_d0c4fa4b-d16f-4f6c-86ab-0349dc5c7dfb_terseLabel_en-US" xlink:label="lab_ocgn_IncreaseDecreaseInLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease obligations</link:label>
    <link:label id="lab_ocgn_IncreaseDecreaseInLeaseObligations_label_en-US" xlink:label="lab_ocgn_IncreaseDecreaseInLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Lease Obligations</link:label>
    <link:label id="lab_ocgn_IncreaseDecreaseInLeaseObligations_documentation_en-US" xlink:label="lab_ocgn_IncreaseDecreaseInLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Lease Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_IncreaseDecreaseInLeaseObligations" xlink:href="ocgn-20210930.xsd#ocgn_IncreaseDecreaseInLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_IncreaseDecreaseInLeaseObligations" xlink:to="lab_ocgn_IncreaseDecreaseInLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_EB5ProgramBorrowingsMember_48e27022-3135-4e82-ac86-5070baf41e1d_terseLabel_en-US" xlink:label="lab_ocgn_EB5ProgramBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EB-5 Loan Agreement</link:label>
    <link:label id="lab_ocgn_EB5ProgramBorrowingsMember_label_en-US" xlink:label="lab_ocgn_EB5ProgramBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E B5 Program Borrowings [Member]</link:label>
    <link:label id="lab_ocgn_EB5ProgramBorrowingsMember_documentation_en-US" xlink:label="lab_ocgn_EB5ProgramBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents borrowings from the U.S. government's Immigrant Investor Program, commonly known as the EB 5 program (the "EB 5 Program").</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EB5ProgramBorrowingsMember" xlink:href="ocgn-20210930.xsd#ocgn_EB5ProgramBorrowingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_EB5ProgramBorrowingsMember" xlink:to="lab_ocgn_EB5ProgramBorrowingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_5da20051-ba79-4959-9e3f-fb5565d56448_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_c599be0b-1529-41c6-8325-298924e73a8c_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9370b0f7-9bf9-4530-bc27-f7e591b9a66f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9ab8db3f-9f21-4b51-84a9-ae42ec097768_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d5da60bb-6ea4-4a4c-bd51-3460756ed600_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_678ed744-a981-4a29-aa2c-592dd7da462b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fa3e320c-7995-4f32-aa7a-bae2ea0893e7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued and sold</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_90ef0c95-8b36-4501-98b7-728109c74f76_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_d68009e4-7d75-41f4-9fd3-dac8caf18cb6_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b7823018-4b94-4505-8d7b-602b0c9705d3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_48f9db4b-a0e7-4570-be08-41357bb974b3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_0c229a7d-d677-4f74-b6d0-8d342c4d9b93_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_4f5b2c59-b031-408a-b0b4-9e369e478b1d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3001438e-c8f9-43be-8f03-14e321139b4c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for option exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a5ebfea0-30d5-4882-91cf-40dbac5fbfc7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b60e6d99-9295-4c80-b5b8-aa363a6533a9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in calculating net loss per common share - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_8d34bf73-f603-4e72-9f52-ab74e96c4664_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_CollaborativeArrangementProfitsGeneratedSharedPercentage_9333d0a2-107f-4f11-9465-46ed70173dce_terseLabel_en-US" xlink:label="lab_ocgn_CollaborativeArrangementProfitsGeneratedSharedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profits generated, shared percentage</link:label>
    <link:label id="lab_ocgn_CollaborativeArrangementProfitsGeneratedSharedPercentage_label_en-US" xlink:label="lab_ocgn_CollaborativeArrangementProfitsGeneratedSharedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Profits Generated, Shared, Percentage</link:label>
    <link:label id="lab_ocgn_CollaborativeArrangementProfitsGeneratedSharedPercentage_documentation_en-US" xlink:label="lab_ocgn_CollaborativeArrangementProfitsGeneratedSharedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Profits Generated, Shared, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborativeArrangementProfitsGeneratedSharedPercentage" xlink:href="ocgn-20210930.xsd#ocgn_CollaborativeArrangementProfitsGeneratedSharedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_CollaborativeArrangementProfitsGeneratedSharedPercentage" xlink:to="lab_ocgn_CollaborativeArrangementProfitsGeneratedSharedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_1f0c4168-dad3-4f5d-87d2-5b8b144b26e5_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_617cd4e6-dc61-4285-ab0a-15c3e0364e03_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_582f4c43-5ce1-47c0-b40c-4021265a21fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2a7163a6-70a6-4790-91c5-556c6fea1df6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8f4efa89-7a06-415a-953f-1f57487a8458_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_b412865a-91da-4877-8d9a-5c84c2bfbc22_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_dc36a895-681a-4304-9873-748621993385_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_cb797b9f-46c2-41c7-9142-a5d5fc8b6bd4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6a26be5c-42c7-4402-9ea3-92762c342bff_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3b41e668-2d0c-4fba-88cc-2ad143496254_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_ee43f2b3-a7d8-4781-ae7d-d93cfa930957_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_2660fa31-7987-43d5-a179-432f23672571_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1fc1930a-ab58-4bfc-ad20-589cc57629f5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_477276d7-6e6d-4d6e-9da0-b739f2048fec_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b57762aa-5ab0-45ef-a374-a3e8faf5d7f2_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e1753a75-812b-4c15-b2ff-402c653d7da2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableGross_5e7b92bc-9609-40b8-9580-75f993c05c73_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory note</link:label>
    <link:label id="lab_us-gaap_NotesReceivableGross_label_en-US" xlink:label="lab_us-gaap_NotesReceivableGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableGross" xlink:to="lab_us-gaap_NotesReceivableGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_SubscriptionAgreementsMember_81f52a81-ed04-421a-8354-9201a9bf7dd8_terseLabel_en-US" xlink:label="lab_ocgn_SubscriptionAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subscription Agreements</link:label>
    <link:label id="lab_ocgn_SubscriptionAgreementsMember_label_en-US" xlink:label="lab_ocgn_SubscriptionAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subscription Agreements [Member]</link:label>
    <link:label id="lab_ocgn_SubscriptionAgreementsMember_documentation_en-US" xlink:label="lab_ocgn_SubscriptionAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subscription Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SubscriptionAgreementsMember" xlink:href="ocgn-20210930.xsd#ocgn_SubscriptionAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_SubscriptionAgreementsMember" xlink:to="lab_ocgn_SubscriptionAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_8b29f71a-91ec-482d-ba68-71b96f0866a5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_15a353a7-e255-4b40-a7ba-ce0c007e423c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_1893345d-849b-4d35-89d1-b84b57af7deb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7139917-59d4-4498-a280-0c988935e36c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cf0c4dac-a2ed-4b13-b4a7-42d21032d882_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Standards and Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_320e1a18-4fb2-45ea-a7f9-5a0f22f58315_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held-for-sale, Not Part of Disposal Group, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:to="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5db19ca9-155e-4dfb-8798-68d33f678ed1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_AdverseEventsSeriousAdverseSideEffectsPercent_925e553a-c344-4e79-9853-a29be45a4d00_terseLabel_en-US" xlink:label="lab_ocgn_AdverseEventsSeriousAdverseSideEffectsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adverse events, serious adverse side effects (less than) (percentage)</link:label>
    <link:label id="lab_ocgn_AdverseEventsSeriousAdverseSideEffectsPercent_label_en-US" xlink:label="lab_ocgn_AdverseEventsSeriousAdverseSideEffectsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adverse Events, Serious Adverse Side Effects, Percent</link:label>
    <link:label id="lab_ocgn_AdverseEventsSeriousAdverseSideEffectsPercent_documentation_en-US" xlink:label="lab_ocgn_AdverseEventsSeriousAdverseSideEffectsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adverse Events, Serious Adverse Side Effects, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AdverseEventsSeriousAdverseSideEffectsPercent" xlink:href="ocgn-20210930.xsd#ocgn_AdverseEventsSeriousAdverseSideEffectsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_AdverseEventsSeriousAdverseSideEffectsPercent" xlink:to="lab_ocgn_AdverseEventsSeriousAdverseSideEffectsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_EfficacyAsymptomaticInfectionPercent_e7f15de5-923a-4c97-9f8a-895e42c47481_terseLabel_en-US" xlink:label="lab_ocgn_EfficacyAsymptomaticInfectionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Efficacy, asymptomatic infection (percentage)</link:label>
    <link:label id="lab_ocgn_EfficacyAsymptomaticInfectionPercent_label_en-US" xlink:label="lab_ocgn_EfficacyAsymptomaticInfectionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Efficacy, Asymptomatic Infection, Percent</link:label>
    <link:label id="lab_ocgn_EfficacyAsymptomaticInfectionPercent_documentation_en-US" xlink:label="lab_ocgn_EfficacyAsymptomaticInfectionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Efficacy, Asymptomatic Infection, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EfficacyAsymptomaticInfectionPercent" xlink:href="ocgn-20210930.xsd#ocgn_EfficacyAsymptomaticInfectionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_EfficacyAsymptomaticInfectionPercent" xlink:to="lab_ocgn_EfficacyAsymptomaticInfectionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_6e02bd63-8f42-488b-a4fc-2114b465e2ef_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_a96f92b6-7843-4a98-9062-a550c2f2869c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_88868f6e-5436-40eb-b37e-8d2cce266977_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_ShareBasedPaymentArrangementPerformanceBasedOptionMember_722c5bfb-10a2-48ea-adab-e094c2206afe_terseLabel_en-US" xlink:label="lab_ocgn_ShareBasedPaymentArrangementPerformanceBasedOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Performance Based Option</link:label>
    <link:label id="lab_ocgn_ShareBasedPaymentArrangementPerformanceBasedOptionMember_label_en-US" xlink:label="lab_ocgn_ShareBasedPaymentArrangementPerformanceBasedOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Performance Based Option [Member]</link:label>
    <link:label id="lab_ocgn_ShareBasedPaymentArrangementPerformanceBasedOptionMember_documentation_en-US" xlink:label="lab_ocgn_ShareBasedPaymentArrangementPerformanceBasedOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Performance Based Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ShareBasedPaymentArrangementPerformanceBasedOptionMember" xlink:href="ocgn-20210930.xsd#ocgn_ShareBasedPaymentArrangementPerformanceBasedOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_ShareBasedPaymentArrangementPerformanceBasedOptionMember" xlink:to="lab_ocgn_ShareBasedPaymentArrangementPerformanceBasedOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ocgn_CollaborationAgreementWithCansinoBiologicsMember_5be66626-3a7a-4208-a0df-e05cff8a0348_terseLabel_en-US" xlink:label="lab_ocgn_CollaborationAgreementWithCansinoBiologicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With Cansino Biologics</link:label>
    <link:label id="lab_ocgn_CollaborationAgreementWithCansinoBiologicsMember_label_en-US" xlink:label="lab_ocgn_CollaborationAgreementWithCansinoBiologicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With Cansino Biologics [Member]</link:label>
    <link:label id="lab_ocgn_CollaborationAgreementWithCansinoBiologicsMember_documentation_en-US" xlink:label="lab_ocgn_CollaborationAgreementWithCansinoBiologicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With Cansino Biologics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementWithCansinoBiologicsMember" xlink:href="ocgn-20210930.xsd#ocgn_CollaborationAgreementWithCansinoBiologicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ocgn_CollaborationAgreementWithCansinoBiologicsMember" xlink:to="lab_ocgn_CollaborationAgreementWithCansinoBiologicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_afde7631-3384-4174-b538-c941a0e1cb39_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4031495b-d195-472b-a018-239022de2d66_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_24aee2a1-50bf-4109-9060-5de35e2f52d5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_60f12a25-5d0d-4121-b317-38474e364f9f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_f0e2def7-fa04-4a3b-9a7d-36db3a459367_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_046f959c-5004-4b22-97f6-850b1bec5035_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>ocgn-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:37cdbff3-15f4-4881-8cd5-68abc4a291de,g:c6584426-cf6c-4c9a-b04f-fdc200c901b8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/Cover" xlink:type="simple" xlink:href="ocgn-20210930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ab8b9d13-aa2b-4baf-ac65-281dffb1571e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_DocumentType_ab8b9d13-aa2b-4baf-ac65-281dffb1571e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_0d860744-acf0-4851-ad14-66767348d665" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_DocumentQuarterlyReport_0d860744-acf0-4851-ad14-66767348d665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_09df07ba-ed30-42db-8805-fd2cf456284d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_DocumentPeriodEndDate_09df07ba-ed30-42db-8805-fd2cf456284d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e5d6eadd-90b8-45d3-8f8e-dbccce53b1e7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_DocumentTransitionReport_e5d6eadd-90b8-45d3-8f8e-dbccce53b1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a80219c8-f779-4542-82db-b5ec7e0912dc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_EntityFileNumber_a80219c8-f779-4542-82db-b5ec7e0912dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0b2d7155-3839-467c-98f3-aef4802184a3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_EntityRegistrantName_0b2d7155-3839-467c-98f3-aef4802184a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0e1c9984-70db-4eed-85ed-b75583f3eac3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0e1c9984-70db-4eed-85ed-b75583f3eac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_dea817af-7aee-4354-886f-5b9e7e9f8bed" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_EntityTaxIdentificationNumber_dea817af-7aee-4354-886f-5b9e7e9f8bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c471ba9a-9572-4289-a9ef-90625b731d8f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_EntityAddressAddressLine1_c471ba9a-9572-4289-a9ef-90625b731d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_baddb837-24c8-4ce7-8770-6223cfb6a0c6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_EntityAddressCityOrTown_baddb837-24c8-4ce7-8770-6223cfb6a0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_cd3d969a-17a4-46b4-aaed-f913cd639fbc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_EntityAddressStateOrProvince_cd3d969a-17a4-46b4-aaed-f913cd639fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_8f3b959a-9459-4c75-a4ae-7ed2d0286172" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_EntityAddressPostalZipCode_8f3b959a-9459-4c75-a4ae-7ed2d0286172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_2ef5a60e-aa74-4861-a9a1-e9aa87a591e1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_CityAreaCode_2ef5a60e-aa74-4861-a9a1-e9aa87a591e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_35403d71-3c8a-4646-b856-07577ff4f1be" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_LocalPhoneNumber_35403d71-3c8a-4646-b856-07577ff4f1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a36a876e-ce7b-4c00-8b33-0d6dc82a7258" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_Security12bTitle_a36a876e-ce7b-4c00-8b33-0d6dc82a7258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a3cd780b-5aee-4a0c-9fc5-765918a502ff" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_TradingSymbol_a3cd780b-5aee-4a0c-9fc5-765918a502ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2ffca956-38ab-4e64-8fee-426361d7faa8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_SecurityExchangeName_2ffca956-38ab-4e64-8fee-426361d7faa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_977caafb-44a6-4b53-a52d-fd05cb89fe3c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_EntityCurrentReportingStatus_977caafb-44a6-4b53-a52d-fd05cb89fe3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_590a43bc-1054-4249-8b74-c89892e41eab" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_EntityInteractiveDataCurrent_590a43bc-1054-4249-8b74-c89892e41eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0c7eaf42-17c9-4922-83c1-beaef8038489" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_EntityFilerCategory_0c7eaf42-17c9-4922-83c1-beaef8038489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2a1dfcc6-2c47-40fe-b011-799af1299861" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_EntitySmallBusiness_2a1dfcc6-2c47-40fe-b011-799af1299861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_cb8dad29-37d6-473e-8a13-dcd7f2bc15e0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_EntityEmergingGrowthCompany_cb8dad29-37d6-473e-8a13-dcd7f2bc15e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_193a0b81-338e-4c0a-86a3-cc489214cddf" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_EntityShellCompany_193a0b81-338e-4c0a-86a3-cc489214cddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_99480996-fce7-425d-bdf1-49abe5e1d671" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_99480996-fce7-425d-bdf1-49abe5e1d671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_158e36a1-d760-4b39-a426-1d9be396c1e6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_EntityCentralIndexKey_158e36a1-d760-4b39-a426-1d9be396c1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e3050758-b443-482c-a3b8-9b80ff3f28eb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_CurrentFiscalYearEndDate_e3050758-b443-482c-a3b8-9b80ff3f28eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0edec0ac-1144-4436-ad65-8471bc779248" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_DocumentFiscalYearFocus_0edec0ac-1144-4436-ad65-8471bc779248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_dc17a0c8-da2e-4840-b776-a32fb069bfbd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_DocumentFiscalPeriodFocus_dc17a0c8-da2e-4840-b776-a32fb069bfbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_41dee740-f655-4dfb-9500-bf7e2e8c454f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7764ac40-751f-4f9a-a7b2-4a844e1170bd" xlink:to="loc_dei_AmendmentFlag_41dee740-f655-4dfb-9500-bf7e2e8c454f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ocgn-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fb3a61d5-84fc-4a49-876a-8450cd8e936c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f16a0502-4938-4082-be71-f3bc12c83c58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb3a61d5-84fc-4a49-876a-8450cd8e936c" xlink:to="loc_us-gaap_StatementTable_f16a0502-4938-4082-be71-f3bc12c83c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_50aa78fc-08f2-4774-ad64-ee6acf12c3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f16a0502-4938-4082-be71-f3bc12c83c58" xlink:to="loc_us-gaap_StatementClassOfStockAxis_50aa78fc-08f2-4774-ad64-ee6acf12c3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4f3f3116-47a4-4fc0-9e23-275f52bf0de8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_50aa78fc-08f2-4774-ad64-ee6acf12c3a3" xlink:to="loc_us-gaap_ClassOfStockDomain_4f3f3116-47a4-4fc0-9e23-275f52bf0de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_9b111810-2fb2-411d-9c9f-d951e029a173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4f3f3116-47a4-4fc0-9e23-275f52bf0de8" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_9b111810-2fb2-411d-9c9f-d951e029a173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_b635fc54-37fd-49f9-b241-a6bdc185231f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4f3f3116-47a4-4fc0-9e23-275f52bf0de8" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_b635fc54-37fd-49f9-b241-a6bdc185231f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f8079163-7221-4028-b22f-e58f7d198f51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f16a0502-4938-4082-be71-f3bc12c83c58" xlink:to="loc_us-gaap_StatementLineItems_f8079163-7221-4028-b22f-e58f7d198f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_cb45d1b9-c09a-4c63-8832-6b913d46eec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f8079163-7221-4028-b22f-e58f7d198f51" xlink:to="loc_us-gaap_AssetsAbstract_cb45d1b9-c09a-4c63-8832-6b913d46eec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_748389f5-f7b5-4415-bf52-a3875230284c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cb45d1b9-c09a-4c63-8832-6b913d46eec6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_748389f5-f7b5-4415-bf52-a3875230284c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_be234b21-daed-4a9f-9c88-516d71a81455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_748389f5-f7b5-4415-bf52-a3875230284c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_be234b21-daed-4a9f-9c88-516d71a81455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvancesOnInventoryPurchases_35e5fa85-270d-4057-b8d0-a10c99366ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvancesOnInventoryPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_748389f5-f7b5-4415-bf52-a3875230284c" xlink:to="loc_us-gaap_AdvancesOnInventoryPurchases_35e5fa85-270d-4057-b8d0-a10c99366ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_528cda44-d3b1-4381-a080-c565378c7a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_748389f5-f7b5-4415-bf52-a3875230284c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_528cda44-d3b1-4381-a080-c565378c7a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_77c7fffb-6678-40e7-a4d2-8b2bd2286227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_748389f5-f7b5-4415-bf52-a3875230284c" xlink:to="loc_us-gaap_AssetsCurrent_77c7fffb-6678-40e7-a4d2-8b2bd2286227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0e5fc3a7-0126-4cf4-b60b-c60119af1d86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cb45d1b9-c09a-4c63-8832-6b913d46eec6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0e5fc3a7-0126-4cf4-b60b-c60119af1d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_030a0d92-8c05-407a-800a-ab2460f60d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cb45d1b9-c09a-4c63-8832-6b913d46eec6" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_030a0d92-8c05-407a-800a-ab2460f60d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5dc93398-bf6b-45af-8c5a-59e78d4fba00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cb45d1b9-c09a-4c63-8832-6b913d46eec6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5dc93398-bf6b-45af-8c5a-59e78d4fba00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1d238d97-4317-4629-b94a-213d6f1c0d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cb45d1b9-c09a-4c63-8832-6b913d46eec6" xlink:to="loc_us-gaap_Assets_1d238d97-4317-4629-b94a-213d6f1c0d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4c2a59c0-b433-4a97-8446-336b7abfef4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f8079163-7221-4028-b22f-e58f7d198f51" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4c2a59c0-b433-4a97-8446-336b7abfef4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_7253c63f-2605-433e-a53c-11595572f855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4c2a59c0-b433-4a97-8446-336b7abfef4c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_7253c63f-2605-433e-a53c-11595572f855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_03646c58-def8-464a-b285-754fa5decc03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7253c63f-2605-433e-a53c-11595572f855" xlink:to="loc_us-gaap_AccountsPayableCurrent_03646c58-def8-464a-b285-754fa5decc03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_4381d913-1e48-4152-b32c-da94f9be4ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7253c63f-2605-433e-a53c-11595572f855" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_4381d913-1e48-4152-b32c-da94f9be4ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_0450bda9-47a7-48eb-ba45-795318c46b89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7253c63f-2605-433e-a53c-11595572f855" xlink:to="loc_us-gaap_ShortTermBorrowings_0450bda9-47a7-48eb-ba45-795318c46b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1fe13b8c-5a32-43d8-981f-c631e9a9a3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7253c63f-2605-433e-a53c-11595572f855" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1fe13b8c-5a32-43d8-981f-c631e9a9a3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bdd5e036-f3c1-4b2d-8480-e4cfe26ddb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7253c63f-2605-433e-a53c-11595572f855" xlink:to="loc_us-gaap_LiabilitiesCurrent_bdd5e036-f3c1-4b2d-8480-e4cfe26ddb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_615ddb05-9e66-4c16-8637-d3a61ab53da3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4c2a59c0-b433-4a97-8446-336b7abfef4c" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_615ddb05-9e66-4c16-8637-d3a61ab53da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2f41d60f-97ac-46a4-9378-086110852c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_615ddb05-9e66-4c16-8637-d3a61ab53da3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2f41d60f-97ac-46a4-9378-086110852c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_b56b4c2b-fcdc-48b0-a4ba-171cce86605e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_615ddb05-9e66-4c16-8637-d3a61ab53da3" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_b56b4c2b-fcdc-48b0-a4ba-171cce86605e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_51e565a8-3eb9-4f78-8669-7dd805ab5af1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_615ddb05-9e66-4c16-8637-d3a61ab53da3" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_51e565a8-3eb9-4f78-8669-7dd805ab5af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_912351ee-d67a-4bb1-8025-aefb3218399c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4c2a59c0-b433-4a97-8446-336b7abfef4c" xlink:to="loc_us-gaap_Liabilities_912351ee-d67a-4bb1-8025-aefb3218399c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_effda86b-8972-4fe5-9285-bf78646185c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4c2a59c0-b433-4a97-8446-336b7abfef4c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_effda86b-8972-4fe5-9285-bf78646185c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_762d5fd8-7fb7-49a4-a6c5-a7c8c04a99a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4c2a59c0-b433-4a97-8446-336b7abfef4c" xlink:to="loc_us-gaap_StockholdersEquityAbstract_762d5fd8-7fb7-49a4-a6c5-a7c8c04a99a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5072d66f-cfe9-49c5-806e-3bbe3f68adc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_762d5fd8-7fb7-49a4-a6c5-a7c8c04a99a3" xlink:to="loc_us-gaap_PreferredStockValue_5072d66f-cfe9-49c5-806e-3bbe3f68adc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_de5c1683-e17c-4596-accc-aca5d5fc358e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_762d5fd8-7fb7-49a4-a6c5-a7c8c04a99a3" xlink:to="loc_us-gaap_CommonStockValue_de5c1683-e17c-4596-accc-aca5d5fc358e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_857e3675-85cb-412a-af0e-3a267c2099b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_762d5fd8-7fb7-49a4-a6c5-a7c8c04a99a3" xlink:to="loc_us-gaap_TreasuryStockValue_857e3675-85cb-412a-af0e-3a267c2099b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4b204bc3-ad02-4fdc-a33d-6de6fbe5f6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_762d5fd8-7fb7-49a4-a6c5-a7c8c04a99a3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_4b204bc3-ad02-4fdc-a33d-6de6fbe5f6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d0b6a3d1-6491-4873-8e29-dd772346350a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_762d5fd8-7fb7-49a4-a6c5-a7c8c04a99a3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d0b6a3d1-6491-4873-8e29-dd772346350a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d5d288af-aeea-40c5-b72a-7bc88759ec74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_762d5fd8-7fb7-49a4-a6c5-a7c8c04a99a3" xlink:to="loc_us-gaap_StockholdersEquity_d5d288af-aeea-40c5-b72a-7bc88759ec74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_75fc6fb3-67ad-4fd6-85c5-f67fe38a1e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4c2a59c0-b433-4a97-8446-336b7abfef4c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_75fc6fb3-67ad-4fd6-85c5-f67fe38a1e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="ocgn-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_58c624ca-911e-435d-860d-bb1a1267ce48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_670f0d2e-49d9-4f69-a6ac-6ad8e5a7955f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_58c624ca-911e-435d-860d-bb1a1267ce48" xlink:to="loc_us-gaap_StatementTable_670f0d2e-49d9-4f69-a6ac-6ad8e5a7955f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6af43b44-efee-4280-8c03-0a617b04e4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_670f0d2e-49d9-4f69-a6ac-6ad8e5a7955f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6af43b44-efee-4280-8c03-0a617b04e4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_22a84a02-b713-4063-a6fa-08d478c8f49a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6af43b44-efee-4280-8c03-0a617b04e4d3" xlink:to="loc_us-gaap_ClassOfStockDomain_22a84a02-b713-4063-a6fa-08d478c8f49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_731bb958-de98-456b-87ac-0b954a4b6e11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_22a84a02-b713-4063-a6fa-08d478c8f49a" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_731bb958-de98-456b-87ac-0b954a4b6e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_472d3ea1-524e-43da-9c8c-0c25b903a4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_22a84a02-b713-4063-a6fa-08d478c8f49a" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_472d3ea1-524e-43da-9c8c-0c25b903a4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f857fc52-b282-4771-b33c-45dc457fb14b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_670f0d2e-49d9-4f69-a6ac-6ad8e5a7955f" xlink:to="loc_us-gaap_StatementLineItems_f857fc52-b282-4771-b33c-45dc457fb14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0eea08da-5bae-47a4-aafc-32c034ee68a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f857fc52-b282-4771-b33c-45dc457fb14b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0eea08da-5bae-47a4-aafc-32c034ee68a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_149b94bd-579c-4975-90fc-cdd4d7a3d990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f857fc52-b282-4771-b33c-45dc457fb14b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_149b94bd-579c-4975-90fc-cdd4d7a3d990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b1f49dfc-b57c-431b-b18c-669846bf0af3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f857fc52-b282-4771-b33c-45dc457fb14b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b1f49dfc-b57c-431b-b18c-669846bf0af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3abc9ed1-33f5-4af3-96b2-60864dcf8f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f857fc52-b282-4771-b33c-45dc457fb14b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3abc9ed1-33f5-4af3-96b2-60864dcf8f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_01713fa2-5edd-4c99-a8a3-d07075f97d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f857fc52-b282-4771-b33c-45dc457fb14b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_01713fa2-5edd-4c99-a8a3-d07075f97d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_5c45ca52-52c5-4a92-9f52-d7effb94dd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f857fc52-b282-4771-b33c-45dc457fb14b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_5c45ca52-52c5-4a92-9f52-d7effb94dd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1ef1f5e4-e095-4dcf-89a4-fe354ca1ae33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f857fc52-b282-4771-b33c-45dc457fb14b" xlink:to="loc_us-gaap_CommonStockSharesIssued_1ef1f5e4-e095-4dcf-89a4-fe354ca1ae33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_228394fe-6d61-4c9b-9acd-3bd1f311889d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f857fc52-b282-4771-b33c-45dc457fb14b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_228394fe-6d61-4c9b-9acd-3bd1f311889d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_e1f93c26-18fb-4468-bb75-82fe18f766b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f857fc52-b282-4771-b33c-45dc457fb14b" xlink:to="loc_us-gaap_TreasuryStockCommonShares_e1f93c26-18fb-4468-bb75-82fe18f766b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="ocgn-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ee752e91-5bb4-46fc-b609-dd6025e595d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_8bb371f1-4760-41fd-b266-3aad5f52ebf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ee752e91-5bb4-46fc-b609-dd6025e595d5" xlink:to="loc_us-gaap_RevenuesAbstract_8bb371f1-4760-41fd-b266-3aad5f52ebf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_8851d86b-34cc-4ec9-b033-0369769d5c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8bb371f1-4760-41fd-b266-3aad5f52ebf3" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_8851d86b-34cc-4ec9-b033-0369769d5c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a9b88367-ca61-488b-8646-52b32a0ce10b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8bb371f1-4760-41fd-b266-3aad5f52ebf3" xlink:to="loc_us-gaap_Revenues_a9b88367-ca61-488b-8646-52b32a0ce10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_3dae676e-0647-486e-a61f-fb928c765465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ee752e91-5bb4-46fc-b609-dd6025e595d5" xlink:to="loc_us-gaap_OperatingExpensesAbstract_3dae676e-0647-486e-a61f-fb928c765465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5b19ad28-bd61-474e-ab71-4e0027cf2070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3dae676e-0647-486e-a61f-fb928c765465" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5b19ad28-bd61-474e-ab71-4e0027cf2070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_e8be883d-53c5-4bb1-9811-93e249e31b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3dae676e-0647-486e-a61f-fb928c765465" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_e8be883d-53c5-4bb1-9811-93e249e31b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e477ba6d-9698-4eb8-a98d-40d54e2defad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3dae676e-0647-486e-a61f-fb928c765465" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e477ba6d-9698-4eb8-a98d-40d54e2defad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_68b7b6ca-a237-4f80-a308-da56c03891d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3dae676e-0647-486e-a61f-fb928c765465" xlink:to="loc_us-gaap_OperatingExpenses_68b7b6ca-a237-4f80-a308-da56c03891d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_604e06e0-3837-4ba9-8278-a72e7779da9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ee752e91-5bb4-46fc-b609-dd6025e595d5" xlink:to="loc_us-gaap_OperatingIncomeLoss_604e06e0-3837-4ba9-8278-a72e7779da9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_63762747-f0d4-4366-ad86-f371789e4e95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ee752e91-5bb4-46fc-b609-dd6025e595d5" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_63762747-f0d4-4366-ad86-f371789e4e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_31cce4d2-2c86-4eb3-ac3c-8eb8e06b9d74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_63762747-f0d4-4366-ad86-f371789e4e95" xlink:to="loc_us-gaap_InvestmentIncomeInterest_31cce4d2-2c86-4eb3-ac3c-8eb8e06b9d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_47057ee7-942e-4f72-b3a1-f5b77dd0eb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_63762747-f0d4-4366-ad86-f371789e4e95" xlink:to="loc_us-gaap_InterestExpense_47057ee7-942e-4f72-b3a1-f5b77dd0eb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c839a43a-5d4d-442c-abaf-0bac7fade374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_63762747-f0d4-4366-ad86-f371789e4e95" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c839a43a-5d4d-442c-abaf-0bac7fade374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2c46ffba-cc44-4b39-849c-963bbfbc68a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_63762747-f0d4-4366-ad86-f371789e4e95" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2c46ffba-cc44-4b39-849c-963bbfbc68a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83665be4-2aa2-4b6b-b233-441f3c6091b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ee752e91-5bb4-46fc-b609-dd6025e595d5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83665be4-2aa2-4b6b-b233-441f3c6091b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0cd33ef9-1204-4bb3-8cd5-a5a5c732272f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ee752e91-5bb4-46fc-b609-dd6025e595d5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0cd33ef9-1204-4bb3-8cd5-a5a5c732272f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ca97053d-f49a-485b-b072-aefcb7298697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ee752e91-5bb4-46fc-b609-dd6025e595d5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_ca97053d-f49a-485b-b072-aefcb7298697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dbcad845-6483-4be6-9755-2d00c3fabf47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ee752e91-5bb4-46fc-b609-dd6025e595d5" xlink:to="loc_us-gaap_NetIncomeLoss_dbcad845-6483-4be6-9755-2d00c3fabf47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_0fb63e6f-d006-42fc-a2b6-909011c2e4af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ee752e91-5bb4-46fc-b609-dd6025e595d5" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_0fb63e6f-d006-42fc-a2b6-909011c2e4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e2d782a3-54cd-4535-aa7f-2fe68637c116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ee752e91-5bb4-46fc-b609-dd6025e595d5" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e2d782a3-54cd-4535-aa7f-2fe68637c116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4089be9e-e957-4dbb-9da2-6817a0eecd59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ee752e91-5bb4-46fc-b609-dd6025e595d5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4089be9e-e957-4dbb-9da2-6817a0eecd59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f255a51c-b48b-4cda-934a-76d691b2aa6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ee752e91-5bb4-46fc-b609-dd6025e595d5" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f255a51c-b48b-4cda-934a-76d691b2aa6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5bdbe2d3-b276-4e35-a57a-dda1068f22e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ee752e91-5bb4-46fc-b609-dd6025e595d5" xlink:to="loc_us-gaap_EarningsPerShareBasic_5bdbe2d3-b276-4e35-a57a-dda1068f22e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_91644114-9149-4fea-933b-554d71e1fa4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ee752e91-5bb4-46fc-b609-dd6025e595d5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_91644114-9149-4fea-933b-554d71e1fa4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS_1" xlink:type="simple" xlink:href="ocgn-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS_1"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="ocgn-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_f022866d-2796-4baa-881b-be5a931e72da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6cdcaec5-3966-4b22-8933-31cbf521b168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_f022866d-2796-4baa-881b-be5a931e72da" xlink:to="loc_us-gaap_StatementTable_6cdcaec5-3966-4b22-8933-31cbf521b168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b1a616c6-8346-4c0c-99c1-37e46b8f7e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6cdcaec5-3966-4b22-8933-31cbf521b168" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b1a616c6-8346-4c0c-99c1-37e46b8f7e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_53e3eb60-c545-4b2d-b3c0-574cd01472ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b1a616c6-8346-4c0c-99c1-37e46b8f7e99" xlink:to="loc_us-gaap_EquityComponentDomain_53e3eb60-c545-4b2d-b3c0-574cd01472ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_7c8e07ac-8d2b-4de6-99c1-a43d88a3c6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_53e3eb60-c545-4b2d-b3c0-574cd01472ed" xlink:to="loc_us-gaap_PreferredStockMember_7c8e07ac-8d2b-4de6-99c1-a43d88a3c6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_95d311da-62df-41a3-bbca-5d5fad3c9a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_53e3eb60-c545-4b2d-b3c0-574cd01472ed" xlink:to="loc_us-gaap_CommonStockMember_95d311da-62df-41a3-bbca-5d5fad3c9a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_d43b92dc-2ad6-4efd-a28f-e9543c068e29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_53e3eb60-c545-4b2d-b3c0-574cd01472ed" xlink:to="loc_us-gaap_TreasuryStockMember_d43b92dc-2ad6-4efd-a28f-e9543c068e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fb4305ec-be7e-48e7-82a7-8c0d7870afdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_53e3eb60-c545-4b2d-b3c0-574cd01472ed" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fb4305ec-be7e-48e7-82a7-8c0d7870afdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cbac6ba5-9bf4-42da-b9b7-d4a7fe73f4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_53e3eb60-c545-4b2d-b3c0-574cd01472ed" xlink:to="loc_us-gaap_RetainedEarningsMember_cbac6ba5-9bf4-42da-b9b7-d4a7fe73f4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a27d323a-6239-450f-af3f-4106caede490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6cdcaec5-3966-4b22-8933-31cbf521b168" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a27d323a-6239-450f-af3f-4106caede490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70071fe8-d216-4478-8d13-f4395131ff2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a27d323a-6239-450f-af3f-4106caede490" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70071fe8-d216-4478-8d13-f4395131ff2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ATMTransactionsMember_e12bdc1e-b9eb-4bf5-91a8-e7ddd908908a" xlink:href="ocgn-20210930.xsd#ocgn_ATMTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70071fe8-d216-4478-8d13-f4395131ff2b" xlink:to="loc_ocgn_ATMTransactionsMember_e12bdc1e-b9eb-4bf5-91a8-e7ddd908908a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_RegisteredDirectOfferingMember_d2a38be8-8e8b-44a1-b39c-c11201a2c98c" xlink:href="ocgn-20210930.xsd#ocgn_RegisteredDirectOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70071fe8-d216-4478-8d13-f4395131ff2b" xlink:to="loc_ocgn_RegisteredDirectOfferingMember_d2a38be8-8e8b-44a1-b39c-c11201a2c98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SubscriptionAgreementsAndWarrantExercisesMember_d677af6c-085c-41bf-848e-ce947bd6e8f5" xlink:href="ocgn-20210930.xsd#ocgn_SubscriptionAgreementsAndWarrantExercisesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70071fe8-d216-4478-8d13-f4395131ff2b" xlink:to="loc_ocgn_SubscriptionAgreementsAndWarrantExercisesMember_d677af6c-085c-41bf-848e-ce947bd6e8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f4979bd5-23e1-425e-b164-44b1194356a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6cdcaec5-3966-4b22-8933-31cbf521b168" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f4979bd5-23e1-425e-b164-44b1194356a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1ebb3c3a-aec4-4258-9729-88ee501a65d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f4979bd5-23e1-425e-b164-44b1194356a1" xlink:to="loc_us-gaap_ClassOfStockDomain_1ebb3c3a-aec4-4258-9729-88ee501a65d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_81e8e4f3-47d0-4f86-adb8-5f954856efaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1ebb3c3a-aec4-4258-9729-88ee501a65d2" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_81e8e4f3-47d0-4f86-adb8-5f954856efaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_c3ba4804-11d5-4cac-b7b4-e9508486a547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1ebb3c3a-aec4-4258-9729-88ee501a65d2" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_c3ba4804-11d5-4cac-b7b4-e9508486a547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0fbb5ae9-056c-4d83-82da-625308cffcb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6cdcaec5-3966-4b22-8933-31cbf521b168" xlink:to="loc_us-gaap_StatementLineItems_0fbb5ae9-056c-4d83-82da-625308cffcb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0fbb5ae9-056c-4d83-82da-625308cffcb1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_d1c680d1-d279-4234-a4db-7d071d1fdaec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_us-gaap_SharesOutstanding_d1c680d1-d279-4234-a4db-7d071d1fdaec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_52d3ef1d-9fca-4445-9c6c-4966cc01e016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_us-gaap_StockholdersEquity_52d3ef1d-9fca-4445-9c6c-4966cc01e016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6444356c-8ce1-4a44-aff0-1a25bce63036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6444356c-8ce1-4a44-aff0-1a25bce63036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a0544414-1211-4ef8-aecb-24c747bf8984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a0544414-1211-4ef8-aecb-24c747bf8984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c7ca9f90-a846-455d-8788-062459360588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c7ca9f90-a846-455d-8788-062459360588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e42ffa81-3b99-4bcf-a638-99dc664b84c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e42ffa81-3b99-4bcf-a638-99dc664b84c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e677ef2b-4cda-4fe8-a9fd-0d490beee8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e677ef2b-4cda-4fe8-a9fd-0d490beee8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised_2a59eedb-1118-4896-b02b-3a790128c7c4" xlink:href="ocgn-20210930.xsd#ocgn_StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_ocgn_StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised_2a59eedb-1118-4896-b02b-3a790128c7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodValueOptionsAndWarrantsExercised_b8cb02d4-cca7-4e10-8eb9-a65201db3125" xlink:href="ocgn-20210930.xsd#ocgn_StockIssuedDuringPeriodValueOptionsAndWarrantsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_ocgn_StockIssuedDuringPeriodValueOptionsAndWarrantsExercised_b8cb02d4-cca7-4e10-8eb9-a65201db3125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodSharesWarrantExchange_15d66189-13e4-4f7f-8d11-e266a6045bce" xlink:href="ocgn-20210930.xsd#ocgn_StockIssuedDuringPeriodSharesWarrantExchange"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_ocgn_StockIssuedDuringPeriodSharesWarrantExchange_15d66189-13e4-4f7f-8d11-e266a6045bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_StockIssuedDuringPeriodValueWarrantExchange_0ef4c15a-cea9-45c8-ac1f-a868c5308abb" xlink:href="ocgn-20210930.xsd#ocgn_StockIssuedDuringPeriodValueWarrantExchange"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_ocgn_StockIssuedDuringPeriodValueWarrantExchange_0ef4c15a-cea9-45c8-ac1f-a868c5308abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_00a75ded-a094-40f2-a98f-eb46b3ca6d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_us-gaap_NetIncomeLoss_00a75ded-a094-40f2-a98f-eb46b3ca6d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_014ec6b4-1b6d-4ae6-a610-ee0dcd1f34d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_us-gaap_SharesOutstanding_014ec6b4-1b6d-4ae6-a610-ee0dcd1f34d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ca2a6363-83ef-45f2-90d3-78122c72b841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68603411-d6d5-44d4-abb3-0dec01a3ece0" xlink:to="loc_us-gaap_StockholdersEquity_ca2a6363-83ef-45f2-90d3-78122c72b841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ocgn-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_95a52e53-b320-4835-8705-9fec68dcbca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_788165ab-32b9-4484-a5d2-a5abd93c8820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_95a52e53-b320-4835-8705-9fec68dcbca2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_788165ab-32b9-4484-a5d2-a5abd93c8820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_64689b6d-7d23-4771-88d3-813e5f2d249b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_788165ab-32b9-4484-a5d2-a5abd93c8820" xlink:to="loc_us-gaap_NetIncomeLoss_64689b6d-7d23-4771-88d3-813e5f2d249b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9a94cff5-a763-4afc-a580-366ba1540ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_788165ab-32b9-4484-a5d2-a5abd93c8820" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9a94cff5-a763-4afc-a580-366ba1540ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c0d26250-7f37-483e-a8e7-cfaaf934bd4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9a94cff5-a763-4afc-a580-366ba1540ba0" xlink:to="loc_us-gaap_Depreciation_c0d26250-7f37-483e-a8e7-cfaaf934bd4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NonCashInterestExpense_61cd33e0-0b10-4541-9477-6a9cdd77bd45" xlink:href="ocgn-20210930.xsd#ocgn_NonCashInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9a94cff5-a763-4afc-a580-366ba1540ba0" xlink:to="loc_ocgn_NonCashInterestExpense_61cd33e0-0b10-4541-9477-6a9cdd77bd45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NoncashLeaseExpense_2536cb58-c01d-4ce0-b3be-44acfe21ff5e" xlink:href="ocgn-20210930.xsd#ocgn_NoncashLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9a94cff5-a763-4afc-a580-366ba1540ba0" xlink:to="loc_ocgn_NoncashLeaseExpense_2536cb58-c01d-4ce0-b3be-44acfe21ff5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_100ebaea-322e-4894-965c-1daaae992591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9a94cff5-a763-4afc-a580-366ba1540ba0" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_100ebaea-322e-4894-965c-1daaae992591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3cf3a36a-cf55-435b-8368-9f21e3505351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9a94cff5-a763-4afc-a580-366ba1540ba0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3cf3a36a-cf55-435b-8368-9f21e3505351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments_ee20d643-922a-41e7-b6e7-f377eadd422f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9a94cff5-a763-4afc-a580-366ba1540ba0" xlink:to="loc_us-gaap_IncomeTaxCreditsAndAdjustments_ee20d643-922a-41e7-b6e7-f377eadd422f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2987a71b-fc8a-4749-996f-ab41747ddae1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9a94cff5-a763-4afc-a580-366ba1540ba0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2987a71b-fc8a-4749-996f-ab41747ddae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLoanLossesExpensed_43d1991c-43fa-42de-b5e2-d57e2a5abe2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForLoanLossesExpensed"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9a94cff5-a763-4afc-a580-366ba1540ba0" xlink:to="loc_us-gaap_ProvisionForLoanLossesExpensed_43d1991c-43fa-42de-b5e2-d57e2a5abe2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_98ab9353-a1d4-450d-930e-a2ff18561d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9a94cff5-a763-4afc-a580-366ba1540ba0" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_98ab9353-a1d4-450d-930e-a2ff18561d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_38cd7408-70e3-4aa6-a353-323dc278d8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9a94cff5-a763-4afc-a580-366ba1540ba0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_38cd7408-70e3-4aa6-a353-323dc278d8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_839d0755-484f-4d27-afa2-4a52c563e47f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_38cd7408-70e3-4aa6-a353-323dc278d8f1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_839d0755-484f-4d27-afa2-4a52c563e47f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d3306959-e497-4699-91f8-d0d7f1f9639c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_38cd7408-70e3-4aa6-a353-323dc278d8f1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d3306959-e497-4699-91f8-d0d7f1f9639c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_98c35a23-a4e7-4db1-8f7e-a38ace68c134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_38cd7408-70e3-4aa6-a353-323dc278d8f1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_98c35a23-a4e7-4db1-8f7e-a38ace68c134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_IncreaseDecreaseInLeaseObligations_ee22c121-f477-46c6-8fc0-bfe86838e2d8" xlink:href="ocgn-20210930.xsd#ocgn_IncreaseDecreaseInLeaseObligations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_38cd7408-70e3-4aa6-a353-323dc278d8f1" xlink:to="loc_ocgn_IncreaseDecreaseInLeaseObligations_ee22c121-f477-46c6-8fc0-bfe86838e2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1336f3e-dfed-43dd-8008-3a49a8640866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_38cd7408-70e3-4aa6-a353-323dc278d8f1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1336f3e-dfed-43dd-8008-3a49a8640866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4dba8f78-8e60-455f-b492-a1da4978bf20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_95a52e53-b320-4835-8705-9fec68dcbca2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4dba8f78-8e60-455f-b492-a1da4978bf20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_12bedb39-0930-4455-bd7a-5b82e8b7559f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4dba8f78-8e60-455f-b492-a1da4978bf20" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_12bedb39-0930-4455-bd7a-5b82e8b7559f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_4fad983b-4080-4d6b-9bde-94a4d2b72616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4dba8f78-8e60-455f-b492-a1da4978bf20" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_4fad983b-4080-4d6b-9bde-94a4d2b72616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_IssuanceOfFinancingReceivable_3f80727c-f3a0-4fe4-a99e-cb23d55e7cfc" xlink:href="ocgn-20210930.xsd#ocgn_IssuanceOfFinancingReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4dba8f78-8e60-455f-b492-a1da4978bf20" xlink:to="loc_ocgn_IssuanceOfFinancingReceivable_3f80727c-f3a0-4fe4-a99e-cb23d55e7cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f52dd6e5-15ed-49bb-893b-08e08f037a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4dba8f78-8e60-455f-b492-a1da4978bf20" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f52dd6e5-15ed-49bb-893b-08e08f037a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb655e0c-f104-4687-aee4-cdedb71926d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_95a52e53-b320-4835-8705-9fec68dcbca2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb655e0c-f104-4687-aee4-cdedb71926d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_54f35888-e23f-4c06-a1d7-7069bb8ff3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb655e0c-f104-4687-aee4-cdedb71926d8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_54f35888-e23f-4c06-a1d7-7069bb8ff3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_81602624-a052-4113-866c-bdc2de090626" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb655e0c-f104-4687-aee4-cdedb71926d8" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_81602624-a052-4113-866c-bdc2de090626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_04a0d316-5edc-43ec-99fb-462d2141e118" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb655e0c-f104-4687-aee4-cdedb71926d8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_04a0d316-5edc-43ec-99fb-462d2141e118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_c45c022f-5d7a-4cab-a19d-1b3afdc0593c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb655e0c-f104-4687-aee4-cdedb71926d8" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_c45c022f-5d7a-4cab-a19d-1b3afdc0593c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_fbe8b1e3-3ae6-47f3-a913-41d23848de6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb655e0c-f104-4687-aee4-cdedb71926d8" xlink:to="loc_us-gaap_RepaymentsOfDebt_fbe8b1e3-3ae6-47f3-a913-41d23848de6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_bc327888-ad9b-4e60-9787-13598f006b83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb655e0c-f104-4687-aee4-cdedb71926d8" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_bc327888-ad9b-4e60-9787-13598f006b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d3034a5-04af-4851-a883-8ce230abaefc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb655e0c-f104-4687-aee4-cdedb71926d8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d3034a5-04af-4851-a883-8ce230abaefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_708515d4-a695-4399-9d9e-49d102fc28c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_95a52e53-b320-4835-8705-9fec68dcbca2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_708515d4-a695-4399-9d9e-49d102fc28c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8f9dfd61-e72f-4234-95bd-0847676303ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_95a52e53-b320-4835-8705-9fec68dcbca2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8f9dfd61-e72f-4234-95bd-0847676303ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15f368e1-ee66-4393-9020-3747899ca486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_95a52e53-b320-4835-8705-9fec68dcbca2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15f368e1-ee66-4393-9020-3747899ca486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_99ee010a-8100-42b4-91f8-9f24353c55c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_95a52e53-b320-4835-8705-9fec68dcbca2" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_99ee010a-8100-42b4-91f8-9f24353c55c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_3fd38e8e-fb7b-4f7a-a1af-e790edbe8dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_99ee010a-8100-42b4-91f8-9f24353c55c8" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_3fd38e8e-fb7b-4f7a-a1af-e790edbe8dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_765bac88-775a-4ac4-98a3-61ca2074241d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_99ee010a-8100-42b4-91f8-9f24353c55c8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_765bac88-775a-4ac4-98a3-61ca2074241d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_GainLossOnForgivenessOfPaycheckProtectionProgramNote_84d23dad-5064-49d2-a3f7-1362ae0feb7b" xlink:href="ocgn-20210930.xsd#ocgn_GainLossOnForgivenessOfPaycheckProtectionProgramNote"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_99ee010a-8100-42b4-91f8-9f24353c55c8" xlink:to="loc_ocgn_GainLossOnForgivenessOfPaycheckProtectionProgramNote_84d23dad-5064-49d2-a3f7-1362ae0feb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_cafcaf3a-9ecf-4c8d-8eb6-b7e924afc7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_99ee010a-8100-42b4-91f8-9f24353c55c8" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_cafcaf3a-9ecf-4c8d-8eb6-b7e924afc7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset_70394d1a-83b1-4ac9-a14c-27cef92fe219" xlink:href="ocgn-20210930.xsd#ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_99ee010a-8100-42b4-91f8-9f24353c55c8" xlink:to="loc_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset_70394d1a-83b1-4ac9-a14c-27cef92fe219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesIssued1_ac76ceb2-2456-46a1-b772-9fd22630a078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesIssued1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_99ee010a-8100-42b4-91f8-9f24353c55c8" xlink:to="loc_us-gaap_NotesIssued1_ac76ceb2-2456-46a1-b772-9fd22630a078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_581d3a7f-4794-4f1d-a6d2-4dcabc2986a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_99ee010a-8100-42b4-91f8-9f24353c55c8" xlink:to="loc_us-gaap_StockIssued1_581d3a7f-4794-4f1d-a6d2-4dcabc2986a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost_b0d1b705-059e-48d3-ac56-8b031073c222" xlink:href="ocgn-20210930.xsd#ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_99ee010a-8100-42b4-91f8-9f24353c55c8" xlink:to="loc_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost_b0d1b705-059e-48d3-ac56-8b031073c222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NatureofBusiness" xlink:type="simple" xlink:href="ocgn-20210930.xsd#NatureofBusiness"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/NatureofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c37cbe53-9211-46ac-b9f3-d789013a96cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_9d09cc6c-7030-4277-805b-0cbef1bc39ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c37cbe53-9211-46ac-b9f3-d789013a96cb" xlink:to="loc_us-gaap_NatureOfOperations_9d09cc6c-7030-4277-805b-0cbef1bc39ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NatureofBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#NatureofBusinessAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/NatureofBusinessAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eff85bb5-c586-4133-9b7e-e5ae81a094c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_36e851e5-0edd-457c-bf56-e20ee02fc2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eff85bb5-c586-4133-9b7e-e5ae81a094c5" xlink:to="loc_us-gaap_NumberOfOperatingSegments_36e851e5-0edd-457c-bf56-e20ee02fc2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfVaccinationDoseRegimen_db879b64-6fab-4e85-9099-118babfabf80" xlink:href="ocgn-20210930.xsd#ocgn_NumberOfVaccinationDoseRegimen"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eff85bb5-c586-4133-9b7e-e5ae81a094c5" xlink:to="loc_ocgn_NumberOfVaccinationDoseRegimen_db879b64-6fab-4e85-9099-118babfabf80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_VaccinationDoseRegimenDurationApart_2fdcc2e9-854f-4a00-8c9b-6103f8a35fc7" xlink:href="ocgn-20210930.xsd#ocgn_VaccinationDoseRegimenDurationApart"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eff85bb5-c586-4133-9b7e-e5ae81a094c5" xlink:to="loc_ocgn_VaccinationDoseRegimenDurationApart_2fdcc2e9-854f-4a00-8c9b-6103f8a35fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_OverallVaccineEfficacyPercent_bf136904-5338-477f-bbc1-3ee9fcbf081b" xlink:href="ocgn-20210930.xsd#ocgn_OverallVaccineEfficacyPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eff85bb5-c586-4133-9b7e-e5ae81a094c5" xlink:to="loc_ocgn_OverallVaccineEfficacyPercent_bf136904-5338-477f-bbc1-3ee9fcbf081b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EfficacySevereCasesPercent_e1335f73-f052-4247-852d-8586b630a7fc" xlink:href="ocgn-20210930.xsd#ocgn_EfficacySevereCasesPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eff85bb5-c586-4133-9b7e-e5ae81a094c5" xlink:to="loc_ocgn_EfficacySevereCasesPercent_e1335f73-f052-4247-852d-8586b630a7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EfficacyAsymptomaticInfectionPercent_17158c62-fe8d-4899-92eb-7bb0a6d876f6" xlink:href="ocgn-20210930.xsd#ocgn_EfficacyAsymptomaticInfectionPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eff85bb5-c586-4133-9b7e-e5ae81a094c5" xlink:to="loc_ocgn_EfficacyAsymptomaticInfectionPercent_17158c62-fe8d-4899-92eb-7bb0a6d876f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AdverseEventsSideEffectsPercent_59bcfa8e-3e49-4102-8dca-1a4891b8dc5d" xlink:href="ocgn-20210930.xsd#ocgn_AdverseEventsSideEffectsPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eff85bb5-c586-4133-9b7e-e5ae81a094c5" xlink:to="loc_ocgn_AdverseEventsSideEffectsPercent_59bcfa8e-3e49-4102-8dca-1a4891b8dc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AdverseEventsSeriousAdverseSideEffectsPercent_30e37c86-d343-4b27-a081-ff1109ad6c32" xlink:href="ocgn-20210930.xsd#ocgn_AdverseEventsSeriousAdverseSideEffectsPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eff85bb5-c586-4133-9b7e-e5ae81a094c5" xlink:to="loc_ocgn_AdverseEventsSeriousAdverseSideEffectsPercent_30e37c86-d343-4b27-a081-ff1109ad6c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EfficacyAgainstDeltaVariantB16172Percent_33e7e0f8-2c60-43ce-b7de-fc76968e54be" xlink:href="ocgn-20210930.xsd#ocgn_EfficacyAgainstDeltaVariantB16172Percent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eff85bb5-c586-4133-9b7e-e5ae81a094c5" xlink:to="loc_ocgn_EfficacyAgainstDeltaVariantB16172Percent_33e7e0f8-2c60-43ce-b7de-fc76968e54be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SingleGeneReplacementTherapiesNumberOfGeneticMutationsTarget_d94479b9-7cf0-42bf-bad1-cef9bba8232a" xlink:href="ocgn-20210930.xsd#ocgn_SingleGeneReplacementTherapiesNumberOfGeneticMutationsTarget"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eff85bb5-c586-4133-9b7e-e5ae81a094c5" xlink:to="loc_ocgn_SingleGeneReplacementTherapiesNumberOfGeneticMutationsTarget_d94479b9-7cf0-42bf-bad1-cef9bba8232a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ModifierGeneTherapyPlatformNumberOfProducts_1c3ad87c-0e2a-4adb-b341-e2adf87057cf" xlink:href="ocgn-20210930.xsd#ocgn_ModifierGeneTherapyPlatformNumberOfProducts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eff85bb5-c586-4133-9b7e-e5ae81a094c5" xlink:to="loc_ocgn_ModifierGeneTherapyPlatformNumberOfProducts_1c3ad87c-0e2a-4adb-b341-e2adf87057cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfOrphanDrugDesignations_b5c0402a-dd21-41e8-8d91-a1dadc8055bf" xlink:href="ocgn-20210930.xsd#ocgn_NumberOfOrphanDrugDesignations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eff85bb5-c586-4133-9b7e-e5ae81a094c5" xlink:to="loc_ocgn_NumberOfOrphanDrugDesignations_b5c0402a-dd21-41e8-8d91-a1dadc8055bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a1625e92-2e76-4564-ba15-d9aae5b7c90f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eff85bb5-c586-4133-9b7e-e5ae81a094c5" xlink:to="loc_us-gaap_NetIncomeLoss_a1625e92-2e76-4564-ba15-d9aae5b7c90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d0a3e071-4f6c-41f6-8ac8-6bc2791ee134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eff85bb5-c586-4133-9b7e-e5ae81a094c5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d0a3e071-4f6c-41f6-8ac8-6bc2791ee134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_882e17d2-f556-471e-8d77-a5a051872982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eff85bb5-c586-4133-9b7e-e5ae81a094c5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_882e17d2-f556-471e-8d77-a5a051872982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ocgn-20210930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_445cf17e-f977-4515-b582-2e759bbf3a23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_0cc3d990-7f65-4021-aedc-20223f2f2088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_445cf17e-f977-4515-b582-2e759bbf3a23" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_0cc3d990-7f65-4021-aedc-20223f2f2088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ocgn-20210930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f975454f-f00e-4a4c-bc47-b22b60b0635e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_985f5c8b-2c50-47c6-a495-1075375131a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f975454f-f00e-4a4c-bc47-b22b60b0635e" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_985f5c8b-2c50-47c6-a495-1075375131a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_d8b99575-fa1f-4f19-8778-743de304143b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f975454f-f00e-4a4c-bc47-b22b60b0635e" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_d8b99575-fa1f-4f19-8778-743de304143b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_68c4eee1-6adc-41e9-b18d-28128ce4d52a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f975454f-f00e-4a4c-bc47-b22b60b0635e" xlink:to="loc_us-gaap_UseOfEstimates_68c4eee1-6adc-41e9-b18d-28128ce4d52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_d35ceb68-4e4c-4dec-b469-8553258c8c36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f975454f-f00e-4a4c-bc47-b22b60b0635e" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_d35ceb68-4e4c-4dec-b469-8553258c8c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_d8a5c6f2-d4fa-4af8-99eb-4d439057575e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f975454f-f00e-4a4c-bc47-b22b60b0635e" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_d8a5c6f2-d4fa-4af8-99eb-4d439057575e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8fff00b3-0afc-44e9-8f54-231f6452696d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f975454f-f00e-4a4c-bc47-b22b60b0635e" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8fff00b3-0afc-44e9-8f54-231f6452696d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_f6a1a2bf-02eb-47d0-ba7a-e1c1ce869701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f975454f-f00e-4a4c-bc47-b22b60b0635e" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_f6a1a2bf-02eb-47d0-ba7a-e1c1ce869701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_48af75b4-a598-49ed-b54a-d7a04135301f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f975454f-f00e-4a4c-bc47-b22b60b0635e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_48af75b4-a598-49ed-b54a-d7a04135301f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_b39857af-3909-44b1-a219-ca1aba75d017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f975454f-f00e-4a4c-bc47-b22b60b0635e" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_b39857af-3909-44b1-a219-ca1aba75d017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b55e69be-3117-491c-b76a-12d9b7090b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f975454f-f00e-4a4c-bc47-b22b60b0635e" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b55e69be-3117-491c-b76a-12d9b7090b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AssetHeldForSalePolicyTextBlock_698dd5f2-7720-479c-a166-af36855d3fb3" xlink:href="ocgn-20210930.xsd#ocgn_AssetHeldForSalePolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f975454f-f00e-4a4c-bc47-b22b60b0635e" xlink:to="loc_ocgn_AssetHeldForSalePolicyTextBlock_698dd5f2-7720-479c-a166-af36855d3fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9cb0a2c4-c732-4dd2-ba8d-3691492092d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f975454f-f00e-4a4c-bc47-b22b60b0635e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9cb0a2c4-c732-4dd2-ba8d-3691492092d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ocgn-20210930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b32469c1-d393-4a6c-91c9-b9085a043ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock_77864463-2860-48a4-97b1-9e0002e05c1a" xlink:href="ocgn-20210930.xsd#ocgn_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b32469c1-d393-4a6c-91c9-b9085a043ac1" xlink:to="loc_ocgn_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock_77864463-2860-48a4-97b1-9e0002e05c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_851c4bcb-0ceb-4eef-9efc-0ef5ec3aca31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0ee0f488-1010-4daf-9dee-a6953352d361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_851c4bcb-0ceb-4eef-9efc-0ef5ec3aca31" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0ee0f488-1010-4daf-9dee-a6953352d361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_ada2527b-4a29-4bd1-a562-f195cffd8e53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_851c4bcb-0ceb-4eef-9efc-0ef5ec3aca31" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_ada2527b-4a29-4bd1-a562-f195cffd8e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0048d617-c5f5-43d6-a633-4e9930299a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_851c4bcb-0ceb-4eef-9efc-0ef5ec3aca31" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0048d617-c5f5-43d6-a633-4e9930299a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_900b1962-1512-4ac1-94c7-884ff937cc89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_4edafe54-c3d8-45dc-a669-c4dd1253be5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_900b1962-1512-4ac1-94c7-884ff937cc89" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_4edafe54-c3d8-45dc-a669-c4dd1253be5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4be1aa8a-f352-4121-889b-b2b1163746dc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_4edafe54-c3d8-45dc-a669-c4dd1253be5e" xlink:to="loc_srt_RangeAxis_4be1aa8a-f352-4121-889b-b2b1163746dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_980eaecb-30d1-4bc9-b1b8-cc7e735d8e58" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4be1aa8a-f352-4121-889b-b2b1163746dc" xlink:to="loc_srt_RangeMember_980eaecb-30d1-4bc9-b1b8-cc7e735d8e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ed350e8e-58a6-4f1b-b371-4f8530980ea9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_980eaecb-30d1-4bc9-b1b8-cc7e735d8e58" xlink:to="loc_srt_MinimumMember_ed350e8e-58a6-4f1b-b371-4f8530980ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a1b58b69-4e48-477f-9e66-aa501065ae64" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_980eaecb-30d1-4bc9-b1b8-cc7e735d8e58" xlink:to="loc_srt_MaximumMember_a1b58b69-4e48-477f-9e66-aa501065ae64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_540a62f5-38c3-4034-b2ce-354f651057d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_4edafe54-c3d8-45dc-a669-c4dd1253be5e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_540a62f5-38c3-4034-b2ce-354f651057d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_864b8443-594f-4c7e-8397-0813b92156d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_540a62f5-38c3-4034-b2ce-354f651057d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_864b8443-594f-4c7e-8397-0813b92156d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c9075b65-90c4-4411-bcf3-2d7c55fdcd78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_864b8443-594f-4c7e-8397-0813b92156d3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c9075b65-90c4-4411-bcf3-2d7c55fdcd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_MachineryMember_2ba83815-a85a-455b-a9b6-8fcd26dcd549" xlink:href="ocgn-20210930.xsd#ocgn_MachineryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_864b8443-594f-4c7e-8397-0813b92156d3" xlink:to="loc_ocgn_MachineryMember_2ba83815-a85a-455b-a9b6-8fcd26dcd549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_63f208e7-a696-4df7-9d58-a56c19e75e95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_4edafe54-c3d8-45dc-a669-c4dd1253be5e" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_63f208e7-a696-4df7-9d58-a56c19e75e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_f407e2f8-9b9c-431e-82d8-2e0e05843fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_63f208e7-a696-4df7-9d58-a56c19e75e95" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_f407e2f8-9b9c-431e-82d8-2e0e05843fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_eff9a60c-2171-487c-be39-9c899eec7d35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_63f208e7-a696-4df7-9d58-a56c19e75e95" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_eff9a60c-2171-487c-be39-9c899eec7d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_07d15a1c-1aa3-45e0-a227-ed89264be54d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_63f208e7-a696-4df7-9d58-a56c19e75e95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_07d15a1c-1aa3-45e0-a227-ed89264be54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_84f0843b-776a-4d82-871e-5e6c8d3a1cee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_63f208e7-a696-4df7-9d58-a56c19e75e95" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_84f0843b-776a-4d82-871e-5e6c8d3a1cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_a30c6ce5-ce0e-4743-bb5f-c1b7abee6882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_63f208e7-a696-4df7-9d58-a56c19e75e95" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_a30c6ce5-ce0e-4743-bb5f-c1b7abee6882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_709af16f-60e8-446a-ac1e-792dd984abea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_63f208e7-a696-4df7-9d58-a56c19e75e95" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_709af16f-60e8-446a-ac1e-792dd984abea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreements" xlink:type="simple" xlink:href="ocgn-20210930.xsd#LicenseandDevelopmentAgreements"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f0664337-eb74-4b4f-b6b4-163a966cf2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_afb412e0-c9a7-4bb6-b795-31ba59982aff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f0664337-eb74-4b4f-b6b4-163a966cf2eb" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_afb412e0-c9a7-4bb6-b795-31ba59982aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreementsDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#LicenseandDevelopmentAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_56e0fb47-74b9-414e-8437-8db4ba5a737c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b426eaee-c1c1-4fb0-b138-46b03f8c8ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_56e0fb47-74b9-414e-8437-8db4ba5a737c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b426eaee-c1c1-4fb0-b138-46b03f8c8ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ad15b116-c6be-4d1d-a85f-a993e29d96e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b426eaee-c1c1-4fb0-b138-46b03f8c8ab2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ad15b116-c6be-4d1d-a85f-a993e29d96e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ccdbce87-61ef-4991-8c48-11939ce9447c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ad15b116-c6be-4d1d-a85f-a993e29d96e2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ccdbce87-61ef-4991-8c48-11939ce9447c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_COVAXINPreferredStockPurchaseAgreementMember_51bd36ee-385a-4027-a2a4-8a29f3cc65c2" xlink:href="ocgn-20210930.xsd#ocgn_COVAXINPreferredStockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ccdbce87-61ef-4991-8c48-11939ce9447c" xlink:to="loc_ocgn_COVAXINPreferredStockPurchaseAgreementMember_51bd36ee-385a-4027-a2a4-8a29f3cc65c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_14ae6b86-dc92-463e-8201-2a8ef99fb344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b426eaee-c1c1-4fb0-b138-46b03f8c8ab2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_14ae6b86-dc92-463e-8201-2a8ef99fb344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c3338336-254b-49e6-8b7c-f8cdd70ed412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_14ae6b86-dc92-463e-8201-2a8ef99fb344" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c3338336-254b-49e6-8b7c-f8cdd70ed412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_4dadb571-a3e9-49c0-954f-9ac8858139a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c3338336-254b-49e6-8b7c-f8cdd70ed412" xlink:to="loc_us-gaap_CollaborativeArrangementMember_4dadb571-a3e9-49c0-954f-9ac8858139a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementWithCansinoBiologicsMember_1b831e8d-605b-4938-92b4-46db4281a112" xlink:href="ocgn-20210930.xsd#ocgn_CollaborationAgreementWithCansinoBiologicsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c3338336-254b-49e6-8b7c-f8cdd70ed412" xlink:to="loc_ocgn_CollaborationAgreementWithCansinoBiologicsMember_1b831e8d-605b-4938-92b4-46db4281a112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c29ed4ba-8426-48ae-9a16-59a6678293cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b426eaee-c1c1-4fb0-b138-46b03f8c8ab2" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c29ed4ba-8426-48ae-9a16-59a6678293cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborativeArrangementProfitsGeneratedSharedPercentage_324b629e-ae1b-4437-b55d-3f3896bacd8e" xlink:href="ocgn-20210930.xsd#ocgn_CollaborativeArrangementProfitsGeneratedSharedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c29ed4ba-8426-48ae-9a16-59a6678293cd" xlink:to="loc_ocgn_CollaborativeArrangementProfitsGeneratedSharedPercentage_324b629e-ae1b-4437-b55d-3f3896bacd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementUpfrontPayment_fbacbc8c-c072-4b0e-a010-9786ca52e1ce" xlink:href="ocgn-20210930.xsd#ocgn_CollaborationAgreementUpfrontPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c29ed4ba-8426-48ae-9a16-59a6678293cd" xlink:to="loc_ocgn_CollaborationAgreementUpfrontPayment_fbacbc8c-c072-4b0e-a010-9786ca52e1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada_1e95f17b-b626-43ed-a3d6-05096d2d9037" xlink:href="ocgn-20210930.xsd#ocgn_CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c29ed4ba-8426-48ae-9a16-59a6678293cd" xlink:to="loc_ocgn_CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada_1e95f17b-b626-43ed-a3d6-05096d2d9037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CollaborationAgreementTerm_d01b4b3a-690a-4f7a-af13-6df80cdb2204" xlink:href="ocgn-20210930.xsd#ocgn_CollaborationAgreementTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c29ed4ba-8426-48ae-9a16-59a6678293cd" xlink:to="loc_ocgn_CollaborationAgreementTerm_d01b4b3a-690a-4f7a-af13-6df80cdb2204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NotesReceivable" xlink:type="simple" xlink:href="ocgn-20210930.xsd#NotesReceivable"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/NotesReceivable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_9f260ae9-cbcd-4429-bf2d-44790364e7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock_1622523f-893d-42c0-ab1a-3a1e8a41157f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_9f260ae9-cbcd-4429-bf2d-44790364e7d8" xlink:to="loc_us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock_1622523f-893d-42c0-ab1a-3a1e8a41157f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NotesReceivableDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#NotesReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/NotesReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_f111b323-d4a3-4def-a5aa-17c96ecc412f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross_75c3b28e-1579-4492-9c75-96d76ecb1509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_f111b323-d4a3-4def-a5aa-17c96ecc412f" xlink:to="loc_us-gaap_NotesReceivableGross_75c3b28e-1579-4492-9c75-96d76ecb1509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_FinancingReceivableInterestRateStatedPercentage_bee8fbff-6436-481c-b889-90198f9cb41a" xlink:href="ocgn-20210930.xsd#ocgn_FinancingReceivableInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_f111b323-d4a3-4def-a5aa-17c96ecc412f" xlink:to="loc_ocgn_FinancingReceivableInterestRateStatedPercentage_bee8fbff-6436-481c-b889-90198f9cb41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="ocgn-20210930.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3e1649a7-90f3-4bd2-ad28-dd53e4287cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_7e149277-04fc-451a-ae2d-e5826510423d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3e1649a7-90f3-4bd2-ad28-dd53e4287cfc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_7e149277-04fc-451a-ae2d-e5826510423d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="ocgn-20210930.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_519afc7b-b01c-44da-9425-60e4062ee572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_648a3af1-75c1-4ae4-9ef1-105964a5bed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_519afc7b-b01c-44da-9425-60e4062ee572" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_648a3af1-75c1-4ae4-9ef1-105964a5bed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9273c18d-b2b0-4b13-abe0-a287b2e9d0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_56718feb-1739-4eba-845d-9ef4d1aa412b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9273c18d-b2b0-4b13-abe0-a287b2e9d0e8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_56718feb-1739-4eba-845d-9ef4d1aa412b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8c30bfd2-90df-4288-b0af-a3faad96cfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_56718feb-1739-4eba-845d-9ef4d1aa412b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8c30bfd2-90df-4288-b0af-a3faad96cfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d22663ee-daa6-4a99-a256-102b102110b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8c30bfd2-90df-4288-b0af-a3faad96cfa5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d22663ee-daa6-4a99-a256-102b102110b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_380447a1-8a69-41aa-8f0a-1e813c0dddaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d22663ee-daa6-4a99-a256-102b102110b0" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_380447a1-8a69-41aa-8f0a-1e813c0dddaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_452c6faa-8af3-47b5-b47c-9b87735a3177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d22663ee-daa6-4a99-a256-102b102110b0" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_452c6faa-8af3-47b5-b47c-9b87735a3177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_a262da0f-8792-46a2-86df-061e483c7cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d22663ee-daa6-4a99-a256-102b102110b0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_a262da0f-8792-46a2-86df-061e483c7cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_03e1f725-378f-4a8c-ad72-f29e646f37a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d22663ee-daa6-4a99-a256-102b102110b0" xlink:to="loc_us-gaap_ConstructionInProgressMember_03e1f725-378f-4a8c-ad72-f29e646f37a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0ede63af-13df-46c0-a202-4f20574d6251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_56718feb-1739-4eba-845d-9ef4d1aa412b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0ede63af-13df-46c0-a202-4f20574d6251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ee7b4a29-0e27-40f1-9565-405f6ac8350a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0ede63af-13df-46c0-a202-4f20574d6251" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ee7b4a29-0e27-40f1-9565-405f6ac8350a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_0762d58b-6695-4d59-ac63-ce0abeb4a71e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0ede63af-13df-46c0-a202-4f20574d6251" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_0762d58b-6695-4d59-ac63-ce0abeb4a71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_33cd801d-7f64-4664-87c4-d5b5e06e06c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0ede63af-13df-46c0-a202-4f20574d6251" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_33cd801d-7f64-4664-87c4-d5b5e06e06c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_66a9c337-eaf7-4776-815f-d86a8379c349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0ede63af-13df-46c0-a202-4f20574d6251" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_66a9c337-eaf7-4776-815f-d86a8379c349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_c32800ed-a3e0-4b07-ab98-c0a50ad28ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0ede63af-13df-46c0-a202-4f20574d6251" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_c32800ed-a3e0-4b07-ab98-c0a50ad28ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8a648e88-2a38-466f-9786-bfc3015776f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_3b37ef82-bfe9-41dc-9fcd-5a9474d14d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8a648e88-2a38-466f-9786-bfc3015776f5" xlink:to="loc_us-gaap_Depreciation_3b37ef82-bfe9-41dc-9fcd-5a9474d14d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/OperatingLeases" xlink:type="simple" xlink:href="ocgn-20210930.xsd#OperatingLeases"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/OperatingLeases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f512966f-e246-4b47-9536-44fe4d5681cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_dec4b80e-f385-4d6e-b89a-a6778e2d8966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f512966f-e246-4b47-9536-44fe4d5681cb" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_dec4b80e-f385-4d6e-b89a-a6778e2d8966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/OperatingLeasesTables" xlink:type="simple" xlink:href="ocgn-20210930.xsd#OperatingLeasesTables"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/OperatingLeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c05b1f47-6ca8-42d1-ae95-aeef650e06b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_a31a1bb0-2bb9-42fd-bf93-917b7360eaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c05b1f47-6ca8-42d1-ae95-aeef650e06b5" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_a31a1bb0-2bb9-42fd-bf93-917b7360eaa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock_7d0e2e92-cbe6-4d33-b03f-a4f6a4f5f210" xlink:href="ocgn-20210930.xsd#ocgn_SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c05b1f47-6ca8-42d1-ae95-aeef650e06b5" xlink:to="loc_ocgn_SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock_7d0e2e92-cbe6-4d33-b03f-a4f6a4f5f210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_72d7a239-3f99-4470-b539-c84861297e42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c05b1f47-6ca8-42d1-ae95-aeef650e06b5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_72d7a239-3f99-4470-b539-c84861297e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#OperatingLeasesOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aacd56b2-6956-4cbf-b98e-65c66de3ac5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9db4ac02-1fe9-4402-a8f9-b7092a0e30d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aacd56b2-6956-4cbf-b98e-65c66de3ac5e" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9db4ac02-1fe9-4402-a8f9-b7092a0e30d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LesseeOperatingLeaseNumberOfRenewalTerms_b8ec2a86-bf10-4581-8bd8-6ffeb19acdc3" xlink:href="ocgn-20210930.xsd#ocgn_LesseeOperatingLeaseNumberOfRenewalTerms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aacd56b2-6956-4cbf-b98e-65c66de3ac5e" xlink:to="loc_ocgn_LesseeOperatingLeaseNumberOfRenewalTerms_b8ec2a86-bf10-4581-8bd8-6ffeb19acdc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_4c3e0bb4-3b8b-40db-822c-454d6c8df7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aacd56b2-6956-4cbf-b98e-65c66de3ac5e" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_4c3e0bb4-3b8b-40db-822c-454d6c8df7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesComponentsOfLeaseExpenseDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#OperatingLeasesOperatingLeasesComponentsOfLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesComponentsOfLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f353352b-ff97-46bb-a17a-7d5d870db222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_0525012f-974e-4eb9-a8c9-168043375db0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f353352b-ff97-46bb-a17a-7d5d870db222" xlink:to="loc_us-gaap_OperatingLeaseCost_0525012f-974e-4eb9-a8c9-168043375db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_ef4e506b-7bb5-457e-8f55-585c06eb1327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f353352b-ff97-46bb-a17a-7d5d870db222" xlink:to="loc_us-gaap_VariableLeaseCost_ef4e506b-7bb5-457e-8f55-585c06eb1327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_66c3d6f5-1cb7-4874-8078-fe256e6d9af3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f353352b-ff97-46bb-a17a-7d5d870db222" xlink:to="loc_us-gaap_LeaseCost_66c3d6f5-1cb7-4874-8078-fe256e6d9af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#OperatingLeasesOperatingLeasesSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ebf64ada-08f5-495b-90cd-0d6393c4154b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_41fc6033-ab98-4b07-a6e7-21920bb235ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ebf64ada-08f5-495b-90cd-0d6393c4154b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_41fc6033-ab98-4b07-a6e7-21920bb235ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_25e7033c-5d26-4a68-bbd8-8e215dabc889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ebf64ada-08f5-495b-90cd-0d6393c4154b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_25e7033c-5d26-4a68-bbd8-8e215dabc889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8eef174e-d1cd-4537-8b69-7dbc37b9e14e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ebf64ada-08f5-495b-90cd-0d6393c4154b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8eef174e-d1cd-4537-8b69-7dbc37b9e14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_587562f8-40e2-48a8-8c29-8ec4c1d24bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ebf64ada-08f5-495b-90cd-0d6393c4154b" xlink:to="loc_us-gaap_OperatingLeaseLiability_587562f8-40e2-48a8-8c29-8ec4c1d24bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesSupplementalInformationRelatedToLeasesDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#OperatingLeasesOperatingLeasesSupplementalInformationRelatedToLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesSupplementalInformationRelatedToLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_36cc2b2b-5694-4416-af44-279a0adee287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e0fb394c-93c0-42a1-bac5-a5774be5470d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_36cc2b2b-5694-4416-af44-279a0adee287" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e0fb394c-93c0-42a1-bac5-a5774be5470d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ba4dd480-3bc8-4c84-9c42-902e1f1b6271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_36cc2b2b-5694-4416-af44-279a0adee287" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ba4dd480-3bc8-4c84-9c42-902e1f1b6271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_083dd3c7-7bda-4699-8ca3-5cdec1aaae24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_78a0d1fc-9ead-4baf-bb89-749fc5656ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_083dd3c7-7bda-4699-8ca3-5cdec1aaae24" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_78a0d1fc-9ead-4baf-bb89-749fc5656ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_276a9b8e-463f-419b-85ea-e15f8410e4db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_083dd3c7-7bda-4699-8ca3-5cdec1aaae24" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_276a9b8e-463f-419b-85ea-e15f8410e4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_64bfb415-2be2-4d23-9636-28a3f83ba3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_083dd3c7-7bda-4699-8ca3-5cdec1aaae24" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_64bfb415-2be2-4d23-9636-28a3f83ba3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_432bed40-9da3-4f61-b3c4-b80dedf343d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_083dd3c7-7bda-4699-8ca3-5cdec1aaae24" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_432bed40-9da3-4f61-b3c4-b80dedf343d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_afdf1972-2f28-4ec6-92be-1e2b964c780f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_083dd3c7-7bda-4699-8ca3-5cdec1aaae24" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_afdf1972-2f28-4ec6-92be-1e2b964c780f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_642fdd49-f85d-4bca-a5df-52e7a38b3a89" xlink:href="ocgn-20210930.xsd#ocgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_083dd3c7-7bda-4699-8ca3-5cdec1aaae24" xlink:to="loc_ocgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_642fdd49-f85d-4bca-a5df-52e7a38b3a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eea3443e-47f8-48b9-aa1f-3cbd6f1f2a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_083dd3c7-7bda-4699-8ca3-5cdec1aaae24" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eea3443e-47f8-48b9-aa1f-3cbd6f1f2a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8a7b45a0-0dfa-4bb0-a2df-77d771a03687" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_083dd3c7-7bda-4699-8ca3-5cdec1aaae24" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8a7b45a0-0dfa-4bb0-a2df-77d771a03687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8cc33c41-c2c1-4c0d-af34-584394d6efc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_083dd3c7-7bda-4699-8ca3-5cdec1aaae24" xlink:to="loc_us-gaap_OperatingLeaseLiability_8cc33c41-c2c1-4c0d-af34-584394d6efc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="ocgn-20210930.xsd#OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="ocgn-20210930.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_47ffcea3-8737-40d5-b720-db02b79bfb28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_e195ae4a-9916-45c1-956d-6eb442d7a344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_47ffcea3-8737-40d5-b720-db02b79bfb28" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_e195ae4a-9916-45c1-956d-6eb442d7a344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="ocgn-20210930.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_af47aeaa-9ea7-4bd3-ba09-df5c1d75857f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d334a4d9-e9cd-41be-ad38-2088cf0f3147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_af47aeaa-9ea7-4bd3-ba09-df5c1d75857f" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d334a4d9-e9cd-41be-ad38-2088cf0f3147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_8e471b38-01e5-4fa9-9aa2-4a76c2c58bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c34786cd-3e04-40ad-ab4c-195b49937da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_8e471b38-01e5-4fa9-9aa2-4a76c2c58bf2" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c34786cd-3e04-40ad-ab4c-195b49937da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_39c72a34-df4d-41a1-9be7-ac164ebbfd73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c34786cd-3e04-40ad-ab4c-195b49937da9" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_39c72a34-df4d-41a1-9be7-ac164ebbfd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_3af53085-0bba-4b7c-9d09-5dd4b8c9b194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_39c72a34-df4d-41a1-9be7-ac164ebbfd73" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_3af53085-0bba-4b7c-9d09-5dd4b8c9b194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_ec4f2de0-b153-4daf-9ead-b4e9b30f0821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3af53085-0bba-4b7c-9d09-5dd4b8c9b194" xlink:to="loc_us-gaap_EmployeeSeveranceMember_ec4f2de0-b153-4daf-9ead-b4e9b30f0821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a8b94260-cc24-420e-acde-764e872a2fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c34786cd-3e04-40ad-ab4c-195b49937da9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a8b94260-cc24-420e-acde-764e872a2fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_47ad22b9-664c-45de-813a-d6b0d7f93545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a8b94260-cc24-420e-acde-764e872a2fa0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_47ad22b9-664c-45de-813a-d6b0d7f93545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c5c7db1c-7fac-43ca-8025-ecdce4401009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_47ad22b9-664c-45de-813a-d6b0d7f93545" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c5c7db1c-7fac-43ca-8025-ecdce4401009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f3e9b1a0-7578-4c6c-84c0-09145ad7686b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_47ad22b9-664c-45de-813a-d6b0d7f93545" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f3e9b1a0-7578-4c6c-84c0-09145ad7686b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c34786cd-3e04-40ad-ab4c-195b49937da9" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ResearchAndDevelopmentExpensesCurrent_8064c81a-848e-4dbc-9827-3b6cb804cb1f" xlink:href="ocgn-20210930.xsd#ocgn_ResearchAndDevelopmentExpensesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:to="loc_ocgn_ResearchAndDevelopmentExpensesCurrent_8064c81a-848e-4dbc-9827-3b6cb804cb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AccruedLiabilitiesClinical_216c4b7a-1b2c-4f1e-862d-03623521064f" xlink:href="ocgn-20210930.xsd#ocgn_AccruedLiabilitiesClinical"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:to="loc_ocgn_AccruedLiabilitiesClinical_216c4b7a-1b2c-4f1e-862d-03623521064f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AccruedLiabilitiesProfessionalFees_7aaa2b19-6084-4e41-8fac-20404eb45383" xlink:href="ocgn-20210930.xsd#ocgn_AccruedLiabilitiesProfessionalFees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:to="loc_ocgn_AccruedLiabilitiesProfessionalFees_7aaa2b19-6084-4e41-8fac-20404eb45383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_edb249f4-9f25-43c3-8d5d-defd0f1ccaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_edb249f4-9f25-43c3-8d5d-defd0f1ccaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_AccruedSeveranceRelatedLiabilitiesCurrent_faf89835-9cde-496d-845e-d5871757eea9" xlink:href="ocgn-20210930.xsd#ocgn_AccruedSeveranceRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:to="loc_ocgn_AccruedSeveranceRelatedLiabilitiesCurrent_faf89835-9cde-496d-845e-d5871757eea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0aec7fd7-9852-4657-80a0-bc5962b0125f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0aec7fd7-9852-4657-80a0-bc5962b0125f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_e6f6d384-c82a-4673-81fc-9b5b1fbd0e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_e6f6d384-c82a-4673-81fc-9b5b1fbd0e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_ce4888e0-3552-438b-b10d-b5e55e183512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_ce4888e0-3552-438b-b10d-b5e55e183512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_9696446e-e3ed-4be1-a284-53a380f2ba18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:to="loc_us-gaap_RestructuringCharges_9696446e-e3ed-4be1-a284-53a380f2ba18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_af2e54a3-6879-4ca1-8ea2-f98c0349becd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:to="loc_us-gaap_SeveranceCosts1_af2e54a3-6879-4ca1-8ea2-f98c0349becd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_d8570c0b-276e-4acd-b1c3-b1543a3d8e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_94c92c22-f12d-4888-ab49-2dce6e44a041" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_d8570c0b-276e-4acd-b1c3-b1543a3d8e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/Debt" xlink:type="simple" xlink:href="ocgn-20210930.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ce234b38-2a99-4a60-aa74-f7cd8258a4d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_41e2094f-6d94-49bf-a559-d2197ebbdf02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ce234b38-2a99-4a60-aa74-f7cd8258a4d1" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_41e2094f-6d94-49bf-a559-d2197ebbdf02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtTables" xlink:type="simple" xlink:href="ocgn-20210930.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9046edfa-d410-46dc-a2c1-890f6d6ad3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_ce1aaf1a-3467-4577-a847-5f061f44266d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9046edfa-d410-46dc-a2c1-890f6d6ad3c4" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_ce1aaf1a-3467-4577-a847-5f061f44266d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesfortheComponentsofDebtDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#DebtSummaryoftheCarryingValuesfortheComponentsofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesfortheComponentsofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_53e6029b-a0a1-4256-b4e7-c0aad4c0c811" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f4b1fbcb-6d8f-42cb-8517-668cd879ec4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_53e6029b-a0a1-4256-b4e7-c0aad4c0c811" xlink:to="loc_us-gaap_DebtInstrumentTable_f4b1fbcb-6d8f-42cb-8517-668cd879ec4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3d098e83-a230-415a-9c97-e1dafde6a315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f4b1fbcb-6d8f-42cb-8517-668cd879ec4c" xlink:to="loc_us-gaap_DebtInstrumentAxis_3d098e83-a230-415a-9c97-e1dafde6a315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e6d7a5be-73db-4d1b-8847-cfcb44e17025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3d098e83-a230-415a-9c97-e1dafde6a315" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e6d7a5be-73db-4d1b-8847-cfcb44e17025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_PaycheckProtectionProgramLoanMember_34ce95c9-47cc-49b4-a11c-9c70597da332" xlink:href="ocgn-20210930.xsd#ocgn_PaycheckProtectionProgramLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e6d7a5be-73db-4d1b-8847-cfcb44e17025" xlink:to="loc_ocgn_PaycheckProtectionProgramLoanMember_34ce95c9-47cc-49b4-a11c-9c70597da332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EB5ProgramBorrowingsMember_c17d0725-9db7-48eb-9d4b-56ba7d14e012" xlink:href="ocgn-20210930.xsd#ocgn_EB5ProgramBorrowingsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e6d7a5be-73db-4d1b-8847-cfcb44e17025" xlink:to="loc_ocgn_EB5ProgramBorrowingsMember_c17d0725-9db7-48eb-9d4b-56ba7d14e012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ed69fc60-89f3-4c2a-bb0b-7e7599f38a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f4b1fbcb-6d8f-42cb-8517-668cd879ec4c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ed69fc60-89f3-4c2a-bb0b-7e7599f38a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_98becf46-70be-4adf-bf56-2073b5d87566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ed69fc60-89f3-4c2a-bb0b-7e7599f38a9e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_98becf46-70be-4adf-bf56-2073b5d87566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_8b2cd57b-c3c9-4a36-b8ac-4e5cb5c6b114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_98becf46-70be-4adf-bf56-2073b5d87566" xlink:to="loc_us-gaap_NotesPayableToBanksMember_8b2cd57b-c3c9-4a36-b8ac-4e5cb5c6b114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_78a75b6c-b07a-4541-89e4-ebed484fde2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_98becf46-70be-4adf-bf56-2073b5d87566" xlink:to="loc_us-gaap_LoansPayableMember_78a75b6c-b07a-4541-89e4-ebed484fde2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2bfc1905-313c-4520-9e17-d26bff77a920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f4b1fbcb-6d8f-42cb-8517-668cd879ec4c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2bfc1905-313c-4520-9e17-d26bff77a920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_858df622-5246-4518-a75a-f5f4d0f8562c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bfc1905-313c-4520-9e17-d26bff77a920" xlink:to="loc_us-gaap_LongTermDebt_858df622-5246-4518-a75a-f5f4d0f8562c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtPPPNoteDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#DebtPPPNoteDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/DebtPPPNoteDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_162f0206-a758-4f3d-b88c-717f02147e81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1f396d43-fc79-4a73-a4d4-112f9d2e403c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_162f0206-a758-4f3d-b88c-717f02147e81" xlink:to="loc_us-gaap_DebtInstrumentTable_1f396d43-fc79-4a73-a4d4-112f9d2e403c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d4a48016-d0fd-4a2c-b06f-ce913745b1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1f396d43-fc79-4a73-a4d4-112f9d2e403c" xlink:to="loc_us-gaap_DebtInstrumentAxis_d4a48016-d0fd-4a2c-b06f-ce913745b1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ec39e1d8-72b4-4c06-9b4e-d2359bdc4ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d4a48016-d0fd-4a2c-b06f-ce913745b1fa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ec39e1d8-72b4-4c06-9b4e-d2359bdc4ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_PaycheckProtectionProgramLoanMember_e84dfd20-4499-45e0-bb9e-21533270956e" xlink:href="ocgn-20210930.xsd#ocgn_PaycheckProtectionProgramLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ec39e1d8-72b4-4c06-9b4e-d2359bdc4ff5" xlink:to="loc_ocgn_PaycheckProtectionProgramLoanMember_e84dfd20-4499-45e0-bb9e-21533270956e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4753ef52-95bf-473b-85e2-70579fee9d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1f396d43-fc79-4a73-a4d4-112f9d2e403c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4753ef52-95bf-473b-85e2-70579fee9d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dc6b0486-ce13-4c41-a588-ca50732c0516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4753ef52-95bf-473b-85e2-70579fee9d89" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dc6b0486-ce13-4c41-a588-ca50732c0516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_8971f4df-481a-4872-afb4-41cef3359133" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dc6b0486-ce13-4c41-a588-ca50732c0516" xlink:to="loc_us-gaap_LoansPayableMember_8971f4df-481a-4872-afb4-41cef3359133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_00308f51-5266-46f0-ba64-af3f4905cce8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1f396d43-fc79-4a73-a4d4-112f9d2e403c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_00308f51-5266-46f0-ba64-af3f4905cce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_de76d5ce-7659-46e7-b6d3-689b775489c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00308f51-5266-46f0-ba64-af3f4905cce8" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_de76d5ce-7659-46e7-b6d3-689b775489c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_933ab3f9-9db7-4292-95c2-8379e46903a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00308f51-5266-46f0-ba64-af3f4905cce8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_933ab3f9-9db7-4292-95c2-8379e46903a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ae97c263-0188-4810-9b46-95a70a012e81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00308f51-5266-46f0-ba64-af3f4905cce8" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ae97c263-0188-4810-9b46-95a70a012e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#DebtEB5LoanAgreementBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fa328992-f059-4319-a3a7-a71c757d0412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_08e9b238-053c-44ee-ae7f-acf41d507326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fa328992-f059-4319-a3a7-a71c757d0412" xlink:to="loc_us-gaap_DebtInstrumentTable_08e9b238-053c-44ee-ae7f-acf41d507326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8dbb4e6e-f692-417c-ae38-7081afd0a1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_08e9b238-053c-44ee-ae7f-acf41d507326" xlink:to="loc_us-gaap_DebtInstrumentAxis_8dbb4e6e-f692-417c-ae38-7081afd0a1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_caa80f4b-3bff-4278-905b-f9daf82901b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8dbb4e6e-f692-417c-ae38-7081afd0a1d3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_caa80f4b-3bff-4278-905b-f9daf82901b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EB5ProgramBorrowingsMember_2d9222b3-c64d-43f5-91ab-ad5298c22ba8" xlink:href="ocgn-20210930.xsd#ocgn_EB5ProgramBorrowingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caa80f4b-3bff-4278-905b-f9daf82901b4" xlink:to="loc_ocgn_EB5ProgramBorrowingsMember_2d9222b3-c64d-43f5-91ab-ad5298c22ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6000bffa-eba9-4ce9-962c-382c15deefc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_08e9b238-053c-44ee-ae7f-acf41d507326" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6000bffa-eba9-4ce9-962c-382c15deefc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1772bab1-1c03-4930-9ae4-2f6885fcf9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6000bffa-eba9-4ce9-962c-382c15deefc5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1772bab1-1c03-4930-9ae4-2f6885fcf9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_1fc24f82-06a5-4795-9d40-ffdc8e8e8851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1772bab1-1c03-4930-9ae4-2f6885fcf9b2" xlink:to="loc_us-gaap_LoansPayableMember_1fc24f82-06a5-4795-9d40-ffdc8e8e8851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_36d63f37-9e62-438c-953e-875c9d40168c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_08e9b238-053c-44ee-ae7f-acf41d507326" xlink:to="loc_us-gaap_DebtInstrumentLineItems_36d63f37-9e62-438c-953e-875c9d40168c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2d1c9428-9817-45db-83da-4440dc579904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36d63f37-9e62-438c-953e-875c9d40168c" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2d1c9428-9817-45db-83da-4440dc579904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LineOfCreditBorrowingEachDraw_d23f4821-e19c-484e-b5fe-dc0b3b40fe24" xlink:href="ocgn-20210930.xsd#ocgn_LineOfCreditBorrowingEachDraw"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36d63f37-9e62-438c-953e-875c9d40168c" xlink:to="loc_ocgn_LineOfCreditBorrowingEachDraw_d23f4821-e19c-484e-b5fe-dc0b3b40fe24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bcb8c0f6-e0fe-48cb-9e7c-e6beb671856d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36d63f37-9e62-438c-953e-875c9d40168c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bcb8c0f6-e0fe-48cb-9e7c-e6beb671856d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_1eddc74a-4e3b-4329-9b73-00e8c264eb20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36d63f37-9e62-438c-953e-875c9d40168c" xlink:to="loc_us-gaap_LineOfCredit_1eddc74a-4e3b-4329-9b73-00e8c264eb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesoftheLoanAgreementBorrowingsDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#DebtSummaryoftheCarryingValuesoftheLoanAgreementBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesoftheLoanAgreementBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3eb5e452-8c5a-4284-8577-8a48d870689b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e7966310-4d5e-4929-ae9b-e6202376652a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3eb5e452-8c5a-4284-8577-8a48d870689b" xlink:to="loc_us-gaap_DebtInstrumentTable_e7966310-4d5e-4929-ae9b-e6202376652a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_39d06da8-7dd0-4706-9d76-2e1985c7cf21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e7966310-4d5e-4929-ae9b-e6202376652a" xlink:to="loc_us-gaap_DebtInstrumentAxis_39d06da8-7dd0-4706-9d76-2e1985c7cf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f1cca789-3f53-427a-93a1-60e8a5f5cc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_39d06da8-7dd0-4706-9d76-2e1985c7cf21" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f1cca789-3f53-427a-93a1-60e8a5f5cc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_EB5ProgramBorrowingsMember_41d763d8-3284-49f5-95aa-5ab1399737d2" xlink:href="ocgn-20210930.xsd#ocgn_EB5ProgramBorrowingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f1cca789-3f53-427a-93a1-60e8a5f5cc7a" xlink:to="loc_ocgn_EB5ProgramBorrowingsMember_41d763d8-3284-49f5-95aa-5ab1399737d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_dd260377-ccbe-4ef0-b85c-c9ac23740d36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e7966310-4d5e-4929-ae9b-e6202376652a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_dd260377-ccbe-4ef0-b85c-c9ac23740d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_01baa96f-3a8f-456f-9dca-46084bcf5d64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_dd260377-ccbe-4ef0-b85c-c9ac23740d36" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_01baa96f-3a8f-456f-9dca-46084bcf5d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_0020f79d-6471-4bf1-b18e-9b9466277558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_01baa96f-3a8f-456f-9dca-46084bcf5d64" xlink:to="loc_us-gaap_LoansPayableMember_0020f79d-6471-4bf1-b18e-9b9466277558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8e542761-a3fe-49f4-8a84-78cad1bb3231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e7966310-4d5e-4929-ae9b-e6202376652a" xlink:to="loc_us-gaap_DebtInstrumentLineItems_8e542761-a3fe-49f4-8a84-78cad1bb3231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ecd05e47-0a91-49b0-8abb-ff65d0eaee77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8e542761-a3fe-49f4-8a84-78cad1bb3231" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ecd05e47-0a91-49b0-8abb-ff65d0eaee77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_174b2bde-6782-4372-9f6e-5cf956c221e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8e542761-a3fe-49f4-8a84-78cad1bb3231" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_174b2bde-6782-4372-9f6e-5cf956c221e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_d1e1d7d9-4112-47d3-a549-31fcdd524033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8e542761-a3fe-49f4-8a84-78cad1bb3231" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_d1e1d7d9-4112-47d3-a549-31fcdd524033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a6b5c201-9b40-4a96-9e11-755aea385bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8e542761-a3fe-49f4-8a84-78cad1bb3231" xlink:to="loc_us-gaap_LongTermDebt_a6b5c201-9b40-4a96-9e11-755aea385bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/Equity" xlink:type="simple" xlink:href="ocgn-20210930.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1e6d7296-b545-4708-8787-c35adda60eea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6cd98293-14bf-4376-8822-56b83825de02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1e6d7296-b545-4708-8787-c35adda60eea" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6cd98293-14bf-4376-8822-56b83825de02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/EquityDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#EquityDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/EquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9ab07775-b6a0-4eb0-914d-e4342c7a7411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a4246d31-2c73-4c73-870e-8d6da41a4ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9ab07775-b6a0-4eb0-914d-e4342c7a7411" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a4246d31-2c73-4c73-870e-8d6da41a4ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_246904e6-3907-494d-8065-d9b876683236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a4246d31-2c73-4c73-870e-8d6da41a4ec0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_246904e6-3907-494d-8065-d9b876683236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0438852-bfdd-49a1-a610-276f17112178" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_246904e6-3907-494d-8065-d9b876683236" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0438852-bfdd-49a1-a610-276f17112178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_COVAXINPreferredStockPurchaseAgreementMember_b7eb979d-5e5f-485c-9c94-9d363f6b99b9" xlink:href="ocgn-20210930.xsd#ocgn_COVAXINPreferredStockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0438852-bfdd-49a1-a610-276f17112178" xlink:to="loc_ocgn_COVAXINPreferredStockPurchaseAgreementMember_b7eb979d-5e5f-485c-9c94-9d363f6b99b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_RegisteredDirectOfferingMember_98ad90e5-21a4-4a99-abdf-7dc86cdd480d" xlink:href="ocgn-20210930.xsd#ocgn_RegisteredDirectOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0438852-bfdd-49a1-a610-276f17112178" xlink:to="loc_ocgn_RegisteredDirectOfferingMember_98ad90e5-21a4-4a99-abdf-7dc86cdd480d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ControlledEquityOfferingSalesAgreementMember_a30ec7a1-48dd-43e1-85ca-2dbc67a46fca" xlink:href="ocgn-20210930.xsd#ocgn_ControlledEquityOfferingSalesAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0438852-bfdd-49a1-a610-276f17112178" xlink:to="loc_ocgn_ControlledEquityOfferingSalesAgreementMember_a30ec7a1-48dd-43e1-85ca-2dbc67a46fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SubscriptionAgreementsMember_da5591fb-3272-4556-975a-2a5d7e627088" xlink:href="ocgn-20210930.xsd#ocgn_SubscriptionAgreementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0438852-bfdd-49a1-a610-276f17112178" xlink:to="loc_ocgn_SubscriptionAgreementsMember_da5591fb-3272-4556-975a-2a5d7e627088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8dfc0592-2e4f-44f0-bdaa-1ad3623b49a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a4246d31-2c73-4c73-870e-8d6da41a4ec0" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8dfc0592-2e4f-44f0-bdaa-1ad3623b49a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fd906450-6fb1-43f3-accd-1e873bec09f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8dfc0592-2e4f-44f0-bdaa-1ad3623b49a2" xlink:to="loc_us-gaap_ClassOfStockDomain_fd906450-6fb1-43f3-accd-1e873bec09f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5e662022-b1f3-435f-82c4-4e2d76f00deb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_fd906450-6fb1-43f3-accd-1e873bec09f5" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5e662022-b1f3-435f-82c4-4e2d76f00deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dcbc4753-dc9b-455c-8a57-2f6dfa8b300a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a4246d31-2c73-4c73-870e-8d6da41a4ec0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dcbc4753-dc9b-455c-8a57-2f6dfa8b300a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a98c6b9b-4b10-46ad-80e8-8a7dd849cb74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dcbc4753-dc9b-455c-8a57-2f6dfa8b300a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a98c6b9b-4b10-46ad-80e8-8a7dd849cb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6aae88b3-fa34-4c8d-a9e3-7726dc2a8022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a98c6b9b-4b10-46ad-80e8-8a7dd849cb74" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6aae88b3-fa34-4c8d-a9e3-7726dc2a8022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e1b2799b-b6f1-435d-a900-37e7790ccd48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a4246d31-2c73-4c73-870e-8d6da41a4ec0" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e1b2799b-b6f1-435d-a900-37e7790ccd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_dbf820e0-db7c-4f8b-b8df-7a03098e26b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e1b2799b-b6f1-435d-a900-37e7790ccd48" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_dbf820e0-db7c-4f8b-b8df-7a03098e26b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_8ad9c0b5-b2f8-46d2-b814-771c1a6d047b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_dbf820e0-db7c-4f8b-b8df-7a03098e26b8" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_8ad9c0b5-b2f8-46d2-b814-771c1a6d047b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a4246d31-2c73-4c73-870e-8d6da41a4ec0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction_3151260c-9df3-463c-a13c-8d0a79c5a838" xlink:href="ocgn-20210930.xsd#ocgn_SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_ocgn_SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction_3151260c-9df3-463c-a13c-8d0a79c5a838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7f077f98-5ab9-4968-898b-a4ac9a818309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7f077f98-5ab9-4968-898b-a4ac9a818309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SaleOfStockAgreementToSellPricePerShare_5e369044-8afb-42be-b8e4-8c831ca62411" xlink:href="ocgn-20210930.xsd#ocgn_SaleOfStockAgreementToSellPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_ocgn_SaleOfStockAgreementToSellPricePerShare_5e369044-8afb-42be-b8e4-8c831ca62411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_fcacf7d7-e351-4db9-8e09-c3aef4297ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_fcacf7d7-e351-4db9-8e09-c3aef4297ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SupplyAgreementNumberOfDoses_484ea425-1772-4d37-95a2-3ee848f566b6" xlink:href="ocgn-20210930.xsd#ocgn_SupplyAgreementNumberOfDoses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_ocgn_SupplyAgreementNumberOfDoses_484ea425-1772-4d37-95a2-3ee848f566b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_25720de1-168f-43f6-ba50-24544e8d0723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_25720de1-168f-43f6-ba50-24544e8d0723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_2f6c41e6-2f9f-4223-8f19-bbe3f70a8bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_2f6c41e6-2f9f-4223-8f19-bbe3f70a8bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_PreferredStockMeasurementInput_cdc3c2e2-ed52-415c-b8f0-7355745b0c2c" xlink:href="ocgn-20210930.xsd#ocgn_PreferredStockMeasurementInput"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_ocgn_PreferredStockMeasurementInput_cdc3c2e2-ed52-415c-b8f0-7355745b0c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d1d05dcc-8aed-41cf-ae68-1888f77d5da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d1d05dcc-8aed-41cf-ae68-1888f77d5da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_cca127e8-5f25-4287-886f-6ba8eb178279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_cca127e8-5f25-4287-886f-6ba8eb178279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5cde5232-6e54-4a03-92d1-090c7b1e3c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5cde5232-6e54-4a03-92d1-090c7b1e3c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_0b70be60-ee05-4bd5-9933-5c7eb35eb265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_0b70be60-ee05-4bd5-9933-5c7eb35eb265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfAtTheMarketOfferings_d9bb620f-b08f-4bb5-bc2b-385737c0ead7" xlink:href="ocgn-20210930.xsd#ocgn_NumberOfAtTheMarketOfferings"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_ocgn_NumberOfAtTheMarketOfferings_d9bb620f-b08f-4bb5-bc2b-385737c0ead7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SaleOfStockOutstandingObligationCancelledInExchangeForStock_1775cb4b-c8c6-4d82-baff-e328b338417c" xlink:href="ocgn-20210930.xsd#ocgn_SaleOfStockOutstandingObligationCancelledInExchangeForStock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_ocgn_SaleOfStockOutstandingObligationCancelledInExchangeForStock_1775cb4b-c8c6-4d82-baff-e328b338417c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SaleOfStockAdditionalDebtCancelledInExchangeForStock_8e8c876d-5942-49b8-a250-8004f6fdf4bc" xlink:href="ocgn-20210930.xsd#ocgn_SaleOfStockAdditionalDebtCancelledInExchangeForStock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_eecda6c9-2548-4e8c-b588-d15f0b814b57" xlink:to="loc_ocgn_SaleOfStockAdditionalDebtCancelledInExchangeForStock_8e8c876d-5942-49b8-a250-8004f6fdf4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/Warrants" xlink:type="simple" xlink:href="ocgn-20210930.xsd#Warrants"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/Warrants" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_35bedda6-f9dd-4c1f-a199-a3b55cbe6a89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_WarrantsTextBlock_8061b40c-40bc-4683-b931-e3d5aa756faa" xlink:href="ocgn-20210930.xsd#ocgn_WarrantsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_35bedda6-f9dd-4c1f-a199-a3b55cbe6a89" xlink:to="loc_ocgn_WarrantsTextBlock_8061b40c-40bc-4683-b931-e3d5aa756faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/WarrantsDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#WarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/WarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_59a737f7-6e78-4db5-8fec-d081f174e4d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_2b31aa8a-05f3-4410-bc5b-39e97a4aa015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_59a737f7-6e78-4db5-8fec-d081f174e4d6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_2b31aa8a-05f3-4410-bc5b-39e97a4aa015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_885de4a5-0bdf-40fe-bad3-f4f96aa5b9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2b31aa8a-05f3-4410-bc5b-39e97a4aa015" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_885de4a5-0bdf-40fe-bad3-f4f96aa5b9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ce32ecf9-a5e6-4b9b-8660-a694805efdaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_885de4a5-0bdf-40fe-bad3-f4f96aa5b9e0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ce32ecf9-a5e6-4b9b-8660-a694805efdaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_CanadaConsultingWarrantsMember_b85948b9-5945-4899-bc5a-d7df9a55cbd6" xlink:href="ocgn-20210930.xsd#ocgn_CanadaConsultingWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ce32ecf9-a5e6-4b9b-8660-a694805efdaa" xlink:to="loc_ocgn_CanadaConsultingWarrantsMember_b85948b9-5945-4899-bc5a-d7df9a55cbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesAWarrantsMember_2557c176-97b9-448b-a632-16d86750f2be" xlink:href="ocgn-20210930.xsd#ocgn_SeriesAWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ce32ecf9-a5e6-4b9b-8660-a694805efdaa" xlink:to="loc_ocgn_SeriesAWarrantsMember_2557c176-97b9-448b-a632-16d86750f2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesBWarrantsMember_3a9278e8-53b8-4a00-8d6d-b3042a05ff29" xlink:href="ocgn-20210930.xsd#ocgn_SeriesBWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ce32ecf9-a5e6-4b9b-8660-a694805efdaa" xlink:to="loc_ocgn_SeriesBWarrantsMember_3a9278e8-53b8-4a00-8d6d-b3042a05ff29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SeriesCWarrantsMember_05f6daeb-a701-4710-9538-77b24ed5af2d" xlink:href="ocgn-20210930.xsd#ocgn_SeriesCWarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ce32ecf9-a5e6-4b9b-8660-a694805efdaa" xlink:to="loc_ocgn_SeriesCWarrantsMember_05f6daeb-a701-4710-9538-77b24ed5af2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_SPAWarrantsMember_58facf01-9d9a-493a-b3a6-815e19150626" xlink:href="ocgn-20210930.xsd#ocgn_SPAWarrantsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ce32ecf9-a5e6-4b9b-8660-a694805efdaa" xlink:to="loc_ocgn_SPAWarrantsMember_58facf01-9d9a-493a-b3a6-815e19150626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_OpCoWarrantsMember_8615fdea-8f56-4ac1-84ba-9edc069fa2f2" xlink:href="ocgn-20210930.xsd#ocgn_OpCoWarrantsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ce32ecf9-a5e6-4b9b-8660-a694805efdaa" xlink:to="loc_ocgn_OpCoWarrantsMember_8615fdea-8f56-4ac1-84ba-9edc069fa2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_fe62b6f6-3dba-46ea-bc47-c02d6a120a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2b31aa8a-05f3-4410-bc5b-39e97a4aa015" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_fe62b6f6-3dba-46ea-bc47-c02d6a120a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_747ee14e-9f9f-49dd-8372-fc8a7599d6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fe62b6f6-3dba-46ea-bc47-c02d6a120a4e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_747ee14e-9f9f-49dd-8372-fc8a7599d6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_WarrantsExchangedForCommonStockMember_f632c832-c618-4376-adf9-8caa99fd17aa" xlink:href="ocgn-20210930.xsd#ocgn_WarrantsExchangedForCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_747ee14e-9f9f-49dd-8372-fc8a7599d6d3" xlink:to="loc_ocgn_WarrantsExchangedForCommonStockMember_f632c832-c618-4376-adf9-8caa99fd17aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b64f8ce5-9abb-4f59-8e3e-12687be1cdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2b31aa8a-05f3-4410-bc5b-39e97a4aa015" xlink:to="loc_us-gaap_DebtInstrumentAxis_b64f8ce5-9abb-4f59-8e3e-12687be1cdd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bf02c857-36bf-4bbe-b6ac-6705a2ba544c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b64f8ce5-9abb-4f59-8e3e-12687be1cdd4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bf02c857-36bf-4bbe-b6ac-6705a2ba544c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_WarrantExchangePromissoryNotesMember_51326767-1b9e-48af-a2a8-3062b8b3ab31" xlink:href="ocgn-20210930.xsd#ocgn_WarrantExchangePromissoryNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bf02c857-36bf-4bbe-b6ac-6705a2ba544c" xlink:to="loc_ocgn_WarrantExchangePromissoryNotesMember_51326767-1b9e-48af-a2a8-3062b8b3ab31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6b31ea10-06fc-4727-8443-b5ac41f018f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2b31aa8a-05f3-4410-bc5b-39e97a4aa015" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6b31ea10-06fc-4727-8443-b5ac41f018f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a6a0e057-c56b-4f31-8fad-1ad400e44d82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6b31ea10-06fc-4727-8443-b5ac41f018f9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a6a0e057-c56b-4f31-8fad-1ad400e44d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_2b74ece8-63e4-4ab3-80d0-18e95c3444bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a6a0e057-c56b-4f31-8fad-1ad400e44d82" xlink:to="loc_us-gaap_NotesPayableToBanksMember_2b74ece8-63e4-4ab3-80d0-18e95c3444bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_addf8eaa-38d9-4b53-820d-23cc216aedc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2b31aa8a-05f3-4410-bc5b-39e97a4aa015" xlink:to="loc_us-gaap_FinancialInstrumentAxis_addf8eaa-38d9-4b53-820d-23cc216aedc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b2f9007-ab5d-4d3d-8d7c-9f32348ad1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_addf8eaa-38d9-4b53-820d-23cc216aedc8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b2f9007-ab5d-4d3d-8d7c-9f32348ad1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_1eb899b5-bf79-4bf7-a6de-9295012abdce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b2f9007-ab5d-4d3d-8d7c-9f32348ad1ca" xlink:to="loc_us-gaap_WarrantMember_1eb899b5-bf79-4bf7-a6de-9295012abdce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4fcbbbb2-3845-4b91-8a54-9de213c6eb39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2b31aa8a-05f3-4410-bc5b-39e97a4aa015" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4fcbbbb2-3845-4b91-8a54-9de213c6eb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6db44efb-f88b-428b-90d6-fa55fc430ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4fcbbbb2-3845-4b91-8a54-9de213c6eb39" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6db44efb-f88b-428b-90d6-fa55fc430ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_64d5d907-03bc-47d8-9d38-3799516e44d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6db44efb-f88b-428b-90d6-fa55fc430ab0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_64d5d907-03bc-47d8-9d38-3799516e44d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2b31aa8a-05f3-4410-bc5b-39e97a4aa015" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightExercisable_66395ac3-5eed-4e93-9eab-ca5bf62413ca" xlink:href="ocgn-20210930.xsd#ocgn_ClassOfWarrantOrRightExercisable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_ocgn_ClassOfWarrantOrRightExercisable_66395ac3-5eed-4e93-9eab-ca5bf62413ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightExpectedMilestonePayment_e22637d6-62d3-40af-8208-a77aaae1d418" xlink:href="ocgn-20210930.xsd#ocgn_ClassOfWarrantOrRightExpectedMilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_ocgn_ClassOfWarrantOrRightExpectedMilestonePayment_e22637d6-62d3-40af-8208-a77aaae1d418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ab53cce6-5d0c-4ee2-a6ef-b5f6e6d2d7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ab53cce6-5d0c-4ee2-a6ef-b5f6e6d2d7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_12d655b6-9744-4cf4-a81e-64cd245d2263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_12d655b6-9744-4cf4-a81e-64cd245d2263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfSeriesOfWarrantsIssued_0c560a68-3583-4eff-8795-f3a8a85653ae" xlink:href="ocgn-20210930.xsd#ocgn_NumberOfSeriesOfWarrantsIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_ocgn_NumberOfSeriesOfWarrantsIssued_0c560a68-3583-4eff-8795-f3a8a85653ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_55239496-d5ab-4bd2-87f8-afeca6f13b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_55239496-d5ab-4bd2-87f8-afeca6f13b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8c6e1289-fa3a-4312-b44b-eb0df1ebf5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8c6e1289-fa3a-4312-b44b-eb0df1ebf5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5330a6d7-7f12-40a1-a2b2-21fae342892f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5330a6d7-7f12-40a1-a2b2-21fae342892f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_a74ff2b4-017b-4985-8a84-1be30c31d1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_us-gaap_RepaymentsOfDebt_a74ff2b4-017b-4985-8a84-1be30c31d1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants_ef270760-65bc-415f-a990-27ea5f1a78aa" xlink:href="ocgn-20210930.xsd#ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants_ef270760-65bc-415f-a990-27ea5f1a78aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock_00c795e7-36d8-4a7c-b16b-f9475673454d" xlink:href="ocgn-20210930.xsd#ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock_00c795e7-36d8-4a7c-b16b-f9475673454d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote_37cb21fd-b324-4a4d-acd2-338d1d63c6ae" xlink:href="ocgn-20210930.xsd#ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote_37cb21fd-b324-4a4d-acd2-338d1d63c6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue_c62aea8d-3229-4e14-99bd-9e1dbc0af357" xlink:href="ocgn-20210930.xsd#ocgn_ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_ocgn_ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue_c62aea8d-3229-4e14-99bd-9e1dbc0af357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfFormerEmployeesWithWarrants_fbd4d4cc-bb60-40b1-bfff-be710faa5af9" xlink:href="ocgn-20210930.xsd#ocgn_NumberOfFormerEmployeesWithWarrants"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9dd6a3a3-4a0f-4b9e-8fc5-bdd24f6e157e" xlink:to="loc_ocgn_NumberOfFormerEmployeesWithWarrants_fbd4d4cc-bb60-40b1-bfff-be710faa5af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="ocgn-20210930.xsd#StockbasedCompensation"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_46fe837d-ddc7-44c0-a415-ea383d2d74a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a85772df-b4cc-4056-9ca1-b79e429794ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_46fe837d-ddc7-44c0-a415-ea383d2d74a7" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a85772df-b4cc-4056-9ca1-b79e429794ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="ocgn-20210930.xsd#StockbasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a00a424-dffa-415c-8a29-72a18bd295a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_345849c8-9705-4c5d-904d-85f5a95b2d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a00a424-dffa-415c-8a29-72a18bd295a8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_345849c8-9705-4c5d-904d-85f5a95b2d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0974b46f-874a-4f1d-b412-b3b91f33b266" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a00a424-dffa-415c-8a29-72a18bd295a8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0974b46f-874a-4f1d-b412-b3b91f33b266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_7b567e95-6662-4ec5-83cf-b9612fcf9591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a00a424-dffa-415c-8a29-72a18bd295a8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_7b567e95-6662-4ec5-83cf-b9612fcf9591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#StockbasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1d53a6e1-9c4f-4a16-993b-108b0d347b83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6627351-5477-416a-b206-9bd8349770c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1d53a6e1-9c4f-4a16-993b-108b0d347b83" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6627351-5477-416a-b206-9bd8349770c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7d5f1c53-5935-44ce-aeb1-4c653306ab73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6627351-5477-416a-b206-9bd8349770c4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7d5f1c53-5935-44ce-aeb1-4c653306ab73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9293a94c-2138-4767-a434-012c8dd36520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7d5f1c53-5935-44ce-aeb1-4c653306ab73" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9293a94c-2138-4767-a434-012c8dd36520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_99eb5e01-78ac-41db-9e6e-7ac41ff62dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9293a94c-2138-4767-a434-012c8dd36520" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_99eb5e01-78ac-41db-9e6e-7ac41ff62dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4838170e-9d18-4282-a704-f90e2165dd16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9293a94c-2138-4767-a434-012c8dd36520" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4838170e-9d18-4282-a704-f90e2165dd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cd949088-c067-4554-921d-55121c1de01c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6627351-5477-416a-b206-9bd8349770c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cd949088-c067-4554-921d-55121c1de01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d4567e03-e75b-42da-a6b1-33125cbe1559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cd949088-c067-4554-921d-55121c1de01c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d4567e03-e75b-42da-a6b1-33125cbe1559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#StockbasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ebd38451-ce4c-4019-98ea-9b4816708642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ff7348c-1920-436e-864f-51f165cf73bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ebd38451-ce4c-4019-98ea-9b4816708642" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ff7348c-1920-436e-864f-51f165cf73bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_67667918-f674-4617-bcd2-0e5f40178296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ff7348c-1920-436e-864f-51f165cf73bd" xlink:to="loc_us-gaap_AwardTypeAxis_67667918-f674-4617-bcd2-0e5f40178296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f88ca255-cf4f-4145-8e70-38521865ca27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_67667918-f674-4617-bcd2-0e5f40178296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f88ca255-cf4f-4145-8e70-38521865ca27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_08948111-297a-409c-a288-2ed9b49ede64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f88ca255-cf4f-4145-8e70-38521865ca27" xlink:to="loc_us-gaap_StockOptionMember_08948111-297a-409c-a288-2ed9b49ede64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_A2019PlanMember_2e4358d6-5262-4536-bed6-a6dc0c25e75c" xlink:href="ocgn-20210930.xsd#ocgn_A2019PlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f88ca255-cf4f-4145-8e70-38521865ca27" xlink:to="loc_ocgn_A2019PlanMember_2e4358d6-5262-4536-bed6-a6dc0c25e75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ShareBasedPaymentArrangementPerformanceBasedOptionMember_aae0deb8-4907-4831-8a6f-e91b1ebf9313" xlink:href="ocgn-20210930.xsd#ocgn_ShareBasedPaymentArrangementPerformanceBasedOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f88ca255-cf4f-4145-8e70-38521865ca27" xlink:to="loc_ocgn_ShareBasedPaymentArrangementPerformanceBasedOptionMember_aae0deb8-4907-4831-8a6f-e91b1ebf9313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b0a1b482-df99-4f3e-8791-33b7f40702d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ff7348c-1920-436e-864f-51f165cf73bd" xlink:to="loc_us-gaap_PlanNameAxis_b0a1b482-df99-4f3e-8791-33b7f40702d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7152052e-5703-4896-b02f-6bc53e8cc298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_b0a1b482-df99-4f3e-8791-33b7f40702d3" xlink:to="loc_us-gaap_PlanNameDomain_7152052e-5703-4896-b02f-6bc53e8cc298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_A2014PlanMember_93428240-d62e-47cf-bd61-17e89f847fa4" xlink:href="ocgn-20210930.xsd#ocgn_A2014PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7152052e-5703-4896-b02f-6bc53e8cc298" xlink:to="loc_ocgn_A2014PlanMember_93428240-d62e-47cf-bd61-17e89f847fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_A2019PlanMember_9011eb2b-2a4d-4fd1-9ef1-9553738d94da" xlink:href="ocgn-20210930.xsd#ocgn_A2019PlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7152052e-5703-4896-b02f-6bc53e8cc298" xlink:to="loc_ocgn_A2019PlanMember_9011eb2b-2a4d-4fd1-9ef1-9553738d94da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9c89d94-5c2e-4b63-a1ee-7e02eec18fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ff7348c-1920-436e-864f-51f165cf73bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9c89d94-5c2e-4b63-a1ee-7e02eec18fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_99cbada0-a2fd-4545-bdc3-d5aa4851b433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9c89d94-5c2e-4b63-a1ee-7e02eec18fb8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_99cbada0-a2fd-4545-bdc3-d5aa4851b433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c4d4677c-f40c-45a9-afbe-a5c3df479500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9c89d94-5c2e-4b63-a1ee-7e02eec18fb8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c4d4677c-f40c-45a9-afbe-a5c3df479500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_58f0c23f-bafa-4471-8f11-c2e85d47b361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9c89d94-5c2e-4b63-a1ee-7e02eec18fb8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_58f0c23f-bafa-4471-8f11-c2e85d47b361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfEquityCompensationPlans_5adac12d-59f1-4ad1-a2ad-9c15eceaf0c5" xlink:href="ocgn-20210930.xsd#ocgn_NumberOfEquityCompensationPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9c89d94-5c2e-4b63-a1ee-7e02eec18fb8" xlink:to="loc_ocgn_NumberOfEquityCompensationPlans_5adac12d-59f1-4ad1-a2ad-9c15eceaf0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_90aafc84-7d4f-46c0-a91a-beb80bb898be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9c89d94-5c2e-4b63-a1ee-7e02eec18fb8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_90aafc84-7d4f-46c0-a91a-beb80bb898be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber_38697ded-aa7c-439e-9780-a70e9ff11e1e" xlink:href="ocgn-20210930.xsd#ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9c89d94-5c2e-4b63-a1ee-7e02eec18fb8" xlink:to="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber_38697ded-aa7c-439e-9780-a70e9ff11e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_37f0455a-2b1a-4a47-adc4-a4ba6d0e4542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9c89d94-5c2e-4b63-a1ee-7e02eec18fb8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_37f0455a-2b1a-4a47-adc4-a4ba6d0e4542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7c058d65-373e-4b82-8b91-e470b6c2e8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9c89d94-5c2e-4b63-a1ee-7e02eec18fb8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7c058d65-373e-4b82-8b91-e470b6c2e8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_e962e81c-b224-43c2-a946-fb255b3f5161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9c89d94-5c2e-4b63-a1ee-7e02eec18fb8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_e962e81c-b224-43c2-a946-fb255b3f5161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b0941426-bddb-483b-9fd1-2a6d149541eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c8b17414-aeac-450d-81bb-411118f8792f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b0941426-bddb-483b-9fd1-2a6d149541eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c8b17414-aeac-450d-81bb-411118f8792f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1a8d31a9-01f1-43dd-8029-c19b53193892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c8b17414-aeac-450d-81bb-411118f8792f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1a8d31a9-01f1-43dd-8029-c19b53193892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ac43991b-2a1e-49a0-b6d5-352535434644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c8b17414-aeac-450d-81bb-411118f8792f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ac43991b-2a1e-49a0-b6d5-352535434644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6c0ed10d-9ea9-4fdc-8942-6ad1f6c99fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c8b17414-aeac-450d-81bb-411118f8792f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6c0ed10d-9ea9-4fdc-8942-6ad1f6c99fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_a57aa52e-b5b9-4228-8259-4e8eb316d9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c8b17414-aeac-450d-81bb-411118f8792f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_a57aa52e-b5b9-4228-8259-4e8eb316d9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d82535e0-5895-44e2-9a30-658139e5442c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c8b17414-aeac-450d-81bb-411118f8792f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d82535e0-5895-44e2-9a30-658139e5442c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6da9ed21-a949-4780-8790-d4d111b5c7da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c8b17414-aeac-450d-81bb-411118f8792f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6da9ed21-a949-4780-8790-d4d111b5c7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_74286cc7-93e7-4124-90ce-53e7b6461fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b0941426-bddb-483b-9fd1-2a6d149541eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_74286cc7-93e7-4124-90ce-53e7b6461fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fd5a500d-b905-4165-8ec5-1ed284c88838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_74286cc7-93e7-4124-90ce-53e7b6461fa6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fd5a500d-b905-4165-8ec5-1ed284c88838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bb951b49-102a-474a-8284-99d24f37b8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_74286cc7-93e7-4124-90ce-53e7b6461fa6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bb951b49-102a-474a-8284-99d24f37b8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_13a9cade-57b5-4aec-943b-dd39863e6858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_74286cc7-93e7-4124-90ce-53e7b6461fa6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_13a9cade-57b5-4aec-943b-dd39863e6858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_0c4d8a5e-ff18-4ada-b37a-33bfb3d58d68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_74286cc7-93e7-4124-90ce-53e7b6461fa6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_0c4d8a5e-ff18-4ada-b37a-33bfb3d58d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_36545407-54fd-49b8-aac1-cfbe45573f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_74286cc7-93e7-4124-90ce-53e7b6461fa6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_36545407-54fd-49b8-aac1-cfbe45573f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2d8c3038-d698-4ea3-82be-02a0a5c5f805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_74286cc7-93e7-4124-90ce-53e7b6461fa6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2d8c3038-d698-4ea3-82be-02a0a5c5f805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d203b687-c070-4050-a56b-3ba2dcf67769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b0941426-bddb-483b-9fd1-2a6d149541eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d203b687-c070-4050-a56b-3ba2dcf67769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1ac3d1fb-958f-492b-b94f-77a0d1e010bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d203b687-c070-4050-a56b-3ba2dcf67769" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1ac3d1fb-958f-492b-b94f-77a0d1e010bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b14b60f7-1f16-4b61-8786-bee5bac8e99a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d203b687-c070-4050-a56b-3ba2dcf67769" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b14b60f7-1f16-4b61-8786-bee5bac8e99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b6879262-1cd6-4002-adb6-67fbaf8af7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d203b687-c070-4050-a56b-3ba2dcf67769" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b6879262-1cd6-4002-adb6-67fbaf8af7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6ee52ec1-81c7-4b4a-94ca-787ef21b0702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d203b687-c070-4050-a56b-3ba2dcf67769" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6ee52ec1-81c7-4b4a-94ca-787ef21b0702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_855c7423-cd8b-4fec-86d5-e28adcdedf20" xlink:href="ocgn-20210930.xsd#ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d203b687-c070-4050-a56b-3ba2dcf67769" xlink:to="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_855c7423-cd8b-4fec-86d5-e28adcdedf20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_80de984b-9752-486d-bca8-b75ca1ad9ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d203b687-c070-4050-a56b-3ba2dcf67769" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_80de984b-9752-486d-bca8-b75ca1ad9ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_27907e4c-839b-4b3d-8bb4-6d45f1b92607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d203b687-c070-4050-a56b-3ba2dcf67769" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_27907e4c-839b-4b3d-8bb4-6d45f1b92607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofRSUActivityDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#StockbasedCompensationScheduleofRSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f76cefe-62ac-4d2e-bd70-5c8d46dd410e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6af7f36-ea26-456d-a761-662403e3fb02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f76cefe-62ac-4d2e-bd70-5c8d46dd410e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6af7f36-ea26-456d-a761-662403e3fb02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4b34d7fe-28d5-4cc2-99ec-b68f3a294eac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6af7f36-ea26-456d-a761-662403e3fb02" xlink:to="loc_us-gaap_AwardTypeAxis_4b34d7fe-28d5-4cc2-99ec-b68f3a294eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc12cde5-cb02-4995-b9b0-69dd9a5bba3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4b34d7fe-28d5-4cc2-99ec-b68f3a294eac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc12cde5-cb02-4995-b9b0-69dd9a5bba3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_247b4786-b3b3-4cbd-ae2a-8d1155b82634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc12cde5-cb02-4995-b9b0-69dd9a5bba3d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_247b4786-b3b3-4cbd-ae2a-8d1155b82634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9949eecb-f09f-490b-a166-874dde361014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6af7f36-ea26-456d-a761-662403e3fb02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9949eecb-f09f-490b-a166-874dde361014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81fcb3e9-aaa0-4d23-8f64-d5fdc5710c57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9949eecb-f09f-490b-a166-874dde361014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81fcb3e9-aaa0-4d23-8f64-d5fdc5710c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_441ee019-7d4e-47ce-8ade-6a3882d8e95c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81fcb3e9-aaa0-4d23-8f64-d5fdc5710c57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_441ee019-7d4e-47ce-8ade-6a3882d8e95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2cceda5c-2b72-4898-92f9-c0f11b30bb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81fcb3e9-aaa0-4d23-8f64-d5fdc5710c57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2cceda5c-2b72-4898-92f9-c0f11b30bb5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7f7a48ce-6ad6-4e6b-946d-f0edbb2f25c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81fcb3e9-aaa0-4d23-8f64-d5fdc5710c57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7f7a48ce-6ad6-4e6b-946d-f0edbb2f25c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d0d734f1-fb7f-4f59-9a81-e7f4b854bf4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81fcb3e9-aaa0-4d23-8f64-d5fdc5710c57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d0d734f1-fb7f-4f59-9a81-e7f4b854bf4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b6b2d5c-09e6-4df1-9213-f0983e3e7f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9949eecb-f09f-490b-a166-874dde361014" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b6b2d5c-09e6-4df1-9213-f0983e3e7f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c4104a5b-7e65-44b7-ba84-7baffbb72284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b6b2d5c-09e6-4df1-9213-f0983e3e7f89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c4104a5b-7e65-44b7-ba84-7baffbb72284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f22deab9-54cf-4a80-911d-0cadfbe23839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b6b2d5c-09e6-4df1-9213-f0983e3e7f89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f22deab9-54cf-4a80-911d-0cadfbe23839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fe3381c1-b973-4ed2-ba44-ed34f111a966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b6b2d5c-09e6-4df1-9213-f0983e3e7f89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fe3381c1-b973-4ed2-ba44-ed34f111a966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_741d53d3-7183-4c09-8ec7-bd6826227aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b6b2d5c-09e6-4df1-9213-f0983e3e7f89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_741d53d3-7183-4c09-8ec7-bd6826227aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_491cb183-70d8-47cb-9c6a-d7c6e8fc4534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9949eecb-f09f-490b-a166-874dde361014" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_491cb183-70d8-47cb-9c6a-d7c6e8fc4534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_e8a0bfd8-f167-45ae-b306-c76adb2dddae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_491cb183-70d8-47cb-9c6a-d7c6e8fc4534" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_e8a0bfd8-f167-45ae-b306-c76adb2dddae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_a8309801-1902-4858-974b-2edce8a344fa" xlink:href="ocgn-20210930.xsd#ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_491cb183-70d8-47cb-9c6a-d7c6e8fc4534" xlink:to="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_a8309801-1902-4858-974b-2edce8a344fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod_12a92519-34d7-438b-bed5-6a41fbd9f417" xlink:href="ocgn-20210930.xsd#ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_491cb183-70d8-47cb-9c6a-d7c6e8fc4534" xlink:to="loc_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod_12a92519-34d7-438b-bed5-6a41fbd9f417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_c05c6054-fb5d-49a3-ae1a-05f712b6242c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_491cb183-70d8-47cb-9c6a-d7c6e8fc4534" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_c05c6054-fb5d-49a3-ae1a-05f712b6242c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStock" xlink:type="simple" xlink:href="ocgn-20210930.xsd#NetLossPerShareofCommonStock"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_69440c4d-ac63-4195-8e76-9cd81f39cc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_3641d098-3822-4cb4-b7ae-9d94b7a339b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_69440c4d-ac63-4195-8e76-9cd81f39cc2b" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_3641d098-3822-4cb4-b7ae-9d94b7a339b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockTables" xlink:type="simple" xlink:href="ocgn-20210930.xsd#NetLossPerShareofCommonStockTables"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6899aa97-8d0b-42ef-9bfa-a57b59a5c82c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_163f2f59-20b4-4430-95fa-f0f70c73d252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6899aa97-8d0b-42ef-9bfa-a57b59a5c82c" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_163f2f59-20b4-4430-95fa-f0f70c73d252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_55025740-c9de-497d-9902-15a34aa2c00c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6899aa97-8d0b-42ef-9bfa-a57b59a5c82c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_55025740-c9de-497d-9902-15a34aa2c00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockComputationofbasicanddilutedearningspershareDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#NetLossPerShareofCommonStockComputationofbasicanddilutedearningspershareDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockComputationofbasicanddilutedearningspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0ac675e1-a39c-4900-8524-b9c6f7cfee76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c3f99333-034c-4fac-a50d-355fe76eee3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0ac675e1-a39c-4900-8524-b9c6f7cfee76" xlink:to="loc_us-gaap_NetIncomeLoss_c3f99333-034c-4fac-a50d-355fe76eee3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_f23bc68e-6d50-4f85-b0ca-185249b48f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0ac675e1-a39c-4900-8524-b9c6f7cfee76" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_f23bc68e-6d50-4f85-b0ca-185249b48f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_25aa968e-96c5-490b-b3cb-36a3a4008bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0ac675e1-a39c-4900-8524-b9c6f7cfee76" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_25aa968e-96c5-490b-b3cb-36a3a4008bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2e83ee00-4e8c-4d07-83a6-c0c9330ec906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0ac675e1-a39c-4900-8524-b9c6f7cfee76" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2e83ee00-4e8c-4d07-83a6-c0c9330ec906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7e6bdb6e-7fe8-4f6e-8ee1-cf20dd68c5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0ac675e1-a39c-4900-8524-b9c6f7cfee76" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7e6bdb6e-7fe8-4f6e-8ee1-cf20dd68c5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_00edeb02-36f6-41c9-9108-5f3e49d48a44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0ac675e1-a39c-4900-8524-b9c6f7cfee76" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_00edeb02-36f6-41c9-9108-5f3e49d48a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d12a3e64-d1fb-4515-a454-25d6a0455108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0ac675e1-a39c-4900-8524-b9c6f7cfee76" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d12a3e64-d1fb-4515-a454-25d6a0455108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1dbbe47e-0c9a-4d41-b6f5-ad5e062099de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0ac675e1-a39c-4900-8524-b9c6f7cfee76" xlink:to="loc_us-gaap_EarningsPerShareBasic_1dbbe47e-0c9a-4d41-b6f5-ad5e062099de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockPotentiallydilutivesecuritieshavebeenexcludedfromthecomputationofdilutedweightedaveragesharesoutstandingDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#NetLossPerShareofCommonStockPotentiallydilutivesecuritieshavebeenexcludedfromthecomputationofdilutedweightedaveragesharesoutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockPotentiallydilutivesecuritieshavebeenexcludedfromthecomputationofdilutedweightedaveragesharesoutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e10fa2e3-66cd-4710-b224-853621ea3902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c6d0274c-5dc9-4487-bc36-525972cadf3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e10fa2e3-66cd-4710-b224-853621ea3902" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c6d0274c-5dc9-4487-bc36-525972cadf3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1944a31a-2bc8-454e-9b6d-2755cf1c0471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c6d0274c-5dc9-4487-bc36-525972cadf3a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1944a31a-2bc8-454e-9b6d-2755cf1c0471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0bf93ae-d25a-4dae-a17f-ad8db1509970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1944a31a-2bc8-454e-9b6d-2755cf1c0471" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0bf93ae-d25a-4dae-a17f-ad8db1509970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_5dce7596-d98d-4f18-9d25-97e121a2bb11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0bf93ae-d25a-4dae-a17f-ad8db1509970" xlink:to="loc_us-gaap_StockOptionMember_5dce7596-d98d-4f18-9d25-97e121a2bb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7d631802-acfe-4ffe-a7f3-6b0d0a6c795d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0bf93ae-d25a-4dae-a17f-ad8db1509970" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7d631802-acfe-4ffe-a7f3-6b0d0a6c795d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b96c4dd8-c7a8-41f2-ad3b-a8819e7b1955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0bf93ae-d25a-4dae-a17f-ad8db1509970" xlink:to="loc_us-gaap_WarrantMember_b96c4dd8-c7a8-41f2-ad3b-a8819e7b1955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_0c4fb03f-c574-4fc3-b686-1730c4ad97ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0bf93ae-d25a-4dae-a17f-ad8db1509970" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_0c4fb03f-c574-4fc3-b686-1730c4ad97ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_8b96cdff-044d-493a-9a5a-17d42e322ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0bf93ae-d25a-4dae-a17f-ad8db1509970" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_8b96cdff-044d-493a-9a5a-17d42e322ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_827172aa-3291-4056-a20b-ff4eb58e7336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c6d0274c-5dc9-4487-bc36-525972cadf3a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_827172aa-3291-4056-a20b-ff4eb58e7336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5fb3130b-dff8-4c00-8997-14fc5138bdec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_827172aa-3291-4056-a20b-ff4eb58e7336" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5fb3130b-dff8-4c00-8997-14fc5138bdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ocgn-20210930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3a6bb26c-8d91-4898-a95d-0d3f1a1c6775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_873aec44-82c7-4271-9ea7-e411a9479fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3a6bb26c-8d91-4898-a95d-0d3f1a1c6775" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_873aec44-82c7-4271-9ea7-e411a9479fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ocgn-20210930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_61aa0151-030d-4410-a75a-9287653355d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_9694e67d-4097-4e2a-9398-94c8c4548160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_61aa0151-030d-4410-a75a-9287653355d9" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_9694e67d-4097-4e2a-9398-94c8c4548160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.deitaxonomy.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ocgn-20210930.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.deitaxonomy.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_fe479bcc-b662-4a9d-ab0f-5415e743c51c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_a3140a9e-40ca-42bc-88ad-7c53db9bd6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_fe479bcc-b662-4a9d-ab0f-5415e743c51c" xlink:to="loc_us-gaap_SubsequentEventTable_a3140a9e-40ca-42bc-88ad-7c53db9bd6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_cde4c73a-735a-48b1-9eea-942f3dbcd514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a3140a9e-40ca-42bc-88ad-7c53db9bd6ba" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_cde4c73a-735a-48b1-9eea-942f3dbcd514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e649ce3d-ace6-466c-8583-403def17f99b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cde4c73a-735a-48b1-9eea-942f3dbcd514" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e649ce3d-ace6-466c-8583-403def17f99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_baf19a58-0fb1-41d7-a2e3-2f406f3adf52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e649ce3d-ace6-466c-8583-403def17f99b" xlink:to="loc_us-gaap_SubsequentEventMember_baf19a58-0fb1-41d7-a2e3-2f406f3adf52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_3b5dd883-6eb7-43e9-85b6-2bbb32f292d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a3140a9e-40ca-42bc-88ad-7c53db9bd6ba" xlink:to="loc_us-gaap_SubsequentEventLineItems_3b5dd883-6eb7-43e9-85b6-2bbb32f292d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ebed01fa-9e39-431d-b9e6-f311979e34b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3b5dd883-6eb7-43e9-85b6-2bbb32f292d1" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ebed01fa-9e39-431d-b9e6-f311979e34b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_BaseRentPaymentsExpectedCost_dd6510f1-b0bc-4d43-b0f0-111d8d5e5ee2" xlink:href="ocgn-20210930.xsd#ocgn_BaseRentPaymentsExpectedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3b5dd883-6eb7-43e9-85b6-2bbb32f292d1" xlink:to="loc_ocgn_BaseRentPaymentsExpectedCost_dd6510f1-b0bc-4d43-b0f0-111d8d5e5ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_NumberOfAdditionalLeaseAgreementExtensions_8bced8ec-de3a-4d55-907b-21aa5eec54a5" xlink:href="ocgn-20210930.xsd#ocgn_NumberOfAdditionalLeaseAgreementExtensions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3b5dd883-6eb7-43e9-85b6-2bbb32f292d1" xlink:to="loc_ocgn_NumberOfAdditionalLeaseAgreementExtensions_8bced8ec-de3a-4d55-907b-21aa5eec54a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ocgn_LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement_f76490ab-d072-4edd-ae59-abc6e6c3a424" xlink:href="ocgn-20210930.xsd#ocgn_LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3b5dd883-6eb7-43e9-85b6-2bbb32f292d1" xlink:to="loc_ocgn_LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement_f76490ab-d072-4edd-ae59-abc6e6c3a424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>ocgn-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ocgn="http://www.deitaxonomy.com/20210930"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ocgn-20210930.xsd" xlink:type="simple"/>
    <context id="i52d9db304374467785253218ec6f15f0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i37c782c18fab4541b52948ee02ff0fe1_I20211102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <instant>2021-11-02</instant>
        </period>
    </context>
    <context id="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6c78f41bc4d34d2f97ae2010184d9723_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i68178daf3b96459db15e2b75995f88d1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0aa9d9e8ef714df892f133c7484c0b4a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i28b02ce452d34ea6b3c2e1dff6d45d00_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i552c85d6331e4cad97ea9f15ee20104a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i429a8518eebf4e0cb714c17e78e150bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifd58335a3dab4d87a7550d4a5dd940cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3ad0bf3a315f43d3b971e83e4328a6c4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i03ee12167fe649b08a8573352b78366f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idf7ffe1af99e468485a7fa0473a357c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i63c582794c9241548ff9038b8f5f5a27_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iebacd414b4044a8fbc5c8c5207a7b86f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib511b5a36eaf40048ec9ee98f00551c1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id9d460c203374d7880f0ec3fae34b578_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i221ecffa66144040873151eb590dd8b3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:ATMTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie2ffbcae57d0459f8b8815522daa3dc3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:ATMTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4b6cae5ed98647219290e0100ca91343_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:ATMTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if2588abf7c6e477fbe29c509564b8f4b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i442e9159fb0046dcaf7dd1b46149c00e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i06dadc3f8b824b8c91fc0f114505344d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if996ab97fcf74a548c34b4f5941439b4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i34d4430baa0f44abb229c0dd32cdcbae_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i86140f763e9c47098d573fe17ae24f7d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3cdbf08cfea2418e9a09ae632d0e329d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7c3ef4ab08b246bea75a9049a1509d61_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9466d66e75764cf9aefaf1eb61c6a86a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i28b699982fb94ef9b501dc59505bd27b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2bfcaa4bfe9b4fd88d8461664e684474_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibb8526a2a5a242e7812303c1e35ea461_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib42ad3d8f0264d0d8f1893b83054daf9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if26f766056584bd6b3d8be57c4c75510_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifd48f822ec024053ba61f26d03cd9402_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i24d28352102d488e81a31df53860a386_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5af0d4e54fa04902b86c568fffb94928_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib49cc7013dca487eac750b80929881ce_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibf8f98fd3caa4d46bcf11d8083135a3c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0071733638ed4178b0c2f37e29b4c541_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id63858f31e204ae6b02d0f95495b173a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iaf7c1094d10a4d97959c21e8669b2a25_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i44f7ffb2eea24ee9a6de6a5ce40eef9e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i098bebd384304520a79fe2559dfb9c27_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie51ec8f7c79f40878c0fde67d905e922_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iaf94f103b7b048a097f0defcf2650f43_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0775f4cfa17343e6913d2da04f38f67a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie0f6174d8ece4a44b930465233df749d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8f39d7650e794a7b81d454b1bb5ac6cd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2ff2e3800b044563861e8dbb3d568544_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2df3c91a1e2141808ceb139a8c692d4f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6e80709cb7a44684bc5d9a7c7d3d7fdc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5ceacdb4b4eb427992b8f810605259bb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if74b21443ee54787a0b6b5788b176165_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8bcc6879e812488a8c638047e2739ebd_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifb3652c42f6d42209a1beabd6597843e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id4a4fa5cea03410b9c6bd3abe049132a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iaeb9a66837754ddcabb2a790c8f98a21_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i092375e2b99d47569a5f2b88a00b645c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4be4818227b84eeb8a47645a43378ca9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iae0a865b8bbb423886ea964fbed8d991_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i72fb329722534fb0a4ca4b9bf0f15d18_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1690154692b5483f8a0c27ebf8b7ea8c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia331e4fce5e04537ac0252d8c85aa3db_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i181e5dd0f5cf473ebe3032f6bdf59b2f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8558526a156344b6bc64e01cde3185fd_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i743620ea9f5e4eb5b6754c10390f4947_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9a53051ca1af479a8e8848d3241934d7_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ieee5f8f38b444a81a3531727a4653ee8_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i619b2ecf063d405c93c789d3a0e98721_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i85efaefef16a413d938e44c4b5777c0e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ib56ddb546f364c00b070ff8a2cab7021_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic5b044d2e6b9422992ea59179bc567f3_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic9973a4a90424a12a7dc55d2dce30953_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ib7939caa4e524cc88ac3e5aff4177860_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if337d9153dc545129019175c2d4f63ac_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i431ea463f15d497aac6934b546008514_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia6e7f2c707054cd683451662d8ed7372_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:SubscriptionAgreementsAndWarrantExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i711b829d5ee345eebc50acfa4b930a61_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:SubscriptionAgreementsAndWarrantExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3e011586eab7413c970320b1703ebf08_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:SubscriptionAgreementsAndWarrantExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic9e589df88b2465ba4294cb791b7dc17_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:ATMTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iede14896071c4ee49fa119a80f14fbab_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:ATMTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia439f49486224935ad3477d5b4185130_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:ATMTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifb4586bd1771477fae5877934605f9b3_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i74784bdd498745d5ae511cab1b360837_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ifc519bce743c46c398e1d5dead4107f7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iafa83b4739574d758beec4c0757ed122_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7d3554a78cc8449d9aad5b8c1c4503fd_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8f107ec3ae1e4116afeb1163e6492976_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="idb989f73c9d1445fa69a483600870562_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6eb68a3826b24dfe8726311fa8f753a4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia772fd167d25491e80c5e09f8d26ca55_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9d2b34877c824fb39ecf988264920e54_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:ATMTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i49fc5d8a06784ed3b66029a5fdb2c35b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:ATMTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id4fa370f40af4910a583132f5726f913_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:ATMTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib8964c98e4b14da7a9f597f5fed0edb0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i878a0f96a8194299acd620d27ea9d9bf_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6cba47cf2f404ee9a035c63dae2423f3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib05383973c11499c94ee4d3e3f64f0b8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id86823ae63164e52b4c42f119b89ed4d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2e710c24c8df431ba6ae05089ef01062_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if224aca6e98d4c9f87473c21091780ac_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7033dd63053e40b9b5c54b579a67eebc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3eb7b92dc9494a35b5033ab8674abe63_D20210701-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="id5d5a29609664c35b78098fb9dd71398_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie2a762caa8434142a4d6522864319751_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i20ba81fe7dcd4e0d8c7f7e1bd42e7108_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ocgn:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i835d59b4a71c4ca48581fa3806494a4a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ocgn:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic0845e0a879f4a8f9b00281ea8a23506_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib31b92c5c40747a3bd257cecf9f1c22b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1978e8a33197491fab4e85b515ca427c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:COVAXINPreferredStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0ce37d1044984e42b76ce49925a5ea86_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i930c6519bb45486a8510eab5f83f11b2_D20190927-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocgn:CollaborationAgreementWithCansinoBiologicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-27</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i83096eac0fe34c3aae4e263271cd518e_I20210413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <instant>2021-04-13</instant>
        </period>
    </context>
    <context id="i5db9a3b809794a18ba41b819b7fb0e60_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="i11ce6b5f7e39456fa1c454b1333db3bf_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia025bf7e0a1345c280160a2e194f23fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia3aea31e66e540dc9949d6f9c0490ecb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i812612c51e3f4f04bd8fb9b027a8a7ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8d4ea904d71e4543b361e76a666f0756_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iefda904c07ce43da981ece8db16559f3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1fa83702d12344a2b6ed8e9210300c3c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i451fd097deb743d79f6ad34002e75526_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic0c6fee7c66143fa90b7e09a8bd0054b_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if6931d48727f42d1b569e46c6b6c8cf1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icdfb9af1602f4e02a9cc734469158ec9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib105875697514235a32c3d55a59c407f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i892c2505d70d4215b4f0550ad9b0627e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i02962ee3f8774d3c8d322068b02a66c8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie8440034266a4aa291b14ebaf3980ba1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i44daf8bae7c343758ee6b618e75c35f6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i01a12a6485e345b6ab72567171ec0eb0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i058f0a613fdb4fac8d51eb184f27c5b6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i92ea040ac4094cb2a62e60e72ca77b3c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i745fb75cca5b4c23886a4754e42262f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85638365ecb449f89cd737e151a543eb_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i5b1b73d8695b4c07b67f45b9ef51765e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0894763e64ad446393df6c07eb805c5f_I20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="if4082401304e4bc3881503b617da5ec7_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i2b01d2f4d0c54ea186a70f5469b418fa_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i48e097bc118a40018d9f9179ffd7ca57_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:EB5ProgramBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie1f83da91a62482bafefc243a5610119_D20210301-20210301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:COVAXINPreferredStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="ia223aa6547ab48e8a989ed4c643adeaa_I20210301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:COVAXINPreferredStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="i246cca5ff04f4a438cabbffe4ac0798c_I20210429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <instant>2021-04-29</instant>
        </period>
    </context>
    <context id="iefbd2c9026804907ae58afb0f262bb0d_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="ide0135d45c4941c9938e0383f70a9804_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:COVAXINPreferredStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie4ef9e6106c44af9adc546620f7b1580_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i90ca97f6066a4d9a810636493e1c9aac_D20210423-20210423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-23</startDate>
            <endDate>2021-04-23</endDate>
        </period>
    </context>
    <context id="i77df7a80e56a4e8facf772024c0e4945_I20210423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-23</instant>
        </period>
    </context>
    <context id="i5862a96aeadd4f89b932761cb5f2e124_D20210427-20210427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-27</startDate>
            <endDate>2021-04-27</endDate>
        </period>
    </context>
    <context id="i15f4aa0e8bfb449a842dfc32748a2a55_D20210207-20210207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-07</startDate>
            <endDate>2021-02-07</endDate>
        </period>
    </context>
    <context id="i8a5e15fc5e9f4ab8b85dee2ee164fe5c_I20210207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-07</instant>
        </period>
    </context>
    <context id="ia8cedc3486594d78b30a563076ebf2ad_D20210210-20210210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-10</startDate>
            <endDate>2021-02-10</endDate>
        </period>
    </context>
    <context id="i8b074737fd3840e3a89e6bc467ec5352_D20200501-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="iab0d59da4af045118182091dce3984c8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i00ccc0ff720749b1b14d75b3c93faa0d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaa7b11c7997941d7a2ebe1202ae40792_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia8019c49fc2b41d8809f0fc4847ce9b0_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5068c87588174140afe885f4e47d066a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8e02ac8495184af4af04566df93db8f7_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="ic8bd5469fd534b5fa1a3c3286b4599c4_I20210715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:CanadaConsultingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-15</instant>
        </period>
    </context>
    <context id="i1e39c130cffe499eaae2b4c55fef5b42_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="i24e2b7c0b5b1441cad39027ec7574d10_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if01d7fad0a3f48a8bd13b30a1b84b704_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i99f2d4d98be64d7ea57dfff1f984ef8b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie002070f257c4c608068b1b07255b1d5_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocgn:WarrantsExchangedForCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i06658032e2704ab282cc346ef006ef8f_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:WarrantExchangePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i8612a2a4329d46479292b57b3cd408f0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:WarrantExchangePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i86fc446c1c3b4958be93eb3d966f598a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocgn:WarrantExchangePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib6e306f60ac94b79a20c2e697c2d41e0_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SPAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i2a0df3b2c63543fd93b3be04483ec5a2_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i0677fbde7da642e0bd593d8fa763f607_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i04d1f309d9f74029a1b219a85f77a940_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:OpCoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i275b6ac4e97c4be5aa1a51af8502831b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:OpCoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iae6a400180f04a07b8febf2d6e0fa554_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocgn:OpCoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie0a8b70d6fb84c5a9789d450871ed83a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8acfe33635854458877463fc16a751b4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7caedf65c1494e419cbafa5a7b2af8d9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i830ec46fb29342e8a14435d6c8374e8f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i34df5c33daa84097bbeb2f7aa78e9881_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6d5d5de7375c464ebdd9941535b546d4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i27f8c3a424b04ee8a9158f75127eec6e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icfe523d076894ad581734cd76ae76f7e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6efde1790e4d4c3f820f75713f6e84b9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ocgn:ShareBasedPaymentArrangementPerformanceBasedOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibe51744fe7ab46b2a3e9f306f2e205ef_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ocgn:ShareBasedPaymentArrangementPerformanceBasedOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iab3b4c48ef4b48df90d794b934740c1f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ocgn:ShareBasedPaymentArrangementPerformanceBasedOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaa3c7dd5eddd468da3b9df0f9934469a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ocgn:ShareBasedPaymentArrangementPerformanceBasedOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3571bc8a75ac48659cc316e5763f4ed2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i05d88bc2fdb94bfb85adba0bb8b27884_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocgn:A2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="idcf0789a7cf8450dac2a8c051cc629b3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocgn:A2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8deb7fe79a024352817ef6e8af8f0441_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5fe71549bdba4e09bf1e6455238c6445_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ocgn:ShareBasedPaymentArrangementPerformanceBasedOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i78eaa94bd702419a8ec49cbc777b5ba7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ocgn:ShareBasedPaymentArrangementPerformanceBasedOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i97535b68d960495f906585585e65538d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i91c5fecaa1c64c49ad9e64d6f08ce782_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieee22d5c75984530a1d4feb9b3bd71e6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4a2d954d52484db09e819f3e3cd26b4b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6eef00380be74ee2b45ff66ba9497e4c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i21ed7d9935d24634bdbfe1f4c69a732b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3904f01ad36d4b3796750e5c00692693_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7d1c263247244eaaa85b9923b449d851_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i89a977d9b97c40d9bc231523d757c614_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if8bcebbd1f9f4a1fa9c7f2ecc3c2a2b4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifb2b6076d55a4c4fbc505ce09032f9ec_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaeb64bda41ad44658c1917090d93aee7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i42cfc7b660d247bca3e1269304b94198_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibb9ae3b6217944d08b6ef5b9486ae59c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia60015f8c05f4fb2a0ff02e090d1939c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0e6344f1ce2a45b3b3086bff6d187fd7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i04f8d6a8b17d410195fd2437e938b245_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1226d893b7c34174b451b927f02c2ad5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4aa5009a02d54151a673eb8679eca4f3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5dfb43b76ce743459ec23fb4489a7d43_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ife7f80154864442eb1f4fff86b29fb57_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia634f5e3056b43e9a810bc77f3d0f942_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i656ac6e78d97406398ff128f89376446_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9c6b3eaa0af149b0b68069f2bcf0750e_I20211015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-15</instant>
        </period>
    </context>
    <context id="i1801f4052b89458296349d07431dc823_D20211015-20211015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-15</startDate>
            <endDate>2021-10-15</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>ocgn:segment</measure>
    </unit>
    <unit id="dose">
        <measure>ocgn:dose</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="geneticmutation">
        <measure>ocgn:geneticMutation</measure>
    </unit>
    <unit id="product">
        <measure>ocgn:product</measure>
    </unit>
    <unit id="orphan_drug_designation">
        <measure>ocgn:orphan_drug_designation</measure>
    </unit>
    <unit id="renewaloption">
        <measure>ocgn:renewalOption</measure>
    </unit>
    <unit id="employee">
        <measure>ocgn:employee</measure>
    </unit>
    <unit id="at-the-marketoffering">
        <measure>ocgn:at-the-marketOffering</measure>
    </unit>
    <unit id="seriesofwarrant">
        <measure>ocgn:seriesOfWarrant</measure>
    </unit>
    <unit id="extension">
        <measure>ocgn:extension</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180L2ZyYWc6MzQ0ZDE3M2MxZjdlNDlhMjk2MzkzMzVmNDQyYmIzYzcvdGFibGU6ZjdkNjE1ZDg1N2Q1NGIwZTgwNTgyMWFkOGU1NDIxZmQvdGFibGVyYW5nZTpmN2Q2MTVkODU3ZDU0YjBlODA1ODIxYWQ4ZTU0MjFmZF8xLTEtMS0xLTA_694bf128-574c-4f86-a02d-5f091498cc23">0001372299</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180L2ZyYWc6MzQ0ZDE3M2MxZjdlNDlhMjk2MzkzMzVmNDQyYmIzYzcvdGFibGU6ZjdkNjE1ZDg1N2Q1NGIwZTgwNTgyMWFkOGU1NDIxZmQvdGFibGVyYW5nZTpmN2Q2MTVkODU3ZDU0YjBlODA1ODIxYWQ4ZTU0MjFmZF8yLTEtMS0xLTA_7fe8f8a7-25f4-49dd-a163-5f1468a7d07e">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180L2ZyYWc6MzQ0ZDE3M2MxZjdlNDlhMjk2MzkzMzVmNDQyYmIzYzcvdGFibGU6ZjdkNjE1ZDg1N2Q1NGIwZTgwNTgyMWFkOGU1NDIxZmQvdGFibGVyYW5nZTpmN2Q2MTVkODU3ZDU0YjBlODA1ODIxYWQ4ZTU0MjFmZF8zLTEtMS0xLTA_aa80a44b-7e27-402d-a854-f04176062354">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180L2ZyYWc6MzQ0ZDE3M2MxZjdlNDlhMjk2MzkzMzVmNDQyYmIzYzcvdGFibGU6ZjdkNjE1ZDg1N2Q1NGIwZTgwNTgyMWFkOGU1NDIxZmQvdGFibGVyYW5nZTpmN2Q2MTVkODU3ZDU0YjBlODA1ODIxYWQ4ZTU0MjFmZF80LTEtMS0xLTA_3f54f82c-8c5f-47c6-a145-03ec9a090122">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180L2ZyYWc6MzQ0ZDE3M2MxZjdlNDlhMjk2MzkzMzVmNDQyYmIzYzcvdGFibGU6ZjdkNjE1ZDg1N2Q1NGIwZTgwNTgyMWFkOGU1NDIxZmQvdGFibGVyYW5nZTpmN2Q2MTVkODU3ZDU0YjBlODA1ODIxYWQ4ZTU0MjFmZF81LTEtMS0xLTA_ade2daed-56a7-4bb5-ab87-a1f83110f95d">false</dei:AmendmentFlag>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id5d5a29609664c35b78098fb9dd71398_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfNDM5ODA0NjU4MjIzNg_2f5f7cef-a3ff-41b9-b3bd-1ded51f7bc02">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i20ba81fe7dcd4e0d8c7f7e1bd42e7108_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfNDM5ODA0NjU4MjMwOQ_2aaf4aaa-5250-4fad-95da-0d6844c093cb">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic0845e0a879f4a8f9b00281ea8a23506_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTI5NTc_1b0f22b6-1741-4551-9fe9-ad65976104fa">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF8yMzA3_7de3de62-0dcd-48e2-9ec9-554e499bad90">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGFibGU6NmQzZDQwY2U0Y2Q4NDVkZjk1YWU4M2Y3NWUwMmYwYzMvdGFibGVyYW5nZTo2ZDNkNDBjZTRjZDg0NWRmOTVhZTgzZjc1ZTAyZjBjM18wLTAtMS0xLTA_1d9040dd-a928-4ac1-bad4-d6008fbdeb97">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF8yMjk3_46848a11-ede7-4508-a099-2f4b87eb94b1">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGFibGU6OGExMDA4YmEzMjNhNGZmYmI1NGZkN2VkY2NjNjY5ZWUvdGFibGVyYW5nZTo4YTEwMDhiYTMyM2E0ZmZiYjU0ZmQ3ZWRjY2M2NjllZV8wLTAtMS0xLTA_07c9c5e5-727e-41a1-b203-914931152154">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF8yMzAx_da0d2faf-624d-4a07-bcbe-2a091612ff72">001-36751</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF8yMzA4_275731aa-1d4c-4da9-9dd2-f36731827034">OCUGEN, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGFibGU6YmVmODNiNjZkMDZhNDk5Njg5ZjRkY2NhOTcyOTBmNjMvdGFibGVyYW5nZTpiZWY4M2I2NmQwNmE0OTk2ODlmNGRjY2E5NzI5MGY2M18wLTAtMS0xLTA_dff505b0-09c7-48e6-9fb2-3552c140db6e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGFibGU6YmVmODNiNjZkMDZhNDk5Njg5ZjRkY2NhOTcyOTBmNjMvdGFibGVyYW5nZTpiZWY4M2I2NmQwNmE0OTk2ODlmNGRjY2E5NzI5MGY2M18wLTEtMS0xLTA_d9d1c38a-de45-4edc-b4dd-16efd7a1577c">04-3522315</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF8yMzAz_b96a211c-1621-4686-9c54-8914f1bfefd8">263 Great Valley Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF8yMjk4_4ede2fb8-6e48-4ccd-a8a4-23fa2bc3d123">Malvern</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF8yMzA1_0c2e2a30-c83e-45ee-8e01-3ec2ac60178b">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF81NDA_cf4d151f-ba3c-427c-8bcf-34adbac8249b">19355</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF82MDU_fb57cdf0-0d0d-4a3c-b0ab-3a6e162d9d51">484</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF8yMjk5_a4c0f8ac-8dee-473b-9a2f-822be2bdcbbd">328-4701</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGFibGU6Yzg4ODEyZTM4NjMwNDA4ZGE4OGNlYmE0MTkzYjc2MWYvdGFibGVyYW5nZTpjODg4MTJlMzg2MzA0MDhkYTg4Y2ViYTQxOTNiNzYxZl8xLTAtMS0xLTA_a648140a-2260-47b9-a7f7-98ce60829863">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGFibGU6Yzg4ODEyZTM4NjMwNDA4ZGE4OGNlYmE0MTkzYjc2MWYvdGFibGVyYW5nZTpjODg4MTJlMzg2MzA0MDhkYTg4Y2ViYTQxOTNiNzYxZl8xLTItMS0xLTA_75424880-5ef5-467d-b607-cbb09c602350">OCGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGFibGU6Yzg4ODEyZTM4NjMwNDA4ZGE4OGNlYmE0MTkzYjc2MWYvdGFibGVyYW5nZTpjODg4MTJlMzg2MzA0MDhkYTg4Y2ViYTQxOTNiNzYxZl8xLTQtMS0xLTAvdGV4dHJlZ2lvbjowM2IzNjVlM2RjMDM0NmFjYmFkZGJlMWZiZTFiYTY2M180_82a8a7c1-9a43-4d6c-a960-d37612265365">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF8yMzA2_84d3fd11-8167-48c1-9d33-d510fece367a">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF8yMzAy_0a9548d0-404f-4980-9920-bea95ebdfb20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGFibGU6ZDI0YWQzMDlkZjJkNDk3OWI2ZjU2NDNjZWQ1ZjVlY2UvdGFibGVyYW5nZTpkMjRhZDMwOWRmMmQ0OTc5YjZmNTY0M2NlZDVmNWVjZV8xLTAtMS0xLTA_851e23e9-c772-47dc-a832-87e158f26968">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGFibGU6ZDI0YWQzMDlkZjJkNDk3OWI2ZjU2NDNjZWQ1ZjVlY2UvdGFibGVyYW5nZTpkMjRhZDMwOWRmMmQ0OTc5YjZmNTY0M2NlZDVmNWVjZV8xLTMtMS0xLTA_57f40c66-875d-40c4-a136-2705a85dcf58">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGFibGU6ZDI0YWQzMDlkZjJkNDk3OWI2ZjU2NDNjZWQ1ZjVlY2UvdGFibGVyYW5nZTpkMjRhZDMwOWRmMmQ0OTc5YjZmNTY0M2NlZDVmNWVjZV8yLTMtMS0xLTA_9f80b374-e87f-4534-984a-241c6abba3be">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF8yMzAw_b5940f64-1509-49a1-9e99-b2bb5ecfef47">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i37c782c18fab4541b52948ee02ff0fe1_I20211102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xL2ZyYWc6NGEyMDUwNTEzYTQ2NGMxZmJlYjUwODBlMDJiODdmYzQvdGV4dHJlZ2lvbjo0YTIwNTA1MTNhNDY0YzFmYmViNTA4MGUwMmI4N2ZjNF8yMjE0_a74cd628-eccf-4a3c-a4c7-f02888522d51"
      unitRef="shares">199185877</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMy0xLTEtMS0w_2ebd21bc-ac1a-4db3-9298-4225e6bd7511"
      unitRef="usd">107349000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMy0zLTEtMS0w_ff063e09-19d6-43e8-ae6d-0efd895900c1"
      unitRef="usd">24039000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfNC0xLTEtMS0w_8a0121d0-9f98-45ba-b23f-320880b240fa"
      unitRef="usd">4988000</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfNC0zLTEtMS0w_377713b0-de40-4281-b153-37d6c3975b85"
      unitRef="usd">0</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfNS0xLTEtMS0w_7df98345-7ec5-4fb6-a6d0-4cdabe7aa19d"
      unitRef="usd">1113000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfNS0zLTEtMS0w_f5135b1f-e3fe-4d6d-a7d4-cf30607f4e06"
      unitRef="usd">1839000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfNi0xLTEtMS0w_9f92ec67-e30e-466f-9380-4871f51894f8"
      unitRef="usd">113450000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfNi0zLTEtMS0w_e3141d7c-1019-4799-bf32-02844dbbbba8"
      unitRef="usd">25878000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfNy0xLTEtMS0w_4e07083f-4120-4ba6-823d-aaecac486c55"
      unitRef="usd">1052000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfNy0zLTEtMS0w_a99a2dc0-47b6-42a1-b4e4-4a4350105ac4"
      unitRef="usd">633000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfOC0xLTEtMS0w_32a07304-9d9d-48bd-b39c-86d7ed20aa96"
      unitRef="usd">151000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfOC0zLTEtMS0w_5944d5f2-f304-4735-8d1d-553a45910b4e"
      unitRef="usd">151000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfOS0xLTEtMS0w_5575c07a-8710-4398-b8a9-4b4817500856"
      unitRef="usd">1659000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfOS0zLTEtMS0w_741bedcb-bd52-46bd-b838-42ad30a84a0f"
      unitRef="usd">714000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTAtMS0xLTEtMA_b995882b-c87c-420b-8f52-d52c8288205d"
      unitRef="usd">116312000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTAtMy0xLTEtMA_98465a6b-b795-437a-a5b0-9da87a8eb31f"
      unitRef="usd">27376000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTMtMS0xLTEtMA_f5d5178c-a79d-45b4-a466-ee3ff44abd71"
      unitRef="usd">2095000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTMtMy0xLTEtMA_06f417bb-7725-42d1-b620-a3a4999ce299"
      unitRef="usd">395000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTQtMS0xLTEtMA_2d8cb57a-7133-4b20-95cd-c0197f6b5f57"
      unitRef="usd">3962000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTQtMy0xLTEtMA_60c9202b-a5a8-46da-bac7-2c611d5f019d"
      unitRef="usd">2941000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:ShortTermBorrowings
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTUtMS0xLTEtMA_7d44c9c5-e160-4b09-995f-ae426ea3603a"
      unitRef="usd">0</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTUtMy0xLTEtMA_781b63dc-770e-4495-9c47-4cfe47f6e98f"
      unitRef="usd">234000</us-gaap:ShortTermBorrowings>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTYtMS0xLTEtMA_cb0b027d-3d57-4f7b-9bc1-c651a86e91e8"
      unitRef="usd">172000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTYtMy0xLTEtMA_20639ad5-b72a-4f42-be32-752224f4dc0a"
      unitRef="usd">44000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTctMS0xLTEtMA_5de89138-841a-4719-9f24-83f1227c9801"
      unitRef="usd">6229000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTctMy0xLTEtMA_75f47771-730b-4517-8c20-fb59713bdfa4"
      unitRef="usd">3614000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTktMS0xLTEtMA_bf4b6883-df37-41fa-8432-29be2860a3b9"
      unitRef="usd">1280000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMTktMy0xLTEtMA_c9efa736-d473-46e3-a8c7-e7c64aed0d9e"
      unitRef="usd">389000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjAtMS0xLTEtMA_2ac289b1-42a3-43f5-9a13-2c37f9ca3cb3"
      unitRef="usd">1693000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjAtMy0xLTEtMA_9ef0dc74-e217-496f-9203-1036309468b3"
      unitRef="usd">1823000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjEtMS0xLTEtMA_64a833e0-6cfc-4f86-91da-cfc34be784c8"
      unitRef="usd">2973000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjEtMy0xLTEtMA_3f68c22c-4f0a-4142-90ed-d95f4d32650b"
      unitRef="usd">2212000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjItMS0xLTEtMA_e8086655-23b5-4dff-ba0f-4b70127b28c8"
      unitRef="usd">9202000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjItMy0xLTEtMA_65a59c69-0d73-405a-acb3-f5157b3c444d"
      unitRef="usd">5826000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjMtMS0xLTEtMA_699c3387-8c3a-4b9e-b9c9-21a62c48c83d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjMtMy0xLTEtMA_068838a4-6a65-4f00-9ffd-98331e7f6000"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjBhZWFiZTQxNGM1ZDQ5MjI5OTIzMWJlNGJjMzBhOWVjXzMz_3317d162-dfab-4605-9799-e41f1feb81cb"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjBhZWFiZTQxNGM1ZDQ5MjI5OTIzMWJlNGJjMzBhOWVjXzMz_47edea46-262a-4936-9c23-8dd3522a17cd"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjBhZWFiZTQxNGM1ZDQ5MjI5OTIzMWJlNGJjMzBhOWVjXzQ3_7113986b-be47-4317-b3bf-f09272336683"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjBhZWFiZTQxNGM1ZDQ5MjI5OTIzMWJlNGJjMzBhOWVjXzQ3_7d1c0132-0bba-481c-8653-1a2237255e89"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i68178daf3b96459db15e2b75995f88d1_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmVlY2EzNjM4OWE2NDQ5NDA5Mjg4NDUxMDczMWQ3NTYwXzE0_7051ef6a-b154-4312-b235-6050faae0698"
      unitRef="shares">7</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0aa9d9e8ef714df892f133c7484c0b4a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmVlY2EzNjM4OWE2NDQ5NDA5Mjg4NDUxMDczMWQ3NTYwXzE0_934568cf-a9ed-4e75-bdbe-03d283342326"
      unitRef="shares">7</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i68178daf3b96459db15e2b75995f88d1_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmVlY2EzNjM4OWE2NDQ5NDA5Mjg4NDUxMDczMWQ3NTYwXzE0_96a24ce6-63d3-471b-9de9-88684aa058af"
      unitRef="shares">7</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0aa9d9e8ef714df892f133c7484c0b4a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmVlY2EzNjM4OWE2NDQ5NDA5Mjg4NDUxMDczMWQ3NTYwXzE0_b934d7c2-b3d7-48bf-b90a-5fd2b567ca5c"
      unitRef="shares">7</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i68178daf3b96459db15e2b75995f88d1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjYtMS0xLTEtMA_6b59a55a-2eec-4dc6-b744-32fc8d45ed98"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i0aa9d9e8ef714df892f133c7484c0b4a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjYtMy0xLTEtMA_b007b200-7ee4-4826-b403-fbd2cfe80e23"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i28b02ce452d34ea6b3c2e1dff6d45d00_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjE4YmY2YmM0NWZjODRlZWNiYzQwMzI0ZTFlOTAwMDZiXzE0_a5fa6a19-54c1-4131-96c9-10d52596da38"
      unitRef="shares">54745</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i28b02ce452d34ea6b3c2e1dff6d45d00_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjE4YmY2YmM0NWZjODRlZWNiYzQwMzI0ZTFlOTAwMDZiXzE0_e37aa7c1-442d-45f9-94de-49d6045f2977"
      unitRef="shares">54745</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i552c85d6331e4cad97ea9f15ee20104a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjE4YmY2YmM0NWZjODRlZWNiYzQwMzI0ZTFlOTAwMDZiXzIx_9b39ab2b-5a5e-4631-a73c-f3741bdf34af"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i552c85d6331e4cad97ea9f15ee20104a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjE4YmY2YmM0NWZjODRlZWNiYzQwMzI0ZTFlOTAwMDZiXzIx_ac2343b7-9c63-4cf8-8447-44126ccd82b0"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i28b02ce452d34ea6b3c2e1dff6d45d00_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjctMS0xLTEtMA_7e420874-578f-475f-87f9-948a4557330d"
      unitRef="usd">1000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i552c85d6331e4cad97ea9f15ee20104a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjctMy0xLTEtMA_a8e06a90-ce47-489e-9173-9b3e2bebb480"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmJiNzk4MjE5MTNmODRmM2E4MTQ5YzkyZDM3YmFmMzA2XzE4_432da948-dc48-45d5-87f4-276c28085d20"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmJiNzk4MjE5MTNmODRmM2E4MTQ5YzkyZDM3YmFmMzA2XzE4_7eeb2967-cb91-4d19-938d-5b87bb08079c"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmJiNzk4MjE5MTNmODRmM2E4MTQ5YzkyZDM3YmFmMzA2XzMy_916204e1-ca35-4cf2-8a82-db05ef3ab0d1"
      unitRef="shares">295000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmJiNzk4MjE5MTNmODRmM2E4MTQ5YzkyZDM3YmFmMzA2XzM5_c9289fee-4be8-4ada-bbe6-84063d1816f5"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmJiNzk4MjE5MTNmODRmM2E4MTQ5YzkyZDM3YmFmMzA2XzYx_9cb81701-3217-414c-abe8-f194afc63e6c"
      unitRef="shares">199049329</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmJiNzk4MjE5MTNmODRmM2E4MTQ5YzkyZDM3YmFmMzA2XzY4_bd101612-4b59-460a-aa33-f6dea7988732"
      unitRef="shares">184133384</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmJiNzk4MjE5MTNmODRmM2E4MTQ5YzkyZDM3YmFmMzA2Xzkw_9455943d-7d49-4ea9-a405-ff9792c41e0f"
      unitRef="shares">198927829</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmJiNzk4MjE5MTNmODRmM2E4MTQ5YzkyZDM3YmFmMzA2Xzk3_eb0b17c0-92d8-4d70-b3e1-f67772bf1247"
      unitRef="shares">184011884</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjgtMS0xLTEtMA_12ec823c-752a-4090-ad54-9ecc2ff1e2cf"
      unitRef="usd">1990000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjgtMy0xLTEtMA_70decc32-d75b-45cb-b5f5-4ddc60ee6062"
      unitRef="usd">1841000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjM4ZjNkZWI2ZTAyODRiYjg4YWU4ZDBmODRlNTEyMzQ0XzI5_3e05ba2c-4600-4817-bd54-bea4b375781a"
      unitRef="shares">121500</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjM4ZjNkZWI2ZTAyODRiYjg4YWU4ZDBmODRlNTEyMzQ0XzI5_7070be8a-d484-4726-b427-624608489957"
      unitRef="shares">121500</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjktMS0xLTEtMA_148c66d2-b0c0-4bea-ace1-05ecf49da022"
      unitRef="usd">48000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMjktMy0xLTEtMA_9aae3ebc-3cb5-46be-b687-527ff8a43222"
      unitRef="usd">48000</us-gaap:TreasuryStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMzAtMS0xLTEtMA_f67af93c-866a-4c2c-b143-63fb6bcfdf61"
      unitRef="usd">222253000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMzAtMy0xLTEtMA_0a19b253-2c04-4106-8364-283e0168b8da"
      unitRef="usd">93059000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMzEtMS0xLTEtMA_19c89db9-bed6-4f9f-a3b0-779ae365f832"
      unitRef="usd">-117086000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMzEtMy0xLTEtMA_946ac030-174b-4ad4-b908-275e3da8564e"
      unitRef="usd">-73302000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMzItMS0xLTEtMA_9766d76b-eaba-45ec-8477-5e8eaa45cf72"
      unitRef="usd">107110000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMzItMy0xLTEtMA_7f1fb959-2a9f-4fb5-8a03-f5c1197edb71"
      unitRef="usd">21550000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMzMtMS0xLTEtMA_0e43fb88-1648-4b48-9152-70bd4e216e4d"
      unitRef="usd">116312000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xOS9mcmFnOjY1MmY5YzAwYWE3NDRjNzRiNTUzMGQyOGU0YWExMTU2L3RhYmxlOjRmZWVhNDczYTljMzQxMzE4ODQ5YTFlNTAwZmJmYTg0L3RhYmxlcmFuZ2U6NGZlZWE0NzNhOWMzNDEzMTg4NDlhMWU1MDBmYmZhODRfMzMtMy0xLTEtMA_feacd00b-336b-471f-b829-0165d09c4a69"
      unitRef="usd">27376000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMy0xLTEtMS0w_a670ad2d-984f-450a-9fe9-4be07bc29570"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMy0zLTEtMS0w_f235b3c1-71e6-4439-b53d-b79014cc0ef7"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMy01LTEtMS0w_3753d65f-5f15-42ab-b2da-502b62f60511"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMy03LTEtMS0w_d04e4456-76fe-45f9-bf7f-473af6c78331"
      unitRef="usd">43000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:Revenues
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfNC0xLTEtMS0w_5dffd211-143d-4aad-9281-a03855b7b0c0"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfNC0zLTEtMS0w_62a8a6b3-ada2-48c2-947d-067cdeb07047"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfNC01LTEtMS0w_84ce4000-83f1-4867-b327-c0aa3a5c6c70"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfNC03LTEtMS0w_2fdb61f1-3ae2-4a42-9ba1-fb6e55edc55e"
      unitRef="usd">43000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfNi0xLTEtMS0w_92fc4f32-0e90-4dcb-b17e-bc5acdcf5a9b"
      unitRef="usd">6281000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfNi0zLTEtMS0w_2ee03027-53b7-4c73-bc96-e76a18fa2348"
      unitRef="usd">1478000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfNi01LTEtMS0w_104227f6-a1ed-4f24-a65c-f556935c2022"
      unitRef="usd">28006000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfNi03LTEtMS0w_605d02a8-6362-43fd-956b-2b65e731c5d7"
      unitRef="usd">4760000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfNy0xLTEtMS0w_e35c8703-9839-402f-a77e-30a2558caa42"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfNy0zLTEtMS0w_d59449b8-f420-4cd5-b2f5-9ebae177179b"
      unitRef="usd">7000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfNy01LTEtMS0w_5e4e8f10-5218-4df0-9148-b7d7cdd45ec5"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfNy03LTEtMS0w_1892b848-898d-437f-afec-8acbcbd2c3b9"
      unitRef="usd">7000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfOC0xLTEtMS0w_197b93a5-389c-4ca1-a7bc-c90844c9cbf8"
      unitRef="usd">4508000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfOC0zLTEtMS0w_707cc179-2cc5-4904-96f4-9a08f11ea234"
      unitRef="usd">1704000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfOC01LTEtMS0w_5204b8d1-ccaa-4d6a-b1fc-1d0094572a73"
      unitRef="usd">15450000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfOC03LTEtMS0w_682ef4a2-5b01-44b6-93b9-6739c4d09125"
      unitRef="usd">5760000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfOS0xLTEtMS0w_d344f02e-9f67-4640-84e0-c086872b2d51"
      unitRef="usd">10789000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfOS0zLTEtMS0w_33080b53-b22c-4ff5-b9ac-aaa193758f2a"
      unitRef="usd">10182000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfOS01LTEtMS0w_94eee86a-98ea-4070-a8b7-798efe768fbb"
      unitRef="usd">43456000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfOS03LTEtMS0w_0f890925-0a97-4e51-b93d-eada2e6d8432"
      unitRef="usd">17520000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTAtMS0xLTEtMA_5a380af2-eb9a-42cc-85bb-364e55863291"
      unitRef="usd">-10789000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTAtMy0xLTEtMA_2637a775-b69f-446d-9086-aaa445c8c8c4"
      unitRef="usd">-10182000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTAtNS0xLTEtMA_2e55d663-21ad-498c-99a8-d83e8880089c"
      unitRef="usd">-43456000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTAtNy0xLTEtMA_b6cafd25-400d-4d83-81fd-6211538edf46"
      unitRef="usd">-17477000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTItMS0xLTEtMA_0344d669-9f00-4deb-ad4f-2e9a2e4f932f"
      unitRef="usd">5000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTItMy0xLTEtMA_2aa6d649-e315-4b03-bd69-a78f53675974"
      unitRef="usd">0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTItNS0xLTEtMA_116e2583-eaa1-4ac3-9c88-ca5c8b481881"
      unitRef="usd">15000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTItNy0xLTEtMA_177bb3ea-0556-45ab-ba89-4f4c1bf58a0f"
      unitRef="usd">0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTMtMS0xLTEtMA_d61389ad-aabd-4070-9203-0177f8e34d64"
      unitRef="usd">19000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTMtMy0xLTEtMA_e3de8c49-a0be-4132-952c-56a2f169a745"
      unitRef="usd">292000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTMtNS0xLTEtMA_e635a147-082c-4aee-9504-5e80121a551e"
      unitRef="usd">59000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTMtNy0xLTEtMA_1575f292-b6c2-4688-82b8-e68a2c120d65"
      unitRef="usd">555000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTQtMS0xLTEtMA_3619d9d9-19c5-453c-9b4c-8306f97d3fd2"
      unitRef="usd">-4000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTQtMy0xLTEtMA_7b102d24-46c1-4710-8473-a0161d8667b7"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTQtNS0xLTEtMA_a85bea18-6c96-470e-9c61-b91d98b650c1"
      unitRef="usd">-336000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTQtNy0xLTEtMA_bd772dc4-7ded-484e-be9c-929ca21ce640"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTUtMS0xLTEtMA_9ed9b219-9dcf-42ad-b25f-4a43b23b9371"
      unitRef="usd">-18000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTUtMy0xLTEtMA_0ef08ae4-d9bc-48fc-93e1-934a5f96dbbc"
      unitRef="usd">-292000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTUtNS0xLTEtMA_abc87bc7-bf54-4065-a403-bdcabf952dc9"
      unitRef="usd">-380000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTUtNy0xLTEtMA_41b2bb3b-b6bd-4d38-b086-5790dc0708a1"
      unitRef="usd">-555000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTYtMS0xLTEtMzM0ODg_f8bcc554-4d41-49db-9611-ada56ae5383d"
      unitRef="usd">-10807000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTYtMy0xLTEtMzM0ODg_c208f031-cabd-48a1-896b-40f3be0c4fa4"
      unitRef="usd">-10474000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTYtNS0xLTEtMzM0ODg_cecfaf09-a592-4a83-a8d0-0febd8a52848"
      unitRef="usd">-43836000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTYtNy0xLTEtMzM0ODg_c3ab767b-caea-4ccb-bcf4-f76e5ca89f28"
      unitRef="usd">-18032000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTctMS0xLTEtMzM0ODg_de6f0946-2ef6-43a8-952b-fbd6ccbe85fb"
      unitRef="usd">-52000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTctMy0xLTEtMzM0ODg_5368821d-1919-430c-a1c8-83a02bb7bd35"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTctNS0xLTEtMzM0ODg_a34381f1-8b68-4583-b4f6-2d1176b70bf9"
      unitRef="usd">-52000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTctNy0xLTEtMzM0ODg_8b943d65-e55a-4323-8554-9e7da0a770f3"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTYtMS0xLTEtMA_24be3b5b-61b8-4250-a2ff-7dff8d1f7a1a"
      unitRef="usd">-10755000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTYtMS0xLTEtMA_a012501e-ce1a-40b8-8dd1-58612b9cf108"
      unitRef="usd">-10755000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTYtMy0xLTEtMA_3e914785-5501-4003-8981-c459a27f9d89"
      unitRef="usd">-10474000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTYtMy0xLTEtMA_9fc574e5-24f2-4be0-bca6-14a4306b10b7"
      unitRef="usd">-10474000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTYtNS0xLTEtMA_0fe9698d-ba0b-4473-a401-4be0e472799a"
      unitRef="usd">-43784000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTYtNS0xLTEtMA_4bd0b560-828b-4731-bd53-a8d1ddfb4e77"
      unitRef="usd">-43784000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTYtNy0xLTEtMA_4dd4d7ca-2ad4-4b71-8bc1-d0a721cbb8a4"
      unitRef="usd">-18032000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTYtNy0xLTEtMA_4e3f82db-8eaf-4366-ae98-c5afbe1ca712"
      unitRef="usd">-18032000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTctMS0xLTEtMA_7189559a-64ad-4d27-9ce8-cd8cd12d97b9"
      unitRef="usd">0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTctMy0xLTEtMA_d0b1d3eb-ace9-4b61-8f92-9b3303deeea5"
      unitRef="usd">0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTctNS0xLTEtMA_ea5b62de-a295-410a-a020-3cdbe51be17c"
      unitRef="usd">0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTctNy0xLTEtMA_de5826f1-1e56-4b1a-82ce-04307a0626ee"
      unitRef="usd">12546000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTgtMS0xLTEtMA_31e2ec02-1016-4caf-bceb-5cd7afc3cadf"
      unitRef="usd">-10755000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTgtMy0xLTEtMA_6f511037-d285-479a-bcdc-d5bcba1b1caf"
      unitRef="usd">-10474000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTgtNS0xLTEtMA_24449db0-a29d-4f09-9caf-e75561becf2e"
      unitRef="usd">-43784000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMTgtNy0xLTEtMA_5b56f2a0-f74a-427e-a441-8fd8eeff68b4"
      unitRef="usd">-30578000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjAtMS0xLTEtMA_7a2916d5-a798-400a-8fd3-022e21583430"
      unitRef="shares">198790980</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjAtMS0xLTEtMA_c0906105-c7a1-4b2a-8584-eac9f18ab700"
      unitRef="shares">198790980</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjAtMy0xLTEtMA_36595e09-cf81-4896-90e0-7390a04d14b8"
      unitRef="shares">141591218</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjAtMy0xLTEtMA_f0cb2bf6-6106-4072-aea9-87d0c6326ede"
      unitRef="shares">141591218</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjAtNS0xLTEtMA_2d67b44a-910d-4001-bfff-484990363d85"
      unitRef="shares">193599525</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjAtNS0xLTEtMA_3f0457d9-1060-4564-9392-c99887f868e3"
      unitRef="shares">193599525</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjAtNy0xLTEtMA_43aba45d-d6f3-4da1-a211-cd7f1ee12746"
      unitRef="shares">92764157</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjAtNy0xLTEtMA_ee8672d0-c974-4ec3-b28f-2e1354a95ffd"
      unitRef="shares">92764157</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjEtMS0xLTEtMA_d674b57b-0fae-4604-8a33-9b0b32d435eb"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjEtMS0xLTEtMA_f1b88b98-8b84-4499-90b2-0a0f55a833a6"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjEtMy0xLTEtMA_25ad9b8c-bb29-4e40-bca0-16573d2c3074"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjEtMy0xLTEtMA_607a3582-010c-4e2d-962e-b9a64311c4e8"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjEtNS0xLTEtMA_7978457e-59ba-4cde-b640-ee6d640be29f"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjEtNS0xLTEtMA_f25d64a5-4e74-4e02-a4a6-d2e0636ef6b0"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjEtNy0xLTEtMA_5b7dda49-8556-42d1-a173-48294b75a7f9"
      unitRef="usdPerShare">-0.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yMi9mcmFnOmJlNmYwNWY5ZjEzNjRmNTJhZmI2ODViNDE5M2EwZDUyL3RhYmxlOmQ0NmUzMDc1ZTlhNjQyNDI4ZWVmNGM1Y2UyMjU3MDBkL3RhYmxlcmFuZ2U6ZDQ2ZTMwNzVlOWE2NDI0MjhlZWY0YzVjZTIyNTcwMGRfMjEtNy0xLTEtMA_7fe76218-97fe-45c6-a47e-b2d3beba8082"
      unitRef="usdPerShare">-0.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesOutstanding
      contextRef="i429a8518eebf4e0cb714c17e78e150bb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMi0xLTEtMS0w_2824cfb3-54dc-4726-a392-b9561e90b910"
      unitRef="shares">7</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i429a8518eebf4e0cb714c17e78e150bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMi0zLTEtMS0w_4f1884de-d72d-42db-9d1a-e5c25aa834e9"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ifd58335a3dab4d87a7550d4a5dd940cd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMi01LTEtMS0w_abadb636-5530-4518-8716-728ee03585e4"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifd58335a3dab4d87a7550d4a5dd940cd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMi03LTEtMS0w_343a5249-2a48-471e-890b-6f8b94aadf4e"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i3ad0bf3a315f43d3b971e83e4328a6c4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMi05LTEtMS0w_2cf61b92-67a7-441b-a2cb-d7962bed510d"
      unitRef="shares">184133384</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3ad0bf3a315f43d3b971e83e4328a6c4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMi0xMS0xLTEtMA_9c75a388-8c9b-4a2d-8028-c559e05f0dc8"
      unitRef="usd">1841000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i03ee12167fe649b08a8573352b78366f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMi0xMy0xLTEtMA_a412807a-3662-4af8-b8e1-8379593d52bc"
      unitRef="usd">-48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idf7ffe1af99e468485a7fa0473a357c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMi0xNS0xLTEtMA_284172ed-3696-4668-8eef-72de2190b849"
      unitRef="usd">93059000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i63c582794c9241548ff9038b8f5f5a27_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMi0xOS0xLTEtMA_59e04768-90d7-44ac-82ce-a358307a4de2"
      unitRef="usd">-73302000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMi0yMS0xLTEtMA_3e216311-b4cc-428a-8f83-7388a741eb98"
      unitRef="usd">21550000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iebacd414b4044a8fbc5c8c5207a7b86f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMy0xNS0xLTEtMA_fe31c671-23eb-449a-81a4-39ba7c650954"
      unitRef="usd">833000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib511b5a36eaf40048ec9ee98f00551c1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMy0yMS0xLTEtMA_84cdae39-67ab-44b9-9e5b-3f7de6976ea2"
      unitRef="usd">833000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id9d460c203374d7880f0ec3fae34b578_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNC05LTEtMS0w_5279b91e-96d9-4559-93bc-e25f44612d5c"
      unitRef="shares">157468</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id9d460c203374d7880f0ec3fae34b578_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNC0xMS0xLTEtMA_a49bc805-2c1e-4124-985d-0298be5166c6"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iebacd414b4044a8fbc5c8c5207a7b86f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNC0xNS0xLTEtMA_4a58c3f1-a925-497b-9ce2-4b4f2b67d93d"
      unitRef="usd">174000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib511b5a36eaf40048ec9ee98f00551c1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNC0yMS0xLTEtMA_77431e53-cde2-488d-b1c9-fd5520cd5074"
      unitRef="usd">176000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i221ecffa66144040873151eb590dd8b3_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNS05LTEtMS0w_0439a765-5bac-458b-ae42-3fad05b927a1"
      unitRef="shares">987000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i221ecffa66144040873151eb590dd8b3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNS0xMS0xLTEtMA_33667c6e-1d5d-49b5-9382-5dbae18f99f5"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie2ffbcae57d0459f8b8815522daa3dc3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNS0xNS0xLTEtMA_c20adb2f-e14d-4644-bddf-fddfc68f834b"
      unitRef="usd">4839000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4b6cae5ed98647219290e0100ca91343_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNS0yMS0xLTEtMA_5d33d6b9-966c-411c-a38e-1b95bef7ea34"
      unitRef="usd">4849000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if2588abf7c6e477fbe29c509564b8f4b_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNi05LTEtMS0w_7940925c-2062-4667-bbf6-73f4a6f64032"
      unitRef="shares">3000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if2588abf7c6e477fbe29c509564b8f4b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNi0xMS0xLTEtMA_1064758c-0ebe-4d35-9a99-ce99391f314c"
      unitRef="usd">30000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i442e9159fb0046dcaf7dd1b46149c00e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNi0xNS0xLTEtMA_23a0c798-b38b-4551-9324-1c41a27bbd83"
      unitRef="usd">21174000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i06dadc3f8b824b8c91fc0f114505344d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNi0yMS0xLTEtMA_2b259250-0382-4beb-be2d-b47c66251af2"
      unitRef="usd">21204000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if996ab97fcf74a548c34b4f5941439b4_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNy01LTEtMS0w_ed51b10e-2372-4be6-9cd0-87442476827f"
      unitRef="shares">54745</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if996ab97fcf74a548c34b4f5941439b4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNy03LTEtMS0w_a077a839-7055-49fc-8232-f7945667c8cb"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i34d4430baa0f44abb229c0dd32cdcbae_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNy0xNS0xLTEtMA_988a899e-d599-4a62-a4b2-5b2dba8c56a5"
      unitRef="usd">4953000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i86140f763e9c47098d573fe17ae24f7d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfNy0yMS0xLTEtMA_9692684b-ddb7-460f-9636-959caa659e15"
      unitRef="usd">4954000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="i3cdbf08cfea2418e9a09ae632d0e329d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfOC0xOS0xLTEtMA_1e1d31f5-eedf-47e9-beb9-9f3236ae635a"
      unitRef="usd">-7077000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib511b5a36eaf40048ec9ee98f00551c1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfOC0yMS0xLTEtMA_68c76649-bb78-4787-aa43-85b9e0b3976a"
      unitRef="usd">-7077000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i7c3ef4ab08b246bea75a9049a1509d61_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfOS0xLTEtMS0w_790b2ad8-3a40-440d-9558-88af6d83cac6"
      unitRef="shares">7</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7c3ef4ab08b246bea75a9049a1509d61_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfOS0zLTEtMS0w_ef377a59-aa49-441e-912f-6d1eb7744339"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i9466d66e75764cf9aefaf1eb61c6a86a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfOS01LTEtMS0w_4af09779-a62d-42db-b3e5-fca8d6b20393"
      unitRef="shares">54745</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9466d66e75764cf9aefaf1eb61c6a86a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfOS03LTEtMS0w_8f1da8a7-ca75-45f2-8c1e-627b68459f3d"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i28b699982fb94ef9b501dc59505bd27b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfOS05LTEtMS0w_7be59f15-15d8-4c60-a26d-4d08d2955944"
      unitRef="shares">188277852</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i28b699982fb94ef9b501dc59505bd27b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfOS0xMS0xLTEtMA_64a4e5c9-5fbc-44c6-b8db-27cec93bcead"
      unitRef="usd">1883000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2bfcaa4bfe9b4fd88d8461664e684474_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfOS0xMy0xLTEtMA_59a2f9c7-789f-4f5e-b64f-d5d6e883be37"
      unitRef="usd">-48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibb8526a2a5a242e7812303c1e35ea461_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfOS0xNS0xLTEtMA_f898f9bb-4553-4837-aa4d-3a6d7df8ca3e"
      unitRef="usd">125032000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib42ad3d8f0264d0d8f1893b83054daf9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfOS0xOS0xLTEtMA_03d4713f-b3d4-4445-b072-410f41a2ceae"
      unitRef="usd">-80379000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if26f766056584bd6b3d8be57c4c75510_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfOS0yMS0xLTEtMA_ee402eb4-1620-4aab-9981-7c978a931a7e"
      unitRef="usd">46489000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifd48f822ec024053ba61f26d03cd9402_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTAtMTUtMS0xLTA_96dadc18-3c7d-4c80-bd04-af6e70ef0a0a"
      unitRef="usd">2095000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i24d28352102d488e81a31df53860a386_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTAtMjEtMS0xLTA_220b036b-d953-446f-a208-8688c8248e91"
      unitRef="usd">2095000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ocgn:StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised
      contextRef="i5af0d4e54fa04902b86c568fffb94928_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTEtOS0xLTEtMA_1154c050-cf22-4db5-907e-eb990e4a72f5"
      unitRef="shares">538893</ocgn:StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised>
    <ocgn:StockIssuedDuringPeriodValueOptionsAndWarrantsExercised
      contextRef="i5af0d4e54fa04902b86c568fffb94928_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTEtMTEtMS0xLTA_3ceffe5b-115b-42b3-8b42-307fdfad1129"
      unitRef="usd">5000</ocgn:StockIssuedDuringPeriodValueOptionsAndWarrantsExercised>
    <ocgn:StockIssuedDuringPeriodValueOptionsAndWarrantsExercised
      contextRef="ifd48f822ec024053ba61f26d03cd9402_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTEtMTUtMS0xLTA_d3c2f81e-ff50-4db5-bd13-bd676b91be73"
      unitRef="usd">366000</ocgn:StockIssuedDuringPeriodValueOptionsAndWarrantsExercised>
    <ocgn:StockIssuedDuringPeriodValueOptionsAndWarrantsExercised
      contextRef="i24d28352102d488e81a31df53860a386_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTEtMjEtMS0xLTA_fb117d47-0061-48b9-866e-5bf8c8c88b00"
      unitRef="usd">371000</ocgn:StockIssuedDuringPeriodValueOptionsAndWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib49cc7013dca487eac750b80929881ce_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTItOS0xLTEtMA_82c6258e-6f6f-4f5e-9322-66724f358a22"
      unitRef="shares">10000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib49cc7013dca487eac750b80929881ce_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTItMTEtMS0xLTA_4bc22bb2-4452-44cf-94c6-ae879a1a97f6"
      unitRef="usd">100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibf8f98fd3caa4d46bcf11d8083135a3c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTItMTUtMS0xLTA_ee34f8d1-e5ff-4807-865b-2f128a375ede"
      unitRef="usd">93306000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0071733638ed4178b0c2f37e29b4c541_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTItMjEtMS0xLTA_c88e9f1d-d83b-4226-80d9-296dfcd55d8b"
      unitRef="usd">93406000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="id63858f31e204ae6b02d0f95495b173a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTMtMTktMS0xLTA_bb46f4b3-7121-4305-93fe-314811f09119"
      unitRef="usd">-25952000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i24d28352102d488e81a31df53860a386_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTMtMjEtMS0xLTA_a3c3af93-a97b-4f4e-8408-9e8f43f91dd0"
      unitRef="usd">-25952000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="iaf7c1094d10a4d97959c21e8669b2a25_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTQtMS0xLTEtMA_79924985-8ac8-4583-a02d-acc2a9c06b1a"
      unitRef="shares">7</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iaf7c1094d10a4d97959c21e8669b2a25_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTQtMy0xLTEtMA_f01fcc2f-1fe5-4e39-95ad-d323273b6805"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i44f7ffb2eea24ee9a6de6a5ce40eef9e_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTQtNS0xLTEtMA_e43b154e-8c01-4bf2-a137-075548dac0fa"
      unitRef="shares">54745</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i44f7ffb2eea24ee9a6de6a5ce40eef9e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTQtNy0xLTEtMA_beb8c10b-3740-4dae-bf70-12c280a39331"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i098bebd384304520a79fe2559dfb9c27_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTQtOS0xLTEtMA_4e0d1214-ecdd-4803-826f-9e14ee5d5038"
      unitRef="shares">198816745</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i098bebd384304520a79fe2559dfb9c27_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTQtMTEtMS0xLTA_a2e99fae-9b42-4c12-8707-d72e4c2cf71d"
      unitRef="usd">1988000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie51ec8f7c79f40878c0fde67d905e922_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTQtMTMtMS0xLTA_98c6c87e-c58c-4f4c-b9d9-0b8bbc3e1509"
      unitRef="usd">-48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaf94f103b7b048a097f0defcf2650f43_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTQtMTUtMS0xLTA_d58c36ad-1e97-4414-8a44-c72b36e4238b"
      unitRef="usd">220799000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0775f4cfa17343e6913d2da04f38f67a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTQtMTktMS0xLTA_20b6ef02-362a-4ece-9f70-fdddb5dd0bd6"
      unitRef="usd">-106331000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie0f6174d8ece4a44b930465233df749d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTQtMjEtMS0xLTA_d992f06a-207a-4cb7-afad-a85976db9ea8"
      unitRef="usd">116409000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8f39d7650e794a7b81d454b1bb5ac6cd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTUtMTUtMS0xLTMw_21980ac8-1ec4-4f92-9efe-5adcce9f5bcb"
      unitRef="usd">1347000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTUtMjEtMS0xLTQ2_7351f53d-7d62-494a-8b5a-27a96810c596"
      unitRef="usd">1347000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i2ff2e3800b044563861e8dbb3d568544_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTYtOS0xLTEtMjkxNDE_cb9046e2-2304-494c-a9f5-e9a0270fb2a5"
      unitRef="shares">232584</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2ff2e3800b044563861e8dbb3d568544_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTYtMTEtMS0xLTI5MTQx_7804f815-3711-44a4-bbe3-57df5e873910"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8f39d7650e794a7b81d454b1bb5ac6cd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTYtMTUtMS0xLTI5MTQx_25624325-0268-4be5-8028-062727516e3b"
      unitRef="usd">107000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTYtMjEtMS0xLTI5MTQx_0ea0b0c3-daa6-43f0-965e-b8aa4baec1fe"
      unitRef="usd">109000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="i2df3c91a1e2141808ceb139a8c692d4f_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTYtMTktMS0xLTMw_49cc143b-26fb-490e-bba2-5cfe66a5e370"
      unitRef="usd">-10755000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTYtMjEtMS0xLTQ2_b21d0013-25ff-4e74-bc65-6240e121da19"
      unitRef="usd">-10755000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i6e80709cb7a44684bc5d9a7c7d3d7fdc_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTctMS0xLTEtMzA_fafb3c55-f44a-43a0-a25b-490203d203fa"
      unitRef="shares">7</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6e80709cb7a44684bc5d9a7c7d3d7fdc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTctMy0xLTEtMzA_36ca400e-dc64-44bc-8953-4b5662c7f0c4"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i5ceacdb4b4eb427992b8f810605259bb_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTctNS0xLTEtMzA_cc0009a0-d443-46e9-813d-2cb6996bba34"
      unitRef="shares">54745</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5ceacdb4b4eb427992b8f810605259bb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTctNy0xLTEtMzA_16fdde93-e131-4abc-a320-01489f9ea7f6"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="if74b21443ee54787a0b6b5788b176165_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTctOS0xLTEtMzA_1e4b16e1-8803-46a9-bc3d-2d7c4d0a0ac3"
      unitRef="shares">199049329</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if74b21443ee54787a0b6b5788b176165_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTctMTEtMS0xLTMw_3c27cf60-e51a-4877-b377-181ff0ff952e"
      unitRef="usd">1990000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8bcc6879e812488a8c638047e2739ebd_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTctMTMtMS0xLTMw_7bdd09f9-9ec5-4c43-9412-cf818d50ef38"
      unitRef="usd">-48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifb3652c42f6d42209a1beabd6597843e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTctMTUtMS0xLTMw_4f383017-c746-4c88-abc2-09c142db0e8c"
      unitRef="usd">222253000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id4a4fa5cea03410b9c6bd3abe049132a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTctMTktMS0xLTMw_ce99159b-de06-4e1c-aa1a-ccc9c6210858"
      unitRef="usd">-117086000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjBhOTFhM2JjNzUxNDRhNDM4ODdhY2RlNjNhMGQxMjMzL3RhYmxlcmFuZ2U6MGE5MWEzYmM3NTE0NGE0Mzg4N2FjZGU2M2EwZDEyMzNfMTctMjEtMS0xLTQ2_af8293db-91d8-4662-bb73-d600d678a60c"
      unitRef="usd">107110000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="iaeb9a66837754ddcabb2a790c8f98a21_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMi0xLTEtMS0w_6b09668c-15b8-44b7-83e1-6b58e2429856"
      unitRef="shares">7</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iaeb9a66837754ddcabb2a790c8f98a21_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMi0zLTEtMS0w_7f7eae7d-d51d-4b73-9b8e-9a77944ca837"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i092375e2b99d47569a5f2b88a00b645c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMi01LTEtMS0w_e9c54dcf-ea0e-4351-b70a-3dd7b53fb513"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i092375e2b99d47569a5f2b88a00b645c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMi03LTEtMS0w_9dbb622e-d07b-4d47-a4f0-36126332e1d8"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i4be4818227b84eeb8a47645a43378ca9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMi05LTEtMS0w_9e033a39-0154-4caa-a2f9-59077af24c2a"
      unitRef="shares">52746728</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4be4818227b84eeb8a47645a43378ca9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMi0xMS0xLTEtMA_b5183880-77ae-442b-913e-8fec2dfd5d62"
      unitRef="usd">528000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iae0a865b8bbb423886ea964fbed8d991_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMi0xMy0xLTEtMA_3e11e0f8-8724-4e4e-8786-e859398d0445"
      unitRef="usd">-48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i72fb329722534fb0a4ca4b9bf0f15d18_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMi0xNS0xLTEtMA_fca1c4a4-7112-49f7-becb-a4103c2b1590"
      unitRef="usd">62019000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1690154692b5483f8a0c27ebf8b7ea8c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMi0xOS0xLTEtMA_b612582f-fbea-4485-a0d3-322dc023311b"
      unitRef="usd">-51480000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia331e4fce5e04537ac0252d8c85aa3db_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMi0yMS0xLTEtMA_0925837b-9ff5-4a61-a203-02eeadcc1c52"
      unitRef="usd">11019000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i181e5dd0f5cf473ebe3032f6bdf59b2f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMy0xNS0xLTEtMA_d0e27e16-5c96-448b-a6dc-b9f1b35cf7d4"
      unitRef="usd">222000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8558526a156344b6bc64e01cde3185fd_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMy0yMS0xLTEtMA_c0a28367-b6aa-45ed-b775-7447a7926f54"
      unitRef="usd">222000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i743620ea9f5e4eb5b6754c10390f4947_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNC0xOS0xLTEtMA_43153485-7eaf-481b-9514-3b1d57d4bc7b"
      unitRef="usd">-3944000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8558526a156344b6bc64e01cde3185fd_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNC0yMS0xLTEtMA_bd1100cf-9fdd-4052-9228-e5e4e8e4280d"
      unitRef="usd">-3944000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i9a53051ca1af479a8e8848d3241934d7_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNS0xLTEtMS0w_aeabbb5b-10e7-4588-af0a-5662f75baa5b"
      unitRef="shares">7</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9a53051ca1af479a8e8848d3241934d7_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNS0zLTEtMS0w_c6599cec-9987-47b3-b931-6911b7d86cf4"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ieee5f8f38b444a81a3531727a4653ee8_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNS01LTEtMS0w_86dd31fd-39b7-4259-8b3c-bb02e8664776"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ieee5f8f38b444a81a3531727a4653ee8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNS03LTEtMS0w_3f7819aa-826a-4cfa-bde7-24ac1aa978dd"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i619b2ecf063d405c93c789d3a0e98721_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNS05LTEtMS0w_d5f2ffad-4d96-4981-9947-89f27d4b7570"
      unitRef="shares">52746728</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i619b2ecf063d405c93c789d3a0e98721_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNS0xMS0xLTEtMA_3a0ebebd-a825-4ea4-931d-01130bade240"
      unitRef="usd">528000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i85efaefef16a413d938e44c4b5777c0e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNS0xMy0xLTEtMA_67798541-1f22-4564-a6b2-fe376baccbf5"
      unitRef="usd">-48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib56ddb546f364c00b070ff8a2cab7021_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNS0xNS0xLTEtMA_507702e5-baad-447c-a309-5b2c3ce0ee46"
      unitRef="usd">62241000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic5b044d2e6b9422992ea59179bc567f3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNS0xOS0xLTEtMA_da344434-fcd1-402f-858e-d83454fce6cf"
      unitRef="usd">-55424000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic9973a4a90424a12a7dc55d2dce30953_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNS0yMS0xLTEtMA_ee66397c-033c-4c88-b6df-bfc87feb6cb8"
      unitRef="usd">7297000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib7939caa4e524cc88ac3e5aff4177860_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNi0xNS0xLTEtMA_bf69eb50-da3b-4ae5-9fe3-d823f3d4290f"
      unitRef="usd">149000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if337d9153dc545129019175c2d4f63ac_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNi0yMS0xLTEtMA_fd8ef64c-462c-4246-96e7-bcec14370494"
      unitRef="usd">149000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ocgn:StockIssuedDuringPeriodSharesWarrantExchange
      contextRef="i431ea463f15d497aac6934b546008514_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNy05LTEtMS0w_4d732e42-069f-49ea-9cf6-f5579c30b5f3"
      unitRef="shares">21920820</ocgn:StockIssuedDuringPeriodSharesWarrantExchange>
    <ocgn:StockIssuedDuringPeriodValueWarrantExchange
      contextRef="i431ea463f15d497aac6934b546008514_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNy0xMS0xLTEtMA_dae6e75a-b8e7-4491-ade3-df5b97afd965"
      unitRef="usd">219000</ocgn:StockIssuedDuringPeriodValueWarrantExchange>
    <ocgn:StockIssuedDuringPeriodValueWarrantExchange
      contextRef="ib7939caa4e524cc88ac3e5aff4177860_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNy0xNS0xLTEtMA_01ad4a7e-a62d-4a0b-8437-931c99605fa3"
      unitRef="usd">-5197000</ocgn:StockIssuedDuringPeriodValueWarrantExchange>
    <ocgn:StockIssuedDuringPeriodValueWarrantExchange
      contextRef="if337d9153dc545129019175c2d4f63ac_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfNy0yMS0xLTEtMA_75b2eb2d-4ffe-43b8-88be-d8d272b1a224"
      unitRef="usd">-4978000</ocgn:StockIssuedDuringPeriodValueWarrantExchange>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia6e7f2c707054cd683451662d8ed7372_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfOC05LTEtMS0w_654b1fec-7317-4b62-a083-6d590567d19b"
      unitRef="shares">1328405</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia6e7f2c707054cd683451662d8ed7372_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfOC0xMS0xLTEtMA_cb240e77-c064-420a-bb81-4a2b3860a17c"
      unitRef="usd">13000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i711b829d5ee345eebc50acfa4b930a61_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfOC0xNS0xLTEtMA_24030a00-1c4e-49a5-b12b-6fe86eac9d55"
      unitRef="usd">319000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3e011586eab7413c970320b1703ebf08_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfOC0yMS0xLTEtMA_c67c15de-ac7d-48af-9a2d-64ece53431ef"
      unitRef="usd">332000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic9e589df88b2465ba4294cb791b7dc17_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfOS05LTEtMS0w_138164e2-81f6-43ec-81e4-0d62ba50b4d9"
      unitRef="shares">59132191</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic9e589df88b2465ba4294cb791b7dc17_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfOS0xMS0xLTEtMA_2be52a65-10fb-4e3f-86d3-79aa4ececb33"
      unitRef="usd">591000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iede14896071c4ee49fa119a80f14fbab_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfOS0xNS0xLTEtMA_5b82b9e7-b78a-4d17-bf20-cfca0d2215ce"
      unitRef="usd">14846000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia439f49486224935ad3477d5b4185130_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfOS0yMS0xLTEtMA_cce127fb-13e8-4d1d-8b77-5f79d2dd3f8e"
      unitRef="usd">15437000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="ifb4586bd1771477fae5877934605f9b3_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTAtMTktMS0xLTA_eb5d6a47-964a-4fb6-b241-a1b00926b456"
      unitRef="usd">-3614000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if337d9153dc545129019175c2d4f63ac_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTAtMjEtMS0xLTA_0f3231b5-d66c-4508-9048-e2c30e10bce5"
      unitRef="usd">-3614000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i74784bdd498745d5ae511cab1b360837_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTEtMS0xLTEtMA_da1eb964-0c70-42eb-86aa-ed3c28516964"
      unitRef="shares">7</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i74784bdd498745d5ae511cab1b360837_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTEtMy0xLTEtMA_230e9b8c-6fed-4a6d-887d-7ae4d8ce0d8e"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ifc519bce743c46c398e1d5dead4107f7_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTEtNS0xLTEtMA_474b0d80-f00f-4978-8d3b-af45cd1ce24b"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifc519bce743c46c398e1d5dead4107f7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTEtNy0xLTEtMA_c1b11fc6-5974-4812-b7b3-ff04114163b4"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="iafa83b4739574d758beec4c0757ed122_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTEtOS0xLTEtMA_042e4291-39bd-4f84-a470-8a14c40afb90"
      unitRef="shares">135128144</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iafa83b4739574d758beec4c0757ed122_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTEtMTEtMS0xLTA_5403ada5-3d4c-4d85-9508-0f3518bc999f"
      unitRef="usd">1351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7d3554a78cc8449d9aad5b8c1c4503fd_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTEtMTMtMS0xLTA_8a0de34f-17b4-4307-b832-9206c2f4b4d7"
      unitRef="usd">-48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8f107ec3ae1e4116afeb1163e6492976_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTEtMTUtMS0xLTA_28f4b13b-caf2-4a25-bfd1-dc8e086d06cc"
      unitRef="usd">72358000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idb989f73c9d1445fa69a483600870562_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTEtMTktMS0xLTA_37239c4c-d2c9-496a-9b4d-d6b3d9c9529a"
      unitRef="usd">-59038000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6eb68a3826b24dfe8726311fa8f753a4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTEtMjEtMS0xLTA_43756001-b46c-40af-b699-c7124b0ce5e0"
      unitRef="usd">14623000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia772fd167d25491e80c5e09f8d26ca55_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTItMTUtMS0xLTUy_59b6095b-b87d-41e1-b473-be6dd66f0b0e"
      unitRef="usd">126000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTItMjEtMS0xLTUy_c89cdd79-9a20-4f29-8c46-481c9eb6f2da"
      unitRef="usd">126000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i9d2b34877c824fb39ecf988264920e54_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTMtOS0xLTEtMzA1_727e2135-1884-4689-a4df-cac337dfda8f"
      unitRef="shares">27019829</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9d2b34877c824fb39ecf988264920e54_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTMtMTEtMS0xLTMwNQ_6b5902fd-dea0-4822-bfaf-43cd593e4d87"
      unitRef="usd">270000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i49fc5d8a06784ed3b66029a5fdb2c35b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTMtMTUtMS0xLTMwNQ_f3b76d4e-148e-4196-b202-26519218a0e5"
      unitRef="usd">9876000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id4fa370f40af4910a583132f5726f913_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTMtMjEtMS0xLTMwNQ_39f7992e-9606-4189-85f2-e02939f2e5fb"
      unitRef="usd">10146000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="ib8964c98e4b14da7a9f597f5fed0edb0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTMtMTktMS0xLTUy_3f200b72-1cdc-4587-ad7b-55f702744b8a"
      unitRef="usd">-10474000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTMtMjEtMS0xLTUy_f235fd71-f37d-48ca-acc0-0792b34bcf5f"
      unitRef="usd">-10474000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i878a0f96a8194299acd620d27ea9d9bf_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTQtMS0xLTEtNTc_a996d782-1420-4c49-ba1c-5819a22be26f"
      unitRef="shares">7</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i878a0f96a8194299acd620d27ea9d9bf_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTQtMy0xLTEtNTc_75cf4deb-93d1-4b6b-b7b3-9fe20ec3eec2"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i6cba47cf2f404ee9a035c63dae2423f3_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTQtNS0xLTEtNTc_6fd1c1ff-6d58-4009-9bc3-ac7d5362fc1d"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6cba47cf2f404ee9a035c63dae2423f3_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTQtNy0xLTEtNTc_092a3bb5-b63f-466c-8927-2ab79f6e02e8"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ib05383973c11499c94ee4d3e3f64f0b8_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTQtOS0xLTEtNTc_7b82f39a-14bf-4132-8c1a-18db272e8184"
      unitRef="shares">162147973</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib05383973c11499c94ee4d3e3f64f0b8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTQtMTEtMS0xLTU3_2dbf6162-1c28-4b1f-8076-6d09eb39f2f3"
      unitRef="usd">1621000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id86823ae63164e52b4c42f119b89ed4d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTQtMTMtMS0xLTU3_d47135fc-38b6-4c11-86e7-ebb7ce8f846c"
      unitRef="usd">-48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2e710c24c8df431ba6ae05089ef01062_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTQtMTUtMS0xLTU3_dd552bad-2984-40a4-a21d-83e6813ebb61"
      unitRef="usd">82360000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if224aca6e98d4c9f87473c21091780ac_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTQtMTktMS0xLTU3_5545bcc1-55c1-4571-86b7-c2adf305f73d"
      unitRef="usd">-69512000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7033dd63053e40b9b5c54b579a67eebc_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yNS9mcmFnOmI3NDgzNDBjYWZhNTQzOWI4ODBkOTBiOGFjYWU2OTVmL3RhYmxlOjlhMjU4YWM3ZDc5MDQwZmNiNmQxYmJjNjA2NTVlODEwL3RhYmxlcmFuZ2U6OWEyNThhYzdkNzkwNDBmY2I2ZDFiYmM2MDY1NWU4MTBfMTQtMjEtMS0xLTU3_47f1de40-7d1a-4c3c-8195-e660c5f19fb6"
      unitRef="usd">14421000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMy0xLTEtMS0w_7512aaca-5d85-4645-a5e4-550dca4b5a07"
      unitRef="usd">-43784000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMy0zLTEtMS0w_9bf01cab-16da-4e81-aa40-03c1dacaacbc"
      unitRef="usd">-18032000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfNS0xLTEtMS0w_a53106a0-4445-4c76-a1f6-86872a173c9d"
      unitRef="usd">151000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfNS0zLTEtMS0w_163adf78-9650-4c5d-8042-31f0c0555dc3"
      unitRef="usd">58000</us-gaap:Depreciation>
    <ocgn:NonCashInterestExpense
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfNi0xLTEtMS0w_cdd4f012-1b33-42f6-97ee-d3258cb2b08c"
      unitRef="usd">59000</ocgn:NonCashInterestExpense>
    <ocgn:NonCashInterestExpense
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfNi0zLTEtMS0w_cf7b8146-0905-4b14-ad63-d6347bc4eb47"
      unitRef="usd">555000</ocgn:NonCashInterestExpense>
    <ocgn:NoncashLeaseExpense
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfNy0xLTEtMS0w_ed3e4a0e-1faf-4959-b0c2-08f353cef607"
      unitRef="usd">200000</ocgn:NoncashLeaseExpense>
    <ocgn:NoncashLeaseExpense
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfNy0zLTEtMS0w_3df17e9d-287d-43c9-96c0-c85aed104705"
      unitRef="usd">143000</ocgn:NoncashLeaseExpense>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfOC0xLTEtMS0w_d662f777-f07e-4df0-93d1-006b15c332d5"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfOC0zLTEtMS0w_7f03da04-7b77-4784-89fa-4c2015abdcb5"
      unitRef="usd">7000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfOS0xLTEtMS0w_2ada2827-4748-4bb8-86d7-66d49a06f094"
      unitRef="usd">4275000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfOS0zLTEtMS0w_2c1f3943-6f0f-4cda-afda-24b9717f1229"
      unitRef="usd">497000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTAtMS0xLTEtMzM3NTc_0d706d5a-cf00-4098-8b47-c84b71f93ef3"
      unitRef="usd">-52000</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTAtMy0xLTEtMzM3NjQ_84aa61d4-de94-4004-b9c0-38743b550550"
      unitRef="usd">0</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTAtMS0xLTEtMA_f0d54dbf-91fe-499a-9267-21ce4594ff80"
      unitRef="usd">426000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTAtMy0xLTEtMA_34414bdd-f3d6-41a7-9b13-a1b7df61e3da"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ProvisionForLoanLossesExpensed
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTEtMS0xLTEtMA_48fa6c97-dc61-419c-867e-f1647c7ab015"
      unitRef="usd">761000</us-gaap:ProvisionForLoanLossesExpensed>
    <us-gaap:ProvisionForLoanLossesExpensed
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTEtMy0xLTEtMA_da0332bd-ff75-4b32-bd4e-7f2cdd159a64"
      unitRef="usd">0</us-gaap:ProvisionForLoanLossesExpensed>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTItMS0xLTEtMA_9db6abdc-5292-4820-9659-6dd31beaefec"
      unitRef="usd">0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTItMy0xLTEtMA_0f04337f-dcd8-4ae5-a00a-f368fb2d0d35"
      unitRef="usd">166000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTQtMS0xLTEtMA_16189653-a127-44af-bf05-e2daed804d8f"
      unitRef="usd">-845000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTQtMy0xLTEtMA_c4da0086-1701-44c7-a673-833ab8b5e740"
      unitRef="usd">-796000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTUtMS0xLTEtMA_c9096443-aad6-45de-bbee-efbeec19751c"
      unitRef="usd">2925000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTUtMy0xLTEtMA_ef8a3c7d-40a1-4022-8bb5-ac9415535dda"
      unitRef="usd">-1133000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTYtMS0xLTEtMA_50ced664-dbfd-479f-9e0c-878cd9bd6916"
      unitRef="usd">-100000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTYtMy0xLTEtMA_d1a2d0e2-7e4a-4d54-b604-8d148a6904ba"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <ocgn:IncreaseDecreaseInLeaseObligations
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTctMS0xLTEtMA_b9deeea2-55f4-4e5a-8a95-792a1d305ca5"
      unitRef="usd">-191000</ocgn:IncreaseDecreaseInLeaseObligations>
    <ocgn:IncreaseDecreaseInLeaseObligations
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTctMy0xLTEtMA_a1e8a198-f429-4c21-9c98-79ed1aba4975"
      unitRef="usd">-144000</ocgn:IncreaseDecreaseInLeaseObligations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTgtMS0xLTEtMA_a66663ba-20ef-47d2-b0d3-dd80bdd16eb7"
      unitRef="usd">-35137000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMTgtMy0xLTEtMA_c2227e33-6ee9-488a-a4ee-7125a5af4638"
      unitRef="usd">-10426000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjAtMS0xLTEtMA_76962014-d50d-439a-9415-655769805709"
      unitRef="usd">747000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjAtMy0xLTEtMA_1d470252-2ab2-40e1-83f5-2acb9b96fbf1"
      unitRef="usd">56000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjEtMS0xLTEtMjQ1MTE_a6378680-348f-4c00-bfad-cb0311060a5c"
      unitRef="usd">127000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjEtMy0xLTEtMjQ1MTE_db80b9dd-776d-4a91-bfe2-5fb5317a4e4e"
      unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <ocgn:IssuanceOfFinancingReceivable
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjEtMS0xLTEtMA_0780062b-c788-4265-83be-5357c9074b21"
      unitRef="usd">750000</ocgn:IssuanceOfFinancingReceivable>
    <ocgn:IssuanceOfFinancingReceivable
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjEtMy0xLTEtMA_60ad9005-47de-43cd-9b35-18850fee5414"
      unitRef="usd">0</ocgn:IssuanceOfFinancingReceivable>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjItMS0xLTEtMA_9e5d5156-a345-4461-b151-e2f22fbdf5e5"
      unitRef="usd">-1624000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjItMy0xLTEtMA_2459bbb1-3f77-48f3-b7c8-0141e9726e4a"
      unitRef="usd">-56000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjQtMS0xLTEtMA_71ae7612-4371-4aa4-8707-452d06a5f306"
      unitRef="usd">128606000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjQtMy0xLTEtMA_a5cdfbe5-b04d-4561-b71a-c26b6f62f17f"
      unitRef="usd">26693000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjUtMS0xLTEtMA_f9cafa29-9f16-426a-b1dc-4064e0935c96"
      unitRef="usd">8525000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjUtMy0xLTEtMA_e85555a7-1fcd-47b0-b586-125285c16de3"
      unitRef="usd">1084000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjYtMS0xLTEtMA_e67713b7-c8a5-4109-8a45-27a6278931cd"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjYtMy0xLTEtMA_a191cf37-432f-4893-96d6-7f20136f7cd4"
      unitRef="usd">921000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjctMS0xLTEtMA_dffae2da-2e5d-45a8-b1bf-bcdaa829e605"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjctMy0xLTEtMA_2d77ef6a-c090-45c9-b621-19482430fff5"
      unitRef="usd">6000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:RepaymentsOfDebt
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjgtMS0xLTEtMA_e4195afb-b069-4fe7-8b92-1484c95df8b9"
      unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjgtMy0xLTEtMA_bf6d9ddf-0f0a-4312-a196-259ef742152c"
      unitRef="usd">4362000</us-gaap:RepaymentsOfDebt>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjktMS0xLTEtMA_8d1bde1b-6ff1-4d49-a27e-40523e61144e"
      unitRef="usd">10000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMjktMy0xLTEtMA_80ef52af-04fa-4ccc-9ab8-165a37dab35d"
      unitRef="usd">18000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMzAtMS0xLTEtMA_2dd0f4bb-07e3-4a1d-b4e9-a1b6e0272f8e"
      unitRef="usd">120071000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMzAtMy0xLTEtMA_fcfc4c0b-4b75-4447-87d2-92bbc1f6965a"
      unitRef="usd">22144000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMzEtMS0xLTEtMA_f7bcb4ac-30bc-4c0e-afc8-a25c93f10832"
      unitRef="usd">83310000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMzEtMy0xLTEtMA_7f7559b7-021e-4f04-83f7-825e0564dc16"
      unitRef="usd">11662000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMzItMS0xLTEtMA_c3cf625c-069b-4bae-ad7b-63155377afb5"
      unitRef="usd">24190000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia331e4fce5e04537ac0252d8c85aa3db_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMzItMy0xLTEtMA_173c3370-ce6e-4c08-9c52-7fdcbbe64892"
      unitRef="usd">7595000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMzMtMS0xLTEtMA_92462991-4818-4c0a-879f-f772a83fdc2d"
      unitRef="usd">107500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7033dd63053e40b9b5c54b579a67eebc_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOjQ3ODE2ZjFkYWZlZTRhZmFiZmJjZWU1MzRhMGQzM2EwL3RhYmxlcmFuZ2U6NDc4MTZmMWRhZmVlNGFmYWJmYmNlZTUzNGEwZDMzYTBfMzMtMy0xLTEtMA_22276e7a-59c2-470d-b3b9-fb32fa638df9"
      unitRef="usd">19257000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfNC0xLTEtMS0yNjY1Mw_38dcb490-fa39-401d-b404-3c41f47287e6"
      unitRef="usd">603000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfNC0zLTEtMS0yNjY1Mw_ce2a0cd2-b09b-4eab-b328-56907a2d84d6"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfMy0xLTEtMS0yMzE1_5ea198db-f4d7-4f98-a814-b2e02f4102b3"
      unitRef="usd">4988000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfMy0zLTEtMS0yMzMz_262c6864-fd9f-4d02-82aa-eb9dee5b4fbf"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <ocgn:GainLossOnForgivenessOfPaycheckProtectionProgramNote
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfNS0xLTEtMS0yMzE1_79842eef-ab85-4550-b908-70e32da5a2c3"
      unitRef="usd">426000</ocgn:GainLossOnForgivenessOfPaycheckProtectionProgramNote>
    <ocgn:GainLossOnForgivenessOfPaycheckProtectionProgramNote
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfNS0zLTEtMS0yMzMz_bb9198b3-3524-4859-a8be-258b4c4bfc58"
      unitRef="usd">0</ocgn:GainLossOnForgivenessOfPaycheckProtectionProgramNote>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfNy0xLTEtMS0yNjY5Ng_942f12a1-47ec-43f4-a267-1ce8cb24f41f"
      unitRef="usd">9000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfNy0zLTEtMS0yNjY5Ng_cec4a2d5-481e-47e6-95db-2c5bed1b069a"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <ocgn:NoncashOrPartNoncashOperatingLeaseRightOfUseAsset
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfOC0xLTEtMS0yNjY5Ng_be01db9c-e7ad-4a07-a0af-ec44f695a24f"
      unitRef="usd">926000</ocgn:NoncashOrPartNoncashOperatingLeaseRightOfUseAsset>
    <ocgn:NoncashOrPartNoncashOperatingLeaseRightOfUseAsset
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfOC0zLTEtMS0yNjY5Ng_4fd20d98-85b7-48c0-8c8a-d203c5e0854c"
      unitRef="usd">0</ocgn:NoncashOrPartNoncashOperatingLeaseRightOfUseAsset>
    <us-gaap:NotesIssued1
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfNi0xLTEtMS0yMzE1_7934850b-4c8d-4a37-983a-2b1ee7a74964"
      unitRef="usd">0</us-gaap:NotesIssued1>
    <us-gaap:NotesIssued1
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfNi0zLTEtMS0yMzMz_03cd5e0e-68f4-46e6-ae33-e8f4641195d2"
      unitRef="usd">5625000</us-gaap:NotesIssued1>
    <us-gaap:StockIssued1
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfNy0xLTEtMS0yMzE1_11c8d39a-ffc0-40a6-a63e-8a14c8450043"
      unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfNy0zLTEtMS0yMzMz_bd9c6ef5-22a8-4e62-9e28-8794ef6f2f31"
      unitRef="usd">331000</us-gaap:StockIssued1>
    <ocgn:NoncashOrPartNoncashAmountOfDeferredTransactionCost
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfOC0xLTEtMS0yMzE1_7a5bef6e-d804-4d17-b481-cbf82727e722"
      unitRef="usd">0</ocgn:NoncashOrPartNoncashAmountOfDeferredTransactionCost>
    <ocgn:NoncashOrPartNoncashAmountOfDeferredTransactionCost
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18yOC9mcmFnOmQxNWU2N2ZiYTRkZTRkNmI5MDFiMWFiOTNlYzk4ZGI3L3RhYmxlOmRlMDc4MzJmMDAwZDQ0YjJhYmNhMjVjNzcwN2U5Zjc0L3RhYmxlcmFuZ2U6ZGUwNzgzMmYwMDBkNDRiMmFiY2EyNWM3NzA3ZTlmNzRfOC0zLTEtMS0yMzMz_46dd6649-c8e3-4a41-88da-d05a91274e03"
      unitRef="usd">25000</ocgn:NoncashOrPartNoncashAmountOfDeferredTransactionCost>
    <us-gaap:NatureOfOperations
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfMTA3NTU_a8e0db34-a94c-4294-82fa-d0cd80ab0301">Nature of Business&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ocugen, Inc., together with its wholly owned subsidiaries (&#x201c;Ocugen&#x201d; or the &#x201c;Company&#x201d;), is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The Company is headquartered in Malvern, Pennsylvania, and manages its business as one operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;COVID-19 Vaccine&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the Company entered into a Co-Development, Supply and Commercialization Agreement with Bharat Biotech International Limited ("Bharat Biotech"), pursuant to which the Company obtained an exclusive right and license under certain of Bharat Biotech's intellectual property rights, with the right to grant sublicenses to develop, manufacture, and commercialize BBV152, known as COVAXIN outside the United States, for the prevention of COVID-19 caused by SARS-CoV-2 in humans in the United States, its territories, and possessions. In June 2021, the Company entered into an amendment to the Co-Development, Supply and Commercialization Agreement (as so amended, the "Covaxin Agreement") pursuant to which the parties agreed to expand the Company's rights to develop, manufacture, and commercialize COVAXIN to include Canada in addition to the United States, its territories, and possessions (the &#x201c;Ocugen Covaxin Territory&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus, an antigen, and an adjuvant. COVAXIN requires a two-dose vaccination regimen given 28 days apart and is stored in standard vaccine storage conditions (2-8&#xb0;C). COVAXIN has been authorized for emergency use in India for ages 18 years and older. In November 2021, COVAXIN was awarded an Emergency Use Listing ("EUL") by the World Health Organization ("WHO").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, the Company announced that COVAXIN demonstrated an overall vaccine efficacy against COVID-19 disease of 77.8%, with efficacy against severe COVID-19 disease of 93.4%, and efficacy against asymptomatic COVID-19 disease of 63.6% in the Phase 3 clinical trial conducted by Bharat Biotech in India. Adverse events in the COVAXIN and control arms of the Phase 3 clinical trial were observed in 12.4% of subjects, with less than 0.5% of subjects experiencing serious adverse side effects. The majority of the symptomatic cases identified in aggregate in the COVAXIN and control arms in the Phase 3 clinical trial were COVID-19 variants, the majority of which were identified to be the Delta variant, B.1.617.2. Subjects vaccinated with COVAXIN in the Phase 3 clinical trial showed protection against the Delta variant, B.1.617.2, showing a vaccine efficacy of 65.2%. Additionally, in in-vitro studies conducted by the Indian Council of Medical Research ("ICMR") &#x2014; National Institute of Virology, COVAXIN demonstrated potential effectiveness against the Zeta variant, B.1.1.28.2, the Alpha variant, B.1.1.7, and the Beta variant, B.1.351.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the U.S. Food and Drug Administration (the "FDA") provided feedback to the Company regarding the data and information contained in a "Master File" that was previously submitted to the FDA and recommended that the Company pursue a Biologics License Application ("BLA") submission instead of an Emergency Use Authorization ("EUA") application for COVAXIN for ages 18 years and older in the United States. As part of the feedback provided by the FDA regarding the "Master File," the FDA also requested additional information and data. The Company has continued discussions with the FDA regarding the appropriate regulatory pathway for COVAXIN for ages 18 years and older in the United States as well as the data requirements for COVAXIN under a BLA submission. In October 2021, the Company filed an Investigational New Drug ("IND") application with the FDA to initiate a Phase 3 immuno-bridging study evaluating COVAXIN for ages 18 years and older. The Company will also initiate a safety-bridging study under the IND, if required by the FDA, to support a BLA submission. The Company anticipates filing a BLA submission with the FDA by the end of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the Company submitted a request to the FDA for EUA for COVAXIN for pediatric use in children ages two to 18 years in the United States. The EUA submission was based on the results of a Phase 2/3 immuno-bridging pediatric clinical trial conducted by Bharat Biotech in India.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also pursuing approval for COVAXIN in Canada. In July 2021, the Company announced it had completed its rolling submission to Health Canada for COVAXIN. The rolling submission process, which permits companies to submit safety and efficacy data and information as they become available, was recommended and accepted under the Minister of Health&#x2019;s &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the "Interim Order") and transitioned to a New Drug Submission ("NDS") for COVID-19. The submission was conducted through the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company's Canadian affiliate, Vaccigen, Ltd. ("Vaccigen"). The Interim Order expired on September 16, 2021. The expiration of the Interim Order has not impacted the Company's NDS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is evaluating its commercialization strategy for COVAXIN in the United States and Canada, if authorized or approved in either jurisdiction. In June 2021, the Company selected Jubilant HollisterStier as its manufacturing partner for COVAXIN to prepare for the potential commercial manufacturing for the Ocugen Covaxin Territory. The Company expects to enter into a master services agreement with Jubilant HollisterStier for the manufacture of COVAXIN and the technology transfer process to Jubilant HollisterStier has been initiated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Company entered into a Development and Commercial Supply Agreement (the &#x201c;Supply Agreement&#x201d;) with Bharat Biotech, pursuant to which &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bharat Biotech will supply the Company with clinical trial materials and commercial supplies of COVAXIN finished drug product prior to the completion of the Company&#x2019;s technology transfer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Jubilant HollisterStier&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Following the completion of the Company&#x2019;s technology transfer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Jubilant HollisterStier&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Bharat Biotech will supply COVAXIN drug product components and continue to supply finished drug product as necessary for commercial manufacture and supply of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;COVAXIN &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subsequent to a regulatory authorization or approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Modifier Gene Therapy Platform&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is developing a breakthrough modifier gene therapy platform to generate therapies designed to fulfill unmet medical needs in the area of retinal diseases, including inherited retinal diseases ("IRDs") and dry age-related macular degeneration ("AMD"). The Company's modifier gene therapy platform is based on nuclear hormone receptors (&#x201c;NHRs&#x201d;), which have the potential to restore homeostasis, the basic biological processes in the retina. Unlike single-gene replacement therapies, which only target one genetic mutation, the Company believes that its gene therapy platform, through its use of NHRs, represents a novel approach in that it may address multiple retinal diseases with one product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that OCU400, its first product candidate being developed with its modifier gene therapy platform, has the potential to be broadly effective in restoring retinal integrity and function across a range of genetically diverse IRDs, including retinitis pigmentosa ("RP") and leber congenital amaurosis ("LCA"). OCU400 has received four Orphan Drug Designations ("ODDs") from the FDA for the treatment of certain disease genotypes: nuclear receptor subfamily 2 group E member 3 ("&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NR2E3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;"), centrosomal protein 290 ("&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;CEP290&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;"), rhodopsin ("&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RHO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;"), and phosphodiesterase 6B ("&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;PDE6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#xdf;") mutation-associated inherited retinal degenerations. In November 2021, the Company filed an IND application with the FDA for OCU400 for the treatment of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NR2E3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RHO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; disease genotypes. The Company is planning to initiate a Phase 1/2 clinical trial for OCU400 for the treatment of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NR2E3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RHO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; disease genotypes in the United States near the end of 2021. OCU400 additionally has received Orphan Medicinal Product Designation ("OMPD") from the European Commission ("EC"), based on the recommendation of the European Medicines Agency ("EMA"), for RP and LCA, which the Company believes further supports the potential broad spectrum application of OCU400 to treat many IRDs. The Company is currently evaluating options to commence OCU400 clinical trials in Europe in 2022. The Company's second gene therapy candidate, OCU410, is being developed to utilize the nuclear receptor genes RAR-related orphan receptor A ("&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RORA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;") for the treatment of dry AMD. The Company is currently executing IND-enabling preclinical studies to support a Phase 1/2 clinical trial. The Company has engaged CanSino Biologics, Inc. ("CanSinoBIO") to manufacture clinical supplies and be responsible for the chemistry, manufacturing, and controls ("CMC") development for OCU400 and OCU410. See Note 3 for additional information about the Company's collaboration with CanSinoBIO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Novel Biologic Therapy for Retinal Diseases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's biologic product candidate, OCU200, is a novel fusion protein being developed to treat diabetic macular edema ("DME"), diabetic retinopathy ("DR"), and wet AMD. The Company is currently executing IND-enabling preclinical studies to support a Phase 1 clinical trial. The Company has completed the technology transfer of manufacturing processes to the Company's contract development and manufacturing organization ("CDMO") that will manufacture OCU200 clinical supplies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred recurring net losses since inception and has funded its operations to date through the sale of common stock, warrants to purchase common stock, the issuance of convertible notes, debt, and grant proceeds. The Company incurred net losses of approximately $43.8&#160;million and $18.0&#160;million for the nine months ended September 30, 2021 and 2020, respectively. As of September&#160;30, 2021, the Company had an accumulated deficit of $117.1&#160;million and cash, cash equivalents, and restricted cash totaling $107.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a limited operating history and its prospects are subject to risks, expenses, and uncertainties frequently encountered by companies in its industry. The Company intends to continue its research, development, and commercialization efforts for its product candidates, which will require significant additional funding. If the Company is unable to obtain additional financing in the future or its research, development, and commercialization efforts require higher than anticipated capital, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital through public and private placements of equity and/or debt, payments from potential strategic research and development arrangements, sales of assets, government grants, licensing and/or collaboration arrangements with pharmaceutical companies or other institutions, or other funding from the government or other third parties. Such financing may not be available at all, or on terms that are favorable to the Company. While management of the Company believes that it has a plan to fund ongoing operations, its plan may not be successfully implemented. Failure to generate sufficient cash flows from operations, raise additional capital, or appropriately manage certain discretionary spending could have a material adverse effect on the Company&#x2019;s ability to achieve its intended business objectives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of these factors, together with the anticipated increase in spending that will be necessary to continue to research, develop, and commercialize the Company&#x2019;s product candidates, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. The condensed consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfMzQx_5f9e61ff-233b-4867-96cc-e55d758fa66b"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <ocgn:NumberOfVaccinationDoseRegimen
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfMTQ0NA_a18ef404-99c9-4d8e-9b06-243f6ed05ff1"
      unitRef="dose">2</ocgn:NumberOfVaccinationDoseRegimen>
    <ocgn:VaccinationDoseRegimenDurationApart
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfMTQ3OA_0ec79baa-82a5-4bff-a04b-28b18e3f7f66">P28D</ocgn:VaccinationDoseRegimenDurationApart>
    <ocgn:OverallVaccineEfficacyPercent
      contextRef="i3eb7b92dc9494a35b5033ab8674abe63_D20210701-20210731"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfMTc4Nw_5bcf729e-61ac-45dd-8eae-b53b2e31c13d"
      unitRef="number">0.778</ocgn:OverallVaccineEfficacyPercent>
    <ocgn:EfficacySevereCasesPercent
      contextRef="i3eb7b92dc9494a35b5033ab8674abe63_D20210701-20210731"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfMTg0MA_94269ba3-7fd3-4dbe-ae02-3d80461a8e21"
      unitRef="number">0.934</ocgn:EfficacySevereCasesPercent>
    <ocgn:EfficacyAsymptomaticInfectionPercent
      contextRef="i3eb7b92dc9494a35b5033ab8674abe63_D20210701-20210731"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfMTg5OA_9ea89c7c-681a-44e5-9d96-7ecc3dd713d0"
      unitRef="number">0.636</ocgn:EfficacyAsymptomaticInfectionPercent>
    <ocgn:AdverseEventsSideEffectsPercent
      contextRef="i3eb7b92dc9494a35b5033ab8674abe63_D20210701-20210731"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfMjA2NA_c5cf4507-05d4-491b-93b9-326f21f21464"
      unitRef="number">0.124</ocgn:AdverseEventsSideEffectsPercent>
    <ocgn:AdverseEventsSeriousAdverseSideEffectsPercent
      contextRef="i3eb7b92dc9494a35b5033ab8674abe63_D20210701-20210731"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfMjA5NQ_e82e68ad-4dd9-4e98-a0b4-8072d7a6b7e8"
      unitRef="number">0.005</ocgn:AdverseEventsSeriousAdverseSideEffectsPercent>
    <ocgn:EfficacyAgainstDeltaVariantB16172Percent
      contextRef="i3eb7b92dc9494a35b5033ab8674abe63_D20210701-20210731"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfMjUzNA_6dfc99cd-6fa2-4775-a3ab-e91444fe6d1b"
      unitRef="number">0.652</ocgn:EfficacyAgainstDeltaVariantB16172Percent>
    <ocgn:SingleGeneReplacementTherapiesNumberOfGeneticMutationsTarget
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfNTg0NQ_194849eb-7b73-410f-90d6-c0555a27b6a2"
      unitRef="geneticmutation">1</ocgn:SingleGeneReplacementTherapiesNumberOfGeneticMutationsTarget>
    <ocgn:ModifierGeneTherapyPlatformNumberOfProducts
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfNjAyNg_79be4072-cf5c-471c-b4dd-5fcbf8a42704"
      unitRef="product">1</ocgn:ModifierGeneTherapyPlatformNumberOfProducts>
    <ocgn:NumberOfOrphanDrugDesignations
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfNjM4NQ_13f8e567-bea1-459e-981d-1b8756df9ebd"
      unitRef="orphan_drug_designation">4</ocgn:NumberOfOrphanDrugDesignations>
    <us-gaap:NetIncomeLoss
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfODYzNA_4d1b1d0a-23f1-4f28-9651-f87ebebb08ce"
      unitRef="usd">-43800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfODY0MQ_ff71793b-d1e8-4da5-abea-a64396781e5c"
      unitRef="usd">-18000000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfODcyOQ_226a10ab-a52b-4850-97a0-4c2499b503fe"
      unitRef="usd">-117100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNC9mcmFnOjQ5ZTY1ZTQwNzRhNDQ2NDliZTA1MjE2Nzc5M2UyZmJhL3RleHRyZWdpb246NDllNjVlNDA3NGE0NDY0OWJlMDUyMTY3NzkzZTJmYmFfODc4OQ_c36dc4a8-3775-43da-b6d0-550c6f99f41d"
      unitRef="usd">107500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MzE_da79b299-974b-4b9d-b3f3-e626c4ccd959">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements included herein have been prepared in conformity with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) and under the rules&#160;and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim reporting. The accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, that are necessary to present fairly the Company&#x2019;s financial position, results of operations, and cash flows. The condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosures of the Company normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted under the SEC&#x2019;s rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto for the year ended December&#160;31, 2020, included in the Company's Annual Report on Form 10-K filed with the SEC on March 19, 2021 (the "2020 Annual Report").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of Ocugen and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform with current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In preparing the condensed consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions primarily include those used in the accounting for research and development accruals, the fair value measurement of equity instruments, and the collectibility of the note receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses whether collaboration agreements are subject to Financial Accounting Standards Board ("FASB") Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 808&#x201d;), based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of ASC 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner represent consideration from a customer, the Company accounts for those payments within the scope of FASB ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. However, if the Company concludes that its collaboration partner is not a customer, the Company will record royalty payments received as collaboration revenue in the period in which the underlying sale occurs and record expenses and expense reimbursements as either research and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;development expense or general and administrative expense, or a reduction thereof, based on the underlying nature of the expense or expense reimbursement. During the nine months ended September 30, 2020, the Company recorded collaboration revenue from an agreement accounted for as a collaborative arrangement within the scope of ASC 808. No collaboration revenue was recorded during the nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exit and Disposal Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records liabilities for one-time termination benefits in accordance with FASB ASC Topic 420, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exit and Disposal Cost Obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASC 420"). In accordance with ASC 420, an arrangement for one-time termination benefits exists at the date the plan of the termination meets the following criteria: (i) management commits to a plan of termination, (ii) the plan identifies the impacted employees and expected completion date, (iii) the plan identifies the terms of the benefits arrangement, (iv) it is unlikely significant changes to the plan will be made or the plan will be withdrawn, and (v) the plan has been communicated to employees. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits, are recognized ratably over the future service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records liabilities for employee termination benefits covered by ongoing benefit arrangements in accordance with FASB ASC Topic 712, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nonretirement Postemployment Benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASC 712"). In accordance with ASC 712, costs for termination benefits under ongoing benefits arrangements are recognized when management has committed to a plan of termination and the costs are probable and estimable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Severance-related charges, once incurred, are recognized as either research and development expense or general and administrative expense within the condensed consolidated statements of operations and comprehensive loss depending on the job function of the former employee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows the provisions of FASB ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 820&#x201d;), which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 &#x2014; quoted prices in active markets for identical assets or liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 &#x2014; quoted prices for similar assets and liabilities in active markets or inputs that are observable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 &#x2014; inputs that are unobservable (for example cash flow modeling inputs based on assumptions)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of certain financial instruments, including cash and cash equivalents, accounts payable, and accrued expenses approximates their fair values due to the short-term nature of these instruments. As of September&#160;30, 2021, the Company believes the fair value using Level 2 inputs of the borrowings under the EB-5 Loan Agreement (as defined in Note 8) approximate their carrying value. See Note 8 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash equivalents may include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposit, commercial paper, and U.S. government and U.S. government agency obligations. The Company&#x2019;s restricted cash balance consists of cash held to collateralize a corporate credit card account.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash in the condensed consolidated balance sheets to the total amount shown in the condensed consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is recorded at historical cost. Significant additions or improvements are capitalized, and expenditures for repairs and maintenance are charged to expense as incurred. Gains and losses on disposal of assets are included in the condensed consolidated statements of operations and comprehensive loss. Depreciation is calculated using the straight-line method and is recognized over the expected useful life of the underlying asset. The Company's property and equipment currently includes furniture and fixtures, machinery and equipment, leasehold improvements, and construction in progress. The Company's furniture and fixtures have an expected useful life of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfNDM5ODA0NjU4MjIzNg_2f5f7cef-a3ff-41b9-b3bd-1ded51f7bc02"&gt;three&lt;/span&gt; to seven years. The Company's machinery and equipment have an expected useful life of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfNDM5ODA0NjU4MjMwOQ_2aaf4aaa-5250-4fad-95da-0d6844c093cb"&gt;five&lt;/span&gt; to seven years. Leasehold improvements are amortized over the shorter of their expected useful lives or the remaining lease term. If a leasehold improvement transfers ownership to the Company at the end of the lease term, the leasehold improvement is amortized over its expected useful life. Construction in progress is not depreciated until such time that the asset is completed and placed into service. Once placed into service, the asset is depreciated over its expected useful life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company&#x2019;s current and historical lease agreements include lease and non-lease components, which the Company has elected not to account for separately for all classes of underlying assets. Lease expense for variable lease components is recognized when the obligation is probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases are included in other assets and operating lease obligations in the Company&#x2019;s condensed consolidated balance sheets. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. Operating lease payments are recognized as lease expense on a straight-line basis over the lease term and recognized as research and development expense or general and administrative expense based on the underlying nature of the expense. The Company currently leases real estate classified as operating leases. FASB ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASC 842") requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. The implicit interest rate was not readily determinable in the Company&#x2019;s current and historical operating leases, therefore the incremental borrowing rate was used based on the information available at the commencement date in determining the present value of lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease term for the Company&#x2019;s leases includes the non-cancellable period of the lease plus any additional periods covered by either an option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease payments included in the measurement of the lease liability are comprised of fixed payments, variable payments that depend on index or rate, and amounts probable to be payable under the exercise of an option to purchase the underlying asset if reasonably certain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable payments not dependent on an index or rate associated with the Company&#x2019;s leases are recognized when the event, activity, or circumstance is probable. Variable payments include the Company's proportionate share of certain utilities and other operating expenses and are presented as operating expenses in the Company&#x2019;s condensed consolidated statements of operations and comprehensive loss in the same line item as expense arising from fixed payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation &#x2014; Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 718&#x201d;). The Company has issued stock-based compensation awards including stock options and restricted stock units ("RSUs"), and also accounts for certain issuances of preferred stock and warrants in accordance with ASC 718. ASC 718 requires all stock-based payments, including grants of stock options and RSUs, to be recognized in the condensed consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options granted. For RSUs, the fair value of the RSUs is determined by the market price of a share of the Company's common stock at the grant date. The Company recognizes forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation expense related to stock-based compensation awards granted with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Stock-based compensation awards generally vest over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTI5NTc_1b0f22b6-1741-4551-9fe9-ad65976104fa"&gt;one&lt;/span&gt; to three year requisite service period and have a contractual term of 10 years. To the extent a stock-based compensation award is subject to performance-based vesting conditions, the amount of compensation expense recorded reflects an assessment of the probability of achieving the performance conditions. Compensation expense for stock-based compensation awards with performance-based vesting conditions is only recognized when the performance-based vesting condition is deemed probable to occur. Shares issued upon stock option exercise and RSU vesting are newly issued common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating the fair value of stock options requires the input of subjective assumptions, including the expected life of the stock option, stock price volatility, the risk-free interest rate, and expected dividends. The assumptions used in the Company&#x2019;s Black-Scholes option-pricing model represent management&#x2019;s best estimates and involve a number of variables, uncertainties, assumptions, and the application of management&#x2019;s judgment, as they are inherently subjective. If any assumptions change, the Company&#x2019;s stock-based compensation expense could be materially different in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Asset Held for Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company had an intangible asset held for sale that was carried at its original fair value less cost to sell of $7.0&#160;million. The Company concluded during the three and nine months ended September&#160;30, 2020, that a sale of the intangible asset was no longer probable to be completed within one year from the date the intangible asset was initially recorded as held for sale. As such, the carrying value of the intangible asset was reduced to zero with the corresponding charge of $7.0&#160;million recognized as in-process research and development expense in the condensed consolidated statements of operations and comprehensive loss during the three and nine months ended September&#160;30, 2020 as the in-process research and development did not have an alternative future use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued Accounting Standards Update ("ASU") No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocations, and calculating income taxes in interim periods. This standard also adds guidance to reduce complexity in certain areas, including recognizing franchise tax, recognizing deferred taxes for the tax basis of goodwill, allocating taxes to the members of a consolidated group, and recognizing the effect of enacted changes in tax laws or rates during an interim period. This standard was effective for the Company on January 1, 2021. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the FASB issued ASU No. 2021-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share (Topic 260), Debt &#x2014; Modifications and Extinguishments (Subtopic 470-50), Compensation &#x2014; Stock Compensation (Topic 718), and Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard will have an effective and transition date of January 1, 2022. This standard clarifies and reduces diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options, including warrants, that remain equity-classified after modification or exchange. The standard requires an entity to treat a modification or an exchange of a freestanding equity-classified written call option that remains equity-classified after the modification or exchange as an exchange of the original instrument for a new instrument. The standard additionally provides guidance on measuring and recognizing the effect of a modification or an exchange. The Company does not currently expect the adoption of this standard to have a material impact on the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt &#x2014; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2014; Contracts in Entity's Own Equity (Subtopic 815-40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard will have an effective and transition date of January 1, 2024. Early adoption is currently permitted. This standard simplifies an issuer's accounting for convertible instruments by eliminating two of the three models that require separate accounting for embedded conversion features as well as simplifies the settlement assessment that entities are required to perform to determine whether a contract qualifies for equity classification. This standard also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of potential share settlement (if the effect is more dilutive) for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. The standard requires new disclosures about events that occur during the reporting period and cause conversion contingencies to be met and about the fair value of a public business entity's convertible debt at the instrument level, among other things. The Company does not currently expect the adoption of this standard to have a material impact on the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2014; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The FASB subsequently issued amendments to ASU No. 2016-13, which have the same effective date and transition date of January 1, 2023. ASU No. 2016-13, as amended, requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company does not currently expect the adoption of this standard to have a material impact on the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MjA_a69c4a75-6d79-413f-9925-10099ca8cc1b">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements included herein have been prepared in conformity with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) and under the rules&#160;and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim reporting. The accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, that are necessary to present fairly the Company&#x2019;s financial position, results of operations, and cash flows. The condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosures of the Company normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted under the SEC&#x2019;s rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto for the year ended December&#160;31, 2020, included in the Company's Annual Report on Form 10-K filed with the SEC on March 19, 2021 (the "2020 Annual Report").&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2Mjk_b6d6fcde-01ee-4b59-95ed-8e3417ea9b2e">The condensed consolidated financial statements include the accounts of Ocugen and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform with current period presentation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MzI_2917eae5-9301-4b27-a263-f7db0e635a46">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In preparing the condensed consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions primarily include those used in the accounting for research and development accruals, the fair value measurement of equity instruments, and the collectibility of the note receivable.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MTU_8a6b8e7a-c453-42b2-b540-45428eb22965">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses whether collaboration agreements are subject to Financial Accounting Standards Board ("FASB") Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 808&#x201d;), based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of ASC 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner represent consideration from a customer, the Company accounts for those payments within the scope of FASB ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. However, if the Company concludes that its collaboration partner is not a customer, the Company will record royalty payments received as collaboration revenue in the period in which the underlying sale occurs and record expenses and expense reimbursements as either research and &lt;/span&gt;&lt;/div&gt;development expense or general and administrative expense, or a reduction thereof, based on the underlying nature of the expense or expense reimbursement. During the nine months ended September 30, 2020, the Company recorded collaboration revenue from an agreement accounted for as a collaborative arrangement within the scope of ASC 808. No collaboration revenue was recorded during the nine months ended September 30, 2021.</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMzgxOQ_fa091602-941a-433f-9a1e-34a416757b57"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MTY_cd909a24-f52f-4894-9340-93e73d1e1e86">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exit and Disposal Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records liabilities for one-time termination benefits in accordance with FASB ASC Topic 420, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exit and Disposal Cost Obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASC 420"). In accordance with ASC 420, an arrangement for one-time termination benefits exists at the date the plan of the termination meets the following criteria: (i) management commits to a plan of termination, (ii) the plan identifies the impacted employees and expected completion date, (iii) the plan identifies the terms of the benefits arrangement, (iv) it is unlikely significant changes to the plan will be made or the plan will be withdrawn, and (v) the plan has been communicated to employees. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits, are recognized ratably over the future service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records liabilities for employee termination benefits covered by ongoing benefit arrangements in accordance with FASB ASC Topic 712, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nonretirement Postemployment Benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASC 712"). In accordance with ASC 712, costs for termination benefits under ongoing benefits arrangements are recognized when management has committed to a plan of termination and the costs are probable and estimable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Severance-related charges, once incurred, are recognized as either research and development expense or general and administrative expense within the condensed consolidated statements of operations and comprehensive loss depending on the job function of the former employee.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MzA_a5978c98-a5ce-4671-ba0d-1727793bbcce">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows the provisions of FASB ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 820&#x201d;), which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 &#x2014; quoted prices in active markets for identical assets or liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 &#x2014; quoted prices for similar assets and liabilities in active markets or inputs that are observable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 &#x2014; inputs that are unobservable (for example cash flow modeling inputs based on assumptions)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of certain financial instruments, including cash and cash equivalents, accounts payable, and accrued expenses approximates their fair values due to the short-term nature of these instruments. As of September&#160;30, 2021, the Company believes the fair value using Level 2 inputs of the borrowings under the EB-5 Loan Agreement (as defined in Note 8) approximate their carrying value. See Note 8 for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MTc_979dc4af-c378-4a9c-af54-c1142dafa0b7">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash equivalents may include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposit, commercial paper, and U.S. government and U.S. government agency obligations. The Company&#x2019;s restricted cash balance consists of cash held to collateralize a corporate credit card account.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <ocgn:ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MjM_3f61d5d5-60d8-403a-9a3d-055a28fa75b7">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash in the condensed consolidated balance sheets to the total amount shown in the condensed consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ocgn:ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RhYmxlOmE0M2U4NGRlZTEzYTRmMTNhYmM5NTlkZmY0NTZhMjNkL3RhYmxlcmFuZ2U6YTQzZTg0ZGVlMTNhNGYxM2FiYzk1OWRmZjQ1NmEyM2RfMi0xLTEtMS0w_0c165c14-af22-4890-a140-deceee729097"
      unitRef="usd">107349000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7033dd63053e40b9b5c54b579a67eebc_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RhYmxlOmE0M2U4NGRlZTEzYTRmMTNhYmM5NTlkZmY0NTZhMjNkL3RhYmxlcmFuZ2U6YTQzZTg0ZGVlMTNhNGYxM2FiYzk1OWRmZjQ1NmEyM2RfMi0zLTEtMS0w_bf1c5683-4758-4e94-bc1e-a8f6c5bbd6fe"
      unitRef="usd">19106000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RhYmxlOmE0M2U4NGRlZTEzYTRmMTNhYmM5NTlkZmY0NTZhMjNkL3RhYmxlcmFuZ2U6YTQzZTg0ZGVlMTNhNGYxM2FiYzk1OWRmZjQ1NmEyM2RfMy0xLTEtMS0w_040b9cb5-7782-43ba-9070-68c59e01b1f9"
      unitRef="usd">151000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i7033dd63053e40b9b5c54b579a67eebc_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RhYmxlOmE0M2U4NGRlZTEzYTRmMTNhYmM5NTlkZmY0NTZhMjNkL3RhYmxlcmFuZ2U6YTQzZTg0ZGVlMTNhNGYxM2FiYzk1OWRmZjQ1NmEyM2RfMy0zLTEtMS0w_94b8de90-bf9d-4410-b045-ec31b487e655"
      unitRef="usd">151000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RhYmxlOmE0M2U4NGRlZTEzYTRmMTNhYmM5NTlkZmY0NTZhMjNkL3RhYmxlcmFuZ2U6YTQzZTg0ZGVlMTNhNGYxM2FiYzk1OWRmZjQ1NmEyM2RfNC0xLTEtMS0w_f19deda4-b82c-4655-99b5-353db656e212"
      unitRef="usd">107500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7033dd63053e40b9b5c54b579a67eebc_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RhYmxlOmE0M2U4NGRlZTEzYTRmMTNhYmM5NTlkZmY0NTZhMjNkL3RhYmxlcmFuZ2U6YTQzZTg0ZGVlMTNhNGYxM2FiYzk1OWRmZjQ1NmEyM2RfNC0zLTEtMS0w_b0a8ee2d-f842-4fd2-a8ca-01bc5016c36d"
      unitRef="usd">19257000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MjE_a02c0b00-d075-4814-8ff1-c813d44cc0c1">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is recorded at historical cost. Significant additions or improvements are capitalized, and expenditures for repairs and maintenance are charged to expense as incurred. Gains and losses on disposal of assets are included in the condensed consolidated statements of operations and comprehensive loss. Depreciation is calculated using the straight-line method and is recognized over the expected useful life of the underlying asset. The Company's property and equipment currently includes furniture and fixtures, machinery and equipment, leasehold improvements, and construction in progress. The Company's furniture and fixtures have an expected useful life of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfNDM5ODA0NjU4MjIzNg_2f5f7cef-a3ff-41b9-b3bd-1ded51f7bc02"&gt;three&lt;/span&gt; to seven years. The Company's machinery and equipment have an expected useful life of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfNDM5ODA0NjU4MjMwOQ_2aaf4aaa-5250-4fad-95da-0d6844c093cb"&gt;five&lt;/span&gt; to seven years. Leasehold improvements are amortized over the shorter of their expected useful lives or the remaining lease term. If a leasehold improvement transfers ownership to the Company at the end of the lease term, the leasehold improvement is amortized over its expected useful life. Construction in progress is not depreciated until such time that the asset is completed and placed into service. Once placed into service, the asset is depreciated over its expected useful life.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie2a762caa8434142a4d6522864319751_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMzg0ODI5MDc0OTI0OA_e06a2f6d-478a-479a-9186-50ea74cd4bd4">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i835d59b4a71c4ca48581fa3806494a4a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMzg0ODI5MDc0OTI2OQ_62c212d7-4c40-4cec-9b4f-da1185192bfd">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MjU_0b3b396f-cbac-4b3c-bd77-4b138b46f256">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company&#x2019;s current and historical lease agreements include lease and non-lease components, which the Company has elected not to account for separately for all classes of underlying assets. Lease expense for variable lease components is recognized when the obligation is probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases are included in other assets and operating lease obligations in the Company&#x2019;s condensed consolidated balance sheets. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. Operating lease payments are recognized as lease expense on a straight-line basis over the lease term and recognized as research and development expense or general and administrative expense based on the underlying nature of the expense. The Company currently leases real estate classified as operating leases. FASB ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASC 842") requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. The implicit interest rate was not readily determinable in the Company&#x2019;s current and historical operating leases, therefore the incremental borrowing rate was used based on the information available at the commencement date in determining the present value of lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease term for the Company&#x2019;s leases includes the non-cancellable period of the lease plus any additional periods covered by either an option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease payments included in the measurement of the lease liability are comprised of fixed payments, variable payments that depend on index or rate, and amounts probable to be payable under the exercise of an option to purchase the underlying asset if reasonably certain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable payments not dependent on an index or rate associated with the Company&#x2019;s leases are recognized when the event, activity, or circumstance is probable. Variable payments include the Company's proportionate share of certain utilities and other operating expenses and are presented as operating expenses in the Company&#x2019;s condensed consolidated statements of operations and comprehensive loss in the same line item as expense arising from fixed payments.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MzQ_9bf83d60-dfc4-483f-a347-f2a9afaf49aa">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation &#x2014; Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 718&#x201d;). The Company has issued stock-based compensation awards including stock options and restricted stock units ("RSUs"), and also accounts for certain issuances of preferred stock and warrants in accordance with ASC 718. ASC 718 requires all stock-based payments, including grants of stock options and RSUs, to be recognized in the condensed consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options granted. For RSUs, the fair value of the RSUs is determined by the market price of a share of the Company's common stock at the grant date. The Company recognizes forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation expense related to stock-based compensation awards granted with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Stock-based compensation awards generally vest over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTI5NTc_1b0f22b6-1741-4551-9fe9-ad65976104fa"&gt;one&lt;/span&gt; to three year requisite service period and have a contractual term of 10 years. To the extent a stock-based compensation award is subject to performance-based vesting conditions, the amount of compensation expense recorded reflects an assessment of the probability of achieving the performance conditions. Compensation expense for stock-based compensation awards with performance-based vesting conditions is only recognized when the performance-based vesting condition is deemed probable to occur. Shares issued upon stock option exercise and RSU vesting are newly issued common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating the fair value of stock options requires the input of subjective assumptions, including the expected life of the stock option, stock price volatility, the risk-free interest rate, and expected dividends. The assumptions used in the Company&#x2019;s Black-Scholes option-pricing model represent management&#x2019;s best estimates and involve a number of variables, uncertainties, assumptions, and the application of management&#x2019;s judgment, as they are inherently subjective. If any assumptions change, the Company&#x2019;s stock-based compensation expense could be materially different in the future.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ib31b92c5c40747a3bd257cecf9f1c22b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MTg_91fddb1f-ce67-4859-b425-cc35b4635970">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTMwMjc_cd4feb19-cc09-4fd4-b9bc-a577a9ed65a5">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <ocgn:AssetHeldForSalePolicyTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMzg0ODI5MDczMzYzNA_767a9464-7655-4a5c-a901-0b383c7a5610">&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Asset Held for Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company had an intangible asset held for sale that was carried at its original fair value less cost to sell of $7.0&#160;million. The Company concluded during the three and nine months ended September&#160;30, 2020, that a sale of the intangible asset was no longer probable to be completed within one year from the date the intangible asset was initially recorded as held for sale. As such, the carrying value of the intangible asset was reduced to zero with the corresponding charge of $7.0&#160;million recognized as in-process research and development expense in the condensed consolidated statements of operations and comprehensive loss during the three and nine months ended September&#160;30, 2020 as the in-process research and development did not have an alternative future use.&lt;/span&gt;&lt;/div&gt;</ocgn:AssetHeldForSalePolicyTextBlock>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="ia331e4fce5e04537ac0252d8c85aa3db_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTA5OTUxMTY1NTA5NA_815398e4-8b41-4d3b-b073-6ffc63e0105f"
      unitRef="usd">7000000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="i7033dd63053e40b9b5c54b579a67eebc_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTA5OTUxMTY1NTU3NQ_6384a34f-ab44-4b33-a1c1-0b0011291a64"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTA5OTUxMTY1NTYzMA_7ab41a7e-9d1d-47e5-873d-dcc3217c7bff"
      unitRef="usd">7000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTA5OTUxMTY1NTYzMA_bf6279e0-09d2-4139-bcf8-7d504e917413"
      unitRef="usd">7000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTg2MjY_47c32c31-4015-410a-8434-96f920e0addd">&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued Accounting Standards Update ("ASU") No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocations, and calculating income taxes in interim periods. This standard also adds guidance to reduce complexity in certain areas, including recognizing franchise tax, recognizing deferred taxes for the tax basis of goodwill, allocating taxes to the members of a consolidated group, and recognizing the effect of enacted changes in tax laws or rates during an interim period. This standard was effective for the Company on January 1, 2021. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the FASB issued ASU No. 2021-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share (Topic 260), Debt &#x2014; Modifications and Extinguishments (Subtopic 470-50), Compensation &#x2014; Stock Compensation (Topic 718), and Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard will have an effective and transition date of January 1, 2022. This standard clarifies and reduces diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options, including warrants, that remain equity-classified after modification or exchange. The standard requires an entity to treat a modification or an exchange of a freestanding equity-classified written call option that remains equity-classified after the modification or exchange as an exchange of the original instrument for a new instrument. The standard additionally provides guidance on measuring and recognizing the effect of a modification or an exchange. The Company does not currently expect the adoption of this standard to have a material impact on the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt &#x2014; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2014; Contracts in Entity's Own Equity (Subtopic 815-40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard will have an effective and transition date of January 1, 2024. Early adoption is currently permitted. This standard simplifies an issuer's accounting for convertible instruments by eliminating two of the three models that require separate accounting for embedded conversion features as well as simplifies the settlement assessment that entities are required to perform to determine whether a contract qualifies for equity classification. This standard also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of potential share settlement (if the effect is more dilutive) for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. The standard requires new disclosures about events that occur during the reporting period and cause conversion contingencies to be met and about the fair value of a public business entity's convertible debt at the instrument level, among other things. The Company does not currently expect the adoption of this standard to have a material impact on the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2014; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The FASB subsequently issued amendments to ASU No. 2016-13, which have the same effective date and transition date of January 1, 2023. ASU No. 2016-13, as amended, requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company does not currently expect the adoption of this standard to have a material impact on the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180MC9mcmFnOmQ3NTI3ZjBkNTk3YzRjNzdiNWMyZTRhY2ZlNzFlOGFiL3RleHRyZWdpb246ZDc1MjdmMGQ1OTdjNGM3N2I1YzJlNGFjZmU3MWU4YWJfNDMwMA_0c7d43d5-3e62-4f64-ae21-9c7583db264f">License and Development Agreements&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Co-Development, Supply and Commercialization Agreement with Bharat Biotech&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into the Covaxin Agreement with Bharat Biotech to co-develop COVAXIN, a whole-virion inactivated COVID-19 vaccine being developed to prevent COVID-19 infection, for the U.S. and Canadian markets. The Covaxin Agreement was originally entered into in February 2021 with respect to the U.S. market and was subsequently amended in June 2021 to add rights to the Canadian market. Pursuant to the Covaxin Agreement, the Company obtained an exclusive right and license under certain of Bharat Biotech&#x2019;s intellectual property rights, with the right to grant sublicenses, to develop, manufacture, and commercialize COVAXIN in the Ocugen Covaxin Territory. In consideration of the license and other rights granted by Bharat Biotech to the Company, the parties agreed to share any profits generated from the commercialization of COVAXIN in the Ocugen Covaxin Territory, with the Company retaining 45% of such profits, and Bharat Biotech receiving the balance of such profits. In consideration of the expansion of the Ocugen Covaxin Territory to include Canada, the Company paid Bharat Biotech a non-refundable, upfront payment of $15.0&#160;million in June 2021, which was recognized as research and development expense in the condensed consolidated statements of operations and comprehensive loss during the nine months ended September 30, 2021. The Company additionally agreed to pay Bharat Biotech $10.0&#160;million within 30 days after the first commercial sale of COVAXIN in Canada. The Covaxin Agreement is a collaboration arrangement within the scope of ASC 808.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Covaxin Agreement, the Company and Bharat Biotech will collaborate to develop COVAXIN for their respective territories. Except with respect to manufacturing rights under certain circumstances subsequently described, the Company has the exclusive right and is solely responsible for researching, developing, manufacturing, and commercializing COVAXIN for the Ocugen Covaxin Territory. Bharat Biotech is responsible for researching, developing, manufacturing, and commercializing COVAXIN outside of the Ocugen Covaxin Territory. Bharat Biotech has agreed to provide to the Company all preclinical and clinical data, and to transfer to the Company certain proprietary technology owned or controlled by Bharat Biotech, that is necessary for the successful commercial manufacture and supply of COVAXIN to support commercial sale in the Ocugen Covaxin Territory. In September 2021, the Company entered into the Supply Agreement with Bharat Biotech, pursuant to which &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bharat Biotech will supply the Company with clinical trial materials and commercial supplies of COVAXIN finished drug product prior to the completion of the Company&#x2019;s technology transfer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Jubilant HollisterStier&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Following the completion of the Company&#x2019;s technology transfer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Jubilant HollisterStier&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Bharat Biotech will supply COVAXIN drug product components and continue to supply finished drug product as necessary for commercial manufacture and supply of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;COVAXIN &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subsequent to a regulatory authorization or approval. The technology transfer process to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Jubilant HollisterStier has been initiated. In March 2021, the Company issued shares of Series B Convertible Preferred Stock (as defined in Note 9) as an advance payment for the supply of COVAXIN to be provided by Bharat Biotech under the Supply Agreement. See Note 9 for additional information about the Series B Convertible Preferred Stock issuance to Bharat Biotech. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Covaxin Agreement continues in effect for the commercial life of COVAXIN, subject to the earlier termination of the Covaxin Agreement in accordance with its terms. The Covaxin Agreement also contains customary representations and warranties made by both parties and customary provisions relating to indemnification, limitation of liability, confidentiality, information and data sharing, and other matters. The Supply Agreement expires upon expiration of the Covaxin Agreement and may be earlier terminated by either party in the event of an uncured material breach or bankruptcy of the other party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Co-Development and Commercialization Agreement with CanSinoBIO&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company entered into a co-development and commercialization agreement with CanSinoBIO with respect to the development and commercialization of OCU400. The co-development and commercialization agreement was subsequently amended in September 2021 (as so amended, the "CanSinoBIO Agreement"), whereby OCU410 was added to the Company's existing collaboration with CanSinoBIO. Pursuant to the CanSinoBIO Agreement, the Company and CanSinoBIO will collaborate on the development of OCU400 and OCU410 and CanSinoBIO will be responsible for the CMC development and manufacture of clinical supplies of such products and be responsible for the costs associated with such activities. CanSinoBIO will have an exclusive option to obtain a non-exclusive license from the Company to manufacture OCU400 and OCU410 for commercial sale by the Company. CanSinoBIO has an exclusive license to develop, manufacture, and commercialize OCU400 and OCU410 in and for China, Hong Kong, Macau, and Taiwan (the &#x201c;CanSinoBIO Territory&#x201d;), and the Company maintains exclusive development, manufacturing, and commercialization rights with respect to OCU400 and OCU410 outside the CanSinoBIO Territory (the &#x201c;Company Territory&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CanSinoBIO will pay to the Company an annual royalty between mid- and high-single digits based on Net Sales (as defined in the CanSinoBIO Agreement) of OCU400 and OCU410 in the CanSinoBIO Territory. The Company will pay to CanSinoBIO an annual royalty between low- and mid-single digits based on Net Sales (as defined in the CanSinoBIO Agreement) of OCU400 and OCU410 in the Company Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated in accordance with its terms, the CanSinoBIO Agreement will continue in force on a country-by-country and product-by-product basis until the later of (a) the expiration of the last valid claim of patent rights of the Company covering such products and (b) the 10th anniversary of the first commercial sale of such products in such country.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ocgn:CollaborativeArrangementProfitsGeneratedSharedPercentage
      contextRef="i1978e8a33197491fab4e85b515ca427c_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180MC9mcmFnOmQ3NTI3ZjBkNTk3YzRjNzdiNWMyZTRhY2ZlNzFlOGFiL3RleHRyZWdpb246ZDc1MjdmMGQ1OTdjNGM3N2I1YzJlNGFjZmU3MWU4YWJfOTUw_0e1ebbc9-e048-480f-8d45-748eceeafa1c"
      unitRef="number">0.45</ocgn:CollaborativeArrangementProfitsGeneratedSharedPercentage>
    <ocgn:CollaborationAgreementUpfrontPayment
      contextRef="i0ce37d1044984e42b76ce49925a5ea86_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180MC9mcmFnOmQ3NTI3ZjBkNTk3YzRjNzdiNWMyZTRhY2ZlNzFlOGFiL3RleHRyZWdpb246ZDc1MjdmMGQ1OTdjNGM3N2I1YzJlNGFjZmU3MWU4YWJfMTE4Mw_b9035c59-cd1b-4373-b85d-abb6787d14f9"
      unitRef="usd">15000000</ocgn:CollaborationAgreementUpfrontPayment>
    <ocgn:CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada
      contextRef="i0ce37d1044984e42b76ce49925a5ea86_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180MC9mcmFnOmQ3NTI3ZjBkNTk3YzRjNzdiNWMyZTRhY2ZlNzFlOGFiL3RleHRyZWdpb246ZDc1MjdmMGQ1OTdjNGM3N2I1YzJlNGFjZmU3MWU4YWJfMTQyMA_afbbc667-8186-496f-8574-78f089c5e44d"
      unitRef="usd">10000000</ocgn:CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada>
    <ocgn:CollaborationAgreementTerm
      contextRef="i930c6519bb45486a8510eab5f83f11b2_D20190927-20190927"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180MC9mcmFnOmQ3NTI3ZjBkNTk3YzRjNzdiNWMyZTRhY2ZlNzFlOGFiL3RleHRyZWdpb246ZDc1MjdmMGQ1OTdjNGM3N2I1YzJlNGFjZmU3MWU4YWJfMzg0ODI5MDc1OTE0Mw_6c5c8377-a226-42c5-9d0c-eb3e424bbbca">P10Y</ocgn:CollaborationAgreementTerm>
    <us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180My9mcmFnOmNlZTg5ZTQ5NGVlMjRhYjFhYmI4NWQ2YzE0NDE2ZjlmL3RleHRyZWdpb246Y2VlODllNDk0ZWUyNGFiMWFiYjg1ZDZjMTQ0MTZmOWZfMTQ1OQ_97731b9b-d068-4ce4-848a-f8c156a980b5">Notes Receivable&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 13, 2021, the Company received a promissory note in the principal amount of $0.8&#160;million from a company in connection with a potential collaboration. The promissory note bore interest at a rate per annum of 5% and the outstanding principal balance of the promissory note plus any accrued and unpaid interest thereon was payable in full on April 13, 2022 (the "Maturity Date"). Effective July 2021, the Company accepted an amended and restated promissory note (as so amended and restated, the "Promissory Note") pursuant to which the parties agreed to extend the Maturity Date of the Promissory Note to June 30, 2022 and increase the interest rate per annum to 9% with quarterly interest payments. The Promissory Note may be prepaid in whole or in part at any time, together with accrued and unpaid interest. The Promissory Note contains customary covenants and events of default, including, among others, failure to make payment, breach of agreement, and bankruptcy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the probability of collecting the full principal and accrued interest balance under the terms of the Promissory Note and determined that collection was not probable. During the nine months ended September 30, 2021, the Company wrote off the full principal and accrued interest balance of the Promissory Note and recorded the write-off as a loss within other income (expense) within the condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock>
    <us-gaap:NotesReceivableGross
      contextRef="i83096eac0fe34c3aae4e263271cd518e_I20210413"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180My9mcmFnOmNlZTg5ZTQ5NGVlMjRhYjFhYmI4NWQ2YzE0NDE2ZjlmL3RleHRyZWdpb246Y2VlODllNDk0ZWUyNGFiMWFiYjg1ZDZjMTQ0MTZmOWZfMTEx_cceea330-0428-4cb7-a269-ff74f359a977"
      unitRef="usd">800000</us-gaap:NotesReceivableGross>
    <ocgn:FinancingReceivableInterestRateStatedPercentage
      contextRef="i83096eac0fe34c3aae4e263271cd518e_I20210413"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180My9mcmFnOmNlZTg5ZTQ5NGVlMjRhYjFhYmI4NWQ2YzE0NDE2ZjlmL3RleHRyZWdpb246Y2VlODllNDk0ZWUyNGFiMWFiYjg1ZDZjMTQ0MTZmOWZfMjMy_4fd6f01a-f58f-4f10-8f81-38d75b74f717"
      unitRef="number">0.05</ocgn:FinancingReceivableInterestRateStatedPercentage>
    <ocgn:FinancingReceivableInterestRateStatedPercentage
      contextRef="i5db9a3b809794a18ba41b819b7fb0e60_I20210731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180My9mcmFnOmNlZTg5ZTQ5NGVlMjRhYjFhYmI4NWQ2YzE0NDE2ZjlmL3RleHRyZWdpb246Y2VlODllNDk0ZWUyNGFiMWFiYjg1ZDZjMTQ0MTZmOWZfNjg1_4c5313bc-4b33-4bc0-9205-94967b69cf2e"
      unitRef="number">0.09</ocgn:FinancingReceivableInterestRateStatedPercentage>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RleHRyZWdpb246ODM2ZDI3ZDUzOGM4NGZlNzhjNGIyN2U2ZjkyZTg3N2RfMTk1_ef86e71f-a7c9-4096-9eed-4ab45bde6d66">Property and Equipment&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of the major components of property and equipment as reflected on the condensed consolidated balance sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized depreciation expense of $0.1 million and $0.2 million during the three and nine months ended September&#160;30, 2021, respectively. The Company recognized depreciation expense of $19.8&#160;thousand and $0.1&#160;million during the three and nine months ended September&#160;30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RleHRyZWdpb246ODM2ZDI3ZDUzOGM4NGZlNzhjNGIyN2U2ZjkyZTg3N2RfMTk2_eeeb1134-33db-4fcf-a0f3-2fc58394ec1f">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of the major components of property and equipment as reflected on the condensed consolidated balance sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i11ce6b5f7e39456fa1c454b1333db3bf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfMS0xLTEtMS0w_c9da25a0-3b58-4029-a2b7-68b3aa0b2092"
      unitRef="usd">322000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia025bf7e0a1345c280160a2e194f23fe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfMS0zLTEtMS0w_12e12035-5bf9-47cd-9b52-f1781d8c3c8b"
      unitRef="usd">166000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia3aea31e66e540dc9949d6f9c0490ecb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfMi0xLTEtMS0w_9c340be2-2ed4-4631-a3c7-65f05bcd2c7b"
      unitRef="usd">856000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i812612c51e3f4f04bd8fb9b027a8a7ef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfMi0zLTEtMS0w_c5f8bc61-2ba5-403e-a18e-7a2accb7177a"
      unitRef="usd">452000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8d4ea904d71e4543b361e76a666f0756_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfMy0xLTEtMS0w_f3a8674f-5164-4f52-875e-11037495b2b5"
      unitRef="usd">167000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iefda904c07ce43da981ece8db16559f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfMy0zLTEtMS0w_4aa58c35-d118-47b3-b71d-34fc3ad95acf"
      unitRef="usd">177000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1fa83702d12344a2b6ed8e9210300c3c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfNC0xLTEtMS0yNTg0Mw_f6be2e83-8e7b-48ca-97b5-d532e012748a"
      unitRef="usd">41000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i451fd097deb743d79f6ad34002e75526_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfNC0zLTEtMS0yNTg0Mw_6763879d-ac76-47f2-97ef-4cf0c409dde3"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfNC0xLTEtMS0w_686900c6-1fd7-4940-827c-6d69dba69d10"
      unitRef="usd">0</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfNC0zLTEtMS0w_a6b1c290-55b1-4618-9464-cba00ce761d9"
      unitRef="usd">64000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfNS0xLTEtMS0w_e5a5aa76-6369-4239-a61f-83563e464b0f"
      unitRef="usd">1386000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfNS0zLTEtMS0w_a8885775-5c61-4163-87d5-90a7bbd739a9"
      unitRef="usd">859000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfNi0xLTEtMS0w_3ab30f0c-db35-4941-8656-8680761e5783"
      unitRef="usd">334000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfNi0zLTEtMS0w_caae973d-aacf-4bff-ab23-6db3fee9393b"
      unitRef="usd">226000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfNy0xLTEtMS0w_8ec7574b-d3a3-45dc-9a04-8bb50450b3e4"
      unitRef="usd">1052000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RhYmxlOmVlOTY1MzVmYmI0YjRiMTlhNWY2NjE3NzkxMzdhNmVhL3RhYmxlcmFuZ2U6ZWU5NjUzNWZiYjRiNGIxOWE1ZjY2MTc3OTEzN2E2ZWFfNy0zLTEtMS0w_d4f781e8-821a-43dc-875b-4a8b14fe58a3"
      unitRef="usd">633000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:Depreciation
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RleHRyZWdpb246ODM2ZDI3ZDUzOGM4NGZlNzhjNGIyN2U2ZjkyZTg3N2RfMTY0OTI2NzQ0NDAwOQ_c13b53c8-3a9c-45d3-86bc-787b023d6fe3"
      unitRef="usd">100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RleHRyZWdpb246ODM2ZDI3ZDUzOGM4NGZlNzhjNGIyN2U2ZjkyZTg3N2RfMTY0OTI2NzQ0NDAxMw_d6770e76-7315-48d5-8a21-d931ff1e2cd6"
      unitRef="usd">200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RleHRyZWdpb246ODM2ZDI3ZDUzOGM4NGZlNzhjNGIyN2U2ZjkyZTg3N2RfMjE5OTAyMzI1NzEzNw_7c4bff8e-3777-4cdc-a038-6dd903ea9868"
      unitRef="usd">19800</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180Ni9mcmFnOjgzNmQyN2Q1MzhjODRmZTc4YzRiMjdlNmY5MmU4NzdkL3RleHRyZWdpb246ODM2ZDI3ZDUzOGM4NGZlNzhjNGIyN2U2ZjkyZTg3N2RfMjE5OTAyMzI1NzE1MQ_3f352bfe-21f3-4ded-9f12-6728dac6c48f"
      unitRef="usd">100000</us-gaap:Depreciation>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RleHRyZWdpb246NDYwODhlNjUyZDg4NDBiNzk0MzFhNWQwNzYyZDQyMzRfMTYyOA_4584e6d6-c11a-42d8-89e1-955603028771">Operating Leases&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has commitments under an operating lease for certain facilities used in its operations including for the use of laboratory, office, and storage space located in Malvern, Pennsylvania (the &#x201c;Lease Agreement&#x201d;). The Lease Agreement was determined to have two lease components per ASC 842, a laboratory space lease component (the "Initial Premises") and an office, storage, and future expanded laboratory space lease component (the "Expansion Premises"), with varying commencement dates. The Initial Premises commencement date occurred in December 2020 and the Expansion Premises commencement date occurred in January 2021. The Lease Agreement has an initial term of seven years and the Company has the option to extend the Lease Agreement for one additional five-year term. The option for extension has been excluded from the lease term (and lease liability) for the Lease Agreement as it is not reasonably certain that the Company will exercise such option. The Company terminated a former lease agreement for its previous office space with the same landlord without penalty upon the commencement of the Expansion Premises in January 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term &#x2014; operating leases (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate &#x2014; operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum operating lease base rent payments are approximately as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to September&#160;30, 2021, the Company entered into a lease agreement for additional office space located in Malvern, Pennsylvania. See Note 14 for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RleHRyZWdpb246NDYwODhlNjUyZDg4NDBiNzk0MzFhNWQwNzYyZDQyMzRfNzM2_40702a61-84a3-466e-86a6-2f6de9f3e361">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ocgn:LesseeOperatingLeaseNumberOfRenewalTerms
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RleHRyZWdpb246NDYwODhlNjUyZDg4NDBiNzk0MzFhNWQwNzYyZDQyMzRfODA0_2ed54252-5573-4287-915a-00e0da322c57"
      unitRef="renewaloption">1</ocgn:LesseeOperatingLeaseNumberOfRenewalTerms>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RleHRyZWdpb246NDYwODhlNjUyZDg4NDBiNzk0MzFhNWQwNzYyZDQyMzRfMTYyNA_eecf3fef-245f-4ddb-8833-6eab59892305">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RleHRyZWdpb246NDYwODhlNjUyZDg4NDBiNzk0MzFhNWQwNzYyZDQyMzRfMTYzMA_85fd2873-8e59-422f-badd-82cf45e84a8e">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term &#x2014; operating leases (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate &#x2014; operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjIzNzYzNmU3ODYwODRlNWE5YzhiN2VlNWNhNzc0MTA0L3RhYmxlcmFuZ2U6MjM3NjM2ZTc4NjA4NGU1YTljOGI3ZWU1Y2E3NzQxMDRfMi0xLTEtMS0w_24395344-2696-4c81-ae8b-916816c82a64"
      unitRef="usd">66000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjIzNzYzNmU3ODYwODRlNWE5YzhiN2VlNWNhNzc0MTA0L3RhYmxlcmFuZ2U6MjM3NjM2ZTc4NjA4NGU1YTljOGI3ZWU1Y2E3NzQxMDRfMi0zLTEtMS0w_2f4c2d0d-81f0-4328-9d6a-a83e2cd3d616"
      unitRef="usd">48000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjIzNzYzNmU3ODYwODRlNWE5YzhiN2VlNWNhNzc0MTA0L3RhYmxlcmFuZ2U6MjM3NjM2ZTc4NjA4NGU1YTljOGI3ZWU1Y2E3NzQxMDRfMi01LTEtMS0w_d267d025-5fda-489c-ac5f-50349c12c7ed"
      unitRef="usd">200000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjIzNzYzNmU3ODYwODRlNWE5YzhiN2VlNWNhNzc0MTA0L3RhYmxlcmFuZ2U6MjM3NjM2ZTc4NjA4NGU1YTljOGI3ZWU1Y2E3NzQxMDRfMi03LTEtMS0w_84a1241e-bc89-4ac4-b1c9-e8f3b6ad8f46"
      unitRef="usd">143000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjIzNzYzNmU3ODYwODRlNWE5YzhiN2VlNWNhNzc0MTA0L3RhYmxlcmFuZ2U6MjM3NjM2ZTc4NjA4NGU1YTljOGI3ZWU1Y2E3NzQxMDRfMy0xLTEtMS0w_12db3ec9-d9ea-40fe-b699-dc05eadd5bb0"
      unitRef="usd">26000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjIzNzYzNmU3ODYwODRlNWE5YzhiN2VlNWNhNzc0MTA0L3RhYmxlcmFuZ2U6MjM3NjM2ZTc4NjA4NGU1YTljOGI3ZWU1Y2E3NzQxMDRfMy0zLTEtMS0w_bc2b4a0b-b02e-48b9-b28d-ccdb8f9fdf74"
      unitRef="usd">21000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjIzNzYzNmU3ODYwODRlNWE5YzhiN2VlNWNhNzc0MTA0L3RhYmxlcmFuZ2U6MjM3NjM2ZTc4NjA4NGU1YTljOGI3ZWU1Y2E3NzQxMDRfMy01LTEtMS0w_c1487ffd-1d22-4c9a-9548-53d4c9c9a99d"
      unitRef="usd">79000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjIzNzYzNmU3ODYwODRlNWE5YzhiN2VlNWNhNzc0MTA0L3RhYmxlcmFuZ2U6MjM3NjM2ZTc4NjA4NGU1YTljOGI3ZWU1Y2E3NzQxMDRfMy03LTEtMS0w_53cd61f9-5a6d-4171-8e48-ca1e7e0e8d06"
      unitRef="usd">62000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjIzNzYzNmU3ODYwODRlNWE5YzhiN2VlNWNhNzc0MTA0L3RhYmxlcmFuZ2U6MjM3NjM2ZTc4NjA4NGU1YTljOGI3ZWU1Y2E3NzQxMDRfNC0xLTEtMS0w_1c82fb70-930c-432b-b514-3ac59e4d5a2a"
      unitRef="usd">92000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjIzNzYzNmU3ODYwODRlNWE5YzhiN2VlNWNhNzc0MTA0L3RhYmxlcmFuZ2U6MjM3NjM2ZTc4NjA4NGU1YTljOGI3ZWU1Y2E3NzQxMDRfNC0zLTEtMS0w_e8f4b05f-0fbb-4a03-a8b3-5388571b0cd8"
      unitRef="usd">69000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjIzNzYzNmU3ODYwODRlNWE5YzhiN2VlNWNhNzc0MTA0L3RhYmxlcmFuZ2U6MjM3NjM2ZTc4NjA4NGU1YTljOGI3ZWU1Y2E3NzQxMDRfNC01LTEtMS0w_f7055964-2016-4e18-abf9-32450e499451"
      unitRef="usd">279000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjIzNzYzNmU3ODYwODRlNWE5YzhiN2VlNWNhNzc0MTA0L3RhYmxlcmFuZ2U6MjM3NjM2ZTc4NjA4NGU1YTljOGI3ZWU1Y2E3NzQxMDRfNC03LTEtMS0w_57c67914-00b7-4b74-8bd7-5595af7016e0"
      unitRef="usd">205000</us-gaap:LeaseCost>
    <ocgn:SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RleHRyZWdpb246NDYwODhlNjUyZDg4NDBiNzk0MzFhNWQwNzYyZDQyMzRfMTYyMg_2d852568-9689-484c-8866-9852ed1b4edb">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ocgn:SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjI1YjUxM2Y4OTU0YjQ3YjM5YWM2ZjhiN2FlYTEyMjAxL3RhYmxlcmFuZ2U6MjViNTEzZjg5NTRiNDdiMzlhYzZmOGI3YWVhMTIyMDFfMS0xLTEtMS0w_917875fa-fe63-4683-a94d-e310c43e1a15"
      unitRef="usd">1430000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjI1YjUxM2Y4OTU0YjQ3YjM5YWM2ZjhiN2FlYTEyMjAxL3RhYmxlcmFuZ2U6MjViNTEzZjg5NTRiNDdiMzlhYzZmOGI3YWVhMTIyMDFfMS0zLTEtMS0w_c5707f6c-3b4e-44d1-b9d3-13fd62c41f88"
      unitRef="usd">434000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjI1YjUxM2Y4OTU0YjQ3YjM5YWM2ZjhiN2FlYTEyMjAxL3RhYmxlcmFuZ2U6MjViNTEzZjg5NTRiNDdiMzlhYzZmOGI3YWVhMTIyMDFfMy0xLTEtMS0w_a87c1e44-7e5c-4949-a3b5-1acf2d99d18e"
      unitRef="usd">172000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjI1YjUxM2Y4OTU0YjQ3YjM5YWM2ZjhiN2FlYTEyMjAxL3RhYmxlcmFuZ2U6MjViNTEzZjg5NTRiNDdiMzlhYzZmOGI3YWVhMTIyMDFfMy0zLTEtMS0w_53e5e061-2ddf-42ab-aa3f-03b571dfc376"
      unitRef="usd">44000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjI1YjUxM2Y4OTU0YjQ3YjM5YWM2ZjhiN2FlYTEyMjAxL3RhYmxlcmFuZ2U6MjViNTEzZjg5NTRiNDdiMzlhYzZmOGI3YWVhMTIyMDFfNC0xLTEtMS0w_1fea1e0e-2110-44c2-979e-287a08000525"
      unitRef="usd">1280000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjI1YjUxM2Y4OTU0YjQ3YjM5YWM2ZjhiN2FlYTEyMjAxL3RhYmxlcmFuZ2U6MjViNTEzZjg5NTRiNDdiMzlhYzZmOGI3YWVhMTIyMDFfNC0zLTEtMS0w_4238623a-9eee-4250-863d-6d6af946a010"
      unitRef="usd">389000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjI1YjUxM2Y4OTU0YjQ3YjM5YWM2ZjhiN2FlYTEyMjAxL3RhYmxlcmFuZ2U6MjViNTEzZjg5NTRiNDdiMzlhYzZmOGI3YWVhMTIyMDFfNS0xLTEtMS0w_5bc3b16c-8b05-4da4-bd4c-22bed19513b6"
      unitRef="usd">1452000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjI1YjUxM2Y4OTU0YjQ3YjM5YWM2ZjhiN2FlYTEyMjAxL3RhYmxlcmFuZ2U6MjViNTEzZjg5NTRiNDdiMzlhYzZmOGI3YWVhMTIyMDFfNS0zLTEtMS0w_add4522e-5983-4efe-8e3c-260f89be12d6"
      unitRef="usd">433000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjA1M2U0ZWZjZTQ1OTQ5NDQ5ZmM0MWIzMjY0ZGUyNGFlL3RhYmxlcmFuZ2U6MDUzZTRlZmNlNDU5NDk0NDlmYzQxYjMyNjRkZTI0YWVfMi0xLTEtMS0w_930e412d-ebb9-4dbb-9275-38cdc2632085">P6Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i7033dd63053e40b9b5c54b579a67eebc_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjA1M2U0ZWZjZTQ1OTQ5NDQ5ZmM0MWIzMjY0ZGUyNGFlL3RhYmxlcmFuZ2U6MDUzZTRlZmNlNDU5NDk0NDlmYzQxYjMyNjRkZTI0YWVfMi0zLTEtMS0w_d49397d2-b7d5-447a-823d-92355b22b5c2">P1Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjA1M2U0ZWZjZTQ1OTQ5NDQ5ZmM0MWIzMjY0ZGUyNGFlL3RhYmxlcmFuZ2U6MDUzZTRlZmNlNDU5NDk0NDlmYzQxYjMyNjRkZTI0YWVfMy0xLTEtMS0w_9481b31d-2363-4486-a0ee-e430d8ce6b8a"
      unitRef="number">0.046</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i7033dd63053e40b9b5c54b579a67eebc_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOjA1M2U0ZWZjZTQ1OTQ5NDQ5ZmM0MWIzMjY0ZGUyNGFlL3RhYmxlcmFuZ2U6MDUzZTRlZmNlNDU5NDk0NDlmYzQxYjMyNjRkZTI0YWVfMy0zLTEtMS0w_327d4755-54fd-46f5-b49e-58745b95816d"
      unitRef="number">0.076</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RleHRyZWdpb246NDYwODhlNjUyZDg4NDBiNzk0MzFhNWQwNzYyZDQyMzRfMTYzMw_7b8e2740-18ef-40ac-889b-552220d4e8db">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum operating lease base rent payments are approximately as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOmE0MjFhYTFlMTEwZDQwMTA5OWYwYzlkMDZlYzZlMmYzL3RhYmxlcmFuZ2U6YTQyMWFhMWUxMTBkNDAxMDk5ZjBjOWQwNmVjNmUyZjNfMS0xLTEtMS0w_0a46f606-6a2b-4905-9d02-e3c52f0695b6"
      unitRef="usd">41000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOmE0MjFhYTFlMTEwZDQwMTA5OWYwYzlkMDZlYzZlMmYzL3RhYmxlcmFuZ2U6YTQyMWFhMWUxMTBkNDAxMDk5ZjBjOWQwNmVjNmUyZjNfMi0xLTEtMS0w_858e7bc9-848c-4c60-a9d3-c029fa5075a4"
      unitRef="usd">252000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOmE0MjFhYTFlMTEwZDQwMTA5OWYwYzlkMDZlYzZlMmYzL3RhYmxlcmFuZ2U6YTQyMWFhMWUxMTBkNDAxMDk5ZjBjOWQwNmVjNmUyZjNfMy0xLTEtMS0w_852572ed-ff91-4451-bbc4-e9414984dd91"
      unitRef="usd">261000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOmE0MjFhYTFlMTEwZDQwMTA5OWYwYzlkMDZlYzZlMmYzL3RhYmxlcmFuZ2U6YTQyMWFhMWUxMTBkNDAxMDk5ZjBjOWQwNmVjNmUyZjNfNC0xLTEtMS0w_caa7dbd3-501e-4c4e-b8f9-e1fcd036570e"
      unitRef="usd">269000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOmE0MjFhYTFlMTEwZDQwMTA5OWYwYzlkMDZlYzZlMmYzL3RhYmxlcmFuZ2U6YTQyMWFhMWUxMTBkNDAxMDk5ZjBjOWQwNmVjNmUyZjNfNS0xLTEtMS0w_d3a72f8a-beb8-42e1-a4ba-b37aaee131a3"
      unitRef="usd">277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <ocgn:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOmE0MjFhYTFlMTEwZDQwMTA5OWYwYzlkMDZlYzZlMmYzL3RhYmxlcmFuZ2U6YTQyMWFhMWUxMTBkNDAxMDk5ZjBjOWQwNmVjNmUyZjNfNi0xLTEtMS0w_d39f6b46-ae98-49b4-9a9b-cc6a795c39d9"
      unitRef="usd">578000</ocgn:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOmE0MjFhYTFlMTEwZDQwMTA5OWYwYzlkMDZlYzZlMmYzL3RhYmxlcmFuZ2U6YTQyMWFhMWUxMTBkNDAxMDk5ZjBjOWQwNmVjNmUyZjNfNy0xLTEtMS0w_6ac340f2-acbf-438b-954f-98591a7ffafc"
      unitRef="usd">1678000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOmE0MjFhYTFlMTEwZDQwMTA5OWYwYzlkMDZlYzZlMmYzL3RhYmxlcmFuZ2U6YTQyMWFhMWUxMTBkNDAxMDk5ZjBjOWQwNmVjNmUyZjNfOC0xLTEtMS0w_112e5133-62ba-4978-8a1f-3586bb7167b5"
      unitRef="usd">226000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N180OS9mcmFnOjQ2MDg4ZTY1MmQ4ODQwYjc5NDMxYTVkMDc2MmQ0MjM0L3RhYmxlOmE0MjFhYTFlMTEwZDQwMTA5OWYwYzlkMDZlYzZlMmYzL3RhYmxlcmFuZ2U6YTQyMWFhMWUxMTBkNDAxMDk5ZjBjOWQwNmVjNmUyZjNfOS0xLTEtMS0w_aec7675c-16cd-4f41-ae64-1a105259bb20"
      unitRef="usd">1452000</us-gaap:OperatingLeaseLiability>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfMTE5OQ_c875e796-7075-43fd-9f0e-52f61a50f980">Accrued Expenses and Other Current Liabilities&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research&#160;and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance-related (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) In June 2020, the Company communicated notice to five employees of the termination of their employment as a result of the discontinuation of a product candidate. This reduction represented one-third of the Company&#x2019;s workforce at the time of communication. All terminations were &#x201c;without cause&#x201d; and each employee received termination benefits upon departure. The termination dates varied for each employee and ranged from June 30, 2020 to December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized no severance-related charges and a de minimis amount of severance-related charges during the three and nine months ended September&#160;30, 2021, respectively. The Company recognized severance-related charges of $0.4 million and $1.1 million during the three and nine months ended September&#160;30, 2020, respectively. For the three months ended September 30, 2020, the Company recognized a de minimis amount of severance-related charges within general and administrative expense and $0.4 million of severance-related charges within research and development expense. For the nine months ended September 30, 2020, the Company recognized $0.2 million of severance-related charges within general and administrative expense and $0.9 million of severance-related charges within research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company made severance payments of $0.1&#160;million and $0.6&#160;million during the three and nine months ended September&#160;30, 2021, respectively. The Company made severance payments of $0.2 million during the three and nine months ended September&#160;30, 2020. The Company expects to pay the remaining severance benefits of $0.1&#160;million throughout the remainder of 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfMTIwNA_58c8b5dc-16a2-495a-b165-603b4c4103f0">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research&#160;and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance-related (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) In June 2020, the Company communicated notice to five employees of the termination of their employment as a result of the discontinuation of a product candidate. This reduction represented one-third of the Company&#x2019;s workforce at the time of communication. All terminations were &#x201c;without cause&#x201d; and each employee received termination benefits upon departure. The termination dates varied for each employee and ranged from June 30, 2020 to December 31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <ocgn:ResearchAndDevelopmentExpensesCurrent
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfMS0xLTEtMS0w_1ac08317-c431-400a-b18b-bfe7e2e4d039"
      unitRef="usd">1100000</ocgn:ResearchAndDevelopmentExpensesCurrent>
    <ocgn:ResearchAndDevelopmentExpensesCurrent
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfMS0zLTEtMS0w_d1e2928f-ac87-44ff-9a5d-33b7668f7b8a"
      unitRef="usd">512000</ocgn:ResearchAndDevelopmentExpensesCurrent>
    <ocgn:AccruedLiabilitiesClinical
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfMi0xLTEtMS0w_ddc30696-5024-4a1d-8f14-7bf909448b77"
      unitRef="usd">585000</ocgn:AccruedLiabilitiesClinical>
    <ocgn:AccruedLiabilitiesClinical
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfMi0zLTEtMS0w_b6d2d94e-75ca-4a6a-9e65-f8f9dd87d88d"
      unitRef="usd">117000</ocgn:AccruedLiabilitiesClinical>
    <ocgn:AccruedLiabilitiesProfessionalFees
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfMy0xLTEtMS0w_38ea2b04-f619-41e4-bbde-8cddbe0e2790"
      unitRef="usd">610000</ocgn:AccruedLiabilitiesProfessionalFees>
    <ocgn:AccruedLiabilitiesProfessionalFees
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfMy0zLTEtMS0w_5f7bc660-4408-40d8-bc01-8f99345cd5a0"
      unitRef="usd">405000</ocgn:AccruedLiabilitiesProfessionalFees>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfNC0xLTEtMS0w_90a5889c-2fef-4d24-8e1a-06c3964621a4"
      unitRef="usd">1155000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfNC0zLTEtMS0w_93918847-17c4-4d43-81fc-b71c10753782"
      unitRef="usd">963000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <ocgn:AccruedSeveranceRelatedLiabilitiesCurrent
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfNS0xLTEtMS0w_321cf29b-ce91-4e11-8576-d7bc9dc7cf40"
      unitRef="usd">90000</ocgn:AccruedSeveranceRelatedLiabilitiesCurrent>
    <ocgn:AccruedSeveranceRelatedLiabilitiesCurrent
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfNS0zLTEtMS0w_f5061c8b-5af6-4339-a7cf-af630998c3f2"
      unitRef="usd">712000</ocgn:AccruedSeveranceRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfNi0xLTEtMS0w_d51cf85b-9707-4b47-bde4-0476b7673be1"
      unitRef="usd">422000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfNi0zLTEtMS0w_de524347-1724-4449-8fb3-01206e8a18aa"
      unitRef="usd">232000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfNy0xLTEtMS0w_9f8537bf-2d35-44ac-a236-44c6235a3bab"
      unitRef="usd">3962000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RhYmxlOjZhNWJiZGVjMzI2MzRjMjY4NzU3OWFhMmFlY2VlZDNkL3RhYmxlcmFuZ2U6NmE1YmJkZWMzMjYzNGMyNjg3NTc5YWEyYWVjZWVkM2RfNy0zLTEtMS0w_cc021caa-485f-4567-9f06-96b87b322701"
      unitRef="usd">2941000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="ic0c6fee7c66143fa90b7e09a8bd0054b_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfMjEz_a555f8b1-01db-4b41-a13b-f25fd7915c76"
      unitRef="employee">5</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringCharges
      contextRef="if6931d48727f42d1b569e46c6b6c8cf1_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfNjE2_4284e81e-e17f-45b9-8419-8707ec0f2d98"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="icdfb9af1602f4e02a9cc734469158ec9_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfMjE5OTAyMzI2Mjk3OQ_9657b61f-6d35-452b-b9b2-001dfe1a0a5f"
      unitRef="usd">400000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ib105875697514235a32c3d55a59c407f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfMTY0OTI2NzQ0Mjg5NA_1db3a6ea-8338-45d8-8e6e-e6be91af9306"
      unitRef="usd">1100000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i892c2505d70d4215b4f0550ad9b0627e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfMjE5OTAyMzI2MjE4Mw_23db16d0-8639-4918-a37f-e610d2b95534"
      unitRef="usd">400000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i02962ee3f8774d3c8d322068b02a66c8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfMjE5OTAyMzI2MjIxNQ_b83be5ac-ec3b-4568-acb8-2a9f8cf9e810"
      unitRef="usd">200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ie8440034266a4aa291b14ebaf3980ba1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfMjE5OTAyMzI2MjIzNA_bed42898-c2c9-427b-90e6-915677ffe799"
      unitRef="usd">900000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfOTcx_87345347-1482-4c8f-95c5-fa578959dd18"
      unitRef="usd">100000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfOTc4_d09b8e49-e539-4a26-ba0c-38ef23daeb14"
      unitRef="usd">600000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfMTY0OTI2NzQ0Mjk5OA_12364b95-d9cc-4438-afd5-597091522219"
      unitRef="usd">200000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfMTY0OTI2NzQ0Mjk5OA_de32f680-b723-4af0-8a21-22b9acf3618e"
      unitRef="usd">200000</us-gaap:SeveranceCosts1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i44daf8bae7c343758ee6b618e75c35f6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181Mi9mcmFnOjlkZGU3YzU0NTU1MDQ4NzZiMDhlMTkzMjYyZTBhZGViL3RleHRyZWdpb246OWRkZTdjNTQ1NTUwNDg3NmIwOGUxOTMyNjJlMGFkZWJfMTE2NQ_01bf22ad-1a02-433f-b629-707a8c5918ac"
      unitRef="usd">100000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RleHRyZWdpb246N2FkNDczODUxZmU3NDk2N2E4ZGZiYzM2ODNiMTczMGJfMjk4Mg_15faa3ff-4575-4ba8-aaf7-a8cf22a38dc1">Debt&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of the carrying values for the components of debt as reflected on the condensed consolidated balance sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PPP Note&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EB-5 Loan Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying value of debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;PPP Note&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, the Company was granted a loan from Silicon Valley Bank ("SVB"), in the amount of $0.4&#160;million, pursuant to the Paycheck Protection Program (the &#x201c;PPP&#x201d;) of the Coronavirus Aid, Relief and Economic Security Act of 2020 (the &#x201c;CARES Act&#x201d;). Under the PPP, the loan was eligible for forgiveness to the extent the funds received were used for qualifying expenses as described by the CARES Act. The loan was in the form of a promissory note dated April 30, 2020 in favor of SVB (the "PPP Note"). The PPP Note had a maturity date of April 30, 2022 and bore interest at a rate of 1.0% per annum. The Company did not provide any collateral or guarantees for the loan, nor did the Company pay any facility charge to obtain the loan. The PPP Note provided for customary events of default, including, among others, failure to make payment, bankruptcy, breaches of representations, and material adverse events. In May 2021, the Company received notice from the Small Business Administration that the PPP Note was forgiven in its entirety, including both principal and accrued interest. The Company recognized a $0.4&#160;million gain on loan extinguishment within other income (expense) for the forgiveness of the PPP Note within the condensed consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;EB-5 Loan Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September&#160;2016, pursuant to the U.S. government&#x2019;s Immigrant Investor Program, commonly known as the EB-5 program (the &#x201c;EB-5 Program&#x201d;), the Company entered into an arrangement (the &#x201c;EB-5 Loan Agreement&#x201d;) to borrow up to $10.0&#160;million from EB5 Life Sciences,&#160;L.P. (&#x201c;EB-5 Life Sciences&#x201d;) in $0.5&#160;million increments. Borrowings may be limited by the amount of funds raised by EB-5 Life Sciences and are subject to certain job creation requirements by the Company. Borrowings are at a fixed interest rate of 4.0% per annum and are to be utilized in the clinical development, manufacturing, and commercialization of the Company&#x2019;s product candidates and for the general working capital needs of the Company. Outstanding borrowings pursuant to the EB-5 Loan Agreement, including accrued interest, become due upon the seventh anniversary of the final disbursement. Amounts repaid cannot be re-borrowed. The EB-5 Loan Agreement borrowings are secured by substantially all assets of the Company, except for any patents, patent applications, pending patents, patent licenses, patent sublicenses, trademarks, and other intellectual property rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms and conditions of the EB-5 Loan Agreement, the Company borrowed $1.0 million in 2016 and an additional $0.5 million in March 2020. Issuance costs were recognized as a reduction to the loan balance and are amortized to interest expense over the term of the loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of the EB-5 Loan Agreement borrowings as of September&#160;30, 2021 and December&#160;31, 2020 are summarized below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plus: accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RleHRyZWdpb246N2FkNDczODUxZmU3NDk2N2E4ZGZiYzM2ODNiMTczMGJfMjk3NQ_c53d0bc0-daec-4167-9c6d-839c35c0f7a6">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of the carrying values for the components of debt as reflected on the condensed consolidated balance sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PPP Note&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EB-5 Loan Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying value of debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of the EB-5 Loan Agreement borrowings as of September&#160;30, 2021 and December&#160;31, 2020 are summarized below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plus: accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:LongTermDebt
      contextRef="i01a12a6485e345b6ab72567171ec0eb0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjVhZjIyY2I0MTc5MDQ0MTdhNjgwNmRmMzZmODNlYTgyL3RhYmxlcmFuZ2U6NWFmMjJjYjQxNzkwNDQxN2E2ODA2ZGYzNmY4M2VhODJfMS0xLTEtMS0w_ce7b15bc-76b9-4068-a1e9-e577d6d10512"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i058f0a613fdb4fac8d51eb184f27c5b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjVhZjIyY2I0MTc5MDQ0MTdhNjgwNmRmMzZmODNlYTgyL3RhYmxlcmFuZ2U6NWFmMjJjYjQxNzkwNDQxN2E2ODA2ZGYzNmY4M2VhODJfMS0zLTEtMS0w_4979565a-49ab-4c9a-9525-bdd5044506ae"
      unitRef="usd">421000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i92ea040ac4094cb2a62e60e72ca77b3c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjVhZjIyY2I0MTc5MDQ0MTdhNjgwNmRmMzZmODNlYTgyL3RhYmxlcmFuZ2U6NWFmMjJjYjQxNzkwNDQxN2E2ODA2ZGYzNmY4M2VhODJfMi0xLTEtMS0w_1d365688-58a7-451c-a253-c5438662a186"
      unitRef="usd">1693000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i745fb75cca5b4c23886a4754e42262f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjVhZjIyY2I0MTc5MDQ0MTdhNjgwNmRmMzZmODNlYTgyL3RhYmxlcmFuZ2U6NWFmMjJjYjQxNzkwNDQxN2E2ODA2ZGYzNmY4M2VhODJfMi0zLTEtMS0w_e88a52d8-d9f9-465e-a5c8-98939b2760a3"
      unitRef="usd">1636000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjVhZjIyY2I0MTc5MDQ0MTdhNjgwNmRmMzZmODNlYTgyL3RhYmxlcmFuZ2U6NWFmMjJjYjQxNzkwNDQxN2E2ODA2ZGYzNmY4M2VhODJfMy0xLTEtMS0w_2a37604a-88cf-49b0-b755-70cdfe35370c"
      unitRef="usd">1693000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjVhZjIyY2I0MTc5MDQ0MTdhNjgwNmRmMzZmODNlYTgyL3RhYmxlcmFuZ2U6NWFmMjJjYjQxNzkwNDQxN2E2ODA2ZGYzNmY4M2VhODJfMy0zLTEtMS0w_783343f1-ea21-4786-888c-84c4035703e1"
      unitRef="usd">2057000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i85638365ecb449f89cd737e151a543eb_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RleHRyZWdpb246N2FkNDczODUxZmU3NDk2N2E4ZGZiYzM2ODNiMTczMGJfMjc3_d623168f-7eb5-4079-a002-7c6a00cbc061"
      unitRef="usd">400000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i85638365ecb449f89cd737e151a543eb_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RleHRyZWdpb246N2FkNDczODUxZmU3NDk2N2E4ZGZiYzM2ODNiMTczMGJfNzMx_4308e78b-64a4-4cbb-b923-2d854f9a5e7f"
      unitRef="number">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i5b1b73d8695b4c07b67f45b9ef51765e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RleHRyZWdpb246N2FkNDczODUxZmU3NDk2N2E4ZGZiYzM2ODNiMTczMGJfMTI2Nw_a130f55b-17ae-436d-a9af-4d21c4f6aaca"
      unitRef="usd">400000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i0894763e64ad446393df6c07eb805c5f_I20160930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RleHRyZWdpb246N2FkNDczODUxZmU3NDk2N2E4ZGZiYzM2ODNiMTczMGJfMTcxNg_9233c948-071e-46f9-a3ed-702b619c1818"
      unitRef="usd">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <ocgn:LineOfCreditBorrowingEachDraw
      contextRef="if4082401304e4bc3881503b617da5ec7_D20160901-20160930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RleHRyZWdpb246N2FkNDczODUxZmU3NDk2N2E4ZGZiYzM2ODNiMTczMGJfMTc3NA_df7bec3f-ac2c-4693-813e-31af61684a1a"
      unitRef="usd">500000</ocgn:LineOfCreditBorrowingEachDraw>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0894763e64ad446393df6c07eb805c5f_I20160930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RleHRyZWdpb246N2FkNDczODUxZmU3NDk2N2E4ZGZiYzM2ODNiMTczMGJfMTk4Mg_553759cc-4a17-43c8-aa63-a7e993e4eaec"
      unitRef="number">0.040</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCredit
      contextRef="i2b01d2f4d0c54ea186a70f5469b418fa_I20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RleHRyZWdpb246N2FkNDczODUxZmU3NDk2N2E4ZGZiYzM2ODNiMTczMGJfMjY5Mw_2f9d7766-4f3f-4b2b-a03b-27dcc9d106ac"
      unitRef="usd">1000000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i48e097bc118a40018d9f9179ffd7ca57_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RleHRyZWdpb246N2FkNDczODUxZmU3NDk2N2E4ZGZiYzM2ODNiMTczMGJfMjcyMg_5349fb3d-cddd-47ee-ba14-562c7f92baac"
      unitRef="usd">500000</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i92ea040ac4094cb2a62e60e72ca77b3c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjc2MzMzYjY3MGI2YTRlY2ZiYzZiMmYxZWQ2NjEyOWY0L3RhYmxlcmFuZ2U6NzYzMzNiNjcwYjZhNGVjZmJjNmIyZjFlZDY2MTI5ZjRfMS0xLTEtMS0w_cee502da-6c68-44aa-a64c-1c6c6052ed3f"
      unitRef="usd">1500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i745fb75cca5b4c23886a4754e42262f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjc2MzMzYjY3MGI2YTRlY2ZiYzZiMmYxZWQ2NjEyOWY0L3RhYmxlcmFuZ2U6NzYzMzNiNjcwYjZhNGVjZmJjNmIyZjFlZDY2MTI5ZjRfMS0zLTEtMS0w_32911d1f-e2bb-40ee-b9b8-61826cc0e567"
      unitRef="usd">1500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i92ea040ac4094cb2a62e60e72ca77b3c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjc2MzMzYjY3MGI2YTRlY2ZiYzZiMmYxZWQ2NjEyOWY0L3RhYmxlcmFuZ2U6NzYzMzNiNjcwYjZhNGVjZmJjNmIyZjFlZDY2MTI5ZjRfMi0xLTEtMS0w_e9cab1db-e4b1-4e25-9f29-659649427525"
      unitRef="usd">226000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i745fb75cca5b4c23886a4754e42262f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjc2MzMzYjY3MGI2YTRlY2ZiYzZiMmYxZWQ2NjEyOWY0L3RhYmxlcmFuZ2U6NzYzMzNiNjcwYjZhNGVjZmJjNmIyZjFlZDY2MTI5ZjRfMi0zLTEtMS0w_1c904be2-83fa-49c7-8b0d-7bffdd92e3ab"
      unitRef="usd">181000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i92ea040ac4094cb2a62e60e72ca77b3c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjc2MzMzYjY3MGI2YTRlY2ZiYzZiMmYxZWQ2NjEyOWY0L3RhYmxlcmFuZ2U6NzYzMzNiNjcwYjZhNGVjZmJjNmIyZjFlZDY2MTI5ZjRfMy0xLTEtMS0w_06463af5-4585-49b2-a84a-6a15e2292892"
      unitRef="usd">33000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i745fb75cca5b4c23886a4754e42262f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjc2MzMzYjY3MGI2YTRlY2ZiYzZiMmYxZWQ2NjEyOWY0L3RhYmxlcmFuZ2U6NzYzMzNiNjcwYjZhNGVjZmJjNmIyZjFlZDY2MTI5ZjRfMy0zLTEtMS0w_1d45b0e8-ddfb-49b2-a9cc-dc8dc094cc9d"
      unitRef="usd">45000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i92ea040ac4094cb2a62e60e72ca77b3c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjc2MzMzYjY3MGI2YTRlY2ZiYzZiMmYxZWQ2NjEyOWY0L3RhYmxlcmFuZ2U6NzYzMzNiNjcwYjZhNGVjZmJjNmIyZjFlZDY2MTI5ZjRfNC0xLTEtMS0w_8a717057-539e-497a-8cec-730a669d59cf"
      unitRef="usd">1693000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i745fb75cca5b4c23886a4754e42262f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181NS9mcmFnOjdhZDQ3Mzg1MWZlNzQ5NjdhOGRmYmMzNjgzYjE3MzBiL3RhYmxlOjc2MzMzYjY3MGI2YTRlY2ZiYzZiMmYxZWQ2NjEyOWY0L3RhYmxlcmFuZ2U6NzYzMzNiNjcwYjZhNGVjZmJjNmIyZjFlZDY2MTI5ZjRfNC0zLTEtMS0w_d8506e2f-e685-4f9f-8cd9-001caa08c294"
      unitRef="usd">1636000</us-gaap:LongTermDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNjE5Mw_0cdd37a4-f895-4b38-b554-82befeb26cc9">Equity&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;COVAXIN Preferred Stock Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 1, 2021, the Company entered into a preferred stock purchase agreement, pursuant to which the Company agreed to issue and sell 0.1&#160;million shares of the Company&#x2019;s Series B Convertible Preferred Stock, par value $0.01 per share (the &#x201c;Series B Convertible Preferred Stock&#x201d;), at a price per share equal to $109.60, to Bharat Biotech. On March 18, 2021, the Company issued the Series B Convertible Preferred Stock as an advance payment for the supply of COVAXIN to be provided by Bharat Biotech pursuant to the Supply Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each share of Series B Convertible Preferred Stock is convertible, at the option of Bharat Biotech, into 10 shares of the Company&#x2019;s common stock (the "Conversion Ratio") only after (i) the Company received stockholder approval to increase the number of authorized shares of common stock under its Sixth Amended and Restated Certificate of Incorporation and (ii) the Company&#x2019;s receipt of shipments by Bharat Biotech of the first 10.0&#160;million doses of COVAXIN manufactured by Bharat Biotech pursuant to the Supply Agreement, and further on the terms and subject to the conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (the "Certificate of Designation"). In April 2021, the Company's stockholders approved an increase in the number of the Company's authorized shares of common stock from 200.0&#160;million to 295.0&#160;million. As of September&#160;30, 2021, the conversion condition relating to the delivery of the first 10.0&#160;million doses of COVAXIN had not been met. The conversion rate of the Series B Convertible Preferred Stock is subject to adjustment in the event of a stock dividend, stock split, reclassification, or similar event with respect to the Company&#x2019;s common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bharat Biotech is entitled to receive dividends on the Series B Convertible Preferred Stock equal (on an as-converted to common stock basis) to and in the same form as dividends actually paid on shares of common stock, when and if such dividends are paid. Except as provided by law and certain protective provisions set forth in the Certificate of Designation, the Series B Convertible Preferred Stock has no voting rights. Upon a liquidation or dissolution of the Company, holders of Series B Convertible Preferred Stock would be entitled to receive the same amount that a holder of common stock would receive if the Series B Convertible Preferred Stock were fully converted to common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounted for the issuance of the Series B Convertible Preferred Stock in accordance with ASC 718 and recorded the fair value of $5.0&#160;million within equity during the nine months ended September 30, 2021, with a corresponding short-term asset for the advanced payment for the doses of COVAXIN. The Company utilized the traded common stock price, adjusted by the Conversion Ratio, to value the Series B Convertible Preferred Stock and the Finnerty model to estimate a 15% discount rate for the lack of marketability of the instrument. The valuation incorporates Level 3 inputs in the fair value hierarchy, including the estimated time until the instrument's liquidity and the estimated volatility of the Company's common stock as of the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Registered Direct Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 23, 2021, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company agreed to issue and sell in a registered direct offering (the "April 2021 Registered Direct Offering") an aggregate of 10.0&#160;million shares of the Company's common stock at an offering price of $10.00 per share. The closing of the April 2021 Registered Direct Offering occurred on April 27, 2021 and the Company received net proceeds of $93.4&#160;million after deducting equity issuance costs of $6.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 7, 2021, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company agreed to issue and sell in a registered direct offering (the "February 2021 Registered Direct Offering") an aggregate of 3.0&#160;million shares of the Company's common stock at an offering price of $7.65 per share. The closing of the February 2021 Registered Direct Offering occurred on February 10, 2021 and the Company received net proceeds of $21.2&#160;million after deducting equity issuance costs of $1.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;At-the-Market Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company commenced three separate at-the-market offerings (each an "ATM", and collectively, the "ATMs") in May 2020, June 2020, and August 2020. The offerings were made pursuant to the Company's effective "shelf" registration statement on Form S-3 filed with the SEC on March 27, 2020, the base prospectus contained therein dated May 5, 2020, and the prospectus supplements related to the offerings dated May 8, 2020, June 12, 2020, and August 17, 2020. During the nine months ended September 30, 2021, the Company sold 1.0&#160;million shares of the Company's common stock under the August 2020 ATM and received net proceeds of $4.8&#160;million after deducting equity issuance costs of $0.1&#160;million. During the three and nine months &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ended September&#160;30, 2020, the Company sold an aggregate of 27.0&#160;million and 86.2&#160;million shares of the Company's common stock under the ATMs, respectively. During the three months ended September 30, 2020, the Company received net proceeds of $10.1&#160;million after deducting equity issuance costs of $0.4&#160;million. During the nine months ended September 30, 2020, the Company received net proceeds of $25.6&#160;million after deducting equity issuance costs of $1.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Subscription Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company entered into a subscription agreement with an accredited investor for the issuance of 1.3&#160;million shares of the Company's common stock in a private placement. The shares of common stock were issued as part of a transaction in settlement of an outstanding obligation of the Company to the accredited investor, in which (i) the Company agreed to make certain cash payments, (ii) the Company issued the 1.3&#160;million shares of the Company's common stock in exchange for the accredited investor's agreement to cancel $0.3&#160;million of the outstanding obligation, and (iii) the accredited investor agreed to cancel an additional portion of the amount owed by the Company representing a discount of $0.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, the Company entered into a subscription agreement with an accredited investor for the issuance of 1,000 shares of the Company's common stock in a private placement for an aggregate offering price of $395 (the "April 2020 Subscription Agreement").&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <ocgn:SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction
      contextRef="ie1f83da91a62482bafefc243a5610119_D20210301-20210301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMTk1_94ab77d0-0e6a-4ebf-b094-684ea0bf0a6e"
      unitRef="shares">100000</ocgn:SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia223aa6547ab48e8a989ed4c643adeaa_I20210301"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMjcw_fa946827-0697-40ab-90ea-9a70e4ee8b8a"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <ocgn:SaleOfStockAgreementToSellPricePerShare
      contextRef="ia223aa6547ab48e8a989ed4c643adeaa_I20210301"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMzU5_638875c6-7070-4837-8090-f749b5969c36"
      unitRef="usdPerShare">109.60</ocgn:SaleOfStockAgreementToSellPricePerShare>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="ia223aa6547ab48e8a989ed4c643adeaa_I20210301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNzc5_1d670f34-9d55-48da-a42e-4cc0534e1eaf"
      unitRef="shares">10</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <ocgn:SupplyAgreementNumberOfDoses
      contextRef="ia223aa6547ab48e8a989ed4c643adeaa_I20210301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMTEwNg_10e47db9-7a39-402d-bf3e-cfc474afed07"
      unitRef="dose">10000000</ocgn:SupplyAgreementNumberOfDoses>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i246cca5ff04f4a438cabbffe4ac0798c_I20210429"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMTUzOA_62c7f5d9-d315-4ab8-b1b0-a7d9555550dc"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iefbd2c9026804907ae58afb0f262bb0d_I20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMTU0NA_405a3213-38d2-4ed9-8b5a-4ecd1bec8943"
      unitRef="shares">295000000</us-gaap:CommonStockSharesAuthorized>
    <ocgn:SupplyAgreementNumberOfDoses
      contextRef="ide0135d45c4941c9938e0383f70a9804_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMzg0ODI5MDcxODk4Mg_2ea28c8c-95ab-4b06-8499-8a5fc6213679"
      unitRef="dose">10000000</ocgn:SupplyAgreementNumberOfDoses>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="i28b02ce452d34ea6b3c2e1dff6d45d00_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMjcwOQ_c2acdc91-d83b-4570-8322-acb7a86641b8"
      unitRef="usd">5000000</us-gaap:PreferredStockValueOutstanding>
    <ocgn:PreferredStockMeasurementInput
      contextRef="ie4ef9e6106c44af9adc546620f7b1580_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMzAwMw_d253c799-b84a-483b-8b7a-1ce3fdcdb8c0"
      unitRef="number">0.15</ocgn:PreferredStockMeasurementInput>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i90ca97f6066a4d9a810636493e1c9aac_D20210423-20210423"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMzU2OQ_9d6f58fc-78e6-4ba9-9cb7-04204e9a427c"
      unitRef="shares">10000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i77df7a80e56a4e8facf772024c0e4945_I20210423"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMzYzMw_4f1c7361-5562-4ba5-9422-a4fb7c80e1bc"
      unitRef="usdPerShare">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i5862a96aeadd4f89b932761cb5f2e124_D20210427-20210427"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMzc3Mg_df20ba1b-c0ed-4765-8d45-23211476fab6"
      unitRef="usd">93400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i5862a96aeadd4f89b932761cb5f2e124_D20210427-20210427"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMzgxNg_b114a7fe-794e-4bb2-9e2f-3d186dcd4f9c"
      unitRef="usd">6600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i15f4aa0e8bfb449a842dfc32748a2a55_D20210207-20210207"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNDA4Nw_b23d675c-5638-42b7-a5fa-c10cfcf01d13"
      unitRef="shares">3000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i8a5e15fc5e9f4ab8b85dee2ee164fe5c_I20210207"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNDE1MQ_58741986-cbb2-4d70-b7ea-7ac68cbfd59a"
      unitRef="usdPerShare">7.65</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ia8cedc3486594d78b30a563076ebf2ad_D20210210-20210210"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNDI5Ng_a9514965-67e1-4869-84d5-8cffde61ee1b"
      unitRef="usd">21200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="ia8cedc3486594d78b30a563076ebf2ad_D20210210-20210210"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNDM0MA_7afd78ba-ca41-4c72-82e0-05f7d3183f33"
      unitRef="usd">1700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <ocgn:NumberOfAtTheMarketOfferings
      contextRef="i8b074737fd3840e3a89e6bc467ec5352_D20200501-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNDM5MA_6dd9829b-c61d-4de0-abf3-3d8f91b39274"
      unitRef="at-the-marketoffering">3</ocgn:NumberOfAtTheMarketOfferings>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iab0d59da4af045118182091dce3984c8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNDg4NA_2c7447c0-b943-40d6-a150-d42772d25518"
      unitRef="shares">1000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iab0d59da4af045118182091dce3984c8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNDk3OQ_b9c3e743-1800-4eb0-9f7b-446825b1c24b"
      unitRef="usd">4800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="iab0d59da4af045118182091dce3984c8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNTAyMw_712591a5-7520-4787-8f59-afb006def3d5"
      unitRef="usd">100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i00ccc0ff720749b1b14d75b3c93faa0d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMTY0OTI2NzQ0ODY3NQ_8b19801a-0489-44ca-b03a-d5016bf1c1f7"
      unitRef="shares">27000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iaa7b11c7997941d7a2ebe1202ae40792_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMTY0OTI2NzQ0ODY4OQ_4a349284-22e4-4d1d-a128-11fe0c663057"
      unitRef="shares">86200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i00ccc0ff720749b1b14d75b3c93faa0d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMTY0OTI2NzQ0ODc4Nw_58c02766-6d7e-4d09-9bcc-90ef1069549b"
      unitRef="usd">10100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i00ccc0ff720749b1b14d75b3c93faa0d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMTY0OTI2NzQ0ODgwMg_3238fa2d-dca1-4a27-8633-9187eb303ec6"
      unitRef="usd">400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iaa7b11c7997941d7a2ebe1202ae40792_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMTY0OTI2NzQ0ODg1Nw_4c2494bb-d6f2-423c-a334-9a9dd2517477"
      unitRef="usd">25600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="iaa7b11c7997941d7a2ebe1202ae40792_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfMTY0OTI2NzQ0ODg3Mg_ac469bde-36e3-47ed-ab5d-3dfba87074b3"
      unitRef="usd">1100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ia8019c49fc2b41d8809f0fc4847ce9b0_D20200601-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNTM3MQ_788565d6-d5a9-4955-b8a4-b599154e3d1b"
      unitRef="shares">1300000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ia8019c49fc2b41d8809f0fc4847ce9b0_D20200601-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNTY3Ng_8198e8a9-eb88-43b9-adde-d1a05a0f746b"
      unitRef="shares">1300000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <ocgn:SaleOfStockOutstandingObligationCancelledInExchangeForStock
      contextRef="i5068c87588174140afe885f4e47d066a_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNTc2NA_c3e403f3-b757-4b03-8217-46f5d0a1b83c"
      unitRef="usd">300000</ocgn:SaleOfStockOutstandingObligationCancelledInExchangeForStock>
    <ocgn:SaleOfStockAdditionalDebtCancelledInExchangeForStock
      contextRef="i5068c87588174140afe885f4e47d066a_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNTkzMg_d5f9e1fb-e0fb-48b0-9263-9d2a55a38a85"
      unitRef="usd">200000</ocgn:SaleOfStockAdditionalDebtCancelledInExchangeForStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i8e02ac8495184af4af04566df93db8f7_D20200401-20200430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNjA0OQ_e81cda54-130e-4c5f-825f-5bf90a82cedc"
      unitRef="shares">1000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i8e02ac8495184af4af04566df93db8f7_D20200401-20200430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N181OC9mcmFnOjhlNGQyYWVhNDk2YjQ5Y2FhYzY0ZjEzYzFjMjIzYjA1L3RleHRyZWdpb246OGU0ZDJhZWE0OTZiNDljYWFjNjRmMTNjMWMyMjNiMDVfNjE0Nw_0fb6bcf8-5cd3-49a9-952d-504b8f1105b9"
      unitRef="usd">395</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ocgn:WarrantsTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMzU3OQ_6fbe9e89-dd4a-4531-b443-33cacc60c9c3">Warrants&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Canada Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 15, 2021, the Company entered into a consulting agreement with an individual to provide services to the Company with regard to the Company's Canadian operations (the "Canada Consulting Agreement"). Compensation under the Canada Consulting Agreement includes, among other forms of compensation, the issuance of warrants to purchase up to 0.2&#160;million shares of the Company's common stock (the "Canada Warrants") and cash payments of up to $3.0&#160;million upon the achievement of certain milestones related to COVAXIN. The Canada Consulting Agreement terminates on July 15, 2023, unless earlier terminated in accordance with its terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Canada Warrants were issued on July 15, 2021 in a private placement transaction. The warrantholder has the right to exercise the Canada Warrants to purchase up to 0.2 million shares of the Company's common stock at an exercise price of $6.36 per share upon the achievement of certain milestones related to COVAXIN. The Canada Warrants terminate on July 15, 2031, unless earlier terminated in accordance with their terms. As of September&#160;30, 2021, all of the Canada Warrants were outstanding and unvested. The Canada Warrants are accounted for in accordance with ASC 718.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;SPA Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, the Company issued three series of warrants to purchase shares of the Company&#x2019;s common stock (the &#x201c;Series A Warrants,&#x201d; the &#x201c;Series B Warrants&#x201d;, and the &#x201c;Series C Warrants&#x201d; and collectively, the &#x201c;SPA Warrants&#x201d;) under a securities purchase agreement with certain accredited investors. In April 2020, the Company entered into the April 2020 Subscription Agreement, as discussed within Note 9, which represented a dilutive issuance as defined by the Series A Warrants and resulted in adjustments to the number of issuable Series A Warrants and the exercise price of the Series A Warrants. Immediately prior to the Company entering into the April 2020 Subscription Agreement, 8.8&#160;million Series A Warrants, 1,000 Series B Warrants, and 1,000 Series C Warrants were outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contemporaneously with the April 2020 Subscription Agreement, the Company and OpCo entered into Amendment and Exchange Agreements (each an "Exchange Agreement" and collectively, the "Exchange Agreements") with the accredited investors. Pursuant to the Exchange Agreements, the Company, OpCo, and the accredited investors agreed, among other things, after giving effect to the dilutive issuance, to amend the Series A Warrants to provide for an adjustment to the number of common stock issuable upon the exercise of the Series A Warrants. Concurrently with such amendments, the accredited investors exchanged the Series A Warrants for (i) an aggregate of 21.9&#160;million shares of the Company's common stock and (ii) promissory notes of $5.6&#160;million (the "Warrant Exchange Promissory Notes" and collectively with the common stock issued, the "Warrant Exchange"). During the three and nine months ended September&#160;30, 2020, the Company made payments to the Warrant Exchange Promissory Notes holders of $3.2&#160;million and $4.4&#160;million, respectively. As of December&#160;31, 2020, the Warrant Exchange Promissory Notes had been repaid in full. Immediately following the consummation of the Warrant Exchange and the concurrent exercise of the remaining Series B Warrants and Series C Warrants, there were no SPA Warrants outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounted for the Warrant Exchange by recognizing the fair value of the consideration transferred in excess of the carrying value of the Series A Warrants as a reduction of additional paid-in capital. The fair value of the Series A Warrants immediately prior to the Warrant Exchange was $1.1&#160;million, which was estimated using a Black-Scholes valuation model utilizing Level 3 inputs. The fair value of the consideration transferred to settle the Series A Warrants was approximately $13.6&#160;million, comprised of $8.6&#160;million in shares of the Company's common stock and the fair value of the Warrant Exchange Promissory Notes of $5.0&#160;million. The fair value of consideration transferred to settle the Series A Warrants was in excess of the fair value of the Series A Warrants immediately prior to the Warrant Exchange by approximately $12.5&#160;million. The excess consideration was accounted for as a deemed dividend to the Series A Warrant holders and was reflected as an additional net loss to common stockholders in the calculation of basic and diluted net loss per common share for the nine months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;OpCo Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2016, OpCo issued warrants to purchase the Company's common stock (the "OpCo Warrants") to investors of the Company pursuant to a stockholders' agreement and to two employees of the Company pursuant to their respective employment agreements. As of September&#160;30, 2021 and December&#160;31, 2020, 0.8 million and 0.9 million OpCo Warrants were outstanding, respectively. As of September&#160;30, 2021 the outstanding OpCo Warrants had a weighted-average exercise price of $4.97. The outstanding OpCo Warrants expire between 2026 and 2027.&lt;/span&gt;&lt;/div&gt;</ocgn:WarrantsTextBlock>
    <ocgn:ClassOfWarrantOrRightExercisable
      contextRef="ic8bd5469fd534b5fa1a3c3286b4599c4_I20210715"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfNDM5ODA0NjU0MzUxNg_ac6fe7b9-a7ca-4128-bec1-b571f5231578"
      unitRef="shares">200000</ocgn:ClassOfWarrantOrRightExercisable>
    <ocgn:ClassOfWarrantOrRightExpectedMilestonePayment
      contextRef="ic8bd5469fd534b5fa1a3c3286b4599c4_I20210715"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfNDM5ODA0NjU0MzYxMw_23f6f237-3ea1-4265-be82-b7d3e0c8ae5d"
      unitRef="usd">3000000</ocgn:ClassOfWarrantOrRightExpectedMilestonePayment>
    <ocgn:ClassOfWarrantOrRightExercisable
      contextRef="ic8bd5469fd534b5fa1a3c3286b4599c4_I20210715"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfNDM5ODA0NjU0Mzk3Ng_7dcff5d3-adb9-4e33-b8e4-bf88dd27af2f"
      unitRef="shares">200000</ocgn:ClassOfWarrantOrRightExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic8bd5469fd534b5fa1a3c3286b4599c4_I20210715"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfNDM5ODA0NjU0NDA0MQ_848ccbee-5234-44fb-b6e6-70f2693ac490"
      unitRef="usdPerShare">6.36</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ocgn:NumberOfSeriesOfWarrantsIssued
      contextRef="i1e39c130cffe499eaae2b4c55fef5b42_D20191001-20191031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfNjc_a21f9bd2-f76c-49b0-989e-e62045ef26cf"
      unitRef="seriesofwarrant">3</ocgn:NumberOfSeriesOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i24e2b7c0b5b1441cad39027ec7574d10_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfNzYz_12103ee1-6549-49b1-833a-8eea9d8de295"
      unitRef="shares">8800000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="if01d7fad0a3f48a8bd13b30a1b84b704_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfNzg1_f8b658d7-993d-42a9-a63e-2642d27228dd"
      unitRef="shares">1000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i99f2d4d98be64d7ea57dfff1f984ef8b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfODEx_a5cdec48-2cb7-4a35-a10c-d0675bf4aeae"
      unitRef="shares">1000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ie002070f257c4c608068b1b07255b1d5_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMTUwNQ_f17950fb-741e-4355-a34c-f876107ef270"
      unitRef="shares">21900000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i06658032e2704ab282cc346ef006ef8f_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMTU2Mg_7277543c-78f4-4ada-891f-5196a2a1926d"
      unitRef="usd">5600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="i8612a2a4329d46479292b57b3cd408f0_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMTY0OTI2NzQ0NTI5Nw_314c3627-b87c-4c93-bbae-3060cf875eda"
      unitRef="usd">3200000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i86fc446c1c3b4958be93eb3d966f598a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMTY0OTI2NzQ0NTMxMQ_fae4c506-121f-40ba-950e-209c4cbfc959"
      unitRef="usd">4400000</us-gaap:RepaymentsOfDebt>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ib6e306f60ac94b79a20c2e697c2d41e0_I20200430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMjAyMw_a9580c13-d3d6-4c06-a344-55dd01b2a04d"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i2a0df3b2c63543fd93b3be04483ec5a2_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMjM1MQ_c216df03-49b6-4c3d-9bd0-f8b483e3424d"
      unitRef="usd">1100000</us-gaap:WarrantsAndRightsOutstanding>
    <ocgn:ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants
      contextRef="i0677fbde7da642e0bd593d8fa763f607_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMjUzNw_68faf1b6-6b0b-40e7-aac5-e44c98d98fef"
      unitRef="usd">13600000</ocgn:ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants>
    <ocgn:ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock
      contextRef="i0677fbde7da642e0bd593d8fa763f607_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMjU1NA_e498c2b1-79ca-49bb-abe3-518ebb95005a"
      unitRef="usd">8600000</ocgn:ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock>
    <ocgn:ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote
      contextRef="i0677fbde7da642e0bd593d8fa763f607_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMjY0Ng_521329ae-7ddf-4a3c-9b65-0e417c187f89"
      unitRef="usd">5000000</ocgn:ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote>
    <ocgn:ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue
      contextRef="i0677fbde7da642e0bd593d8fa763f607_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMjg0Mg_a705dc5d-e65b-4ccf-80a8-85c78691aaa0"
      unitRef="usd">12500000</ocgn:ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue>
    <ocgn:NumberOfFormerEmployeesWithWarrants
      contextRef="i04d1f309d9f74029a1b219a85f77a940_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMzI4Nw_30a1015d-12b3-4e3c-a244-2bd7eb6f411c"
      unitRef="employee">2</ocgn:NumberOfFormerEmployeesWithWarrants>
    <ocgn:ClassOfWarrantOrRightExercisable
      contextRef="i275b6ac4e97c4be5aa1a51af8502831b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMjE5OTAyMzI2MDY5Mw_49825420-e335-47d5-9c61-b2a401e308e1"
      unitRef="shares">800000</ocgn:ClassOfWarrantOrRightExercisable>
    <ocgn:ClassOfWarrantOrRightExercisable
      contextRef="iae6a400180f04a07b8febf2d6e0fa554_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMjE5OTAyMzI2MDY5Nw_1fb6a745-7397-4354-99f5-68611becbae3"
      unitRef="shares">900000</ocgn:ClassOfWarrantOrRightExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i275b6ac4e97c4be5aa1a51af8502831b_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182MS9mcmFnOjA5YjFiYmE4OWJhODQwYWViMTk2ODgxZmNhYTJiMDcxL3RleHRyZWdpb246MDliMWJiYTg5YmE4NDBhZWIxOTY4ODFmY2FhMmIwNzFfMjE5OTAyMzI2MTQ5Mg_53d72b79-2afa-412c-9198-8190f58e3e5b"
      unitRef="usdPerShare">4.97</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMjE3NA_a4162556-c72f-4e9d-90e1-f47f21c41963">Stock-Based Compensation&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense for stock options and RSUs is reflected in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense during the three and nine months ended September&#160;30, 2021 included $41.3&#160;thousand and $1.1 million of expense related to stock options with performance-based vesting conditions, respectively. No stock-based compensation expense during the three and nine months ended September&#160;30, 2020 was related to stock options with performance-based vesting conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the Company had $13.9&#160;million of unrecognized stock-based compensation expense related to stock options and RSUs outstanding. This expense is expected to be recognized over a weighted-average period of 2.2 years as of September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains two equity compensation plans, the 2014 Ocugen OpCo, Inc. Stock Option Plan (the &#x201c;2014 Plan&#x201d;) and the Ocugen, Inc. 2019 Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;, collectively with the 2014 Plan, the "Plans"). As of September&#160;30, 2021, the 2014 Plan and 2019 Plan authorize for the granting of up to 0.8&#160;million and 11.5&#160;million equity awards in respect to the Company's common stock, respectively. In addition to stock options and RSUs granted under the Plans, the Company has granted certain stock options and RSUs as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4), which were granted outside of the Plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Options to Purchase Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,224,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,469,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(901,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,518,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options not yet exercisable as of September&#160;30, 2021 includes 1.5&#160;million stock options with performance-based vesting conditions. There were no stock options with performance-based vesting conditions as of December&#160;31, 2020. The weighted-average grant date fair values of stock options granted during the three and nine months ended September&#160;30, 2021 were $5.97 and $2.77, respectively. The weighted-average grant date fair value of stock options granted during both the three and nine months ended September&#160;30, 2020 was $0.34 per share. The total fair values of stock options vested during the three and nine months ended September&#160;30, 2021 were $0.1&#160;million and $0.7&#160;million, respectively. The total fair values of stock options vested during the three and nine months ended September&#160;30, 2020 were $0.1&#160;million and $0.3&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the RSU activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding at September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMjE3MQ_8786fef0-eced-4f4f-b926-cc3e7e77ebb4">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense for stock options and RSUs is reflected in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie0a8b70d6fb84c5a9789d450871ed83a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmUxYTA1YTU4YWExYzQ1YmRiOWZmZTRlNmViYjA2NTA5L3RhYmxlcmFuZ2U6ZTFhMDVhNThhYTFjNDViZGI5ZmZlNGU2ZWJiMDY1MDlfMi0xLTEtMS0w_c0e619c2-0276-4356-bb36-6971df6d1517"
      unitRef="usd">840000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8acfe33635854458877463fc16a751b4_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmUxYTA1YTU4YWExYzQ1YmRiOWZmZTRlNmViYjA2NTA5L3RhYmxlcmFuZ2U6ZTFhMDVhNThhYTFjNDViZGI5ZmZlNGU2ZWJiMDY1MDlfMi0zLTEtMS0w_8a163584-550c-43e3-a65f-74638f59a8dd"
      unitRef="usd">101000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7caedf65c1494e419cbafa5a7b2af8d9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmUxYTA1YTU4YWExYzQ1YmRiOWZmZTRlNmViYjA2NTA5L3RhYmxlcmFuZ2U6ZTFhMDVhNThhYTFjNDViZGI5ZmZlNGU2ZWJiMDY1MDlfMi01LTEtMS0w_62a9a875-3e11-4f3c-a94f-5df2c27b2676"
      unitRef="usd">2957000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i830ec46fb29342e8a14435d6c8374e8f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmUxYTA1YTU4YWExYzQ1YmRiOWZmZTRlNmViYjA2NTA5L3RhYmxlcmFuZ2U6ZTFhMDVhNThhYTFjNDViZGI5ZmZlNGU2ZWJiMDY1MDlfMi03LTEtMS0w_7536fd42-e8a1-47da-9bd8-fb536d61af0e"
      unitRef="usd">248000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i34df5c33daa84097bbeb2f7aa78e9881_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmUxYTA1YTU4YWExYzQ1YmRiOWZmZTRlNmViYjA2NTA5L3RhYmxlcmFuZ2U6ZTFhMDVhNThhYTFjNDViZGI5ZmZlNGU2ZWJiMDY1MDlfMy0xLTEtMS0w_3720d38a-55f0-469a-b6e3-b54757278569"
      unitRef="usd">507000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6d5d5de7375c464ebdd9941535b546d4_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmUxYTA1YTU4YWExYzQ1YmRiOWZmZTRlNmViYjA2NTA5L3RhYmxlcmFuZ2U6ZTFhMDVhNThhYTFjNDViZGI5ZmZlNGU2ZWJiMDY1MDlfMy0zLTEtMS0w_ef1530e8-ecc4-4045-af67-5376c90ca7cb"
      unitRef="usd">25000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i27f8c3a424b04ee8a9158f75127eec6e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmUxYTA1YTU4YWExYzQ1YmRiOWZmZTRlNmViYjA2NTA5L3RhYmxlcmFuZ2U6ZTFhMDVhNThhYTFjNDViZGI5ZmZlNGU2ZWJiMDY1MDlfMy01LTEtMS0w_26c33a1a-2acd-4512-a628-b83c1eaee9b6"
      unitRef="usd">1318000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icfe523d076894ad581734cd76ae76f7e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmUxYTA1YTU4YWExYzQ1YmRiOWZmZTRlNmViYjA2NTA5L3RhYmxlcmFuZ2U6ZTFhMDVhNThhYTFjNDViZGI5ZmZlNGU2ZWJiMDY1MDlfMy03LTEtMS0w_9b496e4a-74f9-4aab-9cc5-afe5e4dbbb43"
      unitRef="usd">249000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmUxYTA1YTU4YWExYzQ1YmRiOWZmZTRlNmViYjA2NTA5L3RhYmxlcmFuZ2U6ZTFhMDVhNThhYTFjNDViZGI5ZmZlNGU2ZWJiMDY1MDlfNC0xLTEtMS0w_9fe4b025-1713-42d0-b87d-d3501b027df1"
      unitRef="usd">1347000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmUxYTA1YTU4YWExYzQ1YmRiOWZmZTRlNmViYjA2NTA5L3RhYmxlcmFuZ2U6ZTFhMDVhNThhYTFjNDViZGI5ZmZlNGU2ZWJiMDY1MDlfNC0zLTEtMS0w_3e1d7cb7-ade4-460b-976c-fa728c29de75"
      unitRef="usd">126000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmUxYTA1YTU4YWExYzQ1YmRiOWZmZTRlNmViYjA2NTA5L3RhYmxlcmFuZ2U6ZTFhMDVhNThhYTFjNDViZGI5ZmZlNGU2ZWJiMDY1MDlfNC01LTEtMS0w_71ce3fd1-65f4-4fa6-9264-680c1b06d0dd"
      unitRef="usd">4275000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmUxYTA1YTU4YWExYzQ1YmRiOWZmZTRlNmViYjA2NTA5L3RhYmxlcmFuZ2U6ZTFhMDVhNThhYTFjNDViZGI5ZmZlNGU2ZWJiMDY1MDlfNC03LTEtMS0w_87223300-3e76-4e03-a577-9dac050e46e6"
      unitRef="usd">497000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6efde1790e4d4c3f820f75713f6e84b9_D20210701-20210930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMjg2_22748423-4b7b-4aa7-9096-a5d654b51e1b"
      unitRef="usd">41300</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibe51744fe7ab46b2a3e9f306f2e205ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMTY0OTI2NzQ0OTQ3Nw_344dd615-ea97-4b44-81eb-cb5ed8a8c1f2"
      unitRef="usd">1100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iab3b4c48ef4b48df90d794b934740c1f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMzY4_b05027b5-91ed-43a1-9900-a049933e0f97"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaa3c7dd5eddd468da3b9df0f9934469a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMzY4_b4b37c43-e687-42e9-b098-7991d86e557f"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfNTMy_f9c85acc-3e01-4669-acbc-0f8b1d6f043f"
      unitRef="usd">13900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i3571bc8a75ac48659cc316e5763f4ed2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfNzAx_6ca5b447-ef84-41fd-805d-21e642a29923">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <ocgn:NumberOfEquityCompensationPlans
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfNzQ5_0015d221-9abb-43f8-a50b-a11a28863133"
      unitRef="segment">2</ocgn:NumberOfEquityCompensationPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i05d88bc2fdb94bfb85adba0bb8b27884_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMTAzMA_f3c9d261-e371-4a91-8ee3-44dd36bcc350"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="idcf0789a7cf8450dac2a8c051cc629b3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMTAzNw_37796ef5-c4ed-4d26-b018-1ad1d57ae0cd"
      unitRef="shares">11500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMjE3Mg_454ae3de-8763-4ae9-a4a0-be12f3e9f778">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,224,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,469,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(901,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,518,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfMS0xLTEtMS0w_63973849-8859-4ad2-94b2-3fb0803f1550"
      unitRef="shares">4224433</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfMS0zLTEtMS0w_23abd1f3-636e-4136-aaa6-d6f8f3c3726a"
      unitRef="usdPerShare">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i8deb7fe79a024352817ef6e8af8f0441_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfMS01LTEtMS0w_c8aaf517-8a85-4e15-adac-02b71c93bf72">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i6c78f41bc4d34d2f97ae2010184d9723_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfMS03LTEtMS0w_3f01a169-4e3d-4cd4-91d3-9483c5ed3ab0"
      unitRef="usd">5496000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfMi0xLTEtMS0w_03b09915-4ca2-4f80-9f9f-2d152b1ca7b1"
      unitRef="shares">7469300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfMi0zLTEtMS0w_0907a94e-29a3-4e14-a8bb-98838c116004"
      unitRef="usdPerShare">3.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfMy0xLTEtMS0w_9336f842-ec0b-4e7a-a420-8bbf754c5f99"
      unitRef="shares">901250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfMy0zLTEtMS0w_3b2ee551-2534-4a83-b2be-ccacb5e03ca2"
      unitRef="usdPerShare">0.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfMy03LTEtMS0w_b8c71a7e-b398-4dc9-baa4-18dabfebb846"
      unitRef="usd">8042000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfNC0xLTEtMS0w_2c0c8b78-9d21-4ac0-bb67-b7dab4d1f51f"
      unitRef="shares">274220</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfNC0zLTEtMS0w_7a90d29b-c335-473c-b7ff-afa61eac760a"
      unitRef="usdPerShare">2.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <ocgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfNC03LTEtMS0w_04a7bb02-44f8-4c11-a396-94e10cd724fa"
      unitRef="usd">1146000</ocgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfNS0xLTEtMS0w_4ec77515-5997-43b4-b964-ecfdb8d9a499"
      unitRef="shares">10518263</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfNS0zLTEtMS0w_8a3e0566-a043-4aea-a558-5f9fe0eac92e"
      unitRef="usdPerShare">2.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfNS01LTEtMS0w_21d2db93-4745-4d87-a965-0583da1ef1a5">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfNS03LTEtMS0w_5dc6f4a8-7d0f-4d89-9db4-8153aaf3fc0e"
      unitRef="usd">49552000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfNi0xLTEtMS0w_f5ab33b1-430d-41b3-9672-238b85c25677"
      unitRef="shares">991429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfNi0zLTEtMS0w_94a8ad39-e745-4ac3-bcd9-67906cb6075b"
      unitRef="usdPerShare">1.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfNi01LTEtMS0w_4841858f-9cad-483f-8c43-a22e64fc6119">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ib4b81d02d5c54e628ce7e36b656ecacc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOjc4M2FjZGE1NjAxZTQyNTU4ZDM4NzIyYTg0MGI2ODIxL3RhYmxlcmFuZ2U6NzgzYWNkYTU2MDFlNDI1NThkMzg3MjJhODQwYjY4MjFfNi03LTEtMS0w_c4e24adb-1cc8-427a-8b6d-864979022a49"
      unitRef="usd">5629000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <ocgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber
      contextRef="i5fe71549bdba4e09bf1e6455238c6445_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMTY0OTI2NzQ0OTk1Mw_ccf6a1b1-c738-40b5-8d7a-bad43a23841e"
      unitRef="shares">1500000</ocgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i78eaa94bd702419a8ec49cbc777b5ba7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMTY0OTI2NzQ0OTc5Mg_e5a46cfe-b781-4853-a2d1-402bb6925611"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMTc1NQ_0f52e449-2e35-4f83-9a3e-9893baebbe62"
      unitRef="usdPerShare">5.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMTc2Mg_b51ae21c-3bb3-4bf0-ad38-ab74c99d2823"
      unitRef="usdPerShare">2.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMTg4NA_1facc052-b4f1-41cf-890d-e747f67df243"
      unitRef="usdPerShare">0.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMTg4NA_8a7af7b5-facc-414e-b69d-f446cd1ea0e8"
      unitRef="usdPerShare">0.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMTk4OA_f33625da-e1f4-4bcf-aacd-99c9ebef16df"
      unitRef="usd">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMTk5NQ_febb8593-46b5-4a15-9e1d-dfb24d0a949c"
      unitRef="usd">700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMjA5Mg_f96447dd-0dac-41cc-8d60-6a94b9845313"
      unitRef="usd">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMjA5OQ_8bd9d238-95fe-46ac-815b-59701a03750d"
      unitRef="usd">300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RleHRyZWdpb246MjIxOWFmMGQ1OTM2NGVjYzhhNmJhZDFhNDlmM2MyZGVfMjE3Mw_f8b408ac-3339-464d-bd3c-d428d88647e2">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the RSU activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding at September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i97535b68d960495f906585585e65538d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmFjMmJkMDgzMWFiNjQ3YzViY2FiYzFkNzY4NjY1YjYwL3RhYmxlcmFuZ2U6YWMyYmQwODMxYWI2NDdjNWJjYWJjMWQ3Njg2NjViNjBfMS0xLTEtMS0w_b3e20854-41bb-47ed-b729-d2c1449e001b"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i97535b68d960495f906585585e65538d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmFjMmJkMDgzMWFiNjQ3YzViY2FiYzFkNzY4NjY1YjYwL3RhYmxlcmFuZ2U6YWMyYmQwODMxYWI2NDdjNWJjYWJjMWQ3Njg2NjViNjBfMS0zLTEtMS0w_56fd9ca9-87b7-4b3d-bfa9-d21467335a09"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i97535b68d960495f906585585e65538d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmFjMmJkMDgzMWFiNjQ3YzViY2FiYzFkNzY4NjY1YjYwL3RhYmxlcmFuZ2U6YWMyYmQwODMxYWI2NDdjNWJjYWJjMWQ3Njg2NjViNjBfMS01LTEtMS0w_942993f8-a5ef-4e28-a0a4-b171e7a22883"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i91c5fecaa1c64c49ad9e64d6f08ce782_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmFjMmJkMDgzMWFiNjQ3YzViY2FiYzFkNzY4NjY1YjYwL3RhYmxlcmFuZ2U6YWMyYmQwODMxYWI2NDdjNWJjYWJjMWQ3Njg2NjViNjBfMi0xLTEtMS0w_6def0ff7-9d8e-46e1-98f8-e75b2dc1bc8b"
      unitRef="shares">179951</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i91c5fecaa1c64c49ad9e64d6f08ce782_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmFjMmJkMDgzMWFiNjQ3YzViY2FiYzFkNzY4NjY1YjYwL3RhYmxlcmFuZ2U6YWMyYmQwODMxYWI2NDdjNWJjYWJjMWQ3Njg2NjViNjBfMi0zLTEtMS0w_d2352132-779e-4789-8144-7808db00ef20"
      unitRef="usdPerShare">6.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <ocgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted
      contextRef="i91c5fecaa1c64c49ad9e64d6f08ce782_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmFjMmJkMDgzMWFiNjQ3YzViY2FiYzFkNzY4NjY1YjYwL3RhYmxlcmFuZ2U6YWMyYmQwODMxYWI2NDdjNWJjYWJjMWQ3Njg2NjViNjBfMi01LTEtMS0w_53adfac6-c248-4264-a194-6f7d164af89e"
      unitRef="usd">1280000</ocgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i91c5fecaa1c64c49ad9e64d6f08ce782_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmFjMmJkMDgzMWFiNjQ3YzViY2FiYzFkNzY4NjY1YjYwL3RhYmxlcmFuZ2U6YWMyYmQwODMxYWI2NDdjNWJjYWJjMWQ3Njg2NjViNjBfMy0xLTEtMS0w_7f24e97e-26cc-4fa0-8bba-8c4df0e7ae7c"
      unitRef="shares">900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i91c5fecaa1c64c49ad9e64d6f08ce782_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmFjMmJkMDgzMWFiNjQ3YzViY2FiYzFkNzY4NjY1YjYwL3RhYmxlcmFuZ2U6YWMyYmQwODMxYWI2NDdjNWJjYWJjMWQ3Njg2NjViNjBfMy0zLTEtMS0w_03391200-5593-437e-891b-aceff3a98f68"
      unitRef="usdPerShare">8.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <ocgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod
      contextRef="i91c5fecaa1c64c49ad9e64d6f08ce782_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmFjMmJkMDgzMWFiNjQ3YzViY2FiYzFkNzY4NjY1YjYwL3RhYmxlcmFuZ2U6YWMyYmQwODMxYWI2NDdjNWJjYWJjMWQ3Njg2NjViNjBfMy01LTEtMS0w_07a635ef-3c2e-4cc6-bea3-6ee31025d236"
      unitRef="usd">6000</ocgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ieee22d5c75984530a1d4feb9b3bd71e6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmFjMmJkMDgzMWFiNjQ3YzViY2FiYzFkNzY4NjY1YjYwL3RhYmxlcmFuZ2U6YWMyYmQwODMxYWI2NDdjNWJjYWJjMWQ3Njg2NjViNjBfNC0xLTEtMS0w_9f300bde-fe69-43b9-baf8-e43c43553113"
      unitRef="shares">179051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ieee22d5c75984530a1d4feb9b3bd71e6_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmFjMmJkMDgzMWFiNjQ3YzViY2FiYzFkNzY4NjY1YjYwL3RhYmxlcmFuZ2U6YWMyYmQwODMxYWI2NDdjNWJjYWJjMWQ3Njg2NjViNjBfNC0zLTEtMS0w_ab0e29bc-ae44-4522-addc-36e11f7cec5c"
      unitRef="usdPerShare">6.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="ieee22d5c75984530a1d4feb9b3bd71e6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182NC9mcmFnOjIyMTlhZjBkNTkzNjRlY2M4YTZiYWQxYTQ5ZjNjMmRlL3RhYmxlOmFjMmJkMDgzMWFiNjQ3YzViY2FiYzFkNzY4NjY1YjYwL3RhYmxlcmFuZ2U6YWMyYmQwODMxYWI2NDdjNWJjYWJjMWQ3Njg2NjViNjBfNC01LTEtMS0w_78293f10-b8a3-46ad-a57c-00641d54c07a"
      unitRef="usd">1286000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RleHRyZWdpb246OWVlNjEyOGE1OTRmNDRjZDhlMjI3MDk2M2U1MjE3ZTlfNDAz_25014c38-f45b-4a7f-be9f-a1de25b22dfa">Net Loss Per Share of Common Stock&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per share for the three and nine months ended September&#160;30, 2021 and 2020 (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss &#x2014; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deemed dividend related to Warrant Exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,546)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in calculating net loss per common share &#x2014; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,790,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,591,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,599,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,764,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per common share &#x2014; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding, as their inclusion would have been antidilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,518,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,268,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,518,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,268,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred Stock (as converted to common stock)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Convertible Preferred Stock (as converted to common stock)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,194,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,138,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,194,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,138,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RleHRyZWdpb246OWVlNjEyOGE1OTRmNDRjZDhlMjI3MDk2M2U1MjE3ZTlfNDA0_25424df8-8961-4759-aaa2-db5c4441f553">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per share for the three and nine months ended September&#160;30, 2021 and 2020 (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss &#x2014; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deemed dividend related to Warrant Exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,546)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in calculating net loss per common share &#x2014; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,790,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,591,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,599,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,764,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per common share &#x2014; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfMi0xLTEtMS0w_750dfbb2-dfe1-49fa-bfb2-8434f2856693"
      unitRef="usd">-10755000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfMi0zLTEtMS0w_8d40be6f-f19a-49b7-8700-98bd2dab7904"
      unitRef="usd">-10474000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfMi01LTEtMS0w_1b52db52-cb9f-4ab6-a660-39acca5cdee5"
      unitRef="usd">-43784000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfMi03LTEtMS0w_bf1fe4cd-3b92-489e-a4c0-debde0693e5e"
      unitRef="usd">-18032000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfMy0xLTEtMS0w_e45aa646-d9c5-4de3-bae2-2333a008da39"
      unitRef="usd">0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfMy0zLTEtMS0w_f0be2921-13a4-4198-b50d-4e8193cf18f1"
      unitRef="usd">0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfMy01LTEtMS0w_59ab5fa0-0142-4c79-8be1-18c40db49945"
      unitRef="usd">0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfMy03LTEtMS0w_fbdfd729-fbab-4720-975f-8387df7f112f"
      unitRef="usd">12546000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNC0xLTEtMS0w_500605f3-65b2-421b-a348-1b71c6ebff24"
      unitRef="usd">-10755000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNC0xLTEtMS0w_b918c329-d165-4bb1-92cf-f909415cfc4f"
      unitRef="usd">-10755000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNC0zLTEtMS0w_3227bfaf-183c-41f0-b0fe-930969676b8c"
      unitRef="usd">-10474000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNC0zLTEtMS0w_9675abcb-bce7-46cd-ba2b-d1bf3001bf57"
      unitRef="usd">-10474000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNC01LTEtMS0w_36cc12c6-696c-4143-8dc5-5e8ff6167490"
      unitRef="usd">-43784000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNC01LTEtMS0w_74aea869-2ef4-4139-8339-75ad024e2d62"
      unitRef="usd">-43784000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNC03LTEtMS0w_589db492-afe3-44e5-b65d-1da464e5c336"
      unitRef="usd">-30578000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNC03LTEtMS0w_5d5e406f-bbac-48be-8536-09c3c330c170"
      unitRef="usd">-30578000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNS0xLTEtMS0w_94723c6b-5dc0-4e12-8c1a-103d0fc166e9"
      unitRef="shares">198790980</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNS0xLTEtMS0w_979c7182-f8b0-4e98-94ef-4edd3761803f"
      unitRef="shares">198790980</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNS0zLTEtMS0w_73fa6ab4-600f-4eed-99e4-74acb81353c0"
      unitRef="shares">141591218</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNS0zLTEtMS0w_b837220e-4303-427e-8b70-e7c1d094a46b"
      unitRef="shares">141591218</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNS01LTEtMS0w_48dee16f-10e7-4957-a751-ec7a9bdf6eb3"
      unitRef="shares">193599525</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNS01LTEtMS0w_5d939db3-f73e-4f25-ab13-0a21127c94c7"
      unitRef="shares">193599525</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNS03LTEtMS0w_0423dcc1-8943-40fb-b4df-30b004313f5f"
      unitRef="shares">92764157</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNS03LTEtMS0w_cb9ffc46-cb70-4ad4-b768-7d3c2c99b8c8"
      unitRef="shares">92764157</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNi0xLTEtMS0w_61701a2b-38a1-4fe9-8640-23fc1d18d05e"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNi0xLTEtMS0w_b988e84d-7ab9-4dbc-9c28-3fa5744c6439"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNi0zLTEtMS0w_157021aa-6201-4780-91f8-2c0f64ffc8a6"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNi0zLTEtMS0w_8fc9e1d4-b981-40b1-87b0-975f6289a0fe"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNi01LTEtMS0w_0bfd0435-fd9b-4968-99c4-aca5c7b3b7fe"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNi01LTEtMS0w_fe83490f-df9b-4cf6-ac37-7830b480b85f"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNi03LTEtMS0w_6b4910bd-4daf-43b3-9aa0-89469d64366a"
      unitRef="usdPerShare">-0.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOmM1NzA0MGUwY2M1NzQyMTI5ZDY3ZWMzNjBjZGM3OWM3L3RhYmxlcmFuZ2U6YzU3MDQwZTBjYzU3NDIxMjlkNjdlYzM2MGNkYzc5YzdfNi03LTEtMS0w_e1ea5883-5895-42cb-8a6b-4cdd19688d9e"
      unitRef="usdPerShare">-0.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RleHRyZWdpb246OWVlNjEyOGE1OTRmNDRjZDhlMjI3MDk2M2U1MjE3ZTlfNDA2_4424af15-d7d0-4ed5-ace1-ce11d7cc3408">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding, as their inclusion would have been antidilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,518,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,268,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,518,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,268,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred Stock (as converted to common stock)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Convertible Preferred Stock (as converted to common stock)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,194,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,138,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,194,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,138,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4a2d954d52484db09e819f3e3cd26b4b_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfMi0xLTEtMS0w_e3997be7-fc26-4edd-84ad-8fb0440a048a"
      unitRef="shares">10518263</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6eef00380be74ee2b45ff66ba9497e4c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfMi0zLTEtMS0w_58a9589d-b6b4-41f4-888e-570b397f6785"
      unitRef="shares">4268277</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i21ed7d9935d24634bdbfe1f4c69a732b_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfMi01LTEtMS0w_d470744d-073e-4583-9d8c-c19a84ee39eb"
      unitRef="shares">10518263</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3904f01ad36d4b3796750e5c00692693_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfMi03LTEtMS0w_38598dd1-53e5-4fd3-8da3-c616ac27d9a5"
      unitRef="shares">4268277</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7d1c263247244eaaa85b9923b449d851_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfMy0xLTEtMS0w_1c07ca18-1050-4be3-8c21-116a28fbcb96"
      unitRef="shares">179051</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i89a977d9b97c40d9bc231523d757c614_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfMy0zLTEtMS0w_d27070dc-942d-499b-82d9-bdda9e5845f4"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if8bcebbd1f9f4a1fa9c7f2ecc3c2a2b4_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfMy01LTEtMS0w_7f2af3f7-9c69-40a5-bf1b-f0be01d1d44c"
      unitRef="shares">179051</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifb2b6076d55a4c4fbc505ce09032f9ec_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfMy03LTEtMS0w_1ad04b87-30c3-405e-bbd2-b7510ff97216"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaeb64bda41ad44658c1917090d93aee7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNC0xLTEtMS0w_35da35b0-67f8-42f8-8216-5ee22c9b2650"
      unitRef="shares">946179</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i42cfc7b660d247bca3e1269304b94198_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNC0zLTEtMS0w_617dafac-8321-458a-afca-cb1450bc19f7"
      unitRef="shares">870017</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibb9ae3b6217944d08b6ef5b9486ae59c_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNC01LTEtMS0w_ee689824-e0a4-496d-b167-5ac5681c2499"
      unitRef="shares">946179</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia60015f8c05f4fb2a0ff02e090d1939c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNC03LTEtMS0w_100821a9-0f46-471c-aeb5-5edb6883d2a9"
      unitRef="shares">870017</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0e6344f1ce2a45b3b3086bff6d187fd7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNS0xLTEtMS0w_6d83e4c5-03a4-4424-9d06-b6e89c2cf47f"
      unitRef="shares">3115</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i04f8d6a8b17d410195fd2437e938b245_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNS0zLTEtMS0w_9f97db0f-78aa-4e4c-90f7-00d02eb33f11"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1226d893b7c34174b451b927f02c2ad5_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNS01LTEtMS0w_36fb0787-6ba2-49af-ad6a-5bc1a6bdffe7"
      unitRef="shares">3115</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4aa5009a02d54151a673eb8679eca4f3_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNS03LTEtMS0w_109731c8-7c28-4311-97f2-b457b6b7206c"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5dfb43b76ce743459ec23fb4489a7d43_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNi0xLTEtMS0w_b5e36d63-b1d0-4cbd-be4a-f3bb63a0078b"
      unitRef="shares">547450</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ife7f80154864442eb1f4fff86b29fb57_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNi0zLTEtMS0w_7de745e1-1bad-4c78-bc41-3906c1b7ee10"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia634f5e3056b43e9a810bc77f3d0f942_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNi01LTEtMS0w_205e5a70-4041-423c-a6f1-0a91eea40deb"
      unitRef="shares">547450</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i656ac6e78d97406398ff128f89376446_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNi03LTEtMS0w_ebb159fb-c89e-4285-8a1b-6369db621b1a"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaa7ec21690a84b519c8521689d101b83_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNy0xLTEtMS0w_0aa456b9-c61b-4946-b2e5-93105b26f1b7"
      unitRef="shares">12194058</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idcc60dad254140709cd5d25fc29bac9c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNy0zLTEtMS0w_e9bb8383-213d-47d6-9f1b-7e8ee79a4cb7"
      unitRef="shares">5138294</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNy01LTEtMS0w_8c8a5d44-bb27-4a62-9626-1bc9a34db9a1"
      unitRef="shares">12194058</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i744ac9ce9ab84ad798a41967823df857_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N182Ny9mcmFnOjllZTYxMjhhNTk0ZjQ0Y2Q4ZTIyNzA5NjNlNTIxN2U5L3RhYmxlOjU1MDRmZmJjNTZiMjQ5NmU4OTc0OTczNDJmYzAyNDE5L3RhYmxlcmFuZ2U6NTUwNGZmYmM1NmIyNDk2ZTg5NzQ5NzM0MmZjMDI0MTlfNy03LTEtMS0w_6a125ca4-4c18-48ea-9a3f-de92d97ad111"
      unitRef="shares">5138294</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N183MC9mcmFnOmI0NDQyYWNjMGZhMDRjZmY4NDlhNmIzNjgzNzM3NTFlL3RleHRyZWdpb246YjQ0NDJhY2MwZmEwNGNmZjg0OWE2YjM2ODM3Mzc1MWVfMjgwMQ_ac665305-f250-454e-b731-0eebabbdbdc5">Commitments and Contingencies&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has commitments under certain license agreements, lease agreements, debt agreements, separation agreements, and consulting agreements. Commitments under certain license agreements primarily include annual payments, payments upon the achievement of certain milestones, and royalty payments based on net sales of licensed products. Commitments under the Company's licensing agreements are more fully described within Note 3 and within the Company's 2020 Annual Report. Commitments under lease agreements are future minimum lease payments for operating leases. See Note 6 and Note 14 for additional information about commitments under lease agreements. Commitments under debt agreements are the future payment of principal and accrued interest under the EB-5 Loan Agreement. See Note 8 for additional information about commitments under debt agreements. Commitments under separation agreements are severance payments to be paid throughout the remainder of 2021 as a result of the reduction in force in connection with the Company's discontinuation of a product candidate. See Note 7 for additional information about commitments under separation agreements. Commitments under consulting agreements include payments upon the achievement of certain milestones related to COVAXIN. See Note 10 for additional information about commitments under consulting agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 17, 2021, a securities class action lawsuit was filed against the Company and certain of its officers and directors in the U.S. District Court for the Eastern District of Pennsylvania (Case No. 2:21-cv-02725) that purported to state a claim for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, based on statements made by the Company concerning the announcement of the Company's decision to pursue the submission of a BLA for COVAXIN for ages 18 years and older rather than pursuing EUA for the vaccine candidate. On July 16, 2021, a second securities class action was filed against the Company and certain of its officers and directors in the U.S. District Court for the Eastern District of Pennsylvania (Case No. 2:21-cv-03182) that also purported to state a claim for alleged violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder, based on the same statements as the first complaint. The complaints seek unspecified damages, interest, attorneys&#x2019; fees, and other costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 30, 2021, a stockholder derivative lawsuit was filed derivatively on behalf of the Company against certain of its officers and directors and the nominal defendant Ocugen in the U.S. District Court for the Eastern District of Pennsylvania (Case No. 2:21-cv-03876) that purported to state a claim for breach of fiduciary duty and contribution for violations of Sections 10(b) and 21(d) of the Exchange Act, based on facts and circumstances relating to the securities class action lawsuits and seeking contribution and indemnification in connection with claims asserted in the securities class action lawsuits. On September 22, 2021, a second stockholder derivative lawsuit was filed derivatively on behalf of the Company against certain of its officers and directors and the nominal defendant Ocugen in the U.S. District Court for the Eastern District of Pennsylvania (Case No. 2:21-cv-04169) that purported to state a claim for breach of fiduciary duties, unjust enrichment, abuse of control, waste of corporate assets, and contribution for violations of Sections 10(b) and 21(d) of the Exchange Act, based on the same allegations as the first complaint. The parties to both stockholder derivative lawsuits have stipulated to the consolidation of the two stockholder derivative lawsuits and also have submitted to the court in each action a proposed order requesting a stay of the litigation pending a decision on any motion to dismiss filed in the securities class action lawsuits, which remains pending before each court, and this status could change.&lt;/span&gt;&lt;/div&gt;The Company believes that the lawsuits are without merit and intends to vigorously defend against them. At this time, no assessment can be made as to their likely outcome or whether the outcome will be material to the Company. No information is available to indicate that it is probable that a loss has been incurred and can be reasonably estimated as of the date of the condensed consolidated financial statements and, as such, no accrual for the loss has been recorded within the condensed consolidated financial statements.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i52d9db304374467785253218ec6f15f0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xMTM4L2ZyYWc6N2FkMTA3ZWI3NTlmNGEyY2EwNTJjMzBlN2NjYWQ3ZmEvdGV4dHJlZ2lvbjo3YWQxMDdlYjc1OWY0YTJjYTA1MmMzMGU3Y2NhZDdmYV8zODQ4MjkwNjk4Mjkw_ce39f265-4498-4e9b-bc72-040f77be6623">Subsequent EventsOn October 15, 2021, the Company entered into a lease agreement for additional office space located in Malvern, Pennsylvania. The lease has an expected commencement date in 2022 and has an initial term of seven years. The aggregate estimated base rent payments due over the initial seven year term are $3.8&#160;million. Additionally, the Company will be responsible for the operating expenses and utilities associated with the leased premises. The Company has the option to extend the lease agreement for two additional five year terms, provided the Company is not under an event of default pursuant to the terms of the lease agreement</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i9c6b3eaa0af149b0b68069f2bcf0750e_I20211015"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xMTM4L2ZyYWc6N2FkMTA3ZWI3NTlmNGEyY2EwNTJjMzBlN2NjYWQ3ZmEvdGV4dHJlZ2lvbjo3YWQxMDdlYjc1OWY0YTJjYTA1MmMzMGU3Y2NhZDdmYV8yMTk5MDIzMjU2NTY0_554703eb-8aa7-40c9-a11d-40f55a1d5777">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i9c6b3eaa0af149b0b68069f2bcf0750e_I20211015"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xMTM4L2ZyYWc6N2FkMTA3ZWI3NTlmNGEyY2EwNTJjMzBlN2NjYWQ3ZmEvdGV4dHJlZ2lvbjo3YWQxMDdlYjc1OWY0YTJjYTA1MmMzMGU3Y2NhZDdmYV8zODQ4MjkwNzAyMjY0_6b46a6f4-2098-4eb9-b789-a40dac2cc5dc">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ocgn:BaseRentPaymentsExpectedCost
      contextRef="i9c6b3eaa0af149b0b68069f2bcf0750e_I20211015"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xMTM4L2ZyYWc6N2FkMTA3ZWI3NTlmNGEyY2EwNTJjMzBlN2NjYWQ3ZmEvdGV4dHJlZ2lvbjo3YWQxMDdlYjc1OWY0YTJjYTA1MmMzMGU3Y2NhZDdmYV8yMTk5MDIzMjU2MjE3_abae822d-76fd-4d43-ad69-6373dfeae9df"
      unitRef="usd">3800000</ocgn:BaseRentPaymentsExpectedCost>
    <ocgn:NumberOfAdditionalLeaseAgreementExtensions
      contextRef="i1801f4052b89458296349d07431dc823_D20211015-20211015"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xMTM4L2ZyYWc6N2FkMTA3ZWI3NTlmNGEyY2EwNTJjMzBlN2NjYWQ3ZmEvdGV4dHJlZ2lvbjo3YWQxMDdlYjc1OWY0YTJjYTA1MmMzMGU3Y2NhZDdmYV8zODQ4MjkwNzAyMjM2_5fdda312-33fc-4c2a-8cf8-e6a255e55834"
      unitRef="extension">2</ocgn:NumberOfAdditionalLeaseAgreementExtensions>
    <ocgn:LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement
      contextRef="i1801f4052b89458296349d07431dc823_D20211015-20211015"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18xMTM4L2ZyYWc6N2FkMTA3ZWI3NTlmNGEyY2EwNTJjMzBlN2NjYWQ3ZmEvdGV4dHJlZ2lvbjo3YWQxMDdlYjc1OWY0YTJjYTA1MmMzMGU3Y2NhZDdmYV8zODQ4MjkwNzAyMjc5_5e8d563b-19da-4ebf-a5f0-2395653555cf">P5Y</ocgn:LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557996489288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Nov. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OCUGEN, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3522315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">263 Great Valley Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Malvern<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">328-4701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OCGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,185,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001372299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557981045288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 107,349<span></span>
</td>
<td class="nump">$ 24,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Advance for COVAXIN supply</a></td>
<td class="nump">4,988<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,113<span></span>
</td>
<td class="nump">1,839<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">113,450<span></span>
</td>
<td class="nump">25,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">1,052<span></span>
</td>
<td class="nump">633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,659<span></span>
</td>
<td class="nump">714<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">116,312<span></span>
</td>
<td class="nump">27,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,095<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">3,962<span></span>
</td>
<td class="nump">2,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligation</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,229<span></span>
</td>
<td class="nump">3,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease obligation, less current portion</a></td>
<td class="nump">1,280<span></span>
</td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long term debt, net</a></td>
<td class="nump">1,693<span></span>
</td>
<td class="nump">1,823<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">2,973<span></span>
</td>
<td class="nump">2,212<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,202<span></span>
</td>
<td class="nump">5,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $0.01 par value; 295,000,000 and 200,000,000 shares authorized, 199,049,329 and 184,133,384 shares issued, and 198,927,829 and 184,011,884 shares outstanding at September&#160;30, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">1,990<span></span>
</td>
<td class="nump">1,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 121,500 shares at September&#160;30, 2021 and December&#160;31, 2020</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">222,253<span></span>
</td>
<td class="nump">93,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(117,086)<span></span>
</td>
<td class="num">(73,302)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">107,110<span></span>
</td>
<td class="nump">21,550<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">116,312<span></span>
</td>
<td class="nump">27,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock issued</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesOnInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesOnInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557980693560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">295,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">199,049,329<span></span>
</td>
<td class="nump">184,133,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">198,927,829<span></span>
</td>
<td class="nump">184,011,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">121,500<span></span>
</td>
<td class="nump">121,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">54,745<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">54,745<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557980276152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">6,281,000<span></span>
</td>
<td class="nump">1,478,000<span></span>
</td>
<td class="nump">28,006,000<span></span>
</td>
<td class="nump">4,760,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,508,000<span></span>
</td>
<td class="nump">1,704,000<span></span>
</td>
<td class="nump">15,450,000<span></span>
</td>
<td class="nump">5,760,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">10,789,000<span></span>
</td>
<td class="nump">10,182,000<span></span>
</td>
<td class="nump">43,456,000<span></span>
</td>
<td class="nump">17,520,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(10,789,000)<span></span>
</td>
<td class="num">(10,182,000)<span></span>
</td>
<td class="num">(43,456,000)<span></span>
</td>
<td class="num">(17,477,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(19,000)<span></span>
</td>
<td class="num">(292,000)<span></span>
</td>
<td class="num">(59,000)<span></span>
</td>
<td class="num">(555,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(336,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(18,000)<span></span>
</td>
<td class="num">(292,000)<span></span>
</td>
<td class="num">(380,000)<span></span>
</td>
<td class="num">(555,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(10,807,000)<span></span>
</td>
<td class="num">(10,474,000)<span></span>
</td>
<td class="num">(43,836,000)<span></span>
</td>
<td class="num">(18,032,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">(52,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(52,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">(10,755,000)<span></span>
</td>
<td class="num">(10,474,000)<span></span>
</td>
<td class="num">(43,784,000)<span></span>
</td>
<td class="num">(18,032,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(10,755,000)<span></span>
</td>
<td class="num">(10,474,000)<span></span>
</td>
<td class="num">(43,784,000)<span></span>
</td>
<td class="num">(18,032,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Deemed dividend related to Warrant Exchange</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,546,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss to common stockholders</a></td>
<td class="num">$ (10,755,000)<span></span>
</td>
<td class="num">$ (10,474,000)<span></span>
</td>
<td class="num">$ (43,784,000)<span></span>
</td>
<td class="num">$ (30,578,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in calculating net loss per common share - basic (in shares)</a></td>
<td class="nump">198,790,980<span></span>
</td>
<td class="nump">141,591,218<span></span>
</td>
<td class="nump">193,599,525<span></span>
</td>
<td class="nump">92,764,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating net loss per common share - diluted (in shares)</a></td>
<td class="nump">198,790,980<span></span>
</td>
<td class="nump">141,591,218<span></span>
</td>
<td class="nump">193,599,525<span></span>
</td>
<td class="nump">92,764,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock - basic (in USD per share)</a></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock - diluted (in USD per share)</a></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123385629&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557903993528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series B Preferred Stock</div></th>
<th class="th"><div>At-the-market Issuance</div></th>
<th class="th"><div>Registered Direct Offering</div></th>
<th class="th"><div>Subscription Agreements and Warrant Exercises</div></th>
<th class="th">
<div>Preferred Stock </div>
<div>Series A Preferred Stock</div>
</th>
<th class="th">
<div>Preferred Stock </div>
<div>Series B Preferred Stock</div>
</th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th">
<div>Common&#160;Stock </div>
<div>At-the-market Issuance</div>
</th>
<th class="th">
<div>Common&#160;Stock </div>
<div>Registered Direct Offering</div>
</th>
<th class="th">
<div>Common&#160;Stock </div>
<div>Subscription Agreements and Warrant Exercises</div>
</th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Series B Preferred Stock</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>At-the-market Issuance</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Registered Direct Offering</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Subscription Agreements and Warrant Exercises</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">52,746,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 11,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (48)<span></span>
</td>
<td class="nump">$ 62,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (51,480)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,944)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,944)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">52,746,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">7,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">62,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,424)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">52,746,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">11,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">62,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,480)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,032)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">162,147,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">14,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">82,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,512)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">52,746,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">7,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">62,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,424)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,132,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,328,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_StockIssuedDuringPeriodSharesWarrantExchange', window );">Warrant Exchange (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,920,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_StockIssuedDuringPeriodValueWarrantExchange', window );">Warrant Exchange</a></td>
<td class="num">(4,978)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,614)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,614)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">135,128,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">14,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">72,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59,038)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,019,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(10,474)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,474)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">162,147,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">14,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">82,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,512)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">184,133,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">21,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">93,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,302)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for option exercises</a></td>
<td class="nump">176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">987,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,954<span></span>
</td>
<td class="nump">$ 4,849<span></span>
</td>
<td class="nump">$ 21,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,953<span></span>
</td>
<td class="nump">$ 4,839<span></span>
</td>
<td class="nump">$ 21,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,077)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,077)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">54,745<span></span>
</td>
<td class="nump">188,277,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">46,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">125,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80,379)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">184,133,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 21,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">93,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,302)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for option exercises (in shares)</a></td>
<td class="nump">901,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (43,784)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">54,745<span></span>
</td>
<td class="nump">199,049,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">107,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">222,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(117,086)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">54,745<span></span>
</td>
<td class="nump">188,277,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">46,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">125,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80,379)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">2,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised', window );">Issuance of common stock for option and warrant exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">538,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_StockIssuedDuringPeriodValueOptionsAndWarrantsExercised', window );">Issuance of common stock for option and warrant exercises</a></td>
<td class="nump">371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(25,952)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,952)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">54,745<span></span>
</td>
<td class="nump">198,816,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">116,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">220,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(106,331)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for option exercises</a></td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(10,755)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,755)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">54,745<span></span>
</td>
<td class="nump">199,049,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 107,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (48)<span></span>
</td>
<td class="nump">$ 222,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (117,086)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Options And Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_StockIssuedDuringPeriodSharesWarrantExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrant Exchange</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_StockIssuedDuringPeriodSharesWarrantExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_StockIssuedDuringPeriodValueOptionsAndWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Options And Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_StockIssuedDuringPeriodValueOptionsAndWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_StockIssuedDuringPeriodValueWarrantExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrant Exchange</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_StockIssuedDuringPeriodValueWarrantExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557981658648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (43,784,000)<span></span>
</td>
<td class="num">$ (18,032,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">151,000<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_NonCashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">59,000<span></span>
</td>
<td class="nump">555,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">143,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">4,275,000<span></span>
</td>
<td class="nump">497,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxCreditsAndAdjustments', window );">Income tax benefit</a></td>
<td class="num">(52,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on forgiveness of PPP Note</a></td>
<td class="num">(426,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForLoanLossesExpensed', window );">Impairment on note receivable</a></td>
<td class="nump">761,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(166,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">845,000<span></span>
</td>
<td class="nump">796,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">2,925,000<span></span>
</td>
<td class="num">(1,133,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_IncreaseDecreaseInLeaseObligations', window );">Lease obligations</a></td>
<td class="num">(191,000)<span></span>
</td>
<td class="num">(144,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(35,137,000)<span></span>
</td>
<td class="num">(10,426,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(747,000)<span></span>
</td>
<td class="num">(56,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Asset acquisition</a></td>
<td class="num">(127,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_IssuanceOfFinancingReceivable', window );">Issuance of note receivable</a></td>
<td class="num">(750,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,624,000)<span></span>
</td>
<td class="num">(56,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">128,606,000<span></span>
</td>
<td class="nump">26,693,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of equity issuance costs</a></td>
<td class="num">(8,525,000)<span></span>
</td>
<td class="num">(1,084,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">921,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,362,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing lease principal payments</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="num">(18,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">120,071,000<span></span>
</td>
<td class="nump">22,144,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">83,310,000<span></span>
</td>
<td class="nump">11,662,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">24,190,000<span></span>
</td>
<td class="nump">7,595,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">107,500,000<span></span>
</td>
<td class="nump">19,257,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="nump">603,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Series B Convertible Preferred Stock issuance</a></td>
<td class="nump">4,988,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_GainLossOnForgivenessOfPaycheckProtectionProgramNote', window );">Forgiveness of PPP Note</a></td>
<td class="nump">426,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset', window );">Right-of-use asset related to operating leases</a></td>
<td class="nump">926,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Issuance of Warrant Exchange Promissory Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,625,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Obligation settled with common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">331,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost', window );">Equity issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_GainLossOnForgivenessOfPaycheckProtectionProgramNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Forgiveness Of Paycheck Protection Program Note</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_GainLossOnForgivenessOfPaycheckProtectionProgramNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_IncreaseDecreaseInLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Lease Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_IncreaseDecreaseInLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_IssuanceOfFinancingReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Financing Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_IssuanceOfFinancingReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of non-cash interest expense during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash or part noncash amount of deferred transaction cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-to-use asset recognized upon adoption of ASU 2018-11.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxCreditsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxCreditsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForLoanLossesExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of credit loss expense (reversal of expense) for financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForLoanLossesExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557979494872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text">Nature of Business<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ocugen, Inc., together with its wholly owned subsidiaries (&#8220;Ocugen&#8221; or the &#8220;Company&#8221;), is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The Company is headquartered in Malvern, Pennsylvania, and manages its business as one operating segment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Vaccine</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company entered into a Co-Development, Supply and Commercialization Agreement with Bharat Biotech International Limited ("Bharat Biotech"), pursuant to which the Company obtained an exclusive right and license under certain of Bharat Biotech's intellectual property rights, with the right to grant sublicenses to develop, manufacture, and commercialize BBV152, known as COVAXIN outside the United States, for the prevention of COVID-19 caused by SARS-CoV-2 in humans in the United States, its territories, and possessions. In June 2021, the Company entered into an amendment to the Co-Development, Supply and Commercialization Agreement (as so amended, the "Covaxin Agreement") pursuant to which the parties agreed to expand the Company's rights to develop, manufacture, and commercialize COVAXIN to include Canada in addition to the United States, its territories, and possessions (the &#8220;Ocugen Covaxin Territory&#8221;).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus, an antigen, and an adjuvant. COVAXIN requires a two-dose vaccination regimen given 28 days apart and is stored in standard vaccine storage conditions (2-8&#176;C). COVAXIN has been authorized for emergency use in India for ages 18 years and older. In November 2021, COVAXIN was awarded an Emergency Use Listing ("EUL") by the World Health Organization ("WHO").</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company announced that COVAXIN demonstrated an overall vaccine efficacy against COVID-19 disease of 77.8%, with efficacy against severe COVID-19 disease of 93.4%, and efficacy against asymptomatic COVID-19 disease of 63.6% in the Phase 3 clinical trial conducted by Bharat Biotech in India. Adverse events in the COVAXIN and control arms of the Phase 3 clinical trial were observed in 12.4% of subjects, with less than 0.5% of subjects experiencing serious adverse side effects. The majority of the symptomatic cases identified in aggregate in the COVAXIN and control arms in the Phase 3 clinical trial were COVID-19 variants, the majority of which were identified to be the Delta variant, B.1.617.2. Subjects vaccinated with COVAXIN in the Phase 3 clinical trial showed protection against the Delta variant, B.1.617.2, showing a vaccine efficacy of 65.2%. Additionally, in in-vitro studies conducted by the Indian Council of Medical Research ("ICMR") &#8212; National Institute of Virology, COVAXIN demonstrated potential effectiveness against the Zeta variant, B.1.1.28.2, the Alpha variant, B.1.1.7, and the Beta variant, B.1.351.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the U.S. Food and Drug Administration (the "FDA") provided feedback to the Company regarding the data and information contained in a "Master File" that was previously submitted to the FDA and recommended that the Company pursue a Biologics License Application ("BLA") submission instead of an Emergency Use Authorization ("EUA") application for COVAXIN for ages 18 years and older in the United States. As part of the feedback provided by the FDA regarding the "Master File," the FDA also requested additional information and data. The Company has continued discussions with the FDA regarding the appropriate regulatory pathway for COVAXIN for ages 18 years and older in the United States as well as the data requirements for COVAXIN under a BLA submission. In October 2021, the Company filed an Investigational New Drug ("IND") application with the FDA to initiate a Phase 3 immuno-bridging study evaluating COVAXIN for ages 18 years and older. The Company will also initiate a safety-bridging study under the IND, if required by the FDA, to support a BLA submission. The Company anticipates filing a BLA submission with the FDA by the end of 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company submitted a request to the FDA for EUA for COVAXIN for pediatric use in children ages two to 18 years in the United States. The EUA submission was based on the results of a Phase 2/3 immuno-bridging pediatric clinical trial conducted by Bharat Biotech in India.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also pursuing approval for COVAXIN in Canada. In July 2021, the Company announced it had completed its rolling submission to Health Canada for COVAXIN. The rolling submission process, which permits companies to submit safety and efficacy data and information as they become available, was recommended and accepted under the Minister of Health&#8217;s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the "Interim Order") and transitioned to a New Drug Submission ("NDS") for COVID-19. The submission was conducted through the </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company's Canadian affiliate, Vaccigen, Ltd. ("Vaccigen"). The Interim Order expired on September 16, 2021. The expiration of the Interim Order has not impacted the Company's NDS.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is evaluating its commercialization strategy for COVAXIN in the United States and Canada, if authorized or approved in either jurisdiction. In June 2021, the Company selected Jubilant HollisterStier as its manufacturing partner for COVAXIN to prepare for the potential commercial manufacturing for the Ocugen Covaxin Territory. The Company expects to enter into a master services agreement with Jubilant HollisterStier for the manufacture of COVAXIN and the technology transfer process to Jubilant HollisterStier has been initiated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into a Development and Commercial Supply Agreement (the &#8220;Supply Agreement&#8221;) with Bharat Biotech, pursuant to which </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bharat Biotech will supply the Company with clinical trial materials and commercial supplies of COVAXIN finished drug product prior to the completion of the Company&#8217;s technology transfer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jubilant HollisterStier</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Following the completion of the Company&#8217;s technology transfer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jubilant HollisterStier</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bharat Biotech will supply COVAXIN drug product components and continue to supply finished drug product as necessary for commercial manufacture and supply of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVAXIN </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent to a regulatory authorization or approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Modifier Gene Therapy Platform</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is developing a breakthrough modifier gene therapy platform to generate therapies designed to fulfill unmet medical needs in the area of retinal diseases, including inherited retinal diseases ("IRDs") and dry age-related macular degeneration ("AMD"). The Company's modifier gene therapy platform is based on nuclear hormone receptors (&#8220;NHRs&#8221;), which have the potential to restore homeostasis, the basic biological processes in the retina. Unlike single-gene replacement therapies, which only target one genetic mutation, the Company believes that its gene therapy platform, through its use of NHRs, represents a novel approach in that it may address multiple retinal diseases with one product.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that OCU400, its first product candidate being developed with its modifier gene therapy platform, has the potential to be broadly effective in restoring retinal integrity and function across a range of genetically diverse IRDs, including retinitis pigmentosa ("RP") and leber congenital amaurosis ("LCA"). OCU400 has received four Orphan Drug Designations ("ODDs") from the FDA for the treatment of certain disease genotypes: nuclear receptor subfamily 2 group E member 3 ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NR2E3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"), centrosomal protein 290 ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CEP290</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"), rhodopsin ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RHO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"), and phosphodiesterase 6B ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PDE6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#223;") mutation-associated inherited retinal degenerations. In November 2021, the Company filed an IND application with the FDA for OCU400 for the treatment of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NR2E3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RHO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disease genotypes. The Company is planning to initiate a Phase 1/2 clinical trial for OCU400 for the treatment of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NR2E3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RHO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disease genotypes in the United States near the end of 2021. OCU400 additionally has received Orphan Medicinal Product Designation ("OMPD") from the European Commission ("EC"), based on the recommendation of the European Medicines Agency ("EMA"), for RP and LCA, which the Company believes further supports the potential broad spectrum application of OCU400 to treat many IRDs. The Company is currently evaluating options to commence OCU400 clinical trials in Europe in 2022. The Company's second gene therapy candidate, OCU410, is being developed to utilize the nuclear receptor genes RAR-related orphan receptor A ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RORA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">") for the treatment of dry AMD. The Company is currently executing IND-enabling preclinical studies to support a Phase 1/2 clinical trial. The Company has engaged CanSino Biologics, Inc. ("CanSinoBIO") to manufacture clinical supplies and be responsible for the chemistry, manufacturing, and controls ("CMC") development for OCU400 and OCU410. See Note 3 for additional information about the Company's collaboration with CanSinoBIO.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novel Biologic Therapy for Retinal Diseases</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's biologic product candidate, OCU200, is a novel fusion protein being developed to treat diabetic macular edema ("DME"), diabetic retinopathy ("DR"), and wet AMD. The Company is currently executing IND-enabling preclinical studies to support a Phase 1 clinical trial. The Company has completed the technology transfer of manufacturing processes to the Company's contract development and manufacturing organization ("CDMO") that will manufacture OCU200 clinical supplies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred recurring net losses since inception and has funded its operations to date through the sale of common stock, warrants to purchase common stock, the issuance of convertible notes, debt, and grant proceeds. The Company incurred net losses of approximately $43.8&#160;million and $18.0&#160;million for the nine months ended September 30, 2021 and 2020, respectively. As of September&#160;30, 2021, the Company had an accumulated deficit of $117.1&#160;million and cash, cash equivalents, and restricted cash totaling $107.5&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a limited operating history and its prospects are subject to risks, expenses, and uncertainties frequently encountered by companies in its industry. The Company intends to continue its research, development, and commercialization efforts for its product candidates, which will require significant additional funding. If the Company is unable to obtain additional financing in the future or its research, development, and commercialization efforts require higher than anticipated capital, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital through public and private placements of equity and/or debt, payments from potential strategic research and development arrangements, sales of assets, government grants, licensing and/or collaboration arrangements with pharmaceutical companies or other institutions, or other funding from the government or other third parties. Such financing may not be available at all, or on terms that are favorable to the Company. While management of the Company believes that it has a plan to fund ongoing operations, its plan may not be successfully implemented. Failure to generate sufficient cash flows from operations, raise additional capital, or appropriately manage certain discretionary spending could have a material adverse effect on the Company&#8217;s ability to achieve its intended business objectives.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these factors, together with the anticipated increase in spending that will be necessary to continue to research, develop, and commercialize the Company&#8217;s product candidates, there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. The condensed consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557977896536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements included herein have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) and under the rules&#160;and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. The accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, that are necessary to present fairly the Company&#8217;s financial position, results of operations, and cash flows. The condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosures of the Company normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted under the SEC&#8217;s rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto for the year ended December&#160;31, 2020, included in the Company's Annual Report on Form 10-K filed with the SEC on March 19, 2021 (the "2020 Annual Report").</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of Ocugen and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform with current period presentation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the condensed consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions primarily include those used in the accounting for research and development accruals, the fair value measurement of equity instruments, and the collectibility of the note receivable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether collaboration agreements are subject to Financial Accounting Standards Board ("FASB") Accounting Standards Codification (&#8220;ASC&#8221;) Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;), based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of ASC 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner represent consideration from a customer, the Company accounts for those payments within the scope of FASB ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. However, if the Company concludes that its collaboration partner is not a customer, the Company will record royalty payments received as collaboration revenue in the period in which the underlying sale occurs and record expenses and expense reimbursements as either research and </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development expense or general and administrative expense, or a reduction thereof, based on the underlying nature of the expense or expense reimbursement. During the nine months ended September 30, 2020, the Company recorded collaboration revenue from an agreement accounted for as a collaborative arrangement within the scope of ASC 808. No collaboration revenue was recorded during the nine months ended September 30, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exit and Disposal Activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records liabilities for one-time termination benefits in accordance with FASB ASC Topic 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit and Disposal Cost Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 420"). In accordance with ASC 420, an arrangement for one-time termination benefits exists at the date the plan of the termination meets the following criteria: (i) management commits to a plan of termination, (ii) the plan identifies the impacted employees and expected completion date, (iii) the plan identifies the terms of the benefits arrangement, (iv) it is unlikely significant changes to the plan will be made or the plan will be withdrawn, and (v) the plan has been communicated to employees. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits, are recognized ratably over the future service period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records liabilities for employee termination benefits covered by ongoing benefit arrangements in accordance with FASB ASC Topic 712, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nonretirement Postemployment Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 712"). In accordance with ASC 712, costs for termination benefits under ongoing benefits arrangements are recognized when management has committed to a plan of termination and the costs are probable and estimable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance-related charges, once incurred, are recognized as either research and development expense or general and administrative expense within the condensed consolidated statements of operations and comprehensive loss depending on the job function of the former employee.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the provisions of FASB ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8212; quoted prices in active markets for identical assets or liabilities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8212; quoted prices for similar assets and liabilities in active markets or inputs that are observable</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8212; inputs that are unobservable (for example cash flow modeling inputs based on assumptions)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of certain financial instruments, including cash and cash equivalents, accounts payable, and accrued expenses approximates their fair values due to the short-term nature of these instruments. As of September&#160;30, 2021, the Company believes the fair value using Level 2 inputs of the borrowings under the EB-5 Loan Agreement (as defined in Note 8) approximate their carrying value. See Note 8 for additional information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash equivalents may include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposit, commercial paper, and U.S. government and U.S. government agency obligations. The Company&#8217;s restricted cash balance consists of cash held to collateralize a corporate credit card account.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash in the condensed consolidated balance sheets to the total amount shown in the condensed consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,257&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is recorded at historical cost. Significant additions or improvements are capitalized, and expenditures for repairs and maintenance are charged to expense as incurred. Gains and losses on disposal of assets are included in the condensed consolidated statements of operations and comprehensive loss. Depreciation is calculated using the straight-line method and is recognized over the expected useful life of the underlying asset. The Company's property and equipment currently includes furniture and fixtures, machinery and equipment, leasehold improvements, and construction in progress. The Company's furniture and fixtures have an expected useful life of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfNDM5ODA0NjU4MjIzNg_2f5f7cef-a3ff-41b9-b3bd-1ded51f7bc02">three</span> to seven years. The Company's machinery and equipment have an expected useful life of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfNDM5ODA0NjU4MjMwOQ_2aaf4aaa-5250-4fad-95da-0d6844c093cb">five</span> to seven years. Leasehold improvements are amortized over the shorter of their expected useful lives or the remaining lease term. If a leasehold improvement transfers ownership to the Company at the end of the lease term, the leasehold improvement is amortized over its expected useful life. Construction in progress is not depreciated until such time that the asset is completed and placed into service. Once placed into service, the asset is depreciated over its expected useful life.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company&#8217;s current and historical lease agreements include lease and non-lease components, which the Company has elected not to account for separately for all classes of underlying assets. Lease expense for variable lease components is recognized when the obligation is probable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases are included in other assets and operating lease obligations in the Company&#8217;s condensed consolidated balance sheets. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. Operating lease payments are recognized as lease expense on a straight-line basis over the lease term and recognized as research and development expense or general and administrative expense based on the underlying nature of the expense. The Company currently leases real estate classified as operating leases. FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 842") requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. The implicit interest rate was not readily determinable in the Company&#8217;s current and historical operating leases, therefore the incremental borrowing rate was used based on the information available at the commencement date in determining the present value of lease payments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease term for the Company&#8217;s leases includes the non-cancellable period of the lease plus any additional periods covered by either an option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease payments included in the measurement of the lease liability are comprised of fixed payments, variable payments that depend on index or rate, and amounts probable to be payable under the exercise of an option to purchase the underlying asset if reasonably certain.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable payments not dependent on an index or rate associated with the Company&#8217;s leases are recognized when the event, activity, or circumstance is probable. Variable payments include the Company's proportionate share of certain utilities and other operating expenses and are presented as operating expenses in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss in the same line item as expense arising from fixed payments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation &#8212; Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 718&#8221;). The Company has issued stock-based compensation awards including stock options and restricted stock units ("RSUs"), and also accounts for certain issuances of preferred stock and warrants in accordance with ASC 718. ASC 718 requires all stock-based payments, including grants of stock options and RSUs, to be recognized in the condensed consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options granted. For RSUs, the fair value of the RSUs is determined by the market price of a share of the Company's common stock at the grant date. The Company recognizes forfeitures as they occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to stock-based compensation awards granted with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Stock-based compensation awards generally vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTI5NTc_1b0f22b6-1741-4551-9fe9-ad65976104fa">one</span> to three year requisite service period and have a contractual term of 10 years. To the extent a stock-based compensation award is subject to performance-based vesting conditions, the amount of compensation expense recorded reflects an assessment of the probability of achieving the performance conditions. Compensation expense for stock-based compensation awards with performance-based vesting conditions is only recognized when the performance-based vesting condition is deemed probable to occur. Shares issued upon stock option exercise and RSU vesting are newly issued common shares.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of stock options requires the input of subjective assumptions, including the expected life of the stock option, stock price volatility, the risk-free interest rate, and expected dividends. The assumptions used in the Company&#8217;s Black-Scholes option-pricing model represent management&#8217;s best estimates and involve a number of variables, uncertainties, assumptions, and the application of management&#8217;s judgment, as they are inherently subjective. If any assumptions change, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Held for Sale</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company had an intangible asset held for sale that was carried at its original fair value less cost to sell of $7.0&#160;million. The Company concluded during the three and nine months ended September&#160;30, 2020, that a sale of the intangible asset was no longer probable to be completed within one year from the date the intangible asset was initially recorded as held for sale. As such, the carrying value of the intangible asset was reduced to zero with the corresponding charge of $7.0&#160;million recognized as in-process research and development expense in the condensed consolidated statements of operations and comprehensive loss during the three and nine months ended September&#160;30, 2020 as the in-process research and development did not have an alternative future use.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued Accounting Standards Update ("ASU") No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocations, and calculating income taxes in interim periods. This standard also adds guidance to reduce complexity in certain areas, including recognizing franchise tax, recognizing deferred taxes for the tax basis of goodwill, allocating taxes to the members of a consolidated group, and recognizing the effect of enacted changes in tax laws or rates during an interim period. This standard was effective for the Company on January 1, 2021. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share (Topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8212; Stock Compensation (Topic 718), and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard will have an effective and transition date of January 1, 2022. This standard clarifies and reduces diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options, including warrants, that remain equity-classified after modification or exchange. The standard requires an entity to treat a modification or an exchange of a freestanding equity-classified written call option that remains equity-classified after the modification or exchange as an exchange of the original instrument for a new instrument. The standard additionally provides guidance on measuring and recognizing the effect of a modification or an exchange. The Company does not currently expect the adoption of this standard to have a material impact on the Company's condensed consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt &#8212; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8212; Contracts in Entity's Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard will have an effective and transition date of January 1, 2024. Early adoption is currently permitted. This standard simplifies an issuer's accounting for convertible instruments by eliminating two of the three models that require separate accounting for embedded conversion features as well as simplifies the settlement assessment that entities are required to perform to determine whether a contract qualifies for equity classification. This standard also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of potential share settlement (if the effect is more dilutive) for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. The standard requires new disclosures about events that occur during the reporting period and cause conversion contingencies to be met and about the fair value of a public business entity's convertible debt at the instrument level, among other things. The Company does not currently expect the adoption of this standard to have a material impact on the Company's condensed consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8212; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The FASB subsequently issued amendments to ASU No. 2016-13, which have the same effective date and transition date of January 1, 2023. ASU No. 2016-13, as amended, requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company does not currently expect the adoption of this standard to have a material impact on the Company's condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557979533032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Development Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Development Agreements</a></td>
<td class="text">License and Development Agreements<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Co-Development, Supply and Commercialization Agreement with Bharat Biotech</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into the Covaxin Agreement with Bharat Biotech to co-develop COVAXIN, a whole-virion inactivated COVID-19 vaccine being developed to prevent COVID-19 infection, for the U.S. and Canadian markets. The Covaxin Agreement was originally entered into in February 2021 with respect to the U.S. market and was subsequently amended in June 2021 to add rights to the Canadian market. Pursuant to the Covaxin Agreement, the Company obtained an exclusive right and license under certain of Bharat Biotech&#8217;s intellectual property rights, with the right to grant sublicenses, to develop, manufacture, and commercialize COVAXIN in the Ocugen Covaxin Territory. In consideration of the license and other rights granted by Bharat Biotech to the Company, the parties agreed to share any profits generated from the commercialization of COVAXIN in the Ocugen Covaxin Territory, with the Company retaining 45% of such profits, and Bharat Biotech receiving the balance of such profits. In consideration of the expansion of the Ocugen Covaxin Territory to include Canada, the Company paid Bharat Biotech a non-refundable, upfront payment of $15.0&#160;million in June 2021, which was recognized as research and development expense in the condensed consolidated statements of operations and comprehensive loss during the nine months ended September 30, 2021. The Company additionally agreed to pay Bharat Biotech $10.0&#160;million within 30 days after the first commercial sale of COVAXIN in Canada. The Covaxin Agreement is a collaboration arrangement within the scope of ASC 808.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Covaxin Agreement, the Company and Bharat Biotech will collaborate to develop COVAXIN for their respective territories. Except with respect to manufacturing rights under certain circumstances subsequently described, the Company has the exclusive right and is solely responsible for researching, developing, manufacturing, and commercializing COVAXIN for the Ocugen Covaxin Territory. Bharat Biotech is responsible for researching, developing, manufacturing, and commercializing COVAXIN outside of the Ocugen Covaxin Territory. Bharat Biotech has agreed to provide to the Company all preclinical and clinical data, and to transfer to the Company certain proprietary technology owned or controlled by Bharat Biotech, that is necessary for the successful commercial manufacture and supply of COVAXIN to support commercial sale in the Ocugen Covaxin Territory. In September 2021, the Company entered into the Supply Agreement with Bharat Biotech, pursuant to which </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bharat Biotech will supply the Company with clinical trial materials and commercial supplies of COVAXIN finished drug product prior to the completion of the Company&#8217;s technology transfer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jubilant HollisterStier</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Following the completion of the Company&#8217;s technology transfer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jubilant HollisterStier</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bharat Biotech will supply COVAXIN drug product components and continue to supply finished drug product as necessary for commercial manufacture and supply of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVAXIN </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent to a regulatory authorization or approval. The technology transfer process to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jubilant HollisterStier has been initiated. In March 2021, the Company issued shares of Series B Convertible Preferred Stock (as defined in Note 9) as an advance payment for the supply of COVAXIN to be provided by Bharat Biotech under the Supply Agreement. See Note 9 for additional information about the Series B Convertible Preferred Stock issuance to Bharat Biotech. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Covaxin Agreement continues in effect for the commercial life of COVAXIN, subject to the earlier termination of the Covaxin Agreement in accordance with its terms. The Covaxin Agreement also contains customary representations and warranties made by both parties and customary provisions relating to indemnification, limitation of liability, confidentiality, information and data sharing, and other matters. The Supply Agreement expires upon expiration of the Covaxin Agreement and may be earlier terminated by either party in the event of an uncured material breach or bankruptcy of the other party.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Co-Development and Commercialization Agreement with CanSinoBIO</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company entered into a co-development and commercialization agreement with CanSinoBIO with respect to the development and commercialization of OCU400. The co-development and commercialization agreement was subsequently amended in September 2021 (as so amended, the "CanSinoBIO Agreement"), whereby OCU410 was added to the Company's existing collaboration with CanSinoBIO. Pursuant to the CanSinoBIO Agreement, the Company and CanSinoBIO will collaborate on the development of OCU400 and OCU410 and CanSinoBIO will be responsible for the CMC development and manufacture of clinical supplies of such products and be responsible for the costs associated with such activities. CanSinoBIO will have an exclusive option to obtain a non-exclusive license from the Company to manufacture OCU400 and OCU410 for commercial sale by the Company. CanSinoBIO has an exclusive license to develop, manufacture, and commercialize OCU400 and OCU410 in and for China, Hong Kong, Macau, and Taiwan (the &#8220;CanSinoBIO Territory&#8221;), and the Company maintains exclusive development, manufacturing, and commercialization rights with respect to OCU400 and OCU410 outside the CanSinoBIO Territory (the &#8220;Company Territory&#8221;).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CanSinoBIO will pay to the Company an annual royalty between mid- and high-single digits based on Net Sales (as defined in the CanSinoBIO Agreement) of OCU400 and OCU410 in the CanSinoBIO Territory. The Company will pay to CanSinoBIO an annual royalty between low- and mid-single digits based on Net Sales (as defined in the CanSinoBIO Agreement) of OCU400 and OCU410 in the Company Territory.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated in accordance with its terms, the CanSinoBIO Agreement will continue in force on a country-by-country and product-by-product basis until the later of (a) the expiration of the last valid claim of patent rights of the Company covering such products and (b) the 10th anniversary of the first commercial sale of such products in such country.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557977948216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Receivable<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock', window );">Notes Receivable</a></td>
<td class="text">Notes Receivable<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 13, 2021, the Company received a promissory note in the principal amount of $0.8&#160;million from a company in connection with a potential collaboration. The promissory note bore interest at a rate per annum of 5% and the outstanding principal balance of the promissory note plus any accrued and unpaid interest thereon was payable in full on April 13, 2022 (the "Maturity Date"). Effective July 2021, the Company accepted an amended and restated promissory note (as so amended and restated, the "Promissory Note") pursuant to which the parties agreed to extend the Maturity Date of the Promissory Note to June 30, 2022 and increase the interest rate per annum to 9% with quarterly interest payments. The Promissory Note may be prepaid in whole or in part at any time, together with accrued and unpaid interest. The Promissory Note contains customary covenants and events of default, including, among others, failure to make payment, breach of agreement, and bankruptcy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the probability of collecting the full principal and accrued interest balance under the terms of the Promissory Note and determined that collection was not probable. During the nine months ended September 30, 2021, the Company wrote off the full principal and accrued interest balance of the Promissory Note and recorded the write-off as a loss within other income (expense) within the condensed consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a company, excluding disclosure for allowance for credit losses. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Also excludes disclosure for financing receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557979580024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the major components of property and equipment as reflected on the condensed consolidated balance sheets (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,386&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,052&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized depreciation expense of $0.1 million and $0.2 million during the three and nine months ended September&#160;30, 2021, respectively. The Company recognized depreciation expense of $19.8&#160;thousand and $0.1&#160;million during the three and nine months ended September&#160;30, 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557977943528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text">Operating Leases<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has commitments under an operating lease for certain facilities used in its operations including for the use of laboratory, office, and storage space located in Malvern, Pennsylvania (the &#8220;Lease Agreement&#8221;). The Lease Agreement was determined to have two lease components per ASC 842, a laboratory space lease component (the "Initial Premises") and an office, storage, and future expanded laboratory space lease component (the "Expansion Premises"), with varying commencement dates. The Initial Premises commencement date occurred in December 2020 and the Expansion Premises commencement date occurred in January 2021. The Lease Agreement has an initial term of seven years and the Company has the option to extend the Lease Agreement for one additional five-year term. The option for extension has been excluded from the lease term (and lease liability) for the Lease Agreement as it is not reasonably certain that the Company will exercise such option. The Company terminated a former lease agreement for its previous office space with the same landlord without penalty upon the commencement of the Expansion Premises in January 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current lease obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental information related to leases was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term &#8212; operating leases (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate &#8212; operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum operating lease base rent payments are approximately as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of minimum lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to September&#160;30, 2021, the Company entered into a lease agreement for additional office space located in Malvern, Pennsylvania. See Note 14 for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557979533032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">Accrued Expenses and Other Current Liabilities<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research&#160;and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee-related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance-related (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,962&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,941&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) In June 2020, the Company communicated notice to five employees of the termination of their employment as a result of the discontinuation of a product candidate. This reduction represented one-third of the Company&#8217;s workforce at the time of communication. All terminations were &#8220;without cause&#8221; and each employee received termination benefits upon departure. The termination dates varied for each employee and ranged from June 30, 2020 to December 31, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized no severance-related charges and a de minimis amount of severance-related charges during the three and nine months ended September&#160;30, 2021, respectively. The Company recognized severance-related charges of $0.4 million and $1.1 million during the three and nine months ended September&#160;30, 2020, respectively. For the three months ended September 30, 2020, the Company recognized a de minimis amount of severance-related charges within general and administrative expense and $0.4 million of severance-related charges within research and development expense. For the nine months ended September 30, 2020, the Company recognized $0.2 million of severance-related charges within general and administrative expense and $0.9 million of severance-related charges within research and development expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made severance payments of $0.1&#160;million and $0.6&#160;million during the three and nine months ended September&#160;30, 2021, respectively. The Company made severance payments of $0.2 million during the three and nine months ended September&#160;30, 2020. The Company expects to pay the remaining severance benefits of $0.1&#160;million throughout the remainder of 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557977943528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the carrying values for the components of debt as reflected on the condensed consolidated balance sheets (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PPP Note</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EB-5 Loan Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,057&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PPP Note</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company was granted a loan from Silicon Valley Bank ("SVB"), in the amount of $0.4&#160;million, pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) of the Coronavirus Aid, Relief and Economic Security Act of 2020 (the &#8220;CARES Act&#8221;). Under the PPP, the loan was eligible for forgiveness to the extent the funds received were used for qualifying expenses as described by the CARES Act. The loan was in the form of a promissory note dated April 30, 2020 in favor of SVB (the "PPP Note"). The PPP Note had a maturity date of April 30, 2022 and bore interest at a rate of 1.0% per annum. The Company did not provide any collateral or guarantees for the loan, nor did the Company pay any facility charge to obtain the loan. The PPP Note provided for customary events of default, including, among others, failure to make payment, bankruptcy, breaches of representations, and material adverse events. In May 2021, the Company received notice from the Small Business Administration that the PPP Note was forgiven in its entirety, including both principal and accrued interest. The Company recognized a $0.4&#160;million gain on loan extinguishment within other income (expense) for the forgiveness of the PPP Note within the condensed consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EB-5 Loan Agreement</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September&#160;2016, pursuant to the U.S. government&#8217;s Immigrant Investor Program, commonly known as the EB-5 program (the &#8220;EB-5 Program&#8221;), the Company entered into an arrangement (the &#8220;EB-5 Loan Agreement&#8221;) to borrow up to $10.0&#160;million from EB5 Life Sciences,&#160;L.P. (&#8220;EB-5 Life Sciences&#8221;) in $0.5&#160;million increments. Borrowings may be limited by the amount of funds raised by EB-5 Life Sciences and are subject to certain job creation requirements by the Company. Borrowings are at a fixed interest rate of 4.0% per annum and are to be utilized in the clinical development, manufacturing, and commercialization of the Company&#8217;s product candidates and for the general working capital needs of the Company. Outstanding borrowings pursuant to the EB-5 Loan Agreement, including accrued interest, become due upon the seventh anniversary of the final disbursement. Amounts repaid cannot be re-borrowed. The EB-5 Loan Agreement borrowings are secured by substantially all assets of the Company, except for any patents, patent applications, pending patents, patent licenses, patent sublicenses, trademarks, and other intellectual property rights.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms and conditions of the EB-5 Loan Agreement, the Company borrowed $1.0 million in 2016 and an additional $0.5 million in March 2020. Issuance costs were recognized as a reduction to the loan balance and are amortized to interest expense over the term of the loan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of the EB-5 Loan Agreement borrowings as of September&#160;30, 2021 and December&#160;31, 2020 are summarized below (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal outstanding</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557980202776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text">Equity<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVAXIN Preferred Stock Purchase Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2021, the Company entered into a preferred stock purchase agreement, pursuant to which the Company agreed to issue and sell 0.1&#160;million shares of the Company&#8217;s Series B Convertible Preferred Stock, par value $0.01 per share (the &#8220;Series B Convertible Preferred Stock&#8221;), at a price per share equal to $109.60, to Bharat Biotech. On March 18, 2021, the Company issued the Series B Convertible Preferred Stock as an advance payment for the supply of COVAXIN to be provided by Bharat Biotech pursuant to the Supply Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Series B Convertible Preferred Stock is convertible, at the option of Bharat Biotech, into 10 shares of the Company&#8217;s common stock (the "Conversion Ratio") only after (i) the Company received stockholder approval to increase the number of authorized shares of common stock under its Sixth Amended and Restated Certificate of Incorporation and (ii) the Company&#8217;s receipt of shipments by Bharat Biotech of the first 10.0&#160;million doses of COVAXIN manufactured by Bharat Biotech pursuant to the Supply Agreement, and further on the terms and subject to the conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (the "Certificate of Designation"). In April 2021, the Company's stockholders approved an increase in the number of the Company's authorized shares of common stock from 200.0&#160;million to 295.0&#160;million. As of September&#160;30, 2021, the conversion condition relating to the delivery of the first 10.0&#160;million doses of COVAXIN had not been met. The conversion rate of the Series B Convertible Preferred Stock is subject to adjustment in the event of a stock dividend, stock split, reclassification, or similar event with respect to the Company&#8217;s common stock. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bharat Biotech is entitled to receive dividends on the Series B Convertible Preferred Stock equal (on an as-converted to common stock basis) to and in the same form as dividends actually paid on shares of common stock, when and if such dividends are paid. Except as provided by law and certain protective provisions set forth in the Certificate of Designation, the Series B Convertible Preferred Stock has no voting rights. Upon a liquidation or dissolution of the Company, holders of Series B Convertible Preferred Stock would be entitled to receive the same amount that a holder of common stock would receive if the Series B Convertible Preferred Stock were fully converted to common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for the issuance of the Series B Convertible Preferred Stock in accordance with ASC 718 and recorded the fair value of $5.0&#160;million within equity during the nine months ended September 30, 2021, with a corresponding short-term asset for the advanced payment for the doses of COVAXIN. The Company utilized the traded common stock price, adjusted by the Conversion Ratio, to value the Series B Convertible Preferred Stock and the Finnerty model to estimate a 15% discount rate for the lack of marketability of the instrument. The valuation incorporates Level 3 inputs in the fair value hierarchy, including the estimated time until the instrument's liquidity and the estimated volatility of the Company's common stock as of the grant date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Registered Direct Offerings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2021, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company agreed to issue and sell in a registered direct offering (the "April 2021 Registered Direct Offering") an aggregate of 10.0&#160;million shares of the Company's common stock at an offering price of $10.00 per share. The closing of the April 2021 Registered Direct Offering occurred on April 27, 2021 and the Company received net proceeds of $93.4&#160;million after deducting equity issuance costs of $6.6&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2021, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company agreed to issue and sell in a registered direct offering (the "February 2021 Registered Direct Offering") an aggregate of 3.0&#160;million shares of the Company's common stock at an offering price of $7.65 per share. The closing of the February 2021 Registered Direct Offering occurred on February 10, 2021 and the Company received net proceeds of $21.2&#160;million after deducting equity issuance costs of $1.7&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Offerings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company commenced three separate at-the-market offerings (each an "ATM", and collectively, the "ATMs") in May 2020, June 2020, and August 2020. The offerings were made pursuant to the Company's effective "shelf" registration statement on Form S-3 filed with the SEC on March 27, 2020, the base prospectus contained therein dated May 5, 2020, and the prospectus supplements related to the offerings dated May 8, 2020, June 12, 2020, and August 17, 2020. During the nine months ended September 30, 2021, the Company sold 1.0&#160;million shares of the Company's common stock under the August 2020 ATM and received net proceeds of $4.8&#160;million after deducting equity issuance costs of $0.1&#160;million. During the three and nine months </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended September&#160;30, 2020, the Company sold an aggregate of 27.0&#160;million and 86.2&#160;million shares of the Company's common stock under the ATMs, respectively. During the three months ended September 30, 2020, the Company received net proceeds of $10.1&#160;million after deducting equity issuance costs of $0.4&#160;million. During the nine months ended September 30, 2020, the Company received net proceeds of $25.6&#160;million after deducting equity issuance costs of $1.1&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subscription Agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into a subscription agreement with an accredited investor for the issuance of 1.3&#160;million shares of the Company's common stock in a private placement. The shares of common stock were issued as part of a transaction in settlement of an outstanding obligation of the Company to the accredited investor, in which (i) the Company agreed to make certain cash payments, (ii) the Company issued the 1.3&#160;million shares of the Company's common stock in exchange for the accredited investor's agreement to cancel $0.3&#160;million of the outstanding obligation, and (iii) the accredited investor agreed to cancel an additional portion of the amount owed by the Company representing a discount of $0.2&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company entered into a subscription agreement with an accredited investor for the issuance of 1,000 shares of the Company's common stock in a private placement for an aggregate offering price of $395 (the "April 2020 Subscription Agreement").</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557978149192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_WarrantsTextBlock', window );">Warrants</a></td>
<td class="text">Warrants<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Canada Warrants</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2021, the Company entered into a consulting agreement with an individual to provide services to the Company with regard to the Company's Canadian operations (the "Canada Consulting Agreement"). Compensation under the Canada Consulting Agreement includes, among other forms of compensation, the issuance of warrants to purchase up to 0.2&#160;million shares of the Company's common stock (the "Canada Warrants") and cash payments of up to $3.0&#160;million upon the achievement of certain milestones related to COVAXIN. The Canada Consulting Agreement terminates on July 15, 2023, unless earlier terminated in accordance with its terms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Canada Warrants were issued on July 15, 2021 in a private placement transaction. The warrantholder has the right to exercise the Canada Warrants to purchase up to 0.2 million shares of the Company's common stock at an exercise price of $6.36 per share upon the achievement of certain milestones related to COVAXIN. The Canada Warrants terminate on July 15, 2031, unless earlier terminated in accordance with their terms. As of September&#160;30, 2021, all of the Canada Warrants were outstanding and unvested. The Canada Warrants are accounted for in accordance with ASC 718.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SPA Warrants</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company issued three series of warrants to purchase shares of the Company&#8217;s common stock (the &#8220;Series A Warrants,&#8221; the &#8220;Series B Warrants&#8221;, and the &#8220;Series C Warrants&#8221; and collectively, the &#8220;SPA Warrants&#8221;) under a securities purchase agreement with certain accredited investors. In April 2020, the Company entered into the April 2020 Subscription Agreement, as discussed within Note 9, which represented a dilutive issuance as defined by the Series A Warrants and resulted in adjustments to the number of issuable Series A Warrants and the exercise price of the Series A Warrants. Immediately prior to the Company entering into the April 2020 Subscription Agreement, 8.8&#160;million Series A Warrants, 1,000 Series B Warrants, and 1,000 Series C Warrants were outstanding. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contemporaneously with the April 2020 Subscription Agreement, the Company and OpCo entered into Amendment and Exchange Agreements (each an "Exchange Agreement" and collectively, the "Exchange Agreements") with the accredited investors. Pursuant to the Exchange Agreements, the Company, OpCo, and the accredited investors agreed, among other things, after giving effect to the dilutive issuance, to amend the Series A Warrants to provide for an adjustment to the number of common stock issuable upon the exercise of the Series A Warrants. Concurrently with such amendments, the accredited investors exchanged the Series A Warrants for (i) an aggregate of 21.9&#160;million shares of the Company's common stock and (ii) promissory notes of $5.6&#160;million (the "Warrant Exchange Promissory Notes" and collectively with the common stock issued, the "Warrant Exchange"). During the three and nine months ended September&#160;30, 2020, the Company made payments to the Warrant Exchange Promissory Notes holders of $3.2&#160;million and $4.4&#160;million, respectively. As of December&#160;31, 2020, the Warrant Exchange Promissory Notes had been repaid in full. Immediately following the consummation of the Warrant Exchange and the concurrent exercise of the remaining Series B Warrants and Series C Warrants, there were no SPA Warrants outstanding.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for the Warrant Exchange by recognizing the fair value of the consideration transferred in excess of the carrying value of the Series A Warrants as a reduction of additional paid-in capital. The fair value of the Series A Warrants immediately prior to the Warrant Exchange was $1.1&#160;million, which was estimated using a Black-Scholes valuation model utilizing Level 3 inputs. The fair value of the consideration transferred to settle the Series A Warrants was approximately $13.6&#160;million, comprised of $8.6&#160;million in shares of the Company's common stock and the fair value of the Warrant Exchange Promissory Notes of $5.0&#160;million. The fair value of consideration transferred to settle the Series A Warrants was in excess of the fair value of the Series A Warrants immediately prior to the Warrant Exchange by approximately $12.5&#160;million. The excess consideration was accounted for as a deemed dividend to the Series A Warrant holders and was reflected as an additional net loss to common stockholders in the calculation of basic and diluted net loss per common share for the nine months ended September 30, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">OpCo Warrants</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2016, OpCo issued warrants to purchase the Company's common stock (the "OpCo Warrants") to investors of the Company pursuant to a stockholders' agreement and to two employees of the Company pursuant to their respective employment agreements. As of September&#160;30, 2021 and December&#160;31, 2020, 0.8 million and 0.9 million OpCo Warrants were outstanding, respectively. As of September&#160;30, 2021 the outstanding OpCo Warrants had a weighted-average exercise price of $4.97. The outstanding OpCo Warrants expire between 2026 and 2027.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_WarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_WarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557979444776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for stock options and RSUs is reflected in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,275&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense during the three and nine months ended September&#160;30, 2021 included $41.3&#160;thousand and $1.1 million of expense related to stock options with performance-based vesting conditions, respectively. No stock-based compensation expense during the three and nine months ended September&#160;30, 2020 was related to stock options with performance-based vesting conditions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company had $13.9&#160;million of unrecognized stock-based compensation expense related to stock options and RSUs outstanding. This expense is expected to be recognized over a weighted-average period of 2.2 years as of September&#160;30, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Plans</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains two equity compensation plans, the 2014 Ocugen OpCo, Inc. Stock Option Plan (the &#8220;2014 Plan&#8221;) and the Ocugen, Inc. 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;, collectively with the 2014 Plan, the "Plans"). As of September&#160;30, 2021, the 2014 Plan and 2019 Plan authorize for the granting of up to 0.8&#160;million and 11.5&#160;million equity awards in respect to the Company's common stock, respectively. In addition to stock options and RSUs granted under the Plans, the Company has granted certain stock options and RSUs as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4), which were granted outside of the Plans.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options to Purchase Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,224,433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,469,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(901,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274,220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,518,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991,429&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,629&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options not yet exercisable as of September&#160;30, 2021 includes 1.5&#160;million stock options with performance-based vesting conditions. There were no stock options with performance-based vesting conditions as of December&#160;31, 2020. The weighted-average grant date fair values of stock options granted during the three and nine months ended September&#160;30, 2021 were $5.97 and $2.77, respectively. The weighted-average grant date fair value of stock options granted during both the three and nine months ended September&#160;30, 2020 was $0.34 per share. The total fair values of stock options vested during the three and nine months ended September&#160;30, 2021 were $0.1&#160;million and $0.7&#160;million, respectively. The total fair values of stock options vested during the three and nine months ended September&#160;30, 2020 were $0.1&#160;million and $0.3&#160;million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSUs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the RSU activity:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(900)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,051&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.68&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557977918632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share of Common Stock</a></td>
<td class="text">Net Loss Per Share of Common Stock<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share for the three and nine months ended September&#160;30, 2021 and 2020 (in thousands, except share and per share amounts):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss &#8212; basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,755)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,474)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,784)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,032)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend related to Warrant Exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,546)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,755)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,474)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,784)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,578)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in calculating net loss per common share &#8212; basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,790,980&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,591,218&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,599,525&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,764,157&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share &#8212; basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.33)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding, as their inclusion would have been antidilutive:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,518,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,268,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,518,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,268,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock (as converted to common stock)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock (as converted to common stock)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,194,058&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,138,294&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,194,058&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,138,294&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557980163240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has commitments under certain license agreements, lease agreements, debt agreements, separation agreements, and consulting agreements. Commitments under certain license agreements primarily include annual payments, payments upon the achievement of certain milestones, and royalty payments based on net sales of licensed products. Commitments under the Company's licensing agreements are more fully described within Note 3 and within the Company's 2020 Annual Report. Commitments under lease agreements are future minimum lease payments for operating leases. See Note 6 and Note 14 for additional information about commitments under lease agreements. Commitments under debt agreements are the future payment of principal and accrued interest under the EB-5 Loan Agreement. See Note 8 for additional information about commitments under debt agreements. Commitments under separation agreements are severance payments to be paid throughout the remainder of 2021 as a result of the reduction in force in connection with the Company's discontinuation of a product candidate. See Note 7 for additional information about commitments under separation agreements. Commitments under consulting agreements include payments upon the achievement of certain milestones related to COVAXIN. See Note 10 for additional information about commitments under consulting agreements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 17, 2021, a securities class action lawsuit was filed against the Company and certain of its officers and directors in the U.S. District Court for the Eastern District of Pennsylvania (Case No. 2:21-cv-02725) that purported to state a claim for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, based on statements made by the Company concerning the announcement of the Company's decision to pursue the submission of a BLA for COVAXIN for ages 18 years and older rather than pursuing EUA for the vaccine candidate. On July 16, 2021, a second securities class action was filed against the Company and certain of its officers and directors in the U.S. District Court for the Eastern District of Pennsylvania (Case No. 2:21-cv-03182) that also purported to state a claim for alleged violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder, based on the same statements as the first complaint. The complaints seek unspecified damages, interest, attorneys&#8217; fees, and other costs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, a stockholder derivative lawsuit was filed derivatively on behalf of the Company against certain of its officers and directors and the nominal defendant Ocugen in the U.S. District Court for the Eastern District of Pennsylvania (Case No. 2:21-cv-03876) that purported to state a claim for breach of fiduciary duty and contribution for violations of Sections 10(b) and 21(d) of the Exchange Act, based on facts and circumstances relating to the securities class action lawsuits and seeking contribution and indemnification in connection with claims asserted in the securities class action lawsuits. On September 22, 2021, a second stockholder derivative lawsuit was filed derivatively on behalf of the Company against certain of its officers and directors and the nominal defendant Ocugen in the U.S. District Court for the Eastern District of Pennsylvania (Case No. 2:21-cv-04169) that purported to state a claim for breach of fiduciary duties, unjust enrichment, abuse of control, waste of corporate assets, and contribution for violations of Sections 10(b) and 21(d) of the Exchange Act, based on the same allegations as the first complaint. The parties to both stockholder derivative lawsuits have stipulated to the consolidation of the two stockholder derivative lawsuits and also have submitted to the court in each action a proposed order requesting a stay of the litigation pending a decision on any motion to dismiss filed in the securities class action lawsuits, which remains pending before each court, and this status could change.</span></div>The Company believes that the lawsuits are without merit and intends to vigorously defend against them. At this time, no assessment can be made as to their likely outcome or whether the outcome will be material to the Company. No information is available to indicate that it is probable that a loss has been incurred and can be reasonably estimated as of the date of the condensed consolidated financial statements and, as such, no accrual for the loss has been recorded within the condensed consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557979499464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsOn October 15, 2021, the Company entered into a lease agreement for additional office space located in Malvern, Pennsylvania. The lease has an expected commencement date in 2022 and has an initial term of seven years. The aggregate estimated base rent payments due over the initial seven year term are $3.8&#160;million. Additionally, the Company will be responsible for the operating expenses and utilities associated with the leased premises. The Company has the option to extend the lease agreement for two additional five year terms, provided the Company is not under an event of default pursuant to the terms of the lease agreement<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557981305752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements included herein have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) and under the rules&#160;and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. The accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, that are necessary to present fairly the Company&#8217;s financial position, results of operations, and cash flows. The condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosures of the Company normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted under the SEC&#8217;s rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto for the year ended December&#160;31, 2020, included in the Company's Annual Report on Form 10-K filed with the SEC on March 19, 2021 (the "2020 Annual Report").</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">The condensed consolidated financial statements include the accounts of Ocugen and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform with current period presentation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the condensed consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions primarily include those used in the accounting for research and development accruals, the fair value measurement of equity instruments, and the collectibility of the note receivable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Arrangements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether collaboration agreements are subject to Financial Accounting Standards Board ("FASB") Accounting Standards Codification (&#8220;ASC&#8221;) Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;), based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of ASC 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner represent consideration from a customer, the Company accounts for those payments within the scope of FASB ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. However, if the Company concludes that its collaboration partner is not a customer, the Company will record royalty payments received as collaboration revenue in the period in which the underlying sale occurs and record expenses and expense reimbursements as either research and </span></div>development expense or general and administrative expense, or a reduction thereof, based on the underlying nature of the expense or expense reimbursement. During the nine months ended September 30, 2020, the Company recorded collaboration revenue from an agreement accounted for as a collaborative arrangement within the scope of ASC 808. No collaboration revenue was recorded during the nine months ended September 30, 2021.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock', window );">Exit and Disposal Activities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exit and Disposal Activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records liabilities for one-time termination benefits in accordance with FASB ASC Topic 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit and Disposal Cost Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 420"). In accordance with ASC 420, an arrangement for one-time termination benefits exists at the date the plan of the termination meets the following criteria: (i) management commits to a plan of termination, (ii) the plan identifies the impacted employees and expected completion date, (iii) the plan identifies the terms of the benefits arrangement, (iv) it is unlikely significant changes to the plan will be made or the plan will be withdrawn, and (v) the plan has been communicated to employees. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits, are recognized ratably over the future service period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records liabilities for employee termination benefits covered by ongoing benefit arrangements in accordance with FASB ASC Topic 712, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nonretirement Postemployment Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 712"). In accordance with ASC 712, costs for termination benefits under ongoing benefits arrangements are recognized when management has committed to a plan of termination and the costs are probable and estimable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance-related charges, once incurred, are recognized as either research and development expense or general and administrative expense within the condensed consolidated statements of operations and comprehensive loss depending on the job function of the former employee.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the provisions of FASB ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8212; quoted prices in active markets for identical assets or liabilities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8212; quoted prices for similar assets and liabilities in active markets or inputs that are observable</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8212; inputs that are unobservable (for example cash flow modeling inputs based on assumptions)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of certain financial instruments, including cash and cash equivalents, accounts payable, and accrued expenses approximates their fair values due to the short-term nature of these instruments. As of September&#160;30, 2021, the Company believes the fair value using Level 2 inputs of the borrowings under the EB-5 Loan Agreement (as defined in Note 8) approximate their carrying value. See Note 8 for additional information.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash equivalents may include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposit, commercial paper, and U.S. government and U.S. government agency obligations. The Company&#8217;s restricted cash balance consists of cash held to collateralize a corporate credit card account.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is recorded at historical cost. Significant additions or improvements are capitalized, and expenditures for repairs and maintenance are charged to expense as incurred. Gains and losses on disposal of assets are included in the condensed consolidated statements of operations and comprehensive loss. Depreciation is calculated using the straight-line method and is recognized over the expected useful life of the underlying asset. The Company's property and equipment currently includes furniture and fixtures, machinery and equipment, leasehold improvements, and construction in progress. The Company's furniture and fixtures have an expected useful life of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfNDM5ODA0NjU4MjIzNg_2f5f7cef-a3ff-41b9-b3bd-1ded51f7bc02">three</span> to seven years. The Company's machinery and equipment have an expected useful life of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfNDM5ODA0NjU4MjMwOQ_2aaf4aaa-5250-4fad-95da-0d6844c093cb">five</span> to seven years. Leasehold improvements are amortized over the shorter of their expected useful lives or the remaining lease term. If a leasehold improvement transfers ownership to the Company at the end of the lease term, the leasehold improvement is amortized over its expected useful life. Construction in progress is not depreciated until such time that the asset is completed and placed into service. Once placed into service, the asset is depreciated over its expected useful life.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company&#8217;s current and historical lease agreements include lease and non-lease components, which the Company has elected not to account for separately for all classes of underlying assets. Lease expense for variable lease components is recognized when the obligation is probable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases are included in other assets and operating lease obligations in the Company&#8217;s condensed consolidated balance sheets. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. Operating lease payments are recognized as lease expense on a straight-line basis over the lease term and recognized as research and development expense or general and administrative expense based on the underlying nature of the expense. The Company currently leases real estate classified as operating leases. FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 842") requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. The implicit interest rate was not readily determinable in the Company&#8217;s current and historical operating leases, therefore the incremental borrowing rate was used based on the information available at the commencement date in determining the present value of lease payments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease term for the Company&#8217;s leases includes the non-cancellable period of the lease plus any additional periods covered by either an option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease payments included in the measurement of the lease liability are comprised of fixed payments, variable payments that depend on index or rate, and amounts probable to be payable under the exercise of an option to purchase the underlying asset if reasonably certain.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable payments not dependent on an index or rate associated with the Company&#8217;s leases are recognized when the event, activity, or circumstance is probable. Variable payments include the Company's proportionate share of certain utilities and other operating expenses and are presented as operating expenses in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss in the same line item as expense arising from fixed payments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation &#8212; Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 718&#8221;). The Company has issued stock-based compensation awards including stock options and restricted stock units ("RSUs"), and also accounts for certain issuances of preferred stock and warrants in accordance with ASC 718. ASC 718 requires all stock-based payments, including grants of stock options and RSUs, to be recognized in the condensed consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options granted. For RSUs, the fair value of the RSUs is determined by the market price of a share of the Company's common stock at the grant date. The Company recognizes forfeitures as they occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to stock-based compensation awards granted with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Stock-based compensation awards generally vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlmZjM0OGYxY2ExMDRlYzU5OGEzNWM2MWZhOWZjOTc3L3NlYzo5ZmYzNDhmMWNhMTA0ZWM1OThhMzVjNjFmYTlmYzk3N18zNy9mcmFnOmRiODkwYzIwYWIwZjQxMjViNDcwM2U3NDc3ZGUxYzQyL3RleHRyZWdpb246ZGI4OTBjMjBhYjBmNDEyNWI0NzAzZTc0NzdkZTFjNDJfMTI5NTc_1b0f22b6-1741-4551-9fe9-ad65976104fa">one</span> to three year requisite service period and have a contractual term of 10 years. To the extent a stock-based compensation award is subject to performance-based vesting conditions, the amount of compensation expense recorded reflects an assessment of the probability of achieving the performance conditions. Compensation expense for stock-based compensation awards with performance-based vesting conditions is only recognized when the performance-based vesting condition is deemed probable to occur. Shares issued upon stock option exercise and RSU vesting are newly issued common shares.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of stock options requires the input of subjective assumptions, including the expected life of the stock option, stock price volatility, the risk-free interest rate, and expected dividends. The assumptions used in the Company&#8217;s Black-Scholes option-pricing model represent management&#8217;s best estimates and involve a number of variables, uncertainties, assumptions, and the application of management&#8217;s judgment, as they are inherently subjective. If any assumptions change, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_AssetHeldForSalePolicyTextBlock', window );">Asset Held for Sale</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Held for Sale</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company had an intangible asset held for sale that was carried at its original fair value less cost to sell of $7.0&#160;million. The Company concluded during the three and nine months ended September&#160;30, 2020, that a sale of the intangible asset was no longer probable to be completed within one year from the date the intangible asset was initially recorded as held for sale. As such, the carrying value of the intangible asset was reduced to zero with the corresponding charge of $7.0&#160;million recognized as in-process research and development expense in the condensed consolidated statements of operations and comprehensive loss during the three and nine months ended September&#160;30, 2020 as the in-process research and development did not have an alternative future use.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards and Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued Accounting Standards Update ("ASU") No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocations, and calculating income taxes in interim periods. This standard also adds guidance to reduce complexity in certain areas, including recognizing franchise tax, recognizing deferred taxes for the tax basis of goodwill, allocating taxes to the members of a consolidated group, and recognizing the effect of enacted changes in tax laws or rates during an interim period. This standard was effective for the Company on January 1, 2021. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share (Topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8212; Stock Compensation (Topic 718), and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard will have an effective and transition date of January 1, 2022. This standard clarifies and reduces diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options, including warrants, that remain equity-classified after modification or exchange. The standard requires an entity to treat a modification or an exchange of a freestanding equity-classified written call option that remains equity-classified after the modification or exchange as an exchange of the original instrument for a new instrument. The standard additionally provides guidance on measuring and recognizing the effect of a modification or an exchange. The Company does not currently expect the adoption of this standard to have a material impact on the Company's condensed consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt &#8212; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8212; Contracts in Entity's Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard will have an effective and transition date of January 1, 2024. Early adoption is currently permitted. This standard simplifies an issuer's accounting for convertible instruments by eliminating two of the three models that require separate accounting for embedded conversion features as well as simplifies the settlement assessment that entities are required to perform to determine whether a contract qualifies for equity classification. This standard also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of potential share settlement (if the effect is more dilutive) for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. The standard requires new disclosures about events that occur during the reporting period and cause conversion contingencies to be met and about the fair value of a public business entity's convertible debt at the instrument level, among other things. The Company does not currently expect the adoption of this standard to have a material impact on the Company's condensed consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8212; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The FASB subsequently issued amendments to ASU No. 2016-13, which have the same effective date and transition date of January 1, 2023. ASU No. 2016-13, as amended, requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company does not currently expect the adoption of this standard to have a material impact on the Company's condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_AssetHeldForSalePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Held For Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_AssetHeldForSalePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557978158808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock', window );">Schedule of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash in the condensed consolidated balance sheets to the total amount shown in the condensed consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,257&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents, restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557978223800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Major Components of Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the major components of property and equipment as reflected on the condensed consolidated balance sheets (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,386&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,052&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557980381400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Expense</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental information related to leases was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term &#8212; operating leases (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate &#8212; operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock', window );">Supplemental Balance Sheet Information Related to Leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current lease obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum operating lease base rent payments are approximately as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of minimum lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information, Leases Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557979531624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research&#160;and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee-related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance-related (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,962&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,941&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) In June 2020, the Company communicated notice to five employees of the termination of their employment as a result of the discontinuation of a product candidate. This reduction represented one-third of the Company&#8217;s workforce at the time of communication. All terminations were &#8220;without cause&#8221; and each employee received termination benefits upon departure. The termination dates varied for each employee and ranged from June 30, 2020 to December 31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557979670808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the carrying values for the components of debt as reflected on the condensed consolidated balance sheets (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PPP Note</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EB-5 Loan Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,057&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of the EB-5 Loan Agreement borrowings as of September&#160;30, 2021 and December&#160;31, 2020 are summarized below (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal outstanding</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557997904792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense for Options Granted Reflected in the Consolidate Statement of Operations and Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for stock options and RSUs is reflected in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,275&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,224,433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,469,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(901,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274,220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,518,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991,429&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,629&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Share-based Payment Arrangement, Restricted Stock Unit, Activity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the RSU activity:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(900)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,051&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.68&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557979419800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share for the three and nine months ended September&#160;30, 2021 and 2020 (in thousands, except share and per share amounts):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss &#8212; basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,755)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,474)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,784)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,032)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend related to Warrant Exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,546)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,755)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,474)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,784)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,578)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in calculating net loss per common share &#8212; basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,790,980&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,591,218&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,599,525&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,764,157&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share &#8212; basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.33)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding, as their inclusion would have been antidilutive:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,518,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,268,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,518,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,268,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock (as converted to common stock)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock (as converted to common stock)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,194,058&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,138,294&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,194,058&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,138,294&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557981350584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>geneticMutation </div>
<div>product </div>
<div>dose </div>
<div>segment </div>
<div>orphan_drug_designation</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_NumberOfVaccinationDoseRegimen', window );">Number of vaccination dose regimen | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_VaccinationDoseRegimenDurationApart', window );">Vaccination dose regimen, duration apart</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_OverallVaccineEfficacyPercent', window );">Overall vaccine efficacy (percentage)</a></td>
<td class="nump">77.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_EfficacySevereCasesPercent', window );">Efficacy, severe cases (percentage)</a></td>
<td class="nump">93.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_EfficacyAsymptomaticInfectionPercent', window );">Efficacy, asymptomatic infection (percentage)</a></td>
<td class="nump">63.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_AdverseEventsSideEffectsPercent', window );">Adverse events, side effects (percentage)</a></td>
<td class="nump">12.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_AdverseEventsSeriousAdverseSideEffectsPercent', window );">Adverse events, serious adverse side effects (less than) (percentage)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_EfficacyAgainstDeltaVariantB16172Percent', window );">Efficacy against delta variant, B.1.617.2 (percentage)</a></td>
<td class="nump">65.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_SingleGeneReplacementTherapiesNumberOfGeneticMutationsTarget', window );">Single gene replacement therapies, number of genetic mutations target | geneticMutation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ModifierGeneTherapyPlatformNumberOfProducts', window );">Modifier gene therapy platform, number of products | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_NumberOfOrphanDrugDesignations', window );">Number of ODDs received (orphan drug designation) | orphan_drug_designation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,755<span></span>
</td>
<td class="nump">$ 25,952<span></span>
</td>
<td class="nump">$ 7,077<span></span>
</td>
<td class="nump">$ 10,474<span></span>
</td>
<td class="nump">$ 3,614<span></span>
</td>
<td class="nump">$ 3,944<span></span>
</td>
<td class="nump">$ 43,784<span></span>
</td>
<td class="nump">$ 18,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,500<span></span>
</td>
<td class="nump">$ 19,257<span></span>
</td>
<td class="nump">$ 24,190<span></span>
</td>
<td class="nump">$ 7,595<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_AdverseEventsSeriousAdverseSideEffectsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adverse Events, Serious Adverse Side Effects, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_AdverseEventsSeriousAdverseSideEffectsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_AdverseEventsSideEffectsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adverse Events, Side Effects, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_AdverseEventsSideEffectsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_EfficacyAgainstDeltaVariantB16172Percent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Efficacy Against Delta Variant, B.1.617.2, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_EfficacyAgainstDeltaVariantB16172Percent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_EfficacyAsymptomaticInfectionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Efficacy, Asymptomatic Infection, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_EfficacyAsymptomaticInfectionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_EfficacySevereCasesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Efficacy, Severe Cases, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_EfficacySevereCasesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ModifierGeneTherapyPlatformNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Modifier Gene Therapy Platform, Number of Products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ModifierGeneTherapyPlatformNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_NumberOfOrphanDrugDesignations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Orphan Drug Designations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_NumberOfOrphanDrugDesignations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_NumberOfVaccinationDoseRegimen">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Vaccination Dose Regimen</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_NumberOfVaccinationDoseRegimen</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_OverallVaccineEfficacyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Overall vaccine efficacy, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_OverallVaccineEfficacyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_SingleGeneReplacementTherapiesNumberOfGeneticMutationsTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Single Gene Replacement Therapies, Number Of Genetic Mutations Target</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_SingleGeneReplacementTherapiesNumberOfGeneticMutationsTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_VaccinationDoseRegimenDurationApart">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vaccination Dose Regimen, Duration Apart</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_VaccinationDoseRegimenDurationApart</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557977996648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 107,349<span></span>
</td>
<td class="nump">$ 24,039<span></span>
</td>
<td class="nump">$ 19,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash</a></td>
<td class="nump">$ 107,500<span></span>
</td>
<td class="nump">$ 24,190<span></span>
</td>
<td class="nump">$ 19,257<span></span>
</td>
<td class="nump">$ 7,595<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557981531336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>RECENT ACCOUNTING PRONOUNCEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Asset held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>RECENT ACCOUNTING PRONOUNCEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>RECENT ACCOUNTING PRONOUNCEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Machinery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>RECENT ACCOUNTING PRONOUNCEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>RECENT ACCOUNTING PRONOUNCEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>RECENT ACCOUNTING PRONOUNCEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Machinery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>RECENT ACCOUNTING PRONOUNCEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123398962&amp;loc=d3e400-110220<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123385629&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ocgn_MachineryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ocgn_MachineryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557980156760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Development Agreements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Covaxin Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_CollaborationAgreementUpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada', window );">Additional payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ocgn_CollaborationAgreementWithCansinoBiologicsMember', window );">Collaboration Agreement With Cansino Biologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_CollaborationAgreementTerm', window );">Collaboration Agreement Term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ocgn_COVAXINPreferredStockPurchaseAgreementMember', window );">COVAXIN Preferred Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_CollaborativeArrangementProfitsGeneratedSharedPercentage', window );">Profits generated, shared percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Additional Payment Within 30 Days Of First Commercial Sale In Canada</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_CollaborationAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_CollaborationAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_CollaborativeArrangementProfitsGeneratedSharedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Profits Generated, Shared, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_CollaborativeArrangementProfitsGeneratedSharedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ocgn_CollaborationAgreementWithCansinoBiologicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ocgn_CollaborationAgreementWithCansinoBiologicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ocgn_COVAXINPreferredStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ocgn_COVAXINPreferredStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557979625256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Receivable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Apr. 13, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_FinancingReceivableInterestRateStatedPercentage', window );">Promissory note, interest rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_FinancingReceivableInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Interest Rate, Stated Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_FinancingReceivableInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 79<br> -URI http://asc.fasb.org/extlink&amp;oid=124267575&amp;loc=SL82922352-210448<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 80<br> -URI http://asc.fasb.org/extlink&amp;oid=124267575&amp;loc=SL82922355-210448<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (1)<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (2)<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1404<br> -Paragraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557984012984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Financing lease right-of-use asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">1,386<span></span>
</td>
<td class="nump">859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less: accumulated depreciation</a></td>
<td class="num">(334)<span></span>
</td>
<td class="num">(226)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Total property and equipment, net</a></td>
<td class="nump">1,052<span></span>
</td>
<td class="nump">633<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">322<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">856<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557976452808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 19,800<span></span>
</td>
<td class="nump">$ 151,000<span></span>
</td>
<td class="nump">$ 58,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557977945256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Operating Leases (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>renewalOption</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Leases, term of contract (in years)</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_LesseeOperatingLeaseNumberOfRenewalTerms', window );">Operating lease, number of renewal terms</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_LesseeOperatingLeaseNumberOfRenewalTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number of Renewal Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_LesseeOperatingLeaseNumberOfRenewalTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557978083896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Operating Leases, Components Of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557976521640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Operating Leases, Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">$ 1,430<span></span>
</td>
<td class="nump">$ 434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current lease obligations</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current lease obligations</a></td>
<td class="nump">1,280<span></span>
</td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 1,452<span></span>
</td>
<td class="nump">$ 433<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557996297416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Operating Leases, Supplemental Information Related To Leases (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease terms&#8212;operating leases (years)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate&#8212;operating leases</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">7.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557980918424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Operating Leases, Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2021</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">1,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="num">(226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of minimum lease payments</a></td>
<td class="nump">$ 1,452<span></span>
</td>
<td class="nump">$ 433<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, after Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557996382808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>employee</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ResearchAndDevelopmentExpensesCurrent', window );">Research&#160;and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 512,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_AccruedLiabilitiesClinical', window );">Clinical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">585,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">585,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_AccruedLiabilitiesProfessionalFees', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee-related</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">963,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_AccruedSeveranceRelatedLiabilitiesCurrent', window );">Severance-related</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">422,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">422,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,962,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,962,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,941,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance-related charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees given notice of termination | employee</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected severance benefits to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance-related charges | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance-related charges | General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_AccruedLiabilitiesClinical">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Clinical</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_AccruedLiabilitiesClinical</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_AccruedLiabilitiesProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Professional Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_AccruedLiabilitiesProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_AccruedSeveranceRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Severance-Related Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_AccruedSeveranceRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557996755944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Summary of the Carrying Values for the Components of Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total carrying value of debt, net</a></td>
<td class="nump">$ 1,693<span></span>
</td>
<td class="nump">$ 2,057<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_PaycheckProtectionProgramLoanMember', window );">PPP Note | Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total carrying value of debt, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_EB5ProgramBorrowingsMember', window );">EB-5 Loan Agreement | Loans payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total carrying value of debt, net</a></td>
<td class="nump">$ 1,693<span></span>
</td>
<td class="nump">$ 1,636<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocgn_PaycheckProtectionProgramLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocgn_PaycheckProtectionProgramLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocgn_EB5ProgramBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocgn_EB5ProgramBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557981891256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - PPP Note (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="nump">$ 426<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_PaycheckProtectionProgramLoanMember', window );">PPP Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocgn_PaycheckProtectionProgramLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocgn_PaycheckProtectionProgramLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557984032936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - EB 5 Loan Agreement Borrowings (Details) - EB-5 Loan Agreement - Loans payable - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_LineOfCreditBorrowingEachDraw', window );">Borrowing increments</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Company borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_LineOfCreditBorrowingEachDraw">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of borrowing that can be borrowed each draw from a line of credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_LineOfCreditBorrowingEachDraw</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocgn_EB5ProgramBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocgn_EB5ProgramBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557993221528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Summary of the Carrying Values of the Loan Agreement Borrowings (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value</a></td>
<td class="nump">$ 1,693<span></span>
</td>
<td class="nump">$ 2,057<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_EB5ProgramBorrowingsMember', window );">EB-5 Loan Agreement | Loans payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal outstanding</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Plus: accrued interest</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Less: unamortized debt issuance costs</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value</a></td>
<td class="nump">$ 1,693<span></span>
</td>
<td class="nump">$ 1,636<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocgn_EB5ProgramBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocgn_EB5ProgramBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557980809480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details)<br> $ / shares in Units, dose in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 27, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 23, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 01, 2021 </div>
<div>dose </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 10, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 07, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>at-the-marketOffering</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>dose </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 29, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_NumberOfAtTheMarketOfferings', window );">Number of at-the-market offerings | at-the-marketOffering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Warrants | Level 3 | Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_PreferredStockMeasurementInput', window );">Preferred stock, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ocgn_COVAXINPreferredStockPurchaseAgreementMember', window );">COVAXIN Preferred Stock Purchase Agreement | Series B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction', window );">Agreement to sell, number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_SaleOfStockAgreementToSellPricePerShare', window );">Agreement to sell, price per share (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock, shares issued upon conversion (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_SupplyAgreementNumberOfDoses', window );">Supply agreement, number of doses | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ocgn_RegisteredDirectOfferingMember', window );">Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued and sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="nump">$ 93,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Commissions, fees and expenses</a></td>
<td class="nump">$ 6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ocgn_ControlledEquityOfferingSalesAgreementMember', window );">ATMs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued and sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">86,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="nump">$ 25,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Commissions, fees and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ocgn_SubscriptionAgreementsMember', window );">Subscription Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued and sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_SaleOfStockOutstandingObligationCancelledInExchangeForStock', window );">Accredited investors agreement to cancel outstanding obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_SaleOfStockAdditionalDebtCancelledInExchangeForStock', window );">Accredited investors agreement to cancel additional portion owed representing a discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_NumberOfAtTheMarketOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of At-The-Market Offerings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_NumberOfAtTheMarketOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_PreferredStockMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_PreferredStockMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_SaleOfStockAdditionalDebtCancelledInExchangeForStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Additional Debt Cancelled In Exchange For Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_SaleOfStockAdditionalDebtCancelledInExchangeForStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Agreement to Sell, Number of Shares Issued in Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_SaleOfStockAgreementToSellPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Agreement to Sell, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_SaleOfStockAgreementToSellPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_SaleOfStockOutstandingObligationCancelledInExchangeForStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Outstanding Obligation Cancelled In Exchange For Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_SaleOfStockOutstandingObligationCancelledInExchangeForStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_SupplyAgreementNumberOfDoses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supply Agreement, Number of Doses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_SupplyAgreementNumberOfDoses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ocgn_COVAXINPreferredStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ocgn_COVAXINPreferredStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ocgn_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ocgn_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ocgn_ControlledEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ocgn_ControlledEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ocgn_SubscriptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ocgn_SubscriptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557981117000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>seriesOfWarrant</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 15, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>employee</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_NumberOfSeriesOfWarrantsIssued', window );">Number of series of warrants issued | seriesOfWarrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrants | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrants</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocgn_WarrantExchangePromissoryNotesMember', window );">Warrant Exchange Promissory Notes | Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal outstanding</a></td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ocgn_WarrantsExchangedForCommonStockMember', window );">Warrants Exchanged For Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued and sold | shares</a></td>
<td class="nump">21,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_CanadaConsultingWarrantsMember', window );">Canada Consulting Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ClassOfWarrantOrRightExercisable', window );">Class of warrant or right, exercisable (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ClassOfWarrantOrRightExpectedMilestonePayment', window );">Expected milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Initial exercise price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesAWarrantsMember', window );">Series A Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants', window );">Fair value of consideration transferred to settle warrants</a></td>
<td class="nump">$ 13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock', window );">Consideration transferred, common stock</a></td>
<td class="nump">8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote', window );">Consideration transferred, warrant exchange promissory notes</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue', window );">Fair value of consideration transferred to settle warrants in excess of fair value of warrants</a></td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesBWarrantsMember', window );">Series B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesCWarrantsMember', window );">Series C Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_SPAWarrantsMember', window );">SPA Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_OpCoWarrantsMember', window );">OpCo Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ClassOfWarrantOrRightExercisable', window );">Class of warrant or right, exercisable (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Initial exercise price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_NumberOfFormerEmployeesWithWarrants', window );">Number of former employees with warrants | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Consideration Transferred In Excess Of Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ClassOfWarrantOrRightExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ClassOfWarrantOrRightExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ClassOfWarrantOrRightExpectedMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Expected Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ClassOfWarrantOrRightExpectedMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Fair Value Of Consideration Transferred To Settle Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Fair Value Of Consideration Transferred To Settle Warrants, Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Fair Value Of Consideration Transferred To Settle Warrants, Promissory Note</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_NumberOfFormerEmployeesWithWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Former Employees With Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_NumberOfFormerEmployeesWithWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_NumberOfSeriesOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Series of Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_NumberOfSeriesOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocgn_WarrantExchangePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocgn_WarrantExchangePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ocgn_WarrantsExchangedForCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ocgn_WarrantsExchangedForCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_CanadaConsultingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocgn_CanadaConsultingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocgn_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_SPAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocgn_SPAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocgn_OpCoWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocgn_OpCoWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557984383848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Compensation Expense for Options Granted (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,347<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">$ 4,275<span></span>
</td>
<td class="nump">$ 497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">840<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">2,957<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 507<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 1,318<span></span>
</td>
<td class="nump">$ 249<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557996381656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>segment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>segment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="nump">$ 1,347,000<span></span>
</td>
<td class="nump">$ 126,000<span></span>
</td>
<td class="nump">$ 4,275,000<span></span>
</td>
<td class="nump">$ 497,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense | $</a></td>
<td class="nump">$ 13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_NumberOfEquityCompensationPlans', window );">Number of equity compensation plans | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="nump">10,518,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,518,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,224,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options, grants in period, weighted average grant date fair value (in USD per share) | $ / shares</a></td>
<td class="nump">$ 5.97<span></span>
</td>
<td class="nump">$ 0.34<span></span>
</td>
<td class="nump">$ 2.77<span></span>
</td>
<td class="nump">$ 0.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Options, vested in period, fair value | $</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ocgn_A2014PlanMember', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for grant (in shares)</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ocgn_A2019PlanMember', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for grant (in shares)</a></td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense related to options outstanding, weighted average period for expense to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ocgn_ShareBasedPaymentArrangementPerformanceBasedOptionMember', window );">Share-based Payment Arrangement, Performance Based Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="nump">$ 41,300<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber', window );">Options not yet exercisable (in shares)</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_NumberOfEquityCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Equity Compensation Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_NumberOfEquityCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Not Yet Exercisable, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ocgn_A2014PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ocgn_A2014PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ocgn_A2019PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ocgn_A2019PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ocgn_ShareBasedPaymentArrangementPerformanceBasedOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ocgn_ShareBasedPaymentArrangementPerformanceBasedOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557980862936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule Options to Purchase Common Stock (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, options outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">4,224,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">7,469,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(901,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(274,220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, options outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">10,518,263<span></span>
</td>
<td class="nump">4,224,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">991,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance, weighted average exercise price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 0.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (in USD per share) | $ / shares</a></td>
<td class="nump">3.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised (in USD per share) | $ / shares</a></td>
<td class="nump">0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, cancelled (in USD per share) | $ / shares</a></td>
<td class="nump">2.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance, weighted average exercise price (in USD per share) | $ / shares</a></td>
<td class="nump">2.56<span></span>
</td>
<td class="nump">$ 0.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, options exercisable (in USD per share) | $ / shares</a></td>
<td class="nump">$ 1.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Beginning balance, weighted average remaining contractual life</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, options exercisable</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, beginning balance | $</a></td>
<td class="nump">$ 5,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, exercised | $</a></td>
<td class="nump">8,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue', window );">Aggregate intrinsic value, forfeited | $</a></td>
<td class="nump">1,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, ending balance | $</a></td>
<td class="nump">49,552<span></span>
</td>
<td class="nump">$ 5,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, options exercisable | $</a></td>
<td class="nump">$ 5,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited in Period, Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557984471784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of RSU Activity (Details) - RSUs<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance outstanding (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">179,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(900)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance outstanding (in shares) | shares</a></td>
<td class="nump">179,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant-Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in USD per share) | $ / shares</a></td>
<td class="nump">6.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in USD per share) | $ / shares</a></td>
<td class="nump">8.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 6.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Beginning balance | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted', window );">Aggregate intrinsic value, granted | $</a></td>
<td class="nump">1,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod', window );">Aggregate intrinsic value, forfeited | $</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Ending balance | $</a></td>
<td class="nump">$ 1,286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Forfeitures In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557981523272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock - Computation of basic and diluted earnings per share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss - basic and diluted</a></td>
<td class="num">$ (10,755)<span></span>
</td>
<td class="num">$ (25,952)<span></span>
</td>
<td class="num">$ (7,077)<span></span>
</td>
<td class="num">$ (10,474)<span></span>
</td>
<td class="num">$ (3,614)<span></span>
</td>
<td class="num">$ (3,944)<span></span>
</td>
<td class="num">$ (43,784)<span></span>
</td>
<td class="num">$ (18,032)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Deemed dividend related to Warrant Exchange</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,546)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss to common stockholders</a></td>
<td class="num">(10,755)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,474)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,784)<span></span>
</td>
<td class="num">(30,578)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss to common stockholders</a></td>
<td class="num">$ (10,755)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,474)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (43,784)<span></span>
</td>
<td class="num">$ (30,578)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in calculating net loss per common share - basic (in shares)</a></td>
<td class="nump">198,790,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,591,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,599,525<span></span>
</td>
<td class="nump">92,764,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating net loss per common share - diluted (in shares)</a></td>
<td class="nump">198,790,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,591,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,599,525<span></span>
</td>
<td class="nump">92,764,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock - diluted (in USD per share)</a></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic and diluted (in USD per share)</a></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557981919448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock - Potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding excluded from the computation of diluted weighted average shares outstanding</a></td>
<td class="nump">12,194,058<span></span>
</td>
<td class="nump">5,138,294<span></span>
</td>
<td class="nump">12,194,058<span></span>
</td>
<td class="nump">5,138,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding excluded from the computation of diluted weighted average shares outstanding</a></td>
<td class="nump">10,518,263<span></span>
</td>
<td class="nump">4,268,277<span></span>
</td>
<td class="nump">10,518,263<span></span>
</td>
<td class="nump">4,268,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding excluded from the computation of diluted weighted average shares outstanding</a></td>
<td class="nump">179,051<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">179,051<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding excluded from the computation of diluted weighted average shares outstanding</a></td>
<td class="nump">946,179<span></span>
</td>
<td class="nump">870,017<span></span>
</td>
<td class="nump">946,179<span></span>
</td>
<td class="nump">870,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding excluded from the computation of diluted weighted average shares outstanding</a></td>
<td class="nump">3,115<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,115<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding excluded from the computation of diluted weighted average shares outstanding</a></td>
<td class="nump">547,450<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">547,450<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557981018984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Oct. 15, 2021 </div>
<div>USD ($) </div>
<div>extension</div>
</th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Leases, term of contract (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Leases, term of contract (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_BaseRentPaymentsExpectedCost', window );">Estimated base rent payments | $</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_NumberOfAdditionalLeaseAgreementExtensions', window );">Number of additional lease agreement extensions | extension</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocgn_LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement', window );">Leases, term of contract for additional lease agreement</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_BaseRentPaymentsExpectedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Base Rent Payments, Expected Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_BaseRentPaymentsExpectedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Term Of Contract For Additional Lease Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocgn_NumberOfAdditionalLeaseAgreementExtensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Additional Lease Agreement Extensions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocgn_NumberOfAdditionalLeaseAgreementExtensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>67
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MSOW8';%#-[,/SY:GOA%B6Z!*+;NA.;3P.HJ-U69:X7A XF%'_]#-_U^8@G[
MVV#3@:2_"[%9Q6A .U&G!.@0)2@/F<4-6F2A_"3JH[59H1WYV$?;Z0*"!Z!]
M#2$TQDY4*]!':%J%,1I0+K33*[@5YIP512;U1FE#WBDK]0JF9:K0@O=73%(
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M^N9&LJHYFEXR*5G17*XI4=70!NKY'5-[JO9&GW9O_[LQ^Q=02P,$%     @
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M0%Y?4"H^)NKP6?[9Z/\#4$L#!!0    ( .-*:5-V(?O*\P4  ,@;   8
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&ULI5E=;Z,X%/TK5K0/'6G38 ,!JC92
MFS [E?JEIC/S["9.@@9P%IRT\^_7!@))?#%HM@\-D',/G..+?0+7'SS[E6\8
M$^@SB=/\9K 18GLU&N6+#4MH?LFW+)7?K'B64"%WL_4HWV:,+HNB)!X1RQJ/
M$AJE@\EU<>PEFUSSG8BCE+UD*-\E"<U^W[&8?]P,\.!PX#5:;X0Z,)I<;^F:
MS9GXOGW)Y-ZH9EE&"4OSB*<H8ZN;P2V^"LE8%12('Q'[R(^VD9+RSODOM7._
MO!E8ZHI8S!9"45#YL6=3%L>*25['OQ7IH#ZG*CS>/K!_+<1+,>\T9U,>_XR6
M8G,S\ =HR59T%XM7_O&-58)<Q;?@<5[\1Q\5UAJ@Q2X7/*F*Y14D45I^TL_*
MB*,"R0,7D*J G!<X+05V56#W/8-3%3A]S^!6!87T4:F],&Y&!9U<9_P#90HM
MV=1&X7Y1+?V*4M4H<Y');R-9)R;3YZ=9^#0/9TANS9\?[F>W;W)G_B8_'L.G
MMSEZ_HJ>7\+7V[=["4"W3PKY^/(:?I-E]S]"]/ \GZ,A^CZ?H8N_OER/A+PJ
MQ3U:5%=P5UX!:;D"&SWR5&QR%*9+M@3J9^;ZP% _DF[4EI"#)7?$2#AGVTMD
M6W\C8A$,7,^T?[D%R?E_9P__^.PG9MAU?]@%G]W"]\KV+-VQW$#EU%1.0>6T
MM1J/8_K.,RK*2:8@AOJEI!D7-&JBVT^DDOWQ"'0B9IV(4$<XMF4UJ!.-;JW1
M-6I\XX+&!VTY)*ZL=PWB.A&S3D2H(PSBQK6XL;$7GK=,#5ZZ1NQ3+E2YL2N\
MFM0S.O;*<D:SQ0;1="EG^+U<NK9R(1*0=YZF:DQ\?*RK=%#'8<?S-=Q,QQ&)
M&FO 4 <ZGH*U&.K7VGVC]OMTN,WX@N6Y;)G^-OB=+:0C/,NR= ,ZF<)NIA/E
M0:T\,"K_AZ6RE^)"+5W*=2W*A>JM/3@A!+K]KJ6/YU3'8<]R=-D SI6,^KCK
M0-<T[MAJ5EVKQSS!.VZH:OFT],NU/#_0]8-([!/= 0#IV(X+M#[$Z;G$8,)1
M],!&$QZX;/Q5QI.#$3R%#<#:)0S;' "AL 4 M,T#B-5S/*_=!-*80,R3JMBP
M#$7I@B<,751]\,4PL>)FZ<9VQ_0BF)Q71,4.6FOK'0ZXJJ,T-W4(UIE"(].I
MS"968'.NJ&56YH$Z'6 $H?X!<"2 N@< NCIA".)<M[UQFJ2!S5&C3^-4XO4T
M,-1GQ2D TU0#3+8-W3$FKE/!3?K XSYS9G_98V#,@54#PL%C#@!M'U@V(*!Q
MT)NPA,UIJ9@RW]F*9^S@@:"?+>N&GEKD7.A;'F !"'4\8.V$H([M@TT L?J6
M3=J-:)(3[HI.!_'2CI2M(C I83V^#%U]9*< 3M/=CRHT4IV*;<(2-J>E)R90
MK$9>Q26I>YNQC7I6LV?%85"Y'EW4FNE"LSL(A0<?@#JVY^O0$&0U#CYITA,Q
MIZ>#'Y!PHN>5-N$P%!0.05N$@ZQFX4UB(N;$-&,L8?+W0;2/EDSV0L9B*N0!
MP=%/FF4T%2C\7&QHN@970:+G&,V33LBL&Q("D"$FKC-N]Z )3(3TNQFD:'DO
M)#Q%N>"+7QL>+UD&]P31?NNW]@0(A7L"@+;U! "U+??T-^FI'TW*(^:4-]]0
MF7[0+I=]$*5H0>/%+BY_5:0'JV2\KKU2<#143U>C!;J(JB,YN(02(-4%OA=8
M@:\9!T =[ :88/_<.(C5=H/ )>ZY<3HT(-Y8$GLMOC6QD9ACXQ_ZMHSBG;KE
MNIS3<U^K<P"TS3F(M<4Y'=KA7),\B3EY/AW;4_K"5R?WXDE_J2?#-1(VJSR?
M=WQ[6)>6>VX4#*L>2!S^\+EG8!6QS_T"8;;=8E:36HDYM?8RZ[BI>M@U[F<7
M#.NR"ZS2[0)AFEVCHS<3"<O6Q2NA7,K?I:)\"%T?K5\[W18O6\Z.W^&K*0:.
MS_!56+Y4:NC+=UR/-%M':8YBMI*GLBX].<!9^=JHW!%\6[P7>>="\*38W# J
MUQ %D-^O.!>''76"^N7=Y#]02P,$%     @ XTII4_H(BL(U"P  448  !@
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M=WE>;=[4WYBP_1:9D_\#4$L#!!0    ( .-*:5/RG($\>@<  )L@   8
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&ULG9I=<]LH%\>_"N/9BV=GZEH"^:V3
M9"9QDMW.M(FG[FZOL81CMK+P(IR7;_\<D".<<(3=O:DMYP!_CCCG=X">/2G]
MLUX+8<CSIJSJ\][:F.VGP:#.UV+#ZX]J*RKXRTKI#3?PJ!\&]58+7KA&FW)
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M%<1%359:;0B$FN9&5@_-6I5&BCHR3-8.D[EALHYA[B"V2U77V MH6HY<2QO
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MI)$YO5/?5K1G0CO4'13[9W36J A3= 5+@Y;.X'VY)-G*/-?,1^3]3\I9/$E
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MCY[^&"QB9YITFW*%I! ,9GLG/S\>/?^Q :B;)3T]%AF"*X=F;S4'Z"JO,Q\
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MK>F'M1.O^UK5Y?[[@&=$]BP@^^+L5H"7:C,7YXN9.%N<G=X"[SP2?T[PS@_
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M/TF&:C6X>3E$<YGL<Y)E,)7 :5 =;> ^.L8MP0 KT$HP6(T&*' MWN@R]]!
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MSKHF?X&Q#*@\6*\0#E0D;'L4G.H$);*W1RJ!%&K_QP1B, -:7JH\HY)O^Z^
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M[4R2J:V!Y5TR#(H+-G][/%^(3K>M+YCM#B 6(V%<I:,BRQU'W[#EZ.<#FY
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MWJ01-I1RKXK7?OXD$"0Q!\S]7$Y2@T-0:TPM 8/9UZ@E 937H>S6B)4Q-4X
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ML'!DV';@R 8$MD EQX2E/[.3^V;)!C N&#],@<BL,T:J_^TDY<B[@]B3C3E
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M2B*-+=ULY5]<681T7^NW!UF3WDW"M]T@8,B\U;F]?O.>"GPQFS^[IU')UMU
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ML-E1FH^4+N9O MYR.Z'%[)#FL_G1&WB+78J+A+=X!>\QN4#_G.<A>DCAWS>
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M=WZZZ/DPIP6&HC O:45Q-G'GX-,WE-P'^%"0;);5SC4)>,EX,P45:*-!A"P
M'OK_CIG?55D#6&S&QU,CI0B6= M/<B05XWG!):U8.;_VOEF]LK95',W()M\$
M;H7NVY=*!(6D\ER+.'S,,,GWQ'3TUL!J;8ET-!:#%$=3!@Z^D<)&2#-GB^BF
MR4]$NR/XFK71:BH]LMI==\!]/#"I VE/I0TXEY0'I*E9K;LLS%78BG:IC0$
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MMJ#?#JB= ;W/E;+=@PO0_QI9?@902P,$%     @ XTII4R3+RA6]!P  YQ$
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MV[@5_BL8-6WC&84B)=^RL3TC.\DTG4V3B7>WG>GT 2(A$1N28 #0BOOK^QT
MO$B6'<G3Z4-?;)' .3B7[]S B[727TTNA&7?RZ(REZ/<VOJGR<2DN2BYB50M
M*JPLE2ZYQ:->34RM!<\<45E,IG%\.BFYK$97%^[=9WUUH1I;R$I\ULPT9<GU
M_;4HU/IRE(S:%U_D*K?T8G)U4?.5N!7VU_JSQM.DXY+)4E1&JHIIL;P<S9.?
MKH]IO]OPFQ1K,_C-2).%4E_IX4-V.8I)(%&(U!('CG]WXD84!3&"&-\"SU%W
M)!$.?[?<WSO=H<N"&W&CBK_+S.:7H_,1R\22-X7]HM9_$4&?$^*7JL*XOVSM
M]R;8G#;&JC(00X)25OX__Q[L," XCQ\AF :"J9/;'^2D?,LMO[K0:LTT[08W
M^N%4==003E;DE%NKL2I!9Z_>?6NDO;^86/"B-Y,TT%U[NNDC=*_91U79W+!W
M52:R3?H)9.@$F;:"7$^?9'@KZHC-XC&;QM/D"7ZS3K&9XS=[4C'VS_G"6 W?
M_^L)GL<=SV/'\_A@8^U#QVX^_3;_QX>_L<\ GM!:9.S6JO0K^]SH- >RV'RE
MA0#B+?M4L8\<;UGB#3)F-A?L1I4UK^X9=@@BEY55C+.ZXV<<O[KEQUM^8WIG
M&@[.H%CG$IR'#-W&C-:D,0T(*_!"I+ X2H"ZHJ  ,CG7PC"U')+^Z0_GT^3L
MC6&W0DNL7F.ANA/:RD4AMC6%&%RS.U[@B!=Q%">L%MKS92^)*7&;QF_VX>6V
M)F^.QHQ;9P.9B@$[\:WA!2GT(HE?1Z? %7Y?8PF[KZ6R(LVC@97/=YG9V2)S
MK_:1B'$#PS&>W?&*9.'WSI5(G(Z%:>JZN"?SM3B 1 OLT^I.(H;8XGY+P VG
M.2D\BPXF$7O'L<UK#,9[22D-2_ME9S[BK6J7)<%E4XBQ1UD2_\#_J2I+ HD[
MPSESY*5PZ?L+!_?1$5,5Y.=+P)>]E$<;UM8B%4C0 <2Y*C)LXC69QWM25BG*
M#F!-5%53+K .87AC<Z7EOXFRDW!#FJ8B5M("I/*[S=D<MB.#$\J_"&.YQ<,-
M&60I4SP0@P]5JG2M-/>U SM?RDV!.\V=X+4E*I/+FAQC=C@SV&TIM;$P9Q1W
M@94IXZ5N@5'RJEDB9S7Z6; 8.WF7C<8B3%2Y33!Y:7Q@-XO?41-;:H ADZ2E
M0<@[N,)$TA-M&>6M,')5\18H'ED"8#=CYLJY/^!G64K+/<M]41D0\^AYHZ,(
M/F%SQ'GQ,%3_;(:H,0$VSL4];()./7(V&?P81TNM2IP]=!UL.'U]TK^(V#SH
M7%OASFE+VK@U=AL2G=T!H (Z5JO6(YDH$ CZ_A#(Y#QCE;)(**)BI4!J^&7S
M.!ULNG<V0YX8((5GOZ,9<0DMV%'<T0,%8#!/)BF/5=DX/)NZD, BPJ/@QGBW
M0I(Q0T(T@$B!6N"9K"4@!XO7 U@^E5^B[8B K. C;>&+6$@EG42F#8*]%/>E
MXZ4+>^3T5R%;>M8;@$ [*,V1,T^5M78QO!041275@UX""F=>($QK+C.V44Z'
M/,>HSL(G'(E\TD"Y 0\M'#GR_O<4"*,3AN6CX&M'F4)<]..T9H5K>_TV<VB4
MC_>W&AH. )#=*8=D[;)!Q'ZMR8RLD.B LI X-#0R1A5-FT<&[AZS-H3W31QK
MU109U=%= .C\P4O54,+,7;,0BLMV?'M6+:T\(%;62(-(N.3>1]'B([+KN-*4
M),*VMC^@;L,U#@<%:>4XZ<Q1NCB:W]ZPL^3< 0&Z8"WT,$LNV^8+1[P89"U'
M"%;"]ZE9HUTVHF2)3I:5OM/W17-79G/G<FBK*8@IKX'<()O:5U1V -. .<<S
M-$C9@PYI.ZEM6@QP*5QV=M5,<Q)FPWVN!1R'3.4#PB-KLPMQG: WP_Z=7>6/
M?2^K"GON81(D:6*$]D&6%#B<)2=_)&0[O_ITVRI6</" 7AA[OPK+%U#$=ME=
M5AA0&M_.D;XDFH\4V?4@$/!GI,J"S?"R;E!G0^@.?)I+H:F9O:>.+2V:K/5A
M*R)4P#B-;@B&W#H9Y<^'*,G5*MO3W2DJ4$.A^[*YX0+>M8<K30T*0EY$Z+%6
MTOB)Y:W4E.,_+6%>R&>H!0\U?;;'I&-$"FQ:<MC#(<?#L,U]I)RT+L<@FTOX
M%B)J\]Q!B (-X=0IDGE%5% D]"]]>_*$TFB#J;"L<-0JI-R-VKZSSWY@:4M,
MNN/]^$-A3:SB?A *?4"A#&T+//<2DZD4QJ8%U?GHS/NH@\B#WKU"G*/4I#"B
MT^#%ZUETW&GF&W\$;I.Z*A'R39?Y4F6L)SN-3ON6"AAY+Q:ZX6B)SOX/4-(I
M<SA09O\UG)Q%IR<_@,F^<FX@I2-*XH/!,DVBZ3/ DD1G@_X;-2<7KSZZ5#M(
M-,-20A82K@39')Z$[VKN$C;WQ#Y/=U8S[*6@.1N&',U_^3CR\U6JBL(W5\6]
MAR,M&CA-TK6"LQI,\-<&%=3_)*IYLT)U<B^\S?M#7!-1HJX]&/!ZWPKL]@W=
MR.2B6(X"VL*<ZF99AW+R!/6@MZ]FF!^H+7*X=Q7OW0TM^YN/$-*QUX#N-\DE
MKA-OW$4!A8DONEI L<P5!%+O9#Q0BX@'=.ZN0_A)V$TW/EKLAKX]J_/QT%C)
M=/S08$F0,V)O#^U.AMA#VYFQY- @\A<(+G/V[F/P=MMD/8+GX^C\&7 >W+EM
M:.NQ2B?NH7>\0^_M9#(]&QB"^)Z?#N+O4,L ^^-VB'-!L4/X@V1^W*[)\%KR
M$,,>[S3LX>9\(H6=])7KH!0V\/EMLS"IEOY"KKO5,73_,<@F3Q7 (8.MRL?=
MQ(#-TCH"7_%V3B%)-#L,#:[\H<3<$<!J=+VB;VL?N5-Q22]<M-(TRW6X4T!*
MJPQ/0R-,0ZLM0FI;NI*&+MAR/VJH12%7?,<XV2:='1I3EQQ*^_9-9%_>2_Y5
M=+U"RDW>SBR ^O9]X/"Z^#F6$]_1J52K?FK8(31=4W7NI/F27%40LOOSPD&[
M[3-NKS*#[+N@T*L?V+M+;7]7A28) \G0TF&R5NOAQ-5&20W-:2Z'#+R?C7PL
M3GO #R_V_C?('L?Q(Q?:^V':<=W*IP]:K-GKD^VY('XDN$='T:[O4Y/!A[U2
MZ)7[?$D"PHS^&U_WMOM".O<?!OOM_O,JROT*W2XKQ!*D<71V,O*W-.V#5;7[
M3+A0UJK2_<P%NA%-&["^5,JV#W1 ]]WXZC]02P,$%     @ XTII4_ Y$+;J
M!P  #Q@  !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&ULK5EKC]LV%OTK
MA'>P30#'SWFEF1G ,TFQ6;3-H--M%UCL!UJZMKFA1)6DQN/^^CV7E&1K).>Q
M&R!(+)'W\#[.?5"YVAK[T6V(O'C*=.ZN!QOOB^_'8Y=L*)-N9 K*L;(R-I,>
MCW8]=H4EF0:A3(]GD\GY.),J']Q<A7?W]N;*E%ZKG.ZM<&662;N[)6VVUX/I
MH'[QBUIO/+\8WUP5<DT/Y/]1W%L\C1N45&64.V5R86EU/5A,O[\]Y?UAPV^*
MMN[@MV!+EL9\Y(?WZ?5@P@J1IL0S@L0_CW1'6C,0U/BCPAPT1[+@X>\:_8=@
M.VQ92D=W1O^N4K^Y'EP.1$HK66K_B]G^C2I[SA@O,=J%O\4V[IUB<U(Z;[)*
M&!ID*H__RJ?*#P<"EY,C K-*8!;TC@<%+=]*+V^NK-D*R[N!QC^"J4$:RJF<
M@_+@+585Y/S-[]):F7MW-?9 XW?CI)*\C9*S(Y*OQ4\F]QLGWN4II6WY,;1H
M5)G5JMS./@GX0,5(S"=#,9O,II_ FS>FS0/>_ C>NS]*Y7?B7XNE\Q;1__<G
M,$\;S-. >?H_N.O+),6=S&4J1?/\(1=_+_5.3,^BY4/A-R3N3%;(?"<H]V0I
M%2KW1DB1F-R!;RI?"[FV1$@/#\;XC9 Y]J3J4:6EU *;"VOP0,*1?50).7YW
MB!RD+*VE39\M?5<IJ8")[+>2\\>)%[QE4*E_MU=D42LR>#D*$$C9(")*,,-&
MY.-24#O194IN*&1FL&(@8 77&R?,"B;O$:-OE'.ES!/BU6WM1K:XM,D&&2K*
M@A\GHQDR1FO6Q&VDI0#7MA/@&2][DWQL&UC'9_ 2KDU%(MU&%'+'&@><>,;)
M?#1I#BD+_,48,MDH>HS6L05D/<HC[R.<E$,12UIZ"HZ_^_#;XI_O?QZ)7S_C
M)Q !!0!B.+_-F?D0K@:V$R2M5NSS>B\S!_HDQJ;!92'JBOV%':YU:,/(+1@7
MG SI9R=- QRXI1X!+@HMDTHYB#H9*FT$K0*S,9HY@+ $SU@NDFPU/9%-%&+E
M>Q3X!K&4GC.B.04*1[Z<G(_FYP*DCC#?,&9[[6O?/W/>?/J588):RM:!6@2+
M42,]94N(UH426:-UXXR^2*(5.P\.AZ(!*I?Y(TRBM%][=@HK4N:L%;*P3[/%
MPYVXF%Z.Q,/]8B_Z/A<?$F]8N]ED^KI=R"H^^0WHS#5)Q1#VYF]OA/_ZE\O9
M].)-7\[RTFSRYB&B[C4:AH7I&]'==-MLJO8,@V^Z&^^>;XSEP.@P5SR2W@U;
M4@<.J01>5G50PNRDM,HS;&/KLS)>\PX>1]E7D1D<+V-! GAX 2IKCOSD$XV"
M%_8;Q4.Y=(E512C*34&!Q4ZDRF'*<!#DXW'PSP;$1>RV&Y5P?\"HYRAP06*S
M+MGF?05F!%JAU:5BN0O'=H(0_ 40U+.*YNE_,-?$0EKIFI>!TPAX0%[J8SB\
MN9O4O>?"6UD&%R*[D(+8"RH_:X'!9YP67^.TR]%E4XJZC!/3X60R$1V617JU
M%N^.YRGW4>B6%0;K9$JG=TU)^!(=#XWD<S\4=Z;-D 4VIH%VO/[N"63,U[3'
M0+LGE$0NHH/NZN!($O1LY0;:J-[/ZOO2,IU\'9X>D)9)PV#//F'[4&->I>V9
M@@F^YE"LX FQQK"$)5JM8$1]=H?B0UZ1[*TC]#X8M;A:RD."=_G=*EX-V9LN
MU'#[.*O!#%01"_2:%*[D0-4!K7S5ZQ2J/'O,%C;@A7H9C%BO>3CT0979=/3Z
M*_LO_/5" 0J^R6"GL3N1&Q_E3LY&YPU<G+HJ%?:QO]_+<4ER7<KM:=5Q*@>^
M%Y9'U+=ER'E>C]V(@7/4,)'%"PWQA:;;:I\5W$PBXLU$6 7ZLV:(.!!%-\P/
MIAI6XN1T=%J_&'+-+&I;Z_[_EI)*I^FA3E]PK$2%)N*+="%5J,.K4NMVD5S!
MNV9;.R?<-7!5#\6EBG;GH#H'DX:5'0Y;XH\#C-JIBD&\4PZ#32B(H2KFICUD
MM*KDKX=UKC6T]"J+%F4I,>M<_5D;N9(8L1ZE+AMUV6PD<[SUQ+EV13863DX@
MGM_JK3A@QT@M@)[.A3\X.2V3VI<R16KB-ZYJ'(Y7@$YDH;S4T:BN6EU4=:R]
M=>S>0H&3Z6BZYU;L[OP>E4%E80(M79@0Q2V&^H^O'A(P%0>R$M$5F4E)"U1'
M'=WW(\9E+>9P2U%Z=TSOX^Z$MHZ\UW3$/M9.%J@?3T%!6'DRG>\+QS#<#*WB
MV863Z?*@IJBOJ%+]+/A\1L4ZUMS^^NS__VSOT.W;D@+)\-R[L]%9VYSJ_+8=
M(2ZM9 O\3KE5IR)\@@C=TO2JV!1 ]CU#65IQ2><!T\7NV:1&3EYHXT)U/8Q;
M#:'R*@UU4NJF3BVE4TF #\T<P T.W_MJH'#]JTO%EY3_41RC&E??TEKE>1P?
M^<)S'N>2^J;3>[/Y[->'UA$8G2"\;]]M,C-J,S?)EF>^.[A6R"H66TR 6:'-
MCCIIT4**M\Y]\ZFD(E8SD!V_D(8#>_K4Y&!NYBV3@Y&B[=CGTW!_*^PYF4TZ
MO.VV8;D%2H#S)PA*7\E'$'K==YU &WY]$1/@.!H]%0IJ+LEON:WB_/-@%GY<
MC/J^-(X//M)F9-?A4S1S 'D4O]<V;YNOW8OXD7>_/7XJ_TE:4,\)32N(3D87
M9X/X9:5^\*8(GWR7QGN3A9\;PKQB>0/65P8EK'K@ YK_ [CY+U!+ P04
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M<(T[7>Q: O36U =TO/_*3$.D:]"@Z_A#KVBN%G199.!LQF''>AV8;HDN\\F
M"1S(HWU?*<:#[T*-\DO^^L7[;,R?B/K1_@/;+']7>EB>O\[])/V2X!FUP-;)
MT?GI2/C\Q2N_1-?R5R;0(+J&'VN%ALO3 LPO'!KP[H44])\=K_\-4$L#!!0
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M"FG7H@(S;OG\!PZZ%P+C9_J HP:<=%N"M4&K[%GFU]*1&@EFJ8 C$Q/P<34
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M,MBNS7JI&R>XPFL#MI&2F<=+%/JPBM*H-]SP?>6\(5XO:[;'6W2_U=>&9O&
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MFH#OQF9W"*Z)HZIP@0=?W.[X3X-> 'R_<?R<^H,8&/Y=RZ]02P,$%     @
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MIB[(F@6UG2C- OJ^$:25?F "#(WL_!]02P,$%     @ XTII4ZEK\F!^!0
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MSNFB/,F7%XIGYN3YPI4^QYIF3'!(1#% WX\X5V\718#Z?<KX/U!+ P04
M" #C2FE3\^6P^-,"  "$"   &0   'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6S-5FU/VS 0_BNG:)- 8LU+WP"UE4K1-"88%1TP:=H'-[DF%DZ<V6X+_WYG
M-V1%M!G:)[XT/L?/\]Q+?9?!6JH'G2$:>,Q%H8=>9DQYZOLZSC!GNB5++.C-
M0JJ<&3)5ZNM2(4L<*!=^% 0]/V>\\$8#MS=5HX%<&L$+G"K0RSQGZND,A5P/
MO=![WKCA:6;LAC\:E"S%&9K;<JK(\FN6A.=8:"X+4+@8>N/P=!(Z@#MQQW&M
MM]9@0YE+^6"-BV3H!=8C%!@;2\'HL<()"F&9R(_?%:E7:UK@]OJ9_;,+GH*9
M,XT3*>YY8K*A=^Q!@@NV%.9&KK]@%5#7\L52:/<+Z^ILX$&\U$;F%9@\R'FQ
M>;+'*A%;@+"S!Q!5@.BM@'8%:+M -YZYL,Z98:.!DFM0]C2QV87+C4-3-+RP
M99P916\YX<SHDL=4$P16)'".*RIK244R,$X5HEUI.#A'P[C0A_ );F?G</#A
M$#X +^"*"T&ET /?D">6SX\KU;.-:K1'=89E"Z+^$41!>+(#/FF&?UT6+6@'
M%AZ%+^$^Q5\G(:J3$#F^SAZ^B5RQ1PJH#KJ!LUUSMAUG>R^G$&PN%;-_4Q@K
MQ8K4<;M4;]O7)D,%)F,%O 3]O"1.N#"8ZU\-'G5JCSJ-4=Z6"R5)KV1/KV/<
MI'U#T',$M@&L1F%WX*]VB'9KT6ZCZ#A)N+VO3#3I=E_K!KMU>[5N[Q\EK3,I
MMPH+]]QD,&'4A@H)9UP*F?)8-V2W7POVWTF]CVN/CO\K!=]1Y;NN;#-;&, 3
M,M64JI/:L9-FQZ[OQC\NOL&4.C8JA0G,C(P?8+I4<48M^4WW, S^=KC@G50F
MW.JZ86,*IDHN./76% LD#4R.0&?,IJ)$11W9T C=V1>;:3O=5A!\W.6AOS4B
M['R^8BKEA0:!"V(*6GVZ@FHS\C:&D:6;&G-I: :Y94:?":CL 7J_D-(\&W80
MU1\>HS]02P,$%     @ XTII4WA$@&,7 @  _00  !D   !X;"]W;W)K<VAE
M971S+W-H965T,S,N>&ULE51=:]LP%/TKPG300F?Y(]FRXAB2E+$-.D)"MX>Q
M!\6YB44ERY.4N/WWNY)=+S G;"^6KG3/.?=<2\H:I9],"6#)LQ25F0:EM?4=
MI:8H03(3JAHJW-DI+9G%4.^IJ36PK0=)09,H>D<EXU609WYMJ?-,':S@%2PU
M,0<IF7Z9@U#--(B#UX45WY?6+= \J]D>UF ?ZZ7&B/8L6RZA,EQ51,-N&LSB
MN\7(Y?N$;QP:<S(GSLE&J2<7?-Y.@\@5! (*ZQ@8#D=8@!".",OXU7$&O:0#
MGLY?V3]Z[^AEPPPLE/C.M[:<!I. ;&''#L*N5/,).C]CQU<H8?R7-&WN&!6+
M@[%*=F",):_:D3UW?3@!Q*,S@*0#)/\*2#M ZHVVE7E;]\RR/-.J(=IE(YN;
M^-YX-+KAE?N+:ZMQER/.YE^5!4-64  _LHT <GT/EG%A;LA;\KB^)]=7-^2*
M\(H\<"&P\2:C%G4=FA:=QKS52,YH?#F(D*3Q+4FB)!Z +R[#9[4.29P.P2FZ
M[2TGO>7$\Z5G^/Z8->3';&.LQK/T\P)QVA.GGGATAGBIE>3&*/U"*FSKD-.6
M8.()W 4[YE$XR>AQ0'74JX[^1_46_Y4%#<82S0:+F%_F^Q!&T9NAVB_#QG_#
M6COTY'"ZA^&!Z3VO#!&P0Z(H?#\.B&XO6QM85?OSNE$63[^?EO@^@78)N+]3
M:+,+W!7H7[S\-U!+ P04    " #C2FE39((A1V #  "/#   &0   'AL+W=O
M<FMS:&5E=',O<VAE970S-"YX;6R]5UUOFS 4_2L6VL,FM04#(6F51%K339O4
M2E'3;@_3'EQP@E5C,]LT[;_?-:%  F'3I.XEL<W]./?8/ERF6ZD>=4JI0<\9
M%WKFI,;D%ZZKXY1F1)_)G IXLI8J(P:F:N/J7%&2E$X9=WW/B]R,,.',I^7:
M4LVGLC"<";I42!=91M3+)>5R.W.P\[IPRS:IL0ON?)J3#5U1<Y\O%<S<.DK"
M,BHTDP(INIXY'_'% D^L0VGQC=&M;HV1+>5!RD<[^9K,',\BHIS&QH8@\/=$
M%Y1S&PEP_*J".G5.Z]@>OT;_7!8/Q3P031>2?V>)26?.Q$$)79."FUNY_4*K
M@D8V7BRY+G_1MK+U'!07VLBL<@8$&1.[?_)<$=%RP.$1![]R\/_6(:@<@K+0
M';*RK"MBR'RJY!8I:PW1[*#DIO2&:IBPV[@R"IXR\#/SI8(3H<P+(B)!GWX5
M+(<],N@4K># ) 6G2*[1$:/W5]00QO4',+]?7:'W[SZ@=X@)=)?*0H.MGKH&
M,-I,;ESAN=SA\8_@6='\# 7>"?(]'_>X+X;=KV@,[KAT]_;=76"FIL>OZ?'+
M>,$?Z#E!2TZ@Y'T"?ER#.?IJ:*9_#B0+ZF1!F2P\DNPS$T3$3&P0IW RD;)'
M\%2N3PN8$*VIZ>-S%S,J8]I+^S2'PI_:E'4MHK VV4,:UDC#0:1WTA".\O:Q
MH*^L]&'<11NU$.!@$AW [!I-1N?].$<USM$@SFNJ]05(15QD!2>&)G##0>UB
M1JR&]"$==4"<!D%X@+3'R/>C?JA1#37Z9TI/D.C?^ZC+JS?R#]!VC:(@Z <[
MKL&.AT]JH00SA:(ESC5[MF,]< 4F=>#)V]^W\SK9^6 53;*\3M;B?*.D[E6P
M\PZA@7](>M<&1T=."/8:K?8& =^0.(4E-7CC]F.WW@/X[9G'C:YB_TVXK\+N
MJ\2ADO08A:UKL0^Y46<\+,_75I13R1/$,KBG3]1"'3KTN)%3'/X'\AM5Q,.R
M^,_D=X4/1^-#\GN,QN,CY#?JB(?E<2&%-JK8]7[08L &;$!R!NEOU R/_P/]
MC<;AR=O0/^F\R$-\R'[7QCO@WFUUB[95OR%JPX2&IF,-/M[9&+9.[;K?W<3(
MO&P@'Z2!=K0<IO#%0)4U@.=K*<WKQ/:D]3?(_#=02P,$%     @ XTII4VH8
MZ[YI @  FP8  !D   !X;"]W;W)K<VAE971S+W-H965T,S4N>&ULI55=;]HP
M%/TK5K2'5NKJ?-&U*$0JA&E[Z(2*NCU,>S#)A5AU[-0VA?[[V4[(:!L8VG@@
M]LT]Y_C:UR?)1LA'50)HM*T85R.OU+H>8JSR$BJB+D4-W+Q9"ED1;:9RA54M
M@10.5#$<^OX5K@CE7IJXV$RFB5AK1CG,)%+KJB+R90Q,;$9>X.T"]W15:AO
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M"T0: #Q?"J&W!Q.@^?P8_P%02P,$%     @ XTII4TA_48:= @  I 8  !D
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MM.$ [2^-\9M): %]QY_^ 5!+ P04    " #C2FE3[T/@%=D"  !*"   &0
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M45]<]43QTO3^%5=XDYAABI<]"+T!WZ\Y5V\3?9VT?Q^F?P%02P,$%     @
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M\67Y57Q9N5'F$&D4[$"YB%J_2OA^ =MO@7T J40>J5RP;(MF7*HBY?4PB"=
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M%*+@&,(@[.R@C_?3)Y@:>L?1@Y=TW\339A2V&85.+]J7T1576E;F_&KX<VT
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M!AJ,YJ97JAF]C8&R<L-H*]&,-K?<F]L*E'4P[W=2XM&P MW]E_P!4$L#!!0
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MHFNRB^43VW^B9D!]C1>R6.3_P=Z\Z_= N!.2)<98,4BBM/@DKR80%0,T;#!
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M>K0^N[DQ)Q9.,[T\^/E.N7HY!$IAI435AD"%CY=G*>6#9%MS'+%D4K+,W&Z
MQL#U!/7_BC&Y?] &ZA.M^=]02P,$%     @ XTII4X M!/QK P  GPL  !D
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M"99+A0+(YRM*Q>Y&O:#]^V/R-U!+ P04    " #C2FE3!FBOM\(#  !Y$0
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ME@9[K[LL<7<$92?@\XV4YF5@&[#?;[.?4$L#!!0    ( .-*:5/\F9 +#P,
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M==D<\EGW<<#D$U!+ 0(4 Q0    ( .-*:5,'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ XTII4P*%
M2<;O    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ XTII4YE<G",0!@  G"<  !,              ( !S0$
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #C2FE31(Z\H3(%  !8
M%0  &               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ XTII4VG[MY G!@  Z1@  !@              ("!=@T
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( .-*:5,Q(WW?
M.@,  '@,   8              " @=,3  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    " #C2FE3=B'[RO,%  #(&P  &
M@(%#%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ XTII
M4_H(BL(U"P  448  !@              ("!;!T  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( .-*:5/RG($\>@<  )L@   8
M      " @=<H  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M" #C2FE3!XUQH'83   [-   &               @(&',   >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ XTII4R_3,"_X&   -TX  !@
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M970Q,BYX;6Q02P$"% ,4    " #C2FE3L.M#%G$$  "9#   &0
M    @($]=0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M .-*:5,DR\H5O0<  .<1   9              " @>5Y  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ XTII4US_.YYO"0  0QX  !D
M             ("!V8$  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    " #C2FE3\#D0MNH'   /&   &0              @(%_BP  >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( .-*:5,702N?;P8
M ! 2   9              " @:"3  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ XTII4],[8&(0!   $0H  !D              ("!
M1IH  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #C2FE3
MX@PZBLP&  ""%   &0              @(&-G@  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( .-*:5-T?,3;#P,  ,P&   9
M      " @9"E  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ XTII4[!A2X(P&0  -%$  !D              ("!UJ@  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #C2FE34^5W:,4"   Q!@
M&0              @($]P@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( .-*:5,!SGZ]#@,  (P&   9              " @3G%  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ XTII4[41]WPA
M!   - H  !D              ("!?L@  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    " #C2FE3UI7:(98#  #!!P  &0
M@('6S   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( .-*
M:5/@=K_)&@,  ,<&   9              " @:/0  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ XTII4YFO;Z-H!   '@L  !D
M         ("!]-,  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M    " #C2FE3&I%-.4($  #4"@  &0              @(&3V   >&PO=V]R
M:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( .-*:5.I:_)@?@4  #45
M   9              " @0S=  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
M4$L! A0#%     @ XTII4T</D 6E @  C@<  !D              ("!P>(
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #C2FE3N7G>
M2NX#  !;$0  &0              @(&=Y0  >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;%!+ 0(4 Q0    ( .-*:5/SY;#XTP(  (0(   9
M  " @<+I  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
MXTII4WA$@&,7 @  _00  !D              ("!S.P  'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    " #C2FE39((A1V #  "/#   &0
M            @($:[P  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    ( .-*:5-J&.N^:0(  )L&   9              " @;'R  !X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ XTII4R#-<?U6 @
MO@4  !D              ("!4?4  'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    " #C2FE3D(.D-=,"  "*"   &0              @('>
M]P  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( .-*:5-(
M?U&&G0(  *0&   9              " @>CZ  !X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ XTII4\_@N&UG @  _04  !D
M     ("!O/T  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .-*:5,+- XTF (   L'   9              "
M@<X- 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ XTII
M4\ZR?V/* @  XP<  !D              ("!G1 ! 'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6Q02P$"% ,4    " #C2FE3"S\N+%4&   .'@  &0
M        @(&>$P$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0
M   ( .-*:5,Q.RC@TP4  &4;   9              " @2H: 0!X;"]W;W)K
M<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ XTII4\Z]XTDC P  R0H
M !D              ("!-" ! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q0
M2P$"% ,4    " #C2FE3OI0_W^0$  #W%   &0              @(&.(P$
M>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( .-*:5-5T'/2
MJ 0  -T2   9              " @:DH 0!X;"]W;W)K<VAE971S+W-H965T
M-3 N>&UL4$L! A0#%     @ XTII4X M!/QK P  GPL  !D
M ("!B"T! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " #C
M2FE3FR:)J#\$   *$0  &0              @($J,0$ >&PO=V]R:W-H965T
M<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( .-*:5,&:*^WP@,  'D1   9
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M<U!+ 0(4 Q0    ( .-*:5-XBHH.9P0  ,PC   /              "  79
M 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #C2FE3#Y142-H!  !9(
M&@              @ $*10$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " #C2FE3(5VG)LT!   D(   $P              @ $<1P$
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     /@ ^ .D0   :20$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>221</ContextCount>
  <ElementCount>356</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>14</UnitCount>
  <MyReports>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/NatureofBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - License and Development Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreements</Role>
      <ShortName>License and Development Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - Notes Receivable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.deitaxonomy.com/role/NotesReceivable</Role>
      <ShortName>Notes Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112105 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2116106 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2132109 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2134110 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2136111 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2142112 - Disclosure - Net Loss Per Share of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/NetLossPerShareofCommonStock</Role>
      <ShortName>Net Loss Per Share of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2146113 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2147114 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2313302 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/PropertyandEquipment</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/OperatingLeases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2324304 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/Debt</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2337306 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/StockbasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2343307 - Disclosure - Net Loss Per Share of Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockTables</Role>
      <ShortName>Net Loss Per Share of Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/NetLossPerShareofCommonStock</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Nature of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/NatureofBusinessAdditionalInformationDetails</Role>
      <ShortName>Nature of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - License and Development Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreementsDetails</Role>
      <ShortName>License and Development Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Notes Receivable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.deitaxonomy.com/role/NotesReceivableDetails</Role>
      <ShortName>Notes Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/NotesReceivable</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Property and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/PropertyandEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Operating Leases - Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesDetails</Role>
      <ShortName>Operating Leases - Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Operating Leases - Operating Leases, Components Of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Operating Leases - Operating Leases, Components Of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Operating Leases - Operating Leases, Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Operating Leases - Operating Leases, Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Operating Leases - Operating Leases, Supplemental Information Related To Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesSupplementalInformationRelatedToLeasesDetails</Role>
      <ShortName>Operating Leases - Operating Leases, Supplemental Information Related To Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Operating Leases - Operating Leases, Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Operating Leases - Operating Leases, Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Debt - Summary of the Carrying Values for the Components of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesfortheComponentsofDebtDetails</Role>
      <ShortName>Debt - Summary of the Carrying Values for the Components of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Debt - PPP Note (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/DebtPPPNoteDetails</Role>
      <ShortName>Debt - PPP Note (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - Debt - EB 5 Loan Agreement Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails</Role>
      <ShortName>Debt - EB 5 Loan Agreement Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2431417 - Disclosure - Debt - Summary of the Carrying Values of the Loan Agreement Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesoftheLoanAgreementBorrowingsDetails</Role>
      <ShortName>Debt - Summary of the Carrying Values of the Loan Agreement Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/Equity</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2435419 - Disclosure - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/WarrantsDetails</Role>
      <ShortName>Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/Warrants</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2438420 - Disclosure - Stock-based Compensation - Schedule of Compensation Expense for Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Compensation Expense for Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2439421 - Disclosure - Stock-based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2440422 - Disclosure - Stock-based Compensation - Schedule Options to Purchase Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails</Role>
      <ShortName>Stock-based Compensation - Schedule Options to Purchase Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2441423 - Disclosure - Stock-based Compensation - Schedule of RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofRSUActivityDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2444424 - Disclosure - Net Loss Per Share of Common Stock - Computation of basic and diluted earnings per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockComputationofbasicanddilutedearningspershareDetails</Role>
      <ShortName>Net Loss Per Share of Common Stock - Computation of basic and diluted earnings per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2445425 - Disclosure - Net Loss Per Share of Common Stock - Potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockPotentiallydilutivesecuritieshavebeenexcludedfromthecomputationofdilutedweightedaveragesharesoutstandingDetails</Role>
      <ShortName>Net Loss Per Share of Common Stock - Potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ocgn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2448426 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.deitaxonomy.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.deitaxonomy.com/role/SubsequentEvents</ParentRole>
      <Position>54</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ocgn-20210930.htm">ocgn-20210930.htm</File>
    <File>ocgn-20210930.xsd</File>
    <File>ocgn-20210930_cal.xml</File>
    <File>ocgn-20210930_def.xml</File>
    <File>ocgn-20210930_lab.xml</File>
    <File>ocgn-20210930_pre.xml</File>
    <File>ocgn-20210930x10qxex101.htm</File>
    <File>ocgn-20210930x10qxex102.htm</File>
    <File>ocgn-20210930x10qxex311.htm</File>
    <File>ocgn-20210930x10qxex312.htm</File>
    <File>ocgn-20210930x10qxex321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>73
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ocgn-20210930.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "contextCount": 221,
   "dts": {
    "calculationLink": {
     "local": [
      "ocgn-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ocgn-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ocgn-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ocgn-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ocgn-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ocgn-20210930.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 432,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 3,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 8
   },
   "keyCustom": 61,
   "keyStandard": 295,
   "memberCustom": 21,
   "memberStandard": 25,
   "nsprefix": "ocgn",
   "nsuri": "http://www.deitaxonomy.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.deitaxonomy.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - Notes Receivable",
     "role": "http://www.deitaxonomy.com/role/NotesReceivable",
     "shortName": "Notes Receivable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112105 - Disclosure - Property and Equipment",
     "role": "http://www.deitaxonomy.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116106 - Disclosure - Operating Leases",
     "role": "http://www.deitaxonomy.com/role/OperatingLeases",
     "shortName": "Operating Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "role": "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Debt",
     "role": "http://www.deitaxonomy.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132109 - Disclosure - Equity",
     "role": "http://www.deitaxonomy.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ocgn:WarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134110 - Disclosure - Warrants",
     "role": "http://www.deitaxonomy.com/role/Warrants",
     "shortName": "Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ocgn:WarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136111 - Disclosure - Stock-based Compensation",
     "role": "http://www.deitaxonomy.com/role/StockbasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142112 - Disclosure - Net Loss Per Share of Common Stock",
     "role": "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStock",
     "shortName": "Net Loss Per Share of Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146113 - Disclosure - Commitments and Contingencies",
     "role": "http://www.deitaxonomy.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "ib4b81d02d5c54e628ce7e36b656ecacc_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "ib4b81d02d5c54e628ce7e36b656ecacc_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdvancesOnInventoryPurchases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147114 - Disclosure - Subsequent Events",
     "role": "http://www.deitaxonomy.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ocgn:ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ocgn:ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313302 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.deitaxonomy.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Operating Leases (Tables)",
     "role": "http://www.deitaxonomy.com/role/OperatingLeasesTables",
     "shortName": "Operating Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324304 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "role": "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - Debt (Tables)",
     "role": "http://www.deitaxonomy.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337306 - Disclosure - Stock-based Compensation (Tables)",
     "role": "http://www.deitaxonomy.com/role/StockbasedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2343307 - Disclosure - Net Loss Per Share of Common Stock (Tables)",
     "role": "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockTables",
     "shortName": "Net Loss Per Share of Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Nature of Business - Additional Information (Details)",
     "role": "http://www.deitaxonomy.com/role/NatureofBusinessAdditionalInformationDetails",
     "shortName": "Nature of Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "ib4b81d02d5c54e628ce7e36b656ecacc_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "ib4b81d02d5c54e628ce7e36b656ecacc_I20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "ib4b81d02d5c54e628ce7e36b656ecacc_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ocgn:ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i7033dd63053e40b9b5c54b579a67eebc_I20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "iaa7ec21690a84b519c8521689d101b83_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i0ce37d1044984e42b76ce49925a5ea86_D20210601-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ocgn:CollaborationAgreementUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - License and Development Agreements (Details)",
     "role": "http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreementsDetails",
     "shortName": "License and Development Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i0ce37d1044984e42b76ce49925a5ea86_D20210601-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ocgn:CollaborationAgreementUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i83096eac0fe34c3aae4e263271cd518e_I20210413",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesReceivableGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Notes Receivable (Details)",
     "role": "http://www.deitaxonomy.com/role/NotesReceivableDetails",
     "shortName": "Notes Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i83096eac0fe34c3aae4e263271cd518e_I20210413",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesReceivableGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "ib4b81d02d5c54e628ce7e36b656ecacc_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)",
     "role": "http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
     "shortName": "Property and Equipment - Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "ib4b81d02d5c54e628ce7e36b656ecacc_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "iaa7ec21690a84b519c8521689d101b83_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Property and Equipment - Narrative (Details)",
     "role": "http://www.deitaxonomy.com/role/PropertyandEquipmentNarrativeDetails",
     "shortName": "Property and Equipment - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "iaa7ec21690a84b519c8521689d101b83_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "ib4b81d02d5c54e628ce7e36b656ecacc_I20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Operating Leases - Operating Leases (Details)",
     "role": "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesDetails",
     "shortName": "Operating Leases - Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ocgn:LesseeOperatingLeaseNumberOfRenewalTerms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "renewaloption",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "iaa7ec21690a84b519c8521689d101b83_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Operating Leases - Operating Leases, Components Of Lease Expense (Details)",
     "role": "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesComponentsOfLeaseExpenseDetails",
     "shortName": "Operating Leases - Operating Leases, Components Of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "iaa7ec21690a84b519c8521689d101b83_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ocgn:SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "ib4b81d02d5c54e628ce7e36b656ecacc_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Operating Leases - Operating Leases, Supplemental Balance Sheet Information (Details)",
     "role": "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesSupplementalBalanceSheetInformationDetails",
     "shortName": "Operating Leases - Operating Leases, Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ocgn:SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "ib4b81d02d5c54e628ce7e36b656ecacc_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "ib4b81d02d5c54e628ce7e36b656ecacc_I20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Operating Leases - Operating Leases, Supplemental Information Related To Leases (Details)",
     "role": "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesSupplementalInformationRelatedToLeasesDetails",
     "shortName": "Operating Leases - Operating Leases, Supplemental Information Related To Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "ib4b81d02d5c54e628ce7e36b656ecacc_I20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "iaa7ec21690a84b519c8521689d101b83_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "iaa7ec21690a84b519c8521689d101b83_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "ib4b81d02d5c54e628ce7e36b656ecacc_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Operating Leases - Operating Leases, Future Minimum Lease Payments (Details)",
     "role": "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails",
     "shortName": "Operating Leases - Operating Leases, Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "ib4b81d02d5c54e628ce7e36b656ecacc_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "ib4b81d02d5c54e628ce7e36b656ecacc_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ocgn:ResearchAndDevelopmentExpensesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "role": "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i6c78f41bc4d34d2f97ae2010184d9723_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ocgn:ResearchAndDevelopmentExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "ib4b81d02d5c54e628ce7e36b656ecacc_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Debt - Summary of the Carrying Values for the Components of Debt (Details)",
     "role": "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesfortheComponentsofDebtDetails",
     "shortName": "Debt - Summary of the Carrying Values for the Components of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i01a12a6485e345b6ab72567171ec0eb0_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Debt - PPP Note (Details)",
     "role": "http://www.deitaxonomy.com/role/DebtPPPNoteDetails",
     "shortName": "Debt - PPP Note (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i85638365ecb449f89cd737e151a543eb_I20200430",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i0894763e64ad446393df6c07eb805c5f_I20160930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - Debt - EB 5 Loan Agreement Borrowings (Details)",
     "role": "http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails",
     "shortName": "Debt - EB 5 Loan Agreement Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i0894763e64ad446393df6c07eb805c5f_I20160930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "ib4b81d02d5c54e628ce7e36b656ecacc_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431417 - Disclosure - Debt - Summary of the Carrying Values of the Loan Agreement Borrowings (Details)",
     "role": "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesoftheLoanAgreementBorrowingsDetails",
     "shortName": "Debt - Summary of the Carrying Values of the Loan Agreement Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i92ea040ac4094cb2a62e60e72ca77b3c_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "ib4b81d02d5c54e628ce7e36b656ecacc_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Equity (Details)",
     "role": "http://www.deitaxonomy.com/role/EquityDetails",
     "shortName": "Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "iefbd2c9026804907ae58afb0f262bb0d_I20210430",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i1e39c130cffe499eaae2b4c55fef5b42_D20191001-20191031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ocgn:NumberOfSeriesOfWarrantsIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "seriesofwarrant",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435419 - Disclosure - Warrants (Details)",
     "role": "http://www.deitaxonomy.com/role/WarrantsDetails",
     "shortName": "Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i1e39c130cffe499eaae2b4c55fef5b42_D20191001-20191031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ocgn:NumberOfSeriesOfWarrantsIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "seriesofwarrant",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "iaa7ec21690a84b519c8521689d101b83_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438420 - Disclosure - Stock-based Compensation - Schedule of Compensation Expense for Options Granted (Details)",
     "role": "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails",
     "shortName": "Stock-based Compensation - Schedule of Compensation Expense for Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "ie0a8b70d6fb84c5a9789d450871ed83a_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "iaa7ec21690a84b519c8521689d101b83_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439421 - Disclosure - Stock-based Compensation - Narrative (Details)",
     "role": "http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails",
     "shortName": "Stock-based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "iaa7ec21690a84b519c8521689d101b83_D20210701-20210930",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "iaeb9a66837754ddcabb2a790c8f98a21_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)",
     "role": "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i8558526a156344b6bc64e01cde3185fd_D20200101-20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i6c78f41bc4d34d2f97ae2010184d9723_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440422 - Disclosure - Stock-based Compensation - Schedule Options to Purchase Common Stock (Details)",
     "role": "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails",
     "shortName": "Stock-based Compensation - Schedule Options to Purchase Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i97535b68d960495f906585585e65538d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441423 - Disclosure - Stock-based Compensation - Schedule of RSU Activity (Details)",
     "role": "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofRSUActivityDetails",
     "shortName": "Stock-based Compensation - Schedule of RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i97535b68d960495f906585585e65538d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "iaa7ec21690a84b519c8521689d101b83_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444424 - Disclosure - Net Loss Per Share of Common Stock - Computation of basic and diluted earnings per share (Details)",
     "role": "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockComputationofbasicanddilutedearningspershareDetails",
     "shortName": "Net Loss Per Share of Common Stock - Computation of basic and diluted earnings per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "iaa7ec21690a84b519c8521689d101b83_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "iaa7ec21690a84b519c8521689d101b83_D20210701-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445425 - Disclosure - Net Loss Per Share of Common Stock - Potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding (Details)",
     "role": "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockPotentiallydilutivesecuritieshavebeenexcludedfromthecomputationofdilutedweightedaveragesharesoutstandingDetails",
     "shortName": "Net Loss Per Share of Common Stock - Potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "iaa7ec21690a84b519c8521689d101b83_D20210701-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "ib4b81d02d5c54e628ce7e36b656ecacc_I20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448426 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.deitaxonomy.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i9c6b3eaa0af149b0b68069f2bcf0750e_I20211015",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ocgn:NonCashInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of Business",
     "role": "http://www.deitaxonomy.com/role/NatureofBusiness",
     "shortName": "Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - License and Development Agreements",
     "role": "http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreements",
     "shortName": "License and Development Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ocgn-20210930.htm",
      "contextRef": "i52d9db304374467785253218ec6f15f0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 51,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ocgn_A2014PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2014 Plan",
        "label": "2014 Plan [Member]",
        "terseLabel": "2014 Plan"
       }
      }
     },
     "localname": "A2014PlanMember",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_A2019PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Plan",
        "label": "2019 Plan [Member]",
        "terseLabel": "2019 Plan"
       }
      }
     },
     "localname": "A2019PlanMember",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_ATMTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Transactions",
        "label": "ATM Transactions [Member]",
        "terseLabel": "At-the-market Issuance"
       }
      }
     },
     "localname": "ATMTransactionsMember",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_AccruedLiabilitiesClinical": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities, Clinical",
        "label": "Accrued Liabilities, Clinical",
        "terseLabel": "Clinical"
       }
      }
     },
     "localname": "AccruedLiabilitiesClinical",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_AccruedLiabilitiesProfessionalFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities, Professional Fees",
        "label": "Accrued Liabilities, Professional Fees",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedLiabilitiesProfessionalFees",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_AccruedSeveranceRelatedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Severance-Related Liabilities, Current",
        "label": "Accrued Severance-Related Liabilities, Current",
        "terseLabel": "Severance-related"
       }
      }
     },
     "localname": "AccruedSeveranceRelatedLiabilitiesCurrent",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_AdverseEventsSeriousAdverseSideEffectsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adverse Events, Serious Adverse Side Effects, Percent",
        "label": "Adverse Events, Serious Adverse Side Effects, Percent",
        "terseLabel": "Adverse events, serious adverse side effects (less than) (percentage)"
       }
      }
     },
     "localname": "AdverseEventsSeriousAdverseSideEffectsPercent",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/NatureofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocgn_AdverseEventsSideEffectsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adverse Events, Side Effects, Percent",
        "label": "Adverse Events, Side Effects, Percent",
        "terseLabel": "Adverse events, side effects (percentage)"
       }
      }
     },
     "localname": "AdverseEventsSideEffectsPercent",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/NatureofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocgn_AssetHeldForSalePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Held For Sale",
        "label": "Asset Held For Sale [Policy Text Block]",
        "terseLabel": "Asset Held for Sale"
       }
      }
     },
     "localname": "AssetHeldForSalePolicyTextBlock",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ocgn_BaseRentPaymentsExpectedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base Rent Payments, Expected Cost",
        "label": "Base Rent Payments, Expected Cost",
        "terseLabel": "Estimated base rent payments"
       }
      }
     },
     "localname": "BaseRentPaymentsExpectedCost",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_COVAXINPreferredStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVAXIN Preferred Stock Purchase Agreement",
        "label": "COVAXIN Preferred Stock Purchase Agreement [Member]",
        "terseLabel": "COVAXIN Preferred Stock Purchase Agreement"
       }
      }
     },
     "localname": "COVAXINPreferredStockPurchaseAgreementMember",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/EquityDetails",
      "http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_CanadaConsultingWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Canada Consulting Warrants",
        "label": "Canada Consulting Warrants [Member]",
        "terseLabel": "Canada Consulting Warrants"
       }
      }
     },
     "localname": "CanadaConsultingWarrantsMember",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Consideration Transferred In Excess Of Fair Value",
        "label": "Class Of Warrant Or Right, Consideration Transferred In Excess Of Fair Value",
        "terseLabel": "Fair value of consideration transferred to settle warrants in excess of fair value of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightConsiderationTransferredInExcessOfFairValue",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_ClassOfWarrantOrRightExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercisable",
        "label": "Class of Warrant or Right, Exercisable",
        "terseLabel": "Class of warrant or right, exercisable (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisable",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocgn_ClassOfWarrantOrRightExpectedMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Expected Milestone Payment",
        "label": "Class of Warrant or Right, Expected Milestone Payment",
        "terseLabel": "Expected milestone payment"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExpectedMilestonePayment",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Fair Value Of Consideration Transferred To Settle Warrants",
        "label": "Class Of Warrant Or Right, Fair Value Of Consideration Transferred To Settle Warrants",
        "terseLabel": "Fair value of consideration transferred to settle warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrants",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Fair Value Of Consideration Transferred To Settle Warrants, Common Stock",
        "label": "Class Of Warrant Or Right, Fair Value Of Consideration Transferred To Settle Warrants, Common Stock",
        "terseLabel": "Consideration transferred, common stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsCommonStock",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Fair Value Of Consideration Transferred To Settle Warrants, Promissory Note",
        "label": "Class Of Warrant Or Right, Fair Value Of Consideration Transferred To Settle Warrants, Promissory Note",
        "terseLabel": "Consideration transferred, warrant exchange promissory notes"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightFairValueOfConsiderationTransferredToSettleWarrantsPromissoryNote",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Additional Payment Within 30 Days Of First Commercial Sale In Canada",
        "label": "Collaboration Agreement, Additional Payment Within 30 Days Of First Commercial Sale In Canada",
        "terseLabel": "Additional payment"
       }
      }
     },
     "localname": "CollaborationAgreementAdditionalPaymentWithin30DaysOfFirstCommercialSaleInCanada",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_CollaborationAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement Term",
        "label": "Collaboration Agreement Term",
        "terseLabel": "Collaboration Agreement Term"
       }
      }
     },
     "localname": "CollaborationAgreementTerm",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ocgn_CollaborationAgreementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Upfront Payment",
        "label": "Collaboration Agreement, Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "CollaborationAgreementUpfrontPayment",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_CollaborationAgreementWithCansinoBiologicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement With Cansino Biologics",
        "label": "Collaboration Agreement With Cansino Biologics [Member]",
        "terseLabel": "Collaboration Agreement With Cansino Biologics"
       }
      }
     },
     "localname": "CollaborationAgreementWithCansinoBiologicsMember",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_CollaborativeArrangementProfitsGeneratedSharedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Profits Generated, Shared, Percentage",
        "label": "Collaborative Arrangement, Profits Generated, Shared, Percentage",
        "terseLabel": "Profits generated, shared percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementProfitsGeneratedSharedPercentage",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocgn_ControlledEquityOfferingSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Controlled Equity Offering Sales Agreement",
        "label": "Controlled Equity Offering Sales Agreement [Member]",
        "terseLabel": "ATMs"
       }
      }
     },
     "localname": "ControlledEquityOfferingSalesAgreementMember",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_EB5ProgramBorrowingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents borrowings from the U.S. government's Immigrant Investor Program, commonly known as the EB 5 program (the \"EB 5 Program\").",
        "label": "E B5 Program Borrowings [Member]",
        "terseLabel": "EB-5 Loan Agreement"
       }
      }
     },
     "localname": "EB5ProgramBorrowingsMember",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesfortheComponentsofDebtDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesoftheLoanAgreementBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_EfficacyAgainstDeltaVariantB16172Percent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Efficacy Against Delta Variant, B.1.617.2, Percent",
        "label": "Efficacy Against Delta Variant, B.1.617.2, Percent",
        "terseLabel": "Efficacy against delta variant, B.1.617.2 (percentage)"
       }
      }
     },
     "localname": "EfficacyAgainstDeltaVariantB16172Percent",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/NatureofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocgn_EfficacyAsymptomaticInfectionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Efficacy, Asymptomatic Infection, Percent",
        "label": "Efficacy, Asymptomatic Infection, Percent",
        "terseLabel": "Efficacy, asymptomatic infection (percentage)"
       }
      }
     },
     "localname": "EfficacyAsymptomaticInfectionPercent",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/NatureofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocgn_EfficacySevereCasesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Efficacy, Severe Cases, Percent",
        "label": "Efficacy, Severe Cases, Percent",
        "terseLabel": "Efficacy, severe cases (percentage)"
       }
      }
     },
     "localname": "EfficacySevereCasesPercent",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/NatureofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocgn_FinancingReceivableInterestRateStatedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Interest Rate, Stated Percentage",
        "label": "Financing Receivable, Interest Rate, Stated Percentage",
        "terseLabel": "Promissory note, interest rate"
       }
      }
     },
     "localname": "FinancingReceivableInterestRateStatedPercentage",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocgn_GainLossOnForgivenessOfPaycheckProtectionProgramNote": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Forgiveness Of Paycheck Protection Program Note",
        "label": "Gain (Loss) On Forgiveness Of Paycheck Protection Program Note",
        "terseLabel": "Forgiveness of PPP Note"
       }
      }
     },
     "localname": "GainLossOnForgivenessOfPaycheckProtectionProgramNote",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_IncreaseDecreaseInLeaseObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Lease Obligations",
        "label": "Increase (Decrease) In Lease Obligations",
        "terseLabel": "Lease obligations"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseObligations",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_IssuanceOfFinancingReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Of Financing Receivable",
        "label": "Issuance Of Financing Receivable",
        "negatedTerseLabel": "Issuance of note receivable"
       }
      }
     },
     "localname": "IssuanceOfFinancingReceivable",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_LesseeOperatingLeaseNumberOfRenewalTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number of Renewal Terms",
        "label": "Lessee, Operating Lease, Number of Renewal Terms",
        "terseLabel": "Operating lease, number of renewal terms"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalTerms",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocgn_LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Term Of Contract For Additional Lease Agreement",
        "label": "Lessee, Operating Lease, Term Of Contract For Additional Lease Agreement",
        "terseLabel": "Leases, term of contract for additional lease agreement"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ocgn_LineOfCreditBorrowingEachDraw": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of borrowing that can be borrowed each draw from a line of credit",
        "label": "Line Of Credit Borrowing Each Draw",
        "terseLabel": "Borrowing increments"
       }
      }
     },
     "localname": "LineOfCreditBorrowingEachDraw",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_MachineryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Machinery",
        "label": "Machinery [Member]",
        "terseLabel": "Machinery"
       }
      }
     },
     "localname": "MachineryMember",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_ModifierGeneTherapyPlatformNumberOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Modifier Gene Therapy Platform, Number of Products",
        "label": "Modifier Gene Therapy Platform, Number of Products",
        "terseLabel": "Modifier gene therapy platform, number of products"
       }
      }
     },
     "localname": "ModifierGeneTherapyPlatformNumberOfProducts",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/NatureofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocgn_NonCashInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of non-cash interest expense during the period.",
        "label": "Non-Cash Interest Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestExpense",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Lease Expense",
        "label": "Noncash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_NoncashOrPartNoncashAmountOfDeferredTransactionCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash or part noncash amount of deferred transaction cost.",
        "label": "Noncash Or Part Noncash Amount of Deferred Transaction Cost",
        "terseLabel": "Equity issuance costs"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAmountOfDeferredTransactionCost",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_NoncashOrPartNoncashOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-to-use asset recognized upon adoption of ASU 2018-11.",
        "label": "Noncash or Part Noncash, Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset related to operating leases"
       }
      }
     },
     "localname": "NoncashOrPartNoncashOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_NumberOfAdditionalLeaseAgreementExtensions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Additional Lease Agreement Extensions",
        "label": "Number Of Additional Lease Agreement Extensions",
        "terseLabel": "Number of additional lease agreement extensions"
       }
      }
     },
     "localname": "NumberOfAdditionalLeaseAgreementExtensions",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocgn_NumberOfAtTheMarketOfferings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of At-The-Market Offerings",
        "label": "Number Of At-The-Market Offerings",
        "terseLabel": "Number of at-the-market offerings"
       }
      }
     },
     "localname": "NumberOfAtTheMarketOfferings",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/EquityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocgn_NumberOfEquityCompensationPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Equity Compensation Plans",
        "label": "Number Of Equity Compensation Plans",
        "terseLabel": "Number of equity compensation plans"
       }
      }
     },
     "localname": "NumberOfEquityCompensationPlans",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocgn_NumberOfFormerEmployeesWithWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Former Employees With Warrants",
        "label": "Number Of Former Employees With Warrants",
        "terseLabel": "Number of former employees with warrants"
       }
      }
     },
     "localname": "NumberOfFormerEmployeesWithWarrants",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocgn_NumberOfOrphanDrugDesignations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Orphan Drug Designations",
        "label": "Number Of Orphan Drug Designations",
        "terseLabel": "Number of ODDs received (orphan drug designation)"
       }
      }
     },
     "localname": "NumberOfOrphanDrugDesignations",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/NatureofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocgn_NumberOfSeriesOfWarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Series of Warrants Issued",
        "label": "Number Of Series of Warrants Issued",
        "terseLabel": "Number of series of warrants issued"
       }
      }
     },
     "localname": "NumberOfSeriesOfWarrantsIssued",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocgn_NumberOfVaccinationDoseRegimen": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Vaccination Dose Regimen",
        "label": "Number of Vaccination Dose Regimen",
        "terseLabel": "Number of vaccination dose regimen"
       }
      }
     },
     "localname": "NumberOfVaccinationDoseRegimen",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/NatureofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocgn_OpCoWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OpCo Warrants",
        "label": "OpCo Warrants [Member]",
        "terseLabel": "OpCo Warrants"
       }
      }
     },
     "localname": "OpCoWarrantsMember",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_OverallVaccineEfficacyPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Overall vaccine efficacy, Percent",
        "label": "Overall vaccine efficacy, Percent",
        "terseLabel": "Overall vaccine efficacy (percentage)"
       }
      }
     },
     "localname": "OverallVaccineEfficacyPercent",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/NatureofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocgn_PaycheckProtectionProgramLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck Protection Program Loan",
        "label": "Paycheck Protection Program Loan [Member]",
        "terseLabel": "PPP Note",
        "verboseLabel": "PPP Note"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoanMember",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtPPPNoteDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesfortheComponentsofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_PreferredStockMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Measurement Input",
        "label": "Preferred Stock, Measurement Input",
        "terseLabel": "Preferred stock, measurement input"
       }
      }
     },
     "localname": "PreferredStockMeasurementInput",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/EquityDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ocgn_RegisteredDirectOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registered Direct Offering",
        "label": "Registered Direct Offering [Member]",
        "terseLabel": "Registered Direct Offering"
       }
      }
     },
     "localname": "RegisteredDirectOfferingMember",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.deitaxonomy.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_ResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Research And Development Expenses Current",
        "terseLabel": "Research\u00a0and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_SPAWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SPA Warrants",
        "label": "SPA Warrants [Member]",
        "terseLabel": "SPA Warrants"
       }
      }
     },
     "localname": "SPAWarrantsMember",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_SaleOfStockAdditionalDebtCancelledInExchangeForStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Additional Debt Cancelled In Exchange For Stock",
        "label": "Sale Of Stock, Additional Debt Cancelled In Exchange For Stock",
        "terseLabel": "Accredited investors agreement to cancel additional portion owed representing a discount"
       }
      }
     },
     "localname": "SaleOfStockAdditionalDebtCancelledInExchangeForStock",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Agreement to Sell, Number of Shares Issued in Transaction",
        "label": "Sale of Stock, Agreement to Sell, Number of Shares Issued in Transaction",
        "terseLabel": "Agreement to sell, number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockAgreementToSellNumberOfSharesIssuedInTransaction",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocgn_SaleOfStockAgreementToSellPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Agreement to Sell, Price Per Share",
        "label": "Sale of Stock, Agreement to Sell, Price Per Share",
        "terseLabel": "Agreement to sell, price per share (in USD per share)"
       }
      }
     },
     "localname": "SaleOfStockAgreementToSellPricePerShare",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/EquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ocgn_SaleOfStockOutstandingObligationCancelledInExchangeForStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Outstanding Obligation Cancelled In Exchange For Stock",
        "label": "Sale Of Stock, Outstanding Obligation Cancelled In Exchange For Stock",
        "terseLabel": "Accredited investors agreement to cancel outstanding obligation"
       }
      }
     },
     "localname": "SaleOfStockOutstandingObligationCancelledInExchangeForStock",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents, restricted cash.",
        "label": "Schedule of Cash and Cash Equivalents, Restricted Cash [Table Text Block]",
        "terseLabel": "Schedule of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ocgn_SeriesAWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Series A Warrants.",
        "label": "Series A Warrants [Member]",
        "terseLabel": "Series A Warrants"
       }
      }
     },
     "localname": "SeriesAWarrantsMember",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_SeriesBWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Series B Warrants.",
        "label": "Series B Warrants [Member]",
        "terseLabel": "Series B Warrants"
       }
      }
     },
     "localname": "SeriesBWarrantsMember",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_SeriesCWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Series C Warrants.",
        "label": "Series C Warrants [Member]",
        "terseLabel": "Series C Warrants"
       }
      }
     },
     "localname": "SeriesCWarrantsMember",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Forfeitures In Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Forfeitures In Period",
        "terseLabel": "Aggregate intrinsic value, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeituresInPeriod",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Granted",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Granted",
        "terseLabel": "Aggregate intrinsic value, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited in Period, Intrinsic Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Not Yet Exercisable, Number",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Not Yet Exercisable, Number",
        "terseLabel": "Options not yet exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNotYetExercisableNumber",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocgn_ShareBasedPaymentArrangementPerformanceBasedOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Performance Based Option",
        "label": "Share-based Payment Arrangement, Performance Based Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Performance Based Option"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementPerformanceBasedOptionMember",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_SingleGeneReplacementTherapiesNumberOfGeneticMutationsTarget": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single Gene Replacement Therapies, Number Of Genetic Mutations Target",
        "label": "Single Gene Replacement Therapies, Number Of Genetic Mutations Target",
        "terseLabel": "Single gene replacement therapies, number of genetic mutations target"
       }
      }
     },
     "localname": "SingleGeneReplacementTherapiesNumberOfGeneticMutationsTarget",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/NatureofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocgn_StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Options And Warrants Exercised",
        "label": "Stock Issued During Period, Shares, Options And Warrants Exercised",
        "terseLabel": "Issuance of common stock for option and warrant exercises (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOptionsAndWarrantsExercised",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocgn_StockIssuedDuringPeriodSharesWarrantExchange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Warrant Exchange",
        "label": "Stock Issued During Period, Shares, Warrant Exchange",
        "terseLabel": "Warrant Exchange (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantExchange",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocgn_StockIssuedDuringPeriodValueOptionsAndWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Options And Warrants Exercised",
        "label": "Stock Issued During Period, Value, Options And Warrants Exercised",
        "terseLabel": "Issuance of common stock for option and warrant exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOptionsAndWarrantsExercised",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_StockIssuedDuringPeriodValueWarrantExchange": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Warrant Exchange",
        "label": "Stock Issued During Period, Value, Warrant Exchange",
        "terseLabel": "Warrant Exchange"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantExchange",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocgn_SubscriptionAgreementsAndWarrantExercisesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subscription Agreements And Warrant Exercises",
        "label": "Subscription Agreements And Warrant Exercises [Member]",
        "terseLabel": "Subscription Agreements and Warrant Exercises"
       }
      }
     },
     "localname": "SubscriptionAgreementsAndWarrantExercisesMember",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_SubscriptionAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subscription Agreements",
        "label": "Subscription Agreements [Member]",
        "terseLabel": "Subscription Agreements"
       }
      }
     },
     "localname": "SubscriptionAgreementsMember",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Balance Sheet Information, Leases Disclosure",
        "label": "Supplemental Balance Sheet Information, Leases Disclosure [Table Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information Related to Leases"
       }
      }
     },
     "localname": "SupplementalBalanceSheetInformationLeasesDisclosureTableTextBlock",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ocgn_SupplyAgreementNumberOfDoses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Agreement, Number of Doses",
        "label": "Supply Agreement, Number of Doses",
        "terseLabel": "Supply agreement, number of doses"
       }
      }
     },
     "localname": "SupplyAgreementNumberOfDoses",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/EquityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocgn_VaccinationDoseRegimenDurationApart": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vaccination Dose Regimen, Duration Apart",
        "label": "Vaccination Dose Regimen, Duration Apart",
        "terseLabel": "Vaccination dose regimen, duration apart"
       }
      }
     },
     "localname": "VaccinationDoseRegimenDurationApart",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/NatureofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ocgn_WarrantExchangePromissoryNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Exchange Promissory Notes",
        "label": "Warrant Exchange Promissory Notes [Member]",
        "terseLabel": "Warrant Exchange Promissory Notes"
       }
      }
     },
     "localname": "WarrantExchangePromissoryNotesMember",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_WarrantsExchangedForCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Exchanged For Common Stock",
        "label": "Warrants Exchanged For Common Stock [Member]",
        "terseLabel": "Warrants Exchanged For Common Stock"
       }
      }
     },
     "localname": "WarrantsExchangedForCommonStockMember",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocgn_WarrantsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants",
        "label": "Warrants [Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsTextBlock",
     "nsuri": "http://www.deitaxonomy.com/20210930",
     "presentation": [
      "http://www.deitaxonomy.com/role/Warrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r242",
      "r278",
      "r312",
      "r313",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r465",
      "r499",
      "r500",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r242",
      "r278",
      "r312",
      "r313",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r465",
      "r499",
      "r500",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r242",
      "r278",
      "r303",
      "r312",
      "r313",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r465",
      "r499",
      "r500",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r242",
      "r278",
      "r303",
      "r312",
      "r313",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r465",
      "r499",
      "r500",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r39",
      "r431"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r27",
      "r350",
      "r431"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r347",
      "r348",
      "r349",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r314",
      "r316",
      "r352",
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r292",
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Commissions, fees and expenses"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvancesOnInventoryPurchases": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.",
        "label": "Advances on Inventory Purchases",
        "terseLabel": "Advance for COVAXIN supply"
       }
      }
     },
     "localname": "AdvancesOnInventoryPurchases",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r316",
      "r340",
      "r351"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails",
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities outstanding excluded from the computation of diluted weighted average shares outstanding"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockPotentiallydilutivesecuritieshavebeenexcludedfromthecomputationofdilutedweightedaveragesharesoutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockPotentiallydilutivesecuritieshavebeenexcludedfromthecomputationofdilutedweightedaveragesharesoutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockPotentiallydilutivesecuritieshavebeenexcludedfromthecomputationofdilutedweightedaveragesharesoutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockPotentiallydilutivesecuritieshavebeenexcludedfromthecomputationofdilutedweightedaveragesharesoutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r95",
      "r158",
      "r161",
      "r167",
      "r182",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r370",
      "r373",
      "r389",
      "r429",
      "r431",
      "r472",
      "r487"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r51",
      "r95",
      "r182",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r370",
      "r373",
      "r389",
      "r429",
      "r431"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": {
     "auth_ref": [
      "r203",
      "r431"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.",
        "label": "Assets Held-for-sale, Not Part of Disposal Group, Current",
        "terseLabel": "Asset held for sale"
       }
      }
     },
     "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r317",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails",
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Consolidation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r6",
      "r34",
      "r83"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r16",
      "r84",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r78",
      "r83",
      "r88"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "terseLabel": "Cash, cash equivalents and restricted cash",
        "totalLabel": "Total cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.deitaxonomy.com/role/NatureofBusinessAdditionalInformationDetails",
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r78",
      "r398"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r92",
      "r95",
      "r120",
      "r121",
      "r126",
      "r129",
      "r131",
      "r140",
      "r141",
      "r142",
      "r182",
      "r228",
      "r232",
      "r233",
      "r234",
      "r237",
      "r238",
      "r276",
      "r277",
      "r280",
      "r284",
      "r389",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.deitaxonomy.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r301",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Initial exercise price (in USD per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Number of warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r301",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaboration Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r364",
      "r365",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Development Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Covaxin Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r47",
      "r224",
      "r477",
      "r492"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 13)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r225",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r99",
      "r100",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.deitaxonomy.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r26",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r26",
      "r431"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock; $0.01 par value; 295,000,000 and 200,000,000 shares authorized, 199,049,329 and 184,133,384 shares issued, and 198,927,829 and 184,011,884 shares outstanding at September\u00a030, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r54",
      "r56",
      "r57",
      "r65",
      "r481",
      "r495"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r90",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r24",
      "r25",
      "r287",
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Convertible preferred stock, shares issued upon conversion (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": {
     "auth_ref": [
      "r215",
      "r216",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.",
        "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]",
        "terseLabel": "Exit and Disposal Activities"
       }
      }
     },
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r91",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r256",
      "r263",
      "r264",
      "r266",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r94",
      "r97",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r252",
      "r253",
      "r254",
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r269",
      "r270",
      "r271",
      "r272",
      "r410",
      "r473",
      "r474",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails",
      "http://www.deitaxonomy.com/role/DebtPPPNoteDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesfortheComponentsofDebtDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesoftheLoanAgreementBorrowingsDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r22",
      "r267",
      "r474",
      "r486"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal outstanding"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesoftheLoanAgreementBorrowingsDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r239",
      "r269",
      "r270",
      "r408",
      "r410",
      "r411"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Aggregate amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtPPPNoteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r45",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails",
      "http://www.deitaxonomy.com/role/DebtPPPNoteDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails",
      "http://www.deitaxonomy.com/role/DebtPPPNoteDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesfortheComponentsofDebtDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesoftheLoanAgreementBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r46",
      "r94",
      "r97",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r252",
      "r253",
      "r254",
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r269",
      "r270",
      "r271",
      "r272",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails",
      "http://www.deitaxonomy.com/role/DebtPPPNoteDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesfortheComponentsofDebtDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesoftheLoanAgreementBorrowingsDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r46",
      "r94",
      "r97",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r252",
      "r253",
      "r254",
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r265",
      "r269",
      "r270",
      "r271",
      "r272",
      "r293",
      "r295",
      "r296",
      "r297",
      "r407",
      "r408",
      "r410",
      "r411",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails",
      "http://www.deitaxonomy.com/role/DebtPPPNoteDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesfortheComponentsofDebtDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesoftheLoanAgreementBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r38",
      "r252",
      "r409"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Less: unamortized debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesoftheLoanAgreementBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r81",
      "r204"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.deitaxonomy.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r66",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r117",
      "r120",
      "r129",
      "r130",
      "r131",
      "r136",
      "r137",
      "r385",
      "r386",
      "r482",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share of common stock - basic (in USD per share)",
        "verboseLabel": "Net loss per common share - basic and diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockComputationofbasicanddilutedearningspershareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r66",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r120",
      "r129",
      "r130",
      "r131",
      "r136",
      "r137",
      "r385",
      "r386",
      "r482",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share of common stock - diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockComputationofbasicanddilutedearningspershareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share of Common Stock"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee-related"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense related to options outstanding, weighted average period for expense to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Severance-related charges"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r58",
      "r59",
      "r60",
      "r99",
      "r100",
      "r101",
      "r104",
      "r113",
      "r115",
      "r139",
      "r186",
      "r292",
      "r298",
      "r347",
      "r348",
      "r349",
      "r359",
      "r360",
      "r384",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r503",
      "r504",
      "r505",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r254",
      "r269",
      "r270",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r387",
      "r438",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/EquityDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r254",
      "r269",
      "r270",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r387",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/EquityDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r254",
      "r269",
      "r270",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r438",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/EquityDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r415",
      "r421"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Financing lease principal payments"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "terseLabel": "Financing lease right-of-use asset"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r190",
      "r192",
      "r193",
      "r194",
      "r196",
      "r199",
      "r200",
      "r201",
      "r202",
      "r265",
      "r290",
      "r375",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r81",
      "r273",
      "r274"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Gain on forgiveness of PPP Note",
        "terseLabel": "Gain on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.deitaxonomy.com/role/DebtPPPNoteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r63",
      "r158",
      "r160",
      "r163",
      "r166",
      "r168",
      "r470",
      "r479",
      "r484",
      "r497"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r208",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxCreditsAndAdjustments": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.",
        "label": "Income Tax Credits and Adjustments",
        "terseLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxCreditsAndAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r114",
      "r115",
      "r157",
      "r356",
      "r361",
      "r362",
      "r498"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r61",
      "r156",
      "r406",
      "r409",
      "r483"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r476",
      "r493"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Interest Payable",
        "terseLabel": "Plus: accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesoftheLoanAgreementBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r69",
      "r155"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r424",
      "r426"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesComponentsOfLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease renewal term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Leases, term of contract (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesDetails",
      "http://www.deitaxonomy.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/OperatingLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r42",
      "r95",
      "r162",
      "r182",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r371",
      "r373",
      "r374",
      "r389",
      "r429",
      "r430"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r31",
      "r95",
      "r182",
      "r389",
      "r431",
      "r475",
      "r491"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r44",
      "r95",
      "r182",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r371",
      "r373",
      "r374",
      "r389",
      "r429",
      "r430",
      "r431"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r22",
      "r23",
      "r95",
      "r182",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r371",
      "r373",
      "r374",
      "r389",
      "r429",
      "r430"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r22",
      "r474",
      "r486"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Company borrowed"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a company, excluding disclosure for allowance for credit losses. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Also excludes disclosure for financing receivables.",
        "label": "Loans, Notes, Trade and Other Receivables, Excluding Allowance for Credit Losses [Text Block]",
        "terseLabel": "Notes Receivable"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NotesReceivable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Loans payable"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails",
      "http://www.deitaxonomy.com/role/DebtPPPNoteDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesfortheComponentsofDebtDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesoftheLoanAgreementBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r22",
      "r253",
      "r268",
      "r269",
      "r270",
      "r474",
      "r489"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Total carrying value of debt, net",
        "totalLabel": "Carrying value"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesfortheComponentsofDebtDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesoftheLoanAgreementBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails",
      "http://www.deitaxonomy.com/role/DebtPPPNoteDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesfortheComponentsofDebtDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesoftheLoanAgreementBorrowingsDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r46",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtEB5LoanAgreementBorrowingsDetails",
      "http://www.deitaxonomy.com/role/DebtPPPNoteDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesfortheComponentsofDebtDetails",
      "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesoftheLoanAgreementBorrowingsDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r143",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NatureofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r78",
      "r79",
      "r82"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r53",
      "r55",
      "r60",
      "r64",
      "r82",
      "r95",
      "r103",
      "r108",
      "r109",
      "r110",
      "r111",
      "r114",
      "r115",
      "r127",
      "r158",
      "r160",
      "r163",
      "r166",
      "r168",
      "r182",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r386",
      "r389",
      "r480",
      "r494"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS_1": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      },
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockComputationofbasicanddilutedearningspershareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss - basic and diluted"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.deitaxonomy.com/role/NatureofBusinessAdditionalInformationDetails",
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockComputationofbasicanddilutedearningspershareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r111",
      "r117",
      "r118",
      "r128",
      "r131",
      "r158",
      "r160",
      "r163",
      "r166",
      "r168"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockComputationofbasicanddilutedearningspershareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r119",
      "r122",
      "r123",
      "r124",
      "r125",
      "r128",
      "r131"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockComputationofbasicanddilutedearningspershareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net loss to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockComputationofbasicanddilutedearningspershareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r110",
      "r116",
      "r136",
      "r175",
      "r176",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r227",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r357",
      "r358",
      "r359",
      "r360",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r428",
      "r467",
      "r468",
      "r469",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Standards and Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesIssued1": {
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of notes issued in noncash investing and financing activities.",
        "label": "Notes Issued",
        "terseLabel": "Issuance of Warrant Exchange Promissory Notes"
       }
      }
     },
     "localname": "NotesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableToBanksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a bank.",
        "label": "Notes Payable to Banks [Member]",
        "terseLabel": "Notes payable"
       }
      }
     },
     "localname": "NotesPayableToBanksMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtSummaryoftheCarryingValuesfortheComponentsofDebtDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesReceivableGross": {
     "auth_ref": [
      "r172",
      "r189",
      "r193",
      "r195",
      "r197",
      "r198",
      "r532",
      "r533",
      "r534"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of financing receivable.",
        "label": "Financing Receivable, before Allowance for Credit Loss",
        "terseLabel": "Promissory note"
       }
      }
     },
     "localname": "NotesReceivableGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NatureofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r158",
      "r160",
      "r163",
      "r166",
      "r168"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r419",
      "r426"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesComponentsOfLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesSupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of minimum lease payments",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails",
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesSupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease obligation",
        "verboseLabel": "Current lease obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesSupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease obligation, less current portion",
        "verboseLabel": "Non-current lease obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r412"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r423",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate\u2014operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesSupplementalInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r422",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease terms\u2014operating leases (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesSupplementalInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r43"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other non-cash"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payments of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of equity issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Asset acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r317",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustments": {
     "auth_ref": [
      "r118",
      "r132"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      },
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS_1": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      },
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockComputationofbasicanddilutedearningspershareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends and Other Adjustments",
        "negatedTerseLabel": "Deemed dividend related to Warrant Exchange"
       }
      }
     },
     "localname": "PreferredStockDividendsAndOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockComputationofbasicanddilutedearningspershareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r25",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.deitaxonomy.com/role/EquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Convertible preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r25",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Convertible preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Convertible preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r25",
      "r431"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockValueOutstanding": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.",
        "label": "Preferred Stock, Value, Outstanding",
        "terseLabel": "Preferred stock, outstanding"
       }
      }
     },
     "localname": "PreferredStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r7",
      "r32",
      "r33"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "terseLabel": "Series B Convertible Preferred Stock issuance"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r206",
      "r414",
      "r418"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r52",
      "r207",
      "r418"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r17",
      "r205",
      "r412"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "totalLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r37",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r209",
      "r515",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r36",
      "r205"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r35",
      "r207",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r17",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Major Components of Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r17",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life (in years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForLoanLossesExpensed": {
     "auth_ref": [
      "r191",
      "r478"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of credit loss expense (reversal of expense) for financing receivable.",
        "label": "Financing Receivable, Credit Loss, Expense (Reversal)",
        "terseLabel": "Impairment on note receivable"
       }
      }
     },
     "localname": "ProvisionForLoanLossesExpensed",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedTerseLabel": "Repayments of debt",
        "terseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r9",
      "r18",
      "r88",
      "r513"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockPotentiallydilutivesecuritieshavebeenexcludedfromthecomputationofdilutedweightedaveragesharesoutstandingDetails",
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r211",
      "r214",
      "r217",
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Expected severance benefits to be paid"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities.",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "terseLabel": "Number of employees given notice of termination"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r81",
      "r210",
      "r215",
      "r217"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r211",
      "r212",
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r28",
      "r298",
      "r350",
      "r431",
      "r490",
      "r507",
      "r512"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/NatureofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r99",
      "r100",
      "r101",
      "r104",
      "r113",
      "r115",
      "r186",
      "r347",
      "r348",
      "r349",
      "r359",
      "r360",
      "r384",
      "r503",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "auth_ref": [
      "r363",
      "r367"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r62",
      "r95",
      "r153",
      "r154",
      "r159",
      "r164",
      "r165",
      "r169",
      "r170",
      "r171",
      "r182",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r389",
      "r484"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.deitaxonomy.com/role/EquityDetails",
      "http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreementsDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued and sold"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/EquityDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price per share (in USD per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/EquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockPotentiallydilutivesecuritieshavebeenexcludedfromthecomputationofdilutedweightedaveragesharesoutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r46",
      "r97",
      "r269",
      "r271",
      "r293",
      "r295",
      "r296",
      "r297",
      "r407",
      "r408",
      "r411",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r316",
      "r339",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense for Options Granted Reflected in the Consolidate Statement of Operations and Comprehensive Loss"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r37",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r214",
      "r217",
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r317",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails",
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails",
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Restricted Stock Unit, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r324",
      "r334",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockPotentiallydilutivesecuritieshavebeenexcludedfromthecomputationofdilutedweightedaveragesharesoutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock",
        "verboseLabel": "Series B Warrants"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.deitaxonomy.com/role/EquityDetails",
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockPotentiallydilutivesecuritieshavebeenexcludedfromthecomputationofdilutedweightedaveragesharesoutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Severance costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance outstanding (in shares)",
        "periodStartLabel": "Beginning balance outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in USD per share)",
        "periodStartLabel": "Beginning balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- Average Grant-Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails",
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofCompensationExpenseforOptionsGrantedDetails",
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Additional Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, options exercisable (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, cancelled (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Options, grants in period, weighted average grant date fair value (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, ending balance",
        "periodStartLabel": "Aggregate intrinsic value, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r326",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of shares, options outstanding, ending balance (in shares)",
        "periodStartLabel": "Number of shares, options outstanding, beginning balance (in shares)",
        "terseLabel": "Options outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails",
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance, weighted average exercise price (in USD per share)",
        "periodStartLabel": "Beginning balance, weighted average exercise price (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r315",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails",
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r317",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value (in thousands)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life, options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Beginning balance, weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Options, vested in period, fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r19",
      "r431",
      "r473",
      "r488"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-term Debt",
        "terseLabel": "Short-term debt, net"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r89",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r92",
      "r95",
      "r120",
      "r121",
      "r126",
      "r129",
      "r131",
      "r140",
      "r141",
      "r142",
      "r182",
      "r228",
      "r232",
      "r233",
      "r234",
      "r237",
      "r238",
      "r276",
      "r277",
      "r280",
      "r284",
      "r292",
      "r389",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.deitaxonomy.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r49",
      "r58",
      "r59",
      "r60",
      "r99",
      "r100",
      "r101",
      "r104",
      "r113",
      "r115",
      "r139",
      "r186",
      "r292",
      "r298",
      "r347",
      "r348",
      "r349",
      "r359",
      "r360",
      "r384",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r503",
      "r504",
      "r505",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r139",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Obligation settled with common stock"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r25",
      "r26",
      "r292",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r25",
      "r26",
      "r292",
      "r298",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Issuance of common stock for option exercises (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.deitaxonomy.com/role/StockbasedCompensationScheduleOptionstoPurchaseCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r25",
      "r26",
      "r292",
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r49",
      "r292",
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock for option exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockPotentiallydilutivesecuritieshavebeenexcludedfromthecomputationofdilutedweightedaveragesharesoutstandingDetails",
      "http://www.deitaxonomy.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r26",
      "r29",
      "r30",
      "r95",
      "r173",
      "r182",
      "r389",
      "r431"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r93",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r291",
      "r298",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r405",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r405",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r405",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r405",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r432",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.deitaxonomy.com/role/EquityDetails",
      "http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreementsDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing transactions:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r265",
      "r290",
      "r375",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r48",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r48",
      "r299",
      "r300"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost, 121,500 shares at September\u00a030, 2021 and December\u00a031, 2020"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/LicenseandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r211",
      "r212",
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r420",
      "r426"
     ],
     "calculation": {
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesComponentsOfLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/OperatingLeasesOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockPotentiallydilutivesecuritieshavebeenexcludedfromthecomputationofdilutedweightedaveragesharesoutstandingDetails",
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Fair value of warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/WarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r119",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Shares used in calculating net loss per common share - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockComputationofbasicanddilutedearningspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r117",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used in calculating net loss per common share - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.deitaxonomy.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.deitaxonomy.com/role/NetLossPerShareofCommonStockComputationofbasicanddilutedearningspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 14
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/subtopic&trid=2196772"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "79",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "80",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123398962&loc=d3e400-110220"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=123385629&loc=SL5834089-161433"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r521": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r522": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r523": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r524": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r525": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r526": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r527": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r528": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r529": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r530": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r531": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r532": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1404"
  },
  "r533": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(1)"
  },
  "r534": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(2)"
  },
  "r535": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>74
<FILENAME>0001628280-21-022421-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-022421-xbrl.zip
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MK!WS0*SD6O.HE,>/A_G5VX;CI&"47ST\[/RTG;ELT @="X_P&5PM#X+&^LL
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M1[ENF;&[6V9B-GDHA'FB* >P$0"S"@H;BGWD5 EDX)\Y '<I]HV;B#P+G*4
M8HV(5<)QH6),6JHFZND1Q:,>FCX^0"W3SDG87^\,4S(88._(*J2)5@J[L$P
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M2.>C>6C!;2EK[&VO?Y5!.8"'AV+0TG+ M"M=N&6I7V"49%>U\5SF5UE^F5H
M9$JFKL3H4^*A?"5&?VL4X'<4HT4\1JO7AD?TJP"!VO:_A]G@HO;'5HB9RP9_
M/BE)RI==DO*G(TGYDY"D?"5)GS(;%2M)^ENC@+JC)'UE^JW:ZW;O[,KR7%Z>
MII9=2JJG(R75DY"2:B4EGS*+5"LI^3NC ,4IQWT :QKT:K>(RYN.;U<,X*E
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M2A,'Z/9#_[I@7 <"/4V&_LA.'_$J0!28)=U:L(6O!GB@S=HI/A?HM+A<L$U
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M^?!T4&C[=MB'U?:K)XW]_"NP/R38IQRZR7/< Y8ZF/0FWF1C5?$28W/*3.G
M8RL(;@(,N=G',(DBI[V$>UGQC+:Y&*O!!8^'!99F7>CF($;*SV/#+8RLUVG=
M=H4UCZ5/5.<'Q1D2 'P82I7A%J?230ZEF@T)"2KT&IU$3,B9\OCJZCI@1[LX
M(P"PCTXK)HXNT^%6YD!V)(RNCN&*FZ94'YN< P7R?;M2>& EVT:>SC1[>712
M#4_N&=!SB[.<\F0,9NR9L5"L-!) WA4F/A0F3O.N=$Q2J+.%J3$&]15C&)G+
MA5E^,WH.NZ6C:71,?'5:5MZ<<"$/"<%74'TD_E)P^8N1,W0L<?JN%=)"3&D+
M%YI_[P8UHE!8)NZ;$&*W>5M&2NK$X68OAU4GFV/8':2 P;^NZ3?7E:>IIUSW
MX]ZH$)7LQ,18#"J<.^,U Q=LG0$.5L<P[=*!6[EU?_06,+)\B9,A,+%T!+M2
MJAY:J9J(G4@RZLK&37QJF$HN5!Z])-5.4US#%#Y=6<3IR"8'H_<;W6O*Q0TP
M/C;=2OL:G=Y-S%)8]6!W]]>GK&CX>ISWAJ>UTV'N6J9_PTP^.40S.RR/]M.\
MR175'R1[("EX66HK?3LNK>)9UUZ0V^-95Z&I"[*656CJ$JW^)T-35\+L9X59
M>7Q:F?Q9QP[S?AD3^3W;_K9CT97B\;A1(:6RD)7AA,F<[A8F[""X\OPZJ8?E
MR'9YNE18ORFXL=T.98PI# >%9E"&ZOD00Q4<<O.@(ED,E._C%(0\F-9]5L!_
M)."/(9Y^+[4MT.=:V6D9^!RS035XY$DKU<S*5DDW?0D7$T$>O>K@\.K0I0B,
MZ";M;T)UO2$.9'T<2S2QO-!/9S59OS45J3094E(\[EDRU*O'I+6OT.?1?'HN
M'V:#Q!SR4.!10H=^$5R6Q>2]+P[\DE=E?0(GUD>FR2AH'CA"O]?MAG819]T;
M359$*9X'-ZQ"KF'&[YH1*^@^F$<EF7?=XP2K%!+S/=_',4COO%N M7)-),=[
MY7N8,"N35G *+*!C7!@.1H[>PF4Z:>6^2<$WC2DK]EUB08 *$Q%94SZ<=OAJ
MKIX^<>RP$BT/K0-FG=/DA2A\&3<YKWHE44]Z*4;>_?7:<;MG 0NJV +7 A8P
M$CO7Y<LU]\05NDP+E;_2X!7 'XI=%/36,8,! "&Y@%*OX9"<XSZ4<:.M8 JH
M5/%QDP7R1XDU]TS[*A.HO\TM*!&ET&,O*D;@>VY8.59#D?EP=53Y8?O5HN>'
M'(1Q\DV9PE5$KY0'2(6UU:Y"; =E8&Z_4-&GPE]]64OP*C/DNUE'L'T7O6&M
MWRK.V]-SX1$N'?SZ89@*>/W^5!NUS:F4LV)97ZMLI?(H/^6436:9%0>!M[S4
M-T&]4V_U_3RR!/B.^1(V:K";+?,UC/)/_ VY<Z.C9) 52<],1P>3Z3BC^^Z<
MEU/-=Q.J%E:. ^&4[K^BEGYI:X%AE0U2GLX-5#/.1RO.F^#UJGRX:FO+M#]S
MV_Z#3/_.YO\H#W2\F;O?A3_078$]>8CMT1G%U;G]E8"8R"4T[M_#K/3?)M=S
M"IK-2Z?RR*T+WTYZ@!:U]"+#HDS$M!E08'_6_0H6PP3H+\H5+SBI'UZ170X,
M\ZX(EC;VBL>-0%2@>9GG95+^95FFJ3Q.^N&THTB]=FG#C_EE@:,I^;<Z>#"#
MR=S2Z8S08MN_FT5Z5BVU).N-E&D63@=IN9/QGFUSMEX<?)3H5.0JEM$#/3 )
MCTNU$EYK>%JD*A3H=#M36G 4V.F.+=SU;PAO7.=D1.TC)C"9=CIQTXCRBD/.
M=$<<A4IEW8*_C,/"*TVY2M^\(3GY*EVT.(W*KLHH3APR)B"DD*"1VE? HSS.
M^J$T+]"L50CG*V96Q'%./BM]ZA?1^0;LQ.*AL*JL/*+O3Z>XKG][>X61[2JW
MI. 4(U2_\CM,O/:$$"PS7\OL74!_E]YMBM:N@N,!;8#>@ 47YFK63;A\D819
M;[VTD(M4DEY<+[)ZQ[L_L=);(#"1:3L.9:AD3&)XA5*<CT57*!>>H (K:Z>0
MA'3C:6^4)CPIJT$P_CNU(8\7Q:(J3^UWN'L9B=V_15!NU*8P^?J)]IT>45"]
M:YNLT@G&3L@1?J5P<=C[')A_@0 _SH^^4A;>Y=G7!,*)9->W\*=B)WLA@2(I
M,.E96&N^Z(SC0Z^=H)NV =X5I&,6B@2E06[ ;#&=*EZE^)HBCOIE<:*\RD>_
MFS9S>AJ PR1@IL;T9<(+EJS(BM]OU/H7'=MK ]QL<;575',:ETA*F)GP<2H/
MOJ*D]9'&?F8NUL=D=14P!>9$TI>J6(@4CY5R<ZH@BE)QFHCK*"1&X<@L7<M%
M\IHI%SPQ+)59RJ\_I"CU5-XW>AZ\QL0NILG&F[A>Y"V,IRS+7EP-7I\>FKAT
MR+\FCT4)@K$V67&B_#2I,:78&^_<78&3AQ&9E'[UDDBR?$1WA>LLO?)WA.#J
M_'WM!9U)/2FZJB>U.K1?'=H_Z*%]B>LO_K;YLQ??LK0[$JI8F_6,>NW'6L+"
MU+S:??7QS79SO6JXWKR;.XPNT N\VFUN;3<_;&_5X-.'W;<[6YO[\.7EYMO-
MYJOMVH=_;F_?K537(KW4'X7,[PUA#@^:0R@-XWXK"?DB*AX4E^I;)X68]O_\
MT1M.R(B_%O6E/W;-T"?+[(=O\[VEEUE]8[TD!_93+WQ$I_WP?/3AK^13:IN+
MYUFW6$AQTU_3>Y4D[[6ZM\7SRLM70GD#E8*YJHQ</;FZO%%<&E7>G;HF] :2
M_-;+: /?>NU[TV*ZP;'^J6F_?XTJ]B"+)>1.T]ZQEC]*]8LGYKM?L>,2BVXM
M=SQ3LE _HHH"K3X Y8>.!8*GJ*RK-":.'[_A4]N,K>"JO<#%7J"IO?@!AECC
MOJ3XY:ZO5\MU+@30A:YM0:WX6VK>/ZB##7SH\9EEL1.;8*TFY>B'J'#K6U>L
ML=!(DG#IM3-?2PO_ZQ[8\\,]_94Y[KG">X,_%O^[$?QR8<!_4V5QT'J&>>%'
M-S^/!M?>_J< ]=!SS)2B]4(#U/3+.@DN?4C''U]-N[1_IF%[GU='M?O6\Y_'
MJ__O7WK%R5<K_'8+]6Y_9^?/N[WNZR)2J=>M#;O98"]9P<.^7QM5OR]^R"RS
M"GM$/'><!4&4"S)08047P1GG/N\DX8\T16LUL*^SCFGW_[%6!VHHCPU@BO/!
M\^ZP4_>]P@)/(]9JR1&9'E<_-N;T>4*SS:Y/?[:O<&QS\,KD>2H7^BDEY )]
MP?:%@M(*F]?33Q=VJ_?U+=G[>D@;0W^R_?7HC3[9/6EWCDX::/?-X?DAV3YO
M;.VU#R\_\MTWVY?-@P9I'!RU=@^.3G;W'7U+FW"MQX\ZAY?-K5:G<=!L-?8W
MT=%! ^_NMUJ-RT\GS9/7G</]-HSX0IM8G>]^T!W7>=W=/3G$C<XA/[S</#L\
MV*;-K;V3YN5>UMS_>-EX\_YB]\U'!+^?-_8_DK=TKW78.6_OGNQUC@X^M9I;
M[A+F/&E<OC]O7&ZSW:WW_'#_=;NYOWEVU/D7/.\8C>Z!9PV/R$?1?'/4/CK8
M1LW+)JR_ >O=OFSL'[/F5KO5./B(&ULO.X<=>+>MO=BX0.=O][<'C0_H[#,)
MUA-L7=TX;.K,6UK71*LZ(X0'8;WD&*^]P$BN4Z;_?C:-'"]*(_Q7J&'$Z^Y!
M%;,4[BO>]$1YDW!210:(S3QEGD0M32 ((ZR8UY+0@C<A3"A>\:;%XDV78]X4
M(Q(T(%W'VHLZHT'531"^CD+T2G.-D />1-@ZHHO$FF:IU2^V"KA9E5B=K(M4
MQL#>JM^3^^W#C3QWJ1G3HRA-%6#^/WOOVM36L;0-_Q45S_TANTKMS*'GE.R7
M*F)('O83((EQ<MM?7'.TY8#D+8GX\.O?F25L9 .VA(18DF;O"A;HM-;T7-=<
MW=/3/3KI'Y:=]9))_MOD!'0<53Z:@X^.'T]I)6WS@I%M!R85A22<!<=X LZ(
MUL0Q),GN[&+7:+TH'7V%$NY+*<WJ&6\]@I<C+5+O70SP(0X'%;SW!]XK,<&5
M4I0[DBD3279O- 5'!0>N@O3<*.&TF)Q7H.S'%L%W>P)*OPWC&]L+GRKY3YV,
M\K,%#[]&3;,Z=&M-32L1%Y=V.IB8*?L_3:/R27C_,LI;:6H>FGHRI3%4R-J"
MHP 5O0!,3H*567*@#]9%96WVA79V:9=2WB*79]E;+5L/Y)6$+RJ0EP[DJ>"%
MH%PXFB#R% &##&!50/")$TE4PDAD ;+>V-A%VW<D3P>E:\P2I,7E&'Q[\W<S
MN6HU$8W*2G=EI=Z4O##)L.BERJQ$,BM)F<!PG>6%5C0SEC:8=&8ERKLHR)*\
MH-EPL4;AC6T%^DI$207Z D"_DA^14Z1!><CF,8#*&'"),R!,(P:7_V<ST)GH
M:K6L8.7]XGR9<9"V*Y/?ILN1E<R:RZY?_3BNL8\'CGU,+/-;Z?F2/::#C\;)
MCW]NVD+&7TM[B#_*/9RDI]FM*GRV5PY/[7E_<5[J^L2P'TN5^%YSWB2_<^]\
MD(=\4I*V4MX\E#>=RI(]*D4T3X"4947CK 3->':[;+$_:NF%*!X7$:Q%'E<-
MG;1&I52HMQOJ5^K&&F-9\!GERDE 9BDXC AHD8ML:Y'QOK,K>9MBI-L46ODC
MEJI[DR83=O2J9H,L7[1\3E97 UZ2T8X'?5\=J+DIYF0ZV8,S2Q0G"":8 *A=
M ,>-!RV#BH$1:TV)WPK:HKWBFNK14BU1X;D<>%XI &$0@T@,4L$H*BY !QI
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MZ(77Y7<5Z)WRSJT6+EJJ099FPJA(]LZ]+&?[:3#:24$\W=GE? DG8"IH6[@
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M$V6)9#+&G5W*N@(7*7BQ&C;8JOSP\:"DAY\/RA5D@+P:G.6AK?GA=;.CY0G
M>__8WIG-N#\=/&[F[Y.IZ?N3'?5\Y?.Y^/SE9XT?:631$P;9H)G/O4W@?'8
MA0_*)L^]#>G6%.&6A;?K?F^EP(W,"*X4N'P*O)*T,@E*"5<0F,YNKC(V4V#P
M$(3SSE)',REN63G(2H&5 A\\Y:]2X/U2X/'TR4$L%;7+>4$3 $M!2U.D8,RJ
M3U(7?6+QUC3 2H&5 C>= MN0UE4I</D4>*4"A1,R,4L@*;2 3$6PB&7_,^@R
MYZ5VN+/+25>H1?HDKC+/Z^-5?)SUHB&X96^!S/ 9,X1Q%_GX>HGK>HG;$(!_
M\LH.\Z==C&+H]/J=?%7^XJSIE=7I?XS-OXG#3\'Y\O+.Y:9JQQ5:;TJ[A-[9
MQ3B&1=H)K>%VXZU+=#-,H^6&J\E<:_-?S77&L)?'R[Z,QQ?G+@Y/TL3<)Q?C
MT3B;+0_WYRLSJ2OSMU?FUWN?I2AFIX3*(,!FV57.=-NR*',@C$5&A>:8S;B&
M,V5_@NAK$Z;.E;O/%4\,D90(\,J60XXLSQ6A$6)6[XEJZQ3)<X4:W56&=,T-
M?3(7S6.Y>85:EX8,&[]$+!C.KTM$BV _5?9#"B,B,>"3SK#71H(AD8#BF> )
M!HI.K^-,J4O$\N=*(MXQER3D=4)F.:$8V&@-:!6(EYS)&$H&$]*N,+3+Z'5O
MORX1&[U$++C=48'?)N!/;W($J1RB!4-)*'X$!9=2RLL%&D.XY$&+=9PK54XL
M>Z;P1%"H8""O$ 102 3##0-OC-8J::DC+UX$STN$Z6:3UR5BNY:(!;>#*NQ;
M!/NIL__<.HLB0)") P9+P3)*P0>5:(R4*93K.%.JF%C^7(E12\4"R6N"0L#H
M.3BF$[!(N4!K1$IA9]>PKI+8I>)Z2_(6K1#;4!;B>'JK9;+',DB?'8B8?<]E
MQEVPR?U>VPA;Y#Q8ZX9U]LR1I8Y-N[7$5Q-+?HO#AHB7NR'!;NV0=&"'_3QN
MHX_?6U7"_,Q_,+W%D+W(;"#E@"0; 25!T)9S,(XXS@)R$=W73TT_]!2XU -U
M$MQ]$J1L$.V,!IUE'2 : X8X!L22)(35G-LL%<DCLM2Z^LODT <^05W7T+J&
M+GL-77#'IJZA]TR?5]X3$S88ISTXQTSVGK"IPTZ 2J%X8)X3]8VRBP\]!>H:
MNO DD$19+G1>-"GQ>1*P $:R",Y8B9Q2CU$W:^@,SG-=0^L:6M?0):RA"VYH
MU37T?NES:I-*&:51J @B+VV /F3FE'DAC5&&_*^+S*0[K:$KFP)U#5UX$B0F
MLK&MR,MG$X8F#"Q:"8%%(KF,23I2UE#&ZQI:U]"ZAJYD#5UPSZ^NH?=,G].'
M_E0(%DUI="T!6:!@J>* FAET2EB5OM$N[J&G0%U#%YX$*D4EL[X!DQ\!"B_S
M&IIUE6.!N^BL)IJ5-91OW!K:;/Q^/RYGBO._H??/[K_SCX_7?&Z'+WO]R1E5
M]OG:Y6.>Z\/54S)K#M3%V+&^M#JW_??-,;K!.%[6M^N'V"\'[?*CYDQM4_H_
M]?JV[WOV+%]I_D-3 _+1)T-]>=N7WX7LD1+Y>MX,1KUBVA^:1@*]?^*/;WMA
M_.ICVM#4&R]M2*[>8EV^B S/6]_2UB$6GX_.],]R]0W#F)0XZD2]I02C%YGB
M>,8.3=8D;Y1ZP4HVY>1-KSZ=17YC7V9D#:/]&VS*-_B#/7MKWX]VOO]\7/*@
M?&&';PSAY>"74;Q]S%*ZMS&;F"XS^&!H&]MGJ,=A>56^'-N::^F\&I;UZ?]\
MVWIJ9_>T$$/GW]_;M;V#05KGJ^\\+I(BDU5S$S<@LE5,HFYDDI/'3W\Y..Y.
MDIL.CQ_?SKM3=\!;= ./3[)4.7YRL-_)CYZ<_'JXOW>:?WERFO\Y.C@^?=(Y
M^3G_=O+X__W?DU_W#_YXTJ01J1\[![\_/3Q]UOEN_^#GP\>'I_]:MQO_KM?O
MC%\-+O)GA%&W$]_Y6"I5-*E3]CQ+F?'HF_<TQ<H_MO4VG_;M1>AEG;"0A1H1
M=:4$&MF6;^',OAG%'SX^^#'T1F_.[/L?>OWF0IHW_?CY6)6U[@O1UGS?Y.FK
M9? 1F2R%EWE[E]]\^?2CYJDO-.CE<^*1,>;6I\DC>OM;O_*Q\I$FMS_[M4_]
M^G.,LWJM]5KKM=9KW<1KO2&$_7&-Z \:WV'^5Z[3_<]SK93/]*DW%[]B]"O%
MK[YYYLE<>^D- ?V)%EA-]%I_2]M,2@_E=^4/VRN.1'-91:-\ZI/1:>K'W5I0
M:&N&YZ<Z/#<.SZ3(X,1S^^98# =OOSP>.$M!L:^\;2W&Z'08[>AB^'YYDV4#
M!F4O7VN)>]BS?[OA][N_V5Z [$P^MF]ZX_RWY<^B9:V<&V4$[R_.+YK>MXT5
M]F/J^=ZX8O@ZA@=?SLI;ZF>R123$5([";;4_;]C6:??(34Z4SL!Z,]WR5@W=
M7A-!6]*"L7&C4R=6G5AU8K5KZ!:;6&M=Z7>V ?K)GMF^CQT[[NQ''TOMA0ZG
MW4Y)\%FD;._,4^BA2ZU\.4S+J+2"S%@MJ([1)8S$.T714Q65CE00YUX<EN&E
MC-/I_*G#XY^_3)QJ;_6+XR<?4Z8.^?'^R_R^GUX_RY]Y?/K[AY._#O%D_Z>_
M3TY_ZIW\\G/^^U-V<OKG^:>4J=<_O3HY_?G5$?O/Z^,/3]\=[__QZGC_*+\G
MO'K&_C@[?IV__Y??WQV]/OKP9<K4T2\'XNBO@P_/SH_X\>D!.?[E@!Q]>(G'
M[.?7SW]YRB;I60?OCSX<IZ/>9;K4$_+V!=,,?7(<! 8/J)@$6\HC.2,DC88X
M0\G.[O53.W>K<#$/@ZYEPY"98/QP9'??+4.NW?YZLM?UGB%WHZ[9FZ!/M_\X
M^.]%;_R^-?T_UH32/GRB-$Q4:PP1@F*A) ([,(%:B,(S8:WF&,W26IVO&;%5
MK3*C5DE!:,Z%Y<$Z#%I9)00):$4(!HD/7]$J,R*^:IC% $\_ =XZ&YSD$H3@
MI<0CU: 5E:!8YFO"A181MQ7P5<E4);,$8JM*9G7$QC\1&T=N!4,#S*+.SAF-
MH+-+!C)I9]#:D+7HMA);53(S*AEN W&)6TY%0AZX,WD>:1Z1,VVEQQF5S#?*
ME58YLR#JQ55(QB=)G6$@,SD#(G5@F7?9G3&2N1@$)6%GEVKL4LZ[_(8NKIN-
M_"IIJJ19 L-]*6F^17!5URP:=)ZJN6B\RA)49T?-&P=H60!-F 8OA(E$)!*\
MSAS7U4@KNU5VVSAVFZ=?->&E7CV5*D6)QA%MM5#9A6-.:2YENIW>;JD[4*EL
M<2J[*CE@D3)-E(5L"Y:I+&EP.E+07!EA>,AV\CN[>)^-IBN%50IKLT +2:44
MJ4W&1)0:=2G&8@FJK-F$\J(*M':PVG2#K:R\%(LALYJ1@%)FJ99G+R@6(J.&
M.(UF9]?P+A%FRQ3:/9[SJI2YT90YC^J3W O-E$%O&%*!.B5#N'8ZB20L4S.H
MODJ>JR3/DROR+#XLJDR9AH02P;,>-/,12HEDGJ4B9@[=V56\RPFKLK!RW"9Q
MW#P4YY5.2)W'P#&P9)2-K-31TQB,8KS*PE8PV_NIN!W/XD]R2L&A]X!,6]!)
M<U!<:ZN01F?TSBZC72'(NLC"M6Z9-ALH&Q" LY-R>N=O8G_45+/JQ'?E<;Q3
M2OL-P[ >^Z>7&^9S3L>;K?Z0]8ZKE:J5JI6JE:J5JI6JE:J5JI6JE=;+2G,$
M"V*^[8 4'1)$JY/SPFLO&%%6.2W3EYUL^/6HP>>!@;WP^F(T;@J(GPZNRMR4
M"C>'_<OZ-DU68^,V/9[RFOZ(_[WHC7KC^"0._^GY^%N^]T'X(_K!RW[S*7_:
MLXM8PPSSA!G>?[;[E"*G7JIL2AY=:<EJ05.+P(VSRDM!C,"=77U#%?_- ?Q]
MU$+:2!*I5+\.5IJ#ZIV@U G+9;0I?QCJZ$V,1B="A*">5JI?<ZJ?CBAK],%&
M;DJV>Z%Z9\!$X8 G%:(T*D\"UC:JWZ@"*#?#]7 TNF@JH Q2B1B?#\H%#/S?
M9>NE,WAS&3R.0]\;?:4&SPQG<]:/R>ZVWMP\!5J1QU*M5*U4K52M5*VTUE::
M[UAH, $E\2RK9X5!:4T2B9ZGK,70":6_(;+G/A]:Q$,1%3'L7PSSP$Z4].38
M://D22,J1@>7HJ(];1#7050?/YXZ0"J8,L[0"$8& RA$EM3<>8A,)$1)61!^
M9Y<*U45Y_5A"1?EZHOR&M/O%('[=C[X%Q(T/_'4,5\=X)@Q/'Y&T:)S71 #S
M&<I(&8+1(@!A1KLHJ)1>[NQ>SQ^M^&TU?JN66@<K/>3&5&79^V;9J9TFM$+G
M)9&"-4P &N7 ^,@@FS,Q)U4PO!3;4,LJLM%&!*]ZIVEM6:%R]SI8Z2%WFBIW
MWS-W3V\=*86<1L'!A\+86@=PU!M(0>3EUP=!%!;NEBWB[BTX;+ WAO&K".=V
M^'<<?[YYU+O<5>IV^O'V]@,;N?]=LQ2JE:J5JI6JE:J5VF2E^7:-&*/1IV2E
MI(@$B5:<"AJ=,"0$[?@J=XWR_3=/C>I.T3P:^LG43A%!;JR2 D2>T8!".[ 1
M&?!D Q'.,&7ISJ[1JIOG8(L2L"JRE^L'+PCK^?S@Z[BMON],N)W>'>)<2N5E
M!!I$ #1.@.&:@0C.1JJ3,4EDW[>"=LU 6T73.EAIGNTAEI+S-@H5" J3M-.:
M"L%8L)8'/PNU+BZ8*N\NQ+M3^T6>$1L<2Q I9MZ5B.!"2)#R#R]++11T.[O8
MU7SALG@M!G4]FU3I?(.L-$\C0"<+F<=@M$3%J&&&Q,S>Q%M#.58Z;S^=3V\A
MB<!YD.7,D939 :;4@^4ZJVIGA(M)1<NQH7-L$YUOP?FC/^++WF@<AS%T0F\8
M_;@S2"D6""Q[1VEM][EK-D*U4K52M5*U4K52FZPT9Z-=)K2V+I5@)BJ57&3&
MEP(?$IU.Z.J.4NLE]73S.F60&"9\-E;IAB*E N>2!,436IDD$LYV=GG93UK&
MGE+%=DNP?4.CV<6 7?>45H+<Z3TE2B0JH3V0Z")@X *,-09\-(8;FCA%G[%;
M0;MFH*VR:1VL-$\0$EDT5)CD"$$9O$TJ!.I04C2>D%B#D.WGW>E>2]P2KXP&
MQ[4KY[4I&,X0J$=JF7(N:-X4U:_'D.HQI,KG:V*E>3I\RF"#YR4W@&5Q[+/6
M\B11BH((CA@JG[>>SZ<WE9AC(OO !$C)R$(7'63G)X##[ M))JA-K.%S1MK$
MYUMP-.E)?E?^L)\ZCP?]YK+<6>S\-HPI#LM.TY-Z2*FF*U0K52L]0!C<&&F=
M4<DGA5:@]KR4(! &*7+CL(;!6R\"WA/Z*0P>@Z".D@B,JT8"2# ^$- J^^ZE
M-213:6=78%>A:%%B207VDF/@BZ&ZQL!7 EO^";:6*&4U-Z"(*-5@4FG<RADD
M95"4 Q?:NYU=6A&[7HBM@JE:J5JI6FE[K#2'1N$8$#EQUI*$:)UCS'@2 F<^
M>&?K9E+[!<ST9I+1VFIC(@1A#*"5#"PZ!L*QX*SV0EI1,MJ-:%-'C7I J=)Y
MI?-ET+F6%$E2DD?C41&C@U \1:IL9)A4W4MJ/YU/[R49:9C4Z" $IP E26 D
MEV"$\=9*82*]I/.%MY+J :5Y('D<QYVSP:CV/JJI!]5*U4K52M5*U4K52M5*
MU4K52M5*U4HU_?N>+/_=/,%]'UPBVJ=H&5(=C27&1LE9()$S,TLT:)3O-S^:
M*RR4G>/#OA^<QU^SAUS#/W.$?TX>DW<G4T?R(@V<)@$QA@2HH@$72[F:Q!F7
MQ9+"[NRJ+E'J6OCG7YO "EN/X"6T**D(7C&"IP.X4GLE)6;<.J4S@K4":Y&#
M%LY$XKA1LET(WJAC .I&_/UDSYK>]G;<.;)#_ZK#:;=3T+-(MK\;#$,<PGCP
MYH<R]*/!62]TRJVL(4'-E[NL/(\)K2/:,90N6B6L(6@L%<0$25\<WIJR_,5N
M4O/I)Q?CT=CVRY#5!.1YB.<CZ4SJ<!#';-# +1) ) &,$!JTMDD&S;TMW4.O
M4\[=]HQFF_L/O$5\CP!NV^;4_]R/ ><P7)M(Z[JHNAMC?;DWGGKO8H /<3BX
M<5O\U> LC^GHX+\7O?'[*J'F8[(/5T<I$E?*"E-DD\E,5OJ:4Y9 !AJ=4HB<
MFT_AD&WBLRI.9A$G!J4,4D8EE$2?C(W)ICQS)/72:FF_(D[FR8.IRF4QO%\=
MG4*;B%$JXUVR ,B" \>C@.2M#M(QP@U?\M&IM8![E2]5OBS$:;><)JLR90':
MNCHZIA,-5EL%/HM)0)$8:)^UBF3*25TZ?S2-Q+>)L:I F:FEGG;2&*-9<@9C
M,DX0&KPP@@@7\N2I J452)\J<>IB1C,50$70@%X2L$QFJ1*(#LP(8;"TG=:Z
MRY3J:L&V"?-5I525LA"QW>4 0I4PB\2,IS>KT&(4WH!(S@-F;@.GLP/&E(_>
M<.>C+2*FJ_6R#H]54JND]N W/<]^/'/)6XLN1>,P!:V#1DFEQ)A5/BJ\G=4^
M;<-7!ELV@[V_:NAD+$O&*U#:), D(CB)"8((,F;:<I&KG5W4"^RU5^:JS-66
MFYXGD<AE5T1:9H5ER*+2E''"/8U<1(NS[GE5.7;?9#9UEC]IH[-N;FI"<T#-
MF]RA -S*H$+2WO*8Y1@37<*WRLN\CZ3A2I6;395S)5TBLX$'G0B3&$A^0'5V
M?S0G H--9@:15TESE:0YE3)->$!%>0*7'V0?%@4X4HHP4I)*/?WLPV;8:]+E
MZGI/SZH"*[6M'[7-U95))B4E$5)H=$%FD&@7A?+HE1"45!78"D*;SB"/$0F+
M#H%*1@"M=6",IJ"\4=H:3JW*A(:RBWI938KOE]6VH#I(@P!P=A3++9Z_B?V1
M;: 9WY7'L58-J:>2JI6JE:J5JI6JE:J5JI6JE:J5JI7:%"D(J)-F+'K"D CN
MK*2)R4"X#R9[I)<'S_'CP7/)R0(A@[WP^F(T/H_]\>ATL)>'M5R>/?O-]L)A
M_[%]TQO;LR:'L?&I'D^Y5'_$_U[T1KUQ?!*'__1\G%0@_2/ZP<M^\RE-,=(:
M@)@C )'O87QT^G0\"4*4(J2E/R'5P+T*@%X3<($@V"2C(C$12^S.+NL2L_")
MC!830BU04Y>"#;+2/#E/&)CF(I,\RXN"CII:3D,27$MB\X^Z%&SV4O#ZX--2
MP!AQA$L'P924!)0)+",:M-3::X8Z&MJ^I6"C:IK<#.?#RZZEG4$J$>?S0;F
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MTMV%BT&L$V=5D3*+2"%&Y[D3N$9.4#!BE4F1"6%"<MDW456DM /K4R=5,9)
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M6>%I)P(-03O$7<S*4"4!HX5+5*I XV6-%!+?9N'IQZ3RF<)D"G,C7,OUIN_
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MZ)&/\SLY]?V13HKIO\9_^UQ;)*<N92EE*64I92EE*64I92EE*64I92FMD)]
M2TF#(X5T5'!%?(DM6)DJE(X65@M19Z?+)CM=756;?]-]G(S&)[X_'AT.-F'E
MX@AT[XWNNM?]+7W:'>M>BE1,9M-6RVIZZ_\SZ8ZZ8W_@AY^[UE>U2-]Z.SCJ
MIZ>DLJ39P["4A^%UZZ+IW=D'H4R!E3#(Q.PK3GQT-DB&C"^<*XJ #8[U2.F-
MBTNOL,KG0C49[)^0E):Y[[*VP$Y'J"<<,%U9)^"'8*F"!5$V@_VC!_NI.QG
MWI8@8"=5;%V*$0]4H=+R(N:O6.5-$:C3JP;V]U2[Y,%<QKF#:6YCD*64I92E
ME*64I;3J4EHNS5,Y:A@OI;0EY<$PY6U094ECY"WV@E]!KW,'TQ6@T+NS)-!O
MF^2#I-)3P@0B9<D1+TJ%-'<!66UC6<?@=!G67E"YCHE:+ZE:H1XN6<%OUWB^
MH7;G+J;WH[ZS1,?=+WM_?BB,4)@&!R"JP08N*44FZ( XLTXH%JM/R:C .&ON
MX]+<3* >@Y26P%>N@A6NU+B0)?>.F:+ 5&D1G*&6"7,-?,V=[QX<?-^UP3<P
M(PO'/2*\](@3%8N?8XIH(8BB!&0=*R<#<9*YF6EN9IHA_5%(:9G[)AXTDSC$
M4':N"-:B9(31("0M@B(L0_HC@/2/<WR:J2"5HAZI A< Z6 0ER)0Y.&LAM>H
M%\&LO2!XG:Q4@^JGGHF0NYGF (4LI2RE+*4LI2RE+*4LI2RE+*4LI2RE'"1^
MMY)?IMZ.*57!K2H]-X0[+;4*0LD@@G?8.X.OX0_*K1#OWZ?_:192S *(Q4B*
MB'6Q%V(ID7;2("&"Q%1R;DJ=W#]<KD@SQ S?MUTTZ^9)!%F)'\Z+"TH<*!/!
M28("BTE@I=5(6XL1EBJ&N!@+B+Q:2OQTL@*N;&=ZX$_'_L3XX6WV-*U6\U<&
MR^\&$]/S58V?Q]F1X^(E7"Y4LY2EQD$5NB2*4Z6T=07%CDJOE5,FU.6Q+HK0
MS$TW;A.:_IQV/-T[M!^T4H63)= +'C.6+%?(:&*1 #%I2HVG1;BHY6FC(@]B
M^=R@[M:-]/)Q%!N\?>A9M5[4/UJ*\&8K\SC!^()ZU3^$Q+?2""TC]#41^FR&
MT%+8P)TW2#%'$#>%J3JAJ> I]I9Y;^GEG= R3J]V-%*FBQ?3Q<(:S:4--'#,
MO5<:,V$+YK2GG++ OD,7<__9^P&IO1:-+((CEH2 "B=*!'B@D#*6@94KG6 %
M#9:X#%*K!%*93&8R>0MD\L=P.I/)^\3I%IG$BFIFC$"F8 'QHK"H5%0BJHU4
MH?"8^C+C]"KA=":3-R>3!@M6,B69)80K914@%7?,LU#P@$UY33*9NP'?,5+M
MMQBE-"4-3&E$N &D(HRBTA+XL72&2H I4O*U%Z2@ZX3+=9!M1JL50*O,*C.K
MO 56^6. G7NIW+N?<IKZ_XY]H,Z$ @ 9$4M+Q T)J,2R0(7#RIN8JA18;')<
MT/--CC-69ZS.6+TZ2[)4>%)9E)1I7S!2<"^HX9;30(@RI?*.N\O!.G=NOCM@
MWIT!L^.2,!$L8J4I$(<S%96%E\@;(ZTO0\D+>ZNMFS,J9E1\BJBX!"A2+PFV
ME-O2!<Z(T87V6&! Q( )GC8ZS0SVP8'R70LHG8#C2SM$5:P]AS5'FA*'2N:+
MDC# RX*LO2CI.BO.5Z_*%/9I5'S)!T ^ &Z#%@=*N;:Z\*ITW*I02BZ9I00K
M(DNL[35H<3X*[O<H^#0["H3@PEA+D!#P!Q<R<F8CD:7:!89%D,RMO2C4NB T
M\^8,FQDV;X<W2\R8<P5H&/,<&V6$%=P(J70AO3??0<T,EO<*EA];GE\N W$@
M+B0=T8A;9E%)E$"^*+ 5@:A@BM1&FV?7[YVF9=U>YG1^9WYG?N>/O3,K:7YG
M?N>*OS,K:7YG?N>*OS,IZ2]C#>P:_G;=SR_^%_YH/G&BAT?=?D6UZ;Q3P'JP
M*8>W;>T2?)590:-9<>!]1UL[.('O/@/&W^D/QO#T\2":NL[W1SXN0#^9!GH,
M/X1N7_=M5_=@I/"+U-US8VJ6+$Z[_BY.-Z2 \9P.1JE]YZ]#W]/C[F?_VY>N
M&Q\WIG?K@[7%@F<?T08&,1E?_I%576(YOSKM/^/HDPFO0F"\#,1J@KFW0I4Z
MYB:0H%6P2LH/M%QK/G0\;&9PJH\\,D.O/R$=8(*_ZMX7?39:^V5^76!1%N1P
MQ1+6BQ]7\?(U"^'.UJP2G?-V,$SM8'\%P]8/X[M@.'IEQM(Y'D8_T']=+3VY
M]N(P D/G?W_1CW8&@_"81]_9BJX[ *LTB0LT<J60Y)QO,B')_M:[WW?VUBM7
MT.N]K<MQMS4#MD(3V-K?V][9.]C9[L"_#O;_>+V]>0@_'!S"7[L[>X<'G?U7
MG:W-@W]U7OVQ__?!8YO>3]U^9WP\F, SW.CGJT8_<\K]MJKS>=?7$]>%8__*
MR7QOZ(D3S0[VY'.$*?3TZ<C_VOSCMX93=?MI(.E#O\TO53RZ%HLRQ>^K7IZ=
M:ANX.MEJDZG^YOKEC?32@@.U>JU0&UB*2U_&&^32U[[W6,(V!%$_]-COO\9*
M?B>#I?1:C[W"++TR$$*=>^L%5V;5+EJE&Z(]^$WG!-YV/.IX.(S<?%6N.1?]
M39>H=<EYF:_^ G?]:J\?Q?%F9?X>XT<G_-P6#B^SNU:X;\G5!U":\98>'7="
M;_!EU G#P4EG<.HC"P0S-5[(?0;#T%_>U.0:"W%K>^P6*@G?XB!OJ2!BNO63
ME<6X EMDN=XVR\SU@6,UKCG3I8,U5B'HXIIS6R9835"GG&&8,\EY(64IJ&"4
ME-X6@8A0U8DFF%0E9LG3+C&[O]7$8/SY=>_O=W2/ON_^<_CVTWOX;^_DM=C=
M?M7=_?M5=_\P/OL3?__[:S:+P?B3[6_OT/<?7WWZY^_W/?C,\?N35]WW)__^
M^/[O=V3WV]OCW=___+9+S\=@[&U;OGOX'L88/_-7;^]W&-??_S[YYV0/GO/N
MV][O.U_>;^]^^R?&8-1%'78/\)</4A"JM=5(N%(@7G"!M/ <"8&=U=P(C<%:
MYVQ=EC<I+_L=1%O1H+,,2*LTMV4 "6 HEK;V2IN2:R=5J6,W4UE2YD(I9%WS
MFCR+FM>/!)"^30%)F8")U0:1PFG$?4F0UAPCS"QQ %3:&KOV@I3KF-U"].P*
MM2M\%/1NTWV<C,;IEBE>2@T]:)[M]GRG7_.^^-OX;QM-A4F\KNKV+[03?KV)
MH; JML"=TWVB5GDW;/M3V '==!'0\5]/X_WD30J@KU(QH6LNP?T2Y?D3I[W\
M^<!9XL!IRD^F T<+1G"A,>(<R"^WLD":A *512FI)I)9Y># $>?#CW/OZR>C
MF[? &;-NWI9NSL@@*9AV099(%2*V&! .E9A3Q$C %@LAG&5K+\3Y\@./OGGU
M(SC]]P9]E&A>-WKF_6A\(PJP@NV85I@"#"S,&@00/?*OZ^7?J58_H\TR:--M
M,0'K' ?CDR)B&$.< @E0TGOD&!6E-=3@$DQ/H6Z*-KEAVNIJZ*T1@:RAMZ:A
M,SY@@S0EX07""HM8)XXC[0J&X#\NC>7>< D:*L0*J>CS<0=,"4'/ZY'/#H%[
M9P-Q\?^(:Y^!Y@> IGTMYAWS7&./2- !<244,MA2A,O !+,^%/%:#/!_A2R/
M[!18=2Z0]?-F^CDC B  (KURB):Q*RJS"JG"8F1+H;TCF$LL8MF \Z6]LV?@
M[G7L=1^=#@?6CT8=H+U>#^UQ1_<=Z,9GWQN<QNNC["NX!W9PO3XI;VL1;?;=
M]DQ K_MO*A%FD%H"I/:W6B3"%04-4DH4L/2(NX"K1GP8%X8(RQAUXO*.*=FI
M\&14^1:(Q!*!*%F?;U6?9Z1#!LR<QAQ) TK-9<E1J4*L6D0Q$=HX:T"?Y3J^
MN5F0_0\_H)&I-A<RNDJ2/HG\(H<F/ 37N *@-GN]@8W9ZZGMT<LHKZV6N+)Q
M] ,XU8YHH-II6M((43QVTS E*@LG45$XKC0N E9\[05?I_+&?M+LOEA=I;[U
MF(:LMW>AMS-^02T)3'&&0$,#L JGD0[P!^5&22(#H52!WBJY0EK[G)P:,;B[
M,]9?.\;W?>B.GYGOXJ&2@N9!J!+#H?ZZ-?2N.QZ!E=,*2L[@LTS<_>%F78@5
M .C;+DM=7IW$A1,:V8 QXE@!=S!<(EMR(TE0S,=.7.(FH??94_&D.</UG(Y9
MC6]7C<]::OSQSP\@/%T0Q\$$4[$=">;(*(L1*R5G1@@,_U]%U^/S<5;\KF-B
M3#^JRU'W,Q"*T:@S")TW;]YT]@;CY^:KN&=N,8]%412CF+7G1_M@Q<1$I4EW
M=!R1:#]L>S/.</2CK&+S0\!.<&<"4B1XQ)722-%"(DJLYT+Q$$I (DZ+U4CF
MRUZ(Q\HHLA;?&:G8_, X)]PXAP)S!>)$2Z0,84@3(UTHB&=.WQJ?R.Z)'W%/
MG)SJ[C"%5H!"QK*Q,3O7=S_'PFW/S%/QD&3BS7#PN3N";WTU&/XQT/T*D6K?
MJ,L8M!0&[;29!"^#+JR2R-F"  8IB\I">A1(P:65VF 2KU^+&R=J9@?%ZNKK
MO=&)K,>WJ\<S+N$T9HP:X!)!QB0.1I%QW",9J'6."*4+GGT3#\DE]L?'?@@<
MHDKG>&:NB%4,T4P"J0/(*\]IOFS]$1QZW>83(+HB!FTA015%O*0XIIDK5#C'
MB/':!V]7T:;)+HH5K!B6]?6.]'7&&W  H&4R /]W)>+:"Z0QUBBPH@R&.NQ8
MS/DH5L23^)S*@FT=Z_X1/*[;[VB@R>-12O?H=;7I]G*UKR?""M\,_:GNNB::
MMI+Q(%'%2NB9*#Y(.,PP9A1N^^KO&.:?Q+0-]&4X]*X^>#;[+AU*FTE2^1A:
MZACZLTT;24%*X(G1]QU#;+D.R 0LD*=.>U=B[LJP]J+D.;;V"2OT;=:8S0K]
M$ H]XY66.^"198&(!'%Q;B72A62H9 RD:X27'*^]D.H\K\SW6O=0<=9:F <P
MRE-]EAH71=:AK1U._(R*Y/NMU<CL.0]>C?C>5-*+87Z5[/Z8&0<9O)8"KW=M
M-F(55@7GP$9TO)@7SB-CO$<^P)^6*"F(77M!UQ5=I9I(^5IL!5U8/U+T/BO\
M_2C\C*WX4&IF8]$3K(&M8$I1:8Q ('U.A&#"Q4@<LD[8^=HG#Q*C_WP<)/O9
M%[)BOI DD?VF^T VE7X ?/YILPV!K7=%P9$S 1!(JH"4QQ:5LK1.&5<H4@#X
MY+)H3UF![S-'*.OS'>AS*Q2':.JPITAZKA%W@B-38(Y*1WBI"X6YR6&]#\HI
M4KG SL# ,%*2_7-S=3QLTG$JW'@>AI)0]F<RR1"T% 39-J4PRGGO-45"!(ZX
M%QJ56@DD%=7$,2RLCK?ZZGQ4;\XX?A):>_M7*5EK[TAK9\1!$U]JHDH4.%6Q
M !I!RL*/4GG@%$9S)5/]U9OT#%T]'\0JT(2+.W/O7:?EWDU\$I=VO7[J\/1P
M[8UCYXB4A>"\>WGV#@0+!M#4]IE*-</84C!VU"8?NH#_,:-!=#X@+AU%!CN&
MG"NQ<8X4WLBU%TRL$W:^Z-+24877TZ%'Y.=XMJ#P<"V&,RC<$2BTXD$HI=(S
MA@KO@=N4I4::>X\DH4(+'7C!RNCD7+^5H@5W"PJWY"A97>(3]:$3>H,OHTX8
M#DZ ^GSVH^ORGAQ[_'A"S-],AO8X^<)"YW08Z>WX+,4"^?],NJG"]3.[<GO0
MDCEO]%DJU'4XV+2P_D/_IA;)FY[NCS?[;J>12CZ)ECF)/L[5SI&%*B@F'#F!
M8Y>36#N'$X$*(>"E$@N)U=H+R6^!FSY2!OK$]?;6$].RWMZ=WLX8)'%<8BHH
MHMI0Q+$GJ&1!P(_6**.*8 )9>R&>8J+:*E.(=%\,O!"V^*@;USO?I3T@8WC=
M'^O^43?&".9[_.4!IU4:Y^.?9/=PYX,NF"R+$B/&RU@^'&-D@H9]:S C!!=8
M"PMV*[T)6\@W:3DN)ZOR[:ORV;PJ.U-BHYQ#4A9 _+4BH,J>(A&,8$1J[KE_
MZB5R5II*O!Z-)KIODS?B-FKM/0]SYG8;'C<RV ^ONGWX!RS<VZD4,@3]*)O8
M_(!EB7%!#;*R+!&GA0#SQ7@DF)!68<D-!?-%BO-1OMGML+)ZNDI$(JOOW3&(
MS0] ])W"6,3[;!][(SND#!.(E*7 P7O!R>W5UUL]/\0JD(9K!NDL=5EU#?OF
MV=['KU:0SNM&K/D^_@?Q;+Y.GQ=.$%$@S3B &B_ &"*"($\#I<&X('R,-5PO
MZ"U$&ZY&C,XM^CR>+2;<78F6K/9WI_8S&D.Y4,88@EB(W9;+P)"1MD28<.*5
MI(7G^H:7*/>B\T\^]G@Q!"<T=/ZF(3C7-=@>\AG/J<IC:B#O71-IU7*!V<')
MR2".9V _/;-+M96MQ=-(ZQ4(:V9K;R5)I4[I^7!:ZG":*P(HB?:R(!3,:TD0
MUYJC4F(XID#&N- B,!P3X6FY7N ;UPW+EVZKJ].W["O+.GW?.MW*:1/6!>,%
M,I@[T.1H9X*>(TL+4X2"!B+#V@M:K!?J?&F=)W+GMNH,I+IYCI0CAOV.SV8L
MQ Y&SZ[JSCV[R)8!JCI$8#\D6&JP:BL**6/44A@U5^XO**N#I@JI0(IX-:>1
M(<XBC@ON06;"*N =Y;JXH-Q?OIQ[$HI\SXPC*_(M*G*KC%\IX']:(A)LK*1E
M,#(BUB"F@I;"DL)Y%IW:N+R)4WOU;N<>!\VXU-'AO/FQ/*-G80S=6S^LB^V@
MW.1W:4R:J^[G062$&8ELJ07B(!\$9XM 5.J"RE(Q8MTJ1AUFI\;J.36ROMZ5
MOK:+\"AB Y.(,QH0!P5%JG!%;*2)"2N"M(ZOO5!TE1KB/D-OQ:@A#L_;6;&2
M/&)JW40LRL;-CP/37$T_%X*.[9 0]2)Z4G6)##$!&>NT+JGR!1:K&(&8G14K
MZ*S(&GMG&ML*MG%2^E!H9+'"H+%6(5-0@HCB)>4,PU8%C<T)R_>K:6_]Z0*%
MR+Z'!^<,,Z%D"^8'8&>N_IZ'PT#H8)#!A4(\>(E*HR@BO.16"3@BC,H>A\>J
MO:M[JY%U^*8Z/*,.)A2 O"X@'+!&G!&*-$@.4:%\D)P20>W:"[[."KH:A0>>
M39+R-*^NTTM=!$Z'7?CQ5/<ZS>Y_9BZ(!RV 4DG#IRKD;QI)-.9,!J"E .A3
MFT24CACGB4%%" 1QQQ725'K$L:#,%X3P6"R!Y&SE)ZJIM^YCR)IZJYHZHPHE
M]D%0#52!!Z *UEH4A89((3233ALF'&AJN1J:^GSRD4_K3+:..5LN>^>YY1^N
M;+SE)2F)4P:84Q)_#+^^S=5CI<[AP(U!6'J&N"8.&>Z!;A!3>$PE#65D&A2O
M8WE;EZXY(?F) ,+]>C@R(-P=(,P(3;#!<HL-XD;&T@1<HC(V$5'4&$M"H8#8
MK+V@=/VB3DBKB =//EDY<IYNW1HLEF")_&>]8D$QH^0S: *0_/5467[H1^-A
MUXZ!&,4WY/9)J\Z"(N+%_W9FDGP[E6%\8;/OYG_1>N<;6(R!.]\VSO8F44 [
M7^VQ[A_YMWKL=T+P-CN-EP/.N1)S01IKX#Q$#!L;:]5ZI(,MD:;"*A8(+AE=
M>U&R=7:!W^;' D16@TC=HEOGN6+*_1*IC"FKC2DS,B:#%$(9B> @\8B'V,>:
M!6!D5'@L"NYL:DY/UHL+;J)6$5.>O -JZ_KDJZ/''>./NOU^=$W%'D!)M7(\
MS&4H65A9!DZ,Y8YQ1X.2VM,(BB5W2E+VX74$1T(9>2APS%BW%-;-U<2SS(8"
MN!+"A8K6IP;^Y*1!!2-","EU, (,3[Y.U(WY4XZ;65TMUXP1SX/U<,1Q$+RV
ML>^,*VTIM&;.1"TG*FOY8]+R5A\AR2QC$B/K"Q^MI!(I*RB2P5EC?,%+!5:2
M7!?J?+;_HT_Q>3*TQ<.O+R4LUV28U0K_RD D;C Q/=]IIGDI!;V6(7C1PCXH
M]OWW R[0DSD5##<E<9@Z807W!2VMEYX5IA"%M]K:Q/T>U-F63X6E3H7=N7K(
ME!=4*8)X2<IX*FA42A50D))JL'B=I3&* L.Y@&_9>78+6O; #K:,MQEO;]\C
MB1ESKF!8,,^Q42;BKA%2Z4)Z;RJ\?5!'9,;;9?&VE1M'J2R\U$@H2Q&7V"'#
MC$+!,!ITP4H7%."M6J?B?&N]QPJWB<3_,HZ]6.!OU_W\XG_ACV;@M:)P6F7@
MGPZJ?IJ_#GU/C[N?_6]?NFY\W"A2ZX/UC/#L(]K X"?CRS]RHH='W7XU53J/
MIA:VMA_>/S[0.,9R*M2T.NT_CX?-8$[UD4=FZ/4GI .,]5?=^Z+/1FN_S$\1
MYK>PI%>L1KV.<4$NGWX(=S;]2@J 5(.A3F*$/>R'\5TP'+TR8^D<#R- _U=7
MA1"[8A*K">;>"E5J)FQ!@E;!*BD_R+47AW&S=_[W%_UH9S (CWGTG:UXIJ:L
M%)C$!<IUJ1H 0/[6@@GV("AQSE>04&)_Z]WO.WOKU3'P>F]K8WYBCW%*6_M[
MVSM[!SO;'?C7P?X?K[<W#^&'@T/X:W=G[_"@L_^JL[5Y\*_.JS_V_S[H_ 1O
M.WR]]VYG^^?'/_F?NOW.^'@P@6>XT5.8S[N^GK@N,,9;GDRB#K-C/]$5F%1/
MGX[\K\T_?G/=T6E/G_W:[:>AI0_]-O]]\31<=/W%[ZM>GAV4&[@Z+&O/8_W-
M]<L;Z:4%^E6]5J@-+,6E+^,-<NEKWWLL81N"J!]Z[/=?8R6_D\%2>JW'7N'=
MO?+*1IU[ZP5F<K6+[L<<+*\7-PB_Z9S VXY'T:'K7>? GX[]B?'##L/K<P3_
MIDO4<F]<-[Y@M1<O>ANOTP'FRMD^JR7#RVRJQQ\,<C Y/>WYF&.G>QTX%VQO
M,)H,ZP[+?91N4UH-$_NNE:HT'L(75Q;WZ-<?ZC5T[>CJ'^H@=-W[[-L?X7.J
MM[?SU0]M=Y2VS!<]A#UQ/L/]QKFRC]^#^S1]L+>>K]^N6?IWM9N:#?9$W*DG
M;WN[T2WZ[=\GN]N;7]YO_XG_^?AO> V^]R-\US?[98^^$^\_6KSH3GW_^[LO
M>]^.ONV>_/-E=_OEI[WMM]W=DU==F.,9S(OM?=MD[V&<>]_>AKVMVI5Z@,_V
M/OY#=K]\8*6SABL,NX8IQ'%*I,,<,<M)X)*6TA=K+PI\XSXKJY>XGP'HB0+0
MG7=-S\!T^\#T;0&8K*<:6T>1P3&NTFN##*,E$H7"4E-7<E>L8N72Y]2=X0 ^
M!D][&?W%:5#1T?1FZ(,?#J-='ON43$LMWR0 [JG![T53?#+PNPK--:>;,.W!
MS;ZK?N'AQ2?4G>^>T'EZ P_HO/MMAWP07A-5.H,"=Q+QH$JD2\*1H1[3P FF
MAL5"<ZH\7T#FT8>\9]QZHKCU(+0Q0]9=0=:W&63M?OM "VJ+LN H.!40=YBB
MDFJ-O%'.>V%X,&$5Z]L^)Z_AJ\'PJ/O9]_TH5=E^\^9-9V\POCYQS';[XP;@
M6W,<#BS,^G?=[?\Q&(WV^ZU]!3"KS^RQMY\ A,<^#0G^=334)W&K98Q=QF@_
M6*"%<&)R"LB'X  5B N!D5&X1!)[1IT6FMI("^F-V[!G7V+&I*=""C-6W1-6
MS?-!8Q28L(8A)BA'O!0*3%CC$16EX9:;8$69W8L/RP??3(;V6%>WR*?#P2F,
MZRR%&\1<S],8GY!]BL_$-K_U.^4M?=H=Z][.UU/?=]WQ9.A'K_MV$NWOEY,Q
MX.L_?OQ&=UU&V650]FSN?EGL'7U0G 9"-4%<>HLX"QQI6DA$K"^MH3QP G:W
M6B&+.[L),Q2MA)LP0]3=0-2W!8BRWG)-G8A9W#[B5(&4< 91*XQW)#;$TMDU
M^+!4\&W\-QH$- $ZJ$<C/^ZD#$?O.N-!)U)#/9ZVU\FAAL_%.K]=C^'>H!]C
MF_>';_1PW/S0;*W4@R1MP_WP;N0WXQ[,R+L$\NYOG2.'QF/BC++(2^T0UU@B
MC75  ,@\%$IHX(>Q;7IV&&9(>BR0=#\.PPQ5=PQ5BR21!T>Q4R4JA9' %"U&
MI2TU@M\R*SPN!;?97_BP)+&)I8C^PCH<M],4=NZ\&0Y.NJ/18'B6+I6OSQ&S
MO?ZX ?G>VE&G;17W(!B-4[C%&6ZOMLF[YRZ2&2]%;.9BR\@+F42J9!I10SQ0
M1<E5P5?1(L^NPPQ%J],OX4(\RO3O6G@T?UD,%,\!Q_.H* -'O/ %TIXQY.''
M@A.BA*-K+\1Z09]@]=]'0?WV#0P@U3SJ@+$S[GG7^=(='\.\3T[B[V( ;?8*
M/A,3_-X87XK+SHSO9A?%B?$1 DR/*8U" ,N:8PT(6S"/2DV  W*!09BK:%YG
M;V"&HGOMB'XAY&12M]S%;Q4!Z)0M?!"(4EVB6)P=*4_+6,&;^U $&AA9>\'8
MC=L'9V_>C]60^<^D.SZ;I@_#?$=+%)')IO+C!LX[YW"77J-LGL BC_?#=IV.
M=SBK:+4%6S"#[@_>^5:>/2T,@*M'KL1@23LBD>$E0=:$DDHJO:0T>_8R7*W$
MW!Z"YV58NN?[W<0%>>%<47"%;.D9XB [5)9.(X>%5H1*[C&8GZOGW;NT+<"J
MENH_\+ZCK1V<P'>?Q8"]?G12QQ@^4"?G^Z/8K6O03[444W1?75E2]V"D\(N8
M]#&ZO')W[H:08NG;J[-8MCV!PY5%X*/IDULHY!8*N87"_;50>$ D^6['A,YU
MFB6L6C7]O?W#G8/.X7[GDAX)KU[O;>YMO=[\H]4MX9IE]Y.,5G3:WVTB<$WH
MYVO7V*,UA4'1(/F5%<T2=.,A/OX5Q=\\T!*0C8J4G?^SYO-[DQ-XLKT%?\/"
M?;N..3K[H8[#!!;SL%3\VUY#Q3_^*=X?_D/>'_X)%/GM\=[VGW1ON]=]?[A)
M=C_N4*#58I>^.WM_\N]CH-4]_Z^W9^__=J>&\@+>U]O[^%=O;WN3[?V^@_>V
M_\'[?_\;:/J[L]W#?X!6?_KV_C!V[WH58#QL[_#=!UUZ#&O)D5;<(DX51R4-
MD4U;,/NUP0R3RG[J]B?>;48?C5644\*#*N!/YX.6V)1!4JP$Q<+KM8X' ^<4
MEGL\G,"Y7"UVC/1[.1EU8[I\P\UK\2Z +KQ6?V%U2YP$<_67S@\R&&H%*0*S
MN.2\Y"HX)TF0,HC",>*_2Q ?B [NV\F1[P.(]^W&.A#M(S\^]L/J=KP['G6^
M' ]ZO;/.X$L?V/9H8D9=U]6IK.-/T0U#\6_5$](/Y+?.8-B!!W3JU[8J)E^_
M^/-ZISOJZ([I#DZ/]?!$6S])%DRG9OR=,+"3R/%! LY_]KW!:30"X/$^/G6H
M3[NU-1"%:V V+E4#<MU12NQ)V=^M#^K.9[ F8D,(^,Q(?_:='K#\42<,!R>
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MY)YO<FA.AY'>5JG/LS2$^BHS^5#[5=1@A.=3W:UKO=:54/647IYU?H)W^FB
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M.X=SCUAO];"@]O&@9V?FN:R.W<]Y PMR)OC^")XVFF_>\I<6U/;]*WL^LSI
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MC":R)I15'."U@U/ IXH*,U16F)JHUYJ55;9_66@8WUKS"A3S/*U;5S(E%%_
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M_3GB0D/6RPZ&WV?:N*BX8\/GQN$:W7UN< /EWL.W8S 9H_ISDYZST!P<N1J
MYR&&"Z42>V@,.0-B%DJ6A(:4?\#VH];+6EQEW<7Y)Y13BR85B,<8[4M\?Q^6
MP]%%*-)H6_G!?:T<Q6Q;UZMSAK[#1#I\1CG\H [B1UBVL 81-?,K-'"4.S!J
MH(&F#GPX&"Y"RVV,LND^.8T-O]*14+A/KO4CK&/]A\H SE6%91Y3K<PW3)OH
M6U(@B@___?MWX<LRR"B&MSX(H8N5J(R'^:SDOOW1G$#G]W?S<.1J?6'9IV.D
M6!A.CE!\[,0$WM!!)6,%]T%-RY\G_*E)6EU '_,4\>^)[F)!VM9_@[1W1S B
MG\ $'Z[D7.-!'!Z7E?IB,^"_N*WK2W?D8GF5*V-F0=0J^145Z8,WNL0W+!FX
M="&I>3"]%7H^YCR6W5_)B9OJ*L'="3O[$08YH8-!3<;'H!E=3N/OSW"W5;U<
M75VV8LJ$\=5<.4%UT,[U"^Z8$*P7,J70B%W<#TO^\)R*$*3HDT-%L?6Z"*S,
M X[>5[3>>0;17PIY#7WP\<+VVX'UT,I>%%D6RGX/_J#2WS+5!I;L\]J5ZLTR
MM^BT,M/\-KT!#77%B_/S^6D4PTRIM2K2ZE8=*\G,L6FS;=EHW71@W:0XS*8X
M)$V*0Y/BL%H]>(XI#O<Z]5X]U\ER[U&I4H7@YB+HN-QO:DI320%;G0#7J(Z#
MAT+!=.!.4ZL!7BG1"QZKQ3(6>!2']UYYNAL"NK&Q(8713$8PNJC<52RO-;=P
MD;2)F]6I K,?MD68CN/I>2"JDM43PNXY*MAR"]*"<&QBW6F_"C!?S\/>JIY5
MP=/KV"J?UQM7^0<SVR=ZO=4X+P11N3OR0TVX!/I<='G!C';(X@VM#;3&KJ+T
MOGI8\<%%(/C\=,R4[L1AN"C] /E!?%G;W$QP)Z^BU'!;,2&,7*O^M^'D;&PN
MJM3/Z;-6( +YIT) ;A?Z\4;U/W7[@]<[NX_?W9L"KA>Y16?<-JH6U%$-P.*Q
MM[IJ ):&3]S\/)"<W3>?H=&YQ-^U#=>$8\PZK()VC30B9=0P-F^MUOQJ9K$X
MSSER+\/JP*9%-+Q&A02865_??V'YR&Y)3U[WML\-SI)@CR5O7O16SPSOG*>Z
MB!.M#U<UF'G65M[X9<\)D;BSGMGPZO:;A2FKF\88U%LZN.H>K/*$&NWL'$JO
M> &&$X\6"IZ&VXO:I<&?/M_<*O&J\GE/B\CF83'%"?7T@C)<I(K@*(=UQB_O
MEHS7G&L@.$CUC*MOIH''51;\W)OO$!RSV(ANODM@6]X< UJO@T4*0O9_![A;
MM)51D_PY>ZI[#F__"UM75+>JM:WRX):EKJ:TY.5P8/I_OG].>V#KD7 W..9S
M<2_.-N8A8+%?I>]^;@E,@Q-F>E*T<:$;*["Y7.^XF9-?/"R>/V? ">YCZ-5P
M<*%Z8]RBQ^?H8CCM6E(43C\Z)IBS@%'QW2-4AZKJ1!TW#DS7HWFOP578\F(Y
M."S>4?/ZUX_!Z_VH77UU-WJ#\[P;V)_?U(MY>5EU.?G<#V3<2S2SZ]3A]2N'
MI]PD"H\H/ 0 )"?/P.U]TA\/+XB^(,6O80@+V,:/2T]ISG2%^9^]//0.=3\<
M^;_4BS+6:$[S[*G1&!,ENH&YI1MJY)RI4"2EP(99]WE>/3Z4SEO8._[2^5NN
M"V'/8FH2$65:<\%EHJ2(J%-:>!G[*-(,XR>BC&8L)>4O-];8N29: B3J]+E%
M.TRK#,"UV[1]?I@8862<ID0QEA#.C""9I88X'3O.N-;:J&7%<\88Z-,/U#UH
M7!62<&64PZQ$@!"'#PJ9O3'#Y0[Y+/'JYK/P)I_EM^:S_#. MJ'C>[0W5-9M
M]FW@//@88C)#M9?M'P7_TV:93O=V,,Q3./,,SI5)>*F(8#N]@[TC<;#W073>
M?>FU3P <3MX>[Y_N\,[7#VS_<IMVMK;9 ;1G'BCVV9?>[E:OU]GZ!N_Z? '@
MT&U_?=O=/SF*#K:@]7L?:'OOX!3:B6%1T>Z'0UA16"Y/$TL32;C! @1<*N*E
MB42B,DFUF,\=B6-NLY0FB>66)U)F*G91A(XT[E7B%GA@PP2UII-RC_26&U^Y
M@FK";K^U>3:$S1@S7Q=/F_+ 88RL1-0\[8)U!2C;QU.<0C&"F_NF>X;A+%5V
MYEVB%65,L\0I0[V+N8F5<MRQ)&9I9*R =5:$G2/]]?V)R,/D3N?VW7"P.NSC
MC["HMG\<&HPJCV-**&>XI#3NO$E&O$^YCT6F8,VMO:(;\H9 PV #JW!P'DXG
M0P1Y/T^NR75+5:.?F'%DY$; O%CIP;!6P2LPU 67!')>H#E0+Y%XR\R&^XG8
M?&9#D4'?/YK*T4[1S(_0P$\8.+R:"0V_6[Y.VA>'W-O$TP@P6DA/N(\HD5Y&
M))8V%1ID+(U OI;E,Y1>!#3G2];!*<C4<A?&2Z3GK#<9M8K*Z,/ (P!/F_1#
MWD$E5+C[.A1/, S![%0Y[4K+3Y# < X/6>XU6&LC(PWRP&S!-*^]V&AM5VP#
M?T]Z%TN@$UK@ A$WVK&%Z["LWAWLL/FVSWH19ZXM7(KOIW<@HJV]6!+FMCP1
M*125S,=UIB?E.,X]&6\)L?9%W#HKR65"FGJ1L5\KLE=;G=<5IUFZ.H75L%%J
M2;,TXRJ26O%(2S"_4J^I2VBQ.M/9DD_-ZKSGZNS 9X?<B#B*M<F+SG!M*,D8
M!9.+9TFJD\QX!BI1MF1U!DC_GPD(F$/:J4H*RFKO.:C/BU-Q3'0V=,5*S/,Y
M6X%;*(AK0'ITH8)R@\E_1SDK4[Z#7+V6E[]NR;D=^@3ZJ@SL*MB"0/BM\VK2
M&]<X6&?X>$;KR-/00V]N<.Y^JZ)DUJO3*C\]-,A]F-/#JU5W$LUD["(714X@
M<KQ0WQ4W;H2[L@3H)(0R5YH?,B05DU1)1(G4TY"@X&&Z"G'R=)VJP'W.MU*\
MM<!JI,(H"W9MM+;NEGDS"\[GPT$ /W_G[ES3_(K[!"] 6EQ'\ WHQ,^3A<JB
M8D&T"Z+ZOXJ\I!?US(F'24ZZE3^C"8":!D"E5P= W<'UDZPU45--U%03-?7+
MHJ96SJ,J&H_J;_6HOB\8)=YC//5FWR++Z]EJ4@1UNH5Z?W)TV3G]<-%A'Z+V
MY?')[M;'TX,]P_<O/W;;)[;7.=T7[=//',M@S:OWNUMM=K"U$Q]L?;[<?=?F
MG7=X#'-\TGFW \_[#";!MPLP'>(.^^C;>]^B0^=EXM+($Y6:C'":)20#0Y!P
MI;G0UB46ZV#-^DM9:F N,Y50"RN4)UK'0C-G\".AJ)KWEY9SD)>W*"?@'E[3
M&U_\:-+TC&6('3KG=!3%G,2QU81[ ])$?4R8-T+&&8!WY.]02^T1#1P_S;H*
M.WM5  +VQ\GI:>W8\%2=Y $Z91)08/.KR;DK12-G&O"]G.MQ<*W67EH.HV/G
ML/1+T/$'$^B6';UX>0<+,6]^I7>#J3$DP:-Z-G(ORU_^;;NCLYZZ>-GMA^$(
M-_U[5EU$Q3)D5!C5*Q3OL'?G7T]US@V:ZYWC(?QORS<77V^$K_XUMHO?)=D&
M3<657].-Z,KOKGML%&^(*+O78Z__+I;\ES26L5L]]E]A?/,QAFE$>?C_UN*U
MJ>T0JA"^I*THB$'YO&LN96<_\.)%RVI^VO,9?^C%*6]2$H)8+=KHU5JXN8=_
MVF!410[CG)B6SHS%#1*RF+"'QSN@ZE\S!%C3\O<,P,U0'4;@[638[U99DK[[
M(U# SXO$33TN8#&@YMFX%5"XA8V?&0O:>@HC\K]^4>?KG0X15"O5ZSN<'4=8
M!40+GSI02$2")%E<<!W%J+/$VA='!_-%K.-;:X"S!\7QT]0#C_=/?_1V3[_T
M=O?VX?HOI_NG.W3_!*[=ZQUWONZSSLEVW+G\]J-]:8\[IU^.RWO@79,#]CDY
M^/I9=$X^0Q\.NG@?Z(P_=K]N1P<G^ZP-?=G=@_ZQ;7;P]:UO?Z(__MG;'L._
MYX<FLXJ!#D]B+238(2PCBNF4)%+'2E'-:,;67L6,77'(_&OD'[^ZXSJX9I>Y
M$7OG=ZH&P1H$JQ!,428TX!=58&H)PR0%N5?,11GW+/9Y: *-V.SA9X-@OQ;!
M+BL$BV J&(T%@5G*"$^-)9D6C/@HE9&5)C928^9T\B00[,YJ9,'[\)34R+9"
M!B@WG#/8KS0MV-VZOQ1WGS8$Q<JI.'))X@2GUF09SVSB,T-Y1IW1C1+U^R&H
M6U.B,A-SJATCS%E.>!)'1,4&E"CAJ=#&,I,"!$GQTQ"T?+'_4E5I[I57&O7/
M?I'*B"41,R)RL>>><FVEUYFF+%52I<XW>L)C+-*IGF"$E]HD$6%:88'!V!$5
M24=2Q90Q.HW25"%_\T];.@^X2)^#4^D?C%<\'O0L5L 9#KZ7I2ONH0PLZ?T?
MB#.6.Y51;M/(<<%C'2>12Q.5)(FGJ4@:9>#WX\Q%31GPL9))RCT140+*@ =3
M1*;"D2BB<<HSH9D6:(^D#V2/K)#?I%FDY2)UWN(:-30UCL?PNXR<<=+J*!$B
M\W&C##S&(ITJ UPI(4TLB(TB27BJ8P(:@"4Q]R96-A/*>(PV7*5%^AQ< V\&
MH?1EOKYR%N6CH1O=3QUX%F9'Y)6,4\HL@ GGBNG$6>DRT !B2DUL&G7@MR--
MYTVE#EQT]HXP=]XGVC$G8R)=J@F71I$LU0 _(F8.]H&42S0^HA6R/1H'P0.O
M5"XB;VF66J=3T G2S"?*QO!8YE(A6'*U3E!/H_7='\Z22S<<-"OX5Z[@R[D5
MG*1)+-/,$F72!#0&SV %.T^X\=1PFEGK8HST#66@5V@9/P<70I59V.J%Y,<P
M+&3@"9:/5Z.1N]_9PK.P5#37,K*@/P@CN$N8-"YU<:(3D3BCS#7ZP^U0*9\;
M%[P\'[&)N_[SR&WBI+QV\ BW:<SD=!+J8F_FA:=#Y'&#5_?3. "I9)*!ZI<0
MV&Y2PC-.B62I(8E-,JL5_(CH@R%5XX18W:6=F%1Z'FG#0<VPS&>I<@SC["62
MH+!;.R&:)?Q[58[S0Y7HR+",$B%T1'@229+QA!.C%:QLER:1S=9>)7R%5N]S
M\$[L#<;U8KD/%KWP$_%D3QJ@'D;WN(%8Z$JS"'Z_"[)M(:TX\M8B,V"_ ;I[
M UT]_-0))90"@RJ)DXQP%F=$)9$G,A9)[ #R-$4_['HL'RIV8C4"4!_0:?)<
MP>.AM)L&'U8.'VJ*D)12I*D@F(%.>)3$1*96D(RJ5&N;QIG*,+)JD0=G%='A
M.?AB_G&CT4OD9BG7!2R^Z<)X9GZ8OWZ+,O0@>-8@V<,C63U&-%8ZIIX:8G4L
MT"L3$0E3"S\D!7O.B53&:Z_B>-&F>]$X8_Z$]?W(^DJSOG_%^JZ%ERKELC2V
M1"GC"=?>$Z593!)8[]ZY+,YBO?:*L44[YE'6]W-WUZRW^HNG0K?4#@N*AAB&
MW@XF2/@0-,3GF17XD$.SVF#_ASBV-I'<KMD-'GXWJ <!2V=2D7)-;*QBPH4U
M)%.4$ZFUH%Q0+)F!?BWZ8.D&#[$ ']GKU<!O []_@FNP0=A?AK!3?=MRG\K(
M22)9I B/ 6%E*C3A2NJ(>R>D GLZB>,_ %^#LOZO0!-69PJND_BM)*U;K43)
MX*@/-\\Z UL%K_)=ZY$HE3K#HB2C2G(MHLQ( 7]*#&R)M(P+0L%TAE#PWH5)
MZJMW90J2_'Z^P7VZN[?#.I<?:&=K\WSWPZ&)8BUB(TFL,H,J3DQDH@U)9:HI
MBVWB,2"2;BS&-+?*RB1HD=UEXN_%)-E,_ -._(\V("^,/'5I0M(X$H1+*XA4
M+"(VBR/O(\>,37#B%S7;:N+ME!A^?#QT.9_8-13Q.61/>>*+(J/=[ZXW5ZCR
M@:'&&I-0JRP3/.* *)FQ O[PAF6P4V0F2!PMH88N2!S[>8E[HIK!_27N9%OL
M[FU>M"]WHLXE].'\,#7H3Y..Q&F:$FY@KU<TEB2Q-J.Q4YE,)%A3V96ED$HR
MSSLC#N ,3K/+E)9<V323BD=9DDH ."]%6LQ_=-7\-XCSL_,?M3\<QCX63'M'
M6.3!F@9H()F/&$E2)JTRB>'2+]]J9BMA_13LT#G8><!*E-DM*E&6BB1!8_5E
MG)06;!<);<<O"7[R2-SJR<:5!.>_N&RC W/+[>9%-OI'P19;F4*,NY_*=?.!
MM;>.^ %:2*<?^.[6A_/]$R,Z6^T?^WM?OK6W#(//:1O:,K]N.EO[Y[M;QSVP
MD"X.X!F=K===L*9H^_(M6%<?SCN7^_#Y!U@K8:>^V-T\Y$)R9 \G)D*[B%FP
MD#(7D4R(A,:4R32-YHG%N54:[.74>+@9@[ <3 $ 79J(1%N[0")=C7@K'_)[
M4(K?_,K9)J:)%+#I>I?$&0"QE5DBE , \+ 12TR>6VT3".O$8[';[C@O#I.7
MW($V#:JQS'-70OUY, :QJKU7!LO[8)VPR2@O"XUEH&M59:J22.$^!+9)KN04
M-?P&PXMUK*'3-47E^1%\I(Y<"\;#8 D:4]:;;JL>V*#]]=9[U^^/+GK?5;^K
M9NJQA[F>5INNJK$'_6ONRU ,J%XK:  C\!U@]WQ0]+-&X8V5R38_O6E)SM:Q
M#D_5]+*5LS<4Y=YV8-?&@H7OA^ZT"T*X]B*O"M2O^EOT->^XGP3B6M #50#Y
M6[YE&Z\?H=A.W[.>U[SZKH87./*AAG'?Y/U&/O&BPM9\ Q<O; V,F0R'^014
M],*XUU0E]A;??\-C_E:PSH9YM;OE4X.BJ#"[.F\>SE&M8.-2K+[+><:2,MOG
M@Z$=N?YMX!M+;>]Z+"^"6_@S@_#.99L=HIG!5!(14#A!V4D2!W:U2@CSB769
MCV'<H[57(ZR/UL+ZY0OH6\E.'7M"N<:S@+^SM0;GI0-QY$H%>>CZ[ESU\@<]
MK'$>J@7.RP[HRW.R$RH)+A.<3BA<N.L_YDU$.9KFO-)G)DB[6YOTD#DK.!.,
M")&"(,'.3[)(*$*I Y,V9LP(+$34=XMV.JJ:^!O PVK 0FU6G]E4HEK7V3QT
MSOC8.T\8%QY,(*N)E'%,$J<T6!09BZE8>^7!-"$("@N8@"B?;P<%"N Z#S 0
M-A>$".T<^DE0H8"M)%0-1H#(]\6P2_R%R)+_W>L6I0=?5)K'/)+ ([OC5C<O
M"HA524&>=.^BTFY"_<"9BG]@ID$#W-# /M<:3;!RX]FT#'%Y6:Y4!+U%!;&"
M/3-OE)I!,525P)[^W@7;O] )BJT^;-_XYA$('F@"?0L*H0T?#R9CT$= \,<7
MK<E9536DMN,6A4B6;,SSN^^"&OQ+32$8@#>#T3B41GO&-M!E>_-0"F\![I!M
M0V!6"?-$ Z01R8SGPL'&*MV"#>0-FN<J\MQQH1W83)&$?=@8ZC.LA/PD"NG,
M%L;)5T7I^CQW6+AA5!3;>195;F*YD21)4^6F:>POJQ]TNQI*/UL_*'N:)7/V
M@I?UZK*_#U%-Z(D.3>?Z@LAWJ2UTAX)+5\8I+ E56.WQNV4QJEMU^+D-''V(
M=?>'CDTC5 \B5,\AU7%WSG5OP/QJBJ$UI81^6>#:0H#JK),,S?^5"1NYI^F?
M!Y2>[%R"67_9.?T<[P;S_V.O\W5;[%\>=SOL"_S>.>Y<&HIMF \HA>?$G9,V
MP]"$SLDF[[S['$&[3G;?[<0'7^%WA@&I'["_LT4\&(\S$7-.6)(EA!L9$>6D
M)AE,4)08] 7PM5=/I(Q04PBM0:^'1J^?C85KT.O!T6L:#L\\-\Q22V3D*>$Q
MDR2SB2)*QAB0&=LD2M9>\:L"Y!KT:M#KST:OGXT=;]#KP=$KFB;SL"2UE DB
MO%6$R\P0980G@L8\,Q$SJ;-H9-(&OAKX>I;P];.!Z U\/3A\Q=-L;ZXBQB-'
MM)$9@8GB1$<F(T[Z6"?*2L]!^8KX3^<B-B5H'VCE?5'#;CC$OMISUQ2N^&5N
MJW+T&^BY%_34B28B!DJM ZRQF0/-B7H H22#/PT5#J12:$U!<VHJS_[!Z_/!
M'3/-^OS)]3GURVC#-%=4$TV9 \M&9T0S"?)IK)8^\]:G'-9G4_CI#UZ?#^YZ
M:-;G3Z[/J>?!1%RFWEL26<8(-YDBF>"2B-C"'_!GEMFU5^E#\0LWZW,%U^>#
MV];-^OS)]3DUK45L;!+YC B56,*C-"+2P?HT*G*IHTY:"J9UTA1M?PQJS9\.
M>VFHW'[1T/PQV/S@OH<&D^^#R3,%YB(CF=<I)3#8!L^:P;H1$2>Q,B)SW K%
MU-JK[*<Q^0$7Q-,XRFG@L('#W^SJ:>#PGG X=?$XZ;FFPA/J-?)/TI@HJ6,P
M(;%V3:2IL1)4U)\V(1LX;."P@<-?ZUEKX/"><#CUJ/F4"I$E'$8\2@AWD21*
M@P$?,RZHXUG&1;3VBOV\2ZW!PP8/&SS\M9[,!@_OB8<U#V9JDC0#\YA2G1*N
M4ZP"85,"("D4@&64.#RAI^(/P,-;$)7_&AJ40 OU:7)VU@LD+:KW6O60GO_3
ML7/CG7Y./@1CFO,5;G5'IC<838;NN;.E7+2/#IG%@4XDR1*,7I/<$"F3A&3P
ML;.1YL[JU6<_J4]^2^>SWQKA]+>ZT_EO#5U>E')<\!". E/A\V)%2;(-FMZ.
MM^+/YNY@OX6[8_'2)Y'2/4-'T;IE9OR?.A@5.6<<Y630SR[9/=2X(0-/D&!6
M89F;T=UJZ#59"\\O:^&WU,&;8XJ<K<7TI]@MT?[)YQ]MML]W]S[3_9,/\?Y)
M6^Q#NPY.T'9YV]O?V[YHGVS^6+1;OG0[>]N7!R='HK/WL=O9LMWV9>]X__+@
M%&V7_:]?H.T[%^VMMQ[LE>DI7Q:E,A5>$>3<)CR1,5$9M\3%$34\=I&*!):P
MXW&3E=7@V_/$MX<J--= V -"6*TFLTAIZA-#8C!B"><V(CJS,8EB;Q-F>.2E
M7'O%E]1<7T4 *[3,LA6ES(K<^'S@H-!;/*/6VWDOTT,\_C&:^!P4^3=8*J _
M+H+W!AI:E!>3^)DRY'_H?O9G[EKWU\JOV[7^*1G!"P%KMJV[;%OUG#XE4Q,Y
MSDGJA"$\XQE1L18D4L8SFV4VD@XT[_2A NR>D';=8,XJ]>W1->4&<WX.<RYK
M>19..)I$A%GK"6=*$Z5B3R@ 3QI9;^(4^:,>2E-N> INM\(Z@SXQMU78FHRN
M1_0[5E $4V8:-+HS&LUF&'BG(D>QX&=$P7 WC&1I!G_*5%$)8B98\#TR^=.^
MQR8Q<W67\2]6&IJ5>M^5.M4;.(MEPF)%,N<<Z V"$IG$EB0V43[CB8+I6GL5
MRU5*H'X@+T]X=[J1BA77(>JYFF79KJZ[L[NG"4)M@E!77OEJ@/PN0%X_[A7:
MQ#I*#)&:"L*MXD1;;@ACVMDH$U&LDW#<*YJ\S@8S&\Q\4IIN XMW@\6I?@O2
M!HC''!&9C EWWA'I8H#%A'J9:1<QBWZQ^(&I/5<U>A__+NIF!A_43$AT(?R<
MY3KQV6 4B@B_##'7W>]N&KG\G[,1Y$5OZ?06I:%OD_'5M\R%7R]&CSY2&'HD
M9R/&ZS^/J[/[,W7DB!XZ]8TH#XU]J7KGZF*T]J_9/D('Y\;TAN$H!O+Z,'SO
M?UG_\VD @!H,@WB\! %W0[P*FJ-6IBVMXR&B[G]T,^]C+GUD%-9^-;#&52Q,
M$GF5>9.EZ6$*YE,(Z_\__U)/M@<#_Y1;WWJ#&V5_/ J=6+*XYB IW^#21 K#
M,HQ=S#A@H\P2H5R2PM:JE91J[8K[;BP#O.JI+W=)=FFR6YKLEF=:F;8IO]I4
MRFPJ9?XN2_AK^,-9HJ!5H/O"SG2JNOUIZ4R8I-/6__X/R2+V[]9@MJ[FJ/77
MA5/#T8O;R-N=0W-O$*"5]2HLS:"^B^NUYFR%IIB7=C+$8;[>HU!.Y&8^CQ_+
M:0Q?[L$D1D_:P; 9M=EG>/[!R<'>!WC'![C^ [R_3=M?=R[;)_OTX-WGB\Z[
MM[T%!\/6Y\N#O8^]@]-.K[/U&>[[1CM;V*X//_9/VA>=DX_?#O9VZ/[7+[-E
M)V$N'(^8)4[KC'"K-<E8*D@LC34LB1F58NU5LL$6;?'[KX:?BJU^5BLJI7%L
M;1)3$3M.=:9Q96F19BI)G=/YBJ+-BGKT%35UV5F>Q5EJ&=&I%83S5!'D/X%E
M%0NA&8,I9&NOH@U^[8IZ#M%E"]LRF&\&^C1N@8"Z*_?C)NXL!X?^!,V%!SG]
MO,&1/P<26\4T?819>N^&IA[!0EB#%S?C13W</N,RTG%D"8LQT97+A"CJ''$\
MIA:F+]'H+N(;*U)#YS&6P'_>2]EHXMQN#QMWT3,:V'@\V)BJ&3%++4^%(()[
M2WCB!=$\<T3(E N="1DE6#FD@8T9C6KQ>''V./'7T(--Z>Q&(^>N."1OJ_%D
M"/\^=TZPR_;Y8:JE8RFG!(;7$TX5<H)EF@C!&*.6._D4.,'>3F!&7>L4#*K3
MR>F\'MO2^".D5IRI"SP^&;447*[.SH:#'X"P8]>[>&;48))O,'GUUS]U'G&[
MQ][2V?ZHYM7M/+UO!T,0%]?:1^=E:[N/[6[5B:3NP*?U)%S;FZ>H73R(<_O6
M@2XK;5_GSASH2&O@ES*H/9B/[<\.$KQ%_U=;$7J$Y/QK59WWQ7Y7">BN?]M%
M2V _^"O_A&#!TVWX^^WQ_M[;7GMO^QSTFW-XG]C]NG^^?]F#>PZ@/0>]-KQM
MWB38WP-=Z.O;X_;7SS_:>Z^_=;8VH6_?Q,')ZY-=U)=.H:VGH$N==&8ILZ@"
M,R"A"4D4TX1G5) ,II*XV CF:9()C*'F/UWL\QX>^";#]HJE":N)-0[-E4"C
MK8GKP)OWSEWONVN'V(P&B^Z"1?5S12FD2[7)B.32$&X22A1R7QG*,J\$387"
MPL,_G\VQ>HEYJXXW\;WPYK8,* W>W %O4-_9.Q\T,',7F+F8@1DF4N8L\3Z+
M".<B(EH;3ES&(YY);FV&U5Z2A])Y&K7FUC##&[5FI6#F>.A< S1W )H92A"C
M5&HU*#""1@[T&>Z(ECXC+O+&TC@1*74(-'\@T<"J XUH])E5 IJW@TGCP[D3
MSM1].#96*?-2$>VT))RYB"BNX<\X5<JY*(Y4C.7KTD:A^;TL)L=NZ$*R9*/6
M_"JT"56TKH6:O<%K]UYU[29.1 ,V]P&;[@S89#[1/"'*90 VF>8D4YDFQB0J
MS82),YNMO1*I;)2:WT^9U%2V:2H_/"[)T6VUO@: [P+ =?=5HDS,J6=$&>T)
MCZ4FF> >:Q]FD4J]5]X@ZU'R\Q#\.VM$_-&:(*Z*EZVSH1MAZ-9WU9NXEK(G
MD]$8U\,STP[_6C5C]'._3")Q=ON'@4OSL* &H^Z 4;LS9+@1<R**8Y(PL$-Y
MEDHB5>1)+&2B=1HEJ19@D;+%0..%C-E&/WR85?=^!GP&O@HQS0-+RW#2AF*S
MH8M[NMKG'\TE][N O.Y:5,ZD22H,B1)C"?<\ KL_X212$1*:9UHS^N=0;-Z"
M36[E$@8^3?3(_<\$H7T\F#+"Y(-?ED%>#U'=;P:GT,"+5HC"=K;5[<,=JM@
MU-'0!4(F7&\M'$R<1-6#K<)WL2[YF8*?O8$)]$S=?JNM>C"8_?76>]?OCRYZ
MWU6_JS:@!:[5&8Q=*^+S3ZKQ/&W,L6(MY>@+2_5&OBW!UFY.:"C%@^"V\C).
MRKT&(TG[XY<$/_GE$[@0@AXF,*W&XD'?'M_JY;F8+/[\)4VZY8#\XH2J31-4
M_=%[=8$+?;-OX9/AQ-E_ID3CF';8&XPFPU5)JHK:W7+GZ'T[>/<YAF?3SM[G
MJ+WU@7<N#[KMK6/8%;YAWN#%P=[KXX-W7[KS256[7S$OT)YT]CY$<.]Y9^LH
M[ISNG.^^^_QC=P_S!O_NM=^]_7;P]6\/.XS8_7!H9"I<FB4DI:D@//:69)XZ
M(IA/(B6HSR3--WI8NLYNXC9-M8HS;Y/4&<N5\%HX!5,$6X5SB5(+25C%\+>V
M?YRY/G+GJ+YM[0)@#5MEX;]_ZASP5S @7$VL=V.#?K7(?3+'SDYZ;M<OBMHJ
MI>X]@I3MG'<V#X4T4@N+6H9B8"X*1724")+06'/#(QI[NOJI>Z4<N[H<#X(<
M5_60IO.>Y^T]JTR]AN;PM](</M&4O!E2PZ4I:,]H,.JYEZU?Q</W5*K"?'0C
MIX;F.%=1$5VM^^YZ@[-E3O3FZ+,Y^OP]SJ<0@E+*)I@36U.A+%7:%:OU>5\]
MKV N.3CN?/V["Y^=M"]W6/ORXPE<!_=]CG?1QW3ZMK?/OO0.MCK?YOU0G=/M
M:/_T;]#]VOCLR\X[U =!/]PS8O_K]L7^UR\G!U^_?&NSC[-IBI$R5,912@R/
M(P+R@!JBU$1[F$CFN*5QAGXHD(PG<>CY>XNY-"#W'$#N9PNR-#CVJW"L1O08
M.98QZ8DR,B6<>T\R)2R)8YTFB?1I(&X3T0-[TU<[=..IZ)]OX"-LRS.+U_C=
MT;R+/K)RX!O<N0ONS$3M6A/3)$N(H(P3KB)+I(\X2;7/:,:YU&D*N"/%"D7M
M-IR-JZ@@-*OSH5;G5"O0B64VXXZDPBA8G0G6)DX$\=)GULK42FG!NHE^.H%G
M]6*FGLK>_WXX\&XTR@^RO;LGHW230'A_): ^ V]A AJXN0O<U"/(8^D4TY03
MGT09X9'C1&OKB#36:D<=2S.Z]BJ)'LJ5LD(.DV:5_F)EH%FE/[=*ITJ!\*DV
M24()YU023JTDVM (]/8LB[DP5BA8I9S^M,J^>EF]3T4IV#X]ZPTNG"-%U<+&
M,?"HT;_E='S,9Z-NHC1^RSN#T0R524:5D#(SA'DDU[:,$^DB16ABXBSA"8N0
MFBU:CT3C0?B#E_%#U7QO5NH#K]3+6G&V+)*2IR1*#8>5RF,B(V^(3B,3T53$
MJ61KK[+DIZN_-[Z$^RZX3PZ+F_1-I3>T_HJNKA3Y["V5A_0G5$/?(,^#($\]
M1B-FD?$,J4 <\BJZ"&P5D2;$(J>K-:GQ' R6K/$J_,%K]2&]"LU:?>BU.M42
MO*!)9*0F0OF$\#C.B((%2N"OF&:9-+$'+2%]L#B$QKEPYU47,F :C\*O9H8(
MP[SD4+-!F+LCS$S$@0!M0 I-LI2FA&NP2+1UG%">)CI-TEB[:.T59ZM$YM[X
M"U9,'6@6Z:]8I+5P1"<8CX.S ,.".,^(]#HF,"4T<5)%4JFU5RQ>I47Z',A:
M IE?2]TIH;!A;FF86U9,T[K#V<TBN&_V;8#]VD<-T-\%Z&<*AH,J%J?:$V9C
M 4"O#%$L!LN/FX3%0L4:T^#C]2SY$WA<?F]V38.@#8+^*C6X0=#'1="IJFP,
M;')&*<*E\(2+)$4FE(1DB9:ICAE+*58-6L\>NE;BJC!AA1^/P:MQN/R_VS!D
M_ Y6I^6-_BMZT=KIM_Z>]%W(VY]EX#*#T],)!LWCX5]_,$:"K?&@=26DN.*\
M? Y7##6)=RXU21+QV*N,ZM313$EM*15<!VH:2I.<F@9^F571=CIO9Q &^FH0
M9<Y!M$:N/P\P']UH/)P8K#C?/P)L*=SR;P:C<6>") 6[_OU@%,B^1MN][FFW
MCU]7B$.?)N+<G]OF9/OR4 DAO-016-16HQ<L(BJ*-?%,>)MFD3!ILO;*=[^[
M!=!HE9,^0K9.E)ZQ&X9!1='(/^H.BZL"<9L""[$U=*-);US>$HAM:WQ(\+%J
MG0T'%N:Q9<">[%J8I(W6WG%W!+?BQWC9T!5<Q2"> V2+.>X.;?G,0HC_]W](
M%J7_'K5 7+Z!%($(JW'>3EA(>/%4RI'QK;79Z]6[ #>ZH6OA8QC]]WD7R6^P
M39.1"Y]%_P[VKE/FN!H*:)AQ,%AV9BRTZSO?'8]:DS/XR[HS-00A#;V:'33L
MZZCU70V[\ 0DIYM].+YNJ/I'^.5P<)HOWH*$A.+Z7&#C6$)C=S-9X..!TEX-
M@F D!T=]N-E>#3N+FHQ/LCBR7*8L]9S92(LD<SPQ8 T::7Q4D&&E,V184\2A
MLQJ-[_YPEERZX>!:K'ES#(-7TUV>&Y)T3K;9(6>2.QDYXJ(4]0^-95(C^)'2
MU!GJF<WDVJO^8!%'1@OA)B8?T"#P"J8GYP(&!%"!]QK7[M4WV3 G^4+'^G#A
M*7V0M=;I .O?MES?PN57,E$"L)PY:-IWU[O(E^@2D;SZ]="V_W4'@376ZTQY
M: +SW%&F,F/2F/,$L%<ZDQ5;9%IND?->#'$G'?Q:L4V>F=C"!BAV]S8O@HI^
M\BW>_7"8)2+52>1)$MP0@FFB,\T(A>W1NTA1)?S:*[K!%Z48X+"'<XW2=A<!
MT!$5,@682D7$@ZN#F=@*H41F.$U](0!1(P"_@-UOG^[N[;#.)3(9'XG.YB%H
M0;%*G"(RCB4(@)5$N@1 +=$NBY2'T0=]*-I8M*$J ?@I_*'S^/,6M(#IHY8_
MH36]>;P<KNX,HJCN=/NM(]!<ANCI1R"V^  0'X5M*YW^=Y9WF3'#!!4VI9:S
M2&CNJ1!4V4S3A*6N ;S?!'C;O'U^R&*KH\12(I,X(SR+)%$Q[-\NB:AE.A,B
MYC< WFWD:%BPMK3F2-%**9K*^34+Y68QOXL<4I8ES+G8RS3E-C;2QJ#G)U+#
M'IR LMC@[F^2PYT?G0^'6L;:"66(,V!]<I%(+!\D">A#'O3V##1+BG*XZ/V_
MDQS^ CQSDH,Q$W.6)(HKQ;)(1]QIY>-,4JVB1HY^EQQ=POZM'6PJ,I/$, -X
MQE)-,NH2 MITDJ;>NS3+4(X62QH_+)ZMMO.O;M2<*E -J@Y7=5;N:L<H!58>
MBY*,*LFUB#(C!?PI,PN2#ZO[!L/[CLN@"KU%Y]XH>K8K -KYXU""O2A"D R7
MC' C/<F$$2 Z(I69R*R-),K\57[_^UHN]R(>;Z;\YZ><'UJ::>EX1IQ M4VQ
MA&A%#8FE\Z#2*0=[$$[Y8OVJV2G_=;Z2!X*5%$,!,N,RI257-LVDXE&6I!)Z
MZ:5('W9W;61LF6'\3>R"8<SBA(,]0&QF#.$<K&/EK2 B2RELKHRQ*+O3F;,U
M)J%6629XQ&%?R(P5\(<W+-,XY0]K!S8S>^7,6A<SGTA*=,IBP!(/QJ!B,.I@
M_BGCXP00?;GJ_:M\(+-(@BJ5 >08#Q!%PC.'[E2![@YOF"),=<AR1X3AW"HO
MM7*IB6$G$]*Y1&.?4V%BX9,KHL=^0FV?/9K<#MW+?W_.<KG-P P$5=$SIBR)
M%&68]N.)3EB&U5V4-"*+I#*W465 Z :3HW!@-Y47ZX8H'#B=MRKO5"CEA>;,
M69Z2<U8<(;\,I@'L?-.Z$_\Y6_6C"(R@TUN4'@UZD_'5M\Q7A5K@_G\D@R'*
MY@:L]O,.E;!$50GK>#@M=W#DB!XZ]0TV%.CA2]4[5Q>CM7_-#@R,RMQ$W#"&
MQ>A?7V_%^U\V:/G< 1X,AD&F7DY0 /$J:(Y:F;:T )X!!O_CYME+P6X,E5S^
MS[_4D^W!P#_EUL.>"" 0JJ"J5\M6Y),L,">; G._M<#<EM/CU2L@UZE*C]KC
M@ZT/<?OR*()G]D!3%1WX;/?=Q]/]T_9EY^3H<O]D&[Y_O:!Q=-C;;YTM<[F[
M]?G'P>GGN+/UC778-C]X=]#=OVRSW:U.M[UG+MOOT'GXC;>/#F',E(H]1BQ@
M 3FMP*Y1/B6@;J F$DMKHOD"<D)2I9CWTE'+(Y'(6&CA076A@DO+V'PI,!SP
M>Y2%N_$UOZ\L'/9@IX\Z;+#BG[',Q*"E&A%;J@TE5CFPA2,,M36))3+.P&0P
MU*<JF9>9U$J7J-18E6H..X'BW("I8YUF1G!E5[]\'-ID>3&X8-H%5>!L./C>
MM1BITQI-3J&=%V40GE'#X05>&.IYCT(T6_@<K+I!OW0%0?=#6"#L@;U@!;6"
M\HZ7X;XT0L_[H!]BAX,;7JM>,/9&Q\Z-FYIT34VZIB9=4Y/N46K2W90.!5CS
M6$S@[]^' M=-P;FF%M/5T2^1BIA*N!0NYD(G2J=,)&F41LY0I^GM<F:OCH_^
M9] _VG/#4U0<5R:GZY[J8I'3]>7XX&3G8I_M4% '17OK _QKC^':\\[I1[CK
MX!14Q=[^WM'%0D[7U[>G[9._3_9//OSH7'X[[VS!OVP;5,M-=O .VG^ZS]OL
MR_'NUM^S5>6,2W4DM"%IHC/"*4;%1 Y/_=+4)C:B(F)HPDH6L7\_B8I,35VY
M!LL>',N$]%0E4>RMYEX9:47D="2Y9ZD!;+LMB4N#6??'K&D>*L_23"1"$9XI
M3;C)%,D$$T1;*RCG@B;*(:_2 V>AKG8%N=75%K=?$]'Z9P OWCP:.K>L4G%#
M%U4B3<:<HIPJPVG&C08%BKF$NI09E:8Z?ABFD0:&[@M#=7JWR,:)2*0D0JJ4
M<!$AH8B(B1$\EDG"5"0QD6,]R5:):+HA>'O@%9MRX74JC%%"<\-B*1/%4\$=
M9RQA7CX(LT6S8N^_8J>*@Y-2"68EL9D'8R<1CBAA),ED%F>:I0E5<5BQ\551
MC7\PV]OC*0@YU=NL.[]TW:^W^FY!7?@IVI!KF4.>E_WV$ /TQ^#X;^%X:W#\
MOCA>IW)C*@:LYHI(:3Q8@1HC2X4@*376NUC$\,L#:5X/OF">AENK@<X&.E>,
MW*V!SOM#YU0%3F4<\]A'Q&$ /D]E B J#9'<<!J+E,8N<+A1\=.5EE<&.I<P
MN=V.IBB2OS(4)CSQ91=TWZZY1<C>PJ'KS2$HCQ'#L]-O;9X-N[TE:?3G:M0Z
M&JI J:5:/?0(!I*I3UT8 4"8+ZK7<Q>MUZK_K?77VJ<OK]=>K+>Z>;3.E%'B
M3DP0(HEE#':>T9QG7F;&IG'J(A$IP6.G<V"B_*<R+V8CU]XJXS9#8U<FT^+W
MQ["9^- F />)]"1U6A!.TXPH2AE)30+_&FUH$BVG?9C)LUAOG4V&HPD(#6;G
MH"2\5Q?FV)EOK?=#6 VY","O(%BGK;_P@H).#=9+0:+V8DK;-ASTU??N<#)J
M;7;M>NNCZW6=#ZE#VR X@].N:7UR9C+LCB]:FV9<)'/0F0>_V?RX_0F_+1^_
MT?H<,C]"Z]Z_SX4^B#=*/+SBJ(MXA_%I\/]1][OKN]&H[ \(*Z9UXZ\>T',T
M)7@+Y'"344'4]C\3  H?+.0I&_H(Q'9DAEV-D6MYYE+5O#S'J6I'L9!0L"L.
MO-/N:#087B#_HFOE\6_YXJTHW^ NK[X/0EH+K,A\(-9*+%I[D;^D_+MUK'!I
MP\K)AQ ?B7?./)2%\0;4=_#T,?1Q-$;:/-4:%E=?N<#[@6/Q0=9X('Z\;AWO
M%$W["(WZ-,:A>>^&&(FDCERUL@E[9DN[<]G^<0A#*5TJ-4FXXH0;C116+";,
M2L%]IH1+/3(8+98Y^\_6&:P3U8>)G,W L]U  EI&>[9RAM >IK AF0;(W]%$
MA:VC%NB)HKT.MPW#[?6=!K/X\%^O#++^7A3D"KCD!GJLBJ6 ]\_);_'^?,69
MR0BT"(PX==^GX:1>37ICW)=,;X*JR3KN3; H0U6"T3J\L]N;#,.[3M6W*B]Y
MO:5A7QM.SL;F GX?(N]BSN56,4WFG)#K87F<8L^[R"-B0;<9N:()&\BHVH;>
MY<G1<R0U.6P49*IA:\4+/H'$]UJO)Z-N@)W-&BE)"(4M*"NK,4"P*'$*US]F
M/,*[NT,WOJCU&U;P^!@&##[HGI6$)T6YAG)=7TENI^Y& Z CG<96)AFZV&FJ
MD]0C_9_S(DIAY3\L#< [D(_1/X,1 .QN?_O'&/HZZ8Z.<1+S,/7GN[%C6N_Y
MH8IBZH70) ([C_ XL41E*M1$C@SWB5)&W6)K;QWA0H1_PQ;E9@:Z9$')2WV
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MMX"\;FSO-3?&?8N+5K5@6COG9=R67QQL_%HV>"P\$G O_AYU8_5C_M3VZ!#
MMFK]F,5Q^B5%+<:)#?%"1?;4 8[P[K(N!D*CV$D;55A671\HKA@4X6#V<G(I
MST?$&JF=JTN* +$XL'WS9WZYZD%91IZXG('+,26X.T6]U:BXGI/CR?+,N!]A
M8J$X!<O3$YLST\H?GOE<<?^IZB1>5"V68>5P;K[31^G-V<4B=//B@I%JG%N-
MG54/UV?]ND&O<X6^+[]!Y#"XI\%RFS 7!$1<4VQ(\)$9S;U>2HE01YL/J_.'
MO+5]0+WB7'F()0QGB.,@D24"H\"I4C10(8A>WH7W%M'F:-+?>4:%&Z#QXXJ@
M>X@7?I:DU?'"%:+VE>V^/W#&LZA RHC&.-]_Q\@DY1#/%YR%(YYRB!?XEOXI
MX<*CRDT=+MQ&C/:VSYMG!XI088@52 D*8J2T0CH)@_)%#BQ#3"R(&] HS!G!
MPJ<I0&C6'"[0-]4,=-<PT)'+&>AJ,KDU&4M-)O>$1G\MF=Q2 JHU)92Z$CL6
M(H^YZUQX2?AQM\,OC+WW( "*XLR%01SA00G'O&')6ARJ?(,:YQOJ<.01;@CN
MPWO>T=:/]WAW9Y^UWA]H1XS&Q"+,M0$OT5OD,+,H"$RD \TA"72$JFMCDVS7
M5XQ7K7*$Y*)=93@)RM+H(D@JM9%C9<8)*5(+R,\2$ X!!;>,&ZHYHC1RQ ,)
M$+M2C0A)$7LI&18@(%I>>P"Q:O"ZUQQLCF_4%;FK)<[DU2F5!4R[E]#WIZ%:
M'?K>4&I]/M\7VF.JI$0RJ A2BPTRSOM,ZY4(ED; WA75AM?QP#U('/RX0E3'
MP7>6J<.SYN$!HTPG2P,*X$XB;BG$Q)(Q9(A6T3',HI<Y)KZF:'#5Q/!#H-A/
M,[TUBMU4X@B@&/>4&^X<"C)1Q"GSR+),5&5-"%00Q55VSL1U!88/E,U[5"&J
M4>SN,I5KGZWGTK@0$9.1(:XB^'-.!,1"<E8K,$BN* 2X+K/W\P_05RP$^#AR
M ]]OEYQ]$YZ/=2\$>->=/9B]JNAV=GH+U;:VN"4.;VX/BP^45;9+;YZO&,)!
MZ&@\-\E3!Q"@-38))\\U5SX:ARL(D&,(D'=J$%:'<#=*X#=9\_V!TEI($20$
M\A;B>B,$<MIRY(0Q1/#(0JX;(UN7-0%;*6HKRJY/^^UO.5%TVK$^3J_&7L(I
M5M005%RFF6/#]BLBEN%T#_-S!W$X[%25 JDHHYUR C1ZKM,^G-"RS2I'=8:_
M1.KS3=NJI'R1;W%:5GYBO\9)C;JW@Z/Q#78(21=9#V<966OM>?+:L\]:AP>:
MF()6$D6G->+,&60#V,Q +!86)\7EO6I/_.Z/;/=P>OM\B>!FJKX)K&?FDPS9
MG=5N%F&IO59":W ="<<V18")Q#.?8[Y*6W8GNR!GM^.MGR'OV)WHZ9_%H#M9
MW-Y4<W[;ZQ?O?\$RYVEK^\ S<)M98L@IH3*Q%D.9-PIQF43 ECC-? XOKY.Y
M2MB6X^3FF+BUPK!E;L$4!BL1*_BCQPYWXS1WFY]^3\7[TSN;Y>$8AZJG(/V9
M-0C&8*<\"ZO>AWM,J9U&%KF[7BVNR\3UZX]\AU(D$TER*.+<"UKG0A,J&3(A
MWVRR3%M=5 A<DQ9>@SCB.O][<KUX#1UP'2'<]AK\.Z*Y365AC90A&1:<3JIR
M(?C8A5A@W<0/[T&\N#+?XVV\^_X@:N*#%1P1AC.5N$B YO"/<,E@JVF^-Y&[
M2^)EU]WOX'07,K5P<+O2O;-[%[#[R 6^/"%Z@UMG!X"LTOFDD?"!01"7R30$
M#4A@#FM/"!;.;+QF9LEEM 4V%MQ8GO[8^'7K)@58-^MK*<G&DV[ 1W#=@>]1
M.O 53M=GV\]\4X,U:;-'FY,&QMMB__AM>__D#=_]_/?1[L[[,]#W=G/O*]W=
M.?S^Y:1UM+_W=SMSXB[J>'.GTVY^_KN]OW<H\N=;.W^ OK_[OKNWSW=WX/L
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MWGR/?=\>Y"K2=8E)'QU+\]VZW9UMW#K^A %7,S>+!3,454[<*0^XFDN67/0
MKD*1)"@C0ND;Q*<W\\7G!'N,&@5]2)A/'^?GE+*UBA/^TR0KUU[%T&QW<KS:
MC?^4LZC%K!"S_>_-LP/*DDR4*<1B+@JA4H"8:8J<"BQBKVT4X29$(J/3BD#=
M^J-V_#8Y\1@?0IR,]V#NGN(\?>X5")G)>=O=@I2T-V\MV"9('CQ[T(BVWVEG
MM!V_-RRCE\Y-HXJ>.NN>N9E9DK%&SITZ+:P#N2R@GCF0*M>Y,A@5Q7EF9<_[
M5O"Q%SS!)1['6:OUN;8QSTSYO^9C(A5\2@)"<YO;8?'(&'(Z<N22UB%091--
MRVU,XQ8$0A/!NA.!T.TDZ *!T%5B$@M*H<F+@^K5 5F7?,Y/E9T6_&_S_8'F
MVGL7(P)?A"/.DT-.QMQ'-%%IF/7<X,P=QR[6=LTTB;T_LS&%J#'\+R D(RM:
M"AA6NU_9BNM:"=E.9Z(#RS![]C0K.U6C(H4>P_(IY)69;[!P>9^$-3!CJQ8R
M_;/]5"+3=]W&KA_V<C4KQ<0L[61[N0$L^/I[J;*WB]QZD1E/&/:YJYPQT=I(
M'?="I)B$XT7U(3$$%^FG_,/=Z4S*!@)37"N//5XNJ!W[ TM),BY0E)3TB)M\
M"JA-1%%2S$4$*//I"C:3HB'#93'XJMU5YUMO3W5DLVJTW;CXIC\F;ZK>,R4)
MF7_CGXMOO(199?RI&14=M_FN<ADKT6,N.30<S/>#O.I,<HX;^;(3@,VRB=+
MCP:#BGP%OKC5 _PWFU6AU.0@/Q=KP9MS8Z%O,UF4_(28"OJ5J@3@PB94Y!,Y
M,JFLQ;2>=YP\FG:H+)Z<K\4N?T[1Z>""-[3T>V&U3DY@"<%(Y<Y0_78^<NU=
M7+-L6%99M%7;80(X*8^=<(1SXFU@!E,5O1**!X*K$@;&;M.P]DJ7; U;Z#P^
M4/W8_W% <D/@& F2@N>"2$>09LPB':,U08=(C=AXK:\EQK@(+RO*0B875<D&
M;%GBVH([3ECFS2-.<Z>J5H8796&U8K\;R\*+,UH_#LE!TDX*'10RA@7$J37(
M2A81E9Q"V$8I1&^7'LY?,!V;M[C[:DRB@0>C790\J&B%"BDE,*::1QA>+00/
M*02[.V^^'UCA8=VX1C3WI^"6"60)]BA@J81+W$8;KQ."/R\/4]:^P6-!>W"2
M6Q5U8V\TZ)Q/B==N8/_FZJ9!_'=/_^S->Q]%3_G"I<FOC\OG9FY>S)#577QU
MXS+JNB4/VOAU.O3E'M,_"SQU2QXR-Z7-8CY39W#94ZLZR?DSI^P\'69$*"Y<
M';:_%;>M"BZ\23/<1?>I:%-F\VI=XCK-',6-JWNFK4PO^$[S14)C1VJ2*)CX
M39=[3" 9!05Q=S@6BJ)+IAUO:+562Q=E7,E\V5SR!'+=_=VX)2+.#-<X4:$\
M]Q)K+'7N;ZVH  \KB&NJDEX =<#CES/L?3IKO3](1!F1*T(5)Q%Q)@!5&?<H
M:24)5A 1*ESP%9M[858OBYE_S?IQDEN>]L]S"^&X^HUL"0X!9C3"\+AU5%/O
M&9<Q80S_Z%39X[O)4:XH?C?IW_8GJ,0YP,-V44#]DN6&-@\/%%5*<);[1B4.
MUCB 9VY(0H(8::DEALJ0^UM>=].U/(FMX&:*\_],Y2.'MH.+YF5J0BX : ;Y
MI8_-Y0K7$IRMP+I3<JJ.CXHK9+]V+K,-?5<J[92$PM)R1DW@DBM##75".>8#
MQSKA^V4A^!#'$]M-61%>L,!/[^2V]MZ)UMD!(]PS215R6GG$O6'(.1L1PQ)[
M0$X1@\V'R-=RO(/HK28!R7,N/?',<2,@&#$L.A:,E"F7=][O#>Y: I9*0/-[
M$\RFC=P++!&A 'H<.XO C$)$B@TX."YY(TRF[;R&6V*1,*<\==F)?A9ZR"ST
MW !=;&[^';LY"Y@;J[>[11_N^<1: B3MG8V!L*@Q.SF9NYEYX8O&OK6?>)L7
M?--^/+'M;G[JA:"[^/B%*&RSI'\N@['57$HG(ZA;DMAZPYTREF)/HS3*0Z!.
M(E[N 2Q<H$CM[S&@'['?JV/QFRK#<4$X:@%^L"<,!18D0""H OB-' D1 B:.
M6LS!_G=[2T+QF5S[7 !>,XNNQBQ*:V;1FEETO6;P$IE%U[2"_L;M2N8++Y::
M?E?06/4.N^T?8Y=AIBEZ9?S][/6PL@HOQ7Z97LQIIER(,GYK%4K//V#)V>&@
M: ]8L""5GLGLO69P;E!!]U!P"965)1>'=?&I[<L.&"_,^PP&L(I_#E8O@ !0
M+QG$QBD8YIB+F'/-0.0LO9>LQ'@>V]U0EFG51X;9*VGF=G">$AD2SG?O7/9*
M6$#&!8R2=GD/&*?9*[F6+&E\CI[W/PZ&L M9/4:#\E[\'QWKOZ*/'L)X$*PL
M;*7(G_1"[#1&PW:G5)/_1'#J&PS$_W24T[3+Y?-RM0&I+-E4+I'C/#I[>MKO
M?2\&"-*\6@9-J>1"5,%*3B-V09C<T\8JR<"KONZBZ)U+5-_"2OR;%V(WS5TL
MW9NNP%[O8S'_28'^RY7N3S]:9P<2=B<1$&SIL(.@,RIDK1<H<NZ-#D:GF$"Z
MV75)M\WBADV_G>M'5LZ[/CFI^;-(#ZX5!\3/$"#2VCZ(W&A/'4'*Y#LVQCED
M761($!V=,P)C87--Q75)V_8*Z?[ESL+U:8SG+YC3*><9OV#9W,>MPP-!":/&
M1J1"2/EXWX/IE@+AR(GR1*ND33Y0N.9BSC(S>S<3>\%[O5\?$WSKIVO$+Q/U
M@GXGYO=/].(%R_<ASCR>"HO@14!1"C#>WB>DL=5(0XBHI2'66@S&FVY=)(=8
M(N"51,Y+=N$0SD5S10 5<L5$[JV>*Q*ZDZN_BT([.9;*J)T?!9%SI[A/6#QF
MCE,J<QEW>H/BS&L6\<>/:'>K.*_C1YU)6MG90=L7CR]J*BI.Y.(Y^8;$^$'%
M18EQ+'H3PN6G=R6@J+YY(G<"_H@PB&Y9;YMO!<BRV&9\'6!I*?BU5V_G%F#C
MU_SA:4W* C?D;--*.R=G_V>F#MN6DGTI>,:3TT[O/"Y>K\(\D,2P"28ICL$
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M&K17 .TYIAV!L<0B,22% X>,9EI(QC4B3A$OHTN)\L=.K3VLR!3W\&J!N:W
M. .^.LN]A8D4B#M'D*$^H62PX43XY'FZM-3M <\0GL5!:6U$GZ$178>2M]J(
MWC\F3G.5C%+EDDV(:.81)PDCAU-$L)-&0DPKG?:/G<FNC>@:"PS(A+#..^1\
M5(A+'Y"SU(%-=9GY$/X5ZM(ZRMJ(UD;TQ1G1=:BGK!'QOA%Q>C# I/>$>HG
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MTIS$/X'O@/C^R]ZA:/V 9_QHXF:>]<X[W(18OSE;0!V9,<I%A9*GLJ 00OG
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ML+PCRD_$_#H6BIT9'2E2EUH5C$$EGDNY>9+BO.B6W8%4$)):QP1!:8=UO<J
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M'#E&/"\:-+N0MV]SOFZ^7(QDK\I$Y@ W/@GVFY>Y:,R%'H&6DLJ M0F!7#(
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M)$B18]$M4$]UE:HG=7TW</RIO(=E+;Q44"&XC(4WQRX89=$>XR,?HSZQFF/
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M<UK.VZH^2^>1A31P_MZ(ZBXIL*&B.J.(0$XL0$'O6:;K-4KSI;306+C^S%<
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MJ.=BJ<C;K<-M_;6YO_;H05).^WFAJ4?T\L(BW3W8.$3KO.,"#_/W.^7Z+:Q
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MSLM&K!;)9TYX[8=1GN9O@UC&EFZM%-Z6%![T0-UJA? S$\*#GM2VSG"O1ZJ
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M=$_HO(L<Z+O\MN9[?_O0Q0Y&ML#711+!C0*QUQS2*>)/<([8 EJH6 L__P*
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M<C<=%WV4<F4DMU?%N"FWM<'OA+ 9^1.&_O9% WHO)2_;29#J4?AH)+>+K%F
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ML::K7?V\?$'+#W_]T_\#4$L#!!0    ( .1*:5//$:S2-$D  -@W P 5
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M;H@,0K3,EY0E>5#9Z 7'8TGAS<(''XY".XMM:RF1;X:)]D>$6Q?GW^J .J1
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M%>!Q>3>>SE4Q?7DZ/!N.ZH\'":LLD#-E*N.5CRP*GEDT: P*VC(;U8%NAO<
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M)[&<\.\FP_0-HT%E ]?U'K]$<MG)1HL>Z:_)*Y' 2BU$QVWFU@,/@@?-)-S
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MWW0M')AKN=QX8!>P4/%44.-J#%"U[Q:08I+ + Q)1),@P*&3OZX_8"/0J _
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M!(M0/&)_2%?Y73[-\?I&_GS0$'*K9> KM AT?BOB4&",B81)1E*(&$XA8RR
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M *N-&E=MGJM>*_F#.<, 3VM-3$2;4Z/P@2;<PJI[_6D<F (K!4U^:",IN"M
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MUGE[;96'NDZ8?NB=>IN7G,[_+FDQ0T2Q+$49#&E (0H4AA0C!B.I%$UCPH/
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M$A3+/"8*$:3:VV$[+CCHP>,VN.^+X$; -F&1:[ZB?0#M9KX/*$-E&&K0N+V
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M[YA*"]3MZ"<LECW3SUDOB(<&UU;F?BMUG\:G]\+<!]V^>1WNTS#8E-T^\^;
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MDR"FD!"*H!#:-DXBE>>96U6G8>4?&YMNPH<>*SU,[-!SXWWT9Z,+H+4R]2-
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M-4=/NYG! 02BEKT*_O_]VX?MLXY) ,YA;T=% 1#M>\_92&BRB=1Q%SU4PKH
M0U"".=?7H)1R0>%#$KGTN!]M_%/.'I]T,S>FW-*C;.-=Z\JK=R_K<JU7&=UM
MG>B>9I12090V-4W"4L,C)-?;4X0S$E-9*,R=2J8[]3XVBFGJ!;?.P)S.^<N\
M]E-=[+)/2SH5"4' C"[^M9G=!LR.@7H;AIYYJ94;-(*#;1:&9G!VA ]>DL +
MM: TYB;!H.3F!<XAY?DUXGD&1^=2-VTL@_O5C,N69J<JY91&1$!4* *1+#@D
M49'"@B'$$IG%:>Z4I/E<1V.CMTJX'?/I6B/I+,"6AW(!8.O[4([6UYU-/?D:
MP(W)%/!4[@(484_ESG4V[*G<!96/3N4N/1_DH'XGGK#(15)(&4,BF3:/$I)!
MRA6'C*$(D\(4U'#*J':VI['11-BC>O<(S1 X#7Q8WUL8YB4L^CRN?[-@RTM*
M7SBP#Q92V3J\W*F.(IUE[<U&I10XS3,8Y\J$@"L&L9(8%HG*E,P93U*G0QF'
MOD?''SM^0MUU:CV]"5W&Q9)S^D&[;Q8*"+0[-;E#%I:L'/H?EK[<@3DB-(\F
M_"C.^/&MY)-<E+-769>)^V(2HCW0'].TP"IC-(=,9LJX.<:0%9& 2B(I61XG
M:<I=[L Z^AK;S=?FK-E,)+XK=_5K-[KJPMB.G@(AUS,=[4FY7UUR KY4F3.-
MD],$W*S7JQE[6;?5)N]IV*1G%G %I:*N_@:E'@O%#ZG&YA7/ZZOOS_/E3RF_
M27/6H^5O SP1IZ)("HCU#@LBE!*]KY("$KW;XC(F.<J=O*?/]#,ZJZ@5#ZZ:
MA9GK[>NCZXWY.50M+Z:NQZKOBZE&0K 1L8>PS@LPA+V8.M/7L!=3W0H?74Q=
M>#QHAIJ/LX7N8C\S"HYDFB2"P3P7"4289)"9>M@B25C,4AQ%B9/[C7W78[1$
MJ@PUSSN)5%0K=^@L-:?&PHY9^D&X9[*YD*5F(_R066HZ$!LB2\VI[L>0I:8#
M%LLL-5TM^!':PTK2\F7ULSJ4KFI^3),BSXH\43!E,H:(855%?, HY5&2RKA(
MDFRZD(_& +"CKN-.K"80J2?0;E?]S:-6QMH-9P*HYBR]0YV .(DG610U]^+F
M]]_T)U M)O_V/^,\^L\TF@#S@3;AUWSW3W'UI\B-V$Z,B1V!>>(\#%%M &XN
MHBKYPE'1>=V#4LZ);@:EEO-J'E)(QY.>H:1+NBCOZ4^SY6TL]DSEFAIB F-F
M_&V2C$.FB@+JO1'7IH]$:2Z=HDB/NAC;%JB2$#S7(CJ&B1[C9S>MKT.EYVE=
M ])(U\,^Y[SR8>-!C[L9-A3TK)I'4:#GGQPXXWOUGW_(<KTI&A9K1B DUP#
MF/,(HEAS TDE@Q)'2B*%!65.OG@AA1L;E]1YP5]K&8T'BQ;2N^17T%&TO'%Z
MH['I^TKJVE3ODR;C>Z-A4^UP!#G?.W ?1_;W4P+^-?+ =T ;+"-\5Q_>F<FV
M5W/OZ[/<:<(B3!*DB9LPKHVZ(M84'BFHE$"HR%26*B>GH5.=C(V*]Z^>O4ZU
M3V)I1Z37(M0S(>Z#\_X".#X9Q<YJ'SJ-V'%'0^<..ZOJB81AYY_U#M\UF=M;
MZ_%]4X=*%A$7:9I"F1<((APED$J9PTQOX2(2)2QG3J4?3G<SMBG?2NFWF3L#
MI=U\OQZ@GF?\!IM&P@EX'[JJ5S<&H0,W3W4U=*1FA[HG0C.[GO:HC_I-VPNR
M?-<4=&[SZ5*JDBS#,12()WJIIS&D,550[^*BB&=21LSJ_.9\%V.;];60X%U;
M<]REG.=I#+NG?!AD^M[Q'()R^1S'%AV7,O?7HC10>=.'IUD)OE?2@2K6IP1J
MN0)'(/X]5!G[+ERZ"]:??'/ TO1=DN\7H>]\TMLO\/MR41U_'\5F31.:(\;R
M'":97C!0KND/BR37])=&"!<9D853CI*NSL;&@>]WXLTG[;W6<BNO?QAH)^1V
MME$H('NFS ;#YBZKEG2R&]@9U!7P(B*A?0'/=SBT,^!%U4]X UY^Q\>"V@9O
MW0@Q,VL,G9N$K>^-=]%\;N[G;W_P)W.*\W&YJAZ<8AIGN2 %1(JG$ F&((MP
M#F,F)2<QY<2N$H2W!&/C'I-T1&K9*_<4<_2]7)6 /JYD?:RZ7@)>*0/H1D/P
MO%Q5YZ_+/_5;*_ELLL37%>0H$+.R,I5=#!6?@;2Q\GH>GKZ-0!,G>K>)$]VJ
M4.>"WB@!/BU JP;X: P?\T+?^+O8D3V/PT!F9D_CX6A[7H%EMVGJT_" ENL5
M>N\;MM<TY.O211>ETEQ^LQ#:KGZ=&8>Q.]7XCM'Y3E;W!]U#>?I/'Y;?Z4S/
M-)$62B$""QQ)B#*10\RP-I9SA06B(D\X=K&30PHWMK5M(^E^XOQ:6,?XP*"#
M:&=YO]70]+RN>8Z*AP-:>/@"NZX%%'!@I[?PT!Z[R_70A\<VX_-LH1>,]Y61
MO*E5=TOYTX<5_7-*4R5YDA4PC6("$4.:B:,XA9FDF O"<I1:7=5<[FILY+H1
M4.\;]!;BNWU2!PM8+:S[8&#U3'=&3F,VUI*"+6Q&5F"$#8::@TT>#+W!SG@E
MH-_-QM)$?+(-B.LGXQ=.%X#)YK<FJZQ!5FA%@*$NO2F=FS$PB1TK?0.9XE80
M=MK<W2T,9UQ;:;)G1=N]X>L#\RH7+[*\89K%*5]/,\VQA3+%+C!6$,DXACA6
M'!)<($DXCU(BW/Q?]CL8&[.V\KFZNQS 9F=D7@-&S\S9B@;^:(4+:!V>TSNP
M@\M!)P,[MYQ6\=BQY<QS/H>R9K_\J2Q?I/A0.<K4?G%5N,/=LUDCC#W77BO=
M_I K/BNEF.:1$ HQ#DVD-D1$*4BBS%S_Q(QSAG@NK&KC72/$V'C :% %*Q^F
M)#:WF\M*CRK$Z<]:$2 ;19RNT#W'R^;XM?]1Z/L$MD*[5@'4.C2^PTVTU 0T
MB@"MR?:R?J/+  /A<@[;_X ,=13;V\ XGL9>AVCW@:QGVP.>R5ZG_?ZQ[)5M
M^9F:=6Z2!_JCMF1-%S?B?[^4ZVHW.RU2G O,,:0J-@4[&(.,Y@221. LTFL2
MIXF+X=G=W>B6GSK9SIK^T)NKA50=&R<?<.W,TW"0];Q6-&B9@FN-J-7:O"-L
M.-O5#I2@ENR%+@>U:^W4/[1R+=_RL'G?SVE9WJF&G.Y67TTZZH]TMJK92[W7
MY#73;56+8GNLJ85X6'Z3Z_5<MJRVXR@Q);'$J$BY-H!-0B-)4T@3F4,IE,R5
M1((QJYB/O@0<&UGMJ0#66QTF>Z:S@T'6QZA:6,UO/%8]LV2EG3D-;<0$=RM0
M:3@!1L?:>*M.2_?&<T=/\+ $M:8;L\Y4PMTZ?[WQ$#O8XV\\U /9ZF\YY&[6
M?(_CT6GI]]'O<+N 'E';VR'TV8_?[J$)!2T?EC?\OU]F*_E)3Z;%XXS-Y4U9
M2FWC2IX*D<0YY+E"$"&10(K3!$8)*U <L8BGLLW<\V"_C[C8L14-[&?S>1C"
MU] (!ZB1N:P\;]PV%)?QMMM3A(%OF 6SE=4X8C;2@JVXH)8WW,["&IJ@FXO+
MO0ZZO[ &X7"+8?^B9[CH8CVKBM'-7N4WR5]65<*QVQ]\_B*D^*@5,0'L+_6*
M?J<.2X%]WA0X1@FF4BE3WJ_(319F9((M8B@3'J,\5H0CIW2IH00;VZ[BN**=
M8U!JJ &S([:W&(:>^6]7);#5";1*U3?\.VJ9RY+C8>NI\'5HP,-&V882;MBX
MW,"0'D7RAFY_X!Q/S6'X3@S-U^5\_G&Y,G^<1JE@ A48<J%23>RY@H0Q"2E%
MB!..B9).F0/Z$7-L-']8#W"@1$_=0VE'^6\_0'W?P5Z?_*E1=2\:$/QAU 6-
MOB%+F/0Z(./("M4MZE\C/Y05W,$R1=GUYID&5.K>3/&6*>))07.E(,<F>P0R
MP8TF]9_,<")83B*!4I<,YYN6G0A[@ 3F#Z8/,#?B54F!'?-^;@"SXU@O&'JF
MQ4JF256'*6!JST-%PV;TW+0^;"+/0Z6.\G<>/>!Y'+A:/LO5^N>]'JCUS4+<
M_O?+[-DPP+98(18$923AD.5*FB0'RI1_5##)"Z$$SF*NG,RSRUV.S=3ZC?[O
MY:I:R)>+ZEQ+&UVM%A-0Z5'=FV\T<3PBO#P&EF>$09'M^Y"P"\"F2AOHI9:D
M/4QA#PPO=SOLB:$U#$='AO9O7N/B]$WO9RL#Y;,94FV*-(&(<9P(A'()91*;
M"I.(0TQC"N.",Y3((DYCIX/ SM[&QD6-R\Y&6M"*ZQDBV@VU'>\$ [!GRKD"
M.T]WIPN8].#M=*['-W!VNJ#\:5^G2R\%-G,^S$H^7Y8O*[E=;!.*4*H* 3/"
M&-2V#S7I5C@LBI@5N,BTQ>-4P=:E\['132M[+_;-*?"OM'2NA/1-;9ZM[#T5
MT?9!;1@3Z)0 XS"&.J"Q-HNZVO#CL[OGRF=D\7C[PYSHR'+*<I;G.=)&4<1-
M3'<D(48,PRBEN8RTD92PV.48Y:B'<1ZG+%LQ@6SD=..F8R#M".@J>'IFF8UL
MX/82)LX4<E;OH#QQW,N@9'!6R<,9?_[!4![93=!(5<%=(5Z(-$GUG(XE1$E"
M3"U(#ADB&4$IQ5C8IX&[U-O8#)':(W.I-H&#RQ58U1Z9<BNU>])).^B[22$X
MH#T3Q ;+?VZQ;+Q;=P0.B=^U#L:>. [J+>R-9P"'WQ/XN'OO[C;RQJZX)_2Y
M[%=[ZB4/'KY)HI@8&ZY)/HVU+<4SE4"I*(>()!+25!2:=N-4X"@EF2RL:?>@
M\;&QK)&NVILX3/Y#O"RX\@H4>J;&#0 ^R<L/D7!@O2L0&8CD+G\:;CQV1N-.
MVCI\9SB6.B/M'BF=>\8W\?A<_W-I[,M7N7-;WU1U,-'&R_F,_YP*S##G&,,B
M8@@BK@U$3.(4JD(P1!.$)'(*^+7M>&S<M2/WOJ>-XY;0&GB[G6(?</9M'^Z*
MO(OD!&RE!K78X(_F?WLYL7(%+W &<\O.!\YF[@;)<69SQ_<]?47YDQ0O)FVM
MR5.[F_=P<]0;J8@5G!8PBU,%45Y02!3.($FQQ D3@J9.Y^R7NQP;9;42F[V#
MD=G1A_,RQ'84%1:XGLEI%[//R\4CU /UO<YFO9>:M4<' GN\PKH^7NYV6#=&
M:QB.7!+MW_1CG_UF/V]"4B1/,8L5A9*2%*)"Y1 7>D-'<AGA'!,NTMB%<L[T
M,S:>.9@==H$E3L#:$4T N'IF%R^DG GD @Y!6>-<7X-2Q06%#_GATN-^I' 8
M%K-).ED4D<AH3B'G!$-D_) Q2F/(.%=(Y2PGRJJ W:6.QD8+IT+.+F>M=,/6
MCAA"(-8S,_B!Y4P-EY (R@UG.QN4'"ZI?,@.%Y\/>^#2'@,7<28U(\ B34SX
M<48@C8L(*I1FBA1I3.R2&]EU-S:J>+]\I3]F"W#3%ED*<Z9B=60<'K&W.C^Y
M?*@<[(3DU*EJS^<B0Q[*NJEO>P82Y.#VK!O0KZME64Y)H1):&)_E'"&]!2$1
MI)(6D"6(9!FF,8^<O)>[NQL;CVP]X)XW'G"RE7@"'HW,@;P+:[CMJ"4<B#U3
M2Z<'X03\VHE?.(?!/5B&<1&LNQR'4^">^M9N@/MO>693V:_I;?)!<KYZD>+S
MC++9O,H+<,JM5D1,T8+F,(I8 I' U%@O' J..4<HSS,>.25/\9-C;'34"+UQ
ME*OFT]WZ29OX3;ETL*.08QX5SZ&R8ZP!!J!G*FLU (T*=>K99D!VM.C?+_I*
M+,,F0/&49=A\)]<!=I3>Y,KFW*A4R-GT0^,S\?^\T)7FF?G/K]+4AYT*1;)(
MQ::$ ]>;/(D19"E#FB9)P@N5H32UJMK2T<?8*+ 5$VSD!+6@=FS7A68WDP7"
MJ.\#86=XK.G' H 3U%)*_O?'Y>M_Z+=K5M$_5&12T4A7FX-0A(52[?2W>=0[
M?G1E N0_R/I_/RVJ-7WCKMUD7BRP2)'*,$P$,@[510XQR@J3M)HPFF=YD20>
MF2[M>K?ZQH=/=UD;/[0[1>,UH-N9-P$Q'"RVM!(4_-**_#<P6S2VY#8B(W3N
M2S><0L>;VG0]=."I QPG(E!=WKZN4MRTB W)) CR+(KTEDP@2#,N(2=QSN*\
M$"0M7"*VVH:=#(S! K565]6'<ZP+-R)>N%@7S[L(7"^3>M/XFQ1].S<QC_[N
M?3++I12E29C8UBF[4_<:ORKI=EU??2'J7TC]QSH[?DY$)EG"8(X%@4@A;2;0
M3!L,4A2I8)@RY1H/[B'&V/8-W^3*;,[?F13XKW*UKE([;Y2H<]R#6:.>\Y&N
MSSA9'_7VC'[_1\"5 G46V=UZ>X?HFP.5K1ZAR@Z$ 3+TH;&/*$,?)E\!UXE#
MYFM:\[PA[XBZDO>KF1&AK5C0_+6,IRS-4DV?.8PSE9OX! '-73HL"(\4D05G
MQ.G"RTN*L;'GI\5L/=-F45O^$CP;P:OPU=^_?0#:XJS#6"VC6*\;(3OB[!WW
MGGGS<I2F6;]F-95NJB^V#P4TX*X",NQ-OI<DPU[P7P/6T;W_58UY!D)HVW5E
MZ-ED:]23#2=)RCF2D!6HT-9D@2!)N8)$Q8CF*F)*.85K';0_-J+;B%?E/'7-
M4GV G1U178%(SQ2T!>-])QCN$0FG50X;?G#0Q["Q!J<5/ HL.//8F^>[_Z<T
M9"+%C9'O4>YQSC1-,2\B+B!7.=46DB1Z@YG'>K\99P)1G.4IF3Y7M66_K>EJ
M;4D,PTCO,KT.=>AOIKV3C[.%\1(%C,[-!S$!?S9* %IK$=KV&NIK40A'J4E*
METI3GRL3>NW :00+'$<%S:B,6=1\+;<+\1?_5EH-^OM2;NO4^O^?^TPLU\KQ
M#7S?:W _M1DFH-4?-  <["I&6:W!9LS&6KZA4_:_:CT'FP'IL<"#5?=^QE2S
MKVH\_@M$2)+E2'\BF8"(Q1CB!.>0*HQDPF(NW'9!>ZV/;0_4;BG=%HI]P.SH
MW!N&GDFW/7()'_]P4N.@E+7?PZ#$<E*YP^E_^B%WG[C;Q7JV_KE3:;:N*[7#
M#E.%9403G$%FK$ZD,(4DYAAF61JQG$D5*6;K'G>YN[%-XUKBO2+.DZ;XUJXE
M8.\W9X%X][0/CV///' MA$Z^=?;(>+G9630_F,>=O:J[SG<.;_GD,]W-Q[2)
M&WR0J^]340B:YRJ%@LD,HICHA3\3%*)4IHADBJ0YM\]D>K:?L1'(08:J5E1@
M9'7)MGD>V&ZZ" A7WW<UO2/EDI$T"&)#Y2+U0<XQ ^E%/+ISCYY_?<"LHQ=U
MV,\W>OEQSSIXR\6C:<9DO/BBY:Z#CJ8X30J>FT*HL;:V4$$Y9#BA$,>9C.)$
MFU^Y4YZ:T]V,C1^-E*!*YR2TG!.PD*Y%\DZC:;=WNAZCGDEQ/]O5I"DG;0XO
MVUBUW^BZJ0T<L+Y>)RQAB^V=[FK8RGN=ZAZ5X>M^VC/&<UZ-BA2G#W::6,5I
M'"G)<53 E"6F#!9)(.8QAK'Y$>>4T\B)(^RZ'1MG5'9K<TS+=X]SFWH0CC&;
M=M#;$4IX0 <\&M\<>>]F_[R]@*E[Y*431&$#+>VZ'C:NT@F.HS!*M[>ON!-G
MEP^;V9G#YITD[0>'S5^E*?2EE[/WRT65S^>%S@VWQE.B8I8@5$ E$U.0*XX@
M5JJ 12Q$+E*]:R1.3/<&.HR--O]Y>,NY:B77++H1'<QG2D[ LE9[M]"&QYWG
MP!^-P_WG>#^%O]!=Z X2)^Y"-VB '3@";4I',);A[T@'UF/X^]*W&:B3=Z=O
M)(K'F>JW%U;RU>QY[QBBO%F(YA*HO; MFUM#&L>\8 3#/&$91!0GD&5(0!;+
M7.K5E(@(6Q^T.G8^MB5O5_SMP5B=\J6]G]RHX'#(Z#HF%F>T/2+=]XIR!N2;
M4R#[U%AQ1=OAG+='U <Z_'5"/]!IL"=JG4?$KFT.=V[LJ>W>8;)O&P,[,9N\
M9>N?.\G9JV#XAR>Z:-:^+R;PL]0KWL'*]ZM1XH/>B'ZDL]4_Z/Q%?EW.YQ^7
M*]/J-,\5TCNV"+*"IA#%20XIS7.8%$@@F1>IWLTY;^;&H]_85KU6=K@QQ2OQ
MH9$?& 5 I<% /JP]?5,.>[WQ2#VF5?OZ?6"-T5X)CCKWR5K#M-TE;I ZL4>L
MT (''V8O2;9'^B6,P].V)QW_&AZY_0YP,,_=GL7T3ZCW<59R.K^O8C<^ZM^5
M4XR$$ 77Z[U(S3558:ZR20Y1@G%"]-XTYE:'MYV]C&W5W62-JR4%M:B@DM4]
MK]XQJ-T+7C"H>EYVO%#R2J]W%H6K$NP=MSIXBKVSBIU*LG?^8=^*"9O,+_N9
M)VH_0I.70HK?GY>+^L'2[, %YUG$A8(%3R)M_D<28FY\7%@<%47*""\<JU4Z
MRS VLMA-H/.\2>%2ULZQ=3'S*I&._N6+5L1<T#2:N)<[OV;H[*SLG@>D9TKJ
M2&:T<53^M#,66R5"EG3P1C!PG0=W.08N_N -U'%%"/^F?/-"F/Q9-_N]M<?V
M!,59C(U_-,4046DB+HBF2ZS_3[*4XM@I94Y'7V,CPR:MV,WA['--''$>7,O#
M@C"0];UQ/X-6#X%6%H $3C=QOK^!4T]<5/PX#<7E5WQN_ZIFW[?AA,WW+&7"
M\UPP&">20203 :G)9QPGB%+$!%&157K"\UV,E"/>;[(TN=P?G<30YD[N6F2&
MH8(M*%ZW:R?1<;E#NQ:E@6[*'IYF)?A>20>J8*<2J.4*'('X]U"W9%VX=-^%
MG7QSP!NO+LGW[[4ZG_3@N^-\S)_-_]RQ^>RQ^C[*J8@X4IKEH(AS$Y&:F[I:
ME,$H143PC!?"+B+5LK^Q,6$E'UAN!728ZQ;H6M!B6,QZYLA32=H_+4"-XEU?
M*#K09U@T!^+2JU%UHU)[C#IYU:*9X4C67J<]QG5XS8-^;]]E]ZOEXXI^?[=<
MK99_FIJKC46 L$R**$FTT9YFIDY. BG'.<RB(F)4H5C&5G5R+O0S-KJ]?0<S
M\'E)G>N@7L+3@FC#H-0SP=Z"=QEHQ 1;.7U,T0ZT' @U#&H#$>E7^:R;J^[.
MV1:[*LWW^DF"W__^[>_@<?DJ5PLCS+^7X-/W[[/'ZM;\4W7=IRW81MN)"8;Z
MOES,?X)_+99_+@ MJS9NWX$,/#<#](OYS?^H?M6\]C_^%LK@O0Q\)SMWO#X<
M*U_688^-+1X/F'?[YL>LG&:":JVR&#):$(A(1B"1J8**95F>B2Q'R,J_]V)/
M8V/BL\F<P1]&7,?J]><!MKSS" %;WS<;OHB%R6^]BT;_.:RKWMX^3_6NTE:Y
MJ/=>\+Z4-5XAW"Q5GQ85(<FR73EY1@B3$8-QEFB^,$4.<9ID,"&8)$@6*<56
MB5=L.AL=9>S(:DIS/3?2.E^<GH?7^H8T"&C]7X7NX=4*VDL1^\N(A+[:/-_A
MT'>8%U4_<5EY^1U/]J#ED_E_XV#V2N?&%OVJ#<O5C*^E,'^X68C]7^P\.26I
MWOY%JH"$*4TO61I!QI,"JD)F)&;$)'UR3V1]E4PN$VJX]-1&2&VBZ_\"N95U
M4L4BK3:JU _0-6";;-9Z_:ZE=&2MZX:5,BQ8:FH4Z-F$F+8W,:($4HD2R2-2
M%#EVS3@]\*#VGT?:<4BE_O6;#*;0>X8\8@SFDB*(*.*0"3VB*<JC(LNER".G
M2O"##>0@-L+)03PUAD,.65Y@*0J$("58SS^J33=*$PXSD@B32@_E"7.I%#G<
MD U67I+;S[XA1\[2(!QJ//JV&*M!,/\%M[N#L)6]_J,9E,/?[;P0T*X, 6Q8
MP_,JB8:U3$. =V2Z!FG4T^-.MW*G*E^<+R_&5M;_V/'N^[1XT#OQDE9F]531
M5*9)Q&%!2 :12A/-N06%C,I$T@B35!9.+G@.G8]M5:P%-N;*OC>RF<?E<NYH
MOC@-@QV!]@5NSWQIQ#:H-N[%6YCW'8WUWGM'_H >?1ZHA77Q<Q%@6)\_#VB.
MG !]VO ]\]ND<+ZGJ[N5WL)J]JS"N^[EJNIU2B*I(JZY#+,TUWMS/1P$LP(6
M"8XCP@ND"J<JQA9]CHW'FK3C363%,UV!URK$].JJFQ;PVQX-!@6U]Q/"W33N
M6F!SIU"+W 3O:J%K,@MY5F@-4> CP\O]#GQR: W$\0&B_:M^C/2;I.7+JO*0
M^+1X?EE_F)5\^;)8?]4=M;?X.8XB(A$L1&&2P"L$B1(I%)1C3E6,.7,BI,M=
MCHV/6@F!$=&-<BSPM6.<L*CU3#@[PH)*V@G8P["'JPE[?(*RC46W@Y*-/0R'
M7./PIN>VSI"7:?Y.?5KPY7>IMY FG'XEG^2BG+W*YK=-&HDI*W"21C&&B!%3
M/S'2)I$H&,RCA&D#J8@RD3KM[-SZ'QL);<0W&X\]N4$MN$T&CB #8[G7ZP_N
MOK=[(9!VW^7YX15VH^<HP[![/3^ CK9[GLUXYH@O2[DNF[S_FQF$L"*"(09I
M) M-;44$F8PTT\5I5C!&"L2<J.UD+V,CL+;X :V$=<SW?A)&.R*Z&IR>Z::6
M;[(I#M$'N71B$#9=^\F>ALW.WJ7L43+VSH>]J_-)DTMV_FDAY(__6_Z<1CQ)
M""T$%'FA)[PJ$&2YB+1!DZ*$(T$8L9KP9WL8VV2_;0K(U5*"2DR@Y70NNG<
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MXFPYG>%R.1&!YY*2 9&4!<4*0F2<@_4^%"Z\I^AX !S<6'0S''1_V[B[(+O
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M846;%DD/$-1) <#!P+F?1CHXSN\1SWLD^1%CDQ0\>;\R0^VD ,IIVB.,'."
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MYTJ1J0T*GR2MRX!C,&S<S<494%$](._">;T8*'7)T\OYLCXS<L.$$>1N,"U
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M=SSZ8[J<2)^L(#^5S@A5;7D@%S:BA9"X41ACR;9-4X8G"!L7;LT ,6^GG0[
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M4:>HDXF<M[D??9"DO@"TB[[G+83? 8JJ#W;)R 4'U@6KHTD0F0V@="U#\*@
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M8HVZ+CRSH)Y.O+%4U>&<'PX@?PV@.7ZN*=O?VS1(#2;J)$BV/BJR",B>K%U
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MP\ /RT^SSU\V@R]$E#P$%X#I6NNG.",[6Y.=[=';H$)@O.F-^R?6U)6&&(*
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M*?5Z#Q(_Y?-@PX9[$Z%N&& +4UH'$)$VNPK*0LA)05 QF,Q0Z4;UV:.3,NV
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M%$QLJ[5QV-]Q>[27MN[Z+OA>[=!V>.HQ=,]3!#370,[[$+P%EUD$);" CR5
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MFBQ.RXZX$;J9%M8+A':"]I[R[ "?:^OSNN)^,WB*]CM:[0UD[^B\+-R!)UK
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MU(XGD_91Z<T']4>=8/"__]?_!U!+ P04    " #D2FE3YQN[+,E,  #GHP(
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M9>E[R)()WBR7*5VS3,4K)A^%ZVQB X7Y]V1G"!*B6SV7*M*T;DE+\D$HS K
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M#[,6"[^7.E,,.S#EL2]3#TSK@C+Z.-XK&>C%V51F)"Z.M9!)!N-AIL\ED2F
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MV.\B]XK?'2%I0<2<7TO>R(+S;VY^KT$)\Y4]!@HRN<5S "R\&*F?Y[6N4.%
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MD--47!/ @:A"--X"M0!LNR7ZA:6N;JLY.PV(WY\P(!W>C]ZG"<%[9WG8JH6
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ML0#XG8W2@YND/!X/8W\._YMDT_#W_P]02P,$%     @ Y$II4P9-]6B('P
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M0BZ87UH[3:HLC!K)0F 4ERP$'?Q;-2Y3+=G\>/&YP:Y10'^]N#Q;KXC"=N6
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M.RWV*[ZTQT,99RBSG,;2K@OU9J43?F9+,6>U0?"V# +#J]O13FT)/"X&8/P
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M.42INW=1^HE;C U&(9^SFT+/%(@Q-$.P3 B1T&A"H3$YX Q<%HP7<U85SE2
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MMB9X+R]OU.J@+-6-<V %V]<1 ?O_X#N0>0C?G^_T<*-VGW".F\$%4?"NT(7
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M;BTR,#(Q,#DS,"YH=&U02P$"% ,4    " #D2FE3,VAT-FT2  #"O@  $0
M            @ $HV $ ;V-G;BTR,#(Q,#DS,"YX<V102P$"% ,4    " #D
M2FE3&/1B%RT<  !9#@$ %0              @ '$Z@$ ;V-G;BTR,#(Q,#DS
M,%]C86PN>&UL4$L! A0#%     @ Y$II4\\1K-(T20  V#<# !4
M     ( !) <" &]C9VXM,C R,3 Y,S!?9&5F+GAM;%!+ 0(4 Q0    ( .1*
M:5.BC=_T]\D  )N2"  5              "  8M0 @!O8V=N+3(P,C$P.3,P
M7VQA8BYX;6Q02P$"% ,4    " #D2FE3"<>UAB=\  #XM@4 %0
M    @ &U&@, ;V-G;BTR,#(Q,#DS,%]P<F4N>&UL4$L! A0#%     @ Y$II
M4^<;NRS)3   YZ," !L              ( !#Y<# &]C9VXM,C R,3 Y,S!X
M,3!Q>&5X,3 Q+FAT;5!+ 0(4 Q0    ( .1*:5,&3?5HB!\  .@= 0 ;
M          "  1'D P!O8V=N+3(P,C$P.3,P>#$P<7AE>#$P,BYH=&U02P$"
M% ,4    " #D2FE33B&ATM@'  "@)@  &P              @ '2 P0 ;V-G
M;BTR,#(Q,#DS,'@Q,'%X97@S,3$N:'1M4$L! A0#%     @ Y$II4Y.\@HO*
M!P  ;B8  !L              ( !XPL$ &]C9VXM,C R,3 Y,S!X,3!Q>&5X
M,S$R+FAT;5!+ 0(4 Q0    ( .1*:5,%04.3^P4  !,;   ;
M  "  >83! !O8V=N+3(P,C$P.3,P>#$P<7AE>#,R,2YH=&U02P4&      L
,"P#W @  &AH$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
